PEDIATRIC BONE Biology and Diseases
This Page Intentionally Left Blank
PEDIATRIC BONE Biology and Diseases Editor-in-Chief
FRANCIS H. GLORIEUX Genetics Unit, Shriners Hospital McGill University Montreal, Quebec, Canada
Associate Editors II
JOHN M. PETTIFOR
HARALD lUPPNER
Mineral Metabolism Research Unit, Department of Pediatrics Chris Hani Baragwanath Hospital Soweto, Johannesburg, South Africa
Endocrine Unit, Department of Medicine and Pediatrics Massachusetts General Hospital and Harvard Medical Center Boston, Massachusetts
ACADEMIC PRESS A Harcourt Science and Technology Company
Amseterdam Boston Heidelberg London New York Oxford Paris San Diego San Francisco Singapore Sydney Tokyo
This book is printed on acid-free paper. @ Copyright 9 2003, Elsevier Science (USA). All Rights Reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the publisher. Permissions may be sought directly from Elsevier's Science & Technology Rights Department in Oxford, UK: phone: (+44) 1865 843830, fax: (+44) 1865 853333, e-mail:
[email protected]. You may also complete your request on-line via the Elsevier Science homepage (http://elsevier.com), by selecting "Customer Support" and then "Obtaining Permissions." Academic Press An imprint of Elsevier Science 525 B Street, Suite 1900, San Diego, California 92101-4495, USA h ttp ://www. academicpress.com Academic Press 84 Theobald's Road, London WC1X 8RR, UK http://www.academicpress.com Library of Congress Catalog Card Number: 2003107900 International Standard Book Number: 0-12-286551-0 PRINTED IN THE UNITED STATES OF AMERICA 03 04 05 06 07 7 6 5 4 3 2 1
Table of Contents
Contributors xi Foreword xv Preface xvii
1. Structure of Growth Plate and Bone Matrix WILLIAM G. COLE
Introduction 1 Type I Collagen 1 Type V Collagen 6 Type II Collagen 8 Type IX Collagen 10 Type XI Collagen 11 Type X Collagen 14 Aggrecan 16 Cartilage Link Protein 1 16 Small, Leucine-Rich, Interstitial Proteoglycans Perlecan 20 Matrilins 21 Thrombospondins 22 Osteonectin 23 Osteocalcin 24 Matrix Gla Protein 25 Bone Sialoprotein 25 Bone Acidic Glycoprotein-75 26 Dentin Matrix Acidic Phosphoprotein-1 26 Osteopontin 26 References 27
Osteoprogenitor Cells and Regulation of Osteoblast Differentiation and Activity 50 Regulation of Osteoblast Differentiation and Activity 54 Osteocytes 58 Morphological Features of Osteoclasts 59 Mechanisms of Osteoclastic Bone Resorption 60 Origin of Osteoclasts 61 Regulation of Ostoclast Activity and Differentiation 61 Osteoclast Size: Multinucleation and Function 63 Stem Cell, Osteoblast, and Osteoclast Changes in Disease 63 Tissue Engineering and Stem Cell Therapy for Skeletal Diseases 64 References 65
17 3. P r e n a t a l B o n e D e v e l o p m e n t : O n t o g e n y and Regulation BENOITST-JACQUESANDJILLA. HELMS Introduction 77 Skeletogenesis 78 Skeletal Organization and Embryonic Origin of Bones 82 Molecular Regulation of Bone Formation 96 References 104
4. Postnatal B o n e Growth: Growth Plate 2. B o n e Cell Biology: O s t e o b l a s t s , O s t e o c y t e s , and O s t e o c l a s t s JANEE.AUBINANDJOHANN. M. HEERSCHE Introduction 43 Ontogeny of Osteoblasts and Control of Osteoblast Development 44
Biology, Modeling, and Remodeling GERARD KARSENTYAND HENRY M. KRONENBERG
Endochondral and Intramembranous Bone Formation 119 Growth Hormone and Insulin-Like Growth Factor- 1 121
vi
Table of Contents
Fibroblast Growth Factors 122 Thyroid Hormone 124 Estrogen and Androgen 124 Osteoblasts and Bone G r o w t h 124 Endocrine Regulation of Bone Formation References 130
References
9. P e a k B o n e M a s s a n d Its R e g u l a t i o n JEAN-PHILIPPEBONJOUR,THIERRYCHEVALLEY,SERGEFERRARI, AND RENF.RIZZOLI
126
5. P a r a t h y r o i d H o r m o n e a n d C a l c i u m Homeostasis GORDON J. STEWLER
Cellular and Extracellular Calcium Homeostasis Parathyroids and Secretion and Metabolism of Parathyroid Hormone 139 Assay of PTH 147 Parathyroid Hormone Action 148 References 160
135
6. P h o s p h a t e H o m e o s t a s i s R e g u l a t o r y Mechanisms JOSEPH CAVERZASIO, HEINI MURER, AND HARRIET S. TENENHOUSE
Introduction 173 Physiological Aspects 173 Cellular and Molecular Aspects 178 Pathophysiological Aspects 181 References 187
Definition and Importance of Peak Bone Mass 235 Characteristics of Peak Bone Mass Acquisition 235 Calcium-Phosphate Metabolism During Growth 236 Determinants of Bone Mass Gain 238 Conclusions 242 References 243
10. P r e g n a n c y a n d L a c t a t i o n ANN PRENTICE
Introduction 249 Mineral Fluxes from Mother to Offspring Pregnancy 250 Lactation 255 Summary 264 References 264
249
1 1. Fetal M i n e r a l H o m e o s t a s i s CHRISTOPHER S. KOVACS
7. Vitamin D Biology RENEST-ARNAUDANDMARIEB. DEMAY Metabolic Activation of Vitamin D 193 Mechanism of Action 198 Role of Vitamin D in Calcium Homeostasis Summary and Perspectives 208 References 209
201
8. O t h e r Factors C o n t r o l l i n g B o n e G r o w t h a n d D e v e l o p m e n t " C a l c i t o n i n , CGRP, O s t e o s t a t i n , Amylin, a n d A d r e n o m e d u l l i n JILLIANCORNISHANDTHOMASJOHNMARTIN Introduction 217 Calcitonin 217 Calcitonin Gene-Related Peptide 220 Parathyroid Hormone-Related Protein Amylin 225 Adrenomedullin 228
229
Fetal Adaptive Goals 271 Placental Calcium Transport 280 Placental Transport of Magnesium and Phosphate 288 Fetal Parathyroids 288 Calcium-Sensing Receptor 289 Thymus 290 Fetal Kidneys and Amniotic Fluid 290 Fetal Skeleton 291 Maternal Skeleton 292 Fetal Response to Maternal Hyperparathyroidism 293 Fetal Response to Maternal Hypoparathyroidism 293 Integrated Fetal Calcium Homeostasis 293 References 296
12. N o n i n v a s i v e T e c h n i q u e s for B o n e M a s s Measurement STEFANO MORA, LAURA BACHRACH, AND VINCENTE GILSANZ
223
Indications for Bone Mass Measurements 303 Challenges to Interpreting Bone Mass Measurements in Childhood and Adolescence 303 Noninvasive Measurement Techniques 304
~176
Table of Contents
Data Interpretation References 319
316
1 3. A s s e s s m e n t of M a t u r a t i o n " B o n e A g e a n d Pubertal Assessment NO[L CAMERON
Background 325 Initial Considerations 325 Methods of Assessment 329 Reliability 333 Comparability of the Atlas and Bone-Specific Methods 333 Secondary Sexual Development 334 References 337
14. B i o c h e m i c a l M a r k e r s o f B o n e Metabolism ECKHARDSCHONAUAND FRANKRAUCH
Introduction 339 Markers of Bone Formation 341 Markers of Bone Resorption 342 Bone Markers During Normal Development 344 Puberty 346 Bone and Collagen Markers in Metabolic Bone Diseases 346 Clinical and Research Value of Biochemical Markers of Bone Metabolism 352 References 353
15. B o n e H i s t o m o r p h o m e t r y FRANK RAUCH
Introduction 359 Methodology 359 Pediatric Bone Histomorphometry in Health and Disease 366 Indications for Bone Biopsy and Histomorphometry in Pediatric Bone Diseases 372 References 373 16. A D i a g n o s t i c A p p r o a c h t o S k e l e t a l Dysplasias SHEILA UNGER, ANDREA SUPERTI-FURGA, AND DAVID L. RIMOIN
Introduction 375 Background 375
VII
History and Physical Examination 376 Diagnostic Imaging 389 Biochemical Investigations 393 Cartilage Histology 395 Molecular Basis 396 Prenatal Detection of Suspected Skeletal Dysplasia 397 Conclusion 398 References 398
1 7. T h e S p e c t r u m of P e d i a t r i c Osteoporosis LEANNE M. WARD AND FRANCIS H. GLORIEUX
Abstract 401 Introduction 401 Definition and Diagnosis of Osteopenia/Osteoporosis in Pediatric Patients 401 The Role of the Mechanostat in the Pathogenesis of Pediatric Osteoporosis 403 The Scope of the Problem 405 Approach to Prevention and Intervention 426 Differentiating Child Abuse from Bone Fragility Conditions 428 Summary and Future Directions 430 References 431
18. O s t e o g e n e s i s I m p e r f e c t a HORACIAO PLOTKIN, DRAGAN PRIMORAC, AND DAVID ROWE
Introduction 443 Classification 444 Types of OI 445 Differential Diagnosis 449 General Clinical Findings 450 Pathophysiology 453 Therapy 457 References 463
19. S c l e r o s i n g B o n y D y s p l a s i a L. LYNDONKEY,JR.,AND WILLIAML. RIES
Introduction 473 Defects in Osteoclastic Bone Resorption 473 Skeletal Abnormalities Related to Overproduction of Bone: Involvement of Transforming Growth Factors 478 Summary 480 References 481
viii
Table of Contents
20. Parathyroid Disorders MURAT BASTEPE, HARALD JUPPNER, AND RAJESH V THAKKER
Introduction 485 PTH Gene Structure and Function 485 Hypocalcemic Disorders 488 Hypercalcemic Diseases 496 Conclusion 501 References 502
2 1 . Fibrous Dysplasia PAOLO BIANCO, PAMELA GEHRON ROBEY, AND SHLOMO WIENTROUB
Introduction 509 Clinical Features 510 Molecular Genetics 516 Determinants of Phenotypic Variability 518 Pathology 520 Pathogenesis 526 Management and Treatment 530 References 533
22. Nutritional Rickets JOHN M. PETTIFOR
Introduction 541 Definition of Rickets 541 Classification of Rickets 542 Nutritional Rickets 542 References 560
23.Metabolic Bone Disease of Prematurity NICK BISHOP AND MARY FEWTRELL
Introduction 567 In Utero Mineral Accretion and Bone Growth 567 Physiological Changes in Mineral Homeostasis at Birth 568 Metabolic Bone Disease 569 Skeletal Health in Preterm Infants 572 Suggested Guidelines for the Prevention of Metabolic Bone Disease in Preterm Infants 578 Conclusions 579 References 579
24. Rickets Due to Hereditary Abnormalities of Vitamin D Synthesis or Action ANTHONYA. PORTALE AND WALTER L. MILLER
Introduction
583
Biosynthesis of Vitamin D 583 Vitamin D Biosynthetic Enzymes 584 Vitamin D 25-Hydroxylase and 24-Hydroxylase 584 Vitamin D la-Hydroxylase 584 Rickets Due to Abnormalities of Vitamin D Metabolism 585 Rickets Due to Abnormalities of Vitamin D Action 592 References 598
25. Familial Hypophosphatemia and Related Disorders INGRID A. HOLM, MICHAEL J. ECONS. AND THOMAS 0. CARPENTER
Introduction 603 Clinical Description of Disease Entities 603 Treatment 613 Family/Genetic Studies 616 Molecules, Pathophysiology, and Lessons from Animal Models 617 Current Problems and Unresolved Questions 623 References 624
26. Rickets Due to Renal Tubular
Abnormalities RUSSELL W. CHESNEY AND DEBORAH I? IONES
Introduction 633 Fanconi Syndrome 633 Renal Magnesium Wasting 640 Hypercalciuria 642 Renal Tubular Acidosis 644 Conclusion 647 References 647
27. Hypophosphatasia DAVID E. C. COLE
Biology of Alkaline Phosphatase 651 Clinical Hypophosphatasia 661 References 672
28. Renal Osteodystrophy: Pathogenesis, Diagnosis, and Treatment BEATRIZ D. KUIZON AND ISIDRO B. SALUSKY
Introduction 679 The Spectrum of Renal Osteodystrophy 679 Pathogenesis of Renal Osteodystrophy 682
Table of Contents Clinical Manifestations 685 Biochemical Determinations 686 Histologic Manifestations 687 Radiographic Features of Renal Osteodystrophy 689 Long-Term Consequences 690 Treatment 691 References 695
2 9 . B o n e T u m o r s in C h i l d r e n MARCH. ISLERAND ROBERTE. TURCOTTE Introduction 703 General Principles of Treatement 703 Diagnosis 704 Classification and Nomenclature 706
ix
Back Pain and Spinal Neoplasms in Children 707 Fibrous Tumors of Bone 709 Cartilage-Forming Tumors 713 Bone-Forming Tumors 722 Hematopoietic 730 Vascular 731 Neurogenic 733 Adipose 734 Mixed 734 Notochord 735 Tumor-Like 735 Conclusion 740 References 740
Index
745
This Page Intentionally Left Blank
Contributors
Russell W. Chesney (633) University of Tennessee Health Science Center, Deparment of Pediatrics, Memphis, Tennessee 38103
Numbers in parentheses indicate the pages on which the authors' contribution begin.
Jane E. Aubin (43) Department of Medical Genetics and Microbiology, Faculty of Medicine, Toronto, Ontario M5S 1A8, Canada
Thierry Chevalley (235) Department of Internal Medicine, Division of Bone Diseases, World Health Organization Collaboration Center for Osteoporosis and Bone Diseases, University Hospital, CH 1211 Geneva, Switzerland
Laura Baehraeh (303) Division of Endocrinology, Stanford University School of Medicine, Stanford, California 94305
David E. C. Cole (651) Departments of Laboratory Medicine and Pathobiology, Medicine, and Genetics, University of Toronto, Toronto, Ontario MSG 1X8, Canada
Murat Bastepe (485) Endocrine Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston Massachusetts 02115
William G. Cole (1) Division of Orthopaedics and Research Institute, The Hospital for Sick Children, University of Toronto, Toronto, Ontario MSG 1X8, Canada
Paolo Bianeo (509) Department of Experimental Medicine and Pathology, La Sapienza University School of Medicine, 00161 Rome, Italy Nick Bishop (567) Academic Unit of Child Health, University of Sheffield, Sheffield Children's Hospital, Western Bank, Sheffield S10 2TH, United Kingdom
Jillian Cornish (217) Department of Medicine, University of Auckland, Auckland 1020, New Zealand Marie B. Demay (193) Endocrine Unit, Massachusetts General Hospital, Harvard Medical School, Boston Massachusetts 02114
Jean-Philippe Bonjour (235) Department of Internal Medicine, Division of Bone Diseases, World Health Organization Collaborating Center for Osteoporosis and Bone Diseases, University Hospital, CH 1211 Geneva, Switzerland
Michael J. Econs (603) Indiana University School of Medicine, Indianapolis, Indiana 46202 Serge Ferrari (235) Department of Internal Medicine, Division of Bone Diseases, Worlth Health Organization Collaboration Center for Osteoporosis and Bone Diseases, University Hospital, CH 1211 Geneva, Switzerland
Noel Cameron (325) Human Biology Research Centre, Department of Human Sciences, Loughborough University, Loughborough, Leicestershire LEll 3TU, United Kingdom Thomas O. Carpenter (603) Yale University School of Medicine, New Haven, Conneticut 06510
Mary Fewtrell (567) MRC Childhood Nutrition Research Center, Institute of Child Health, London WC 1N 1EH, United Kingdom
Joseph Caverzasio (173) Division of Bone Diseases, Department of Internal Medicine, University Hospital of Geneva, CH-1211 Geneva, Switzerland
Vicente Gilsanz (303) Department of Radiology, Children's Hospital Los Angeles, University of Southern
xi
~176
Xll
Contributors
California School of Medicine, Los Angeles, California 90027 Francis H. Glorieux (401) Departments of Surgery, Pediatrics and Human Genetics, McGill University and the Shriners Hospital for Children, Montreal, Quebec, Canada H3A 2T5
Jill A. Helms (77) Department of Orthopedic Surgery, University of California San Francisco, San Francisco, California 94143-0514 Johan N. M. Herschel (43) Dental Research Institute, Faculty of Dentistry, University of Toronto, Toronto, Ontario M5S 1A8, Canada lngrid A. Holm (603) Harvard Medical School, Boston Massachusetts 02115
Mare H. Isler (703) University of Montreal, Department of Orthopedic Oncology, Hopital Maisonneuve Rosemont and Hopital Sainte Justine, Montreal, Quebec, Canada H 1T 2M4 Deborah P. Jones (633) University of Tennessee Health Science Center, Deparment of Pediatrics, and Children's Foundation Research Center at Le Bonheur Children's Medical Center, Memphis, Tennessee 38103 Harald Jiippner (485) Endocrine Unit, Department of Medicine and Pediatrics, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02115 G6rard Karsenty (119) Department of Molecular and Human Genetics, Baylor College of Medicine, Houston Texas 77030
L. Lyndon Key, Jr. (473) Department of Pediatrics, Medical University of South Carolina, Charleston, South Carolina 29425 Christopher S. Kovacs (271) Faculty of Medicine, Endocrinology, Memorial University of Newfoundland, Health Sciences Centre, St. John's Newfoundland A1B 3V6, Canada Henry M. Kronenberg (119) Endocrine Unit, Massachusetts General Hospital, Boston, Massachusetts 02114 Beatriz D. Kuizon (679) Department of Pediatrics, UCLA School of Medicine, Los Angeles, California 90095 Thomas John Martin (217) St. Vincent's Institute of Medical Research, Melbourne, Victoria, Australia Walter L. Miller (583) Department of Pediatrics, University of California San Francisco, San Francisco, California 94143
Stefano Mora (303) Laboratory of Pediatric Endocrinology, Scientific Institute H San Raffaele, 20132 Milan, Italy Heini Murer (173) Institute of Physiology, University of Zurich, CH-8057 Zurich, Switzerland John M. Pettifor (541) MRC Mineral Metabolism Research Unit, Department of Pediatrics, University of the Witwatersrand and Chris Hani Baragwanath Hospital, Johannesburg, South Africa Horaeio Plotkin (443) Inherited Metabolic Diseases Section, Department of Pediatrics, University of Nebraska Medical Center and Children's Hospital, Omaha, Nebraska 98198 Anthony A. Portale (583) Department of Pediatrics, University of California San Francisco, San Francisco, California 94143 Ann Prentice (249) Medical Research Council Human Nutrition Research, Elsie Widdowson Laboratory, Cambridge CB 1 9NL, United Kingdom Dragan Primorae (443) Laboratory of Clinical and Forensic Genetics, Split University Hospital and School of Medicine, Split, Croatia Frank Raueh (339, 359) Genetics Unit, Shriners Hospital for Children, Montreal, Quebec H3G 1A6, Canada
William L. Ries (473) Department of Pediatrics, Medical University of South Carolina, Charleston, South Carolina 29425 David L. Rimoin (375) Medical Genetics Birth Defects Center, Cedars-Sinai Health System and Department of Pediatrics and Medicine, UCLA School of Medicine, Los Angeles, California 90048 Ren6 Rizzoli (235) Department of Internal Medicine, Division of Bone Diseases, Worlth Health Organization Collaboration Center for Osteoporosis and Bone Diseases, University Hospital, CH 1211 Geneva, Switzerland Pamela Gehron Robey (509) Craniofacial and Skeletal Diseases Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland 20892 David Rowe (443) Department of Genetics and Developmental Biology, University of Connecticut Health Center, Farmington, Conneticut 06030
lsidro B. Salusky (679) Department of Pediatrics, UCLA School of Medicine, Los Angeles, California 90095 Eckllard Sch6nau (339) Children's Hospital and Health Center, University of K61n, 50924 K61n, Germany
Contributors
xiii
Ren~ St-Arnaud (193) Genetics Unit, Shriners Hospital for Children, Montreal, Quebec H3G 1A6 Canada and Departments of Surgery and Human Genetics, McGill University, Montreal, Quebec H3A 2T5 Canada
Rajesh V. Thakker (485) Molecular Endocrinology Group, Nuttfield Department of Medicine, John Radcliffe Hospital Headington, Oxford OX3 9DU, United Kingdom
Benoit St-Jacques (77) Department of Human Genetics,
Robert E. Turcotte (703) University of Montreal and
McGill University and Genetics Unit, Shriners Hospital for Children, Montreal, Quebec H3G 1A6, Canada
McGill University, Department of Orthopedic Oncology, Hopital Maisonneuve Rosemont, Montreal, Quebec, Canada H 1T 2M4
Gordon J. Strewler (135) Walter Bradford Cannon Soci-
Sheila Unger (375) Division of Clinical and Metabolic
ety, Harvard Medical School, Boston, Massachusetts 02115
Genetics, Hospital for Sick Children, University of Toronto, Toronto, Canada M5G 1 X8
Andrea Superti-Furga (375) University of Lausanne, Div-
Leanne M. Ward (401) Department of Pediatrics, Div-
ision of Molecular Pediatrics, Centre Hospitalier Universitaire Vaudois, CH- 1011 Lausanne, Switzerland
ision of Endocrinology and Metabolism, University of Ottawa and the Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada K1H 8L1
Harriet S. Tenenhouse (173) Departments of Pediatrics
and Human Genetics, McGill University, Montreal Children's Hospital Research Institute, Montreal, Quebec H3Z 2Z3 Canada
Shlomo Wientroub (509) Department of Pediatric Orthopedic Surgery, Dana Children's Hospital, Tel Aviv Medical School, 64239 Tel Aviv, Isreal
This Page Intentionally Left Blank
Foreword
Harold Harrison's contributions to our understanding of pediatric bone disease (4). Chapters in the book, each one written by an authoritative member of the corresponding "academy," address particular topics, such as the cellular architecture of bone itself, how it develops, and how it remodels. The vast complexity of calcium and phosphate ion metabolism, and the complexity of their hormonal controls and of the corresponding nutritional dimensions are subjects of other chapters. There are chapters that describe how to measure the features of bone, and there are tables of mutations that point to online databases and the locus specific alleles that are causes of certain bone diseases. A series of twelve chapters address diseases of bone development (skeletal dysplasias), of bone density (osteoporosis), of tensile strength (osteogenetics imperfecta) and remodeling (osteopetrosis). Aberrations of hormonal control and ion homeostasis, are discussed. Acquired diseases of bone (e.g. tumors and renal osteodystrophy) are not forgotten. More important still, the patient with the problem is not forgotten. Between the covers of this book, there is a great deal of information from which the scientist and the clinician can acquire knowledge. More important the reader will gain wisdom about the precious skeleton of youthful Homo sapiens.
The human skeleton is a product of biological evolution; it accommodates an upright bipedal organism. It is still imperfect for the job it must do; there are speculations on how the human skeleton might be improved (1). Meantime, Homo sapiens has what it has. The healthy human skeleton and the organic matrices of which it is made are mysterious and wonderful structures. In the fetus, they are pliable and miniature, they accommodate both fetal growth and development and also the trauma of passage through the maternal pelvis. The infant's skeleton must then grow enormously in volume and span, remodeling itself all the while until adult dimensions are achieved. At the same time, it must be resisting the continuous action of gravity, while maintaining its integrity under physical trauma, on average for 8 decades! A truly mysterious and marvelous structure. This book, which reflects the vision of its outstanding editors, addresses the biology of bone, and the diseases that interfere with its structure and function. Industrialized societies of the northern hemisphere witnessed childhood rickets in epidemic proportions during the 19 th and early 20 th century. Rickets was an important pediatric disease. Then came the discovery of the anti-rachitic factor (vitamin D); awareness of the origins and importance of vitamin D, combined with improvements in living conditions, led to the virtual disappearance of nutritional infantile rickets, leaving the much rarer intrinsic biological forms of rickets to be recognized--the inherited forms of calcium or phosphate dishomeostasis. The first such report appeared in 1937 (2). It heralded the search for, and eventually the molecular definition of, heritable forms of rickets, and of metabolic and organic bone diseases in general in human societies (3). In the past half century, there has been an impressive growth of knowledge about cellular, ionic, organic, and hormonal aspects of bone metabolism, and of the diseases that interfere with the processes of development, growth, remodeling, and mineralization of bone. This book is a record of that understanding at the present time. It is the first of its kind, to my knowledge, to follow an earlier book honoring Helen and
(1)
Olshansky, S. J., Carnes, B. A., Butler, R. N. If humans were built to last. Sci. Am. 284:50-55, 2001.
(2)
Albright, F., Butler, A. M., Bloomberg, E. Rickets resistant to vitamin D therapy. Am. J. Dis. Child 54:529-547, 1937
(3) Scriver, C. R., Tenenhouse, H. S. On the heritability of rickets, a common disease (Mendel, Mammals and Phosphate). Johns Hopkins Med. J. 149:179-187, 1981. (4)
DeLuca H. F., Anast C. S. Pediatric Diseases Related to Calcium. Elsevier. New York. 1980. Charles R. Scriver, M D C M Montreal Children's Hospital, Canada
XV
This Page Intentionally Left Blank
Preface
The description and investigation of bone diseases both in adults and in children have been, for a long time, part of the realms of Endocrinology, Nephrology, Rheumatology and also Orthopedics and Medical Genetics. In the past three decades, as new knowledge and technology rapidly developed, bone biology and its related diseases progressively became a well identified domain in medicine. Thus was published a series of important books in adult medicine dealing with the following: metabolic bone disease, diseases of connective tissue, osteoporosis (a field in itself), and bone biology. In some of these textbooks, chapters dealing with pediatric bone disease have been included. However, not since the book by Maroteaux (1) was published in 1974 in French, which contains a unique collection of radiographs, and not since the Proceedings of a Symposium held in 1980 to celebrate the careers of Harold and Helen Harrison (2), has there been a book attempting to integrate basic knowledge and clinical facts as they concern pediatric bone disease. When we started drawing up the outline for this book, we decided that its usefulness would be greatly enhanced by first providing detailed descriptions of the basic concepts underlying the development, structure, and homeostatic control of bone tissue. We also wanted to provide descriptions of the tools and methodologies now validated for the precise evaluation of most of the disturbances of bone and mineral metabolism in children. Thus the book opens with chapters on the structure of the growth plate and the bone matrix, bone cell biology, mineral ion homeostasis and prenatal and postnatal bone growth. This is followed by the descriptions of how to assess bone maturation by measuring biochemical bone markers in blood and urine, and of the unique information provided by bone histomorphometry. The next part comprises fourteen chapters discussing specific disorders, or groups of disorders, including basic and clinical aspects.
We hope that the book will be useful both to researchers interested in learning about the clinical expression of the biological processes they study at the bench, and to the practitioners who wish to better understand the molecular and genetic intricacies of the conditions they evaluate and treat in the clinical setting. We wish to express our gratitude to Tari Paschall and Jasna Markovac at Academic Press for their understanding and support. We also thank all of the contributors for their willingness to be a part of this large effort. Finally we hope that the summation of knowledge and observations under one single heading will give substance to the concept of "pediatric osteology," which has become an entity of its own and may need to be recognized as a speciality in itself. As such, it may become an important and exciting career opportunity for some of our younger colleagues. (1) Maroteaux, P. (1974). Les maladies osseuses de l'Enfant. Flammarion M6decine-Sciences, Paris. (2) DeLuca, H. F., and Anast, C. E. (Eds.) (1980). Pediatric Diseases Related to Calcium. Elsevier, North Holland, New York, NY. Francis H. Glorieux Harald W. Jueppner John M. Pettifor
m
XVII ~176
This Page Intentionally Left Blank
C
H
A
P
T
E
R
1 Structure of Growth Plate and Bone Matrix WILLIAM G. COLE Division of Orthopaedics and the Research Institute, The Hospital for Sick Children, and University of Toronto, Toronto, Ontario, Canada
INTRODUCTION This chapter focuses on the main macromolecules of the extracellular matrices of the growth plates and bone. These diverse macromolecules often perform critical biomechanical, physiological, and biochemical functions. The hyaline cartilage growth plates are highly organized structures responsible for the elongation of bones by endochondral ossification. The cellular events are described in detail in subsequent chapters. Hydrated hyaline cartilages contain approximately 65-80% water, 10-20% collagen, 4-7% aggrecan, and <5% other proteoglycans, collagens, glycoproteins, and lipids [1]. The highly hydrophilic nature of aggrecan and other proteoglycans, and less so collagen, accounts for the high level of hydration of cartilage. Approximately 20-30% by weight of bone is organic, 10% is water, and the remainder is mineral [2]. The organic matrix contains approximately 90% collagen and 10% noncollagenous proteins, proteoglycans, and lipids. Plasma proteins are also represented in the organic matrix. Many of the plasma proteins are present within the blood vessels of bone but have little or no affinity for bone, whereas others such as OLz-HS glycoprotein have a higher affinity for the mineralized bone matrix. A description of the primary structure, synthesis, and assembly of the major macromolecules of hyaline cartilage growth plates and bone follows. Some of the macromolecules are specific for one or the other of these tissues and many are found in both. The bone collagens are described first, followed by the cartilage collagens, cartilage aggregating and nonaggregating proteoglycans, cartilage glycoproteins, and a group of noncollagenous proteins of bone. Some macromolecules are not
PediatricBone
discussed, including the microfibrillar proteins, such as type VI collagen and the fibrillins, as well as fibronectin, type XII collagen, and the lipoproteins.Details concerning the latter macromolecules as well as other macromolecules of the extracellular matrix and further details about the described macromolecules can be found online at the National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov/), National Library of Medicine, National Institutes of Health.
TYPE i COLLAGEN Type I collagen, the most abundant protein of bone, is also present in periosteum, perichondrium, ligaments, tendons, annulus fibrosus, menisci, dermis, sclera, dentin, fascia, and the adventitial layers of viscera [3,4]. It is one of the fibrillar collagens. The characteristic feature of the fibrillar collagens is that they contain a long, continuous triple helix that assembles into highly organized collagen fibrils [5]. The fibrils have high tensile strength, which is critical for the function of bone and other tissues. Each molecule of type I collagen is composed of two OLl(I) chains and one oL2(I) chain [5]. A small number of molecules contain three OLl(I) chains. The importance of type I collagen in normal development is highlighted by the phenotypes that result from the homozygous or heterozygous loss of the OLl(I) chains. Homozygous loss in the Mov 13 mouse, in which the OLl(I) gene is inactivated by insertional mutagenesis, results in a prenatal lethal phenotype because of the lack of type I collagen in the tissues [6]. Heterozygous loss of one aa(I) allele, either in the Mov 13 mouse or in humans, yields the osteogenesis imperfecta type IA phenotype [7]. Copyright 2003, Elsevier Science (USA). All rights reserved.
2
William G. Cole
The Otl(I) and ot2(I) chains are encoded by the COL1A1 and COL1A2 genes, respectively. The COL1A1 gene is located on chromosome 17q21.3-q22 and the COL1A2 gene on chromosome 7q21.3-q22 [8,9]. Both genes have a similar structure, but because exons 33 and 34 are fused in COL1A1, the COL1A1 gene contains 51 exons, whereas the COL1A2 gene contain 52 exons [10,11]. The differences of 18 kb for COL1A1 and 38 kb for COL1A2 are due to differences in the sizes of their introns. For the pre-pro-oL2(I) chain, the signal peptide is encoded by part of exon 1; the N-propeptide is encoded by part of exon 1, exons 2-5, and part of the junctional exon 6; the N-telopeptide is encoded by part of exon 6; the triple helix is encoded by part of exon 6, exons 7-48, and part of the junctional exon 49; the C-telopeptide is encoded by part of exon 49; the C-propeptide is encoded by part of exon 49 and exons 50-52 [5,10]. The same arrangement exists for the pre-pro-oLl(I) chain, except that the exon numbering is reduced by one beyond exons 33 and 34, which are fused in COL1A1 [5]. The exons encoding the main triple helix of the two chains have similar sizes [9]. Each exon encodes complete Gly-X-Y triplets, where X and Y are often proline so that they commence with a codon for Gly and end with a codon for Y. All exons encoding the triple-helical domain are 45,54,99,108, or 162, base pairs (bps). It is likely that 54 bp was the ancestral exon size. The 108- and 162-bp exons arise from loss on introns. The 45- and 99-bp exons result from recombinations between two 54-bp exons [12]. The pre-pro-otl(I) chain contains 1464 amino acid residues [5,10]. It contains a signal peptide of 22 residues, a N-propeptide of 139 residues, a N-nonhelical telopeptide of 17 residues, a main triple helix of 1014 residues, a C-nonhelical telopeptide of 26 residues, and a C-propeptide of 246 residues. The mature tissue form of the OLl(I) chain contains 1057 residues, including the main triple helix and the N- and C-telopeptides. The N-propeptide begins with a globular domain of 86 residues, including a von Willebrand type C repeat and 10 cysteine residues. It is followed by a triple-helical domain of 48 amino acids and a short globular domain. The procollagen N-proteinase cleavage site is at the Pro161-Gln162 bond, numbered from the start of the signal peptide. Allysine cross-linking sites are located at residues 170 and 1208. There are two hydroxylysines that can be glycosylated at residues 265 and 1108. The mammalian collagenase cleavage site is at the Gly 953Ile 954 bond. Proline residue 1164 may be 3-hydroxylated. There are two potential R G D cell attachment sites at residues 745-747 and 1093-1095. Procollagen C-proteinase cleaves at Alal21S-Asp 1219. The globular C-propeptide contains 4 cysteine residues at positions 1259,1265,1282, and 1291 that are involved in interchain
disulfide bonding [13]. It also contains cysteine residues that are involved in intrachain disulfide bonding between residues 1299 and1462 and between residues 1370 and 1415. There is also a putative Asn 1365 site for attachment of an N-linked oligosaccharide. The pre-pro-oL2(I) chain is shorter than the prepro-oLl(I)chain, although the main triple-helical domains are the same size [11,14]. The pre-pro-ot2(I) chain has a signal peptide of 22 amino acid residues, an N-propeptide of 57 residues, an N-nonhelical telopeptide of 11 residues, a main helical domain of 1014 residues, a C-terminal nonhelical telopeptide of 15 residues, and a globular C-propeptide of 247 residues. The very short globular domain of the N-propeptide contains only 2 cysteine residues. It is followed by a triple-helical domain of 42 residues and a second short globular domain. Procollagen N-proteinase cleaves at the Asn Y9-Glns~ bond. Lysine residues 177 and 1023 are potential sites for hydroxylation and glycosylation. There are potential cell attachment sites at R G D sequences at positions 777-779,822-824, and 1005-1007. The procollagen C-proteinase cleavage site is at the Ala 1119_Asp1120 bond. Three sites for interchain disulfide bonds are at residues 1163, 1186, and 1195. Intrachain disulfide bonds may form between cysteine residues at positions 1203 and 1364 and between cysteine residues at positions 1272 and 1317. There is a potential N-linked oligosaccharide attachment site at A s n 1267. The structures of the C-propeptide of human type III procollagen and the C-telopeptides of type I collagen have been described [15,16]. The structures of the C-propeptides of types I and III procollagen are likely homologous. In contrast to the elongated structure of the C-terminal triple-helical region and the C-telopeptide the C-propeptide has a low-resolution structure composed of three large lobes and one small lobe [16]. This structure is readily interpretable in terms of the subunit composition and known positions of interand intrachain disulfide bonds. Among the eight cysteines found in the C-propeptide domains of type III procollagen, cysteines 1-4 are involved in interchain disulfide bonding, whereas cysteines 5-8 form intrachain disulfide bonds [17]. Consequently, it is likely that the three large lobes correspond to the intrachain disulfide bonded region of each of the three polypeptide chains, whereas the small lobe corresponds to the junction region containing the interchain disulfide bonds and linking to the rest of the procollagen chain. Such an arrangement would place the chain-recognition region at the core of the structure, well positioned to determine the specificity of chain-chain interactions [16]. The C-telopeptide of type I collagen had a hairpin conformation, with the C terminus folded back onto the triple helix [15].
1. Structure of Growth Plate and Bone Matrix
After being transcribed, the pre-mRNA for the prepro-oLl(I) and pre-pro-cx2(I) chains undergoes exon splicing, capping, and the addition of a polyA tail, which gives rise to mature mRNAs. The mRNAs are translated in polysomes bound to the rough endoplasmic reticulum [18]. Formation of the triple-helical heterotrimeric type I procollagen molecule requires the synthesis of the constituent pro-oLl(I) and pro-oL2(I) chains from their distinct mRNAs. Transfer to the Golgi apparatus and movement into the secretory pathway require completion of both posttranslational modifications and triple helix formation. The [pro-oLl(I)]2[pro-oL2(I)] heterotrimer is the major product, whereas stable [proOtl(I)]3 homotrimer is formed in only small amounts. A [pro-otl(I)][pro-ot2(I)]2 heterotrimer or a [pro-oL2(I)]3 homotrimer have not been detected in cell cultures or tissues. Efficient type I procollagen heterotrimeric assembly appears to require that the elongating nascent pro-~l(I) and pro-ot2(I) chains be inserted into the same compartments of the rough endoplasmic reticulum and that a mechanism for chain selection be operational within the compartment. Coordinated expression of the COL1A1 and COL1A2 genes is one way of ensuring that the appropriate 2:1 ratios of the protein chains are available for the assembly of heterotrimers [19-21]. However, the ratios of the pro-oLl(I):pro-oL2(I) mRNAs vary widely, even though the resultant heterotrimers maintain the protein chain ratio of 2:1 [22]. Consequently, chain selection probably plays an important role in molecular assembly [23]. In support of the latter proposal, distinct chain recognition sequences of 15 amino acid residues have been identified within the C-propeptides of the type I procollagen chains [24]. The interactions between the C-propeptides that lead to registration of nascent pro-oLl(I) chains occur while the chains are still associated with polysomes [25-27]. Nascent collagen chains are translated on complex polyribosomal aggregates associated with more than one strand of mRNA. Consequently, it is likely that the organization of the m R N A translocons is a critical factor in molecular assembly [18]. Elongation pauses are also a prominent feature of synthesis of pro-oLl(I) and pro-oL2(I) chains [28]. There also appears to be an interaction between the translation complexes for the synthesis of the two chain types [23]. These interactions may serve two purposes: to bring the translation complexes to the same regions of the endoplasmic reticular membrane to ensure the colocalization of the nascent chains for interaction and to regulate or coordinate the rates of synthesis of the two pro-oL chains. In many systems producing type I collagen, the pro-e~l(I):pro-a2(I) ratio is greater than 2:1 [29]. In such situations, it is likely that all of the pro-~2(I) m R N A is engaged in heterotrimer synthesis,
3
whereas the excess pro-~xl(I) chains may either produce [pro-o~l(I)]3 trimer or be degraded [30]. The signal peptides are removed as the nascent chains enter the rough endoplasmic reticulum. Both procollagen chains undergo hydroxylation and glycosylation of specific residues as a prerequisite for the formation of a stable triple-helical heterotrimer. Many of these enzymatic modifications occur as cotranslational events. Approximately 100 proline residues in the Y position of Gly-X-Y repeats undergo 4-hydroxylation by prolyl 4-hydroxylase. A few proline residues in the X position undergo 3-hydroxylation by prolyl 3-hydroxylase. A variable number of lysine residues, also in the Y position, may undergo lysyl hydroxylation by lysyl hydroxylase. Hydroxylation of proline residues to hydroxyproline is critical for the formation of a stable triple helix. The hydroxylases require the procollagen chains to be in a nascent state and various cofactors need to be present, such as ferrous ions, molecular oxygen, oL-ketoglutarate, and ascorbate [31]. Prolyly 4-hydroxylase, also called procollagen proline 2 oxoglutarate 4-dioxygenase, is a tetramer consisting of two oL and two [3 subunits with a molecular weightof 240 kDa. The [3 subunit is also known as protein disulfide isomerase. The gene for the [3 subunit, P4HB, is located on chromosome 17q25 [32]. The gene is expressed ubiquitously. There are two ot subunits whose genes are named P4HA1 and P4HA2 [33]. The P4HA1 gene is located on chromosome 10q21.3-23.1 [34], and the P4HA2 gene is located on chromosome 5q31 [33]. The mRNAs encoded by P4HA1 and P4HA2 are expressed ubiquitously, although the ratios of the mRNAs vary between tissues. There are twoe~(I) subunit m R N A isoforms that result from mutually exclusive alternative splicing of exons 9 or 10 of P4HA1 [35]. Tetramers containing either two oL(I)/two [3 subunits or two oL1(II)/ two [3 subunits have similar enzyme activities [33]. Coexpression of recombinant P4HA1, P4HA2, and P4HB in insect cells did not show any tetramers that contained both P4HA1 and P4HA2 protein chains [36]. There appear to be at least four lysyl hydroxylases. The enzyme is also called procollagen-lysine 2 oxoglutarate 5-dioxygenease. Lysyl hydroxylase 1, a 85-kDa membrane-bound homodimeric protein, is localized to the cisternae of the rough endoplasmic reticulum [37]. It hydroxylates specific lysine residues in X-Lys-Gly sequences. Its gene, PLOD, is located on chromosome l p36.3-p36.2 [37]. It is expressed in the skeleton and in many other tissues. Lysyl hydroxylase 2 is encoded by PLOD2, which is located on chromosome 3q23-q24 [38]. It also forms homodimers. It is highly expressed in nonskeletal tissues [39]. Lysyl hydroxylase 3 is encoded by PLOD3, which is located on chromosome 7q36 [40,41]. It is also expressed mostly in nonskeletal tissues. There is
4
William G. Cole
also a putative telopeptide lysyl hydroxylase that is specific for bone. The gene called either B R K S or T L H 1 is predicted to be located on chromosome 17p12 [42]. When lysyl residues become hydroxylated, they may serve as a substrate for a glycosyltransferase and for a galactosyltransferase, which add glucose and galactose, respectively, to the hydroxyl group. These modifications also require the chains to be in the nascent state. Increased levels of glycosylation tend to reduce the size of the collagen fibrils presumably due to interference with packing of the molecules. A mannose-rich oligosaccharide may also attach to an asparagine residue in the C-propetide. Chaperones play an important role in the assembly of procollagens in the rough endoplasmic reticulum. Protein disulfide isomerase, which has both enzymatic and chaperone functions, interacts transiently with procollagen chains early in the procollagen assembly pathway [43,44]. Release of prolyl 4-hydroxylase, including its [3 subunit protein disulfide isomerase, from the triplehelical domain coincides with the assembly of thermally stable triple-0helical molecules. However, if triple helix formation is prevented, prolyl 4-hydroxylase remains associated with the triple-helical domain, suggesting a role for the enzyme in preventing aggregation of this domain. Protein disulfide isomerase is also able to independently associate with the C-propeptide of monomeric procollagen chains prior to trimer formation, indicating a role for this isomerease in coordinating the assembly of heterotrimeric molecules [43]. It is also able to catalyze disulfide bond formation within and between the C-propeptides. Hsp47 is a heat shock protein that resides in the endoplasmic reticulum [45]. It interacts transiently with procollagen during its folding, assembly, and transport from the endoplasmic reticulum of mammalian cells. It has been suggested to carry out a diverse range of functions, such as acting as a molecular chaperone facilitating the folding and assembly of procollagen molecules, retaining unfolded molecules within the endoplasmic reticulum, and assisting the transport of correctly folded molecules from the endoplamic reticulum to the Golgi apparatus. The association of Hsp47 with procollagen coincides with the formation of a collagen triple helix. The importance of Hsp47 in normal type I collagen biosynthesis is highlighted by the phenotype of mice lacking the heat shock protein [45]. The homozygous mice did not live longer than 11.5 days, and their tissues were deficient in collagen fibrils. The findings indicated that type I collagen was unable to form a rigid triplehelical structure without the assistance of Hsp47 and that Hsp47 was essential for normal development. The C-propeptides undergo registration and stabilization by the formation of interchain and intrachain disulfide bonds in the rough endoplasmic reticulum.
The formation of the disulfide bonds is catalyzed by the enzyme protein disulfide isomerase, which is also the [3 subunit ofprolyl 4-hydroxylase. This process is critical for the correct alignment of the main triple-helical domain because the helix winds up from the C terminus. Triple helix formation is initiated in the rough endoplasmic reticulum immediately after the synthesis of the pro-oL chains and after the formation of the interchain disulfide bonds within the C-propeptide [46,47]. It is likely that formation of the triple helix is a posttranslational event because the production of triple-helical molecules requires approximately 8 or 9 min after completion of the synthesis of the pro-oL chains. The helix propagates from a single C-terminal nucleation site toward the N terminus and is interrupted by the random occurrence of peptide bonds in the cis configuration. The C-propeptide and C-telopeptide do not appear to play a role in nucleation of triple helix formation [48]. However, a minimum of two hydroxyproline-containing Gly-X-Y triplets at the C-terminal end of the triple helix are required for nucleation to occur [48]. Direct nuclear magnetic resonance measurements of chick calvarial collagen showed that approximately 16% of the X-Pro and 8% of X-Hyp bonds were cis in the unfolded collagen [49]. Studies by Sarkar et al. and many others have shown that the rate-limiting step in the zipper-like propagation of the helix is the process of cis-trans isomerization [46,47,49,50]. Peptidyl prolyl cis-trans isomerase catalyzes the cis-trans isomerization of X-Pro peptide bonds in collagen [51]. Protein disulfide isomerase is also present in the rough endoplasmic reticulum. However, protein disulfide isomerase does not appear to act as a cis-trans isomerase [51]. Full hydroxylation of proline residues in the Y position of Gly-X-Y triplets also enhances the rate of propagation of the triple helix from the site of nucleation to the N terminus [52]. Biophysical studies using model collagen peptides have also shown that the folding of Gly-X-Y peptides is best described as an all-or-none third-order reaction [53-55]. The formation of the triple helix occurs in the rough endoplasmic reticulum. The type I procollagen molecules move to the Golgi apparatus, where oligosaccharides may be added to a C-propeptide asparagine residue. The molecules are secreted from the cell, during which or soon after the Nand C-propeptides are rapidly cleaved. The N-propeptide is specifically cleaved by procollagen 1 N-endoproteinase. The enzyme is encoded by the A D A M T S 2 gene, which is an abbreviation for a disintegrin-like and metalloproteinase with thrombospondin type I motif [56]. The enzyme exists in a long and a short form as a result of alternative splicing [57]. The C-propeptide is cleaved by procollagen C-endoproteinase, which is the same as bone morphogenetic protein-1 (BMP-1) [58]. The gene is located on
1. Structure of Growth Plate and Bone Matrix
chromosome 8q21 [59]. Procollagen C-endoproteinase is a secreted, neutral zinc metalloproteinase. The Drosophila equivalent gene is called tolloid (TLD). There are two isoforms of the human enzyme as a result of alternative splicing [60]. The long form appears to be an inactive proenzyme that can be activated by removal of the prodomain. There are four mammalian BMP-1/TLD-like proteases [61]. One of them, tolloid-like-1 (TLL1), is also an astracin-like metalloproteinase. Its gene, TLL1, is located on chromosome 4q32-q33 [61]. The activity of procollagen C-endoproteinase is enhanced by procollagen C-endopeptidase enhancer, which is a glycoprotein that binds to the C-propeptide and enhances the activity of the C-proteinase enzyme [62]. Its gene, PCOLCE, is located on chromosome 7q21.3-q22 approximately 6 Mb from the COL1A2 gene that encodes pro-oL2(I) chains of type I procollagen [63]. A second procollagen C-endopeptidase enhancer has been isolated. Its gene, PCOLCE2, is located on chromosome 3q21-q24 [64]. A number of functions have been proposed for the released ~l(I) N-propeptide, including prevention of premature intracellular molecular association, facilitation of transcellular transport and secretion, regulation of extracellular fibrillogenesis, and feedback regulation of procollagen synthesis [65]. However, there is little evidence to support these proposals. For example, deletion of exon 2 of collal in mice, which deleted the 65-amino acid cysteine-rich globular domain of the N-propeptide of pro-e~a(I) chains, did not produce any demonstrable anomalies in type I collagen biosynthesis, collagen cross-linking, or collagen fibrillogenesis [65]. Following removal of the N- and C-propeptides, the type I collagen molecules can self-assemble, cross-link, undergo further growth, and pack into thick collagen fibers. The nucleation steps that initiate the formation of collagen fibrils may commence within crypts on cell surfaces [66,67]. Various biophysical studies as well as rotary shadowing electron microscopy have shown that type I collagen monomers are rod-like structures with a length of approximately 300nm and a diameter of approximately 1.4nm. The overall helical symmetry is lefthanded, with 10 residues in three turns and a pitch of approximately 3 nm. The three helical chains are further coiled about a central axis to form a right-handed helix with a repeat distance of approximately 10nm [68, 69]. The high content of glycine and its occurrence in every third residue of the triple-helical domain give rise to a polymer of tripeptide units with the formula (-Gly-X-Y-)n. Glycine is the smallest amino acid; as such, it is the only amino acid that can pack tightly at the center of the triple-stranded collagen fibril monomers. The side chains of amino acids in the remaining - X - and -Y-positions protrude from the chain, and this arrange-
5
ment allows a variety of amino acid residues to be accommodated in the molecule. The high amino acid content, particularly the high 4-hydroxyproline content, has a stabilizing effect on the triple-helical structure. In type I collagen, the triple-helical configuration occurs throughout 95% of the rod-like monomer. The N- and C-telopeptides do not contain glycine residues at every third position. The long triple-helical domain not only provides the molecule with the stability required for its biomechanical functions but also makes it resistant to enzymatic cleavage apart from specific peptide bonds that can be cleaved by mammalian collagenases. The collagen monomers are able to undergo spontaneous self-assembly into fibrils. The fibrils are crossstriated as a result of the assembly of molecules in a parallel array but with a stagger of approximately onequarter of their length. The periodicity of the crossstriated fibril is a result of each monomer having five highly charged regions at approximately 67-nm intervals. The repeat period, called a D period, is approximately 67 nm in length and contains 234 amino acids. The overall length of the collagen fibril monomer is 4.4 D units, which also corresponds to 300 nm. Because of the nonintegral length of the monomers, overlapping by D divides the fibril into overlap zones that include the N and C termini of the molecules and gap zones that do not. The quarter-stagger arrangement of the collagen molecules provides the appropriate substrate conformation for the action of lysyl oxidase. The enzyme, which is a copper-dependent amine oxidase, requires molecular oxygen for activity. It acts on specific lysine and hydroxylysine residues to produce the corresponding aldehydes that are required for the formation of covalent collagen cross-linkages. The enzyme, which is also called proteinlysine 6 oxidase, is encoded by LOX, which is located on chromosome 5q23.3-q31.2 [70]. Alternative splicing produces three m R N A isoforms [70]. There are also two lysyl oxidase-like loci. LOXL1 is located on chromosome 15q22 and LOXL2 on chromosome 8p21-p21.2 [71,72]. The lysine aldehyde pathway occurs primarily in adult dermis, cornea, and sclera, whereas the hydroxylysine aldehyde pathway predominates in bone, ligaments, tendons, and embyronic dermis. The first step in both pathways is the oxidative deamination of the e-amino group in telopeptide lysine and hydroxylysine residues to form their corresponding aldehydes, called allysine and hydroxyallysine, respectively. In the lysine aldehyde pathway, two allysines may condense to form the aldol condensation product, which forms intramolecular bonds. Aldimine cross-links are formed when allysine in the telopeptides reacts with lysine or hydroxylysine residues in adjacent helices to provide covalent intermolecular cross-linkages. In the hydroxylsine aldehyde pathway, hydroxyallysine can condense with an
6
William G. Cole
hydroxylysine residue to form a reducible cross-link that can undergo an Amadori rearrangement to form hydroxylysino-5-oxo-norleucine. The hydroxylyinsederived aldimine cross-links can also occur as galactosyl or glucosylgalactosyl derivatives. In the hydroxylysine aldehyde pathway, the major mature cross-link is based on trivalent 3-hydroxypyrididinium residues [73]. It includes hydroxylysyl-pyridinoline, derived from three hydroxylysine residues, and lysyl-pyridinoline, derived from two hydroxylysine residues and one lysine residue. These two cross-links are naturally fluorescent and can be assayed directly in tissue hydrosylates as well as in blood and urine. The formation of collagen fibrils has been studied extensively. Of particular interest are in vitro studies that use intact procollagen as well as procollagen lacking either the N-propeptide (pC) or C-propeptide (pN) with fibril formation initiated by the addition of specific N- and C-proteases [74,75]. This approach leads to the formation of fibril-like structures with the characteristic collagen D-periodic banding pattern but with a distinctive, bipolar needle-like morphology that is different from that of fibrils isolated from native tissue [67,75]. These fibril structures show a single polarity reversal where the orientation of the collagen is reversed with amino termini at both ends of the fibrils [75]. Newly formed fibrils with characteristic D periodicity have been isolated from various embyronic tissues [76]. These fibrils also frequently show a single polarity reversal [77]. Fibrils may increase in size by the fusion of small (1-10 ~m) segments, and the lateral association of long or short fibrils may lead to thicker fibrils [76,78]. The growth of type I collagen fibrils appears to be partly regulated by other collagen molecules that are included within the heterotypic fibers [79]. For example, other collagens in the heterotypic type I collagen fibrils of dermis include types III, V, XII, and possibly XIV collagen [80]. In bone, the other collagens are type V and type V/XI hybrid molecules [81]. It is likely in these various types of heterotypic type I collagen fibrils that the N-propeptides that remain attached to the collagens, other than type I collagen, play a role in regulating the growth of the fibrils [80]. A number of other molecules, including the small leucine-rich proteoglycans such as decorin, fibromodulin, lumican, as well as hyaluronan, also appear to regulate the growth of fibrils [82]. The molecular packing of collagen fibrils has been determined mainly in tissues such as tendon. X-ray diffraction studies indicate the presence of threedimensional crytallinity admixed with liquid-like lateral order [83,84]. The lateral unit cell, which contains five molecules in cross section, gives rise to row lines with a maximum spacing of 3.8 nm. Electron microscopy of a transverse section of tendon fibrils reveals a similar
periodicity (~4 nm) orientated radially with respect to the fibril center. A feature of the model is that molecules are tilted obliquely in a plane orientated 30 ~ to the fibril surface [84], which results in the helicoidal organization of collagen fibrils. An additional feature of the model is that the fibril surface is coated in molecular ends, which has important consequences for fibril growth. For example, the persistence of the N-propeptides of types III, V, or XI collagen might prevent their incorporation into the center of the fibril, thereby forcing all N termini to the surface of the fibril, with prevention of further accretion and limiting fibril diameter [83]. An alternative molecular packing model is the fivestranded Smith microfibril [84]. The microfibril, with a diameter of approximately 4 nm, is the minimum filamentous structure that possesses an axial D repeat. Although their existence is still debated, evidence indicates that they do exist [83]. Three-dimensional image reconstructions of 25-nm diameter collagen fibrils show evidence of a 4-nm repeat in transverse section, which might correspond to ordered arrays of microfibrils, particularly at the level of gap-overlap junctions. Bone and other connective tissues have distinctive collagen fiber sizes and distinctive suprafibrillar architectures, as seen by polarized light microscopy [85]. In woven bone, the collagen fibrils are randomly distributed. Lamellar bone contains collagen fibrils that are arranged in parallel layers or sheets running in different directions. Bone osteons have a lamellar structure in which the lamellae are arranged in concentric cylinders. TYPE V COLLAGEN Type V collagen was first identified in human placenta and dermis, but later studies showed that it is widely expressed in type I collagen-containing tissues including bone [86,87]. The type V collagen molecules exist as heterotrimers Otl(V)2ot2(V) or Otl(V)otz(V)ot3(V ) and as homotrimers ~1(V)3 [88,89]. An apparently distinct cx4(V) chain is synthesized by Schwann cells [90]. Type V collagen chains also form heterotypic molecules with type XI collagen chains. For example, the highly homologous OLl(V) and oLI(XI) chains may yield an oL1(V)oLI(XI)oL2(V) trimer in bone and cartilage [81]. The following description of type V collagen is limited to the Otl(V ) and ot2(V ) chains because the oL3(V)and 0/.4(7 ) genes are not expressed in bone or cartilage, although the e~3(V) gene is expressed in ligament attachments to bone [91]. The gene for the oLI(V) chain, COL5A1, is located on chromosome 9q34.2-q34.3 [92]. The gene has 66 exons, more than the number of exons in types I and II collagen. Exon 1 encodes the signal peptide of 36 amino acid residues and one base of the N-propeptide. Exons 2-14
1. Structure of Growth Plate and Bone Matrix
encode the remainder of the N-propeptide, with exon 14 being a junctional exon that encodes the end of the N-propeptide and the beginning of the triple-helical domain. The N-propeptide contains 505 amino acid residues and the N-telopeptide contains 17 residues. The pro-eta(V) N-propeptide is similar in size and domain structure to the N-propeptides of the pro-etl(XI) and pro-etz(XI) chains [93-95]. The N-propeptides of the latter three chains all contain a very large globular domain, immediately downstream of the signal peptide, that is much larger than and has no apparent homology to the cysteine-rich globular domains of the types I-III collagen. The globular domains of the pro-etl(V), proetl(XI), and pro-etz(XI) chains are bisected by a cluster of two cysteines into a basic N-terminal subdomain and a C-terminal subdomain rich in acidic residues and tyrosines [93-96]. The latter region contains 27 tyrosine residues and 73% of the total number of tyrosine residues in the pre-pro-~l(V) chain. Approximately 40% of the N-propeptide tyrosine residues are sulfated [97]. The N-terminal subdomain is analogous to the thrombospondin 1 motif and is identical to the proline- and arginine-rich peptide (PARP) motif [98]. The derived three-dimensional structure of PARP suggests a conserved nine [3-stranded structure [99,100]. The PARP motif is also present in the N-propeptides of the proetl(XI) and pro-etz(XI) chains but not in the pro-etz(V) chains. The globular domain of the N-propeptide of the pro-etl(V) chain is followed by an interrupted triple-helical domain of 25 Gly-X-Y repeats and then another short noncollagenous region prior to the main triple-helical domain. Pro-etl(V), pro-etl(XI), and proetz(XI) sequences share similarities in all subdomains of their N-propeptides, with the exception of the acidic globular variable region [94]. There is no evidence of alternative splicing in the N-propeptide of pro-etl(V) chains, although it occurs in the pro-etl(XI) and proetz(XI) N-propeptides [93]. There are two hypothetical N-proteinase cleavage sites (Ala-Gln) at positions 541-542 and 546-547. The main triple-helical domain of etl(V) chains is similar to those of types I-III collagens in that each nonjunctional exon begins with a complete codon for glycine and ends with a complete codon for a residue in the Y position of Gly-X-Y triplets [92,101]. The codons are commonly 45 or 54 bps. The main triple-helical domain is encoded by exons 14-62 [92]. These exons encode a main triple-helical domain of 1014 amino acid residues. Lysine residues at positions 642 and 1482, which are important for intermolecular cross-linkages, are preserved. The helical domain lacks the Gly-Ile/Leu mammalian cleavage site at position 775-776 of types I-III collagens [102]. The absence of this sequence explains the lack of cleavage of the otl(V) chains by mammalian collagenase.
7
Carboxyl terminal of the main triple helix is the C-telopeptide of 33 amino acid residues and the C-propeptide of 233 residues. They are encoded by exons 62-66. The putative C-proteinase cleavage site is located at position 1605-1606 (Ala-Asp). The C-propeptide has a high homology with the same region of pro-eta(XI) chains. Seven cysteine residues and their vicinities are conserved. The pro-et chains that can form homotrimers or both homo- and heterotrimers of pro-et chains have 8 cysteine residues, but the pro-et chains that form heterotrimers only have 7 cysteine residues [12]. The C-propeptide of pro-etl(V) chains has 8 cysteine residues, whereas the C-propeptide of the pro-etl(XI) chains has 7 cysteine residues [103]. The pro-etl(V) chain contains numerous sites for potential attachment of N-linked oligosaccharides. It has a heparin binding site at residues 897-929 [104]. Heparin binding sites are also present in a l(XI) and etz(XI) chains but not etz(g) chains [105]. Binding of chondroitin sulfate E to type V collagen may facilitate cell binding and matrix assembly [106]. There are RGD cell attachment sites at positions 645-647 and 663-665. The gene for the etz(V) chain, COL5A2, resides on chromosome 2q14-q32 [107,108]. The gene, which spans approximately 67 kb, is located in a tail-to-tail orientation with the COL3A1 gene. The intergenic distance is approximately 22 kb. The two genes contain 51 exons and share almost identical structures. The pro-etz(V) N-propeptide is encoded by 4 complete exons and partially by the junctional exon. It encodes a pre-pro-etz(V) chain of 1496 amino acid residues [109,110], and it includes a signal peptide of 26 residues. The N-propeptide of 167 residues includes an amino-terminal globular subdomain of 82 residues, in which there is a von Willibrand type C-like repeat. This subdomain contains a central cluster of 10 cysteine residues flanked on both sides by short, hydrophilic sequences. It is similar to the equivalent subdomain of the N-propeptide of pro-etl(I) chains but dissimilar to the equivalent subdomain of the pro-etl(V) chain [101,111]. The N-propeptide also includes an interrupted helical subdomain of 78 residues and a nonhelical subdomain of 7 residues. The N-proteinase cleavage site is at the Asn-Gln bond at position 193-194 of the full-length chain. The N-telopeptide contains 15 residues, including the lysine cross-linking site at residue 175. The main triple-helical domain contains 1017 residues and is followed by a C-telopeptide of 26 residues and a C-propeptide of 246 residues. The C-proteinase cleavage site is located at the Gly-Asp bond at position 1250-1251. There are seven R G D sequences that are potential cell binding sites. There are several sites for the attachment of N-linked oligosaccarides. Also, there are 3 cysteine residues, at positions 1293, 1299, and 1325, for intermolecular
8
William G. Cole
cross-linking and sites for intrachain disulfide cross-links at positions 1333-1494 and 1402-1447. In contrast to type I procollagen processing, in which the N- and C-propeptides are rapidly cleaved following secretion, type V procollagen molecules retain their N-propeptides. A variety of type V collagen molecules retaining all or parts of the N-propeptides have been extracted from tissues and from tissue culture medium [99,112,113]. Rotary shadowing confirmed the retention of the N-propeptides on some of the type V collagen molecules extracted from tissues [114]. Nonetheless, within pro-e~l(V)zpro-c~z(V) heterotrimers, some proOtl(V) N-propeptides and pro-oLz(V) C-propeptides are enzymatically removed by bone morphogenetic proteinl-like enzymes. PrO-al(V) C-propeptides are processed by furin-like proprotein convertases in vivo [115]. When type V collagen epitopes are unmasked in tissues, this collagen is found to colocalize with type I collagen [116]. The exact spatial relationship between these collagens in the type I collagen fibrils is unclear. However, copolymeric assembly is likely because crosslinkages between types I and V collagens have been isolated from bone [117]. It is also likely that type V collagen regulates the formation of the type I collagen fibrils [118]. Type V collagen molecules are capable of forming homotypic fibrils in vitro with or without an apparent 67-nm cross-striation pattern [119]. Increasing the quantity of type V collagen relative to type I collagen decreased the final fibril diameter [120]. It has been proposed that the retained N-propeptides of type V collagen molecules protrude from the surface of the type I collagen fibrils, where they regulate the growth of the fibrils [79,120]. Confirmation of the importance of the aminoterminal extension of the e~z(V) chain was provided by the phenotype of mice in which the col5a2 gene was engineered to lack exon 6, which normally encodes the N-telopeptide of Cxz(V) chains. The mice showed abnormal type I collagen fibrillogenesis in the dermis [121]. Although type V collagen, with the exception of its N-propeptides, is buried with the type I collagen fibrils, its main triple-helical domain is known to bind to thrombospondin, heparin, heparan sulfate, decorin, and biglycan [104,122-125]. Type V collagen contains seven R G D sequences on the OL2(V) and two on the OLI(V) chains that may enable type V collagen to attach to various cell types. These interactions may involve the OLl[31and az[31integrins [126].
TYPE II COLLAGEN Type II collagen is the main fibrillar collagen of growth plate cartilage and other cartilages. It is also
found in the vitreous humor, intervertebral disks, and inner ear [127]. Its importance is clearly evident from the severe lethal chondrodysplastic phenotype in mice that lack type II collagen [128,129]. There is gross disorganization of the cartilages with abnormal architecture of the chondrocytes and extracellular matrix. There is ectopic expression of types I and III collagens in the cartilage. The skeleton demonstrates membranous and periosteal bone but no endochondral ossification [128]. Type II collagen exists in two molecular forms. The first form is a homotrimeric type II collagen, [OLl(II)]3, which is largely found as the main component of the thickest collagen fibrils of cartilage. The second form is a component of heterotrimeric type XI collagen with a chain composition [txl(XI)oL2(XI)ota(XI)], in which the Ota(XI) chains are an overhydroxylated form of OLl(II) chain [130]. Type XI collagen is described separately. Type II collagen is encoded by the COL2A1 gene on chromosome 12ql 3.11-q 13.2 [127,131]. The gene structure and cDNA sequence show that COL2A1 and COL1A1 are homologous genes, even thought their expression patterns and molecular chain compositions are different [132,133]. Many aspects of type II collagen biosynthesis are the same as those described for type I collagen. Consequently, the following account of type II collagen biosynthesis focuses on specific differences between the biosynthesis of the two collagens. The COL2A1 gene contains 53 exons and encodes two alternatively spliced mRNAs and protein isoforms, referred to as type IIA and type IIB collagens [131,134,135]. Type IIA collagen is the long form, which includes a 69-amino acid cysteine-rich region of the N-propeptide that is encoded by exon 2 [134]. Type IIB collagen lacks the exon 2-encoded sequence [133]. The full-length or type IIA form of the protein has 1487 amino acid residues. It includes a signal peptide of 25 amino acid residues, an N-propeptide of 156 residues, an N-telopeptide of 19 residues, a main triple-helical domain of 1014 residues, a C-telopeptide of 27 residues, and a C-propeptide of 246 residues [133,134]. There are allysine cross-linking precursor residues at positions 190 and 1231, which are within the N- and C-telopeptides, respectively. The N-proteinase cleavage site to remove the N-propeptide is at the Ala-Gln bond 181-182. Potential sites for the hydroxylation and glycosylation of lysine residues are present at positions 287 and 1130. The mammalian collagenase cleavage site is at the Gly-Ile bond at position 834-835. Proline 1186 can be 3-hydroxylated. The C-proteinase cleavage site is at the Ala-Asp bond 1241-1242. Interchain disulfide bonds utilize the cysteine residues at positions 1283, 1289,1306, and 1315. Intrachain disulfide bonds occur between cysteine pairs 1323-1485 and 1393-1438. There is a putative Asn 1388 N-linked oligosaccharide attachment
1. Structure of Growth Plate and Bone Matrix
site. The short type IIB form of the protein contains 1418 amino acid residues due to the loss of the 69 residues encoded by exon 2 [133,134]. The type IIB isoform, lacking exon 2-encoded sequences, is the adult form of the protein that is found as the predominant isoform in the growth plates, other cartilages, vitreous humor, and the inner ear. The type IIA isoform, containing the exon 2-encoded sequence of 69 amino acid residues and rich in cysteine residues, appears to play an important role in the normal development of skeletal and nonskeletal tissues. Many studies have shown that the type IIA isoform is expressed in prechondrocytes, whereas the type IIB form is expressed by chondrocytes. During elongation of the growth plate, mature chondrocytes express the type IIB isoform and then differentiate into hypertrophic chondrocytes and initiate expression of type X collagen. In contrast, notochordal remnants and the inner annulus fibrosus of the vertebral column continue to express the type IIA isoform. However, processing of the N-propeptide of the type IIA isoform appears to be developmentally regulated in the latter tissues. In early fetal development, the N-propeptide remains attached to the main protein chain, whereas in later fetal development the N-propeptide is cleaved. In other prechondrogenic tissues, however, the N-propeptide appears to remain attached to the main type II collagen chain. In solid phase assays, transforming growth factor-j31 (TGF-[31) and BMP-2 bound to the type IIA isoform but not to the type IIB isoform. Antibodies to BMP-2 also immunoprecipitated the type IIA isoform from tissue culture medium. Consequently, the role of the cysteine-rich domain of the N-propeptide in development may, at least in part, be due to its ability to regulate the availability of specific growth factors. The removal of the N- and C-propeptides of types I and II collagens occurs by similar mechanisms. Cleavage of the N-propeptides involves the procollagen N-proteinase ADAMTS2, and cleavage of the C-propeptides involved the procollagen C-endopeptidase BMP-1 and.the procollagen C-endopeptidase enhancer [57,58,62]. Other studies indicate, however, that many other cleavage enzymes and other cleavage sites may be involved in the processing of type II procollagen. Studies of the processing of the N-propeptides of fibrillar procollagens in cattle lacking ADAMTS2 activity showed that the N-propeptides of type I procollagen in the skin were not processed, whereas the N-propeptides of type II procollagen in cartilage were processed normally [136]. The possible existence of other ADAMTS enzymes in cartilage, as an explanation for the latter findings, was investigated in Swarm rat chondrosarcoma RCS-LTC cells, which fail to process the N-propeptides of type II procollagen. Stable transfections of the cells with bovine A D A M T S 2 or human A D A M T S 3 cDNAs partially rescued the
9
processing defect. Normal human skin and skin fibroblasts showed 30-fold higher mRNA levels of ADAMTS2 than A D A M T S 3 . In contrast, A D A M T S 3 mRNA levels were 5-fold higher than A D A M T S 2 mRNA levels in normal human cartilage. Taken together, these findings explain the lack of N-propeptide processing of type I procollagen in skin and the normal processing of type II procollagen in cartilage in animals lacking ADAMTS2 activity. Because ADAMTS3 is normally more abundant that ADAMTS2 in cartilage, it is likely that ADAMTS3 is the physiologically more important enzyme [136]. Some matrix metalloproteinases (MMPs) are also able to cleave at various sites in the N-propeptides and N-telopeptides of type II procollagen [137]. Recombinant trimeric type IIA N-propeptides were exposed to MMP- 1-3, 7-9, - 13, and - 14 [138]. MMP-1, -2, and -8 did not show cleavage, whereas MMP-3, -7, -9,-13, and -14 cleaved at the procollagen N-proteinase cleavage site and in the N-telopeptide. All of the latter enzymes cleaved in domains common to both type IIA and type IIB procollagen, whereas MMP-7 a n d - 1 3 also cleaved in the type II-specific minor helix and MMP-7 cleaved in the type IIA-specific cysteine-rich domain. MMP-7 was also able to remove the N-propeptides from collagen fibrils in the extracellular matrix of fetal cartilage. These findings indicate that some of the MMPs may play an in vivo role in the processing of the N-propeptides of type II procollagen. MMP-3,-9, and -14 are expressed during the early stages of cartilage development. MMP-9 and -13 appear to play a role in the cartilage- to-bone transition in the growth plate. MMP-14 is also expressed in hypertrophic chondrocytes. Cleavage of the N-propeptides and N-telopeptides is likely to contribute to the normal processing and turnover of type II procollagen. In addition, release of the N-propeptides from the type IIA isoform is likely to provide growth factors such as TGF-[31 and BMP-2. The C-propeptide is found in high concentrations in all cartilages including the growth plate [139]. It was initially isolated as a calcium-binding protein from developing growth plate cartilage, particularly from the lower hypertrophic zone. Amino acid sequencing showed that the protein, which was called chondrocalcin, was the C-propeptide of type II procollagen [140]. The main triple-helical domain of type II collagen is susceptible to cleavage by mammalian collagenases at the Gly-Ile bond at position 834-835. The released fragments are readily degraded to small peptides [141]. This finding is in contrast to the resistance of native types IX and XI collagens, isolated from hyaline cartilage, to digestion with mammalian collagenase [141,142]. This observation also applies to the oL3(XI) chain of type XI collagen, which is an overglycosylated form of oLI(II) chain.
10
William G. Cole
Following removal of the N- and C-propeptides, the OLl(II) chains self-assemble, like type I collagen chains, into a quarter-staggered array. Lysyl oxidase-derived cross-linkages form to stabilize the intramolecular and intermolecular interactions. The native molecular packing of type II collagen differs from that of type I collagen [143]. Low-angle X-ray diffraction studies showed that in wet, native type II collagen, the molecules are spaced farther apart than in type I collagen under the same conditions. The type II collagen fibrils are more hydrated than type I collagen fibrils. The additional hydration may enable cartilage to better dissipate compressive loads. The higher content of glycosylated hydroxylysine residues in the type II collagen is likely the main factor modulating the fibrillar hydration. There is considerable variation in the diameter of the collagen fibrils in growth plate and hyaline cartilages. They vary from fine fibrils of approximately 25 nm in fetal cartilage and in parts of the growth plate to fibrils of approximately 30-200 nm in other parts of the growth plate and in articular cartilages [144]. The thin fibrils contain types II, IX, and XI collagens, whereas the large fibrils contain mainly types II and IX collagens. It is likely that the amount of type XI collagens as well as the small leucine-repeat proteoglycans influences the diameters of the heterotypic type II collagen fibrils [144]. Type II collagen fibrils are strengthened by covalent intermolecular bonds provided by 3-hydroxypyridinium cross-linking residues [145]. Purification and sequencing of the cross-linkages identified two hydroxypyridinium cross-linking sites within the triple-helical region of the type II collagen molecule. They were placed symmetrically at opposite ends at residues 87 and 930 of the al(II) chains, where telopeptide aldehydes are known to react to form the initial "head-to-tail" intermolecular bonds. The cross-linkages between type II collagen and other types of collagen in the heterotypic type II collagen fibrils of cartilage are described later.
TYPE IX COLLAGEN Type IX collagen, which belongs to a group of fibrilassociated collagens with interrupted helices (FACIT), is a component of hyaline cartilages, intervertebral disks, vitreous humor, and the inner ear [146]. In these locations it is associated with types II and XI collagens. The type IX collagen molecule is a heterotrimer consisting of three genetically distinct chains, ~I(IX)-c~3(IX), and possesses three collagenous domains, numbered COL 1-COL3 from the C terminus, flanked by four noncollagenous domains, NC1-NC4 [147]. Type IX collagen
is also a proteoglycan because of a glycosaminoglycan side chain covalently attached to the NC3 domain of the et2(IX) chain [148]. The Ul(IX) chain is encoded by the COL9A1 gene located on chromosome 6q12-q14 [149-151]. Three FACIT collagen genes, COL9A1, COL12A1, and COL19A1, are located close together on chromosome 6q12-q13 [152]. The COL9A1 gene is approximately 90kb and contains 38 exons [151]. It encodes two alternatively spliced m R N A and protein isoforms referred to as a long form of 931 amino acid residues and a short form of 688 residues [153]. The long form or isoform 1 contains a signal peptide of 23 amino acid residues, an NC4 domain of 245 residues, a COL3 domain of 137 residues, an NC3 domain of 12 residues, a COL2 domain of 339 residues, an NC2 domain of 30 residues, a COL1 domain of 115 residues, and an NC1 domain of 30 residues. The overall size of the mature chain is 908 residues. There are 4 cysteine residues in the NC4 domain at positions 44,198,242, and 252. There are also 2 cysteine residues in the NC3 domain at positions 411 and 415. There is a putative N-linked oligosaccharide attachment site at A s n 171 in the NC4 domain. The NC4 domain has a calculated isoelectric point of 9.7. The short form of Otl(IX) or isoform 2 contains an NC4 domain, including the signal peptide, of 25 amino acid residues in comparison with the equivalent region of the long isoform that contains 268 residues [153]. The remainder of the amino acid sequences of the long and short isoforms are the same. The long transcript contains the 5' region encoded by exons 1-7 spliced to exon 8. The short transcript contains the 5' region encoded by an alternative exon 1" located in the intron between exons 6 and 7 and spliced to exon 8 [151,153]. The Otz(IX ) chain is encoded by the COL9A2 gene located on chromosome lp33-p32.2 [151,154,155]. The gene is approximately 15 kb and contains 32 exons [151]. There is one transcript that encodes a full-length protein of 689 amino acid residues and a mature protein of 666 residues [154]. The protein contains a signal peptide of 23 amino acid residues, an NC4 domain of 3 residues, a COL3 domain of 137 residues, an NC3 domain of 10 residues, a COL2 domain of 339 residues, an NC2 domain of 31 residues, a COL1 domain of 115 residues, and an NC1 domain of 25 residues. The glycosaminoglycan attached to Ser 169 is in the sequence Gly-Ser-Ala-Asp within the NC3 domain. Direct analyses of type IX collagen extracted from cartilages have shown that up to 70% of the molecules contain a chondroitin sulfate glycosaminoglycan side chain attached to Ser 169 [156]. There are 4 cysteine residues--2 at residues 174 and 178 of the NC3 domain and 2 at residues 664 and 669 of the NC1 domain.
1. Structure of Growth Plate and Bone Matrix
The c~3(IX) chain is encoded by COL9A3, which is located on chromosome 20q13.3 [157,158]. The gene is approximately 23 kb and contains 32 exons [157]. It encodes a single protein chain containing 684 amino acid residues [159]. The full-length ot3(IX) chain contains a signal peptide of 25 amino acid residues and a mature protein chain of 657 residues. The mature chain contains an NC4 domain of 3 amino acid residues, a COL3 domain of 137 residues, an NC3 domain of 15 residues, a COL2 domain of 339 residues, an NC2 domain of 31 residues, a COL1 domain of 112 residues, and an NC1 domain of 22 residues [159]. The domain and exon organization of COL9A3 is almost identical to that of COL9A2. However, exon 2 of the COL9A3 gene codes for one Gly-X-Y triplet less than exon 2 of COL9A2. The difference is compensated for by an insertion of 9bps coding for an additional triplet in exon 4 of COL9A3. As a result, the number of Gly-X-Y triplets in the COL3 domain is the same in both protein chains and consequently the triple helix is in register. However, the COL1 domain of the ot3(IX) chain is one triplet shorter than the corresponding domain in oLI(IX) and Otz(IX) chains. It is likely that the NC2 domain can accommodate this difference so that the register is maintained correctly for the formation of the triple helix involving the COL2 domains. Although there are many possible chain combinations for the formation of type IX collagen, the molecules extracted from the medium of cultured cells and from tissues appear to be limited to disulfide-bonded molecules containing o~I(IX)oLz(IX)oL3(IX) [146,147]. Studies of the molecular assembly of type IX collagen using recombinant chains confirm that otl(IX)oLz(IX)ot3(IX) is the favored heterotrimer. However, the chains are also able to form disulfide-bonded heterotrimers of oLI(IX) and oL3(IX ) chains as well as OLl(IX)3 , OLz(IX)3, and oL3(IX)3 homotrimers [160]. The information required for chain selection and assembly is present in the NC1 domain and the adjoining region of the COL1 domain of the type IX collagen chains. When this region of type IX collagen was prepared from tissues reduced and denatured, three types of disulfide-bonded molecules formed: Otl(IX)3, Otz(IX)3, and OLI(IX)oL2(IX)oL3(IX)[161]. Rotary shadowing electron microscopy has shown that the type IX collagen molecule is approximately 190 nm long with a globular N-terminal end representing the large NC4 domain of the C~l(IX) chain [146]. The molecule also shows a characteristic kink located at the NC3 domain. Disulfide bonds and the glycosaminoglycan side chain are also located at the NC3 domain, and additional disulfide bonds are located at the junction of the NC1 and COL1 domains. Although the heterotypic type II collagen fibrils in cartilages vary considerably in diameter, fibrils of all diameters show type IX collagen
11
distributed along their outer surfaces in a D-periodic pattern [146]. The amount of type IX collagen on individual type II collagen fibrils varies considerably and does not appear to correlate with the diameter of the fibrils. This latter finding is consistent with the observation that purified type IX collagen did not inhibit formation of large fibril-like structures formed by type II collagen in reconstitution experiments in vitro [146]. Therefore, it appears unlikely that type IX collagen, in contrast to type XI collagen, directly controls the lateral growth of the heterotypic type II collagen fibrils. The latter proposal is also consistent with findings in cell lines and mice lacking oLI(IX) chains of type IX collagen. In both instances, type IX collagen molecules did not form, although the COL9A2 and COL9A3 genes were transcribed [162-164]. In mice lacking oLI(IX) chains and type IX collagen molecules, it appeared that type IX collagen was not essential for skeletal morphogenesis or proper fibril formation [163]. However, it is necessary for the functional and mechanical stability of the weight-bearing articular surfaces, presumably reflecting the need for interactions between type IX collagen and other extracellular matrix components. The mice appeared normal at birth but developed premature osteoarthritis [163]. Type IX collagen is extensively cross-linked in cartilage [165]. Most of the cross-linking residues in mature adult cartilage are trivalent pyridinolines. The finding of cross-linkages between type IX and type II collagen molecules is in keeping with electron microscopic images of type IX collagen molecules decorating the surface of type II collagen fibrils [146]. In addition, the divalent reducible cross-links, dihydroxylysinonorleucine and hydroxylysinonorleucine, are also found in type IX collagen. Each of the type IX collagen chains contains a site of cross-linking at the N-terminus of the COL2 triple helix to which the OLl(II) N-telopeptide can bond. The oL3(IX) COL2 domain also has an attachment site for the OLl(II) C-telopeptide. The distance between the C~l(II) N-telopeptide and the C~l(II) C-telopeptide interaction sites, 137 residues, is equal to the length of the gap region (0.6 D) in a type II collagen fibril. These findings imply an antiparallel type II-to-type IX cross-linking relationship [165]. With this arrangement, it is likely that the glycosaminoglycan side chain protrudes into the gap region and that the short COL3 domain and the basic globular NC4 domain project from the surface of the fibril [166].
TYPE X! COLLAGEN Type XI collagen is a component ofheterotypic type II collagen fibrils in cartilage, and the type V/XI hybrid
12.
William G. Cole
collagen molecule is a component of heterotypic type I collagen fibrils in bone and many nonskeletal tissues [167,168]. In cartilage, it assembles with types II and IX collagens to produce an extensive network of thin, heterotypic collagen fibrils 15-25 nm in diameter [169,170]. In noncartilaginous tissues, the component chains, particularly the pro-oLa(XI) chains, take part in the formation of hybrid type V/XI molecules that coassemble with type I collagen to produce the collagen fibrils of bone and other nonskeletal tissues [171,172]. Type XI collagen is a heterotrimeric molecule consisting of c~I(XI)-oL3(XI) chains [173]. The oL3(XI) chain is an overglycosylated form of type II collagen, whereas the oLI(XI) and ~2(XI) chains are the products of distinct genes. All three chains are important in the formation of the type XI collagen molecule because the absence of any one of them results in spondyloepiphyseal dysplastic phenotypes of varying severities. Lack of the e~l(XI) chain in the cho/cho mouse results in a lethal phenotype with disorganization of the cellular and extracellular matrix architecture of the cartilages [174]. The composition of type XI collagen in these mice is not known. Consequently, it is unclear whether the oLI(V) chain substitutes for the oLI(XI) chain in type XI collagen molecules. A milder chondrodysplastic phenotype was observed in mice that lacked oL2(XI) chains. This phenotype appeared to be due to the ability of the oLI(XI) chains to partially rescue the phenotype by forming stable triple-helical molecules in cartilage, although the chain composition of such molecules is unclear [175]. Mice lacking the OLl(II) chain also have a lethal chondrodysplastic phenotype [128]. The type XI collagen molecules, containing only the oLI(XI) and Otz(XI) chains, were unstable [129]. The oLI(XI) gene, C O L l l A 1 , is located on chromosome lp21 [176]. The C O L l l A 1 gene contains 69 exons and encodes a procollagen chain that resembles the proe~l(V) chain. There are three major human pro-oLl(XI) isoforms. The longest isoform, isoform 2, contains 1818 amino acid residues [103]. It includes a signal peptide of 36 residues, an N-propeptide of 487 residues, an N-telopeptide of 16 residues, a main triple-helical domain of 1014 residues, a C-telopeptide of 23 residues, and a C-propeptide of 241 residues. The N-propeptide of the pro-~l(XI) chain contains a proline- and arginine-rich protein (PARP) domain followed by a variable region, a constant region, and a minor triple helix. Alternative splicing within the variable region in humans involves exon 6, which exists as exon 6A encoding 39 amino acid residues and as exon 6B encoding 51 residues [177]. The exon 6A-encoded sequence is highly acidic, with an estimated isoelectric point of 3.2 [177]. In contrast, exon 6B encodes a highly basic amino acid sequence, with an estimated isoelectric point of 10.6
[177]. The three isoforms are isoform 1, which uses exon 6A, isoform 2, which uses exon 6B, and isoform 3, which uses neither exon 6A nor exon 6B. It is unclear whether other isoforms exist in humans, and little information is available about the temporal and spatial expression of them. At least in chick chondrocytes, the different splice variants of pro-oLl(XI) collagen chains undergo uniform amino-terminal processing [178]. More information is available concerning the alternative splicing of the C O L l l A 1 transcript in chick, mouse, and rat tissues and cultured cells [179-182]. In mice, exons 6A, 6B, 7, and 8 of the colllal gene encode the variable region of the amino-terminal domain [183]. A complex pattern of alternative splicing occurs that is both tissue dependent and developmentally regulated. Expression of colllal is predominantly associated with cartilage, in which it plays a critical role in skeletal development. At least five splice forms (6B-7-8, 6A-7-8,7-8,6B-7, and 7) are found in cartilage. Splice forms containing exons 6B or 8 have distinct distributions in the long bone during development, whereas in noncartilage tissues splice form 6A-7-8 is typically expressed. To study the process in more detail, a minigene containing exons 5-11 was transfected into chondrocytic (RCS) and nonchondrocytic (A204) cell lines that endogenously express oLI(XI) chains as well as into 293 cells that do not express oLI(XI) chains. Alternative splicing in RCS and A204 cells reflected the appropriate cartilage and noncartilage patterns, whereas 293 cells produced only the 6A-7-8 isoform. This finding suggested that 6A-7-8 is the default splicing pathway and that cell-or tissue-specific trans-acting factors are required to obtain the pattern of the alternative splicing of Otl(XI) premRNA observed in chondrocytes. Deletional analysis revealed cis-acting regions important for regulating splicing. The presence of the intact exon 7 was required to generate the full complex chondrocytic pattern of splicing. Deletional mapping of exon 6B revealed sequences required for expression of exon 6B in RCS cells, and these may correspond to purine-rich (ESE) and AC-rich (ACE) exonic splicing enhancers. Immunohistochemical studies have also provided new insights into the temporal and spatial expression of the oLI(XI) isoforms in rats [181]. Antibodies to the basic peptide p6b (encoded by exon 6b) and the acidic peptide p8 (encoded by exon 8) localized these epitopes to the surface of the collagen fibrils and were used to determine the pattern of isoform expression during the development of the rat humerus [181]. Expression of the p6b isoform was restricted to the periphery of the cartilage underlying the perichondrium of the diaphysis, a pattern that appears de novo on Embryonic Day (E) 14. p8 isoforms appeared to be associated with early stages of chondrocyte differentiation and were detected
1. Structure of Growth Plate and Bone Matrix
throughout prechondrogenic mesenchyme and immature cartilage. After El6, p8 isoforms gradually disappeared from the diaphysis and then from the epiphysis preceding chondrocyte hypertrophy, but they were highly evident at the periarticular joint surface, where ongoing chondrogenesis accompanies the formation of articular cartilage. The spatially restricted and differentiationspecific distribution of Otl(XI) isoforms suggests that the isoforms perform distinct functions in skeletal development that may go beyond their role in collagen fibrillogenesis. The C O L l l A 2 gene that encodes the pro-oLz(XI) collagen chain resides on chromosome 6p21.3 [184]. It spans approximately 30.5 kbs and contains 66 exons [185,186]. The retinoid X receptor [3 gene is located 1.1 kb upstream of C O L l l A 2 [186]. The overall structure of the C O L l l A 2 gene is similar to that of the C O L l l A 1 gene, including a similar amino-terminal fragment as well as alternative splicing, which involves exons 6-8 [94,177,187]. The signal sequence is encoded by exon 1, the PARP subdomain by exons 2-5, the variable region by exons 5-9, the short triple-helical domain by exons 9-12, and the noncollagenous domain by exons 12-14. The N-telopeptide is encoded by exons 13 and 14. The junctional exon 14 also contains sequences for the beginning of the main triple-helical domain. Studies in mice have shown three Otz(XI) isoforms. Isoform 1 is a full-length mRNA, isoform 2 lacks exons 6 and 8 sequences, and isoform 3 lacks exons 6-8 sequences [95]. However, the number of isoforms involving exon 7 may be greater because of the additional splicing sequences observed in intron 6 [187]. A potential splice acceptor site 450bps and a potential splice donor site 227bps upstream of the published splice acceptor site of exon 7 were identified in humans. A branch point consensus sequence known to be essential for the formation of lariat intermediates in m R N A splicing exists 32-42 nucleotides 3' of these potential splice sites. Usage of these signals would result in three exon 7 splice variants [187]: exons 7A (249 bps) and 7B (227 bps) in addition to the known 63-bp exon 7, designated exon 7C. The main triple helix is encoded by 48 exons and parts of the junctional exons 14 and 63. As with the other fibrillar collagens, the codons encoding the helical domain, apart from the junctional exons, start with a complete codon for Gly and end with a complete codon for the Y residue of Gly-X-Y triplets. However, exon sizes and codon usage differed from the typical arrangements observed in types 1-III collagens. The amino acid sequences and the charge distributions within the triplehelical domains of the oL2(XI), otl(XI), and oL1(V) chains were similar. However, there was relatively little conservation of these characteristics with the oL3(XI)/ otl(II) chain.
13
The C-propeptide of the pro-oL2(XI) chain is approximately 30 amino acids shorter than the C-propeptides for pro-otl(I), pro-oLl(II), pro-oLl(V), pro-cxz(V), and prooL1(XI) because of internal deletions. As with other collagens, type XI collagen molecules assemble from the C-propeptides of their component chains and subsequently undergo cross-linking. Purified type XI collagen from fetal bovine cartilage contained divalent, borohydride-reducible structures, whereas pyridinoline residues were essentially absent [130]. The cross-linking patterns of N-telopeptides to the C-terminal region of the triple-helical domain of type XI collagen were consistent with a head- to-tail interaction of molecules staggered by 4 D periods (D = 67 nm). In addition, oLl(II) C-telopeptide was linked to the aminoterminal site of the oL~(XI) triple helix. However, type XI collagen molecules are primarily cross-linked to each other in cartilage, implying that a homopolymer is initially formed. Links to type II collagen are consistent with eventual cofibrillar assembly. Analysis of cartilage extracts showed that all three chains, OLl(XI)-ot3(XI), had at least in part retained their N-propeptides in cartilage matrix and that the oL3(XI) chain was the IIB splicing variant product of the COL2A1 gene. Of particular note was the finding that the N-telopeptide cross-linking site in both oLI(XI) and otz(XI) is located amino terminal to the putative N-propeptidase cleavage site. This structural feature provides a potential mechanism for the proteolytic depolymerization of type XI collagen by proteases that can cleave between the cross-link and the triple helix. Transglutamination has also been proposed as another mechanism for crosslinking of type XI and type V/XI hybrid molecules [171,188]. Type XI collagen appears to nucleate self-assembly and limit the lateral growth of heterotypic type II collagen fibrils [189]. In general, growth plates and fetal epiphyseal cartilages contain fibrils with diameters less than approximately 25 nm, whereas the permanent cartilage of adult tissues contains fibrils of approximately 30)-200 nm [144]. Human juvenile and newborn growth plates have thin fibrils in the hypertrophic zone, thick fibrils in the resting zone or permanent cartilage, and a mixture of thin and thick fibrils in the proliferative zone. Immunoelectron microscopy with anti-peptide antibodies to the C-telopeptide and to the amino-terminal non-triple-helical domains of oLI(XI) chains showed that both epitopes of type XI collagen were readily accessible to antibodies at the fibrillar surface and that type XI collagen was associated predominantly with fibrils <25 nm in diameter. Type XI collagen was not found in thick fibrils even after disruption with chaotropic agents. In contrast, types II and IX collagens were associated with fibrils of all sizes. These findings, which imply that
14
William G. Cole
higher concentrations of type XI collagen are associated with smaller diameter heterotypic type II collagen fibrils, are consistent with the abnormally thick collagen fibrils and the abnormal growth plate architecture in the cho/ cho mouse, which lacks oLI(XI) chains [174]. Rotary shadowing imaging of type XI collagen molecules shows that the conformation and size of the various subdomains of the N-propeptides, particularly the Otl(XI) chains, would require that the N-propeptide protrude from the surface of the fibril rather than being accommodated within the gap zone of the fibril [189]. This spatial arrangement would place the N-propeptide in an appropriate position to interact with other matrix components as well as other collagen fibrils [190,191]. This proposal is also consistent the location of the type XI collagen molecules in heterotypic type II collagen fibrils as determined by immunoelectron microscopy studies and from the localization of covalent crosslinkages between types XI and II collagens [130,144].
TYPE X COLLAGEN Type X collagen is a short-chain fibrillar-type coliagen [192)-194] specifically produced by hypertrophic chondrocytes of the growth plate [192]. Each type X collagen molecule is a homotrimer consisting of three oLI(X) chains. The gene COLIOA1 is located at chromosome 6q21-q22 [195)-197]. It contains three exons, of which exons 2 and 3 encode the protein chain [195,198]. The 169-bp exon 2 encodes 15bps of the 5' untranslated sequence, 54 bps of the signal peptide, and 100 bps of the N-terminal noncollagenous domain 2 (NC2). The 3' nucleotide of exon 2 encodes the first nucleotide of the codon for the 34th amino acid residue of the NC2 domain. The 2940-bp exon 3 starts with the remaining 14 bps of the NC2 domain. It is followed by 1389 bps encoding the triple-helical domain (COL1), 483 bps encoding the complete NC1 domain, and 1054 bps of 3' untranslated sequence up to and including a potential polyadenylation signal. Consequently, the full-length protein contains 680 amino acid residues, including a signal sequence of 18 residues, an NC2 domain of 38 residues, a COL1 domain of 463 residues, and an NC1 domain of 161 residues. In contrast to the long-fibrillar types I-III collagens, in which the COL1 domains only contain repeating Gly-X-Y triplets, the COL1 domain of type X collagen contains eight interruptions in the triplet-helical repeats [195]. In five instances, the X or the Y amino acid residue is absent, and in three instances the Gly residue is replaced by another residue. Two of the latter interruptions encode mammalian collagenase cleavage sites. The
sequence at residues 151-156 is GISVPG and the sequence at residues 479-484 is GIATKG. The latter sequences correspond to the mammalian collagenase consensus sequence Gly-Ile-Y-X-Y-Gly. There are also several examples of Gly-X-Y triplets containing Gly in the X or Y positions. The first 12 amino acid residues of the NC1 domain share 67% homology with bovine oLI(X) chains, whereas 143 of the remaining 149 amino acid residues are 94% identical [195,199]. The locations of the 13 tyrosine residues, the putative N-linked oligosaccharide attachment site, and the single cysteine residue are all conserved [200]. Many studies of growth plates and isolated growth plate cells show that hypertrophic chondrocytes of the growth plate specifically express the COLIOA1 gene and produce type X collagen [201-204]. The NC1 domain contains the necessary signals to direct the assembly of the homotrimeric molecule [205,206]. This process occurs in the rough endoplasmic reticulum and is aided by chaperonins such as protein disulfide isomerase [207]. The resulting homotrimers are extremely stable because of the high content of hydrophobic residues [208]. The NC1 domain of type X collagen chains is homologous to the NC1 domain of type VIII collagen and to a C lq-like domain [209]. The crystal structure of the C-terminal domain of ACRP30, a serum protein, showed that its C lq-like domain is related to the tumor necrosis factor family both in subunit fold and in oligomeric assembly [210]. The crystal structure of the NC1 domain of human type X collagen has been resolved at 2.0 [211]. The NC 1 trimer has the shape of a squat truncated cone. The polypeptide chain termini of the subunits emerge at the broad base of the NC1 trimer, whereas the apex is constructed from tight loops organized around an intricate arrangement of Ca 2+ ions. The NC1 trimer is formed by the very tight association of three subunits. The intersubunit contacts are almost entirely hydrophobic near the base of the NC1 trimer and become progressively more hydrophilic toward the top of the trimer, forming a pronounced solvent-filled central channel. Approximately 7-11 calcium ions are present per NC1 trimer. The molecular surface of the trimer contains three strips, each containing eight partially exposed aromatic residues, that run across the shallow grooves between subunits. One of these strips has been proposed to be a hydrophobic surface patch involved in the higher order association of type X collagen trimers. There are three appropriately placed patches per NC1 trimer that would enable a polygonal network to form in two or three dimensions. The affinity for Ca 2+ ions and the observed CaZ+-regulated association of NC1 trimers provide a possible mechanism for the aggregation of type X collagen during endochondral ossification [212].
1. Structure of Growth Plate and Bone Matrix
Type X collagen produced by long-term cultured chick hypertrophic chondrocytes associated rapidly into multimeric clusters via their NC1 domains forming structures with a central nodule of NC1 domains and the triple-helical domains radiating outwards [213]. Prolonged incubation resulted in the formation of a regular polygonal lattice by lateral association of the juxtaposed triple-helical domains from adjacent multimeric clusters. These findings suggest that the NC1 domain remains attached to the c~l(X) chain in the extracellular matrix. The aggregates may also be stabilized by disulfide links that involve the single cysteine residue in the NC1 domain [195]. This proposal is in keeping with a report of human type X collagen with a molecular weight of 60 kDa when extracted from cartilage under reducing conditions and as a high-molecular-weight oligomer under nonreducing conditions [214]. The aggregates may also be stabilized by hydroxylysyl- and lysyl-derived cross-linkages [213,215]. Type X collagen extracted from chick growth plate cartilage contained a high concentration of lysylpyridinoline, a nonreducible collagen cross-link, whereas type II collagen from the same source contained hydroxylysylpyridinoline, a cross-link that predominates in cartilage other than the hypertrophic zone of the growth plate [216]. Immunoelectron microscopy of type X collagen in chick growth plate cartilage showed that it exists in two supramolecular forms [217]. In one form, type X collagen is associated with fine filaments <5 nm in diameter within matted structures that are predominately in the pericellular matrix of hypertrophic chondrocytes. It is likely that the nonstriated filamentous mats represent the regular polygonal lattice structures that form in longterm cultures of chick hypertrophic chondrocytes [213]. In a second form, farther away from the hypertrophic chondrocyte, type X collagen is associated with fibrils 10-20 nm in diameter that also contain type II collagen. The type X collagen associated with the striated fibrils most likely represents a secondary association of the molecule with preexisting heterotypic collagen fibrils containing types II, IX, and XI collagens [218,219]. The proteolytic cleavage of type X collagen likely commences with cleavage of the chains at their two mammalian collagenase cleavage sites [195,220]. In the chick, 59-kDa native type X collagen is cleaved at the two sites, yielding a final product of 32 kDa. The 32-kDa fragment has a mean temperature of 43~ due to a very high amino acid content. Consequently, the interstitial collagenase cleavage products are likely to be helical at physiological temperatures. However, the 32-kDa fragments can be readily degraded by cathepsin B at 37~ and at acid pH by osteoclast lysates [221]. One proposal is that during in vivo endochondral bone formation, type X collagen is first cleaved at neutral pH by interstitial
15
collagenase secreted by resorbing cartilage-derived cells. The resulting 32-kDa fragment is further degraded by osteoclast-derived cathepsin B supplied by the invading bone [221]. Other enzymes such as stromelysin-1, which is a neutral tissue metalloproteinase that can be extracted from cartilage, may also be involved in the degradation of type X collagen [137]. It cleaves type X collagen from the growth plate in its triple-helical domain, with a reduction in its chain size by approximately 10 kDa [137]. The proposed functions of type X collagen are based on its restricted expression within the hypertrophic zone of the growth plate. They include supporting the forming bone during the degradation of the cartilage matrix, facilitating the removal of the heterotypic type II collagen fibrils, participating in the mineralization process, and influencing the vascular invasion of the cartilage matrix [217,222]. However, the initial report of mice lacking type X collagen described normal long bone growth and development [223]. In the second study, mice lacking type X collagen had a mild skeletal phenotype resembling Schmid metaphyseal chondrodysplasia [224]. There were mild deformities of the femoral necks, reduced thickness of the resting zone of the growth plates, altered bone content, and atypical distribution of matrix components such as matrix vesicles and proteoglycans. In the third study, a variable skeletohematopoietic phenotype, from mild to lethal, was observed in mice lacking type X collagen [225]. The latter phenotypes were similar to the phenotypes of mice bearing a dominant interference mutation of type X collagen [226]. Perinatal lethality occurred in approximately 11% of null mutants, in which the growth plates were compressed, there was less trabecular bone, and the bone marrow showed hematopoietic aplasia and erythrocytefilled vascular sinusoids [225]. Lymphatic organs, which were reduced to approximately 80% of the size of control organs, displayed altered architecture and lymphocyte content. The thymus showed a paucity of cortical CD3+/CD4+/CD8 + lymphocytes, consistent with the marrow's inability to replenish maturing T cells. In the spleen, an unaltered T cell distribution was coupled with diffuse staining for IgD+/B220 + B cells, whose reduction was prominent in the poorly organized lymphatic nodules. Disorderly arrays of splenic macrophages surrounding periarteriolar lymphatic sheaths and depletion of the red pulp were also observed. Subtle growth plate compressions and hematopoietic changes were also seen in all the null mice that were apparently normal. From these diverse findings, it appears that hypertrophic cartilage and endochondral skeletogenesis may contribute to the marrow microenvironment required for differentiation of the hemopoietic and lymphoid systems. The molecular mechanisms involved in such interactions are unknown.
16
William G. Cole
AGGRECAN The abundant, large cartilage-derived aggrecan belongs to the family of aggregating chondroitin sulfate proteoglycans [227]. This family of hyaluronatebinding proteoglycans also includes versican and two smaller proteoglycans, neurocan and brevican, that are expressed in neural tissue [228-230]. Versican is largely expressed in nonskeletal tissues. It is transiently expressed in the condensing mesenchyme of the developing limb bud as well as in low levels by chondrocytes of the intervertebral disk [231,232]. Consequently, this description of aggregating chondroitin sulfate proteoglycans is limited to aggrecan, which is largely specific for cartilage. Aggrecan and the other hyaluronate-binding proteoglycans form a network of proteoglycan aggregates that fill the space between collagen fibrils in the matrix, with the stability of the network maintained by the cooperative interaction of link protein [233]. In contrast, the leucine-rich repeat proteoglycans are characterized by their ability to interact with the collagen fibrils [234,235]. The human gene A GC1 is located on chromosome 15q26.1 and contains 19 exons spread over more than 50 kbs of genomic DNA [236,237]. Alternative splicing generates a long and a short isoform [238]. The long mRNA isoform encodes 2415 amino acids, whereas the short isoform encodes 2316 amino acids [239]. The protein includes a signal peptide of 19 amino acid residues. The mature protein adopts a conformation possessing three globular domains, G1-G3 [239]. The G1 region is at the N terminus and is separated by a relatively short interglobular domain from the G2 region. The G1 region is homologous to the complete link protein sequence and thus consists of three disulfide-bonded loop structures designated A, B, and Bt motifs, with B and Bt related sequences of approximately 100 amino acids [240]. The G2 region is similar to the G1 region, possessing the B and B' domains but lacking the A domain. The G3 region, at the C terminus, has a complex structure. It contains two additional disulfide-containing domains, a calcium-binding epidermal growth factor (EGF)-like motif, a C-type lectin motif, and a complement regulatory protein motif [238,240]. Alternative splicing generates several isoforms. In juvenile human cartilage, approximately 95% of the transcripts lack the EGF-like and the complement regulatory protein motifs [239]. There is also a full-length transcript and one that lacks the EGF-like motif but retains the complement regulatory protein motifs. The functional significance of the isoforms is unknown. The glycosaminoglycan attachment region lies between the G2 and G3 regions, beginning with a
proline-rich domain adjacent to G2 [239]. Next is a keratan sulfate-rich region from amino acid residues 772-837. It contains 12 consecutive repeating units of 7 conserved residues (E-E-P-Y-T-P-S) for the attachment of keratan sulfate. It is followed by the chondroitin sulfate attachment domain 1 (CS-1) of 649 amino acid residues. The CS-1 domain contains 77 Ser-Gly pairs for the attachment of chondroitin sulfate chains [241,242]. The CS-1 domain is followed by the CS-2 domain of 665 amino acid residues. It contains 69 Ser-Gly pairs. In addition to the many keratan sulfate and chondroitin sulfate chains, there are also many O-linked and N-linked oligosaccharides. There are also complex changes in the extent of the posttranslational modifications with age, and there complex events are involved in the specific degradation of aggrecan. Hyaluronan is a glycosaminoglycan consisting of several thousand repeating disaccharide units [243]. Five of its repeating disaccharide units are necessary for the binding of an individual aggrecan core protein with its associated link protein. The link protein and the hyaluronate binding region of aggrecan bind to hyaluronan with the same specificity and with a similar binding strength. Consequently, many proteoglycan molecules can bind to a single hyaluronan molecule. Ultrastructural studies have shown that proteoglycan aggregates contain a large number of proteoglycan monomers very closely spaced along the hyaluronan central filament. The proteoglycan molecules and link protein appear to bind to the hyaluronan in the extracellular matrix. The proteoglycans have a high fixed-charge density so that they swell if not constrained by collagen fibrils [243].
CARTILAGE LINK PROTEIN 1 Cartilage link protein 1 stabilizes the binding of the hyaluronan-binding regions of aggrecan core protein to hyaluronan in growth plate and articular cartilages. The protein is widely distributed in connective tissues but the latter function is limited to cartilages. The gene for cartilage link protein 1, CRTL1, is located on chromosome 5q 14.3 [244,245]. The full-length protein contains 354 amino acid residues. It includes a signal peptide of 15 residues and a mature protein of 339 residues. It has a modular structure consisting of one immunoglobulin V-type domain from residues 54-141 and two hyaluronan binding sites from residues 157-254 and 258-351. The importance of cartilage link protein 1 in normal cartilage physiology is demonstrated by the severe chondrodysplasia that occurs in mice lacking this protein [246].
1. Structure of Growth Plate and Bone Matrix
SMALL, LEUCINE-RICH, INTERSTITIAL PROTEOGLYCANS The small, leucine-rich, interstitial proteoglycans (SLRPs) are a large family of extracellular matrix glycoproteins/proteoglycans that share a leucine-rich repeating structural motif [247]. Many of the family members bind to various collagens and to growth factors such as TGF-[311248]. The gene family can be divided into subfamilies based on similarities in amino acid sequences and gene organization. The type I subfamily includes decorin and biglycan, which contains an N-terminal domain substituted with chondroitin or dermatan sulfate chains. These proteoglycans show 57% protein sequence identity and are encoded by genes composed of eight exons with exon/intron junctions in conserved positions [249,250]. Fibromodulin and lumican constitute the type II subfamily and exhibit 48% protein sequence identity. Their genes are composed of three exons with conserved exon/intron junctions [251,252]. Other members of the latter family include the proline- and arginine-rich and leucine-rich repeat protein (PRELP) and osteomodulin [253,254]. The class III SLRP expressed in cartilage is epiphycan, also called PG-Lb [255]. Chondroadherin represents its own subfamily, with a different gene organization and a different amino acid composition [256]. The leucine-rich repeating extracellular glycoproteins/ proteoglycans have core proteins of 32-42 kDa [257]. The protein chains can be divided into N-terminal, central, and C-terminal domains. The N-terminal domains are least conserved, but in all members of the family they contain 4 Cys residues, which form intrachain disulfide bonds [258]. The glycosaminoglycan chains in decorin and biglycan are O-glycosidically linked to Ser residues in the N-terminal region, providing polyanionic properties to the proteoglycans. In contrast, the N-terminal domains of fibromodulin and lumican carry clusters of negatively charged Tyr sulfate residues [257]. The different leucine-rich repeat proteoglycans and glycoproteins have similar C-terminal domains, which contain approximately 50 amino acid residues. This domain contains 2 Cys residues involved in an intrachain disulfide bond, leading to the formation of a 34- to 41-residue loop. The common central domain constitutes approximately 60-80% of the total protein. In most of the members of the family, it contains 10 or 11 repeats of a 20- to 25-residue-long leucine-rich motif, with Asn and Leu residues in conserved positions. Each leucine-rich repeat contains the motif LXXLXLXXNXL, with each motif being separated by 9-18 amino acids. Up to 30 adjacent leucine-rich repeats have been described in some leucine-rich repeat proteins. The leucine residues in the motif may be replaced by alanine, valine, isoleucine,
17
phenylalanine, tyrosine, or methionine. The asparagine residue at position 9 may be replaced by cysteine or threonine [256]. There are consensus site Asn residues in the central repeat domain for substitution with carbohydrates. For example, the latter Asn sites are partially substituted with keratan sulfate in fibromodulin and lumican [252]. The three-dimensional structure of one member of the family, ribonuclease inhibitor, showed that the leucinerich repeats form a horseshoe-shaped coil of parallel, alternating c~helices and 13sheets stabilized by interchain hydrogen bonds [259]. Results of structural studies of decorin and biglycan are in accordance with the latter X-ray crystallographic findings [260]. Decorin, fibromodulin, and lumican bind to fibrillar collagens in vitro, leading to delayed fibril formation and the formation of thinner fibrils [261]. These changes are likely due to binding of the leucine-rich repeat glycoproteins/proteoglycans to the surface of the axially growing fibril, which inhibits the incorporation of additional triple-helical collagen monomers [75]. Binding of the leucine-rich repeat proteoglycan to collagen alters the surface properties of the fibrils and may affect the interactions between individual collagen fibrils as well as between the fibrils and the matrix. Competitive binding and displacement of proteoglycans may regulate the growth of collagen fibrils during skeletal development [262]. Decorin and fibromodulin bind to distinct and apparently separate sites in the gap region of the D period of the collagen fibril in vivo [263,264]. Decorin has been shown to bind to a small region of the C terminus of the triple-helical domain of etl(I) chains, close to one of the intermolecular cross-linking sites [265]. This region corresponds to the Cl band of the collagen fibril D period. Proteoglycan core proteins of decorin, biglycan, and fibromodulin, prepared as fusion proteins, each bound TGF-1311266]. There was negligible binding to several other growth factors. Intact decorin, biglycan, and fibromodulin, isolated from bovine tissues, competed with the fusion proteins for TGF-f31binding. Affinity measurements suggest a two-site binding model with KDvalues ranging from 1 to 20 nM for the high-affinity binding site and from 50 to 200nM for the low-affinity binding site. Stoichiometry indicated that the high-affinity binding site was present in 1 of 10 proteoglycan core molecules and that each molecule contained a lowaffinity binding site. Tissue-derived biglycan and decorin were less effective competitors for TGF-f3 binding than fibromodulin or the nonglycosylated fusion proteins. Removal of the chondroitin/dermatan sulfate chains of decorin and biglycan (fibromodulin is a keratan sulfate proteoglycan) increased the activities of decorin and
18
William G. Cole
biglycan, suggesting that the glycosaminoglycan chains may hinder the interaction of the core proteins with TGF-[3. The fusion proteins competed for the binding of radiolabeled TGF-[3 to Mv 1 Lu cells and endothelial cells. Affinity labeling showed that the binding of TGF-[3 to betaglycan and the type-I receptors in Mv 1 Lu cells and to endoglin in endothelial cells was reduced, but the binding to the type II receptors was unaffected. TGF-[32 and-3also bound to all three fusion proteins. Latent recombinant TGF-[31precursor bound slightly to fibromodulin and not at all to decorin and biglycan. These findings indicate that the three decorin-type proteoglycans each bind TGF-[3 isoforms and that slight differences exist in their binding properties. They, and possibly other members of this family of proteoglycans, may regulate TGF-[3 activities by sequestering TGF-[3 in the extracellular matrix. Changes have been reported in the abundance of decorin, biglycan, fibromodulin, and lumican during maturation of the bovine fetal growth plate [267]. Decorin protein and m R N A were readily detectable in both the reserve and proliferating zones of the growth plate but not in the zones of maturation and hypertrophy. In contrast, fibromodulin and biglycan protein and m R N A could be detected throughout the growth plate. although their abundance was decreased in the proliferative and hypertrophic zones. Lumican protein and m R N A were not detected in the growth plate even though its m R N A was detectable in isolated growth plate cells [252]. Representative members of the subfamilies of small, leucine-rich interstitial proteoglycans are described next. Decorin a n d Biglycan The decorin gene, DCN, and the biglycan gene, BGN, are located on chromosomes 12q13.2 and Xq28, respectively [250,268-270]. Both genes have a similar 8exon gene structure. The decorin gene is approximately 45 kbs, whereas the biglycan gene is approximately 8 kbs [249]. Exon 1 of decorin, which encodes the 5' untranslated region, exists as exon l a and exon 1b, which undergo alternative splicing [250]. The decorin transcript can also undergo additional alternative splicing to yield five isoforms, A-E. Isoform A, which contains the full amino acid coding sequence, is the product of transcript variants A1 from exon la and A2 from exon 2b. Isoform B lacks the exons 3 and 4 sequence, isoform C lacks the exons 3-5 sequence, isoform D lacks the exons 4-7 sequence, and isoform E lacks the exons 3-7 sequence. There are several polyadenylation sites, of which two account for the 1.6- and 1.9-kb mRNAs isolated from various connective tissues and cultured cells [250]. The biglycan m R N A sizes, also related to the use of
different polyadenylation sites, are 2.1 and 2.6kbs [249]. The BGN gene is subject to X inactivation because there is no homologous gene on the Y chromosome. However, the pseudoautosomal expression of BGN is probably due to the regulation of the BGN gene by a gene or genes that escape X inactivation [271]. Preprodecorin contains 359 amino acid residues [272]. It includes a signal peptide of 16 residues, an N-propeptide of 14 residues, and a mature chain of 329 residues. Intrachain disulfide bonds are present between Cys 54 and Cys 67 as well as between Cys 313 and Cys 346. Twelve leucine-rich repeats are present in the central domain between residues 73 and 359. The O-linked chondroitin sulfate or dermatan sulfate attachment site is at residue 34. Residues 211,262, and 303 provide potential N-linked oligosaccharide attachment sites. The core protein of 359 amino acid residues has a predicted molecular weightof 39 kDa, whereas the protein extracted from tissues has a molecular weight of approximately 130 kDa, of which the chondroitin sulfate chain contributes approximately 40 kDa [273]. Preprobiglycan contains 368 amino acid residues [249,269,270]. It contains a signal peptide of 16 residues, a propeptide of 21 residues, and a mature protein of 331 residues. A region of proteoglycan N-terminal homology is present from residues 57 to 81 of the full-length protein. Ten leucine-rich repeats are located between residues 91 and 315. Residues 316-368 contain a domain with proteoglycan C-terminal homology. Residues 42,47,180, and 198 are potential chondroitin sulfate or dermatan sulfate attachment sites. Biglycan contains two substituted sites, whereas decorin contains only one. Asn residues 270 and 311 are possible sites for N-linked oligosaccharides. The secreted core protein has a predicted molecular weight of 38 kDa, whereas the intact tissue protein has a molecular weight of approximately 270 kDa, with the two chondroitin sulfate chains contributing 40kDa [274]. BMP-1 cleaves probiglycan at a single site, removing the propeptide and producing a biglycan molecule with an N terminus identical to that of the mature form found in tissues [275]. The BMP-1related proteases, mammalian Tolloid and mammalian Tolloid-like 1 (mTLL-1), have low levels of probiglycancleaving activity. Wild-type mouse embryo fibroblasts produce only fully processed biglycan, whereas the fibroblasts derived from embryos homozygous null for the Bmpl gene, which encodes both BMP-1 and mammalian Tolloid, produce predominantly unprocessed probiglycan, and fibroblasts homozygous null for both the Bmpl gene and the m TLL-1 gene produce only unprocessed probiglycan. Consequently, all detectable probiglycanprocessing activity in the mouse embyronic fibroblasts is accounted for by the products of these two genes. Cartilage contains both proteoglycan and nonproteogly-
1. Structure of Growth Plate and Bone Matrix
can forms of biglycan, with the latter form increasing with age [276]. The importance of decorin and biglycan in the formation of the connective tissues is demonstrated by the anomalies observed in mice that fail to express these genes. In decorin-deficient mice, the mice have fragile skin due to coarse and irregular collagen fibrils, confirming the importance of decorin in normal collagen fibrillogenesis [277]. Biglycan-deficient mice show reduced longitudinal growth and decreased bone mass, indicating an important role for biglycan in bone health [278]. Decorin and biglycan are representative of a subfamily of proteins that also includes epiphycan and asporin [279,280]. The latter small leucine-rich dermatan sulfate-containing proteoglycans have been isolated from cartilage. Fibromodulin a n d Related Small P r o t e o g l y c a n s Representative members of the fibromodulin subfamily also include lumican, PRELP, and osteomodulin, also known as osteoadherin. They are found in most connective tissues but in greatest abundance in cartilage, tendon, and ligament [281]. Fibromodulin was first isolated from bovine articular cartilage and subsequently cloned and sequenced from bovine tracheal cartilage [281,282]. The fibromodulin gene, FMOD, is approximately 8.5 kbs and is located on chromosome lq32 [283]. The gene contains three exons with conserved exon/intron junctions. Exon 1 encodes the 5' untranslated region, exon 2 contains 983 bps and encodes the major part of the translated region, and exon 3 encodes the last 50 nucleotides of the translated region as well as the 3' untranslated region [251]. The fibromodulin m R N A is approximately 3 kbs [283]. The highest expression of the gene is in hyaline cartilages, tendon, and ligament, whereas lower levels of expression occur in most other connective tissues [281]. Fibromodulin is a 59-kDa protein [281]. The fulllength protein contains 376 amino acid residues, including a signal peptide of 18 amino acid residues and a mature protein of 358 amino acid residues [251,283]. The mature protein is composed of a central region containing leucine-rich repeats with up to four keratan sulfate chains flanked by disulfide-bonded terminal domains. The amino-terminal domain contains 10 tryosine residues that are partially sulfated [251]. The keratan sulfate chains were attached by N-glycosidic linkages from N-acetylglucosamine to asparagine residues in the central domain of the molecule [284]. In contrast to other SLRPs, fibromodulin does not contain glycosaminoglycan chains in the amino-terminal domain and does not contain chondroitin/dermatan sulfate in any domain.
19
Mice lacking fibromodulin showed altered tendon structure due to the high proportion of thin, irregular collagen fibrils [257]. These relatively mild changes confirmed the important role of fibromodulin in regulating collagen fibrillogenesis in vivo. The lumican gene, L UM, is located on chromosome 12q21.3-q22 [252,285]. It encodes 338 amino acid residues, including a signal peptide of 18 residues and a mature protein of 320 residues. Residues 37-53 of the full-length protein encompass a Cys-rich domain followed by a central domain of 12 leucine-rich repeat motifs from residues 59-338. An intrachain disulfide bond can form b e t w e e n Cys 295 a n d Cys 328. The residues at positions 88,127,160, and 252 are potential N-linked keratan sulfate attachment sites. The protein is present in the cornea as well as cartilage from all age groups, but it is more abundant in adult cartilage. In adult cartilage, the protein is a glycoprotein that lacks keratan sulfate, whereas in juveniles it is a proteoglycan containing keratan sulfate chains [252]. The important role of lumican in normal collagen fibrillogenesis is confirmed by the finding in lumican knockout mice of skin fragility and corneal opacities due to abnormal collagen fibrillogenesis [286]. The gene for PRELP is located on chromosome lq32 [287]. The gene of 16 kbs contains three exons. The protein is encoded by three mRNAs of 1.7,4.6, and 6.7 kbs. The differences in the size of the mRNAs appear to be due to variations in the length of their 3' untranslated regions. It encodes a 382-amino acid residue protein that includes a signal peptide of 20 residues and a mature PRELP protein of 362 residues [254,287]. The central domain containing 10 leucine-rich repeat motifs is flanked by Cys-rich regions. Potential N-linked oligosaccharide attachment sites are located at residues 124,289, and 320. However, substitution by N-linked keratan sulfate is less than for fibromodulin and lumican. The mRNAs are expressed at a high level in juvenile and adult cartilage, at a low level in neonatal cartilage, and are not detectable in fetal cartilage. The PRELP mRNAs and protein differ in their expression from those of decorin, biglycan, fibromodulin, and lumican. PRELP mRNAs were not detected in trabecular bone, skin, kidney, liver, spleen, or thymus [254]. The molecular weight of the core PRELP protein is 42 kDa, whereas that of PRELP extracted from cartilage is 55 kDa [288]. The gene for osteomodulin (also known as osteoadherin), OMD, is located on chromosome 9q22.2. The full-length human protein contains 421 amino acid residues. The primary structure of bovine osteomodulin was obtained by nucleotide sequencing of a cDNA clone from a primary bovine osteoblast expression library [289,290]. The entire translated primary sequence corresponds to a 49,116-Da protein with a calculated
20
William G. Cole
isoelectric point for the mature protein of 5.2. The dominating feature is a central region consisting of 11 leucinerich repeats ranging in length from 20 to 30 residues. The full, primary sequence contains four putative sites for tyrosine sulfation, three of which are at the N-terminal end of the molecule. There are six potential sites for N-linked glycosylation, some of which are substituted with keratan sulfate chains. Osteomodulin shows highest sequence identity (42%) to bovine keratocan and 37 or 38% identity to bovine fibromodulin, lumican, and human PRELP. Unique to osteomodulin is the presence of a large and very acidic C-terminal domain. The distribution of cysteine residues resembles that of other leucine-rich repeat proteins except for two centrally located cysteines. Northern blot analysis of RNA samples from various bovine tissues showed a 4.5-kilobase pair message for osteomodulin to be expressed in bone only. Osteomodulin m R N A was detected by in situ hybridization in mature osteoblasts located superficially on trabecular bone. Osteomodulin binds to hydroxyapatite and cells. Cell binding is mediated by integrin OLv[33[289,290].
Epiphycan Epiphycan is a dermatan sulfate proteoglycan also known as PG-Lb as well as dermatan sulfate proteoglycan 3. It can be distinguished from decorin and biglycan of epiphyseal cartilage, from which it derives its name [255]. The gene, DSPG3, which is located on chromosome 12q21, contains seven exons [255]. The full-length protein contains 322 amino acid residues. Residues 121-140 contain a leucine-rich repeat N-terminal domain. Two serine residues exhibit the glycosaminoglycan attachment consensus similar to those in aggrecan, decorin, and biglycan. In the mouse, the gene is expressed in cartilage, ligaments, and the placenta. The gene is expressed in a precise temporal and spatial manner in the growth plate. It is expressed by growth plate chondrocytes after type II collagen appears but is not expressed by hypertrophic chondrocytes. However, despite the limited pattern of chondrocyte expression, the protein is widely distrubuted through the resting, proliferative, and hypertrophic zones of the growth plate [291]. Chondroadherin Chondroadherin represents its own subfamily of SLRPs, with a different gene organization and a different amino acid composition [253]. It was initially isolated from bovine cartilage as a 36-kDa protein that was involved in chondrocyte-matrix interactions [292,293]. The human gene, CHAD, is located on chromosome 17q21.33 [256]. It has three exons. Exon 1 encodes the
signal peptide, the N-terminal cysteine-rich region, and the first 9 leucine-rich repeats. Exon 2 encodes the last 2 leucine-rich repeats and part of the C-terminal cysteinerich region. Exon 3 encodes the remainder of the C-terminal cysteine-rich region. There is a single m R N A species of 1.9 kbs. The cDNA contains a 5' untranslated region of 149 bps, a coding region of 1080 bps including the stop codon, and a 3' untranslated region of 561 bps terminating in a poly(A) tail. The full-length protein contains 359 amino acid residues, including a signal peptide of 21 residues and a mature protein of 339 residues. The mature sequence contains 11 leucinerich repeats of 22- to 25-amino acid residues flanked by cysteine-rich regions. The protein is enriched in cartilage and bone [293].
PERLECAN Perlecan is a heparan sulfate proteoglycan and a major component of basement membranes and cartilage [294,295]. The gene, HSPG2, is located on chromosome lp36.1-p35 [296-298]. It encodes a full-length protein of 3205 amino acids [299,300]. The full-length protein contains a signal peptide of 21 amino acid residues and a mature protein of 4373 residues [300]. The mature protein core, without the signal peptide of 21 amino acids, has a molecular weight of 466,564. This large protein is composed of multiple modules homologous to the receptor of low-density lipoprotein, laminin, neural cell adhesion molecules, and epidermal growth factor. Domain I, near the amino terminus, appears to be unique for the proteoglycan since it shares no significant homology with any other proteins. It contains three Ser-Gly-Asp sequences that could act as attachment sites for heparan sulfate glycosaminoglycans [301]. Domain II is highly homologous to the low-density lipoprotein receptor and contains 4 repeats with perfect conservation of all six consecutive cysteines. Next is domain III, which shares homology to the short arm of laminin A chain and contains 4 cysteinerich regions intercalated among three globular domains. Domain IV, the largest module with more than 2000 residues, contains 21 repeats of the immunoglobulin type as found in neural cell adhesion molecule. Near the beginning of this domain, there is a stretch of 29 hydrophobic amino acids that could allow the molecule to interact with the plasma membrane. Domain V, similar to the C-terminal globular G domain of laminin A and to the related protein merosin, contains three globular regions and 4 EGF-like repeats. In situ hybridization and immunoenzymatic studies show a close association of this gene product with a
1. Structure of Growth Plate and Bone Matrix
variety of cells involved in the assembly of basement membranes, in addition to being localized within the stromal elements of various connective tissues. Perlecan interacts with extracellular matrix proteins, growth factors, and receptors, and it influences cellular signaling [302-304]. Perlecan expression occurs during organogenesis of the kidney, lung, liver, spleen, gastrointestinal tract, and cartilage. The levels of perlecan are low in precartilaginous tissues but high in mature cartilage [295]. In vito studies show that perlecan supports chondrocyte differentiation [295,305]. The importance of perlecan in normal cartilage development is demonstrated by the abnormal structure and function of cartilage in mice lacking this proteoglycan [306,307]. The chondrodysplasia is characterized by a reduction of the fibrillar collagen network, shortened collagen fibers, and a reduced amount of glycosaminoglycans in the cartilage. The columnar structure of the growth plate is severely disrupted.
MATRILINS The matrilins are a family of four oligomeric, multidomain, extracellular matrix proteins [308]. The prototype member of the family is matrilin-1, which was initially referred to as cartilage matrix protein [309,310]. The four monomers are named matrilin-l-matrilin-4 [3081. The human M A T N 1 gene, encoding matrilin-1, resides on chromosome lp35. It is 12kbs and contains 8 exons [311]. The m R N A of approximately 1.5kbs is predicted to yield a monomer of 496 amino acids, including a signal peptide of 22 residues, two von Willebrand factor A (vWFA) domains separated by a single EGFlike motif, and a C-terminal coiled-coil oligomerization domain. The mature protein is predicted to have an unmodified molecular weightof 51,344. The higher molecular weight of 52 kDa observed for matrilin-1 from cartilage is likely due to the presence of N-glycosidically linked oligosaccharides [310]. Matrilin-2 is encoded by the M A TN2 gene located on chromosome 8q22 [312]. The m R N A is approximately 2.9 kbs. The cDNA sequence predicts a protein monomer of 956 amino acid residues, including a signal peptide of 23 residues. The two vWFA domains are separated by 10 EGF-like motifs. A sequence that is unique to matrilin-2 is followed by the C-terminal coiled-coil oligomerization domain. Alternative splicing can generate a short form of the protein in which 19 amino acid residues are deleted from the unique sequence domain. The matrilin-3 gene, located on chromosome 2p24-p23, yields a processed m R N A of approximately 1.5 kb [313-315]. The protein monomer is predicted to
21
contain 486 amino acids, including a signal peptide of 28 residues. Adjoining the signal peptide is a short positively charged region followed by a single vWFA domain, four EGF-like motifs, and a C-terminal coiled-coil oligomerization domain. The matrilin-4 gene is located on chromosome 20ql 3.1-13.2 [316,317]. It yields three alternatively spliced m R N A species. The long form encodes a monomer of 582 amino acids, including a signal peptide of 56 residues. The modular structure of the long isoform includes two vWFA domains separated by three EGFlike motifs and followed by the C-terminal coiled-coil domain. The two shorter forms, resulting from alternative splicing, contain either one or two EGF-like motifs. The members of the matrilin family share a similar modular structure consisting of one or two vWFA domains, a varying number of EGF-like motifs, and a C-terminal coiled-coil oligomerization domain [308]. The matrilins can self-assemble into supramolecular structures that form a filamentous network that may stabilize the extracellular matrix [318-321]. At least for matrilin1 and matrilin-3, the filamentous networks can be associated with or be independent of collagen fibrils [322,323]. Matrilin-1 appears to have a periodic association with collagen fibrils and to play a role in collagen fibrillogenesis [324,325]. In the normal zone of maturation, between the zones of proliferation and hypertrophy of the mouse growth plate, matrilin-1 has a periodicity of 59.3 nm along the heterotypic type II collagen fibrils [326]. In mice lacking matrilin-1, the zone of maturation contains abnormal collagen fibrils, in keeping with the importance of this glycoprotein in normal type II collagen fibrillogenesis [326]. Matilin-1 can also interact covalently with aggrecan core protein [309,327], and it may interact with the Otl~ 1 integrin receptor [327]. These various interactions indicate that at least this member of the matrilin family has the ability to link the major collagen and proteoglycan components of the extracellular matrix to specific integrin receptors and their associated cell signaling pathways. Matrilin-2 and matrilin-4 are present in many tissues, whereas matrilin-1 and matrilin-3 are more restricted to skeletal tissues [309,312-317,319-321,328]. In epiphyseal cartilage of growing long bones, matrilin-1 and matrilin3 are present in all cartilage regions, in contrast to matrilin-2, which is expressed in the proliferative and the upper hypertrophic zones [320,321,329]. Similarly, matrilin-4 is detected all over the epiphyseal cartilage, with the weakest expression in the hypertrophic zone. During joint development matrilin-2 and matrilin-4 are present at the developing joint surface, whereas in articular cartilage of 6-week-old mice, all matrilins are only weakly expressed. Matrilin-1 has a more widespread distribution during embyronic development [330].
~
William G. Cole
Electron microscopy of matrilin-1 oligomers from cartilage revealed the presence of a bouquet-like structure consisting of three ellipsoid subunits connected at their C-terminal coiled-coil domains [331]. Although the oligomers are stabilized by disulfide bonds between the coiled-coil domains, formation of the oligomers is not dependent on formation of disulfide bonds. In contrast, oligomerization appears to be dependent on a heptad repeat of seven residues denoted a-g, with a 3,4-hydrophobic repeat of mostly apolar residues at positions a and d [332]. Studies using isolated coiled-coil domains showed .that matrilin-1, matrilin-2, and matrilin-4 formed disulfide-linked, three-stranded, parallel homotrimers, whereas the domain from matrilin-3 produced a disulfide-linked, four-stranded, parallel coiled-coil structure [308]. The preference of matrilin-3 to form tetramers rather than trimers may be due to the fact that matrilin-3 contains a single isoleucine residue at a d position of the third heptad repeat. Nine different oligomers were identified when all possible combinations of two or three different matrilin monomers were mixed in various molar ratios. With the exception of matrilin-3, which interacted only with matrilin-1, heteromer formation was observed for all other chain combinations. For all of these complexes, disulfide-linked heterotrimeric structures were found, except for matrilin-1 and matrilin-3, which folded into disulfide-linked tetramers. The concentration of the individual peptides determined the stoichiometry of the complexes. Consequently, it is likely that the relative levels of expression of the matrilin genes are the main determinant of the types of matrilin oligomers in the extracellular matrix. The molecular heterogeneity is likely to be even greater because of the alternatively spliced isoforms of matrilin-2 and matrilin-4.
THROMBOSPONDINS The five members of the thrombospondin family are designated thrombospondin-l-thrombospondin-5 [333]. Thrombospondin-5 is also known as cartilage oligomeric matrix protein (COMP). The thrombospondins are multimeric, multidomain glycoproteins that function at cell surfaces and in the extracellular matrix. The latter functions are also referred to as matricellar functions. The thrombospondin-1 gene, THBS1, is located on chromosome 15q15 [334-336]. The full-length protein monomer contains 1170 amino acids, including a signal peptide of 31 amino acids. The thrombospondin-2 gene, THBS2, is located on chromosome 6q27 [337,338]. The full-length protein contains 1172 amino acids, including a signal peptide of 18 amino acid residues. The throm-
bospondin-3 gene, THBS3, on chromosome l q21 encodes a protein monomer of 956 amino acids, including a signal peptide of 36 amino acid residues [339,340]. The thrombospondin-4 gene, THB4, on chromosome 5q13 encodes a full-length protein monomer of 961 amino acid residues, including a signal peptide of 21 residues [341,342]. Finally, the thrombospondin-5 gene, COMP, located on chromosome 19pl 3.1 encodes a full-length monomer of 757 amino acids, including a signal peptide of 20 amino acid residues [343]. Each thrombospondin is expressed in multiple tissues, particularly during fetal life. Similarly, most tissues express multiple members of the thrombospondin family [333]. Consequently, most of the thrombospondins are expressed in bone and cartilage during embryogenesis [343-346]. COMP is the most abundant form in postnatal growth plates [345,347]. Thrombospondin-2 and COMP are also present in postnatal bone and bone marrow stromal cells [347]. The thrombospondins are divided into subfamily A and subfamily B [333]. Thrombospondin-1 and thrombospondin-2 monomers, the members of subfamily A, share a complex modular structure and can assemble into disulfide-linked trimers. The modules from the amino terminus include the N-terminal domain; the oligomerization sequence; the procollagen homology region; three type 1, three type 2, and seven type 3 repeating units; and a globular C-terminal domain. Thrombospondins-3-5 are in subfamily B. They have unique N-terminal regions and lack the procollagen homology domain and type 1 repeats, but they contain four copies of the type 2 repeat and are assembled as pentamers. The globular amino- and carboxyl-terminal domains are connected to the remainder of the monomers by thin, flexible stalk regions [348]. The conformations of the stalk regions and the termini are determined, at least in part, by the calcium ion concentration [349]. The oligomerization motifs in all the thrombospondins are likely to be in a coiled-coil conformation, giving rise in subfamily A to trimers and in subfamily B to pentamers [350]. The procollagen homology region of thrombospondin1 also folds into a stable, compact, and disulfide-bonded monomer [350]. Isolated type 3 repeats of COMP produce a 14.2-nm rod-like structure [351]. The C-terminal domain and the adjoining type 3 repeats may fold together, in the presence of calcium, to form a C-terminal globular structure [351]. Thrombospondin-1 and thrombospondin-2 can form homotrimers and heterotrimers [352]. Thrombospondin trimers and pentamers are stabilized by the formation of interchain disulfide bonds between their corresponding oligomerization domains [353]. Pentamerization of COMP involves the formation of interchain disulfide
1. Structureof Growth Plate and Bone Matrix bonds between cysteine residues 68 and 71 [354]. Intrachain disulfide bonds are also present in the type 3 repeats [355]. There are also specific sites for the addition of N- and O-linked sugars and for the C-mannosylation of tryptophan [356,357]. In the extracellular matrix, the thrombospondins bind to other macromolecules as well as to cell surface receptors. Many of the interactions involve specific domains within the monomers. Some of the interactions are sequence specific, but many are also dependent on the ionic environment and the conformation of the monomers. Each thrombospondin-1 monomer can bind approximately 35 calcium ions, whereas subfamily B thrombospondins, such as COMP, are expected to bind almost double the number of calcium ions [358]. Major changes in conformation of the type 3 repeats and the molecule follow the binding of calcium ions. Binding sites are also present for heparin and heparan sulfate proteoglycan, decorin, various integrins, as well as a wide range of proteases, cytokines, and growth factors [357,359]. The binding sites and the consequences of the interactions have been most thoroughly studied for thrombospondin-1 and thrombospondin-2. For example, the activities of thrombin, plasmin, neutrophil cathepsin G, elastase, urokinase plasminogen activator, plasminogen activator inhibitor, and MMP-2 are modified following binding to the latter thrombospondins [360,361]. The small latent TGF-[31complex with the latencyassociated peptide binds to the WSIIWSPW motif in the second type 1 repeat of thrombospondin-1 [362]. An intermolecular activation effect of the KRFK motif in the first type 1 repeat of thrombospondin-1 releases mature, active TGF-[31. Thrombospondin-2, which lacks the KRFK motif, can bind the latent TGF-[31complex but cannot activate it [362]. Thrombospondin-4 and COMP bind to types I and II collagens [363]. COMP also binds type IX collagen and MMP-19 and-20, whereas thrombospondin-4 also binds to laminin, fibronectin, and matrilin-2 [364-366]. Cell surface interactions with thrombospondin-1 have been studied in detail, whereas little information is available concerning the other thrombospondins [333]. The amino-terminal domain, type 1 repeats, type 3 repeats, and the C-terminal domain all interact with the cell surface. Each region appears to act via different cell surface receptors. The interactions are calcium dependent and appear to be important for the maintenance of cell adhesion, spreading, migration, and shape. Cell attachment activity also appears to be important for thrombospondins-2 and-4 and COMP [344,367]. The C-terminal domains of thrombospondin-4 and COMP bind types I, II, and IX collagens in a zincion-dependent manner [363-365]. The binding of the
23
latter thrombospondins is to the amino and carboxyl propeptides and two triple-helical sites of these collagens. The pentameric structure of thrombospondin-4 and COMP favors the use of multiple sites of interaction, which are likely to stabilize the extracellular matrix. A candidate COMP binding site with types II and IX collagens resides between amino acid residues 579 and 595 of the C-terminal domain [364]. Further insights into the functions of thrombospondin-l, thrombospondin-2, and COMP have been obtained from murine gene knockout studies. Mice lacking thrombospondin-1 show decreased embryonic viability, early onset pneumonia, increased circulating monocytes, and reduced TGF-[31activation in the inflamed lungs and pancreas [368]. Mice lacking thrombospondin-2 develop fragile skin, lax tendons, increased thickness and density of the long-bone cortices, increased vascular density, prolonged bleeding time, and accelerated skin wound healing [369]. The changes in the skin indicate that thrombospondin-2 normally plays an important role in collagen fibrillogenesis. Abnormal fibroblast interactions with the extracellular matrix and increased production of active MMP-2 were also identified in cell cultures from thrombospondin-2-deficient mice. In contrast, mice deficient in COMP did not show any anomalies [370].
OSTEONECTIN Osteonectin, initially isolated from demineralized bone matrix, was named according to its ability to bind to Ca 2+, hydroxyapatite, and collagen and to nucleate hydroxyapatite deposition [371,372]. The protein has also been called secreted protein, acidic and rich in cysteine (SPARC), basement membrane 40, or "culture shock" protein [373,374]. Osteonectin is an antiadhesive protein because it inhibits cell spreading, induces rounding of cells, and disassembles focal adhesions [375]. Other activities of osteonectin include calcium-dependent binding to collagens and thrombospondin, binding to plateletderived growth factor-AB and-BB, and regulation of cell proliferation and MMP expression [375]. The gene S P A R C or ON is located on chromosome 5q31.3-q32 [376]. The gene is expressed at high levels in tissues undergoing morphogenesis, remodeling, and wound repair. It is also made by cells of osteoblastic lineage and the hypertrophic chondrocytes of the growth plate [377-381]. The S P A R C gene is also expressed in several postnatal nonskeletal tissues, including salivary and renal tubular epithelium [382]. Osteonectin is the most abundant noncollagenous protein in mineralized bone matrix [372]. The S P A R C
24
William G. Cole
gene encodes a full-length protein of 303 amino acids, including the signal peptide of 17 amino acid residues. The core molecular weightis 33 kDa [383]. The protein extracted from bone has an apparent molecular weight of 43 kDa due to posttranslational modifications such as glycosylation [372]. The mature human protein consists of 286 amino acid residues divided into three domains [384-387]. An amino-terminal acidic segment (residues 1-52) binds five to eight calcium ions with low affinity and mediates interactions with hydroxyapatite. A follistatin-like domain (residues 53-137) contains five disulfides and an N-linked oligosaccharide at Asn 99. Finally, an oL-helical domain contains two EF hand, high-affinity, extracellular calcium binding sites (EC domain, residues 138-286). Crystal structure analysis showed that the follistatin and extracellular calcium domains interact through a small interface that involves the EF hand pair of the extracellular domain [385,388,389]. The elongated follistatin domain is structurally related to serine protease inhibitors of the Kazal family. Residues implicated in cell binding, inhibition of cell spreading, and disassembly of focal adhesions cluster on one side of osteonectin opposite the binding epitope for collagens and the N-linked oligosaccharide. Crystal structure analysis also showed that the collagen-binding epitope in the helix oLA is partially masked by helix oLC [388]. Deletion of helix oLC produced a 10-fold increase in collagen affinity, similar to that seen after proteolytic cleavage of this helix [390]. Five residues were crucial for collagen binding: R149 and N156 in helix otA and L242, M245, and E246 in a loop region connecting the two EF hands of osteonectin [390]. These residues were spatially close and formed a flat ring of 15 A, which matches the diameter of a triple-helical collagen domain. Nearly identical binding characteristics were displayed by types I and IV collagens. Mice deficient in osteonectin are normal at birth and lack any evidence of connective tissue anomalies. By 6 months of age, the mice develop severe eye pathology [391]. Impaired wound healing is also apparent in osteonectin-deficient mice [392]. The anomalies are consistent with osteonectin normally playing a role in the migration of fibroblasts into the wound and in the formation of granulation tissue.
OSTEOCALCIN Osteocalcin is a small protein that accounts for approximately 10% of the noncollagenous protein of bone [393]. It is also called bone ~/-carboxyglutamate or bone Gla protein. It is one of several Gla proteins found in the skeleton. Matrix Gla protein is synthesized in
cartilage [394]. Other Gla proteins, such as protein S, are made elsewhere and are deposited in the bone matrix from the circulation [395]. The Gla proteins have in common the presence of glutamic acid residues that have been ~/-carboxylated by a specific ~/-carboxylase that requires vitamin K as a cofactor [396]. These ~/-carboxyglutamate residues have a high affinity for mineral ions such as Ca 2+ and for hydroxyapatite crystals. The osteocalcin gene, BGLAP, is located on chromosome 1q25-q31 [397,398]. The gene is very small (< 1 kb) and contains only four exons [399]. Exons 1-3 code for the preproosteocalcin, whereas exon 4 codes for the mature protein. The gene is specifically expressed by osteoblasts and is consequently limited to bone, specifically to regions destined for mineralization [400]. Mice lacking osteocalcin develop a phenotype marked by higher bone mass and bones of improved functional quality [401]. Histomorphometric studies performed before and after ovariectomy showed that the absence of osteocalcin leads to an increase in bone formation without impairing bone resorption. These findings, as well as those from detailed studies of bone mineralization in osteocalcin-deficient mice, provide evidence that osteocalcin is a determinant of bone formation and that it is also needed to stimulate bone mineral maturation [401,402]. However, cloning of the mouse osteocalcin gene has shown that the gene structure is complex. It consists of three genes, all transcribed in the same direction, within a 23-kb region of genomic DNA [403]. The genes were named osteocalcin gene 1, osteocalcin gene 2, and osteocalcin-related gene from the 5' end of the osteocalcin cluster. The osteocalcin 1 and osteocalcin 2 genes each contain four exons, whereas the osteocalcinrelated gene contains, in addition to the four exons typical of osteocalcin, exon 1 that is not translated. There is no translational stop codon in any of these genes, and each can be transcribed. The osteocalcin 1 and osteocalcin 2 genes are expressed only in bone, whereas osteocalcin-related gene is expressed in kidney but not in bone. The protein encoded by the osteocalcinrelated gene is the same as nephrocalcin, a calciumbinding protein of the kidney [404]. The osteocalcin promoter has been studied in detail. Responsive elements for 1,25-dihydroxyvitamin D3, glucocorticoids, and tumor necrosis factor-~ have been identified [405-407]. Other transcriptional regulatory sites such as one that binds MSX1 and MSX2, two homeodomain-containing proteins, have also been identified [408]. Two osteoblast-specific elements, OSE1 and OSE2, are present in the mouse osteocalcin gene. OSE2, which is upstream of OSE1, appears to regulate the expression of the osteocalcin gene by mature and immature osteoblasts, whereas OSE 1 appears to regulate expression of the gene by immature osteoblasts.
1. Structure of Growth Plate and Bone Matrix
The full-length protein contains 100 amino acid residues [394,399]. There is a signal peptide of 23 amino acid residues and a propeptide of 28 residues. The mature protein contains 49 amino acid residues. In humans, the protein contains 2 rather than 3 Gla residues seen in other species [409]. The predicted structure of the protein consists of two antiparallel oL-helical domains connected by a 13 turn [410]. A disulfide bond between cysteines 23 and 29 stabilizes the structure. The Gla residues have affinity for free Ca 2+ and Ca2+-containing proteins. Calcium binds to the carboxyl groups of the Gla residues and to the opposing carboxyl groups of aspartic and glutamic acid residues in the two helical domains of osteocalcin [411].
MATRIX Gla PROTEIN Matrix ~/-carboxyglutamic acid protein, or matrix Gla protein, is a highly insoluble protein of bone. It belongs to a family of vitamin K-dependent Gla proteins of the extracellular matrix. It was initially isolated from bovine bone [412]. The gene encoding matrix Gla protein, MGP, is located on chromosome 12p13.1-12.3 [398]. The human gene spans 3.9 kbs of chromosomal DNA and consists of four exons separated by three large intervening sequences that account for more than 80% of the gene. The N-terminal sequences of the known vitamin Kdependent vertebrate proteins reveal a transmembrane signal peptide, followed by a putative ~/-carboxylation recognition site and a Gla-containing domain. Each of these regions corresponds to a separate exon in MGP. The MGP gene also contains a fourth exon of unknown function that codes for 11 residues and lies between the transmembrane signal peptide and the putative recognition site for the ~/-carboxylase. This four-exon organization is essentially identical to that of bone Gla protein and is quite different from the two-exon organization encoding this region in the other known vitamin Kdependent proteins [398]. Analysis of the MGP gene promoter revealed, in addition to the typical TATA and CAT boxes, the presence of a number of putative regulatory sequences homologous to previously identified hormone and transcription factor responsive elements. In particular, two regions of the promoter were delineated containing possible binding sites for retinoic acid and vitamin D receptors [398]. The MGP gene is expressed in many tissues, particularly in lung and cartilage [413,414]. Despite the widespread expression of MGP, gene expression is limited to smooth muscle cells of the arteries and the chondrocytes
25
[414]. In the growth plate, MGP is most highly expressed in proliferative chondrocytes and in the lower hypertrophic chondrocytes at the site where cartilage will calcify [414-416]. MGP expression was not detected in osteoblasts and to only a low level in fibroblasts of the periosteum and perichondrium [417]. The full-length matrix Gla protein contains 103 amino acid residues [394]. It contains a signal peptide of 19 amino acid residues. The mature protein contains residues 20-96. The C-propeptide from residues 97-103 is cleaved. It has been proposed that the amino acid substitution of Lys 79 for Gln 79 in the human protein allows removal of additional basic residues from the C terminus by a carboxypeptidase B-like activity [418]. ~/-Carboxylation of Glu occurs at residues 21,56,60,67, and 71 of the full-length protein [394]. Serine residues at positions 22,25, and 28 of the full-length protein, located in the amino terminus of the mature protein, are partially phosphorylated. Phosphorylation occurs in the recognition motif Ser-X-Glu/Ser(p) [419]. The importance of matrix Gla protein as an inhibitor of mineralization is demonstrated in mice that lack matrix Gla protein. The phenotye consists of calcification of arteries and the inappropriate calcification of cartilages, including growth plates, resulting in short stature, osteopenia, and fractures [417].
BONE SIALOPROTEIN Bone sialoprotein is the second major sialoprotein of bone [2]. It is also referred to as bone sialoprotein-2 or integrin-binding sialoprotein. It constitutes approximately 12% of the noncollagenous protein of human bone [2]. It binds to calcium and hydroxyapatite, cells, and collagens. The gene for bone sialoprotein or integrin-binding sialoprotein (IBSP) is located on chromosome 4q21-q25, which is also the location of the distinct SPP1 gene for osteopontin. Gene expression is more limited than that for osteopontin [243]. The IBSP gene is expressed by hypertrophic chondrocytes in the growth plate, in a subset of osteoblasts at the onset of matrix mineralization, and in osteoclasts [420]. Outside of the skeleton, bone sialoprotein is expressed in odontoblasts and in trophoblast of the placenta. The IBSP m R N A encodes a full-length protein of 317 amino acid residues and a signal peptide of 16 amino acid residues. The mature protein has a deduced core molecular weight of 33,600 [243,421]. Bone sialoprotein purified from bovine bone has a molecular weight of 59 kDa due to its high content of carbohydrate. It is rich in sialic acid and O-linked glycosidically linked
26
William G. Cole
oligosaccharides. Bone sialoprotein also contains stretches of polyglutamic acid as opposed to polyaspartic acid in osteopontin. The stretches of up to 10 glutamic acid residues provide high-affinity binding to Ca 2+. This characteristic is likely important in the role of bone sialoprotein in matrix mineralization. In addition, approximately half of the serine residues in the protein carry phosphate groups. An RGD sequence is located at the C terminus, in contrast to the central location in osteopontin. It enables bone sialoprotein to bind to cells via an integrin receptor of the vitronectin type (OLv[33). The RGD sequence is surrounded by tyrosine sulfation consensus sequences, although it is unclear whether sulfation affects the kinetics of binding. Bone cells attach to intact bone sialoprotein in an RGD-dependent manner, but frag'ments of bone sialoprotein can bind to cells in an RGD-independent manner.
BONE ACIDIC GLYCOPROTEIN-75 Bone acidic glycoprotein-75 (BAG-75) is another sialoprotein of mineralizing tissue. The function of the protein is unclear, but based on its affinity for hydroxyapatite, it is likely involved in mineral nucleation or growth or both. Its amino-terminal amino acid sequence is similar to that of osteopontin and dentin matrix protein-1. Although the complete sequence of BAG-75 and its gene location are unknown, it appears from antibody studies that BAG-75 and dentin matrix protein-1 and osteopontin are distinct proteins [422].
DENTIN MATRIX ACIDIC PHOSPHOPROTEIN- 1 Dentin matrix protein-1 was first isolated by cDNA cloning using a rat odontoblast mRNA library [423]. It was initially postulated to be specific to dentin but later was detected in calvaria and long bones [424]. The gene encoding dentin matrix acidic phosphoprotein-1, DMP1, is located within 150kbs of the bone sialoprotein locus and within 490 kbs of the SPP1 locus for osteopontin on chromosome 4q21. The gene contains six exons [422]. The gene encodes a protein chain of 513 amino acids, including a signal peptide [423]. The amino acid sequence is highly acidic and serine rich. Approximately 55 of the 107 serine residues of rat dentin matrix acidic phosphoprotein-1 are potential sites for phosphorylation [423]. The protein is very difficult to extract from bone. The full-length protein, with its posttranslational modifica-
tions, likely has a molecular weight of 150 kDa [422]. There is also one RGD site for cell binding.
OSTEOPONTIN Osteopontin, also known as secreted phosphoprotein 1, is a secreted glycoprotein with the characteristics of a matricellular protein [425]. It was named osteopontin because it was proposed to act as a "bone bridge" from bone cells to hydroxyapatite [426]. It is highly expressed in bone but also by many cell types, including hypertrophic chondrocytes, odontoblasts, macrophages, as well as endothelial, smooth muscle, and epithelial cells [273,427]. Osteopontin is involved in a diverse range of biological processes, including biomineralization, cell attachment and cell signaling, cell migration, inflammation, and leukocyte recruitment. Osteopontin is a potent inhibitor of apatite formation and growth [428]. The inhibition was dose dependent and was abolished when phosphate groups were removed from the osteopontin [428,429]. Osteopontin blocked crystal elongation [428]. The osteopontin gene, SPP1 (secreted phosphoprotein 1), maps to chromosome 4q21-q25 [421,430]. It contains seven exons spanning approximately 9kbs [431,432]. Differential RNA splicing involving 42 nudeotides of exon 5 generates two alternatively spliced products in humans [430]. Specific sequences in the Y region of the SPP1 gene have been found to be regulated by hormones and growth factors associated with bone formation and bone remodeling. Some of the regulatory factors include TGF-[31, TGF-[32, retinoic acid, PTH, endothelin, proinflammatory cytokines, some BMPs, and 1,25-dihydroxyvitamin D3 [433-438]. Bone cells are a major site of synthesis and secretion of phosphorylated osteopontin [439]. In bone, osteopontin was localized to osteoblasts, lining cells, osteocytes, and cells with fibroblastic morphology associated with the periosteum [440,441]. This protein is also synthesized by hypertrophic chondrocytes [439]. The full-length human osteopontin protein contains 300 amino acid residues, including a signal peptide of 16 amino acid residues [442]. The protein is acidic, phosphorylated, and rich in sialic acid [443]. Three regions of the protein are highly conserved, including the aminoterminal one-fourth of the chain, a segment around the RGD integrin-binding sequence, and the extreme C terminus [442]. Four of the 9 or 10 residues in the poly-Asp region (residues 70-80) are strictly conserved. This sequence may be involved in the attachment of the protein to calcium phosphate apatite and in the regulation of growth of the bone crystals [429].
2,7
1. Structure of Growth Plate and Bone Matrix
Osteopontin has an R G D cell binding site, a calcium binding site, and two heparin-binding domains [444]. The RGD domain (residues 128-130) interacts with cell surface integrins OLv[33, e~v[31, and OLv[35to regulate cell attachment and spreading, intracellular signaling, and cell migration [445,446]. A cryptic SVVYGLRcontaining domain interacts with OL9~1 integrins after thrombin cleavage at residues 137 and 138 [447]. Osteopontin does not bind the standard form of CD44 (hyaluronic acid receptor) but may bind various isoforms of CD44 [448]. Osteopontin contains two conserved amino-terminal domains with heparin-binding homology that are likely to regulate its binding to the extracellular matrix. Osteopontin also binds directly to fibronectin, collagen, and osteocalcin [425]. Serine residues are also highly conserved. Many of them are phosphorylated (Pse) in Ser-X-Glu/Pse/ Asp or Ser-X-X/Glu/Pse motifs [443]. The highly conserved threonines found at positions 107,116, and 121 contain O-linked oligosaccharides [449]. A potential N-glycosylation site is present at residues 63-65. Unidentified sites of sulfation also exist in osteopontin. Extracted osteopontin peptides from bone show that the protein exists as a heterogeneous mixture of molecules that differ in their extent of posttranslational modification [450]. In particular, bone contains osteopontin molecules that differ widely in the extent of serine and threonine phosphorylation. Similar findings have been observed in the osteopontins produced by cultured osteoblasts. In one study, a 55-kDa form, produced by immature osteoblasts, was less phosphorylated and sulfated than a 44-kDa form produced by more mature osteoblasts [451]. The 55-kDa form may have a localized function because it was secreted into cement lines, whereas the 44-kDa form may have a more widespread role in the regulation of mineralization throughout the bone. Glutamines at positions 34 and 36 are substrates for transglutaminase [452]. Transglutaminase-promoted cross-linking may account for the higher-molecularweight aggregates of osteopontin in bone extracts [453]. Mice that lack osteopontin show no evidence of skeletal developmental anomalies in the neonatal period [454]. However, spleen cells from the deficient mice were better able to form osteoclasts than wild-type spleen cells. The phenotype became more pronounced with age. At 4-6 months of age, the osteopontin-deficient mice had two times the trabecular bone volume and three times the number of osteoclasts than wild-type mice [455]. The osteopontin-deficient mice were also resistant to ovariectomy-induced bone resorption, although the osteoclast numbers were not significantly different than those in sham-operated wild-type mice. This finding supports
the proposal that osteopontin is an important regulator of osteoclast activity [455].
References 1. Hascall, V. C., and Sajdera, S. W. (1970). Physical properties and polydispersity of proteoglycan from bovine nasal cartilage. J. Biol. Chem. 245, 4920-4930. 2. Herring, G. (1972). The organic matrix of bone. In The Biochemisty and Physiology of Bone (G. Bourne, Ed.), Vol. 1, pp. 127-189. Academic Press, New York. 3. Click, E. M., and Bornstein, P. (1970). Isolation and characterization of the cyanogen bromide peptides from the alpha 1 and alpha 2 chains of human skin collagen. Biochemistry 9, 4699-4706. 4. Fietzek, P. P., Furthmayr, H., and Kuhn, K. (1974). Comparative sequence studies on alpha2-CB2 from calf, human, rabbit and pigskin collagen. Eur. J. Biochem. 47, 257-261. 5. Bernard, M. P., Chu, M. L., Myers, J. C., Ramirez, F., Eikenberry, E. F., and Prockop, D. J. (1983). Nucleotide sequences of complementary deoxyribonucleic acids for the pro alpha 1 chain of human type I procollagen. Statistical evaluation of structures that are conserved during evolution. Biochemistry 22, 5213-5223. 6. Hartung, S., Jaenisch, R., and Breindl, M. (1986). Retrovirus insertion inactivates mouse alpha l(I) collagen gene by blocking initiation of transcription. Nature 320, 365-367. 7. Bonadio, J., Jepsen, K. J., Mansoura, M. K., Jaenisch, R., Kuhn, J. L., and Goldstein, S. A. (1993). A murine skeletal adaptation that significantly increases cortical bone mechanical properties. Implications for human skeletal fragility. J. Clin. Invest. 92, 1697-1705. 8. Retief, E., Parker, M. I., and Retief, A. E. (1985). Regional chromosome mapping of human collagen genes alpha 2(I) and alpha l(I) (COLIA2 and COLIA1). Hum. Genet. 69, 304-308. 9. de Wet, W., Bernard, M., Benson-Chanda, V., Chu, M. L., Dickson, L., Weil, D., and Ramirez, F. (1987). Organization of the human pro-alpha 2(I) collagen gene. J. Biol. Chem. 262, 16032-16036. 10. Tromp, G., Kuivaniemi, H., Stacey, A., Shikata, H., Baldwin, C. T., Jaenisch, R., and Prockop, D. J. (1988). Structure of a full-length cDNA clone for the prepro alpha l(I) chain of human type I procollagen. Biochem. J. 253, 919-922. 11. Kuivaniemi, H., Tromp, G., Chu, M. L., and Prockop, D. J. (1988). Structure of a full-length cDNA clone for the prepro alpha 2(I) chain of human type I procollagen. Comparison with the chicken gene confirms unusual patterns of gene conservation. Biochem. J.
252, 633-640. 12. Vuorio, E., and de Crombrugghe, B. (1990). The family of collagen genes. Annu. Rev. Biochem. 59, 837-872. 13. Makela, J. K., Raassina, M., Virta, A., and Vuorio, E. (1988). Human pro alpha l(I) collagen: cDNA sequence for the C-propeptide domain. Nucleic Acids Res. 16, 349. 14. Bernard, M. P., Myers, J. C., Chu, M. L., Ramirez, F., Eikenberry, E. F., and Prockop, D. J. (1983). Structure of a cDNA for the pro alpha 2 chain of human type I procollagen. Comparison with chick cDNA for pro alpha 2(I) identifies structurally conserved features of the protein and the gene. Biochemistry 22, 1139-1145. 15. Orgel, J. P., Wess, T. J., and Miller, A. (2000). The in situ conformation and axial location of the intermolecular cross-linked non-helical telopeptides of type I collagen. Struct. Fold. Des. 8, 137-142. 16. Bernocco, S., Finet, S., Ebel, C., Eichenberger, D., Mazzorana, M., Farjanel, J., and Hulmes, D. J. (2001). Biophysical characterization
28
17.
18.
19.
20. 21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31. 32.
33.
34.
William G. Cole of the C-propeptide trimer from human procollagen III reveals a tri-lobed structure. J. Biol. Chem. 276, 48930-48936. Lees, J. F., and Bulleid, N. J. (1994). The role of cysteine residues in the folding and association of the COOH-terminal propeptide of types I and III procollagen. J. Biol. Chem. 269, 24354-24360. Veis, A., Leibovich, S. J., Evans, J., and Kirk, T. Z. (1985). Supramolecular assemblies of mRNA direct the coordinated synthesis of type I procollagen chains. Proc. Natl. Acad. Sci. USA 82, 3693-3697. Vuust, J. (1975). Procollagen biosynthesis by embryonicchick-bone polysomes. Estimation of the relative numbers of active proalphal and proalpha2 messenger ribonucleic acids. Eur. J. Biochem. 60, 41-50. Vuust, J., and Piez, K. A. (1972). A kinetic study of collagen biosynthesis. J. Biol. Chem. 247, 856-862. Vuust, J., Sobel, M. E., and Martin, G. R. (1985). Regulation of type I collagen synthesis. Total pro alpha 1(I) and pro alpha 2(1) mRNAs are maintained in a 2:1 ratio under varying rates of collagen synthesis. Eur. J. Biochem. 151,449-453. Olsen, A. S., and Prockop, D. J. (1989). Transcription of human type I collagen genes. Variation in the relative rates of transcription of the pro alpha 1 and pro alpha 2 genes. Matrix 9, 73-81. Hu, G., Tylzanowski, P., Inoue, H., and Veis, A. (1995). Relationships between translation of pro alpha l(I) and pro alpha2(I) mRNAs during synthesis of the type I procollagen heterotrimer. J. Cell. Biochem. 59, 214-234. Lees, J. F., Tasab, M., and Bulleid, N. J. (1997). Identification of the molecular recognition sequence which determines the typespecific assembly of procollagen. E M B O J. 16, 908-916. Veis, A., and Brownell, A. G. (1977). Triple-helix formation on ribosome-bound nascent chains of procollagen: Deuteriumhydrogen exchange studies. Proc. Natl. Acad. Sci. USA 74, 902-905. Brownell, A. G., and Veis, A. (1976). Intracellular location of triple helix formation of collagen. Enzyme probe studies. J. Biol. Chem. 251, 7137-7143. Brownell, A. G., and Veis, A. (1975). The intracellular location of the glycosylation of hydroxylysine of collagen. Biochem. Biophys. Res. Commun. 63, 371-377. Veis, A., and Kirk, T. Z. (1989). The coordinate synthesis and cotranslational assembly of type I procollagen. J. Biol. Chem. 264, 3884-3889. Kosher, R. A., Kulyk, W. M., and Gay, S. W. (1986). Collagen gene expression during limb cartilage differentiation. J. Cell Biol. 102, 1151-1156. Bienkowski, R. S., Baum, B. J., and Crystal, R. G. (1978). Fibroblasts degrade newly synthesised collagen within the cell before secretion. Nature 276, 413-416. Prockop, D. J., and Kivirikko, K. I. (1984). Heritable diseases of collagen. N. Engl. J. Med. 311, 376-386. Popescu, N. C., Cheng, S. Y., and Pastan, I. (1988). Chromosomal localization of the gene for a human thyroid hormone-binding protein. Am. J. Hum. Genet. 42, 560-564. Helaakoski, T., Annunen, P., Vuori, K., MacNeil, I. A., Pihlajaniemi, T., and Kivirikko, K. I. (1995). Cloning, baculovirus expression, and characterization of a second mouse prolyl 4-hydroxylase alpha-subunit isoform: Formation of an alpha 2 beta 2 tetramer with the protein disulfide-isomerase/beta subunit. Proc. Natl. Acad. Sci. USA 92, 4427-4431. Pajunen, L., Jones, T. A., Helaakoski, T., Pihlajaniemi, T., Solomon, E., Sheer, D., and Kivirikko, K. I. (1989). Assignment of the gene coding for the alpha-subunit of prolyl 4-hydroxylase to human chromosome region 10q21.3-23.1. Am. J. Hum. Genet. 45, 829-834.
35. Helaakoski, T., Veijola, J., Vuori, K., Rehn, M., Chow, L. T., Taillon-Miller, P., Kivirikko, K. I., and Pihlajaniemi, T. (1994). Structure and expression of the human gene for the alpha subunit of prolyl 4-hydroxylase. The two alternatively spliced types of mRNA correspond to two homologous exons the sequences of which are expressed in a variety of tissues. J. Biol. Chem. 269, 27847-27854. 36. Annunen, P., Helaakoski, T., Myllyharju, J., Veijola, J., Pihlajaniemi, T., and Kivirikko, K. I. (1997). Cloning of the human prolyl 4-hydroxylase alpha subunit isoform alpha(II) and characterization of the type II enzyme tetramer. The alpha(I) and alpha(II) subunits do not form a mixed alpha(I)alpha(II)beta2 tetramer. J. Biol. Chem. 272, 17342-17348. 37. Hautala, T., Byers, M. G., Eddy, R. L., Shows, T. B., Kivirikko, K. I., and Myllyla, R. (1992). Cloning of human lysyl hydroxylase: Complete cDNA-derived amino acid sequence and assignment of the gene (PLOD) to chromosome l p36.3-p36.2. Genomics 13, 62-69. 38. Szpirer, C., Szpirer, J., Riviere, M., Vanvooren, P., Valtavaara, M., and Myllyla, R. (1997). Localization of the gene encoding a novel isoform of lysyl hydroxylase. Mamm. Genome 8, 707-708. 39. Valtavaara, M., Papponen, H., Pirttila, A. M., Hiltunen, K., Helander, H., and Myllyla, R. (1997). Cloning and characterization of a novel human lysyl hydroxylase isoform highly expressed in pancreas and muscle. J. Biol. Chem. 272, 6831-6834. 40. Passoja, K., Rautavuoma, K., Ala-Kokko, L., Kosonen, T., and Kivirikko, K. I. (1998). Cloning and characterization of a third human lysyl hydroxylase isoform. Proc. Natl. Acad. Sci. USA 95, 10482-10486. 41. Valtavaara, M., Szpirer, C., Szpirer, J., and Myllyla, R. (1998). Primary structure, tissue distribution, and chromosomal localization of a novel isoform of lysyl hydroxylase (lysyl hydroxylase 3). J. Biol. Chem. 273, 12881-12886. 42. Breslau-Siderius, E. J., Engelbert, R. H., Pals, G., and van der Sluijs, J. A. (1998). Bruck syndrome: a rare combination of bone fragility and multiple congenital joint contractures. J. Pediatr. Orthop. B 7, 35-38. 43. Bottomley, M. J., Batten, M. R., Lumb, R. A., and Bulleid, N. J. (2001). Quality control in the endoplasmic reticulum: PDI mediates the ER retention of unassembled procollagen C-propeptides. Curr. Biol. 11, 1114-1118. 44. Wilson, R., Lees, J. F., and Bulleid, N. J. (1998). Protein disulfide isomerase acts as a molecular chaperone during the assembly of procollagen. J. Biol. Chem. 273, 9637-9643. 45. Nagai, N., Hosokawa, M., Itohara, S., Adachi, E., Matsushita, T., Hosokawa, N., and Nagata, K. (2000). Embryonic lethality of molecular chaperone hsp47 knockout mice is associated with defects in collagen biosynthesis. J. Cell Biol. 150, 1499-1506. 46. Bruckner, P., Eikenberry, E. F., and Prockop, D. J. (1981). Formation of the triple helix of type I procollagen in cellulo. A kinetic model based on cis-trans isomerization of peptide bonds. Eur. J. Biochem. 118, 607-613. 47. Bruckner, P., and Eikenberry, E. F. (1984). Formation of the triple helix of type I procollagen in cellulo. Temperature-dependent kinetics support a model based on cis in equilibrium trans isomerization of peptide bonds. Eur. J. Biochem. 140, 391-395. 48. Bulleid, N. J., Dalley, J. A., and Lees, J. F. (1997). The C-propeptide domain of procollagen can be replaced with a transmembrane domain without affecting trimer formation or collagen triple helix folding during biosynthesis. E M B O J. 16, 6694-6701. 49. Sarkar, S. K., Young, P. E., Sullivan, C. E., and Torchia, D. A. (1984). Detection of cis and trans X-Pro peptide bonds in proteins by 13C NMR: Application to collagen. Proc. Natl. Acad. Sci. USA 81, 4800-4803.
1. Structure of Growth Plate and Bone Matrix 50. Buevich, A. V., Dai, Q. H., Liu, X., Brodsky, B., and Baum, J. (2000). Site-specific NMR monitoring of cis-trans isomerization in the folding of the proline-rich collagen triple helix. Biochemistry 39, 4299-4308. 51. Lang, K., and Schmid, F. X. (1988). Protein-disulphide isomerase and prolyl isomerase act differently and independently as catalysts of protein folding. Nature 331, 453-455. 52. Perret, S., Merle, C., Bernocco, S., Berland, P., Garrone, R., Hulmes, D. J., Theisen, M., and Ruggiero, F. (2001). Unhydroxylated triple helical collagen I produced in transgenic plants provides new clues on the role of hydroxyproline in collagen folding and fibril formation. J. Biol. Chem. 276, 43693-43698. 53. Xu, Y., Bhate, M., and Brodsky, B. (2002). Characterization of the nucleation step and folding of a collagen triple-helix peptide. Biochemistry 41, 8143-8151. 54. Boudko, S., Frank, S., Kammerer, R. A., Stetefeld, J., Schulthess, T., Landwehr, R., Lustig, A., Bachinger, H. P., and Engel, J. (2002). Nucleation and propagation of the collagen triple helix in single-chain and trimerized peptides: Transition from third to first order kinetics. J. Mol. Biol. 317, 459-470. 55. Persikov, A. V., Ramshaw, J. A., Kirkpatrick, A., and Brodsky, B. (2002). Peptide investigations of pairwise interactions in the collagen triple-helix. J. Mol. Biol. 316, 385-394. 56. Hurskainen, T. L., Hirohata, S., Seldin, M. F., and Apte, S. S. (1999). ADAM-TS5, ADAM-TS6, and ADAM-TS7, novel members of a new family of zinc metalloproteases. General features and genomic distribution of the ADAM-TS family. J. Biol. Chem. 274, 25555-25563. 57. Colige, A., Sieron, A. L., Li, S. W., Schwarze, U., Petty, E., Wertelecki, W., Wilcox, W., Krakow, D., Cohn, D. H., Reardon, W., Byers, P. H., Lapiere, C. M., Prockop, D. J., and Nusgens, B. V. (1999). Human Ehlers-Danlos syndrome type VII C and bovine dermatosparaxis are caused by mutations in the procollagen I N-proteinase gene. Am. J. Hum. Genet. 65, 308-317. 58. Kessler, E., Takahara, K., Biniaminov, L., Brusel, M., and Greenspan, D. S. (1996). Bone morphogenetic protein-1: The type I procollagen C-proteinase. Science 271, 360-362. 59. Yoshiura, K., Tamura, T., Hong, H. S., Ohta, T., Soejima, H., Kishino, T., Jinno, Y., and Niikawa, N. (1993). Mapping of the bone morphogenetic protein 1 gene (BMP1) to 8p21: Removal of BMP1 from candidacy for the bone disorder in Langer-Giedion syndrome. Cytogenet. Cell. Genet. 64, 208-209. 60. Sieron, A. L., Tretiakova, A., Jameson, B. A., Segall, M. L., LundKatz, S., Khan, M. T., Li, S., and Stocker, W. (2000). Structure and function ofprocollagen C-proteinase (mTolloid) domains determined by protease digestion, circular dichroism, binding to procollagen type I, and computer modeling. Biochemistry 39, 3231-3239. 61. Scott, I. C., Clark, T. G., Takahara, K., Hoffman, G. G., Eddy, R. L., Haley, L. L., Shows, T. B., and Greenspan, D. S. (1999). Assignment of TLL1 and TLL2, which encode human BMP-1/Tolloid-related metalloproteases, to chromosomes 4q32~ q33 and 10q23---~q24 and assignment ofmurine Tl12 to chromosome 19. Cytogenet. Cell. Genet. 86, 64-65. 62. Scott, I. C., Clark, T. G., Takahara, K., Hoffman, G. G., and Greenspan, D. S. (1999). Structural organization and expression patterns of the human and mouse genes for the type I procollagen COOH-terminal proteinase enhancer protein. Genomics 55, 229-234. 63. Takahara, K., Osborne, L., Elliott, R. W., Tsui, L. C., Scherer, S. W., and Greenspan, D. S. (1996). Fine mapping of the human and mouse genes for the type I procollagen COOH-terminal proteinase enhancer protein. Genomics 31, 253-256. 64. Xu, H., Acott, T. S., and Wirtz, M. K. (2000). Identification and expression of a novel type I procollagen C-proteinase enhancer
65.
66.
67.
68. 69. 70.
71.
72.
73.
74.
75. 76.
77.
78.
79. 80.
81.
82. 83.
29
protein gene from the glaucoma candidate region on 3q21-q24. Genomics 66, 264-273. Bornstein, P., Walsh, V., Tullis, J., Stainbrook, E., Bateman, J. F., and Hormuzdi, S. G. (2002). The globular domain of the proalpha 1(I) N-propeptide is not required for secretion, processing by procollagen N-proteinase, or fibrillogenesis of type I collagen in mice. J. Biol. Chem. 277, 2605-2613. Birk, D. E., and Trelstad, R. L. (1984). Extracellular compartments in matrix morphogenesis: Collagen fibril, bundle, and lamellar formation by corneal fibroblasts. J. Cell Biol. 99, 2024-2033. Silver, D., Miller, J., Harrison, R., and Prockop, D. J. (1992). Helical model of nucleation and propagation to account for the growth of type I collagen fibrils from symmetrical pointed tips: A special example of self-assembly of rod-like monomers. Proc. Natl. Acad. Sci. USA 89, 9860-9864. Ramachandran, G., and Kartha, G. (1954). Structure of collagen. Nature 174, 269-270. Rich, A., and Crick, F. (1955). The structure of collagen. Nature 176. Mariani, T. J., Trackman, P. C., Kagan, H. M., Eddy, R. L., Shows, T. B., Boyd, C. D., and Deak, S. B. (1992). The complete derived amino acid sequence of human lysyl oxidase and assignment of the gene to chromosome 5 (extensive sequence homology with the murine ras recision gene). Matrix 12, 242-248. Kenyon, K., Modi, W. S., Contente, S., and Friedman, R. M. (1993). A novel human cDNA with a predicted protein similar to lysyl oxidase maps to chromosome 15q24-q25. J. Biol. Chem. 268, 18435-18437. Jourdan-Le Saux, C., Le Saux, O., Donlon, T., Boyd, C. D., and Csiszar, K. (1998). The human lysyl oxidase-related gene (LOXL2) maps between markers D8S280 and D8S278 on chromosome 8p21.2-p21.3. Genomics 51, 305-307. Eyre, D. R., and Oguchi, H. (1980). The hydroxypyridinium crosslinks of skeletal collagens: their measurement, properties and a proposed pathway of formation. Biochem. Biophys. Res. Commun. 92, 403-410. Miyahara, M., Hayashi, K., Berger, J., Tanzawa, K., Njieha, F. K., Trelstad, R. L., and Prockop, D. J. (1984). Formation of collagen fibrils by enzymic cleavage of precursors of type I collagen in vitro. J. Biol. Chem. 259, 9891-9898. Kadler, K. E., Holmes, D. F., Trotter, J. A., and Chapman, J. A. (1996). Collagen fibril formation. Biochem. J. 316 (Pt. 1), 1-11. Birk, D. E., Nurminskaya, M. V., and Zycband, E. I. (1995). Collagen fibrillogenesis in situ: Fibril segments undergo postdepositional modifications resulting in linear and lateral growth during matrix development. Dev. Dyn. 202, 229-243. Holmes, D. F., Lowe, M. P., and Chapman, J. A. (1994). Vertebrate (chick) collagen fibrils formed in vivo can exhibit a reversal in molecular polarity. J. Mol. Biol. 235, 80-83. Parkinson, J., Kadler, K. E., and Brass, A. (1994). Self-assembly of rodlike particles in two dimensions: A simple model for collagen fibrillogenesis. Phys. Rev. E 50, 2963-2966. Birk, D. E. (2001). Type V collagen: Heterotypic type I/V collagen interactions in the regulation of fibril assembly. Micron 32, 223-237. White, J. F., Werkmeister, J. A., Darby, I. A., Bisucci, T., Birk, D. E., and Ramshaw, J. A. (2002). Collagen fibril formation in a wound healing model. J. Struct. Biol. 137, 23-30. Niyibizi, C., and Eyre, D. R. (1989). Identification of the cartilage alpha 1(XI) chain in type V collagen from bovine bone. FEBS Lett. 242, 314-318. Scott, J. E., and Parry, D. A. (1992). Control of collagen fibril diameters in tissues. Int. J. Biol. Macromol. 14, 292-293. Hulmes, D. J. (2002). Building collagen molecules, fibrils, and suprafibrillar structures. J. Struct. Biol. 137, 2-10.
30
William G. Cole
84. Orgel, J. P., Miller, A., Irving, T. C., Fischetti, R. F., Hammersley, A. P., and Wess, T. J. (2001). The in situ supermolecular structure of type I collagen. Structure (Cambridge) 9, 1061-1069. 85. Giraud-Guille, M. M. (1996). Twisted liquid crystalline supramolecular arrangements in morphogenesis. Int. Rev. Cytol. 166, 59-101. 86. Chung, E., Rhodes, K., and Miller, E. J. (1976). Isolation of three collagenous components of probable basement membrane origin from several tissues. Biochem. Biophys. Res. Commun. 71, 1167-1174. 87. Rhodes, R. K., and Miller, E. J. (1978). Physicochemical characterization and molecular organization of the collagen A and B chains. Biochemistry 17, 3442-3448. 88. Fessler, L. I., Robinson, W. J., and Fessler, J. H. (1981). Biosynthesis of procollagen [(pro alpha 1 V)2 (pro alpha 2 V)] by chick tendon fibroblasts and procollagen (pro alpha 1 V)3 by hamster lung cell cultures. J. Biol. Chem. 256, 9646-9651. 89. Morris, N. P., Watt, S. L., Davis, J. M., and Bachinger, H. P. (1990). Unfolding intermediates in the triple helix to coil transition of bovine type XI collagen and human type V collagens alpha 1(2) alpha 2 and alpha 1 alpha 2 alpha 3. J. Biol. Chem. 265, 10081-10087. 90. Chernousov, M. A., Rothblum, K., Tyler, W. A., Stahl, R. C., and Carey, D. J. (2000). Schwann cells synthesize type V collagen that contains a novel alpha 4 chain. Molecular cloning, biochemical characterization, and high affinity heparin binding of alpha 4(V) collagen. J. Biol. Chem. 275, 28208-28215. 91. Imamura, Y., Scott, I. C., and Greenspan, D. S. (2000). The proalpha3(V) collagen chain. Complete primary structure, expression domains in adult and developing tissues, and comparison to the structures and expression domains of the other types V and XI procollagen chains. J. Biol. Chem. 275, 8749-8759. 92. Takahara, K., Hoffman, G. G., and Greenspan, D. S. (1995). Complete structural organization of the human alpha 1 (V) collagen gene (COL5A1): Divergence from the conserved organization of other characterized fibrillar collagen genes. Genomics 29, 588-597. 93. Greenspan, D. S., Cheng, W., and Hoffman, G. G. (1991). The pro-alpha 1(V) collagen chain. Complete primary structure, distribution of expression, and comparison with the pro-alpha I(XI) collagen chain. J. Biol. Chem. 266, 24727-24733. 94. Zhidkova, N. I., Brewton, R. G., and Mayne, R. (1993). Molecular cloning of PARP (proline/arginine-rich protein) from human cartilage and subsequent demonstration that PARP is a fragment of the NH2-terminal domain of the collagen alpha 2(XI) chain. FEBS Lett. 326, 25-28. 95. Tsumaki, N., and Kimura, T. (1995). Differential expression of an acidic domain in the amino-terminal propeptide of mouse proalpha 2(XI) collagen by complex alternative splicing. J. Biol. Chem. 270, 2372-2378. 96. Yoshioka, H., and Ramirez, F. (1990). Pro-alpha I(XI) collagen. Structure of the amino-terminal propeptide and expression of the gene in tumor cell lines. J. Biol. Chem. 265, 6423-6426. 97. Fessler, L. I., Chapin, S., Brosh, S., and Fessler, J. H. (1986). Intracellular transport and tyrosine sulfation of procollagens V. Eur. J. Biochem. 158, 511-518. 98. Neame, P. J., Young, C. N., and Treep, J. T. (1990). Isolation and primary structure of PARP, a 24-kDa proline- and argininerich protein from bovine cartilage closely related to the NH2terminal domain in collagen alpha 1 (XI). J. Biol. Chem. 265, 20401-20408. 99. Moradi-Ameli, M., Rousseau, J. C., Kleman, J. P., Champliaud, M. F., Boutillon, M. M., Bernillon, J., Wallach, J., and Van der Rest, M. (1994). Diversity in the processing events at the N-terminus of type-V collagen. Eur. J. Biochem. 221, 987-995.
100. Moradi-Ameli, M., Deleage, G., Geourjon, C., and van der Rest, M. (1994). Common topology within a non-collagenous domain of several different collagen types. Matrix Biol. 14, 233-239. 101. Takahara, K., Sato, Y., Okazawa, K., Okamoto, N., Noda, A., Yaoi, Y., and Kato, I. (1991). Complete primary structure of human collagen alpha 1 (V) chain. J. Biol. Chem. 266, 13124-13129. 102. Fields, G. B., Van Wart, H. E., and Birkedal-Hansen, H. (1987). Sequence specificity of human skin fibroblast collagenase. Evidence for the role of collagen structure in determining the collagenase cleavage site. J. Biol. Chem. 262, 6221-6226. 103. Bernard, M., Yoshioka, H., Rodriguez, E., Van der Rest, M., Kimura, T., Ninomiya, Y., Olsen, B. R., and Ramirez, F. (1988). Cloning and sequencing of pro-alpha 1 (XI) collagen cDNA demonstrates that type XI belongs to the fibrillar class of collagens and reveals that the expression of the gene is not restricted to cartilagenous tissue. J. Biol. Chem. 263, 17159-17166. 104. Yaoi, Y., Hashimoto, K., Koitabashi, H., Takahara, K., Ito, M., and Kato, I. (1990). Primary structure of the heparin-binding site of type V collagen. Biochim. Biophys. Acta 1035, 139-145. 105. Fichard, A., Kleman, J. P., and Ruggiero, F. (1995). Another look at collagen V and XI molecules. Matrix Biol. 14, 515-531. 106. Takagaki, K., Munakata, H., Kakizaki, I., Iwafune, M., Itabashi, T., and Endo, M. (2002). Domain structure of chondroitin sulfate E octasaccharides binding to type V collagen. J. Biol. Chem. 277, 8882-8889. 107. Weil, D., Bernard, M., Gargano, S., and Ramirez, F. (1987). The pro alpha 2(V) collagen gene is evolutionarily related to the major fibrillar-forming collagens. Nucleic Acids Res. 15, 181-198. 108. Emanuel, B. S., Cannizzaro, L. A., Seyer, J. M., and Myers, J. C. (1985). Human alpha l(III) and alpha 2(V) procollagen genes are located on the long arm of chromosome 2. Proc. Natl. Acad. Sci. USA 82, 3385-3389. 109. Myers, J. C., Loidl, H. R., Seyer, J. M., and Dion, A. S. (1985). Complete primary structure of the human alpha 2 type V procollagen COOH-terminal propeptide. J. Biol. Chem. 260, 11216-11222. 110. Valkkila, M., Melkoniemi, M., Kvist, L., Kuivaniemi, H., Tromp, G., and Ala-Kokko, L. (2001). Genomic organization of the human COL3A1 and COL5A2 genes: COL5A2 has evolved differently than the other minor fibrillar collagen genes. Matrix Biol. 20, 357-366. 111. Woodbury, D., Benson-Chanda, V., and Ramirez, F. (1989). Amino-terminal propeptide of human pro-alpha 2(V) collagen conforms to the structural criteria of a fibrillar procollagen molecule. J. Biol. Chem. 264, 2735-2738. 112. Niyibizi, C., and Eyre, D. R. (1993). Structural analysis of the extension peptides on matrix forms of type V collagen in fetal calf bone and skin. Biochim. Biophys. Acta. 1203, 304-309. 113. Fichard, A., Tillet, E., Delacoux, F., Garrone, R., and Ruggiero, F. (1997). Human recombinant alphal(V) collagen chain. Homotrimeric assembly and subsequent processing. J. Biol. Chem. 272, 30083-30087. 114. Bachinger, H. P., Doege, K. J., Petschek, J. P., Fessler, L. I., and Fessler, J. H. (1982). Structural implications from an electronmicroscopic comparison of procollagen V with procollagen I, pC-collagen I, procollagen IV, and a Drosophila procollagen. J. Biol. Chem. 257, 14590-14592. 115. Unsold, C., Pappano, W. N., Imamura, Y., Steiglitz, B. M., and Greenspan, D. S. (2002). Biosynthetic processing of the proalpha l(V)2pro-alpha 2(V) collagen heterotrimer by bone morphogenetic protein- 1 and furin-like proprotein convertases. J. Biol. Chem. 277, 5596-5602.
1. Structure of Growth Plate and Bone Matrix 116. Fitch, J. M., Gross, J., Mayne, R., Johnson-Wint, B., and Linsenmayer, T. F. (1984). Organization of collagen types I and V in the embryonic chicken cornea: Monoclonal antibody studies. Proc. Natl. Acad. Sci. USA 81, 2791-2795. 117. Niyibizi, C., and Eyre, D. R. (1994). Structural characteristics of cross-linking sites in type V collagen of bone. Chain specificities and heterotypic links to type I collagen. Eur. J. Biochem. 224, 943-950. 118. Kypreos, K. E., Birk, D., Trinkaus-Randall, V., Hartmann, D. J., and Sonenshein, G. E. (2000). Type V collagen regulates the assembly of collagen fibrils in cultures of bovine vascular smooth muscle cells. J. Cell. Biochem. 80, 146-155. 119. Adachi, E., Hayashi, T., and Hashimoto, P. H. (1989). Immunoelectron microscopical evidence that type V collagen is a fibrillar collagen: Importance for an aggregating capability of the preparation for reconstituting banding fibrils. Matrix 9, 232-237. 120. Birk, D. E., Fitch, J. M., Babiarz, J. P., Doane, K. J., and Linsenmayer, T. F. (1990). Collagen fibrillogenesis in vitro: Interaction of types I and V collagen regulates fibril diameter. J. Cell Sci. 95 (Pt. 4), 649-657. 121. Andrikopoulos, K., Liu, X., Keene, D. R., Jaenisch, R., and Ramirez, F. (1995). Targeted mutation in the co15a2 gene reveals a regulatory role for type V collagen during matrix assembly. Nature Genet. 9, 31-36. 122. Mumby, S. M., Raugi, G. J., and Bornstein, P. (1984). Interactions of thrombospondin with extracellular matrix proteins: Selective binding to type V collagen. J. Cell Biol. 98, 646-652. 123. Koda, J. E., Rapraeger, A., and Bernfield, M. (1985). Heparan sulfate proteoglycans from mouse mammary epithelial cells. Cell surface proteoglycan as a receptor for interstitial collagens. J. Biol. Chem. 260, 8157-8162. 124. Whinna, H. C., Choi, H. U., Rosenberg, L. C., and Church, F. C. (1993). Interaction of heparin cofactor II with biglycan and decorin. J. Biol. Chem. 268, 3920-3924. 125. Aho, S., and Uitto, J. (1998). Two-hybrid analysis reveals multiple direct interactions for thrombospondin 1. Matrix Biol. 17, 401-412. 126. Ruggiero, F., Champliaud, M. F., Garrone, R., and Aumailley, M. (1994). Interactions between cells and collagen V molecules or single chains involve distinct mechanisms. Exp. Cell Res. 210, 215-223. 127. Cheah, K. S., Stoker, N. G., Griffin, J. R., Grosveld, F. G., and Solomon, E. (1985). Identification and characterization of the human type II collagen gene (COL2A1). Proc. Natl. Acad. Sci. USA 82, 2555-2559. 128. Li, S. W., Prockop, D. J., Helminen, H., Fassler, R., Lapvetelainen, T., Kiraly, K., Peltarri, A., Arokoski, J., Lui, H., Arita, M., et al. (1995). Transgenic mice with targeted inactivation of the Co12 alpha 1 gene for collagen II develop a skeleton with membranous and periosteal bone but no endochondral bone. Genes Dev. 9, 2821-2830. 129. Aszodi, A., Chan, D., Hunziker, E., Bateman, J. F., and Fassler, R. (1998). Collagen II is essential for the removal of the notochord and the formation of intervertebral discs. J. Cell Biol. 143, 1399-1412. 130. Wu, J. J., and Eyre, D. R. (1995). Structural analysis of crosslinking domains in cartilage type XI collagen. Insights on polymeric assembly. J. Biol. Chem. 270, 18865-18870. 131. Sangiorgi, F. O., Benson-Chanda, V., de Wet, W. J., Sobel, M. E., and Ramirez, F. (1985). Analysis of cDNA and genomic clones coding for the pro alpha 1 chain of calf type II collagen. Nucleic Acids Res. 13, 2815-2826. 132. Su, M. W., Lee, B., Ramirez, F., Machado, M., and Horton, W. (1989). Nucleotide sequence of the full length cDNA encoding for human type II procollagen. Nucleic Acids Res. 17, 9473.
31
133. Baldwin, C. T., Reginato, A. M., Smith, C., Jimenez, S. A., and Prockop, D. J. (1989). Structure of cDNA clones coding for human type II procollagen. The alpha 1(II) chain is more similar to the alpha 1(I) chain than two other alpha chains of fibrillar collagens. Biochem. J. 262, 521-528. 134. Ryan, M. C., and Sandell, L. J. (1990). Differential expression of a cysteine-rich domain in the amino-terminal propeptide of type II (cartilage) procollagen by alternative splicing of mRNA. J. Biol. Chem. 265, 10334-10339. 135. Ala-Kokko, L., and Prockop, D. J. (1990). Completion of the intron-exon structure of the gene for human type II procoUagen (COL2A1): Variations in the nucleotide sequences of the alleles from three chromosomes. Genomics 8, 454-460. 136. Fernandes, R. J., Hirohata, S., Engle, J. M., Colige, A., Cohn, D. H., Eyre, D. R., and Apte, S. S. (2001). Procollagen II amino propeptide processing by ADAMTS-3. Insights on dermatosparaxis. J. Biol. Chem. 276, 31502-31509. 137. Wu, J. J., Lark, M. W., Chun, L. E., and Eyre, D. R. (1991). Sites of stromelysin cleavage in collagen types II, IX, X, and XI of cartilage. J. Biol. Chem. 266, 5625-5628. 138. Fukui, N., McAlinden, A., Zhu, Y., Crouch, E., Broekelmann, T. J., Mecham, R. P., and Sandell, L. J. (2002). Processing of type II procollagen amino propeptide by matrix metalloproteinases. J. Biol. Chem. 277, 2193-2201. 139. Niyibizi, C., Wu, J. J., and Eyre, D. R. (1987). The carboxypropeptide trimer of type II collagen is a prominent component of immature cartilages and intervertebral-disc tissue. Biochim. Biophys. Acta 916, 493-499. 140. Van der Rest, M., Rosenberg, L. C., Olsen, B. R., and Poole, A. R. (1986). Chondrocalcin is identical with the C-propeptide of type II procollagen. Biochem. J. 237, 923-925. 141. Gadher, S. J., Eyre, D. R., Duance, V. C., Wotton, S. F., Heck, L. W., Schmid, T. M., and Woolley, D. E. (1988). Susceptibility of cartilage collagens type II, IX, X, and XI to human synovial collagenase and neutrophil elastase. Eur. J. Biochem. 175, 1-7. 142. Eyre, D. R., Wu, J. J., and Woolley, D. E: (1984). All three chains of 1 alpha 2 alpha 3 alpha collagen from hyaline cartilage resist " human collagenase. Biochem. Biophys. Res. Commun. 118, 724-729. 143. Grynpas, M. D., Eyre, D. R., and Kirschner, D. A. (1980). Collagen type II differs from type I in native molecular packing. Biochim. Biophys. Acta 626, 346-355. 144. Keene, D. R., Oxford, J. T., and Morris, N. P. (1995). Ultrastructural localization of collagen types II, IX, and XI in the growth plate of human rib and fetal bovine epiphyseal cartilage: Type XI collagen is restricted to thin fibrils. J. Histochem. Cytochem. 43, 967-979. 145. Wu, J. J., and Eyre, D. R. (1984). Identification of hydroxypyridinium cross-linking sites in type II collagen of bovine articular cartilage. Biochemistry 23, 1850-1857. 146. Bruckner, P., Mendler, M., Steinmann, B., Huber, S., and Winterhalter, K. H. (1988). The structure of human collagen type IX and its organization in fetal and infant cartilage fibrils. J. Biol. Chem. 263, 16911-16917. 147. van der Rest, M., Mayne, R., Ninomiya, Y., Seidah, N. G., Chretien, M., and Olsen, B. R. (1985). The structure of type IX collagen. J. Biol. Chem. 260, 220-225. 148. Irwin, M. H., and Mayne, R. (1986). Use of monoclonal antibodies to locate the chondroitin sulfate chain(s) in type IX collagen. J. Biol. Chem. 261, 16281-16283. 149. Kimura, T., Mattei, M. G., Stevens, J. W., Goldring, M. B., Ninomiya, Y., and Olsen, B. R. (1989). Molecular cloning of rat and human type IX collagen cDNA and localization of the alpha 1
32
William G. Cole
(IX) gene on the human chromosome 6. Eur. J. Biochem. 179, 71-78. 150. Warman, M. L., Tiller, G. E., Polumbo, P. A., Seldin, M. F., Rochelle, J. M., Knoll, J. H., Cheng, S. D., and Olsen, B. R. (1993). Physical and linkage mapping of the human and murine genes for the alpha 1 chain of type IX collagen (COL9A1). Genomics 17, 694-698. 151. Pihlajamaa, T., Vuoristo, M. M., Annunen, S., Perala, M., Prockop, D. J., and Ala-Kokko, L. (1998). Human COL9A1 and COL9A2 genes. Two genes of 90 and 15 kb code for similar polypeptides of the same collagen molecule. Matrix Biol. 17, 237-241. 152. Gerecke, D. R., Olson, P. F., Koch, M., Knoll, J. H., Taylor, R., Hudson, D. L., Champliaud, M. F., Olsen, B. R., and Burgeson, R. E. (1997). Complete primary structure of two splice variants of collagen XII, and assignment of alpha 1(XII) collagen (COL12A1), alpha I(IX) collagen (COL9A1), and alpha I(XIX) collagen (COL 19A 1) to human chromosome 6q 12-q 13. Genomics 41, 236-242. 153. Muragaki, Y., Kimura, T., Ninomiya, Y., and Olsen, B. R. (1990). The complete primary structure of two distinct forms of human alpha 1 (IX) collagen chains. Eur. J. Biochem. 192, 703-708. 154. Perala, M., Hanninen, M., Hastbacka, J., Elima, K., and Vuorio, E. (1993). Molecular cloning of the human alpha 2(IX) collagen cDNA and assignment of the human COL9A2 gene to chromosome 1. F E B S Lett. 319, 177-180. 155. Warman, M. L., McCarthy, M. T., Perala, M., Vuorio, E., Knoll, J. H., McDaniels, C. N., Mayne, R., Beier, D. R., and Olsen, B. R. (1994). The genes encoding alpha 2(IX) collagen (COL9A2) map to human chromosome l p32.3-p33 and mouse chromosome 4. Genomics 23, 158-162. 156. Huber, S., Winterhalter, K. H., and Vaughan, L. (1988). Isolation and sequence analysis of the glycosaminoglycan attachment site of type IX collagen. J. Biol. Chem. 263, 752-756. 157. Brewton, R. G., Wood, B. M., Ren, Z. X., Gong, Y., Tiller, G. E., Warman, M. L., Lee, B., Horton, W. A., Olsen, B. R., Baker, J. R., et al. (1995). Molecular cloning of the alpha 3 chain of human type IX collagen: Linkage of the gene COL9A3 to chromosome 20q13.3. Genomics 30, 329-336. 158. Tiller, G. E., Warman, M. L., Gong, Y., Knoll, J. H., Mayne, R., and Brewton, R. G. (1998). Physical and linkage mapping of the gene for the alpha3 chain of type IX collagen, COL9A3, to human chromosome 20ql 3.3. Cytogenet. Cell. Genet. 81, 205-207. 159. Paassilta, P., Pihlajamaa, T., Annunen, S., Brewton, R. G., Wood, B. M., Johnson, C. C., Liu, J., Gong, Y., Warman, M. L., Prockop, D. J., Mayne, R., and Ala-Kokko, L. (1999). Complete sequence of the 23-kilobase human COL9A3 gene. Detection of Gly-X-Y triplet deletions that represent neutral variants. J. Biol. Chem. 274, 22469-22475. 160. Pihlajamaa, T., Perala, M., Vuoristo, M. M., Nokelainen, M., Bodo, M., Schulthess, T., Vuorio, E., Timpl, R., Engel, J., and Ala-Kokko, L. (1999). Characterization of recombinant human type IX collagen. Association of alpha chains into homotrimeric and heterotrimeric molecules. J. Biol. Chem. 274, 22464-22468. 161. Labourdette, L., and van der Rest, M. (1993). Analysis of the role of the COL1 domain and its adjacent cysteine-containing sequence in the chain assembly of type IX collagen. F E B S Lett. 320, 211-214. 162. Hagg, R., Hedbom, E., Moilers, U., Aszodi, A., Fassler, R., and Bruckner, P. (1997). Absence of the alpha l(IX) chain leads to a functional knock-out of the entire collagen IX protein in mice. J. Biol. Chem. 272, 20650-20654. 163. Fassler, R., Schnegelsberg, P. N., Dausman, J., Shinya, T., Muragaki, Y., McCarthy, M. T., Olsen, B. R., and Jaenisch, R.
(1994). Mice lacking alpha 1 (IX) collagen develop noninflammatory degenerative joint disease. Proc. Natl. Acad. Sci. USA 91, 5070-5074. 164. Mallein-Gerin, F., Ruggiero, F., Quinn, T. M., Bard, F., Grodzinsky, A. J., Olsen, B. R., and van der Rest, M. (1995). Analysis of collagen synthesis and assembly in culture by immortalized mouse chondrocytes in the presence or absence of alpha 1 (IX) collagen chains. Exp. Cell Res. 219, 257-265. 165. Wu, J. J., Woods, P. E., and Eyre, D. R. (1992). Identification of cross-linking sites in bovine cartilage type IX collagen reveals an antiparallel type II-type IX molecular relationship and type IX to type IX bonding. J. Biol. Chem. 267, 23007-23014. 166. van der Rest, M., and Mayne, R. (1988). Type IX collagen proteoglycan from cartilage is covalently cross-linked to type II collagen. J. Biol. Chem. 263, 1615-1618. 167. Mendler, M., Eich-Bender, S. G., Vaughan, L., Winterhalter, K. H., and Bruckner, P. (1989). Cartilage contains mixed fibrils of collagen types II, IX, and XI. J. Cell Biol. 108, 191-197. 168. Nah, H. D., Barembaum, M., and Upholt, W. B. (1992). The chicken alpha 1 (XI) collagen gene is widely expressed in embryonic tissues. J. Biol. Chem. 267, 22581-22586. 169. Petit, B., Ronziere, M. C., Hartmann, D. J., and Herbage, D. (1993). Ultrastructural organization of type XI collagen in fetal bovine epiphyseal cartilage. Histochemistry 100, 231-239. 170. Ruggiero, F., Petit, B., Ronziere, M. C., Farjanel, J., Hartmann, D. J., and Herbage, D. (1993). Composition and organization of the collagen network produced by fetal bovine chondrocytes cultured at high density. J. Histochem. Cytochem. 41, 867-875. 171. Kleman, J. P., Hartmann, D. J., Ramirez, F., and van der Rest, M. (1992). The human rhabdomyosarcoma cell line A204 lays down a highly insoluble matrix composed mainly of alpha 1 type-XI and alpha 2 type-V collagen chains. Eur. J. Biochem. 210, 329-335. 172. Mayne, R., Brewton, R. G., Mayne, P. M., and Baker, J. R. (1993). Isolation and characterization of the chains of type V/ type XI collagen present in bovine vitreous. J. Biol. Chem. 268, 9381-9386. 173. Morris, N. P., and Bachinger, H. P. (1987). Type XI collagen is a heterotrimer with the composition (1 alpha, 2 alpha, 3 alpha) retaining non-triple-helical domains. J. Biol. Chem. 262, 11345-11350. 174. Li, Y., Lacerda, D. A., Warman, M. L., Beier, D. R., Yoshioka, H., Ninomiya, Y., Oxford, J. T., Morris, N. P., Andrikopoulos, K., Ramirez, F., et al. (1995). A fibrillar collagen gene, Colllal, is essential for skeletal morphogenesis. Cell 80, 423-430. 175. Li, S. W., Takanosu, M., Arita, M., Bao, Y., Ren, Z. X., Maier, A., Prockop, D. J., and Mayne, R. (2001). Targeted disruption of Coil la2 produces a mild cartilage phenotype in transgenic mice: Comparison with the human disorder otospondylomegaepiphyseal dysplasia (OSMED). Dev. Dyn. 222, 141-152. 176. Henry, I., Bernheim, A., Bernard, M., van der Rest, M., Kimura, T., Jeanpierre, C., Barichard, F., Berger, R., Olsen, B. R., Ramirez, F., et al. (1988). Mapping of a human fibrillar collagen gene, pro alpha 1 (XI) (COLllA1), to the p21 region of chromosome 1. Genomics 3, 87-90. 177. Zhidkova, N. I., Justice, S. K., and Mayne, R. (1995). Alternative mRNA processing occurs in the variable region of the pro-alpha 1 (XI) and pro-alpha 2(XI) collagen chains. J. Biol. Chem. 270, 9486-9493. 178. Moradi-Ameli, M., de Chassey, B., Farjanel, J., and van der Rest, M. (1998). Different splice variants of cartilage alpha l (XI) collagen chain undergo uniform amino-terminal processing. Matrix Biol. 17, 393-396.
1. Structure of Growth Plate and Bone Matrix 179. Rousseau, J. C., Farjanel, J., Boutillon, M. M., Hartmann, D. J., van der Rest, M., and Moradi-Ameli, M. (1996). Processing of type XI collagen. Determination of the matrix forms of the alphal (XI) chain. J. Biol. Chem. 271, 23743-23748. 180. Davies, G. B., Oxford, J. T., Hausafus, L. C., Smoody, B. F., and Morris, N. P. (1998). Temporal and spatial expression of alternative splice-forms of the alphal (XI) collagen gene in fetal rat cartilage. Dev. Dyn. 213, 12-26. 181. Morris, N. P., Oxford, J. T., Davies, G. B., Smoody, B. F., and Keene, D. R. (2000). Developmentally regulated alternative splicing of the alpha l(XI) collagen chain: Spatial and temporal segregation of isoforms in the cartilage of fetal rat long bones. J. Histochem. Cytochem. 48, 725-741. 182. Gregory, K. E., Oxford, J. T., Chen, Y., Gambee, J. E., Gygi, S. P., Aebersold, R., Neame, P. J., Mechling, D. E., Bachinger, H. P., and Morris, N. P. (2000). Structural organization of distinct domains within the non-collagenous N-terminal region of collagen type XI. J. Biol. Chem. 275, 11498-11506. 183. Chen, Y., Sumiyoshi, H., Oxford, J. T., Yoshioka, H., Ramirez, F., and Morris, N. P. (2001). Cis-acting elements regulate alternative splicing of exons 6A, 6B and 8 of the alpha l (XI) collagen gene and contribute to the regional diversification of collagen XI matrices. Matrix Biol. 20, 589-599. 184. Kimura, T., Cheah, K. S., Chan, S. D., Lui, V. C., Mattei, M. G., van der Rest, M., Ono, K., Solomon, E., Ninomiya, Y., and Olsen, B. R. (1989). The human alpha 2(XI) collagen (COLllA2) chain. Molecular cloning of cDNA and genomic DNA reveals characteristics of a fibrillar collagen with differences in genomic organization. J. Biol. Chem. 264, 13910-13916. 185. Vuristo, M. M., Pihlajamaa, T., Vandenberg, P., Prockop, D. J., and Ala-Kokko, L. (1995). The human COL11A2 gene structure indicates that the gene has not evolved with the genes for the major fibrillar collagens. J. Biol. Chem. 270, 22873-22881. 186. Lui, V. C., Ng, L. J., Sat, E. W., and Cheah, K. S. (1996). The human alpha 2(XI) collagen gene (COLllA2): Completion of coding information, identification of the promoter sequence, and precise localization within the major histocompatibility complex reveal overlap with the KE5 gene. Genomics 32, 401-412. 187. Lui, V. C., Ng, L. J., Sat, E. W., Nicholls, J., and Cheah, K. S. (1996). Extensive alternative splicing within the amino-propeptide coding domain of alpha2(XI) procollagen mRNAs. Expression of transcripts encoding truncated pro-alpha chains. J. Biol. Chem. 271, 16945-16951. 188. Nurminskaya, M. V., Recheis, B., Nimpf, J., Magee, C., and Linsenmayer, T. F. (2002). Transglutaminase factor XIIIA in the cartilage of developing avian long bones. Dev. Dyn. 223, 24-32. 189. Blaschke, U. K., Eikenberry, E. F., Hulmes, D. J., Galla, H. J., and Bruckner, P. (2000). Collagen XI nucleates self-assembly and limits lateral growth of cartilage fibrils. J. Biol. Chem. 275, 10370-10378. 190. Smith, G. N., Jr., Williams, J. M., and Brandt, K. D. (1985). Interaction of proteoglycans with the pericellular (1 alpha, 2 alpha, 3 alpha) collagens of cartilage. J. Biol. Chem. 260, 10761-10767. 191. Vaughan-Thomas, A., Young, R. D., Phillips, A. C., and Duance, V. C. (2001). Characterization of type XI collagenglycosaminoglycan interactions. J. Biol. Chem. 276, 5303-5309. 192. Gibson, G. J., and Flint, M. H. (1985). Type X collagen synthesis by chick sternal cartilage and its relationship to endochondral development. J. Cell Biol. 101, 277-284. 193. Schmid, T. M., and Linsenmayer, T. F. (1985). Developmental acquisition of type X collagen in the embryonic chick tibiotarsus. Dev. Biol. 107, 373-381.
33
194. Kielty, C. M., Kwan, A. P., Holmes, D. F., Schor, S. L., and Grant, M. E. (1985). Type X collagen, a product of hypertrophic chondrocytes. Biochem. J. 227, 545-554. 195. Thomas, J. T., Cresswell, C. J., Rash, B., Nicolai, H., Jones, T., Solomon, E., Grant, M. E., and Boot-Handford, R. P. (1991). The human collagen X gene. Complete primary translated sequence and chromosomal localization. Biochem. J. 280 (Pt. 3), 617-623. 196. Apte, S., Mattei, M. G., and Olsen, B. R. (1991). Cloning of human alpha I(X) collagen DNA and localization of the COL10A1 gene to the q21-q22 region of human chromosome 6. FEBS Lett. 282, 393-396. 197. Reichenberger, E., Beier, F., LuValle, P., Olsen, B. R., von der Mark, K., and Bertling, W. M. (1992). Genomic organization and full-length cDNA sequence of human collagen X. FEBS Lett. 311, 305-310. 198. Apte, S. S., Seldin, M. F., Hayashi, M., and Olsen, B. R. (1992). Cloning of the human and mouse type X collagen genes and mapping of the mouse type X collagen gene to chromosome 10. Eur. J. Biochem. 206, 217-224. 199. Thomas, J. T., Kwan, A. P., Grant, M. E., and BootHandford, R. P. (1991). Isolation of cDNAs encoding the complete sequence of bovine type X collagen. Evidence for the condensed nature of mammalian type X collagen genes. Biochem. J. 273 (Pt. 1), 141-148. 200. LuValle, P., Ninomiya, Y., Rosenblum, N. D., and Olsen, B. R. (1988). The type X collagen gene. Intron sequences split the 5'untranslated region and separate the coding regions for the noncollagenous amino-terminal and triple-helical domains. J. Biol. Chem. 263, 18378-18385. 201. Schmid, T. M., Bonen, D. K., Luchene, L., and Linsenmayer, T. F. (1991). Late events in chondrocyte differentiation: Hypertrophy, type X collagen synthesis and matrix calcification. In Vivo 5, 533-540. 202. Linsenmayer, T. F., Chen, Q. A., Gibney, E., Gordon, M. K., Marchant, J. K., Mayne, R., and Schmid, T. M. (1991). Collagen types IX and X in the developing chick tibiotarsus: Analyses of mRNAs and proteins. Development 111, 191-196. 203. Gibson, G. J., Francki, K. T., Hopwood, J. J., and Foster, B. K. (1991). Human and sheep growth-plate cartilage type X collagen synthesis and the influence of tissue storage. Biochem. J. 277 (Pt. 2), 513-520. 204. Reginato, A. M., Sanz-Rodriguez, C., and Jimenez, S. A. (1995). Biosynthesis and characterization of type X collagen in human fetal epiphyseal growth plate cartilage. Osteoarthritis Cartilage 3, 105-116. 205. Zhang, Y., and Chen, Q. (1999). The noncollagenous domain 1 of type X collagen. A novel motif for trimer and higher order multimer formation without a triple helix. J. Biol. Chem. 274, 22409-22413. 206. Middleton, R. B., and Bulleid, N. J. (1993). Reconstitution of the folding pathway of collagen in a cell-free system: Formation of correctly aligned and hydroxylated triple helices. Biochem. J. 296 (Pt. 2), 511-517. 207. McLaughlin, S. H., and Bulleid, N. J. (1998). Thiol-independent interaction of protein disulphide isomerase with type X collagen during intra-cellular folding and assembly. Biochem. J. 331 (Pt. 3), 793-800. 208. Marriott, A., Ayad, S., and Grant, M. E. (1991). The synthesis of type X collagen by bovine and human growth-plate chondrocytes. J. Cell Sci. 99 (Pt. 3), 641-649. 209. Brass, A., Kadler, K. E., Thomas, J. T., Grant, M. E., and BootHandford, R. P. (1992). The fibrillar collagens, collagen VIII, collagen X and the Clq complement proteins share a similar
34
210.
211.
212.
213.
214. 215. 216.
217.
218.
219.
220.
221.
222.
223.
224.
225.
226.
William G. Cole domain in their C-terminal non-collagenous regions. FEBS Lett. 303, 126-128. Shapiro, L., and Scherer, P. E. (1998). The crystal structure of a complement-lq family protein suggests an evolutionary link to tumor necrosis factor. Curr. Biol. 8, 335-338. Bogin, O., Kvansakul, M., Rom, E., Singer, J., Yayon, A., and Hohenester, E. (2002). Insight into Schmid metaphyseal chondrodysplasia from the crystal structure of the collagen X NC1 domain trimer. Structure (Cambridge) 10, 165-173. Chan, D., Cole, W. G., Rogers, J. G., and Bateman, J. F. (1995). Type X collagen multimer assembly in vitro is prevented by a Gly618 to Val mutation in the alpha I(X) NC1 domain resulting in Schmid metaphyseal chondrodysplasia. J. Biol. Chem. 270, 4558-4562. Kwan, A. P., Cummings, C. E., Chapman, J. A., and Grant, M. E. (1991). Macromolecular organization of chicken type X collagen in vitro. J. Cell Biol. 114, 597-604. Kirsch, T., and vonder Mark, K. (1991). Isolation of human type X collagen and immunolocalization in fetal human cartilage. Eur. J. Biochem. 196, 575-580. Chen, Q., Fitch, J. M., Linsenmayer, C., and Linsenmayer, T. F. (1992). Type X collagen: Covalent crosslinking to hypertrophic cartilage-collagen fibrils. Bone Miner. 17, 223-227. Orth, M. W., Luchene, L. J., and Schmid, T. M. (1996). Type X collagen isolated from the hypertrophic cartilage of embryonic chick tibiae contains both hydroxylysyl- and lysylpyridinoline cross-links. Biochem. Biophys. Res. Commun. 219, 301-305. Schmid, T. M., and Linsenmayer, T. F. (1990). Immunoelectron microscopy of type X collagen: Supramolecular forms within embryonic chick cartilage. Dev. Biol. 138, 53-62. Chen, Q. A., Gibney, E., Fitch, J. M., Linsenmayer, C., Schmid, T. M., and Linsenmayer, T. F. (1990). Long-range movement and fibril association of type X collagen within embryonic cartilage matrix. Proc. Natl. Acad. Sci. USA 87, 8046-8050. Chen, Q., Linsenmayer, C., Gu, H., Schmid, T. M., and Linsenmayer, T. F. (1992). Domains of type X collagen: Alteration of cartilage matrix by fibril association and proteoglycan accumulation. J. Cell Biol. 117, 687-694. Welgus, H. G., Fliszar, C. J., Seltzer, J. L., Schmid, T. M., and Jeffrey, J. J. (1990). Differential susceptibility of type X collagen to cleavage by two mammalian interstitial collagenases and 72-kDa type IV collagenase. J. Biol. Chem. 265, 13521-13527. Sires, U. I., Schmid, T. M., Fliszar, C. J., Wang, Z. Q., Gluck, S. L., and Welgus, H. G. (1995). Complete degradation of type X collagen requires the combined action of interstitial coUagenase and osteoclast-derived cathepsin-B. J. Clin. Invest. 95, 2089-2095. Kirsch, T., Ishikawa, Y., Mwale, F., and Wuthier, R. E. (1994). Roles of the nucleational core complex and collagens (types II and X) in calcification of growth plate cartilage matrix vesicles. J. Biol. Chem. 269, 20103-20109. Rosati, R., Horan, G. S., Pinero, G. J., Garofalo, S., Keene, D. R., Horton, W. A., Vuorio, E., de Crombrugghe, B., and Behringer, R. R. (1994). Normal long bone growth and development in type X collagen-null mice. Nature Genet. 8, 129-135. Kwan, K. M., Pang, M. K., Zhou, S., Cowan, S. K., Kong, R. Y., Pfordte, T., Olsen, B. R., Sillence, D. O., Tam, P. P., and Cheah, K. S. (1997). Abnormal compartmentalization of cartilage matrix components in mice lacking collagen X: Implications for function. J. Cell Biol. 136, 459-471. Gress, C. J., and Jacenko, O. (2000). Growth plate compressions and altered hematopoiesis in collagen X null mice. J. Cell Biol. 149, 983-993. Jacenko, O., LuValle, P. A., and Olsen, B. R. (1993). Spondylometaphyseal dysplasia in mice carrying a dominant negative mu-
tation in a matrix protein specific for cartilage- to-bone transition. Nature 365, 56-61.
227. Hardingham, T. E., Fosang, A. J., and Dudhia, J. (1990). Domain structure in aggregating proteoglycans from cartilage. Biochem. Soc. Trans. 18, 794-796. 228. Zimmermann, D. R., and Ruoslahti, E. (1989). Multiple domains of the large fibroblast proteoglycan, versican. E M B O J. 8, 2975-2981. 229. Rauch, U., Karthikeyan, L., Maurel, P., Margolis, R. U., and Margolis, R. K. (1992). Cloning and primary structure of neurocan, a developmentally regulated, aggregating chondroitin sulfate proteoglycan of brain. J. Biol. Chem. 267, 19536-19547. 230. Yamada, H., Watanabe, K., Shimonaka, M., and Yamaguchi, Y. (1994). Molecular cloning of brevican, a novel brain proteoglycan of the aggrecan/versican family. J. Biol. Chem. 269, 10119-10126. 231. Shinomura, T., Jensen, K. L., Yamagata, M., Kimata, K., and Solursh, M. (1990). The distribution of mesenchyme proteoglycan (PG-M) during wing bud outgrowth. Anat. Embryol. (Berlin) 181, 227-233. 232. Dours-Zimmermann, M. T., and Zimmermann, D. R. (1994). A novel glycosaminoglycan attachment domain identified in two alternative splice variants of human versican. J. Biol. Chem. 269, 32992-32998. 233. Poole, A. R., Pidoux, I., Reiner, A., and Rosenberg, L. (1982). An immunoelectron microscope study of the organization of proteoglycan monomer, link protein, and collagen in the matrix of articular cartilage. J. Cell Biol. 93, 921-937. 234. Hedbom, E., and Heinegard, D. (1993). Binding of fibromodulin and decorin to separate sites on fibrillar collagens. J. Biol. Chem. 268, 27307-27312. 235. Schonherr, E., Witsch-Prehm, P., Harrach, B., Robenek, H., Rauterberg, J., and Kresse, H. (1995). Interaction of biglycan with type I collagen. J. Biol. Chem. 270, 2776-2783. 236. Korenberg, J. R., Chen, X. N., Doege, K., Grover, J., and Roughley, P. J. (1993). Assignment of the human aggrecan gene (AGC1) to 15q26 using fluorescence in situ hybridization analysis. Genomics 16, 546-548. 237. Valhmu, W. B., Palmer, G. D., Rivers, P. A., Ebara, S., Cheng, J. F., Fischer, S., and Ratcliffe, A. (1995). Structure of the human aggrecan gene: Exon-intron organization and association with the protein domains. Biochem. J. 309 (Pt. 2), 535-542. 238. Baldwin, C. T., Reginato, A. M., and Prockop, D. J. (1989). A new epidermal growth factor-like domain in the human core protein for the large cartilage-specific proteoglycan. Evidence for alternative splicing of the domain. J. Biol. Chem. 264, 15747-15750. 239. Doege, K. J., Sasaki, M., Kimura, T., and Yamada, Y. (1991). Complete coding sequence and deduced primary structure of the human cartilage large aggregating proteoglycan, aggrecan. Human-specific repeats, and additional alternatively spliced forms. J. Biol. Chem. 266, 894-902. 240. Doege, K., Sasaki, M., Horigan, E., Hassell, J. R., and Yamada, Y. (1987). Complete primary structure of the rat cartilage proteoglycan core protein deduced from cDNA clones. J. Biol. Chem. 262, 17757-17767. 241. Isemura, M., and Ikenaka, T. (1975). Beta-elimination and sulfite addition reaction of chondroitin sulfate peptidoglycan and the peptide structure of the linkage region. Biochim. Biophys. Acta 411, 11-21. 242. Chopra, R. K., Pearson, C. H., Pringle, G. A., Fackre, D. S., and Scott, P. G. (1985). Dermatan sulphate is located on serine-4 of bovine skin proteodermatan sulphate. Demonstration that most molecules possess only one glycosaminoglycan chain and comparison of amino acid sequences around glycosylation sites in different proteoglycans. Biochem. J. 232, 277-279.
1. Structure of Growth Plate and Bone Matrix 243. Heinegard, D., and Oldberg, A. (1989). Structure and biology of cartilage and bone matrix noncollagenous macromolecules. FASEB J. 3, 2042-2051. 244. Osborne-Lawrence, S. L., Sinclair, A. K., Hicks, R. C., Lacey, S. W., Eddy, R. L., Jr., Byers, M. G., Shows, T. B., and Duby, A. D. (1990). Complete amino acid sequence of human cartilage link protein (CRTL1) deduced from cDNA clones and chromosomal assignment of the gene. Genomics 8, 562-567. 245. Perveen, R., Hart-Holden, N., Dixon, M. J., Wiszniewski, W., Fryer, A. E., Brunner, H. G., Pinkners, A. J., van Beersum, S. E., and Black, G. C. (1999). Refined genetic and physical localization of the Wagner disease (WGN1) locus and the genes CRTL1 and CSPG2 to a 2- to 2.5-cM region of chromosome 5ql 4.3. Genomics 57, 219-226. 246. Watanabe, H., and Yamada, Y. (1999). Mice lacking link protein develop dwarfism and craniofacial abnormalities. Nature Genet. 21, 225-229. 247. Iozzo, R. V. (1997). The family of the small leucine-rich proteoglycans: Key regulators of matrix assembly and cellular growth. Crit. Rev. Biochem. Mol. Biol. 32, 141-174. 248. Fleischmajer, R., Fisher, L. W., MacDonald, E. D., Jacobs, L., Jr., Perlish, J. S., and Termine, J. D. (1991). Decorin interacts with fibrillar collagen of embryonic and adult human skin. J. Struct. Biol. 106, 82-90. 249. Fisher, L. W., Heegaard, A. M., Vetter, U., Vogel, W., Just, W., Termine, J. D., and Young, M. F. (1991). Human biglycan gene. Putative promoter, intron-exon junctions, and chromosomal localization. J. Biol. Chem. 266, 14371-14377. 250. Danielson, K. G., Fazzio, A., Cohen, I., Cannizzaro, L. A., Eichstetter, I., and Iozzo, R. V. (1993). The human decorin gene: Intron-exon organization, discovery of two alternatively spliced exons in the 5' untranslated region, and mapping of the gene to chromosome 12q23. Genomics 15, 146-160. 251. Antonsson, P., Heinegard, D., and Oldberg, A. (1993). Structure and deduced amino acid sequence of the human fibromodulin gene. Biochim. Biophys. Acta 1174, 204-206. 252. Grover, J., Chen, X. N., Korenberg, J. R., and Roughley, P. J. (1995). The human lumican gene. Organization, chromosomal location, and expression in articular cartilage. J. Biol. Chem. 270, 21942-21949. 253. Neame, P. J., Sommarin, Y., Boynton, R. E., and Heinegard, D. (1994). The structure of a 38-kDa leucine-rich protein (chondroadherin) isolated from bovine cartilage. J. Biol. Chem. 269, 21547-21554. 254. Bengtsson, E., Neame, P. J., Heinegard, D., and Sommarinl Y. (1995). The primary structure of a basic leucine-rich repeat protein, PRELP, found in connective tissues. J. Biol. Chem. 270, 25639-25644. 255. Johnson, H. J., Rosenberg, L., Choi, H. U., Garza, S., Hook, M., and Neame, P. J. (1997). Characterization of epiphycan, a small proteoglycan with a leucine-rich repeat core protein. J. Biol. Chem. 272, 18709-18717. 256. Grover, J., Chen, X. N., Korenberg, J. R., and Roughley, P. J. (1997). The structure and chromosome location of the human chondroadherin gene (CHAD). Genomics 45, 379-385. 257. Svensson, L., Aszodi, A., Reinholt, F. P., Fassler, R., Heinegard, D., and Oldberg, A. (1999). Fibromodulin-nuU mice have abnormal collagen fibrils, tissue organization, and altered lumican deposition in tendon. J. Biol. Chem. 274, 9636-9647. 258. Neame, P. J., Choi, H. U., and Rosenberg, L. C. (1989). The primary structure of the core protein of the small, leucine-rich proteoglycan (PG I) from bovine articular cartilage. J. Biol. Chem. 264, 8653-8661.
35
259. Kobe, B., and Deisenhofer, J. (1993). Crystal structure of porcine ribonuclease inhibitor, a protein with leucine-rich repeats. Nature 366, 751-756. 260. Krishnan, P., Hocking, A. M., Scholtz, J. M., Pace, C. N., Holik, K. K., and McQuillan, D. J. (1999). Distinct secondary structures of the leucine-rich repeat proteoglycans decorin and biglycan. Glycosylation-dependent conformational stability. J. Biol. Chem. 274, 10945-10950. 261. Vogel, K. G., and Trotter, J. A. (1987). The effect of proteoglycans on the morphology of collagen fibrils formed in vitro. Coll. Relat. Res. 7, 105-114. 262. Scott, J. E., and Haigh, M. (1988). Identification of specific binding sites for keratan sulphate proteoglycans and chondroitindermatan sulphate proteoglycans on collagen fibrils in cornea by the use of cupromeronic blue in "critical-electrolyteconcentration" techniques. Biochem. J. 253, 607-610. 263. Pringle, G. A., and Dodd, C. M. (1990). Immunoelectron microscopic localization of the core protein of decorin near the d and e bands of tendon collagen fibrils by use of monoclonal antibodies. J. Histochem. Cytochem. 38, 1405-1411. 264. Hedlund, H., Mengarelli-Widholm, S., Heinegard, D., Reinholt, F. P., and Svensson, O. (1994). Fibromodulin distribution and association with collagen. Matrix Biol. 14, 227-232. 265. Keene, D. R., San Antonio, J. D., Mayne, R., McQuillan, D. J., Sarris, G., Santoro, S. A., and Iozzo, R. V. (2000). Decorin binds near the C terminus of type I collagen. J. Biol. Chem. 275, 21801-21804. 266. Hildebrand, A., Romaris, M., Rasmussen, L. M., Heinegard, D., Twardzik, D. R., Border, W. A., and Ruoslahti, E. (1994). Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor beta. Biochem. J. 302 (Pt. 2), 527-534. 267. Alini, M., and Roughley, P. J. (2001). Changes in leucine-rich repeat proteoglycans during maturation of the bovine growth plate. Matrix Biol. 19, 805-813. 268. Vetter, U., Vogel, W., Just, W., Young, M. F., and Fisher, L. W. (1993). Human decorin gene: Intron-exon junctions and chromosomal localization. Genomics 15, 161-168. 269. McBride, O. W., Fisher, L. W., and Young, M. F. (1990). Localization of PGI (biglycan, BGN) and PGII (decorin, DCN, PG-40) genes on human chromosomes Xql3-qter and 12q, respectively. Genomics 6, 219-225. 270. Traupe, H., van den Ouweland, A. M., van Oost, B. A., Vogel, W., Vetter, U., Warren, S. T., Rocchi, M., Darlison, M. G., and Ropers, H. H. (1992). Fine mapping of the human biglycan (BGN) gene within the Xq28 region employing a hybrid cell panel. Genomics 13, 481-483. 271. Geerkens, C., Vetter, U., Just, W., Fedarko, N. S., Fisher, L. W., Young, M. F., Termine, J. D., Robey, P. G., Wohrle, D., and Vogel, W. (1995). The X-chromosomal human biglycan gene BGN is subject to X inactivation but is transcribed like an X-Y homologous gene. Hum. Genet. 96, 44-52. 272. Krusius, T., and Ruoslahti, E. (1986). Primary structure of an extracellular matrix proteoglycan core protein deduced from cloned cDNA. Proc. Natl. Acad. Sci. USA 83, 7683-7687. 273. Fisher, L. W., Hawkins, G. R., Tuross, N., and Termine, J. D. (1987). Purification and partial characterization of small proteoglycans I and II, bone sialoproteins I and II, and osteonectin from the mineral compartment of developing human bone. J. Biol. Chem. 262, 9702-9708. 274. Roughley, P. J., and White, R. J. (1989). Dermatan sulphate proteoglycans of human articular cartilage. The properties of dermatan sulphate proteoglycans I and II. Biochem. J. 262, 823-827.
36
William G. Cole
275. Scott, I. C., Imamura, Y., Pappano, W. N., Troedel, J. M., Recklies, A. D., Roughley, P. J., and Greenspan, D. S. (2000). Bone morphogenetic protein-1 processes probiglycan. J. Biol. Chem. 275, 30504-30511. 276. Roughley, P.J., White, R. J., Magny, M. C., Liu, J., Pearce, R. H., and Mort, J. S. (1993). Non-proteoglycan forms of biglycan increase with age in human articular cartilage. Biochem. J. 295 (Pt. 2), 421-426. 277. Danielson, K. G., Baribault, H., Holmes, D. F., Graham, H., Kadler, K. E., and Iozzo, R. V. (1997). Targeted disruption of decorin leads to abnormal collagen fibril morphology and skin fragility. J. Cell Biol. 136, 729-743. 278. Xu, T., Bianco, P., Fisher, L. W., Longenecker, G., Smith, E., Goldstein, S., Bonadio, J., Boskey, A., Heegaard, A. M., Sommer, B., Satomura, K., Dominguez, P., Zhao, C., Kulkarni, A. B., Robey, P. G., and Young, M. F. (1998). Targeted disruption of the biglycan gene leads to an osteoporosis-like phenotype in mice. Nature Genet. 20, 78-82. 279. Kurita, K., Shinomura, T., Ujita, M., Zako, M., Kida, D., Iwata, H., and Kimata, K. (1996). Occurrence of PG-Lb, a leucine-rich small chondroitin/dermatan sulphate proteoglycan in mammalian epiphyseal cartilage: Molecular cloning and sequence analysis of the mouse cDNA. Biochem. J. 318 (Pt. 3), 909-914. 280. Yamada, S., Murakami, S., Matoba, R., Ozawa, Y., Yokokoji, T., Nakahira, Y., Ikezawa, K., Takayama, S., Matsubara, K., and Okada, H. (2001). Expression profile of active genes in human periodontal ligament and isolation of PLAP-1, a novel SLRP family gene. Gene 275, 279-286. 281. Heinegard, D., Larsson, T., Sommarin, Y., Franzen, A., Paulsson, M., and Hedbom, E. (1986). Two novel matrix proteins isolated from articular cartilage show wide distributions among connective tissues. J. Biol. Chem. 261, 13866-13872. 282. Oldberg, A., Antonsson, P., Lindblom, K., and Heinegard, D. (1989). A collagen-binding 59-kd protein (fibromodulin) is structurally related to the small interstitial proteoglycans PG-S1 and PG-S2 (decorin). E M B O J. 8, 2601-2604. 283. Sztrolovics, R., Chen, X. N., Grover, J., Roughley, P. J., and Korenberg, J. R. (1994). Localization of the human fibromodulin gene (FMOD) to chromosome 1q32 and completion of the cDNA sequence. Genomics 23, 715-717. 284. Antonsson, P., Heinegard, D., and Oldberg, A. (1991). Posttranslational modifications of fibromodulin. J. Biol. Chem. 266, 16859-16861. 285. Chakravarti, S., Stallings, R. L., SundarRaj, N., Cornuet, P. K., and Hassell, J. R. (1995). Primary structure of human lumican (keratan sulfate proteoglycan) and localization of the gene (LUM) to chromosome 12q21.3-q22. Genomics 27, 481-488. 286. Chakravarti, S., Magnuson, T., Lass, J. H., Jepsen, K. J., LaMantia, C., and Carroll, H. (1998). Lumican regulates collagen fibril assembly: Skin fragility and corneal opacity in the absence of lumican. J. Cell Biol. 141, 1277-1286. 287. Grover, J., Chen, X. N., Korenberg, J. R., Recklies, A. D., and Roughley, P. J. (1996). The gene organization, chromosome location, and expression of a 55-kDa matrix protein (PRELP) of human articular cartilage. Genomics 38, 109-117. 288. Melching, L. I., and Roughley, P. J. (1990). A matrix protein of Mr 55,000 that accumulates in human articular cartilage with age. Biochim. Biophys. Acta 1036, 213-220. 289. Sommarin, Y., Wendel, M., Shen, Z., Hellman, U., and Heinegard, D. (1998). Osteoadherin, a cell-binding keratan sulfate proteoglycan in bone, belongs to the family of leucine-rich repeat proteins of the extracellular matrix. J. Biol. Chem. 273, 16723-16729.
290. Wendel, M., Sommarin, Y., and Heinegard, D. (1998). Bone matrix proteins: Isolation and characterization of a novel cellbinding keratan sulfate proteoglycan (osteoadherin) from bovine bone. J. Cell Biol. 141, 839-847. 291. Johnson, J., Shinomura, T., Eberspaecher, H., Pinero, G., Decrombrugghe, B., and Hook, M. (1999). Expression and localization of PG-Lb/epiphycan during mouse development. Dev. Dyn. 216, 499-510. 292. Sommarin, Y., Larsson, T., and Heinegard, D. (1989). Chondrocyte-matrix interactions. Attachment to proteins isolated from cartilage. Exp. Cell Res. 184, 181-192. 293. Larsson, T., Sommarin, Y., Paulsson, M., Antonsson, P., Hedbom, E., Wendel, M., and Heinegard, D. (1991). Cartilage matrix proteins. A basic 36-kDa protein with a restricted distribution to cartilage and bone. J. Biol. Chem. 266, 20428-20433. 294. Hassell, J. R., Robey, P. G., Barrach, H. J., Wilczek, J., Rennard, S. I., and Martin, G. R. (1980). Isolation of a heparan sulfate-containing proteoglycan from basement membrane. Proc. Natl. Acad. Sci. USA 77, 4494-4498. 295. French, M. M., Smith, S. E., Akanbi, K., Sanford, T., Hecht, J., Farach-Carson, M. C., and Carson, D. D. (1999). Expression of the heparan sulfate proteoglycan, perlecan, during mouse embryogenesis and perlecan chondrogenic activity in vitro. J. Cell Biol. 145, 1103-1115. 296. Dodge, G. R., Kovalszky, I., Chu, M. L., Hassell, J. R., McBride, O. W., Yi, H. F., and Iozzo, R. V. (1991). Heparan sulfate proteoglycan of human colon: Partial molecular cloning, cellular expression, and mapping of the gene (HSPG2) to the short arm of human chromosome 1. Genomics 10, 673-680. 297. Kallunki, P., Eddy, R. L., Byers, M. G., Kestila, M., Shows, T. B., and Tryggvason, K. (1991). Cloning of human heparan sulfate proteoglycan core protein, assignment of the gene (HSPG2) to lp36.1-p35 and identification of a BamHI restriction fragment length polymorphism. Genomics 11, 389-396. 298. Cohen, I. R., Grassel, S., Murdoch, A. D., and Iozzo, R. V. (1993). Structural characterization of the complete human perlecan gene and its promoter. Proc. Natl. Acad. Sci. USA 90, 10404-10408. 299. KaUunki, P., and Tryggvason, K. (1992). Human basement membrane heparan sulfate proteoglycan core protein: A 467-kD protein containing multiple domains resembling elements of the low density lipoprotein receptor, laminin, neural cell adhesion molecules, and epidermal growth factor. J. Cell Biol. 116, 559-571. 300. Murdoch, A. D., Dodge, G. R., Cohen, I., Tuan, R. S., and Iozzo, R. V. (1992). Primary structure of the human heparan sulfate proteoglycan from basement membrane (HSPG2/perlecan). A chimeric molecule with multiple domains homologous to the low density lipoprotein receptor, laminin, neural cell adhesion molecules, and epidermal growth factor. J. Biol. Chem. 267, 8544-8557. 301. Costell, M., Mann, K., Yamada, Y., and Timpl, R. (1997). Characterization of recombinant perlecan domain I and its substitution by glycosaminoglycans and oligosaccharides. Eur. J. Biochem. 243, 115-121. 302. Iozzo, R. V., Cohen, I. R., Grassel, S., and Murdoch, A. D. (1994). The biology of perlecan: The multifaceted heparan sulphate proteoglycan of basement membranes and pericellular matrices. Biochem. J. 302 (Pt. 3), 625-639. 303. Aviezer, D., Hecht, D., Safran, M., Eisinger, M., David, G., and Yayon, A. (1994). Perlecan, basal lamina proteoglycan, promotes basic fibroblast growth factor-receptor binding, mitogenesis, and angiogenesis. Cell 79, 1005-1013. 304. SundarRaj, N., Fite, D., Ledbetter, S., Chakravarti, S., and Hassell, J. R. (1995). Perlecan is a component of cartilage matrix
1. Structure of Growth Plate and Bone Matrix
305.
306.
307.
308.
309.
310.
311.
312.
313.
314. 315.
316.
317.
318. 319.
320.
321.
and promotes chondrocyte attachment. J. Cell Sci. 108 (Pt. 7), 2663-2672. French, M. M., Gomes, R. R., Jr., Timpl, R., Hook, M., Czymmek, K., Farach-Carson, M. C., and Carson, D. D. (2002). Chondrogenic activity of the heparan sulfate proteoglycan perlecan maps to the N-terminal domain I. J. Bone Miner. Res. 17, 48-55. Arikawa-Hirasawa, E., Watanabe, H., Takami, H., Hassell, J. R., and Yamada, Y. (1999). Perlecan is essential for cartilage and cephalic development. Nature Genet. 23, 354-358. Costell, M., Gustafsson, E., Aszodi, A., Morgelin, M., Bloch, W., Hunziker, E., Addicks, K., Timpl, R., and Fassler, R. (1999). Perlecan maintains the integrity of cartilage and some basement membranes. J. Cell Biol. 147, 1109-1122. Frank, S., Schulthess, T., Landwehr, R., Lustig, A., Mini, T., Jeno, P., Engel, J., and Kammerer, R. A. (2002). Characterization of the matrilin coiled-coil domains reveals seven novel isoforms. J. Biol. Chem. 277, 19071-19079. Paulsson, M., and Heinegard, D. (1979). Matrix proteins bound to associatively prepared proteoglycans from bovine cartilage. Biochem. J. 183, 539-545. Paulsson, M., and Heinegard, D. (1981). Purification and structural characterization of a cartilage matrix protein. Biochem. J. 197, 367-375. Jenkins, R. N., Osborne-Lawrence, S. L., Sinclair, A. K., Eddy, R. L., Jr., Byers, M. G., Shows, T. B., and Duby, A. D. (1990). Structure and chromosomal location of the human gene encoding cartilage matrix protein. J. Biol. Chem. 265, 19624-19631. Deak, F., Piecha, D., Bachrati, C., Paulsson, M., and Kiss, I. (1997). Primary structure and expression of matrilin-2, the closest relative of cartilage matrix protein within the von Willebrand factor type A-like module superfamily. J. Biol. Chem. 272, 9268-9274. Belluoccio, D., Schenker, T., Baici, A., and Trueb, B. (1998). Characterization of human matrilin-3 (MATN3). Genomics 53, 391-394. Belluoccio, D., and Trueb, B. (1997). Matrilin-3 from chicken cartilage. F E B S Lett. 415, 212-216. Wagener, R., Kobbe, B., and Paulsson, M. (1997). Primary structure of matrilin-3, a new member of a family of extracellular matrix proteins related to cartilage matrix protein (matrilin-1) and von Willebrand factor. F E B S Lett. 413, 129-134. Wagener, R., Kobbe, B., and Paulsson, M. (1998). Genomic organisation, alternative splicing and primary structure of human matrilin-4. F E B S Lett. 438, 165-170. Wagener, R., Kobbe, B., and Paulsson, M. (1998). Matrilin-4, a new member of the matrilin family of extracellular matrix proteins. FEBS Lett. 436, 123-127. Zhang, Y., and Chen, Q. (2000). Changes of matrilin forms during endochondral ossification. Molecular basis of oligomeric assembly. J. Biol. Chem. 275, 32628-32634. Piecha, D., Muratoglu, S., Morgelin, M., Hauser, N., Studer, D., Kiss, I., Paulsson, M., and Deak, F. (1999). Matrilin-2, a large, oligomeric matrix protein, is expressed by a great variety of cells and forms fibrillar networks. J. Biol. Chem. 274, 13353-13361. Klatt, A. R., Nitsche, D. P., Kobbe, B., Morgelin, M., Paulsson, M., and Wagener, R. (2000). Molecular structure and tissue distribution of matrilin-3, a filament-forming extracellular matrix protein expressed during skeletal development. J. Biol. Chem. 275, 3999-4006. Klatt, A. R., Nitsche, D. P., Kobbe, B., Macht, M., Paulsson, M., and Wagener, R. (2001). Molecular structure, processing, and tissue distribution of matrilin-4. J. Biol. Chem. 276, 17267-17275.
37
322. Winterbottom, N., Tondravi, M. M., Harrington, T. L., Klier, F. G., Vertel, B. M., and Goetinck, P. F. (1992). Cartilage matrix protein is a component of the collagen fibril of cartilage. Dev. Dyn. 193, 266-276. 323. Chen, Q., Johnson, D. M., Haudenschild, D. R., Tondravi, M. M., and Goetinck, P. F. (1995). Cartilage matrix protein forms a type II collagen-independent filamentous network: Analysis in primary cell cultures with a retrovirus expression system. Mol. Biol. Cell. 6, 1743-1753. 324. Tondravi, M. M., Winterbottom, N., Haudenschild, D. R., and Goetinck, P. F. (1993). Cartilage matrix protein binds to collagen and plays a role in collagen fibrillogenesis. Prog. Clin. Biol. Res. 383B, 515-522. 325. Chen, Q., Zhang, Y., Johnson, D. M., and Goetinck, P. F. (1999). Assembly of a novel cartilage matrix protein filamentous network: Molecular basis of differential requirement of von Willebrand factor A domains. Mol. Biol. Cell. 10, 2149-2162. 326. Huang, X., Birk, D. E., and Goetinck, P. F. (1999). Mice lacking matrilin-1 (cartilage matrix protein) have alterations in type II collagen fibrillogenesis and fibril organization. Dev. Dyn. 216, 434-441. 327. Hauser, N., Paulsson, M., Heinegard, D., and Morgelin, M. (1996). Interaction of cartilage matrix protein with aggrecan. Increased covalent cross-linking with tissue maturation. J. Biol. Chem. 271, 32247-32252. 328. Aszodi, A., Hauser, N., Studer, D., Paulsson, M., Hiripi, L., and Bosze, Z. (1996). Cloning, sequencing and expression analysis of mouse cartilage matrix protein cDNA. Eur. J. Biochem. 236, 970-977. 329. Klatt, A. R., Paulsson, M., and Wagener, R. (2002). Expression of matrilins during maturation of mouse skeletal tissues. Matrix Biol. 21,289-296. 330. Segat, D., Frie, C., Nitsche, P. D., Klatt, A. R., Piecha, D., Korpos, E., Deak, F., Wagener, R., Paulsson, M., and Smyth, N. (2000). Expression of matrilin-1, -2 and -3 in developing mouse limbs and heart. Matrix Biol. 19, 649-655. 331. Hauser, N., and Paulsson, M. (1994). Native cartilage matrix protein (CMP). A compact trimer of subunits assembled via a coiled-coil alpha-helix. J. Biol. Chem. 269, 25747-25753. 332. Sodek, J., Hodges, R. S., Smillie, L. B., and Jurasek, L. (1972). Amino-acid sequence of rabbit skeletal tropomyosin and its coiled-coil structure. Proc. Natl. Acad. Sci. USA 69, 3800-3804. 333. Adams, J. C. (2001). Thrombospondins: Multifunctional regulators of cell interactions. Annu. Rev. Cell. Dev. Biol. 17, 25-51. 334. Dixit, V. M., Hennessy, S. W., Grant, G. A., Rotwein, P., and Frazier, W. A. (1986). Characterization of a cDNA encoding the heparin and collagen binding domains of human thrombospondin. Proc. Natl. Acad. Sci. USA 83, 5449-5453. 335. Lawler, J., and Hynes, R. O. (1986). The structure of human thrombospondin, an adhesive glycoprotein with multiple calcium-binding sites and homologies with several different proteins. J. Cell Biol. 103, 1635-1648. 336. Hennessy, S. W., Frazier, B. A., Kim, D. D., Deckwerth, T. L., Baumgartel, D. M., Rotwein, P., and Frazier, W. A. (1989). Complete thrombospondin mRNA sequence includes potential regulatory sites in the 3' untranslated region. J. Cell Biol. 108, 729-736. 337. LaBell, T. L., Milewicz, D. J., Disteche, C. M., and Byers, P. H. (1992). Thrombospondin II: Partial cDNA sequence, chromosome location, and expression of a second member of the thrombospondin gene family in humans. Genomics 12, 421-429. 338. LaBell, T. L., and Byers, P. H. (1993). Sequence and characterization of the complete human thrombospondin 2 cDNA: Potential
38
William G. Cole
regulatory role for the 3' untranslated region. Genomics 17, 225-229. 339. Vos, H. L., Devarayalu, S., de Vries, Y., and Bornstein, P. (1992). Thrombospondin 3 (Thbs3), a new member of the thrombospondin gene family. J. Biol. Chem. 267, 12192-12196. 340. Adolph, K. W., Long, G. L., Winfield, S., Ginns, E. I., and Bornstein, P. (1995). Structure and organization of the human thrombospondin 3 gene (THBS3). Genomics 27, 329-336. 341. Lawler, J., McHenry, K., Duquette, M., and Derick, L. (1995). Characterization of human thrombospondin-4. J. Biol. Chem. 270, 2809-2814. 342. Newton, G., Weremowicz, S., Morton, C. C., Jenkins, N. A., Gilbert, D. J., Copeland, N. G., and Lawler, J. (1999). The thrombospondin-4 gene. Mamm. Genome 10, 1010-1 O16. 343. Newton, G., Weremowicz, S., Morton, C. C., Copeland, N. G., Gilbert, D. J., Jenkins, N. A., and Lawler, J. (1994). Characterization of human and mouse cartilage oligomeric matrix protein. Genomics 24, 435-439. 344. DiCesare, P. E., Morgelin, M., Mann, K., and Paulsson, M. (1994). Cartilage oligomeric matrix protein and thrombospondin 1. Purification from articular cartilage, electron microscopic structure, and chondrocyte binding. Eur. J. Biochem. 223, 927-937. 345. DiCesare, P. E., Morgelin, M., Carlson, C. S., Pasumarti, S., and Paulsson, M. (1995). Cartilage oligomeric matrix protein: Isolation and characterization from human articular cartilage. J. Orthop. Res. 13, 422-428. 346. Di Cesare, P. E., Fang, C., Leslie, M. P., TuUi, H., Perris, R., and Carlson, C. S. (2000). Expression of cartilage oligomeric matrix protein (COMP) by embryonic and adult osteoblasts. J. Orthop. Res. 18, 713-720. 347. Carron, J. A., Bowler, W. B., Wagstaff, S. C., and GaUagher, J. A. (1999). Expression of members of the thrombospondin family by human skeletal tissues and cultured cells. Biochem. Biophys. Res. Commun. 263, 389-391. 348. Morgelin, M., Heinegard, D., Engel, J., and Paulsson, M. (1992). Electron microscopy of native cartilage oligomeric matrix protein purified from the Swarm rat chondrosarcoma reveals a five-armed structure. J. Biol. Chem. 267, 6137-6141. 349. Lawler, J., Derick, L. H., Connolly, J. E., Chen, J. H., and Chao, F. C. (1985). The structure of human platelet thrombospondin. J. Biol. Chem. 260, 3762-3772. 350. Misenheimer, T. M., Huwiler, K. G., Annis, D. S., and Mosher, D. F. (2000). Physical characterization of the procollagen module of human thrombospondin 1 expressed in insect cells. J. Biol. Chem. 275, 40938-40945. 351. Maddox, B. K., Mokashi, A., Keene, D. R., and Bachinger, H. P. (2000). A cartilage oligomeric matrix protein mutation associated with pseudoachondroplasia changes the structural and functional properties of the type 3 domain. J. Biol. Chem. 275, 11412-11417. 352. O'Rourke, K. M., Laherty, C. D., and Dixit, V. M. (1992). Thrombospondin 1 and thrombospondin 2 are expressed as both homo- and heterotrimers. J. Biol. Chem. 267, 24921-24924. 353. Sottile, J., Selegue, J., and Mosher, D. F. (1991). Synthesis of truncated amino-terminal trimers of thrombospondin. Biochemistry 30, 6556-6562. 354. Efimov, V. P., Lustig, A., and Engel, J. (1994). The thrombospondin-like chains of cartilage oligomeric matrix protein are assembled by a five-stranded alpha-helical bundle between residues 20 and 83. FEBS Lett. 341, 54-58. 355. Speziale, M. V., and Detwiler, T. C. (1990). Free thiols of platelet thrombospondin. Evidence for disulfide isomerization. J. Biol. Chem. 265, 17859-17867.
356. Furukawa, K., Roberts, D. D., Endo, T., and Kobata, A. (1989). Structural study of the sugar chains of human platelet thrombospondin. Arch. Biochem. Biophys. 270, 302-312. 357. Hofsteenge, J., Huwiler, K. G., Macek, B., Hess, D., Lawler, J., Mosher, D. F., and Peter-Katalinic, J. (2001). C-mannosylation and O-fueosylation of the thrombospondin type 1 module. J. Biol. Chem. 276, 6485-6498. 358. Misenheimer, T. M., and Mosher, D. F. (1995). Calcium ion binding to thrombospondin 1. J. Biol. Chem. 270, 1729-1733. 359. Chen, H., Sottile, J., Strickland, D. K., and Mosher, D. F. (1996). Binding and degradation of thrombospondin-1 mediated through heparan sulphate proteoglycans and low-density-lipoprotein receptor-related protein: Localization of the functional activity to the trimeric N-terminal heparin-binding region of thrombospondin-1. Biochem. J. 318 (Pt. 3), 959-963. 360. Hogg, P. J. (1994). Thrombospondin 1 as an enzyme inhibitor. Thromb. Haemost. 72, 787-792. 361. Hogg, P. J., Jimenez, B. M., and Chesterman, C. N. (1994). Identification of possible inhibitory reactive centers in thrombospondin 1 that may bind eathepsin G and neutrophil elastase. Biochemistry 33, 6531-6537. 362. Schultz-Cherry, S., Chen, H., Mosher, D. F., Misenheimer, T. M., Krutzsch, H. C., Roberts, D. D., and Murphy-Ullrich, J. E. (1995). Regulation of transforming growth factor-beta activation by discrete sequences of thrombospondin 1. J. Biol. Chem. 270, 7304-7310. 363. Rosenberg, K., Olsson, H., Morgelin, M., and Heinegard, D. (1998). Cartilage oligomeric matrix protein shows high affinity zinc-dependent interaction with triple helical collagen. J. Biol. Chem. 273, 20397-20403. 364. Holden, P., Meadows, R. S., Chapman, K. L., Grant, M. E., Kadler, K. E., and Briggs, M. D. (2001). Cartilage oligomeric matrix protein interacts with type IX collagen, and disruptions to these interactions identify a pathogenetic mechanism in a bone dysplasia family. J. Biol. Chem. 276, 6046-6055. 365. Narouz-Ott, L., Maurer, P., Nitsche, D. P., Smyth, N., and Paulsson, M. (2000). Thrombospondin-4 binds specifically to both collagenous and non-collagenous extraceUular matrix proteins via its C-terminal domains. J. Biol. Chem. 275, 37110-37117. 366. Stracke, J. O., Fosang, A. J., Last, K., Mercuri, F. A., Pendas, A. M., Llano, E., Perris, R., Di Cesare, P. E., Murphy, G., and Knauper, V. (2000). Matrix metalloproteinases 19 and 20 cleave aggrecan and cartilage oligomeric matrix protein (COMP). FEBS Lett. 478, 52-56. 367. Chen, H., Sottile, J., O'Rourke, K. M., Dixit, V. M., and Mosher, D. F. (1994). Properties of recombinant mouse thrombospondin 2 expressed in Spodoptera cells. J. Biol. Chem. 269, 32226-32232. 368. Lawler, J., Sunday, M., Thibert, V., Duquette, M., George, E. L., Rayburn, H., and Hynes, R. O. (1998). Thrombospondin-1 is required for normal murine pulmonary homeostasis and its absence causes pneumonia. J. Clin. Invest. 101, 982-992. 369. Kyriakides, T. R., Zhu, Y. H., Smith, L. T., Bain, S. D., Yang, Z., Lin, M. T., Danielson, K. G., Iozzo, R. V., LaMarca, M., McKinney, C. E., Ginns, E. I., and Bornstein, P. (1998). Mice that lack thrombospondin 2 display connective tissue abnormalities that are associated with disordered collagen fibrillogenesis, an increased vascular density, and a bleeding diathesis. J. Cell Biol. 140, 419-430. 370. Svensson, L., Aszodi, A., Heinegard, D., Hunziker, E. B., Reinholt, F. P., Fassler, R., and Oldberg, A. (2002). Cartilage oligomeric matrix protein-deficient mice have normal skeletal development. Mol. Cell. Biol. 22, 4366-4371.
1. Structure of Growth Plate and Bone Matrix 371. Romberg, R. W., Werness, P. G., Lollar, P., Riggs, B. L., and Mann, K. G. (1985). Isolation and characterization of native adult osteonectin. J. Biol. Chem. 260, 2728-2736. 372. Termine, J. D., Kleinman, H. K., Whitson, S. W., Conn, K. M., McGarvey, M. L., and Martin, G. R. (1981). Osteonectin, a bonespecific protein linking mineral to collagen. Cell 26, 99-105. 373. Dziadek, M., Paulsson, M., Aumailley, M., and Timpl, R. (1986). Purification and tissue distribution of a small protein (BM-40) extracted from a basement membrane tumor. Eur. J. Biochem. 161, 455-464. 374. Sage, H., Tupper, J., and Bramson, R. (1986). Endothelial cell injury in vitro is associated with increased secretion of an Mr 43,000 glycoprotein ligand. J. Cell. Physiol. 127, 373-387. 375. Lane, T. F., and Sage, E. H. (1994). The biology of SPARC, a protein that modulates cell-matrix interactions. FASEB J. 8, 163-173. 376. Swaroop, A., Hogan, B. L., and Francke, U. (1988). Molecular analysis of the cDNA for human SPARC/osteonectin/BM-40: Sequence, expression, and localization of the gene to chromosome 5q31-q33. Genomics 2, 37-47. 377. Holland, P. W., Harper, S. J., McVey, J. H., and Hogan, B. L. (1987). In vivo expression of mRNA for the Ca++-binding protein SPARC (osteonectin) revealed by in situ hybridization. J. Cell Biol. 105, 473-482. 378. Metsaranta, M., Young, M. F., Sandberg, M., Termine, J., and Vuorio, E. (1989). Localization of osteonectin expression in human fetal skeletal tissues by in situ hybridization. Calcif. Tissue Int. 45, 146-152. 379. Nomura, S., Wills, A. J., Edwards, D. R., Heath, J. K., and Hogan, B. L. (1988). Developmental expression of 2ar (osteopontin) and SPARC (osteonectin) RNA as revealed by in situ hybridization. J. Cell Biol. 106, 441-450. 380. Pacifici, M., Oshima, O., Fisher, L. W., Young, M. F., Shapiro, I. M., and Leboy, P. S. (1990). Changes in osteonectin distribution and levels are associated with mineralization of the chicken tibial growth cartilage. Calcif. Tissue Int. 47, 51-61. 381. Young, M. F., Day, A. A., Dominquez, P., McQuillan, C. I., Fisher, L. W., and Termine, J. D. (1990). Structure and expression of osteonectin mRNA in human tissue. Connect. Tissue Res. 24, 17-28. 382. Young, M. F., Kerr, J. M., Ibaraki, K., Heegaard, A. M., and Robey, P. G. (1992). Structure, expression, and regulation of the major noncollagenous matrix proteins of bone. Clin. Orthop. 275-294. 383. Bolander, M. E., Young, M. F., Fisher, L. W., Yamada, Y., and Termine, J. D. (1988). Osteonectin cDNA sequence reveals potential binding regions for calcium and hydroxyapatite and shows homologies with both a basement membrane protein (SPARC) and a serine proteinase inhibitor (ovomucoid). Proc. Natl. Acad. Sci. USA 85, 2919-2923. 384. Bork, P., Downing, A. K., Kieffer, B., and Campbell, I. D. (1996). Structure and distribution of modules in extracellular proteins. Q. Rev. Biophys. 29, 119-167. 385. Hohenester, E., Maurer, P., Hohenadl, C., Timpl, R., Jansonius, J. N., and Engel, J. (1996). Structure of a novel extracellular Ca(2+)-binding module in BM-40. Nat. Struct. Biol. 3, 67-73. 386. Maurer, P., Hohenadl, C., Hohenester, E., Gohring, W., Timpl, R., and Engel, J. (1995). The C-terminal portion of BM-40 (SPARC/ osteonectin) is an autonomously folding and crystallisable domain that binds calcium and collagen IV. J. Mol. Biol. 253, 347-357. 387. Maurer, P., Mayer, U., Bruch, M., Jeno, P., Mann, K., Landwehr, R., Engel, J., and Timpl, R. (1992). High-affinity and low-affinity calcium binding and stability of the multidomain
39
extracellular 40-kDa basement membrane glycoprotein (BM-40/ SPARC/osteonectin). Eur. J. Biochem. 205, 233-240. 388. Sasaki, T., Hohenester, E., Gohring, W., and Timpl, R. (1998). Crystal structure and mapping by site-directed mutagenesis of the collagen-binding epitope of an activated form of BM-40/SPARC/ osteonectin. E M B O J. 17, 1625-1634. 389. Hohenester, E., Maurer, P., and Timpl, R. (1997). Crystal structure of a pair of follistatin-like and EF-hand calcium-binding domains in BM-40. E M B O J. 16, 3778-3786. 390. Sasaki, T., Gohring, W., Mann, K., Maurer, P., Hohenester, E., Knauper, V., Murphy, G., and Timpl, R. (1997). Limited cleavage of extracellular matrix protein BM-40 by matrix metalloproteinases increases its affinity for collagens. J. Biol. Chem. 272, 9237-9243. 391. Gilmour, D. T., Lyon, G. J., Carlton, M. B., Sanes, J. R., Cunningham, J. M., Anderson, J. R., Hogan, B. L., Evans, M. J., and Colledge, W. H. (1998). Mice deficient for the secreted glycoprotein SPARC/osteonectin/BM40 develop normally but show severe age-onset cataract formation and disruption of the lens. E M B O J. 17, 1860-1870. 392. Basu, A., Kligman, L. H., Samulewicz, S. J., and Howe, C. C. (2001). Impaired wound healing in mice deficient in a matricellular protein SPARC (osteonectin, BM-40). B M C Cell Biol. 2, 15. 393. Gallop, P. M., Lian, J. B., and Hauschka, P. V. (1980). Carboxylated calcium-binding proteins and vitamin K. N. Engl. J. Med. 302, 1460-1466. 394. Kiefer, M. C., Bauer, D. M., Young, D., Hermsen, K. M., Masiarz, F. R., and Barr, P. J. (1988). The cDNA and derived amino acid sequences for human and bovine matrix Gla protein. Nucleic Acids Res. 16, 5213. 395. Maillard, C., Berruyer, M., Serre, C. M., Dechavanne, M., and Delmas, P. D. (1992). Protein-S, a vitamin K-dependent protein, is a bone matrix component synthesized and secreted by osteoblasts. Endocrinology 130, 1599-1604. 396. Suttie, J. W. (1985). Vitamin K-dependent carboxylase. Annu. Rev. Biochem. 54, 459-477. 397. Puchacz, E., Lian, J. B., Stein, G. S., Wozney, J., Huebner, K., and Croce, C. (1989). Chromosomal localization of the human osteocalcin gene. Endocrinology 124, 2648-2650. 398. Cancela, L., Hsieh, C. L., Francke, U., and Price, P. A. (1990). Molecular structure, chromosome assignment, and promoter organization of the human matrix Gla protein gene. J. Biol. Chem. 265, 15040-15048. 399. Celeste, A. J., Rosen, V., Buecker, J. L., Kriz, R., Wang, E. A., and Wozney, J. M. (1986). Isolation of the human gene for bone gla protein utilizing mouse and rat cDNA clones. E M B O J. 5, 1885-1890. 400. Bronckers, A. L., Gay, S., Finkelman, R. D., and Butler, W. T. (1987). Developmental appearance of Gla proteins (osteocalcin) and alkaline phosphatase in tooth germs and bones of the rat. Bone Miner. 2, 361-373. 401. Ducy, P., Desbois, C., Boyce, B., Pinero, G., Story, B., Dunstan, C., Smith, E., Bonadio, J., Goldstein, S., Gundberg, C., Bradley, A., and Karsenty, G. (1996). Increased bone formation in osteocalcin-deficient mice. Nature 382, 448-452. 402. Boskey, A. L., Gadaleta, S., Gundberg, C., Doty, S. B., Ducy, P., and Karsenty, G. (1998). Fourier transform infrared microspectroscopic analysis of bones of osteocalcin-deficient mice provides insight into the function of osteocalcin. Bone 23, 187-196. 403. Desbois, C., Hogue, D. A., and Karsenty, G. (1994). The mouse osteocalcin gene cluster contains three genes with two separate spatial and temporal patterns of expression. J. Biol. Chem. 269, 1183-1190.
40
William G. Cole
404. Deyl, Z., Vancikova, C., and Macek, K. (1980). Gammacarboxyglutamic acid-containing protein of rat kidney cortex. Changes with high fat diet, and molecular parameters. Hoppe Seylers Z. Physiol. Chem. 361, 1767-1772. 405. Yu, V. C., Delsert, C., Andersen, B., Holloway, J. M., Devary, O. V., Naar, A. M., Kim, S. Y., Boutin, J. M., Glass, C. K., and Rosenfeld, M. G. (1991). RXR beta: A coregulator that enhances binding of retinoic acid, thyroid hormone, and vitamin D receptors to their cognate response elements. Cell 67, 1251-1266. 406. Morrison, N. A., Shine, J., Fragonas, J. C., Verkest, V., McMenemy, M. L., and Eisman, J. A. (1989). 1,25-Dihydroxyvitamin D-responsive element and glucocorticoid repression in the osteocalcin gene. Science 246, 1158-1161. 407. Li, Y. P., and Stashenko, P. (1993). Characterization of a tumor necrosis factor-responsive element which down-regulates the human osteocalcin gene. Mol. Cell. Biol. 13, 3714-3721. 408. Hoffmann, H. M., Catron, K. M., vanWijnen, A. J., McCabe, L. R., Lian, J. B., Stein, G. S., and Stein, J. L. (1994). Transcriptional control of the tissue-specific, developmentally regulated osteocalcin gene requires a binding motif for the Msx family of homeodomain proteins. Proc. Natl. Acad. Sci. USA 91, 12887-12891. 409. Poser, J. W., Esch, F. S., Ling, N. C., and Price, P. A. (1980). Isolation and sequence of the vitamin K-dependent protein from human bone. Undercarboxylation of the first glutamic acid residue. J. Biol. Chem. 255, 8685-8691. 410. Hauschka, P. V., Lian, J. B., Cole, D. E., and Gundberg, C. M. (1989). Osteocalcin and matrix Gla protein: Vitamin K-dependent proteins in bone. PhysioL Rev. 69, 990-1047. 411. Hauschka, P. V., and Carr, S. A. (1982). Calcium-dependent alpha-helical structure in osteocalcin. Biochemistry 21, 2538-2547. 412. Price, P. A., Urist, M. R., and Otawara, Y. (1983). Matrix Gla protein, a new gamma-carboxyglutamic acid-containing protein which is associated with the organic matrix of bone. Biochem. Biophys. Res. Commun. 117, 765-771. 413. Fraser, J. D., and Price, P. A. (1988). Lung, heart, and kidney express high levels of mRNA for the vitamin K-dependent matrix Gla protein. Implications for the possible functions of matrix Gla protein and for the tissue distribution of the gamma-carboxylase. J. Biol. Chem. 263, 11033-11036. 414. Luo, G., D'Souza, R., Hogue, D., and Karsenty, G. (1995). The matrix Gla protein gene is a marker of the chondrogenesis cell lineage during mouse development. J. Bone Miner. Res. 10, 325-334. 415. Hale, J. E., Fraser, J. D., and Price, P. A. (1988). The identification of matrix Gla protein in cartilage. J. Biol. Chem. 263, 5820-5824. 416. Loeser, R., Carlson, C. S., Tulli, H., Jerome, W. G., Miller, L., and Wallin, R. (1992). Articular-cartilage matrix gammacarboxyglutamic acid-containing protein. Characterization and immunolocalization. Biochem. J. 282 (Pt. 1), 1-6. 417. Luo, G., Ducy, P., McKee, M. D., Pinero, G. J., Loyer, E., Behringer, R. R., and Karsenty, G. (1997). Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 386, 78-81. 418. Hale, J. E., Williamson, M. K., and Price, P. A. (1991). Carboxylterminal proteolytic processing of matrix Gla protein. J. Biol. Chem. 266, 21145-21149. 419. Price, P. A., Rice, J. S., and Williamson, M. K. (1994). Conserved phosphorylation of serines in the Ser-X-Glu/Ser(P) sequences of the vitamin K-dependent matrix Gla protein from shark, lamb, rat, cow, and human. Protein Sci. 3, 822-830. 420. Bianco, P., Fisher, L. W., Young, M. F., Termine, J. D., and Robey, P. G. (1991). Expression of bone sialoprotein (BSP) in developing human tissues. Calcif. Tissue Int. 49, 421-426.
421. Fisher, L. W., McBride, O. W., Termine, J. D., and Young, M. F. (1990). Human bone sialoprotein. Deduced protein sequence and chromosomal localization. J. Biol. Chem. 265, 2347-2351. 422. Qin, C., Brunn, J. C., Jones, J., George, A., Ramachandran, A., Gorski, J. P., and Butler, W. T. (2001). A comparative study of sialic acid-rich proteins in rat bone and dentin. Eur. J. Oral Sci. 109, 133-141. 423. George, A., Sabsay, B., Simonian, P. A., and Veis, A. (1993). Characterization of a novel dentin matrix acidic phosphoprotein. Implications for induction of biomineralization. J. Biol. Chem. 268, 12624-12630. 424. MacDougall, M., Gu, T. T., Luan, X., Simmons, D., and Chen, J. (1998). Identification of a novel isoform of mouse dentin matrix protein 1: Spatial expression in mineralized tissues. J. Bone Miner. Res. 13, 422-431. 425. Giachelli, C. M., and Steitz, S. (2000). Osteopontin: A versatile regulator of inflammation and biomineralization. Matrix Biol. 19, 615-622. 426. Oldberg, A., Franzen, A., and Heinegard, D. (1986). Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence. Proc. Natl. Acad. Sci. USA 83, 8819-8823. 427. O'Brien, E. R., Garvin, M. R., Stewart, D. K., Hinohara, T., Simpson, J. B., Schwartz, S. M., and Giachelli, C. M. (1994). Osteopontin is synthesized by macrophage, smooth muscle, and endothelial cells in primary and restenotic human coronary atherosclerotic plaques. Arterioscler. Thromb. 14, 1648-1656. 428. Boskey, A. L., Maresca, M., Ullrich, W., Doty, S. B., Butler, W. T., and Prince, C. W. (1993). Osteopontin-hydroxyapatite interactions in vitro: inhibition of hydroxyapatite formation and growth in a gelatin-gel. Bone Miner. 22, 147-159. 429. Hunter, G. K., Kyle, C. L., and Goldberg, H. A. (1994). Modulation of crystal formation by bone phosphoproteins: Structural specificity of the osteopontin-mediated inhibition of hydroxyapatite formation. Biochem. J. 300 (Pt. 3), 723-728. 430. Young, M. F., Kerr, J. M., Termine, J. D., Wewer, U. M., Wang, M. G., McBride, O. W., and Fisher, L. W. (1990). cDNA cloning, mRNA distribution and heterogeneity, chromosomal location, and RFLP analysis of human osteopontin (OPN). Genomics 7, 491-502. 431. Hijiya, N., Setoguchi, M., Matsuura, K., Higuchi, Y., Akizuki, S., and Yamamoto, S. (1994). Cloning and characterization of the human osteopontin gene and its promoter. Biochem. J. 303 (Pt. 1), 255-262. 432. Crosby, A. H., Lyu, M. S., Lin, K., McBride, O. W., Kerr, J. M., Aplin, H. M., Fisher, L. W., Young, M. F., Kozak, C. A., and Dixon, M. J. (1996). Mapping of the human and mouse bone sialoprotein and osteopontin loci. Mamm. Genome 7, 149-151. 433. Kubota, T., Zhang, Q., Wrana, J. L., Ber, R., Aubin, J. E., Butler, W. T., and Sodek, J. (1989). Multiple forms of SppI (secreted phosphoprotein, osteopontin) synthesized by normal and transformed rat bone cell populations: Regulation by TGFbeta. Biochem. Biophys. Res. Commun. 162, 1453-1459. 434. Kaji, H., Sugimoto, T., Kanatani, M., Fukase, M., Kumegawa, M., and Chihara, K. (1995). Retinoic acid induces osteoclast-like cell formation by directly acting on hemopoietic blast cells and stimulates osteopontin mRNA expression in isolated osteoclasts. Life Sci. 56, 1903-1913. 435. Noda, M., and Rodan, G. A. (1989). Transcriptional regulation of osteopontin production in rat osteoblast-like cells by parathyroid hormone. J. Cell Biol. 108, 713-718. 436. Noda, M., and Rodan, G. A. (1989). Type beta transforming growth factor regulates expression of genes encoding bone matrix proteins. Connect. Tissue Res. 21, 71-75.
1. Structure of Growth Plate and Bone Matrix 437. Shioide, M., and Noda, M. (1993). Endothelin modulates osteopontin and osteocalcin messenger ribonucleic acid expression in rat osteoblastic osteosarcoma cells. J. Cell. Biochem. 53, 176-180. 438. Prince, C. W., and Butler, W. T. (1987). 1,25-Dihydroxyvitamin D3regulates the biosynthesis of osteopontin, a bone-derived cell attachment protein, in clonal osteoblast-like osteosarcoma cells. Coll. Relat. Res. 7, 305-313. 439. Mark, M. P., Butler, W. T., Prince, C. W., Finkelman, R. D., and Ruch, J. V. (1988). Developmental expression of 44-kDa bone phosphoprotein (osteopontin) and bone gamma-carboxyglutamic acid (Gla)-containing protein (osteocalcin) in calcifying tissues of rat. Differentiation 37, 123-136. 440. Chen, J., Singh, K., Mukherjee, 13. B., and Sodek, J. (1993). Developmental expression of osteopontin (OPN) mRNA in rat tissues: Evidence for a role for OPN in bone formation and resorption. Matrix 13, 113-123. 441. Chen, J., Zhang, Q., McCulloch, C. A., and Sodek, J. (1991). Immunohistochemical localization of bone sialoprotein in foetal porcine bone tissues: Comparisons with secreted phosphoprotein 1 (SPP-1, osteopontin) and SPARC (osteonectin). Histochem. J. 23, 281-289. 442. Kiefer, M. C., Bauer, D. M., and Barr, P. J. (1989). The cDNA and derived amino acid sequence for human osteopontin. Nucleic Acids Res. 17, 3306. 443. Prince, C. W., Oosawa, T., Butler, W. T., Tomana, M., Bhown, A. S., Bhown, M., and Schrohenloher, R. E. (1987). Isolation, characterization, and biosynthesis of a phosphorylated glycoprotein from rat bone. J. Biol. Chem. 262, 2900-2907. 444. Mazzali, M., Kipari, T., Ophascharoensuk, V., Wesson, J. A., Johnson, R., and Hughes, J. (2002). Osteopontin--A molecule for all seasons. Qjm 95, 3-13. 445. Liaw, L., Skinner, M. P., Raines, E. W., Ross, R., Cheresh, D. A., Schwartz, S. M., and Giachelli, C. M. (1995). The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins. Role of alpha v beta 3 in smooth muscle cell migration to osteopontin in vitro. J. Clin. Invest. 95, 713-724.
41
446. Liaw, L., Lindner, V., Schwartz, S. M., Chambers, A. F., and Giachelli, C. M. (1995). Osteopontin and beta 3 integrin are coordinately expressed in regenerating endothelium in vivo and stimulate Arg-Gly-Asp-dependent endothelial migration in vitro. Circ. Res. 77, 665-672. 447. Smith, L. L., Cheung, H. K., Ling, L. E., Chen, J., Sheppard, D., Pytela, R., and Giachelli, C. M. (1996). Osteopontin N-terminal domain contains a cryptic adhesive sequence recognized by alpha9betal integrin. J. Biol. Chem. 271, 28485-28491. 448. Weber, G. F., Ashkar, S., Glimcher, M. J., and Cantor, H. (1996). Receptor-ligand interaction between CD44 and osteopontin (Eta-l). Science 271, 509-512. 449. Butler, W. T. (1989). The nature and significance of osteopontin. Connect. Tissue Res. 23, 123-136. 450. Neame, P. J., and Butler, W. T. (1996). Posttranslational modification in rat bone osteopontin. Connect. Tissue Res. 35, 145-150. 451. Sodek, J., Chen, J., Nagata, T., Kasugai, S., Todescan, R., Jr., Li, I. W., and Kim, R. H. (1995). Regulation of osteopontin expression in osteoblasts. Ann. N. Y. Acad. Sci. 760, 223-241. 452. Prince, C. W., Dickie, D., and Krumdieck, C. L. (1991). Osteopontin, a substrate for transglutaminase and factor XIII activity. Biochem. Biophys. Res. Commun. 177, 1205-1210. 453. Sorensen, E. S., Rasmussen, L. K., Moiler, L., Jensen, P. H., Hojrup, P., and Petersen, T. E. (1994). Localization of transglutaminase-reactive glutamine residues in bovine osteopontin. Biochem. J. 304 (Pt. 1), 13-16. 454. Rittling, S. R., Matsumoto, H. N., McKee, M. D., Nanci, A., An, X. R., Novick, K. E., Kowalski, A. J., Noda, M., and Denhardt, D. T. (1998). Mice lacking osteopontin show normal development and bone structure but display altered osteoclast formation in vitro. J. Bone Miner. Res. 13, 1101-1111. 455. Yoshitake, H., Rittling, S. R., Denhardt, D. T., and Noda, M. (1999). Osteopontin-deficient mice are resistant to ovariectomyinduced bone resorption. Proc. Natl. Acad. Sci. USA 96, 8156-8160.
This Page Intentionally Left Blank
C
H
A
P
T
E
R
2 I Bone Cell Biology Osteoblasts, Osteocytes, and Osteoclasts JANE E. AUBIN* and JOHANN. M. HEERSCHE t *Department of Medical Genetics and Microbiology, Faculty of Medicine, Toronto, Ontario, Canada tDental Research Institute, Faculty of Dentistry, University of Toronto, Toronto, Ontario, Canada
latory mechanisms controlling osteoblast development, a process comprising multiple proliferation and differentiation stages, and their activities and lifetimes. In addition, the mesenchymal stem and progenitor cell pools from which osteoblasts derivemwhich are different from those that produce osteoclasts early in mammalian development [5]mare currently the subject of exciting new research with considerable potential clinical application. Osteoclasts are mononuclear or multinuclear cells located on or adjacent to bone surfaces that stain positive for tartrate-resistant acid phosphatase (TRAP), have receptors for the calcium-regulating hormone calcitonin (CT), and are able to resorb bone [6]. They also contain high amounts of proton pumps (V-H+-ATPase) and of the proteolytic enzymes matrix metalloproteinase-9 (MMP-9) and cathepsin K [7]. Osteoclasts are terminally differentiated cells of hemopoietic origin and do not undergo mitosis. Their size and number increase due to differentiation and fusion of mononuclear precursor cells either with each other or with existing osteoclasts. Several stages have been identified in the activity cycle of multinucleated osteoclasts: migration to the bone surface, attachment to bone, followed by formation of a sealing zone delineating and surrounding an area in which extensive membrane ruffling is observed. Once established, this sealed-off area between ruffled border and bone surface is acidified by the plasmalemmal vacuolar-type H+-ATPase (V-ATPase) located on the osteoclast ruffled border membrane [8]. The mineral component of bone is dissolved by protons that are generated by the enzyme carbonic anhydrase II and
INTRODUCTION Bone tissue consists of a mineralized organic matrix formed and maintained by cells that are continuously engaged in modeling and remodeling to adapt the tissue to the demands placed on it. The demands are both mechanical (e.g., adaptation to stress and strain) and physiological (e.g., related to bone being the predominant reservoir of calcium available for instant mobilization). The cells that produce the bone matrix are osteoblasts, which are cuboidal, polar, basophilic cells that line bone surfaces and synthesize and subsequently mineralize the organic bone matrix. They express high levels of alkaline phosphatase (ALP) and synthesize and secrete collagen and a diverse set of noncollagenous proteins that comprise the organic matrix of bone. When their matrixproducing phase terminates, some osteoblasts disappear through programmed cell death (apoptosis), whereas others differentiate into fiat cells lining the bone surface (lining cells) or become cells enclosed in the bone matrix in small lacunae (osteocytes) [1]. Osteocyte access to nutrients is provided and connections to other cells are made via thin cell processes that are located in a canalicular network permeating all bone tissues. In adult humans, approximately 80% of cancellous bone surfaces and 95% of intracortical bone surfaces are covered by lining cells. The remainder are occupied by osteoblasts or by bone resorbing cells called osteoclasts. The regulatory mechanisms that govern which osteoblasts assume which fate are only beginning to be elucidated [2-4]. However, information is rapidly accumulating on genes and regu-
PediatricBone
43
Copyright 2002 Elsevier Science (USA). All rights reserved.
44
Jane E. Aubin and Johan N. M. Heersche
extruded into the extracellular space by V-ATPases. Next, the organic matrix of bone is degraded by several enzymes secreted by osteoclasts, mainly MMPs and cysteine proteinases [9,10]. As mentioned previously, the skeleton adapts to the demands placed on it by forming and/or resorbing bone tissue at appropriate sites. Maintaining the integrity of the adult skeleton requires an equilibrium between the amount of bone formed and the amount resorbed, which appears to be accomplished by close cooperation between osteoclasts resorbing bone and osteoblasts forming it. This coordinated activity is most obvious in the microscopic sites in which bone formation occurs after prior bone resorption (the activation-resorption formation sequence) [1,11]. The first stage, activation, represents the migration of osteoclast precursors to an area of the bone surface to be resorbed, attachment of these precursor cells, and subsequent fusion of these cells into multinuclear osteoclasts. During the resorptive phase, bone is resorbed by osteoclasts, possibly with the help of numerous mononuclear phagocytes present in the area. In the reversal phase [12,13], cells resembling mononuclear phagocytes and/or other cell types modify the resorbed surface and deposit a structure morphologically identified as a cement line. This phase is followed by a formation phase, during which osteoblasts differentiate at the sites previously resorbed and start to deposit osteoid and bone. Upon completion of this phase, the site enters a resting phase, with no discernable osteoid remaining between the lining cells and the mineralized bone. The sites at which this type of remodeling occurs have been defined as bone remodeling units or basic multicellular units (BMUs). In rat cancellous bone, the total duration of a complete remodeling cycle is approximately 1 month, and in humans it is estimated to be approximately 3 months [1]. The cells participating in the BMUs are osteoclasts and their progenitors, osteoblasts and their progenitors, and, importantly, endothelial cells from the capillary vessels associated with this remodeling. These interact in a variety of ways through autocrine and paracrine mechanisms involving various cytokines, growth factors, and other mediators. Despite the close physiological interactions of the two main cellular systems in bone, there are effectively separate and distinct origins of osteoclasts (hemopoietic cell origin) and stromal/osteoblast lineages in the developing fetus and throughout mammalian development [5]. Little is known about the early phenotypic stages of the osteogenic cells, the basic mechanisms governing the stem cell cycle, or the activation mechanisms relating to their physiological recruitment. It is known, however, that they are present on all bone surfaces. The suggestion that the osteoblast and related stem cells circulate
systemically has been revived recently with negligible evidence for relevance in normal physiological bone anabolic processes.
ONTOGENY OF OSTEOBLASTS AND CONTROL OF OSTEOBLAST DEVELOPMENT There are no unique identifying markers for the multipotential stem cells that give rise to a number of mesenchymal tissues, including bone and cartilage; therefore, their existence and presence are usually defined by a variety of phenotypic and functional or retrospective outcome assays [14]. This has led to an often confusing and still evolving nomenclature for these cells, with terms that include connective tissue stem cells, stromal stem cells, marrow stromal cells, stromal fibroblastic stem cells, mesodermal progenitor cells (MPCs), multipotent adult progenitor cells (MAPCs), and mesenchymal stem cells (MSCs). The most commonly used term is MSC, but this term is often used with implications of the presence of a pure population when clearly heterogeneous populations of cells are being assayed and studied. Although the term also obscures distinctions between cellular origin and developmental potential, based on its widespread use in the field the term MSC is used in this chapter. Within this system, there may be a hierarchy of stem and progenitor cells [15], as there is in the hemopoietic system, in which the cells yielding bone are the osteogenic cells. Their development into osteoblasts occurs through a sequence of phenotypic transitions that have been described using morphological and molecular criteria, as discussed later.
S t e m Cells, O s t e o p r o g e n i t o r s , and Plasticity Friedenstein first showed that postnatal bone marrow stroma contains cells that have both significant proliferative capacity and the capacity to form bone when transplanted in vivo in diffusion chambers. Subsequently, he and others demonstrated that in addition to bone, cartilage, adipocytes, and fibrous tissue also form in vivo and all the tissues can arise from transplanted single colonies or colony-forming units-fibroblasts (CFU-Fs) [16-19]. In vivo analyses of stromal cells have been augmented by functional assays in vitro that show formation of a range of differentiated cell phenotypes that include not only osteoblasts, chondrocytes, and adipocytes but also muscle cells and have led many to identify stromal populations as MSCs. However, experiments needed to address whether marrow stroma contains a definitive stem cellmby the definition of self-renewal capacity and
2. Bone Cell Biology
ability to repopulate all the appropriate differentiated lineages or even by less stringent definitions [20]--are only beginning to be done. For example, although expanded populations of human stromal cells are routinely reported to express a capacity to undergo differentiation along multiple mesenchymal lineages, when individual colonies were assessed in one study, only two of six appeared to express multilineage capacity and none were explicitly tested for self-renewal capacity [21]. This supports Friedenstein's original work in which he estimated that approximately 15% of the total CFU-Fs have stem cell-like properties [16,22]. Recent studies also show that CFU-Fs are heterogeneous in size, morphology, and potential for differentiation in vivo [23]. Limiting dilution and very low-density plating experiments have also revealed that only a proportion of CFU-Fs are CFU-alkaline phosphatase (CFU-ALP) and that only a proportion of these are CFU-osteogenic (CFU-O) (clonogenic bone colonies or bone nodules), although some variations are reported between different species. CFU-adipocytic (CFU-A) also comprise only a subset of CFU-Fs [24,25]. These data are consistent with the view that CFU-Fs belong to a lineage hierarchy in which only some of the cells are multipotential stem or primitive progenitors, whereas others are more restricted [15] (Fig. 1). A variety of studies on clonally derived immortalized (e.g., spontaneously or via large T antigen expression) cell lines derived from stroma, bone-derived cells, or other mesenchymal/mesodermal tissues, such as the mouse embryonic fibroblast line C3H10T1/2, the fetal rat calvaria-derived cell lines RCJ3.1 and ROB-C26, and the mesodermally derived C1 line, have also provided evidence for the existence of multipotential mesenchymal progenitor or stem cells capable of giving rise to multiple differentiated cell phenotypes, including osteoblasts, chondroblasts, myoblasts, and adipocytes [15]. However, two different kinds of events have been proposed to underlie MSC commitment. The first is a nonrandom, single-step process in which multipotential progenitors become restricted to a single mesenchymal lineage by particular environmental or culture conditions (e.g., soluble inducers, different substrates, and cell density), such as in C1 [26] (Fig. 1A). A second model comprising a stochastic process with an expanding hierarchy of increasingly restricted progeny has also been proposed (e.g., RCJ3.1) [15] (Fig. 1B). In keeping with the latter concept is the previously mentioned fact that CFU-Fs are heterogeneous with respect to phenotype and function. For examPle, there is evidence that single committed progenitors (i.e., progenitor cells restricted to particular lineages) can be identified by functional assays of their differentiation capacity in vitro (i.e., CFU-O or CFU-A assays). However, a number of studies on rodent
45
FIGURE 1 Schematic of stem cell commitment via either a single-step process (A) or a multistep hierarchical process with increasing lineage restriction (B) to various end-stage mesenchymal cell types. Also depicted is apparent plasticity between osteoblasts and adipocytes. Known transcription factors playing regulatory roles in the mesenchymal lineages are indicated.
and human trabecular bone cells and clonally derived lines of bone marrow stromal cells suggest that bipotential adipocyte-osteoblast precursor cells also exist [27-29]. It has also been suggested that the inverse relationship sometimes seen between expression of the osteoblast and adipocytic phenotypes in marrow stroma (e.g., in osteoporosis or in some culture manipulations) may reflect the ability of single or combinations of agents to alter the commitment or at least the differentiation pathway that these bipotential cells transit [28,30]. In some cases, individual colonies are seen in which both
46
Jane E. Aubin and Johan N. M. Heersche
osteoblast and adipocyte markers are present simultaneously [31]. However, whether a clearly distinguishable bipotential adipo-osteoprogenitor can be identified or other developmental paradigms such as plasticity or transdifferentiation underlie expression in these two lineages needs to be further analyzed. For example, dedifferentiation has been posited to account for observations in some cultures of marrow stroma in which highly differentiated adipocytes are thought to revert to a less differentiated, more proliferative fibroblastic precursor phenotype and then to osteogenic phenotype (Park, 1999 #771]). On the other hand, osteoblasts differentiated to the point of expressing osteocalcin (OCN) are able to undergo rapid differentiation events that lead to essentially 100% of the formerly osteoblastic cells expressing adipogenesis when they are transfected with the nuclear receptor family member peroxisome proliferator activated receptor '~2 (PPAR~/2)[32]. Thus, although OCN is a very late marker of osteoblast maturation, data are consistent with osteoblastic cells being able to transdifferentiate into an adipogenic phenotype, an outcome of significant clinical interest in osteoporosis and the aging or immobilized skeleton [27,28]). A variety of observations suggest that a bipotential osteochondroprogenitor may also exist. However, as for the adipocyte-osteoblast phenotypes, the ability to transdifferentiate or change expression profiles may also characterize the osteoblast-chondroblast lineages [15]. Such observations and their cellular and molecular basis have led to considerable interest in the concept of "plasticity" of stromal and other cell types [33-38]. However, the possible presence of low frequencies of undifferentiated/uncommitted stem cells and multi- and bipotential progenitors in cultures that may also contain higher frequencies of monopotential progenitors with developmental plasticity often complicates the ability to unambiguously determine the nature of the cells being affected. Difficulties in establishing unambiguous evidence for multipotentiality, together with certain discrepancies between results in calvaria versus stromal and other populations, highlight the need for more markers and experiments to distinguish the molecular mechanisms underlying the ability of cells to express multipotentiality, the number and nature of commitment steps to restricted phenotype(s), and both physiological and pathological mechanisms that may govern plasticity. Stem cells in the adult organism (adult stem cells) are receiving much attention for most lineages, including those of the skeleton. Established paradigms suggest that tissue-specific stem cells have the capacity to differentiate only into cells of the tissue of origin; have less selfrenewal ability than, for example, embryonic stem (ES) cells; and, although they differentiate into multiple lineages, do not have pluripotency. Recent work has
challenged these conclusions. For example, in addition to the differentiation capacity summarized previously, transplanted MSCs have been found in the brain, in which they have been suggested to differentiate into astrocytes [39] and to form functional neurons [40,41]. After transplantation of bone marrow or enriched hematopoietic stem cells (HSCs), skeletal myoblasts, cardiac myoblasts, endothelium, hepatic and biliary duct epithelium, lung, gut and skin epithelia, and neuroectodermal cells of donor origin have been detected, suggesting that tissue-specific stem cells can differentiate into lineages other than the tissue of origin [42-44]. Such studies have helped to rekindle interest in concepts of plasticity or transdifferentiation of stem and progenitor populations. However, as noted previously, most studies have not addressed, let alone demonstrated, whether a single tissue-specific stem cell differentiates into functional cells of multiple tissues [44]. The complexities of both the issue and the requirement for sophisticated experimental controls were highlighted by recent reports that at least some of what has been heralded as intrinsic plasticity may actually reflect fusion of donor and recipient cells [45,-47]. Notable are recent studies from Verfaillie and colleague, who identified among populations isolated from the marrow that contain stem cells with the capacity to generate osteoblasts cells they termed multipotent adult progenitor cells (MAPCs), which copurify with MSCs [48,49]. These cells have an extremely high proliferative capacity in vitro and differentiate at the single cell level not only into mesenchymal cells [48] but also into cells with visceral mesoderm, neuroectoderm, and endoderm characteristics in vitro. Strikingly, when injected into early blastocysts, single MAPCs contribute to most, if not all, somatic cell types [49]. Although many questions remain, including whether MAPCs are a rare population of ES cells that have "escaped" into adulthood, cells functionally characterized as MAPCs have been isolated from mouse, rat, and human bone marrow, which should allow comparisons between powerful rodent experimental models, including the classically pluripotent ES cells, and human-derived MAPCs. More transplantation assays, with assay of both longterm culture-initiating cells and cells capable of long-term repopulating ability determined by their ability to serially repopulate mice at limiting dilution, may advance the field [50]. Although such assays may be difficult to achieve for MSCs, especially in vivo, the results for MAPCs lend confidence to the view that strategies are available. Clear quantitation and understanding of the clonality of mesenchymal cell progeny, the ratios of stem to other more restricted progenitors in various stromal populations, the identifiable commitment and restriction points in the stromal cell hierarchy, the self-renewal capacity, and the repopulation capacity
2. Bone Cell Biology
of individual precursor cells should be goals. These issues are also increasingly important as work on stromal and related populations increases based on their proposed utility for tissue regeneration and as vehicles for gene therapy. It is also clear that parallel efforts must continue on alternate sources of cells with MSC and MAPC characteristics. Cells with features similar to adult bone marrow MSC have also been isolated from adult peripheral blood [51,52], fetal cord blood [53], and fetal liver, blood, and bone marrow [54]. Muscle satellite cells have also been found to be multipotential, undergoing myogenic, osteogenic, and adipogenic differentiation in vitro [55]. Cells with MSC-like properties, including the capacity for osteochondrogenic differentiation in vitro, have also been isolated from extramedullary adipose tissue [56,57], including the inguinal fat pad [58]. The relationship of these cells to each other developmentally, phenotypically, and functionally must be investigated further, but the fact that seemingly diverse populations of cells exist with apparently similar regenerative and developmental potential is important for development of cell and gene therapy approaches in the skeleton. Control of O s t e o b l a s t D e v e l o p m e n t In the past several years, significant advances have been made in identifying regulatory mechanisms underlying lineage restriction, commitment, and/or differentiation within some of the mesenchymal lineages (Fig. 1). The presence of master genes, exemplified by the MyoD, myogenin, and Myf-5 helix-loop-helix transcription factors in muscle lineages, is one paradigm in which one transcription factor is induced and starts a cascade that leads to sequential expression of other transcription factors and phenotype-specific genes [59]. A factor of a different transcription factor family, PPAR~/2, together with other transcription factors including the CCAAT/ enhancer binding (C/EBP) protein family, plays a key role in adipocyte differentiation [60]. Sox9, a member of yet another transcription factor family, is essential for chondrocyte differentiation, expression of various chondrocyte genes, and cartilage formation [61,62]. Understanding of genetic control mechanisms in skeletal development is advancing rapidly [63]. Runx2, a member of the runt homology domain transcription factor family, plays a crucial role in osteoblast development. Runx2 was identified in part based on its ability to regulate OCN [64,65]; ectopic expression of Runx2 in nonosteoblastic cells leads to expression of osteoblastspecific genes including OCN, and, strikingly, deletion of Runx2 in mice leads to animals in which the skeleton comprises only chondrocytes and cartilage without any evidence of bone [66] and in which bone is formed post-
47
natally [67]. Haploinsufficiency in mice [66] and in humans leads to the cleidocranial dysplasia phenotype (Mundlos, 1997 #539; Otto, 1997 #538) [68,69]. Runx2 is the earliest osteoblast differentiation marker currently known; its expression during development and after birth is high in osteoblasts, and it is upregulated in cultures treated with bone morphogenetic proteins (BMPs) and other factors that stimulate bone formation [70]. However, in contrast to MyoD and PPAR~/2, Runx2 is not a master gene; it is necessary but not sufficient to support differentiation to the mature osteoblast phenotype [71,72]. Recent data also suggest that a fine balance of Runx2 expression levels may be required for skeletal health since overexpression ofRunx2 in osteoblasts appears to block osteoblast maturation, leading to an osteoporotic phenotype [73]. Interestingly, recent studies have also suggested that at least some hypertrophic chondrocytes express Runx2 and the development/maturation of at least some chondrocytes is aberrant in Runx2-deficient mice, although the skeletal site-specific nature of the defects suggests that much more information is needed [69,74-77];. With respect to the issue of plasticity, it is interesting that PPAR~/2 may transdifferentiate osteoblastic cells to adipocytes via its ability to downregulate Runx2 [78]. The recently identified novel zinc finger-containing transcription factor Osterix (Osx) is also required for osteoblast development and bone formation and lies downstream of Runx2 in osteoblast development [79]. Because Osx null preosteoblasts express typical chondrocyte marker genes, it has been proposed that Runx2-expressing osteoblast precursors are still bipotential for osteoblast-chondroblast development. Ablation of Indian hedgehog (Ihh), a member of the Hedgehog family of secreted growth factors, leads to mice with a disorganized growth plate, as expected based on data indicating that Ihh regulates chondrocyte differentiation. However, Ihh null mice also have no osteoblasts in bone formed by endochondral ossification [80]. Since the aberrant chondrocyte differentiation phenotype can be mimicked by HIP (hedgehog interacting protein) overexpression in transgenic mice that have osteoblasts [81], the data suggest that the failure of osteoblast development in endochondral sites is due specifically to lack of Ihh rather than a secondary effect due to aberrant chondrocytes. Interestingly, Runx2 expression, which is normally high in osteoblasts in endochondral bones, is absent in Ihh -/- mice. Also, consistent with the fact that Ihh is not normally expressed in intramembranous bones, osteoblast differentiation occurs normally in these bones in Ihh -/- animals. These data support the concept that Ihh may be a regulator of Runx2 and osteoblast development but in a skeletal site-specific manner.
48
Jane E. Aubin and lohan N. M. Heersche
The recent elucidation of the osteoprotegerinR A N K - R A N K L pathway underlying the stromal cellhemopoietic cell interactions regulating osteoclast formation and activity [82] also makes it tempting to speculate that a reciprocal or related pathway may regulate osteoblast formation and activity. The fact that hemopoietic cells influence osteoblast development in the bone marrow stromal cell model in vitro [24,83] lends support for this hypothesis. Also, the fact that other apparently osteoblast-specific cis-acting elements have been found in several genes suggests that there are other important osteoblast-associated or-specific transcription factors still to be elucidated. Later, a variety of other transcription factors and receptor signaling pathways that clearly also influence the rate and amount of bone formed are discussed. Antibodies a n d O t h e r Tools for MSC/MAPC Biology Identification and enrichment of stem and progenitor cells in hematopoietic cell populations have been aided enormously by the availability of a large and expanding number of antibodies [84]. Some of the same reagents, and others prepared specifically against osteoblastic and stromal populations, are beginning to be used in MSC and osteoblast biology [14]. In this section, the focus is on antibodies that show promise for identification of stem and precursor populations; later, those more useful in studying cells and gene products of more mature osteoblast lineage cells are discussed. It is also important to recognize that none of the available antibodies is absolutely lineage and cell stage specific. In addition, no single marker or antibody is available by which unambiguously or solely to isolate definitive stem cells in any lineage, including HSCs, and it is combinations of markers that have yielded the greatest advances. Several antibodies reacting with surface antigens on human MSCs in vitro have been generated, including the antibodies STR0-1 [85], SH-2, SB-10 [86,87], and HOP-26 [88] (Fig. 2). The cell surface antigen recognized by STRO-1 is unknown, but its expression is restricted to a subpopulation of cells in fresh adult human bone marrow, including CFU-F, and the STRO-1 + fraction of bone marrow contains osteogenic precursors [89]. Among hybridoma cell lines prepared by Bruder and colleagues [86] by injecting human stromal cells induced with osteogenic medium into mice, SB-10 reacts with marrow stromal cells and osteoprogenitors but not with more differentiated cells (i.e., those already expressing ALP). It is now known that SB- 10 recognizes activated leukocyte cell adhesion molecule (ALCAM) [87], and although culture-expanded human MSCs homogeneously express SB10, ALCAM is not restricted to MSCs or osteoprogenitor
cells. ALCAM is an immunoglobulin (Ig) superfamily ligand for CD6 antigen [90] that is present in lymphoid tissue and may be involved in homing ofhemopoietic cells [91,92]. Nevertheless, ALCAM expression may be useful in combination with other reagents for cell subfractionation, and it is worth considering its role in osteoblast development in more detail since treating human MSCs in vitro with SB-10 accelerates osteogenic differentiation, implicating ALCAM in this process [87]. The SH-2 antibody recognizes endoglin (CD 105), which is a transforming growth factor-13 (TGF-13) receptor accessory molecule (sometimes called TGF-13 receptor III) that is present in many cell types, including connective tissue stromal cells, endothelial cells, syncytiotrophoblasts, and macrophages [93]. Its functions in TGF-13 receptor-ligand interactions and signaling are poorly understood, but it has been proposed to control chondrogenic differentiation of MSCs and interactions between these cells and hematopoietic cells in the bone marrow as well as in dermal embryogenesis and angiogenesis [94]. The HOP-26 antibody, raised against human bone marrow fibroblasts at an early stage of culture, reacts with cells close to newly forming bone in the periosteum and in trabeculae of developing human fetal limb and in adult trabecular bone, with a small proportion of cells located within the bone marrow spaces [88]. Immunopanning with HOP-26 isolates the majority of CFU-F and it is thus a useful antibody for selecting these cells to enrich osteoprogenitor populations from marrow [95]. These examples emphasize the caution needed when using monoclonal antibodies on viable cells versus fixed tissues in which specific epitopes may be masked or unmasked depending on treatment modalities and section site. As mentioned previously, combinations of antibodies, often coupled with other phenotypic traits, are frequently used for enrichment and isolation of progenitors. The STRO-1 bright/VCAM-1 +/COLL-I + population of human bone marrow has extensive proliferative capacity and differentiation capacity for osteogenesis and adipogenesis [96]. The bone/liver/kidney isoform of ALP has been used in a number of studies both in combination with other antibodies and alone [97]. Dual-color fluorescenceactivated cell sorting of human trabecular bone-derived cells with antibodies against STRO-1 and ALP indicates that early osteoblast precursors reside in the STROI+ALP - population, differentiated osteoblasts in the STRO-1-ALP + and STRO-1-ALP- populations, and cells of an intermediate developmental stage in the STRO-I+ALP + population [98]. Similar results have been obtained with human bone marrow stromal cells [99]. Osteogenic cells were sorted from mouse bone marrow based on light scatter characteristics, Sca-1 expression, and their binding to wheat germ agglutinin (WGA) [100]. Cells from the S c a - I + W G A bright gate, but
2.
BoneCell Biology
49 Lidell Apoptosis
Multipotential
Stem Cell
0
0
~
0-//-0
Immature osteoprogenitor
Mature osteoprogenitor
!
0___.
Preosteoblast
t
Osteoblast
t
Q
Osteocyte
t
Heterogeneity in gene expression profiles with some lineage markers as indicated below Transcription
factors
Runx2/Cbfal Osx Surface
markers
+ _
+ -
+ -
+ + +
+ + +
+/_ _
+ -
++
+?
+++
?
(human)
STRO-1 SB- 1 0 / A L C A M HOP-26/CD63 Enzymes
Alkaline phosphatase Phex
-
-
-
+
_ _
Collagen
and non-collagenous
Collagen type I Osteocalcin Bone sialoprotein Osteopontin Factors
. +?
++
+++
-
-
++
++
proteins
.
.
-
+
++
. - ~ _/+
++ ~ _/+
_/+
-/+ -/+
-/+ -/+
-/+ + -/+
++ - -I~ +++ - ~ +
++ - - I ~ +++ - ~ +++ - -I~ +++
- ..~
+++
- ~
+++
and receptors
PTH/PTHrP-R PTHrP PDGF-Rc~
? ? ?
++ ++ +++
+++ ++ +++
++ +++
FIGURE 2 P o s t u l a t e d transitions in the osteoblast lineage with expression profiles o f several well-established markers. The list is n o t exhaustive b u t does include some i m p o r t a n t categories o f molecules in the lineage and their utility to help define transitions in osteoblast differentiation and heterogeneity a m o n g osteoblast populations. Little is k n o w n a b o u t the abruptness o f t u r n - o n or t u r n - o f f o f these markers, and in m a n y cases expression levels m a y vary as changes to a continuum. - , no detectable expression; - / + , + , + + , and + + + , expression ranging f r o m detectable to very high; ~ + + + , heterogeneous expression in individual cells.
not from other gates,synthesized bone proteins and formed a mineralized matrix but lost this capacity when subcultured. Further immunophenotypic characterization showed that FsChighsschighLin-Sca 1+WGA bright cells expressed stromal (KM 16) markers and endothelial (Sab-1 and Sab-2) markers but not hemopoietic cell markers such as c-kit and Thyl.2. Sorted FSChighsschighLin-Sca-1 +WGA bright cells formed bone nodules in vitro. In contradiction to data showing the absence of osteopontin (OPN) expression in the STROI+ALP - population defined previously as comprising stem cells (Gronthos, 1999 # 1107), OPN expression combined with cell size and granularity was used to sort rat calvaria and rat bone marrow stromal cells to attempt to enrich for cells responsive to BMP-7; these were said to
have stem-like properties [101,102]. In any case, studies suggest that combinations of antibodies, with and without other cellular traits, permit the identification of cells of the osteoblast lineage at different stages of differentiation and support previous studies suggesting a hierarchy of marker expression during osteoblastic development in vitro [103] (Fig. 2). The studies discussed previously have clearly fractionated populations into subpopulations with different characteristics and differentiation potentials. Extensive immunophenotyping combined with quantification of the most primitive osteoprogenitors or MSCs and their progeny at single cell or colony levels so that clear lineage relationships and hierarchies can be established analogous to those that have been achieved in hemopoietic
50
Jane E. Aubin and Johan N. M. Heersche
populations is just under way. Pittenger and colleagues reported that culture-expanded human MSCs are uniformly positive for SH2, SH3, CD29, CD44, CD71, CD90, CD106, CD 120a, and CD 124 but negative for CD14, CD34, and the leukocyte common antigen CD45 during culture expansion [21]. The phenotypes of mouse MAPCs (mMAPCs) in fresh bone marrow are unknown, but after extensive culture (in which their pluripotent stem cell properties are functionally tested, as described previously), they are CD34-CD44-CD45-c-Kit- and MHC class I- and II-; mMAPCs express low levels of Flk-1, Sca-1, and Thy-1 and higher levels of CD13 and stagespecific antigen-I [49]. Among other novel new strategies that hold promise are those in which promoters of osteoblast-associated genes expressed at different differentiation stages have been used to drive expression of green fluorescent protein in mice [104] and to fractionate subpopulations of osteoblastic cells from mice [105]. Such approaches are in their infancy but have potential to contribute new understanding of osteoblast lineage and of bone cell activity in general in health and disease [106].
OSTEOPROGENITOR CELLS AND REGULATION OF OSTEOBLAST DIFFERENTIATION AND ACTIVITY O s t e o p r o g e n i t o r Cells The morphological and histological criteria by which osteoblastic cells, including osteoprogenitors, preosteoblasts, osteoblasts, and lining cells or osteocytes, are identified has been extensively reviewed and will not be reiterated in detail here [103]. Morphological definitions are routinely supplemented by analysis of expression of osteoblast and bone-associated macromolecules, including the bone matrix molecules COLL-I, OCN, OPN, and bone sialoprotein (BSP),and transcription factors that regulate them and commitment/differentiation events (e.g., Runx2, Osx, AP-1 family members, Msx-2, and Dlx-5) (Fig. 2). Committed osteoprogenitors (i.e., progenitor cells restricted to osteoblast development and bone formation under default differentiation conditions) can be identified in bone marrow stromal cell populations and populations derived from calvaria and other bones by functional assays of their proliferation and differentiation capacity in vitro or, as often designated, the CFU-O assay. CFU-Os appear to comprise a subset of CFU-F and CFU-ALP [24,25,107,108]. With appropriate culture conditions, cells morphologically identical to cells described in vivo and subject to many of the same regulatory activities can be identified, and the deposited matrix contains the major bone matrix proteins.
Much has been learned from the in vitro bone nodule assay, in which the nature of both the osteoprogenitors and their more differentiated progeny has been investigated. Bone nodules represent the end product of the proliferation and differentiation of CFU-O or osteoprogenitor cells present in the beginning cell population. Estimates by limiting dilution indicate that these osteoprogenitor cells are relatively rare in cell populations digested from fetal rat calvaria (i.e., <1%) [109] and rat [24] and mouse [110] bone marrow stroma (i.e., 0.5-1 • 10-5 of the nucleated cells of unfractionated marrow or <1% of the stromal layer) under standard isolation and culture conditions. The number of nodules or colonies forming bone can be counted for an assessment of osteoprogenitor numbers recoverable from fetal calvaria or other bones (e.g., vertebrae [111,112] and the primary spongiosa of the femur metaphysis [113]) and bone marrow stroma [17] under particular assay conditions. However, evidence from rat calvaria cell bone nodule assays indicates the existence of at least two populations of osteoprogenitors. One population appears capable of constitutive or default differentiation in vitro: that is, in standard differentiation conditions (ascorbic acid, [3-glycerophosphate, and fetal calf serum), differentiation leading to the mature osteoblast phenotype appears to be a default pathway, whereas the other population, apparently more primitive based on cell sorting and immunopanning with ALP antibodies [114], undergoes osteoblastic differentiation only following the addition of specific inductive stimuli (Fig. 3). Thus, the addition of glucocorticoids (often dexamethasone, but natural corticosteroids have also been used [115]), other steroids (e.g., progesterone [116]), or other kinds of factors (e.g., BMPs [117] or bFGF [118]) increases the number of bone nodules or bone colonies in calvariaderived and bone marrow stromal cell cultures, suggesting the presence of "inducible" osteoprogenitor cell populations as well. Whether other precursor stages in addition to the multipotential or committed progenitors discussed previously can also be identified by combinations of assays in vitro remains to be explicitly tested. Whether all progenitors that differentiate to osteoblasts and make bone belong to the same unidirectional lineage pathway (i.e., immature progenitors induced by a variety of agents to undergo differentiation to mature osteoblasts), whether under all developmental situations osteoprogenitor cells must transit all recognizable differentiation stages (or may skip steps under appropriate conditions), and whether recruitment from other parallel lineages and pathways can result in functional osteoblasts remain to be established. However, recently we developed a statistically rigorous map, based on gene expression profiles, of the cell fate decisions that occur during osteoprogenitor differentiation in RC cultures
2. Bone Cell Biology
51
Decreasing Proliferative Capacityand Increasing Differentiation v
Transit amplifyingpopulations
Limited self-renewal Extensive proliferation Ik Asymmetricand/or symmetric divisions?
Unlimited self-renewal Asymmetric divisions Runx2/Cbfal,Osx Multipotential stem cell
Limited proliferation ~
O
Q
O-,-
Immature Mature "//" 0 osteoprogenitor I ~_ osteoprogeni I tor ~
~
O
0
~
~
Post-mitotic ~O O
@
O
Lining Cell
0
Apoptosis
/
O
Requiresstimulus, Defaultdifferentiation Osteocyte e.g.,dexamethasone,in vitrounderstandard Preosteoblast Mature fordifferentiation differentiationconditions osteoblast in vitro FIGURE 3 Postulatedtransitions in the osteoblastlineagewith changesin self-renewalcapacity,proliferation, and differentiationas detectablefrom in vitro colonyformation assaysand in vivo analysis. and showed that different developmental routes can be taken to achieve the same end point osteoblast phenotype [119]. These routes appear to involve both developmental dead ends (leading to the expression of genes not correlated with osteoblast-associated genes or the mature osteoblast phenotype) and developmental flexibility (the existence of multiple gene expression routes to the same developmental end point). Whether such developmental flexibility is an entirely stochastic process is not known, but it seems plausible that various regulatory molecules, including hormones, growth factors, and cytokines, may alter fate choices at specific bifurcation points on these pathways. In addition, as previously discussed, plasticity between mature cell phenotypes normally considered indicative of terminal differentiation can contribute to osteoblast pools at least in vitro. It is also worth considering whether the osteoprogenitors in calvaria, other bones and bone marrow stroma, blood, and other sources (e.g., pericytes) are the same [36,120-122]. As discussed in more detail later, they do appear to reach similar end points with respect to the ability to make and mineralize a bone matrix, but they may not be identical. Recent data have also indicated that in rat stromal populations, as in rat calvaria-derived populations, there are two pools of osteoprogenitors: those that differentiate in the absence of added glucocorticoids (assumed to be more mature) and those that do so only in its presence of glucocorticoids (assumed to be more primitive). However, the number of the former type is relatively low and thus detectable only at relatively high plating cell densities, and the latter type comprises the majority in stromal
populations [24]. Whether the two types or stages of progenitors are identical in other features to the progenitors in calvaria remains to be assessed rigorously, as must their relationship to multilineage CFU-F. It is also worth noting that in rat stroma, unlike in rat calvaria, limiting dilution analysis indicates that more than one cell type is limiting for nodule formation in vitro, suggesting a cell nonautonomous aspect to differentiation of the stromal CFU-O; osteogenic differentiation is enhanced, for example, when the nonadherent fraction of bone marrow or its conditioned medium is added to the adherent stromal layer [24]. A role for accessory cells in osteogenesis of human bone marrow-derived osteoprogenitors has also been reported [83]. The relationship of inducible osteoprogenitors that apparently reside in the nonadherent fraction of bone marrow and that are assayable under particular culture conditions (e.g., in the presence of PGE2 in rat [123] or as colonies in soft agar or methylcellulose in humans [124]) also remains to be determined. Direct and unambiguous comparisons have not been done but should be advanced as more markers for the most primitive progenitors, including stem cells, become available. Morphologically recognizable osteoblasts associated with bone nodules appear in long-term bone cell cultures at predictable and reproducible periods after plating. Recent time-lapse cinematography of individual progenitors forming colonies in low-density rat calvaria cultures indicated that primitive (glucocorticoid-requiring) osteoprogenitors divide approximately eight times prior to achieving cuboidal morphology and matrix deposition, suggesting they are a transit amplifying population
52
Jane E. Aubinand lohan N. M. Heersche
[103,125] (Fig. 3). Interestingly, however, measurement of large numbers of individual bone colonies in lowdensity cultures shows that the size distribution of fully formed bone colonies covers a large range but is unimodal, suggesting that coupling between proliferation and differentiation of osteoprogenitor cells may be governed by a stochastic element but distributed around an optimum corresponding to the peak colony size/division potential [125]. The osteoprogenitors measurable in functional bone nodule assays also appear to have a limited capacity for self-renewal in both calvaria [126] and stromal [127] populations, consistent with the fact that they are committed progenitors with a finite life span [15]. However, in comparison to certain other lineages, most notably hemopoietic cells, relatively little has been done to assess regulation of self-renewal in different osteogenic populations, beyond the effects of glucocorticoids [126,127]. According to signaling threshold models, differentiation of hemopoietic stem cells is suppressed when certain receptor-ligand (soluble or matrixbound) interactions are maintained above a particular threshold and it is increased or more probable when levels are reduced [50,128]; this regulation is sometimes a proliferation-differentiation switch but in some cases is independent of proliferation [129]. Very little has been done to assess comparable issues in the osteoblast lineage, but the differential expression of a variety of receptors for cytokines, hormones, and growth factors during osteoblast development and in different cohorts of osteoblasts indicates that similar mechanisms may play a role in bone formation. Differentiation of O s t e o p r o g e n i t o r Cells to O s t e o b l a s t s and O s t e o c y t e s A fundamental question of osteoblast development remains how progenitors progress from a stem or primitive state to a fully functional matrix-synthesizing osteoblast. Based on bone nodule formation in vitro, the process has been subdivided into three stages: proliferation, extracellular matrix development and maturation, and mineralization, with characteristic changes in gene expression at each stage. Some apoptosis can also be seen in mature nodules. In many studies, it has been found that genes associated with proliferative stages (e.g., histones and protooncogenes such as c-fos and c-myc) characterize the first phase, whereas certain cyclins (e.g., cyclins B and E) are upregulated postproliferatively [130]. Expression of the most frequently assayed osteoblast-associated genes COLL-I, ALP, OPN, OCN, BSP, and parathyroid hormone/parathyroid hormone-related protein (PTHrP) receptor (PTH1R) is asynchronously upregulated, acquired, and/or lost as the progenitor cells differentiate and the matrix matures and mineralizes
[15,130]. In general, ALP increases and then decreases when mineralization is well progressed; OPN peaks twice during proliferation and then again later, prior to certain other matrix proteins, including BSP and OCN; BSP is transiently expressed very early and then upregulated again in differentiated osteoblasts forming bone; and OCN appears approximately concomitantly with mineralization [15]. Notably, however, use of global amplification poly(A) polymerase chain reaction (PCR) combined with replica plating and immunolabeling showed that all these osteoblast-associated markers are upregulated prior to cessation of proliferation in osteoblast precursors except OCN, which is upregulated only in postproliferative osteoblasts. In other words, differentiation is well progressed before osteoblast precursors leave the proliferative cycle. Based on the simultaneous expression patterns of up to 12 markers, osteoblast differentiation can be categorized into a minimum of seven transitional stages [103,131-133] (Fig. 2), not just the three stages mentioned earlier. An interesting issue is whether osteoprogenitor cells in all normal circumstances must transit all stages or can skip some steps under control of particular stimuli or regulatory agents. Although many cell systems have been reported to follow the general proliferation-differentiation outline discussed previously, some discrepancies are not always noted in detail. At least some of the variations may reflect inherent differences in the populations being analyzed (e. g., species differences or different mixtures of more or less primitive progenitors and more mature cells). However, there is growing evidence from both in vitro and in vivo observations that different gene expression profiles for both proliferation and differentiation and regulatory markers may underlie developmental and maturational events in different osteoblasts [14,134]. In other words, high levels of genes typical of some normal osteoblastic cells may not be required in others, leading to heterogeneity among osteoblast developmental pathways and/or the resulting osteoblasts. For example, as already discussed, Ihh is expressed in and required for development of osteoblasts associated with endochondral bones but not other osteoblast populations [80]. It has been evident for some time that not all osteoblasts associated with bone nodules in vitro are identical [135-137]. Single-cell analysis of the most mature cells in mineralizing bone colonies in vitro showed that the heterogeneity of expression of markers by cells classed as mature osteoblasts is extensive and appears not to be related to cell cycle differences [138] (Fig. 2). That extensive diversity in expressed gene repertoires is not a consequence or an artifact of the in vitro environment was confirmed by analysis of osteoblastic cells in vivo. When individual osteoblasts in 21-day-old fetal rat calvaria were analyzed, only two of nine markers
53
2. Bone Cell Biology
sampled (ALP and PTH1R) appeared to be global or ubiquitous markers expressed by all osteoblasts in vivo. Strikingly, all other markers analyzed (including OPN, BSP, OCN, PTHrP, c-fos, Msx-2, and E11) were differentially expressed at both m R N A and protein levels in only subsets of osteoblasts, depending on the maturational state of the bone, the age of the osteoblast, and the environment (endocranium and ectocranium) and the microenvironment (adjacent cells in particular zones) in which the osteoblasts reside [139]. The biological or physiological consequences of the observed differences are not known, but a few differences in expression profiles between younger versus older osteoblasts were reported earlier at other skeletal sites. In the primary versus secondary spongiosa of rat tibiae, collagen type I expression was equivalent in newly differentiated versus more mature osteoblasts, but osteocalcin m R N A was detectable only in the latter cells [140]. Bianco et al. [141] reported differences in BSP expression at the beginning of bone deposition in nascent osteoblasts and its absence in most mature osteoblasts in rat femurs. However, the fact that even osteoblasts of apparently similar age are heterogeneous suggests that different phenotypes may be required for different bone functions and supports the notion that not all mature osteoblasts develop via the same regulatory mechanisms nor are they molecularly or functionally identical. They predict that the makeup of different parts of bones may be significantly different, as previously suggested by the observation that the presence of and amounts of extractable noncollagenous bone proteins are different in trabecular versus cortical bone and in different parts of the human skeleton [134,139,142,143]. They also suggest that global or ubiquitously expressed molecules (e.g., COLL-I and ALP) serve common and nonredundant functions in all osteoblasts, and that only small variations in expression of these molecules may be tolerable; for example, all bones display mineralization defects in ALP knockout mice [144,145]. On the other hand, differentially expressed lineage markers (e.g., BSP, OCN, and OPN) vary much more, both between osteoblasts in different zones and between adjacent cells in the same zone, and may have specific functions associated with only some positionally or maturationally defined osteoblasts. In this regard, it is striking that all the noncollagenous bone matrix molecules are extremely heterogeneously expressed, and that ablation of many of those studied to date (e.g., OCN [146], OPN [147], and BSP [148]) does not result in complete failure of osteoblast differentiation and maturation, although the amount, quality, and remodeling of the bone formed may differ from normal. The observed differences in m R N A and protein expression repertoires in different osteoblasts may also
contribute to the heterogeneity in trabecular microarchitecture seen at different skeletal sites [149], to sitespecific differences in disease manifestation such as seen in osteoporosis [150,151], and to regional variations in the ability of osteoblasts to respond to therapeutic agents. In this regard, recent observations on transgenic mice overexpressing constitutively active PTH1R are interesting [152]. The opposite effects observed in trabecular and endosteal osteoblast populations versus periosteal osteoblast populations are reminiscent of the differential effects of PTH in trabecular versus cortical bone in primary hyperparathyroidism [152,153]. However, consistent with our observations on global expression of PTH1R in all osteoblast populations [139], Calvi et al. [152] found similar levels of transgene m R N A expression in both compartments, suggesting that in this case differential receptor expression cannot account for the different responses elicited by the ligand/ PTH. These data predict exquisite control of a signaling threshold as discussed earlier, other intrinsic differences downstream of the PTH1R in these different osteoblast populations, or that the different bone microenvironments in these sites modulate the osteoblast response. The nature of these and other signals leading to diversity of osteoblast gene expression profiles is not known [134,138]. However, the fact that heterogeneity is apparently controlled both transcriptionally and posttranscriptionally implies that the regulation is complex. Observations also suggest that it will be important to analyze the expression of regulatory molecules, including more transcription factors, not only globally but also at the individual osteoblast level. Another unanswered question is whether the striking diversity of marker expression in different osteoblasts is nonreversible or reversible in a stochastic manner or governed by changes in a microenvironmental signal or receipt of hormonal or growth factor cues or both. Since the heterogeneity observed extends to the expression of regulatory molecules such as cytokines and their receptors, it suggests that autocrine and paracrine effects may be elicited on or by only a subset of cells at any one time and the responses to such stimuli could be varied [134]. The possibility that the heterogeneity can be subdivided further seems likely as new markers for the lineage are identified. O t h e r M a r k e r s of O s t e o b l a s t s and Osteocytes As summarized previously [103], many other molecules are known to be made by osteoblast lineage cells, often with differentiation stage-specific changes in expression levels, but sometimes without known function in bone. Several molecules have recently been identified
54
Jane E. Aubin and Johan N. M. Heersche
to be particularly highly expressed in osteoblasts and osteocytes, suggesting that they may play roles in mechanosensing or other activities in bone. For example, a novel osteocyte factor, termed OF45, was recently identified by subtractive hybridization based on its high expression in bone marrow stromal cells [154]. Northern blot analysis detected the mRNA in bone but not other tissues, and immunohistochemistry revealed that the protein was expressed highly in osteocytes within trabecular and cortical bone. The cDNA was predicted to encode a serine/glycine-rich secreted peptide of 45 kDa containing numerous potential phosphorylation sites and one RGD sequence motif, which may suggest a role for this new protein in integrin binding and osteoblast (or osteoclast) recruitment, attachment, and differentiation. The mRNA for Phex, a phosphate-regulating gene with homology to endopeptidases on the X chromosome that is mutated in X-linked hypophosphatemia, is differentially expressed in osteoblasts as they differentiate [155-157], and the protein is detectable only in osteoblasts and osteocytes [158] (Fig. 2). Two cell surface multifunctional molecules that are regulated by osteotropic hormones and expressed throughout osteoblast differentiation, but most highly in osteoblasts and osteocytes, are galectin-3 [159] and CD44 [160]. Galectin- 1 has also been reported in osteoblasts, with differences in nuclear matrix-binding capacity in proliferative precursors versus mature osteoblasts [161]. Consistent with one of its earlier names (Mac-2) and role as a macrophage marker, ablation of galectin-3, which is thought to have pleiotropic effects in cells in which it is expressed, with diverse roles in adhesion, apoptosis, and other cellular functions, alters monocyte-macrophage function and survival [162]. In addition, growth plate and chondrocyte defects with altered coupling between chondrocyte death and vascular invasion have been reported in galectin-3 null mice [163]; notably, most hypertrophic chondrocyte-osteoblast markers studied (PTH1R, OPN, and Runx2) appeared to be relatively normally distributed, although Ihh expression was altered. Additional work is required to determine whether osteoblasts and bone metabolism are changed in these animals. In contrast, simultaneous ablation of all known CD44 isoforms, some of which are known to bind OPN, altered tissue distribution of myeloid progenitors, with evidence of defective progenitor egress from bone marrow and highly tumorigenic fibroblasts, but there were no detectable effects on bone [Schmits, 1997 # 1186]. With completion of the human genome sequence project and those of other species and significant progress on the mouse and rat, and also with novel new methods for cell-specific gene identification and functional genomics, we can expect continued increases in the number of known osteoblast gene products [164]. For example, in
a small-scale cDNA fingerprinting screen from globally PCR-amplified rat calvaria-derived osteoblast colonies, Candeliere et al. [133] identified several new markers with differential expression during osteoblast differentiation, including glycyl tRNA synthetase and cystatin C, among other novel, previously unknown molecules. Highthroughput serial analysis of gene expression and microarray hybridization of MC3T3-E1 cells at different times after induction of osteoblast differentiation yielded a large number of known and novel osteoblast markers whose expression is differentially regulated during osteoblast maturation [165,166]. Rab24, calponin, calcyclin, cystatin-3, and lumican, among other mRNAs, were upregulated, whereas levels of MSY-1, SH3P2, fibronectin, cx-collagen, procollagen, and LAMPI mRNAs decreased with differentiation in this model. Among unexpected mRNAs identified was the TGF-[3 superfamily member Lefty-1, which in preliminary blocking studies appears to play a role in osteoblast differentiation [165]. In another gene array analysis of differentiating MC3T3-E1 cells [167], the antiproliferative factor Tob was identified, which is known to alter bone formation [168]. Among other new gene products identified were several transcription factors (e.g., SEF2) whose functions have not been studied in osteoblasts.
REGULATION OF OSTEOBLAST DIFFERENTIATION AND ACTIVITY Transcription factors, hormones, cytokines, and growth factors and their receptors can serve both as markers and as stage-specific regulators of osteoblast development and differentiation. It is beyond the scope of this chapter to review every factor that known to influence osteoblast differentiation and bone formation at some level because many will be discussed elsewhere in this book. However, we have chosen examples that emphasize other issues we discuss, including heterogeneity of osteoblast response, proliferation-differentiation coupling, and differentiation stage-specific regulatory mechanisms. Regulation by Transcription Factors It is evident from the preceding discussion that Cbfal/ Runx2 is necessary for osteoblast development. However, several other issues related to Runx2 are of interest, including the role of the multiple isoforms [70]. At least three appear to be able to regulate OCN expression [169] and osteoblast differentiation in/n vitro models [170], but with different efficacies/activities. Identification of the regulatory molecules lying upstream of Runx2 would
2. Bone Cell Biology also be informative. Runx2 regulates itself directly via binding on its own promoter [67,171]. As discussed earlier, regulation of Runx2 by other transcription factors is yielding interesting information on skeletal site-specific regulatory mechanisms for Runx2 specifically and bone development generally. Downregulation of Runx2 expression was observed in both Msx2-deficient [172] and Bapxl-deficient [173] mice. A particularly interesting aspect of the phenotypes was that Msx-2 deficiency caused delayed growth and ossification of the skull and long bones, whereas the axial skeleton was affected in Bapx-l-deficient mice. In addition, Hoxa-2deficient mice exhibit ectopic bone formation associated with ectopic expression of Runx2 in the second branchial arch [174], suggesting that Hoxa-2 may normally inhibit expression of Runx2 and bone formation in this area. Recently, mice carrying a mutation in the F G F receptor 1 (FGFR1) were generated and found to have craniosynostosis (premature fusion of cranial sutures) with increased Runx2 expression and accelerated osteoblast differentiation in the sutures [175]. With respect to other mechanisms of Runx2 regulation, relatively little is known, but inhibitory cofactors (TLE2/Groucho and HES1), phosphorylation via the MAPK pathway, and cAMP-induced Runx2 proteolytic degradation through a ubiquitin/proteosome-dependent mechanism have all been described in vitro [69]. The number of transcription factors that appear to regulate osteoblast recruitment, osteoblast number, and the rate and duration of osteoblast activity is increasing. Ducy et al. [67] used a dominant-negative strategy in transgenic mice to show that Runx2 plays a role beyond osteoblast development in that it appears to regulate the amount of matrix deposited by osteoblasts in postnatal animals. Tob, a member of an emerging family of antiproliferative proteins, has recently been shown to be a negative regulator of osteoblast production through regulation of BMP/Smad signaling [168]. Bone histomorphometry showed that numbers of osteoclasts in tob -/mice are equivalent to those in wild-type littermates, but the osteoblast surface and bone formation rate are increased significantly. The data are consistent with the view that Tob may normally function to inhibit proliferation of osteoblast precursors and their differentiation into mature ALP-positive osteoblasts, although further studies are needed to address the possibility that Tob inhibits the function of mature osteoblasts. Although it has been studied most frequently in the context of craniofacial development [176], Msx-2 appears to play a role in osteoblast differentiation in other bones, as evidenced by the broadly distributed (but not universal) bone abnormalities described in Msx-2 -/- mice [172]. Msx-2 functional haploinsufficiency also causes defects in skull ossification in humans
55
[177]. However, not only Msx-2 loss-of-function studies but also gain-of-function studies have been informative. Mutations in Msx-2 that increase its D N A binding activity [178,179] and overexpression of Msx-2 under the control of a segment of the mouse Msx-2 promoter that drives expression in a subpopulation of cells in the skull and the sutures [180,181] result in enhanced calvarial bone growth and craniosynostosis. The latter data, together with the findings of Dodig et al. [182] on the effect of forced over- or underexpression of Msx-2 on osteogenic cell differentiation in vitro, are consistent with the hypothesis that enhanced expression of Msx-2 keeps osteoblast precursors transiently in a proliferative state, delaying osteoblast differentiation and resulting in an increase in the osteoblast pool and ultimately in an increase in bone growth. More generally, these studies show that perturbations in the timing of proliferation and differentiation of osteoprogenitors have profound consequences on the number and activity of osteoblasts and bone morphogenesis. It is also clear that further analysis of other homeodomain transcription factor expressed in osteoblasts is required. For example, Dlx-5 is differentially expressed as osteoblasts differentiate in vitro [183,184] and in different cohorts of osteoblasts in vivo [185]. The phenotype of Dlx-5 -/- mice is complex, with many tissue abnormalities, but with respect to bone it is characterized by craniofacial abnormalities affecting derivatives of the first four branchial arches, delayed ossification of the roof of the skull, and abnormal bone formation in endochondral bones, the latter perhaps reflecting the differential expression of Dlx-5 at different skeletal sites [185]. Osteosclerosis results when either of two different members of the AP-1 subfamily of leucine zippercontaining transcription factors is overexpressed in transgenic mice: Fra-1 [186], a Fos-related protein encoded by the c-Fos target gene Fosll (referred to as fra-1), and AFosB, a naturally occurring splice variant of FosB [187]. In both cases, the transgenic mice appear normal at birth, but with time much increased bone formation is evident throughout the skeleton (endochondral and intramembranous bones). The osteosclerotic phenotype derives from a cell autonomous modulation of osteoblast lineage cells that is characterized by accelerated and more osteoblast differentiation and bone nodule formation in vitro. Interestingly, it is the further truncated A2AFosB isoform, rather than hFosB, that appears to be responsible for the increased bone formation seen in hFosB transgenic mice. This suggests that further study of differentiation stage-specific aspects of the mechanism may shed additional light on the underlying lineage perturbation since differentiation stage-specific alternative splicing of fosB m R N A and selective initiation site use of AFosB appear to be involved in regulation of osteoblast
56
Jane E. Aubin and lohan N. M. Heersche
development and the increased bone formation seen in AFosB transgenic mice [187]. Notably, since neither Fra-1 nor AFosB (or A2AFosB) possess the typical C-terminal transactivation domain, it seems likely that the transcriptional potential of either resides in or depends on specific heterodimerizing partners or coactivators, either activators or repressors, that remain to be elucidated [188,189]. A decrease in adipocyte development also occurs in AFosB transgenic mice, but the bone phenotype appears not to be due to changes in leptin levels. This is interesting given that mice with leptin or leptin receptor deficiency have increased bone formation, suggesting that leptin may normally be an inhibitor of bone formation acting through the central nervous system [190]. Mice homozygous for mutations in the gene (AIM) encoding the nonreceptor tyrosine kinase c-Abl also have a bone phenotype, including osteoporotic (both thinner cortical and reduced trabecular) bones and reduced mineral apposition rates [191], apparently reflecting no change in osteoclast number or activity but an osteoblast defect manifested by delayed maturation in vitro. Whether a cell-autonomous defect in osteoblasts is responsible for the osteopenia seen in the spontaneous mouse mutant staggerer (sg/sg) [192], which carries a deletion within the retinioic acid receptor-related orphan receptor alpha (RORot) gene, remains to be determined, but since RORet appears to transcriptionally regulate BSP and OCN, this is clearly a possibility, given the increased bone formation seen in OCN null mice [146]. Interestingly, another steroid orphan receptor, estrogen receptor-related receptor alpha (ERRet), appears to play a positive regulatory role in proliferation and differentiation of osteoprogenitor cells, at least in vitro [193]. Recently, it was found that mice with a targeted disruption of the low-density lipoprotein receptor-related protein (Lrp5; a Wnt coreceptor) develop a low bone mass phenotype postnatally, apparently secondary to decreased osteoblast proliferation and functioning in a Cbfal-independent manner [194]. Lrp5 is expressed in osteoblasts and is required for optimal Wnt signaling in osteoblasts [194]. Notably, the phenotypic characteristics of Lrp -/- mice, including persistent embryonic eye vascularization, recapitulate human osteoporosis-pseudoglioma syndrome caused by LRP5 inactivation [195] and are consistent with other recent evidence that certain mutations in Lrp5 are associated with a high bone mass trait in humans [196,197]. These studies indicate the need for further studies of the Wnt signaling pathway in osteoblast lineage cells [198]. It is beyond the scope of this chapter to review all the genes in which mutations or ablation appear to perturb bone formation or cause differences in formation of the craniofacial, appendicular, and axial skeletons [199], but
the available data indicate regulatory paradigms of significant complexity that are likely to become more complex as the roles of other related factors are elucidated. Regulation by H o r m o n e s , Growth Factors, a n d Cytokines In both normal development and bone marrow injury associated with local bleeding, clotting, and neovascularization, there is induction of an environment rich in growth factors [e.g., platelet-derived growth factor (PDGF), FGF, TGF-13, and vascular endothelial growth factor (VEGF)] followed by a process of very active bone formation [200,201]. To elucidate the responding target cells (stem cells, mesenchymal precursors, and committed progenitors) and the precise nature of the responses to these and other systemic or local growth factors, cytokines, and hormones, much attention has focused on in vitro studies. However, definitive conclusions have often been elusive, with differing requirements proposed depending on species studied [202,203] and conflicting results depending on the model cell system under study, the outcome assays used (e.g., total CFU-F or specific subpopulations of CFU-ALP or CFU-O), and the presence or absence of other factors. It is beyond the scope of this chapter to exhaustively summarize all such data. Instead, some examples that have helped establish some important conceptual principles are given. There is growing evidence that at least some of the actions of growth and differentiation factors are dependent on the relative stage of differentiation (either more or less mature) of the target cells, with stimulatory/ mitogenic or inhibitory responses when test factors are added to proliferative/progenitor stages and stimulation or inhibition of differentiation stage-specific precursors and mature osteoblasts when the same factors are added later. This is true, for example, for the inflammatory cytokine interluekin-1 (IL-1), which is stimulatory to CFU-O formation when calvaria-derived cultures are exposed transiently during proliferative culture stages but inhibitory when cells are exposed transiently through differentiation stages or chronically through proliferation and differentiation stages [204]. Many other factors of current interest also have biphasic or multiphasic effects on CFU-O in vitro, including EGF [205], TGF-[3 [206-208], and PDGF [209]. Another example of clinical significance is the reported catabolic versus anabolic effects of PTH. PTH1R is expressed throughout osteoblast differentiation, although levels of expression and activity appear to increase as osteoblasts mature [210]. Chronic exposure to PTH inhibits osteoblast differentiation in an apparently reversible manner at a relatively late preosteoblast stage in rat calvaria cells [211]. However, when the cells
2. Bone Cell Biolosb,
were treated with 1-hr versus 6-hr pulses in 48-hr cycles during a 2- or 3-week culture period, either inhibition (1-hr pulse; apparently related to cAMP/PKA pathways) or stimulation (6-hr pulse; apparently related to cAMP/ PKA, Ca2+/PKC, and IGF-1) in osteoblast differentiation and bone nodule formation was seen [212]. In mice deficient in PTH1R, not only was a well-studied defect in chondrocyte differentiation seen (as seen also in PTHrP knockout mice) [213] but also increased osteoblast number and increased bone mass were seen (a phenotype not seen in PTHrP-deficient mice) [214], supporting the view that PTH plays an important role in regulation of osteoblast number and bone volume. Consistent with this latter view are studies showing that PTH may increase osteoblast lifetime by decreasing osteoblast apoptosis [215]. As already mentioned, when Calvi et al. [152] expressed constitutively active PTH1R in bone [216], osteoblastic function was increased in the trabecular and endosteal compartments but decreased in the periosteum of both long bones and calvaria; interestingly, an apparent increase in both osteoblast precursors and mature osteoblasts was seen in trabecular bone. Because of their ability to induce de novo bone formation at ectopic sites, BMPs, which are members of the TGF-13 superfamily, have been extensively studied in vivo and in vitro as regulators of osteoblast development [70]. Although many reports document a stimulatory effect of BMPs on osteoblast differentiation, a few show inhibitory effects. Interestingly, although mouse knockout experiments have clearly indicated a role for BMPs in skeletal patterning and joint formation, ablation experiments have not provided evidence for a role of BMPs in osteoblast differentiation in vivo [68,217]. This may be the result of functional redundancy among members of this family (there are currently more than 30), and further experiments are required to elucidate unequivocally the role of BMP family members in osteoblast differentiation. However, TGF-13 has been shown to have biphasic effects on osteoblast development in vitro, inhibiting early stage progenitors while stimulating matrix production by more mature cells in the lineage, including osteoblasts [103,218]. These diverse effects may help account for the complex effects seen when TGF-I3 is overexpressed via the OCN promoter in transgenic mice; these mice have low bone mass, with increased resorption, but increased osteocyte numbers and hypomineralized matrix [219]. Studies from Derynck's group showed that when a dominant-negative TGF-[3 type II receptor was expressed in osteoblasts, osteocyte number, bone mass, and bone remodeling were all influenced in a manner suggesting that TGF-I3 increases the steadystate rate of osteoblastic differentiation from osteoprogenitor cell to terminally differentiated osteocyte [220]
57
while also regulating bone remodeling, structure, and biomechanical properties [221]. Given their inclusion in the majority of CFU-F and CFU-O in vitro assays, it is worth considering glucocorticoids (most often dexamethasone in in vitro assays) in more detail. Glucocorticoid effects in vivo and in vitro are complex and often oppositemthat is, stimulation of osteoblast differentiation in vitro [103] but glucocorticoidinduced osteoporosis in vivo [222]. An emerging picture of glucocorticoid-induced stimulation of osteoprogenitor cell recruitment, self-renewal, and differentiation [103] opposed by glucocorticoid-induced inhibition of several molecules synthesized by the mature osteoblast [223] and a glucocorticoid-induced increase in osteoblast apoptosis [222] may account for some of the discrepancy. An area of considerable interest is the stimulatory activity of glucocorticoids on osteoprogenitors [15]. One mechanism by which dexamethasone or other glucocorticoids may act is through autocrine or paracrine regulatory feedback loops in which production of other factors is modulated, including growth factors and cytokines that regulate the differentiation pathway. For example, in rat calvaria cultures, glucocorticoids downregulate endogenous production of LIF, which is known to be inhibitory to bone nodule formation when cells are treated at a late progenitor/preosteoblast stage [224], and upregulate BMP-6, which is stimulatory [225] possibly through LMP-1, a LIM-domain protein [226]. These are but two of a growing list of examples of dexamethasone regulation of endogenously produced factors with apparently autocrine or paracrine activities on osteoblast lineage cells. Many factors of interest have effects on gene expression in mature osteoblasts that may or may not correlate with effects on the differentiation process and may be opposite for different osteoblast genes, with glucocorticoids being a case in point. The molecular mechanisms mediating these complex effects are generally poorly understood. However, the ability to form particular transcription factor complexes, localization and levels of endogenous expression of cytokine/hormone/growth factor receptors, and expression of cognate or other regulatory ligands within specific subgroups of osteogenic cells as they progress from a less to a more differentiated state may all be involved. As noted previously, there is increasing evidence that the probability for selfrenewal versus differentiation of hemopoietic stem cells is regulated, at least in part, by maintenance of required/ critical signaling ligands (soluble or matrix or cellbound) above a threshold level. Although there are few explicit data or experiments examining these issues in MSCs or osteoprogenitor populations, it seems likely that similar threshold controls may apply. It must also be kept in mind that many growth factors, cytokines,
58
Jane E. Aubin and Johan N. M. Heersche
and other soluble regulatory factors may have much more widespread effects and activities on cells not normally considered their targets. For example, although most often considered as osteoclast regulatory factors, granulocyte macrophage colony-stimulating factor (GM-CSF) and IL-3, as well as M-CSF, appear to stimulate the proliferation and/ or differentiation of bone marrow fibroblastic precursors [227].
unique activities in osteocytes, including alteration of connexin 43 expression and stimulation of apoptosis via the CPTHR. This list of gene products expressed in osteocytes is not exhaustive, but it exemplifies the diversity of regulatory activities and functions that one can begin to ascribe to osteocytes and some possible pathways by which they respond to both mechanical and hormonal regulation of bone.
OSTEOCYTES
O s t e o c y t e s as M e c h a n o s e n s o r s a n d Signal Transducers
Markers and Activity Nijweide and colleagues [228] pioneered approaches to the isolation of osteocytes from chick calvariae using a monoclonal antibody to a cell surface molecule that only recently was identified as recognizing Phex [229]. Over several studies [228,230,231], they established a number of osteocyte characteristics, including cell postmitotic status, a dendritic shape maintained in vitro, relatively low expression of ALP and several bone matrix proteins (e.g., collagen type I and fibronectin), and induction of nitrous oxide (NO), Cox-2, and prostaglandin production in response to mechanical strain [232,233]. Recently, Bonewald and colleagues established the mouse MLO-Y4 osteocytic cell line [234,235], which has similar properties, but as an SV40 large T antigenimmortalized line; fit offers some advantages for studies requiring large numbers of cells. These studies, in addition to many other in vitro and in vivo studies in which both gene products and responses to mechanical stimulation have been assessed, have helped to dispel the notion that osteocytes are relatively inactive cells (Fig. 2). It is now clear that osteocytes express a wide variety of molecules also.expressed at high levels in osteoblasts, although the expressed gene repertoires are not identical given that many molecules (e.g., ALP, collagen, and fibronectin) expressed highly in osteoblasts appear to be downregulated in osteocytes. Among those molecules expressed at high levels in both osteoblasts and at least some osteocytes are transcription factors such as ERs [236,237] and E R R s [193], adhesion and signaling molecules such as galectin-3 [159] and CD44 [160,238-241], growth factors including IGF-1 [242,243], the gap junction hemichannel connexin 43 [234,244], clinically relevant enzymes such as Phex [158,229], and some but not all of the bone matrix molecules including OPN [234]. Notably, given-evidence that several hormones, including PTH, modify osteoblastic cell response to mechanical stimulation, Divieti et al. [245] reported that osteocytes also express much higher levels of the receptor for C-terminal PTH fragments (CPTHR) than do osteoblasts and that both PTH(1-84) and PTH(39-84) elicit
It is well established that bone tissue is sensitive to the mechanical demands made on it and that abnormally low mechanical stress (bed rest, immobilization, or lack of gravity such as occurs in space flight) results in decreased bone mass and disuse osteoporosis [Houde, 1995 #1392; Zerwekh, 1998 #1396] [246,247]. As summarized earlier, osteocytes derive from osteoblasts that have become entrapped in the deposited bone matrix. A network of canaliculi comprising unmineralized matrix houses long osteocyte processes that allow intercellular communication via connexin 43-containing gap junctions between osteocytes; the network also connects with osteoblasts and the lining cells that cover the bone surface, which also derive from osteoblasts. Thus, osteoblasts, osteocytes, and lining cells form a network in which cells may act together as signal transducers of changes in strain or mechanical load [248]. Among cells making up the syncytium, osteocytes have long been postulated to be the major force transducers [247,249,250]. Osteocytes make up a large proportion of the cells in adult bone and are extremely sensitive to mechanical stress, which is likely imparted by the flow of interstitial fluid along the surface of the osteocytes and lining cells [249-251]. Huiskes et al. [248] reported an interesting computational model with simulations of bone remodeling as a regulatory process, governed by mechanical usage and orchestrated by osteocyte mechanosensitivity. In the model, they made several assumptions based on known experimental results, including that osteocytes react very quickly to load [252] with production of biochemical messengers such as prostaglandins [253] that are dissipated through canaliculi to the bone surface, where they trigger osteoblast precursor recruitment. The model included a resorption component based on the probability of osteoclast activation per surface site at any time. This computational model is interesting because it predicts the emergence and maintenance of bone trabecular architecture as an optimal mechanical structure as well as its adaptation via cell coupling or feedback from mechanical load [248]. Disruption of the actin-containing cytoskeleton abolishes osteoblast-osteocyte response to stress, including
2. Bone Cell Biology
production of prostaglandins [254], suggesting that the cytoskeleton is involved in mechanotransduction in bone as in other cell types [255-257]. In addition, a variety of hormones, including PTH [258,259] and estrogen [260], modulate bone cell responses to mechanical loading, although the mechanisms by which they do so are not clear but may be multifactorial. Enzymes participating in oxidative responses, including glucose 6-phosphate dehydrogenase (G6PD), were among the first molecules found to be upregulated rapidly in mechanically stimulated osteocytes and osteoblasts [252]. Other upregulated molecules include phospholipase A2, Cox-2 and prostaglandins, NO, protein kinase C, IGF-1, multiple glutamate receptors, and AP-1 family members [249,261]. However, an unambiguous role for any of these in the mechanotransduction response is not known, but recent approaches in which gain-of-function and loss-of-function mutations in some of these and other genes are being studied for their impact on bone cell responses to mechanical loading should help. For example, using a novel device that enables the noninvasive application of controlled mechanical loads to the murine tibia of IGF-1overexpressing transgenic mice, Gross and colleagues [262] concluded that IGF-1 is a synergistic factor required for the periosteal bone formation response to mechanical loading. Data from mice lacking iNOS suggest that NO generated by iNOS plays a critical role in adjusting bone turnover and increasing osteogenic activity in response to an acute increase in mechanical loading after tail suspension [263]. Similarly, the increase in osteoclastic bone resorption and suppression of osteoblastic bone formation in response to reduced mechanical stress was not seen in mice lacking OPN [264]. p53-p21 signaling has also been suggested to play a role in bone loss occurring with mechanical unloading [265]. However, the complexities and caveats in interpretations of data from knockout animals were also well demonstrated in the commentaries elicited in response to the conclusion that glutamate plays no role in bone growth based on studies in mice with GLAST glutamate transporters knocked out [266-268]. The availability of the recently established mouse MLO-Y4 osteocytic cell [234,235] should also help advance the field by aiding with the identification of novel osteocyte markers, molecular studies of osteocyte junctional complexes, and the response to mechanical forces and other stimuli. For example, it has been useful in increasing the understanding of the role of prostaglandins in cellular response to mechanical strain and gap junction-mediated intercellular communication [269-271]. Following up studies by Kumegawa and colleagues [273],who showed that osteocytes produce a small protein inhibitor of osteoclastic bone resorption, Vaananen and colleagues [272] found that MLO-Y4
59
osteocytic cells secrete significant amounts of TGF-[3, which inhibits bone resorption and is modulated by estrogen. This suggests that osteocytes have an active, inhibitory role in the regulation of bone resorption and may participate in the antiresorptive effects of estrogen.
MORPHOLOGICAL FEATURES OF OSTEOCLASTS Osteoclasts are easily recognized in histological sections of bone tissue as large multinucleated cells with up to 25 nuclei and are found in close association with bone surfaces. They are often located in slight indentations on the bone surface called Howship's lacunae, which result from osteoclasts having dissolved a small area of bone underneath the cell. Osteoclasts contain large amounts of the enzyme tartrate-resistant acid phosphatase (TRAP), and when stained histochemically for this enzyme they become quite conspicuous. However, not all osteoclasts contain large numbers of nuclei: Mononuclear TRAP-positive cells can frequently be seen, and osteoclasts containing two to four nuclei are not uncommon. Electron microscopic examination of cross sections through actively resorbing osteoclasts reveals several more morphological features. The area in which the cells closely adhere to bone, the clear zone, is characterized by an abundance of microfilaments and the absence of cellular organelles. The cytoplasm of osteoclasts contains an abundance of vesicular structures: Endocytotic vesicles are located adjacent to the ruffled border, and primary and secondary lysosomes and a variety of vesicles involved in transcytotic transport (from the ruffled border area to the basal surface) of endocytosed matrix degradation products and an extensive Golgi system are located adjacent to the nuclei [274]. When actively resorbing osteoclasts in situ are fixed, stained immunohistochemically with antibodies against F-actin, and then viewed under fluorescence microscopy, the clear zone area appears as a ring-like structure surrounding the ruffled border area [275]. This ring of actin-containing filaments delineates the area where the osteoclast closely adheres to the bone surface, likely via otv[33 integrin receptors, and forms a sealed-offextracellular compartment between the ruffled border and the bone surface in which bone resorption occurs [276]. When resorbing osteoclasts are viewed in situ using scanning electron microscopy, they appear as large, bulging cells with a surface covered with numerous filopodia. Where the osteoclast has moved away from an area it resorbed previously, exposed collagen fibers can frequently be seen, representing remains of the organic matrix after
60
Jane E. Aubin and Johan N. M. Heersche
the osteoclast has removed the mineral component of the bone matrix.
MECHANISMS OF OSTEOCLASTIC BONE RESORPTION Establishment of t h e Extracellular Resorption Z o n e The generally accepted view is that osteoclasts create an extracellular sealed-off compartment in which protons and proteolytic enzymes are secreted. Essential for this is the creation of a tight sealing zone, preventing leakage of ions and enzymes. Evidence indicates that the av[33 integrin is instrumental in establishing this sealing zone [277]. It is unclear, however, whether ctv[33 integrinmediated adhesion is essential for maintaining this zone: Immunohistochemical evidence suggests that this integrin is expressed on both the basolateral aspect and the ruffled border part of the osteoclast plasma membrane but not on the plasma membrane in the area of the sealing zone. However, blocking ctv[33 with RGDcontaining peptides or antibodies to the oLv[33 integrin inhibits osteoclastic bone resorption in vivo and in vitro, strongly suggesting that oLvl33-mediated processes are essential for osteoclastic resorption.
Demineralization Under normal conditions, osteoclasts are solely responsible for removing approximately 500 mg of calcium per day from the adult human skeleton. This is accomplished through an exchange mechanism, whereby calcium ions in the hydroxyapatite crystals are replaced by hydrogen ions. The H § ions required to dissolve the hydroxyapatite crystals comprising the mineral component of the bone matrix during the resorption process are generated by the activity of carbonic anhydrase type II (CAII), an enzyme that uses CO2 and H20 to generate H2CO3, which subsequently dissociates into H + ions and HCO3- ions. The protons thus generated are extruded into the extracellular space by a vacuolar-type H +ATPase (V-ATPase) located on the osteoclast ruffled border membrane and dissolve the bone mineral by H+/Ca 2+ exchange [278]. It is interesting that the osteoclast appears to be essentially self-sufficient in generating the components required to complete this part of the resorptive process: Protons generated by CAII activity, using CO2 produced during the oxidative phosphorylation of glucose in the mitochondria, are extruded by the activity of a V-ATPase requiring ATP, which is similarly generated by mitochondrial oxidative phosphorylation of glucose. The required glucose enters the osteoclast
through a GLUT-2 transporter [279], and all components of the system (mitochondria, the proton pump, the GLUT-2 transporter, and CAII) are abundant in osteoclasts. Proton extrusion into the extracellular resorption zone is accompanied by C1 extrusion via a chloride channel [280]. The driving force behind C1 extrusion is the potential difference that arises from electrogenic proton transport across the ruffled border membrane. In keeping with the self-sufficiency of the osteoclast, the required C1 ions enter the cell through a C1-/HCO3- exchanger located on the basolateral surface of the cell, which is driven by HCO3 accumulated by CAII activity combined with proton extrusion [281]. D e g r a d a t i o n of t h e Organic Matrix After demineralization, the remaining organic matrix of bone (90% type I collagen and 10% other proteins and proteoglycans) is partly degraded outside the cell in the extracellular resorption zone and partly inside the cell in various vesicular structures. Two classes of enzymes, matrix metalloproteinases and cysteine proteinases, play a major role in the degradation of the organic component of the bone matrix. Inhibition of the activity of these two classes of enzymes results in the accumulation of collagen fibers in the extracellular resorption zone [282]. Several recent studies have shown that cathepsin K is the predominant protease involved in bone matrix degradation [10,283-286]. Cathepsin K is secreted into the resorption pits by osteoclasts in its mature form, where it cleaves type I and type II collagens at their helical domains. Upon cleavage of the triple helix, collagen quickly unwinds and becomes susceptible to any proteinase with gelatinolytic activity. The ability to cleave the native triple helix of collagen at multiple sites makes cathepsin K unique among mammalian proteases [287]. The role ofmetalloproteinases in osteoclast function is less clear, although tissue culture experiments have demonstrated that MMP inhibitors have a strong inhibitory effect on collagen type I resorption by osteoclasts [288]. In addition, inhibition of MMPs in osteoclasts plated on bone slices has been shown to result in accumulation of demineralized bone matrix underneath the osteoclasts, further implicating MMPs in organic matrix degradation [282,289]. Also in support of a role for MMPs in the resorptive process is the observation that bone resorption is attenuated in mice carrying a mutation in type I collagen at the site that is targeted by neutral collagenases [290]. In fact, both cysteine proteinases and metalloproteinases may play a role in the resorptive process" Cysteine proteinases may degrade the collagen matrix prior to
2. Bone Cell Biology
subsequent degradation by MMPs [291]. Interestingly, osteoclasts in different parts of the skeleton may differ in terms of the relative importance of MMPs and cysteine proteinases in the resorption process: MMPs could be largely responsible for organic matrix degradation by osteoclasts in intramembranous bone (e.g., the bone of the skull and the scapula), whereas cysteine proteinases appear to be involved in osteoclastic resorption of both long bones and skull bones [289]. Processing of Degradation Products The way in which degradation products are removed from the sealed-off space between ruffled border and bone surface was recently determined by marking the bone surfaces being resorbed with tags that could be traced using either fluorescence or electron microscopy. It has thus become clear that osteoclasts endocytose degraded bone matrix components and solubilized mineral components at the ruffled border, transport it across the cell enclosed in endocytotic vesicles, and subsequently release the vesicle content at the opposite surface by merging the vesicles with the plasma membrane [274,292,293]. Thus, matrix degradation products can be disposed of continuously, without the osteoclasts losing its seal. An alternative mechanism for releasing degradation products from the extraceUular resorption zone is that osteoclasts move away from the resorption area temporarily, thereby allowing accumulated degradation products to diffuse away. Using time-lapse videomicroscopy, resorbing osteoclasts have indeed been observed to move back and forth within a clearly delineated resorption space [294]. A combination of the two mechanisms certainly seems possible.
ORIGIN OF OSTEOCLASTS As mentioned previously, osteoclasts are multinucleated cells of hematopoietic origin. This was first demonstrated by G6thlin and Ericsson using parabiotic rats [295]. They found that osteoclasts were derived from a bloodborne hemopoietic precursor, whereas the osteoblasts were derived from a local progenitor cell of connective tissue origin. Subsequent experiments by Walker [296] proved that osteoclasts are cells from the hemopoietic lineage: He transplanted spleen cells or bone marrow cells from normal mice into irradiated osteopetrotic littermates, which resulted in the formation of normal osteoclasts. This was confirmed by Scheven et al. [297], who cocultured purified bone marrow fractions with living osteoclast-free embryonic mouse longbone rudiments and found that the fraction containing
61
hemopoietic stem cells gave rise to osteoclasts. These authors also demonstrated that, at least in embryonic mouse long bones, proliferating osteoclast progenitors are seeded via the bloodstream in the mesenchyme surrounding the bone rudiments, where they then proliferate, differentiate, and fuse into multinucleated boneresorbing osteoclasts.
REGULATION OF OSTEOCLAST ACTIVITY AND DIFFERENTIATION Stimulation or inhibition of osteoclastic bone resorption may involve changes in activity of existing osteoclasts, changes in the total number of osteoclasts, or changes in size of the osteoclasts. It is often difficult to separate regulation of differentiation and regulation of activity because many factors affecting one of these processes also simultaneously affect the other. From studies on the effects of the bone-resorbing hormones PTH and 1,25 dihydroxyvitamin D3 [1,25(OH)2D3] in vivo and in in vitro bone organ culture systems, it is known that these hormones increase osteoclastic activity. When isolated osteoclast cultures became available, and results obtained with these systems were compared with those obtained using cultures containing both dispersed osteoclasts and stromal cells, it quickly became clear that these hormones did not activate osteoclasts directly, but that the signals were transmitted by other cell types in bone tissue. The first breakthrough toward elucidating this indirect pathway came from studies analyzing the cause of bone defects in the osteopetrotic op/op mouse [298]. These mice almost completely lack osteoclasts and tissue macrophages as a result of a single point mutation in the gene encoding M-CSF. Marrow cells from op/op mice cocultured with osteoblast-like cells or stromal cells from normal littermates (or vice versa) revealed that the defect in osteoclast differentiation in op/op mice resulted from the failure of osteoblastic/stromal cells to produce M-CSF required for osteoclast differentiation. Indeed, PTH and 1,25(OH)2D3 have been shown to upregulate M-CSF production by stromal cells [299] and SAOS-2 cells transfected with the PTH/PTHrP receptor respond to PTH with an increase in M-CSF production [300]. Osteoclast formation and activity in in vivo and in vitro systems containing osteoclasts, osteoclast precursors, and cells from the bone stromal compartment are affected not only by the osteotropic hormones PTH and 1,25(OH)2D3 but also by prostaglandins of the E series, estrogens, androgens, cytokines, and growth factors [e.g., IL-6, IL-11, interferon-~/(IFN-~/), tumor necrosis factor-tx (TNF-et), TGF-[3, BMP-2, oncostatin M, and LIF]. By using a coculture system consisting of spleen
62
Jane E. Aubin and Johan N. M. Heersche
cells and either osteoblastic cells from calvariae or established marrow-derived stromal cell lines, it was discovered that effects on osteoclast differentiation of some of these factors were mediated through the osteoblastic or stromal cell component of the cultures, that others were acting directly on the osteoclast on their precursors, and that still others were likely acting on both. The mediator generated by the stromal cells was discovered relatively recently and initially named osteoclast differentiation factor (ODF) [301]. This factor proved to be identical to the previously identified protein osteoprotegerin ligand (OPGL) [302], which in turn was identical to the previously discovered ligand for the receptor activator of NF-KB (RANKL). Since the receptor on the osteoclast recognizing ODF (= OPGL = RANKL) is the R A N K receptor [303], the ligand is now commonly called RANKL. RANKL is an absolute requirement for osteoclast formation, and this was proven conclusively by the generation of rankl knockout mice that had severe osteopetrosis due to a complete lack of osteoclasts. That R A N K L was indeed produced by cells other than the osteoclasts or their precursors was confirmed by analyzing cocultures of spleen cells from opgl -/- mice with osteoblastic cells from normal mice. Functional osteoclasts were generated in these cocultures, whereas cocultures of spleen cells from normal mice with osteoblastic cells from opgl -/- mice did not form osteoclasts. Thus, lack of R A N K L production in osteoblastic cells of opgl - / - mice was the cause of the osteoclast deficiency. It was discovered virtually simultaneously that osteoclast formation could be inhibited by a soluble receptor for RANKL, OPG, which is secreted by a large variety of cells and organs, including fibroblasts, osteoblasts, lung, heart, kidney, and intestine [304]. OPG-deficient mice are severely osteoporotic [305], whereas mice overexpressing OPG have an osteopetrotic phenotype. OPG acts by binding RANKL, thereby preventing interaction of R A N K L with its receptor and thus inhibiting osteoclast differentiation. The consensus is that osteoclast formation in the bone microenvironment is determined by the amount of unbound R A N K L available to interact with the R A N K receptor on osteoclasts or osteoclast precursors. RANKL-induced osteoclast differentiation in stromal cell-free systems requires the presence of M-CSF. The mechanisms responsible for this were determined by Cappellen et al. [306], who performed a microarray analysis of osteoclast differentiation induced by M-CSF and R A N K L in a purified mouse bone marrow cell culture. They discovered that early stages of differentiation of osteoclast precursors were associated with M-CSF-induced upregulation of m R N A for R A N K and R A N K pathway components (i.e., TNF receptorassociated factor 2A, PI3 kinase, etc.) Interestingly,
M-CSF also upregulated m R N A levels for several cytokine receptors (e.g., IL-11RoL2, gpl30, IFN-~/R) and cytokines (e.g., IL-loL, IL-18, and IFN-[3). This strongly suggests that osteoclasts and their precursors can respond directly to IL-11, IL-6, and IFN-~/and that they also produce cytokines that affect not only their own metabolism (autocrine) but also cells in their immediate environment (paracrine), such as osteoblastic stromal cells and endothelial cells associated with capillary ingrowth. In a separate series of experiments, the same authors demonstrated that a combination of IL-loL, IL6, and IL-11 directly stimulated osteoclastic activity in their culture system. When R A N K L was added together with M-CSF, approximately 70 novel target genes were found to be upregulated in addition to the already known target genes Jun and F O S - C 1 [307]. Upregulated target genes were mostly transcription factors but also genes encoding signaling molecules, chemokines, cytokines growth factors, and their receptors. Interestingly, among these were PDGF-oL and IGF-1 (implicated in the regulation of osteoblast differentiation) and the EP-2 prostaglandin E2 receptor. These studies emphasize that although much more is now known than only a few years ago about the regulation of osteoclast differentiation and function by interactions between osteoblast and osteoclast lineage cells, many aspects of regulation of their activity, differentiation, and interaction remain to be discovered. Recent evidence supports the idea that endothelial cells also participate in the regulation of osteoclast differentiation, as indicated by the observations that both OPG and R A N K L expression in cultured vascular endothelial cells are upregulated by IL-loL and TNF-oL [308]. Also, endothelin-1 (ET-1) produced by endothelial cells has been shown to stimulate proliferation and differentiation of osteoblastic cells [309], whereas VEGF has been shown to stimulate osteoclast formation in osteopetrotic M-CSF-deficient mice [310]. This further illustrates the complexity of the regulatory processes in the previously mentioned BMU: IL-loL, for example, directly affects osteoblastic cells, osteoclast lineage cells, and endothelial cells, and it seems certain that numerous other agonists will be identified in the near future that similarly affect all three cell types (e.g., PGE-2, IL-6, TNF-oL, TGF-[3, and several BMPs) [311,312]. Among factors that downregulate osteoclast activity and/or differentiation, estrogen figures prominently. Estrogen deficiency causes osteoporosis [313]. Closer examination of estrogen deficiency in humans and rats reveals that the major effect of estrogen deficiency in terms of osteoclastic activity is an increase in the rate of bone remodeling. It is also of interest that bone loss in estrogen-deficient rats is not uniform: The amount of cancellous bone in the epiphysis does not decrease significantly,
63
2. Bone Cell Biology
whereas the amount of cancellous bone in the metaphysis of the long bones decreases dramatically [Westerlind, 1997 #1469]. Estrogen treatment of estrogen-deficient postmenopausal women does not change the average depth of the osteoclastic resorption lacunae [313], which suggests that the resorptive activity of individual osteoclasts is not affected by estrogen. Rassi et al. [314] showed that estrogen treatment decreased 1,25(OH)zD3induced osteoclast formation in porcine bone marrow cultures by 50%, possibly through increased apoptosis of osteoclast precursor cells. Alternatively, estrogen may cause the decrease in 1,25(OH)2D3 responsiveness indirectly through downregulation of RANKL-mediated JNK1 activation, as found in cultures of both murine marrow cells and RAW cells [315].
OSTEOCLAST SIZE: MULTINUCLEATION AND FUNCTION The observation that osteoclast size is generally increased in diseases characterized by increased bone resorption (e.g., end-stage renal disease, Paget's disease, periodontal disease, and rheumatoid arthritis) suggests that multinucleation confers increased capacity for resorptive activity. We were able to show in an in vitro culture system that large osteoclasts are indeed more effective resorbers than small osteoclasts because the proportion of large osteoclasts that are resorbing is much greater than the proportion of small osteoclasts that are resorbing [316]. Thus, many small osteoclasts are not as effective as a smaller number of large osteoclasts with the same total number of nuclei. In several other multinucleated cells, the gain or loss of certain characteristics has been associated with cells becoming multinucleated. For example, Vignery and colleagues [317] reported that in multinucleated giant cells (MNGs) gene expression changed with multinuclearity: Mononuclear rat macrophages expressed the oL1 isoform of the Na+/K+-ATPase only, whereas the or3 isoform appeared when these cells fused to produce multinuclear cells. Enelow et al. [318] found that although microbicidal activity of human MNGs was enhanced in parallel with increased size and number of nuclei, the oxidative activity per unit cytoplasmic protein was significantly increased in the larger cells. With regard to osteoclast-like cells, it was reported that chick macrophages expressed high levels of m R N A for retinoic acid receptors alpha and gamma as well as the vitamin D receptor, whereas the osteoclast-like MNGs that formed in long-term cultures of these same cells had lower expression of these transcripts [319]. Formation of large
multinucleated cells has been studied in most detail in the formation of muscle, in which fusion of myoblasts leads to formation of multinucleated myotubes and subsequently striated muscle fibers. Recent evidence clearly indicates that fusion is a multistep process involving differentiation of muscle progenitors into founder cells and of surrounding mesenchymal progenitors into fusion-competent myoblasts [320]. One could speculate that similar processes occur with fusion of osteoclast precursors, and we are only starting to be able to analyze very limited aspects of the complicated mechanisms involved in this process. The mechanisms underlying several other processes of crucial importance to osteoclast function (e.g., exocytosis, proton transport, and cell fusion) are extremely complex and unlikely to be dissected first in osteoclast systems. For example, the processes of exocytosis and acidification of cellular compartments have been and are currently studied extensively in yeast [321]. Evaluation of the mechanisms discovered in other systems by searching for parallel mechanisms in the osteoclast will likely be the major avenue whereby such processes will be elucidated.
STEM CELL, OSTEOBLAST, AND OSTEOCLAST CHANGES IN DISEASE Many studies are beginning to be performed in which cells from patients with skeletal disorders or animal models of skeletal diseases are manipulated in vitro and in vivo to extend genetic understanding to that of the underlying cellular and molecular basis of bone diseases. For example, as described earlier, quantification of colony formation (for stromal cells: CFU-F, CFU-O, etc.; for osteoclasts: CFU-GM, etc.)can be used as an assessment of the stem/progenitor cell pools of an individual or a tissue site. In addition, cell transplantation studies are highly informative, and both kinds of assays help to clarify issues about the cell autonomous or nonautonomous nature of particular diseases. Regarding the latter, some studies showed normal osteoclast formation and cure of osteopetrosis when spleen or bone marrow cells were transplanted from normal mice into irradiated osteopetrotic littermates [296], whereas others did not [322,323]. Of course, these and other studies have led not only to elucidation of the hematopoietic origin of osteoclasts but also to elucidation of the role for cell nonautonomous stromal cell-hematopoietic cell interactions in osteoclastogenesis. Manifestations of skeletal growth and density abnormalities, especially in mice and rats, are routinely
64
Jane E. Aubin and lohan N. M. Heersche
dissected in vitro for clarification of the intrinsic roles of osteoclast lineage or osteoblast lineage cells or both. For example, mutations in mice in several different kinds of molecules (e.g., transcription factors, Wnt and other signaling pathways, and many others) alter bone formation in vivo with cell autonomous effects in osteoblast lineage cells determined by in vitro manipulations. The same kinds of analyses are being done for osteoclast lineage cells (e.g., transcription factors, ligand-receptor signaling pathways, and enzymes). However, far fewer studies have been done on cells from patients with skeletal disease. One exception relates to continuing analysis of the underlying osteoclast defects in malignant juvenile osteopetrosis [324]. Another exception is in quantification of stem and osteoprogenitor pools with aging and in age-related bone disorders. Discrepant data exist regarding whether CFU-F, CFU-O, and CFU-ALP colony size and number decrease or remain the same in humans, mice, and rats with aging and disease status (i.e., osteoporosis and osteoarthritis) [14]. However, the majority of data indicate that at least the CFU-ALP fraction of the CFU-F population declines (often dramatically) in number and/ or size with aging, suggesting that osteogenic capacity declines with age [325-332]. In addition, the responsiveness of CFU-F to systemic or locally released osteotropic growth factors has also been reported to decrease with age, as suggested earlier [333]. For example, the stimulatory effect of TGF-I3 on colony number and cells per colony in human osteoprogenitor cells derived from 98 iliac crest biopsies significantly declined with donor age [334]. Gazit et al. [332] suggest that changes in the osteoprogenitor cell/CFU-F compartment occur with aging in BALB/c mice because of a reduction in the amount and/ or activity of TGF-131. Ligand concentration-dependent ERa induction and loss of receptor regulation and diminution of ligand-receptor signal transduction with increasing donor age have also been reported [335]. In other recent studies, PGE2 was found to exert stimulatory and inhibitory effects on osteoblast differentiation and bone nodule formation through the EP-1/IP-3 pathway and EP-2/EP-4-cAMP pathway, respectively, in cells from young rats. However, the EP-1/IP-3 pathway was reported to be inactive in cells isolated from aged rats [336]. Thus, the known loss of bone with aging or menopause may be due to reduced responsiveness of osteoprogenitor cells to biological factors resulting in alteration of their subsequent differentiation potentials or to local changes in these factors. Bianco et al. [337,338] reported that stromal cells isolated from patients with fibrous dysplasia (FD) and McCune-Albright syndrome FD fail to recapitulate a normal ossicle in an in vivo transplantation assay; instead, they generate a miniature replica of fibrous dys-
plasia with ossicles that fail to establish a hematopoiesissupporting stroma, including adipocytes, and form less structurally sound and/or less abundant bone. Further analysis of these cells should prove useful for the design of effective therapeutic strategies.
TISSUE ENGINEERING AND STEM CELL THERAPY FOR SKELETAL DISEASES During the past few years, there has been much interest in the potential use of stem cells for cell and gene therapy in many disorders of metabolic, environmental, and genetic origins, including diseases of the skeleton. Studies with embryonic stem (ES) cells [339] and postnatal, tissue-derived stem cells, including HSCs and MSCs, are attracting considerable attention [340-343]. As is already evident, bone marrow and HSC transplantation is one paradigm by which osteoclast biology has been advanced. However, for many years, lack of evidence for significant donor stromal cell engraftment in host animals and patients receiving bone marrow transplants led to the conclusion that transplantation of osteogenic cells, particularly by a systemic route of delivery, was an unachievable goal. As already summarized and notwithstanding significant caveats, recent data challenge that conclusion. As outlined previously, MSCs and MAPCs are notable not only because of their potential for significant expansion but also for their apparently robust and multilineage differentiation potential, at least in vitro. They have therefore been proposed as suitable for both cell and gene therapy for skeletal diseases such as osteoporosis and osteoarthritis in which replacement of skeletal mass and refurbishing bone and joint structures are goals [344]. Another goal is replacement of missing or damaged tissue in a number of diseases affecting younger individuals. For example, some forms of osteogenesis imperfecta (OI) may be amenable to cell and gene therapy approaches, and both mouse OI and human studies are under way. Particularly notable are results from Horwitz and colleagues, who found evidence for a beneficial bone effect in OI children transplanted with HLAcompatible sibling bone marrow [345] or allogeneic stromal fibroblasts transplanted after bone marrow transplantation [346]. On the other hand, no conclusive effects have been seen in children transplanted with allogeneic stromal fibroblasts alone [Horwitz, 1999 # 1141]. In these latter studies, few or no donor cells were detectable 6 months posttransplantation, consistent with the low donor cell engraftment seen in most studies in humans and mice in which a low degree (1-5%) of
2. Bone Cell Biology
engraftment of bone or bone marrow stroma is seen, as assessed by a transgenic or unique endogenous genetic marker [347]. As discussed previously, however, in most cases the marker genes used do not discriminate whether the donor cell arises from a mesenchymal or, for example, from a macrophage lineage cell or donor-recipient cell fusion. In this regard, only one study in which whole bone marrow was delivered systemically reported the presence of donor osteoblasts and other osteoblast lineage cells, although the degree of engraftment and contribution of donor cells to bone formation was not assessed [348]. Nevertheless, the studies offer considerable promise and highlight the need for many more detailed studies in which engraftment rates, engraftment longevity, and the underlying mechanisms by which clinically relevant improvements in outcome are achieved are all assessed.
Acknowledgments We thank many members of our labs and other colleagues for valuable input and discussions over many years. This work was supported by CIHR Grants MT-12390 and MOP-49419 to JEA and MT-15654 and MT-14655 to JNMH and a grant from the Stem Cell Network of Centres of Excellence (JEA).
References 1. Parfitt, A. M. (2002). Targeted and nontargeted bone remodeling: Relationship to basic multicellular unit origination and progression. Bone 30, 5-7. 2. Manolagas, S. C. (2000). Birth and death of bone cells: Basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr. Rev. 21, 115-137. 3. Hock, J. M., Krishnan, V., Onyia, J. E., Bidwell, J. P., Milas, J., and Stanislaus, D. (2001). Osteoblast apoptosis and bone turnover. J. Bone Miner. Res. 16, 975-984. 4. Parfitt, A. M. (2001). The bone remodeling compartment: A circulatory function for bone lining cells. J. Bone Miner. Res. 16, 1583-1585. 5. Waller, E. K., Olweus, J., Lund-Johansen, F., Huang, S., Nguyen, M., Guo, G. R., and Terstappen, L. (1995). The "common stem cell" hypothesis reevaluated: Human fetal bone marrow contains separate populations of hematopoietic and stromal progenitors. Blood 85, 2422-2435. 6. Minkin, C. (1982). Bone acid phosphatase: Tartrate-resistant acid phosphatase as a marker of osteoclast function. Calcif. Tissue Int. 34, 285-290. 7. Heersche, J. N. M., and Manolson, M. (2000). The role of osteoclasts in bone. In The Osteoporosis Primer (J. E. Henderson and D. Goltzman, Eds.), pp. 36-45. Cambridge Univ. Press, Cambridge, UK. 8. Baron, R., Neff, L., Louvard, D., and Courtoy, P. J. (1985). Cellmediated extracellular acidification and bone resorption: Evidence for a low pH in resorbing lacunae and localization of a 100-kD lysosomal membrane protein at the osteoclast ruffled border. J. Cell Biol. 101, 2210-2222. 9. Tezuka, K., Nemoto, K., Tezuka, Y., Sato, T., Ikeda, Y., Kobori, M., Kawashima, H., Eguchi, H., Hakeda, Y., and Kumegawa, M.
10.
11.
12.
13.
14.
15.
16.
17.
18. 19.
20. 21.
22.
23.
24.
25.
26.
27.
65
(1994). Identification of matrix metalloproteinase 9 in rabbit osteoclasts. J. Biol. Chem. 269, 15006-15009. Drake, F. H., Dodds, R. A., James, I. E., Connor, J. R., Debouck, C., Richardson, S., Lee-Rykaczewski, E., Coleman, L., Rieman, D., Barthlow, R., Hastings, G., and Gowen, M. (1996). Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts. J. Biol. Chem. 271, 12511-12516. Parfitt, A. M. (1984). The cellular basis of bone remodeling: The quantum concept reexamined in light of recent advances in the cell biology of bone. Calcif Tissue Int. 36, $37-$45. Tran Van, P., Vignery, A., and Baron, R. (1982). An electronmicroscopic study of the bone-remodeling sequence in the rat. Cell Tissue Res. 225, 283-292. Tran Van, P. T., Vignery, A., and Baron, R. (1982). Cellular kinetics of the bone remodeling sequence in the rat. Anat. Rec. 202, 445-451. Aubin, J. E., and Triffitt, J. (2002). Mesenchymal stem cells and the osteoblast lineage. In Principles of Bone Biology (J. P. Bilezikian, L. G. Raisz, and G. A. Rodan, Eds.), 2nd ed., pp. 59-81. Academic Press, New York. Aubin, J. E. (1998). Bone stem cells. 25th anniversary issue: New directions and dimensions in cellular biochemistry. Invited chapter. J. Cell. Biochem. Suppl. 30/31, 73-82. Friedenstein, A. J. (1990). Osteogenic stem cells in the bone marrow. In Bone and Mineral Research~7 (J. N. M. Heersche and J. A. Kanis, Eds.), pp. 243-270. Elsevier, New York. Owen, M. E. (1998). The marrow stromal cell system. In Marrow Stromal Stem Cells in Culture (J. N. Beresford and M. E. Owen, Eds.), Vol. 4, pp. 88-110. Cambridge Univ. Press, Cambridge, UK. Prockop, D. J. (1997). Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 276, 71-74. Bianco, P., Riminucci, M., Kuznetsov, S., and Robey, P. G. (1999). Multipotential cells in the bone marrow stroma: Regulation in the context of organ physiology. Crit. Rev. Eukaryot. Gene Expr. 9, 159-173. Morrison, S. J., Shah, N. M., and Anderson, D. J. (1997). Regulatory mechanisms in stem cell biology. Cell 88, 287-298. Pittenger, M. F., Mackay, A. M., Beck, S. C., Jaiswal, R. K., Douglas, R., Mosca, J. D., Moorman, M. A., Simonetti, D. W., Craig, S., and Marshak, D. R. (1999). Multilineage potential of adult human mesenchymal stem cells. Science 284, 141-147. Friedenstein, A. J. (1980). Stromal mechanisms of bone marrow: Cloning in vitro and retransplantation in vivo. HamatoL Bluttransfus. 25, 19-29. Kuznetsov, S. A., Krebsbach, P. H., Satomura, K., Kerr, J., Riminucci, M., Benayahu, D., and Robey, P. G. (1997). Singlecolony derived strains of human marrow stromal fibroblasts form bone after transplantation in vivo. J. Bone Miner. Res. 12, 1335-1347. Aubin, J. E. (1999). Osteoprogenitor cell frequency in rat bone marrow stromal cell populations: Role for heterotypic cell-cell interactions in osteoblast differentiation. J. Cell. Biochem. 72, 396-410. Wu, X., Peters, J. M., Gonzalez, F. J., Prasad, H. S., Rohrer, M. D., and Gimble, J. M. (2000). Frequency of stromal lineage colony forming units in bone marrow of peroxisome proliferator-activated receptor-alpha-null mice. Bone 26, 21-26. Poliard, A., Nifuji, A., Lamblin, D., Plee, E., Forest, C., and Kellerman, O. (1995). Controlled conversion of an immortalized mesodermal progenitor cell towards osteogemic, chondrogenic or adipogenic pathways. J. Cell Biol. 130, 1461-1472. Aubin, J. E., and Heersche, J. M. N. (1997). Vitamin D and osteoblasts. In Vitamin D (D. Feldman, F. H. Glorieux, and J. W. Pike, Eds.), pp. 313-328. Academic Press, San Diego.
66
Jane E. Aubin and lohan N. NI. Heersche
28. Nuttall, M. E., and Gimble, J. M. (2000). Is there a therapeutic opportunity to either prevent or treat osteopenic disorders by inhibiting marrow adipogenesis? Bone 27, 177-184. 29. Bellows, C. G., and Heersche, J. N. (2001). The frequency of common progenitors for adipocytes and osteoblasts and of committed and restricted adipocyte and osteoblast progenitors in fetal rat calvaria cell populations. J. Bone Miner. Res. 16, 1983-1993. 30. Gimble, J. M., Robinson, C. E., and Kelly, K. A. (1996). The function of adipocytes in the bone marrow stroma: An update. Bone 19, 421-428. 31. Rickard, D. J., Kassem, M., Hefferan, T. E., Sarkar, G., Spelsberg, T. C., and Riggs, B. L. (1996). Isolation and characterization of osteoblast precursor cells from human bone marrow. J. Bone Miner. Res. 11, 312-324. 32. Nuttall, M. E., Patton, A. J., Olivera, D. L., Nadeau, D. P., and Gowen, M. (1998). Human trabecular bone cells are able to express both osteoblastic and adipocytic phenotype: Implications for osteogenic disorders. J. Bone Miner. Res. 13, 371-382. 33. Vescovi, A. L., and Snyder, E. Y. (1999). Establishment and properties of neural stem cell clones: Plasticity in vitro and in vivo. Brain Pathol. 9, 569-598. 34. Williams, J. H., and Klinken, S. P. (1999). Plasticity in the haemopoietic system. Int. J. Biochem. Cell. Biol. 31, 1237-1242. 35. Hole, N. (1999). Embryonic stem cell-derived haematopoiesis. Cells Tissues Organs 165, 181-189. 36. Bianco, P., and Cossu, G. (1999). Uno, nessuno e centomila: Searching for the identity of mesodermal progenitors. Exp. Cell Res. 251, 257-263. 37. Seale, P., and Rudnicki, M. A. (2000). A new look at the origin, function, and "stem-cell" status of muscle satellite cells. Dev. Biol. 218, 115-124. 38. Hodge, C. J., and Boakye, M. (2001). Biological plasticity: The future of science in neurosurgery. Neurosurgery 48, 2-16. 39. Kopen, G. C., Prockop, D. J., and Phinney, D. G. (1999). Marrow stromal cells migrate throughout forebrain and cerebellum, and they differentiate into astrocytes after injection into neonatal mouse brains. Proc. Natl. Acad. Sci. USA 96, 10711-10716. 40. Woodbury, D., Schwarz, E. J., Prockop, D. J., and Black, I. B. (2000). Adult rat and human bone marrow stromal cells differentiate into neurons. J. Neurosci. Res. 61, 364-370. 41. Hofstetter, C. P., Schwarz, E. J., Hess, D., Widenfalk, J., E1 Manira, A., Prockop, D. J., and Olson, L. (2002). Marrow stromal cells form guiding strands in the injured spinal cord and promote recovery. Proc. Natl. Acad. Sci. USA 99, 2199-2204. 42. Hirschi, K. K., and GoodeU, M. A. (2002). Hematopoietic, vascular and cardiac fates of bone marrow-derived stem cells. Gene Ther. 9, 648-652. 43. Wagers, A. J., Christensen, J. L., and Weissman, I. L. (2002). Cell fate determination from stem cells. Gene Ther. 9, 606-612. 44. Orkin, S. H., and Zon, L. I. (2002). Hematopoiesis and stem cells: Plasticity versus developmental heterogeneity. Nat. Immunol. 3, 323-328. 45. Ying, Q. L., Nichols, J., Evans, E. P., and Smith, A. G. (2002). Changing potency by spontaneous fusion. Nature 416, 545-548. 46. Terada, N., Hamazaki, T., Oka, M., Hoki, M., Mastalerz, D. M., Nakano, Y., Meyer, E. M., Morel, L., Petersen, B. E., and Scott, E. W. (2002). Bone marrow cells adopt the phenotype of other cells by spontaneous cell fusion. Nature 416, 542-545. 47. Wurmser, A. E., and Gage, F. H. (2002). Stem cells: Cell fusion causes confusion. Nature 416, 485-487. 48. Reyes, M., Lund, T., Lenvik, T., Aguiar, D., Koodie, L., and Verfaillie, C. M. (2001). Purification and ex vivo expansion of postnatal human marrow mesodermal progenitor cells. Blood 98, 2615-2625.
49. Jiang, Y., Jahagirdar, B. N., Reinhardt, R. L., Schwartz, R. E., Keene, C. D., Ortiz-Gonzalez, X. R., Reyes, M., Lenvik, T., Lund, T., Blackstad, M., Du, J., Aldrich, S., Lisberg, A., Low, W. C., Largaespada, D. A., and Verfaillie, C. M. (2002). Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 418, 41-49. 50. Eaves, C., Miller, C., ConneaUy, E., Audet, J., Oostendorp, R., Cashman, J., Zandstra, P., Rose-John, S., Piret, J., and Eaves, A. (1999). Introduction to stem cell biology in vitro. Threshold to the future. Ann. N. Y. Acad. Sci. 872, 1-8. 51. Huss, R., Lange, C., Weissinger, E. M., Kolb, H. J., and Thalmeier, K. (2000). Evidence of peripheral blood-derived, plastic-adherent CD34(-/low) hematopoietic stem cell clones with mesenchymal stem cell characteristics. Stem Cells 18, 252-260. 52. Kuznetsov, S. A., Mankani, M. H., Gronthos, S., Satomura, K., Bianco, P., and Robey, P. G. (2001). Circulating skeletal stem cells. J. Cell Biol. 153, 1133-1140. 53. Erices, A., Conget, P., and Minguell, J. J. (2000). Mesenchymal progenitor cells in human umbilical cord blood. Br. J. Haematol. 109, 235-242. 54. Campagnoli, C., Roberts, I. A., Kumar, S., Bennett, P. R., Bellantuono, I., and Fisk, N. M. (2001). Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow. Blood 98, 2396-2402. 55. Asakura, A., Komaki, M., and Rudnicki, M. (2001). Muscle satellite cells are multipotential stem cells that exhibit myogenic, osteogenic, and adipogenic differentiation. Differentiation 68, 245-53. 56. Gronthos, S., Franklin, D. M., Leddy, H. A., Robey, P. G., Storms, R. W., and Gimble, J. M. (2001). Surface protein characterization of human adipose tissue-derived stromal cells. J. Cell. Physiol. 189, 54-63. 57. Zuk, P. A., Zhu, M., Mizuno, H., Huang, J., Futrell, J. W., Katz, A. J., Benhaim, P., Lorenz, H. P., and Hedrick, M. H. (2001). Multilineage cells from human adipose tissue: Implications for cell-based therapies. Tissue Eng. 7, 211-228. 58. Huang, J. I., Beanes, S. R., Zhu, M., Lorenz, H. P., Hedrick, M. H., and Benhaim, P. (2002). Rat extramedullary adipose tissue as a source of osteochondrogenic progenitor cells. Plastic Reconstr. Surg. 109, 1033-1041. 59. Perry, R. L., and Rudnicki, M. A. (2000). Molecular mechanisms regulating myogenic determination and differentiation. Frontiers Biosci. 5, D750-D767. 60. Rosen, E. D., and Spiegelman, B. M. (2000). Molecular regulation of adipogenesis. Annu. Rev. Cell. Dev. Biol. 16, 145-171. 61. Bi, W., Deng, J. M., Zhang, Z., Behringer, R. R., and de Crombrugghe, B. (1999). Sox9 is required for cartilage formation. Nature Genet. 22, 85-89. 62. de Crombrugghe, B., Lefebvre, V., Behringer, R. R., Bi, W., Murakami, S., and Huang, W. (2000). Transcriptional mechanisms of chondrocyte differentiation. Matrix Biol. 19, 389-394. 63. Karsenty, G., and Wagner, E. F. (2002). Reaching a genetic and molecular understanding of skeletal development. Dev. Cell 2, 389-406. 64. Ducy, P., Zhang, R., Geoffroy, V., Ridall, A. L., and Karsenty, G. (1997). Osf2/Cbfal: A transcriptional activator of osteoblast differentiation. Cell 89, 747-754. 65. Banerjee, C., McCabe, L., Choi, J.-Y., Hiebert, S. W., Stein, J. L., Stein, G. S., and Lian, J. B. (1997). Runt homology domain proteins in osteoblast differentiation: AML-3 is a major component of a bone specific complex. J. Cell. Biochem. 66, 1-8. 66. Komori, T., Yagi, H., Nomura, S., Yamaguchi, A., Sasaki, K., Deguchi, K., Shimizu, Y., Bronson, R. T., Gao, Y. H., Inada, M., Sato, M., Okamoto, R., Kitamura, Y., Yoshiki, S., and Kishimoto, T. (1997). Targeted disruption of Cbfal results in a complete lack
2. Bone Cell Biology
67.
68. 69. 70.
71.
72.
73.
74.
75. 76.
77. 78.
79.
80.
81.
82.
of bone formation owing to maturational arrest of osteoblasts [see Comments]. Cell 89, 755-764. Ducy, P., Starbuck, M., Priemel, M., Shen, J., Pinero, G., Geoffroy, V., Amling, M., and Karsenty, G. (1999). A Cbfal-dependent genetic pathway controls bone formation beyond embryonic development. Genes Dev. 13, 1025-1036. Karsenty, G. (1999). The genetic transformation of bone biology. Genes Dev. 13, 3037-3051. Ducy, P. (2000). CBFAI: A molecular switch in osteoblast biology. Dev. Dyn. 219, 461-471. Yamaguchi, A., Komori, T., and Suda, T. (2000). Regulation of osteoblast differentiation mediated by bone morphogenetic proteins, hedgehogs, and Cbfal. Endocr. Rev. 21, 393-411. Lee, M. H., Javed, A., Kim, H. J., Shin, H. I., Gutierrez, S., Choi, J. Y., Rosen, V., Stein, J. L., van Wijnen, A. J., Stein, G. S., Lian, J. B., and Ryoo, H. M. (1999). Transient upregulation of CBFA1 in response to bone morphogenetic protein-2 and transforming growth factor betal in C2C12 myogenic cells coincides with suppression of the myogenic phenotype but is not sufficient for osteoblast differentiation. J. Cell. Biochem. 73, 114-125. Wang, D., Christensen, K., Chawla, K., Xiao, G., Krebsbach, P. H., and Franceschi, R. T. (1999). Isolation and characterization of MC3T3-E1 preosteoblast subclones with distinct in vitro and in vivo differentiation/mineralization potential. J. Bone Miner. Res. 14, 893-903. Liu, W., Toyosawa, S., Furuichi, T., Kanatani, N., Yoshida, C., Liu, Y., Himeno, M., Narai, S., Yamaguchi, A., and Komori, T. (2001). Overexpression of Cbfal in osteoblasts inhibits osteoblast maturation and causes osteopenia with multiple fractures. J. Cell. Biol. 155, 157-166. Inada, M., Yasui, T., Nomura, S., Miyake, S., Deguchi, K., Himeno, M., Sato, M., Yamagiwa, H., Kimura, T., Yasui, N., Ochi, T., Endo, N., Kitamura, Y., Kishimoto, T., and Komori, T. (1999). Maturational disturbance of chondrocytes in Cbfaldeficient mice. Dev. Dyn. 214, 279-290. Kim, I. S., Otto, F., Zabel, B., and Mundlos, S. (1999). Regulation of chondrocyte differentiation by Cbfal. Mech. Dev. 80, 159-170. Enomoto, H., Enomoto-Iwamoto, M., Iwamoto, M., Nomura, S., Himeno, M., Kitamura, Y., Kishimoto, T., and Komori, T. (2000). Cbfal is a positive regulatory factor in chondrocyte maturation. J. Biol. Chem. 275, 8695-8702. Komori, T. (2000). A fundamental transcription factor for bone and cartilage. Biochem. Biophys. Res. Commun. 276, 813-816. Lecka-Czernik, B., Gubrij, I., Moerman, E. J., Kajkenova, O., Lipschitz, D. A., Manolagas, S. C., and Jilka, R. L. (1999). Inhibition of Osf2/Cbfal expression and terminal osteoblast differentiation by PPARgamma2. J. Cell. Biochem. 74, 357-371. Nakashima, K., Zhou, X., Kunkel, G., Zhang, Z., Deng, J. M., Behringer, R. R., and de Crombrugghe, B. (2002). The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell 108, 17-29. St.-Jacques, B., Hammerschmidt, M., and McMahon, A. P. (1999). Indian hedgehog signaling regulates proliferation and differentiation of chondrocytes and is essential for bone formation [published erratum appears in Genes Dev. 1999 Oct 1;13 (19): 2617]. Genes Dev. 13, 2072-2086. Chuang, P. T., and McMahon, A. P. (1999). Vertebrate Hedgehog signalling modulated by induction of a Hedgehog-binding protein. Nature 397, 617-621. Hofbauer, L. C., Khosla, S., Dunstan, C. R., Lacey, D., Boyle, W. J., and Riggs, B. L. (2000). The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J. Bone Miner. Res. 15, 2-12.
67
83. Eipers, P. G., Kale, S., Taichman, R. S., Pipia, G. G., Swords, N. A., Mann, K. G., and Long, M. W. (2000). Bone marrow accessory cells regulate human bone precursor cell development. Exp. Hematol. 28, 815-825. 84. Herzenberg, L. A., and De Rosa, S. C. (2000). Monoclonal antibodies and the FACS: Complementary tools for immunobiology and medicine. Immunol. Today 21, 383-390. 85. Simmons, P. J., and Torok-Storb, B. (1991). Identification of stromal cell precursors in human bone marrow by a novel monoclonal antibody, STRO-1. Blood 78, 55-62. 86. Bruder, S. P., Horowitz, M. C., Mosca, J. D., and Haynesworth, S. E. (1997). Monoclonal antibodies reactive with human osteogenic cell surface antigens. Bone 21,223-235. 87. Bruder, S. P., Ricalton, N. S., Boynton, R. E., Connolly, T. J., Jaiswal, N., Zaia, J., and Barry, F. P. (1998). Mesenchymal stem cell surface antigen SB-10 corresponds to activated leukocyte cell adhesion molecule and is involved in osteogenic differentiation. J. Bone Miner. Res. 13, 655-663. 88. Joyner, C. J., Bennett, A., and Triffitt, J. T. (1997). Identification and enrichment of human osteoprogenitor cells by using differentiation stage-specific monoclonal antibodies. Bone 21, 1-6. 89. Gronthos, S., Graves, S. E., Ohta, S., and Simmons, P. J. (1994). The STRO- 1+ fraction of adult human bone marrow contains the osteogenic precursors. Blood 84, 4164-4173. 90. Bowen, M. A., Aruffo, A. A., and Bajorath, J. (2000). Cell surface receptors and their ligands: In vitro analysis of CD6-CD166 interactions. Proteins 40, 420-428. 91. Bowen, M. A., and Aruffo, A. (1999). Adhesion molecules, their receptors, and their regulation: Analysis of CD6-activated leukocyte cell adhesion molecule (ALCAM/CD166) interactions. Transplant Proc. 31, 795-796. 92. Nelissen, J. M., Torensma, R., Pluyter, M., Adema, G. J., Raymakers, R. A., van Kooyk, Y., and Figdor, C. G. (2000). Molecular analysis of the hematopoiesis supporting osteoblastic cell line U2-OS. Exp. Hematol. 28, 422-432. 93. Barry, F. P., Boynton, R. E., Haynesworth, S., Murphy, J. M., and Zaia, J. (1999). The monoclonal antibody SH-2, raised against human mesenchymal stem cells, recognizes an epitope on endoglin (CD 105). Biochem. Biophys. Res. Commun. 265, 134-139. 94. Fleming, J. E. J., Haynesworth, S. E., Cassiede, P., Baber, M. A., and Caplan, A. I. (1998). Monoclonal antibody against adult marrow-derived mesenchymal stem cells recognizes developing vasculature in embryonic human skin. Dev. Dyn. 212, 119-132. 95. Oreffo, R. O. C., Virdi, A. S., and Triffitt, J. T. (2001). Retroviral marking of human bone marrow fibroblasts: In vitro expansion and localization in calvarial sites after subcutaneous transplantation in vivo. J. Cell. Physiol. 186, 201-209. 96. Gronthos, S., Zannettino, A. C. W., Hay, S. J., Shi, S., Graves, S. E., Kortesidis, A., and Simmons, P. J. (2003). Molecular and cellular characterization of highly purified stromal stem cells derived from human bone marrow. J. Cell Sci. 116, 1827-1835. 97. Aubin, J. E., and Turksen, K. (1996). Monoclonal antibodies as tools for studying the osteoblast lineage. Microsc. Res. Technique. 33, 128-140. 98. Gronthos, S., Zannettino, A. C., Graves, S. E., Ohta, S., Hay, S. J., and Simmons, P. J. (1999). Differential cell surface expression of the STRO-1 and alkaline phosphatase antigens on discrete developmental stages in primary cultures of human bone cells. J. Bone Miner. Res. 14, 47-56. 99. Stewart, K., Walsh, S., Screen, J., Jefferiss, C. M., Chainey, J., Jordan, G. R., and Beresford, J. N. (1999). Further characterization of cells expressing STRO-1 in cultures of adult human bone marrow stromal cells. J. Bone Miner. Res. 14, 1345-1356.
68
Jane E. Aubin and lohan N. M. Heersche
100. Van Vlasselaer, P., Falla, N., Snoeck, H., and Mathieu, E. (1994). Characterization and purification of osteogenic cells from murine bone marrow by two-color cell sorting using anti-Sca-1 monoclonal antibody and wheat germ agglutinin. Blood 84, 753-763. 101. Zohar, R., Sodek, J., and McCulloch, C. A. (1997). Characterization of stromal progenitor cells enriched by flow cytometry. Blood 90, 3471-3481. 102. Zohar, R., McCulloch, C. A., Sampath, K., and Sodek, J. (1998). Flow cytometric analysis of recombinant human osteogenic protein-1 (BMP-7) responsive subpopulations from fetal rat calvaria based on intracellular osteopontin content. Matrix Biol. 16, 295-306. 103. Aubin, J. E., and Liu, F. (1996). The osteoblast lineage. In Principles of Bone Biology (J. P. Bilezikian, L. G. Raisz, and G. A. Rodan, Eds.), pp. 51-67. Academic Press, San Diego. 104. Dacic, S., Kalajzic, I., Visnjic, D., Lichtler, A. C., and Rowe, D. W. (2001). Collal-driven transgenic markers of osteoblast lineage progression. J. Bone Miner. Res. 16, 1228-1236. 105. Kalajzic, I., Kalajzic, Z., Kalitema, M., Gronowicz, G., Clark, S. H., Lichtler, A. C., and Rowe, D. (2002). Use of type I collagen green fluorescent protein transgenes to identify subpopulations of cells at different stages of the osteoblast lineage. J. Bone Miner. Res. 17, 15-25. 106. Rowe, D., and Lichtler, A. (2002). A strategy for identifying osteoporosis risk genes. Endocrine 17, 67-75. 107. Herbertson, A., and Aubin, J. (1995). Dexamethasone alters the subpopulation make-up of rat bone marrow stromal cell cultures. J. Bone Miner. Res. 10, 285-294. 108. Herbertson, A., and Aubin, J. E. (1997). Cell sorting enriches osteogenic populations in rat bone marrow stromal cell cultures. Bone 21, 491-500. 109. Bellows, C. G., and Aubin, J. E. (1989). Determination of numbers of osteoprogenitors present in isolated fetal rat calvaria cells in vitro. Dev. Biol. 133, 8-13. 110. Falla, N., Van Vlassalaer, P., Bierkens, J., Borremans, B., Schoeters, G., and Van Gorp, U. (1993). Characterization of a 5-fluorouracil-enriched osteoprogenitor population of the murine bone marrow. Blood 82, 3580-3591. 111. Lomri, A., Marie, P. J., Tran, P. V., Hott, M., Onyia, J. E., Hale, L. V., Miles, R. R., Cain, R. L., Tu, Y., Hulman, J. F., Hock, J. M., and Santerre, R. F. (1988). Characterization ofendosteal osteoblastic cells isolated from mouse caudal vertebrae. Bone 9, 165-175. 112. Ishida, Y., Bellows, C. G., Tertinegg, I., and Heersche, J. N. (1997). Progesterone-mediated stimulation of osteoprogenitor proliferation and differentiation in cell populations derived from adult or fetal rat bone tissue depends on the serum component of the culture media. Osteoporos Int. 7, 323-330. 113. Onyia, J. E., Miller, B., Hulman, J., Liang, J., Galvin, R., Frolik, C., Chandrasekhar, S., Harvey, A. K., Bidwell, J., Herring, J., Hock, J. M., Hale, L. V., Miles, R. R., Cain, R. L., Tu, Y., Hulman, J. F., and Santerre, R. F. (1997). Proliferating cells in the primary spongiosa express osteoblastic phenotype in vitro. Bone 20, 93-100. 114. Turksen, K., and Aubin, J. E. (1991). Positive and negative immunoselection for enrichment of two classes of osteoprogenitor cells. J. Cell Biol. 114, 373-384. 115. Bellows, C. G., Aubin, J. E., and Heersche, J. N. M. (1987). Physiological concentrations of glucocorticoids stimulate formation of bone nodules from isolated rat calvaria cells in vitro. Endocrinology 121, 1985-1992. 116. Ishida, Y., and Heersche, J. N. (1997). Progesterone stimulates proliferation and differentiation of osteoprogenitor cells in bone cell populations derived from adult female but not from adult male rats. Bone 20, 17-25.
117. Hughes, F. J., Collyer, J., Stanfield, M., and Goodman, S. A. (1995). The effects of bone morphogenetic protein-2, -4 and -6 on differentiation of rat osteoblast cells in vitro. Endocrinology 136, 2671-2677. 118. Scutt, A., and Bertram, P. (1999). Basic fibroblast growth factor in the presence of dexamethasone stimulates colony formation, expansion, and osteoblastic differentiation by rat bone marrow stromal cells. Calcif Tissue Int. 64, 69-77. 119. Madras, N., Gibbs, A. L., Zhou, Y., Zandstra, P. W., and Aubin, J. E. (2002). Modeling stem cell development by retrospective analysis of gene expression profiles in single progenitorderived colonies. Stern Cells 20, 230-240. 120. Doherty, M. J., and Canfield, A. E. (1999). Gene expression during vascular pericyte differentiation. Crit. Rev. Eukaryot. Gene Expr. 9, 1-17. 121. Proudfoot, D., Shanahan, C. M., and Weissberg, P. L. (1998). Vascular calcification: New insights into an old problem. J. Pathol. 185, 1-3. 122. Shanahan, C. M., Proudfoot, D., Tyson, K. L., Cary, N. R., Edmonds, M., and Weissberg, P. L. (2000). Expression of mineralisation-regulating proteins in association with human vascular calcification. Z. Kardiol. 89, 63-68. 123. Scutt, A., and Bertram, P. (1995). Bone marrow cells are targets for the anabolic actions of PGE2 on bone: Induction of a transition from nonadherent to adherent osteoblast precursors. J. Bone Miner. Res. 10, 474-487. 124. Long, M. W., Robinson, J. A., and Mann, K. G. (1995). Regulation of human bone marrow-derived osteoprogenitor cells by osteogenic growth factors. J. Clin. Invest. 95, 881-887. 125. Malaval, L., Liu, F., Roche, P., and Aubin, J. E. (1999). Kinetics of osteoprogenitor proliferation and osteoblast differentiation in vitro. J. Cell. Biochem. 74, 616-627. 126. Bellows, C. G., Heersche, J. N. M., and Aubin, J. E. (1990). Determination of the capacity for proliferation and differentiation of osteoprogenitor cells in the presence and absence of dexamethasone. Dev. Biol. 140, 132-138. 127. McCulloch, C. A. G., Strugurescu, M., Hughes, F., Melcher, A. H., and Aubin, J. E. (1991). Osteogenic progenitor cells in rat bone marrow stromal populations exhibit self-renewal in culture. Blood 77, 1906-1911. 128. Zandstra, P. W., Jervis, E., Haynes, C. A., Kilburn, D. G., Eaves, C. J., and Piret, J. M. (1999). Concentration-dependent internalization of a cytokine/cytokine receptor complex in human hematopoietic cells. Biotechnol. Bioeng. 63, 493-501. 129. Ramsfjell, V., Bryder, D., Bjorgvinsdottir, H., Kornfalt, S., Nilsson, L., Borge, O. J., and Jacobsen, S. E. (1999). Distinct requirements for optimal growth and In vitro expansion of human CD34 (+)CD38(-) bone marrow long-term culture-initiating cells (LTC-IC), extended LTC-IC, and murine in vivo long-term reconstituting stem cells. Blood 94, 4093-4102. 130. Stein, G. S., Lian, J. B., Stein, J. L., van Wijnen, A. J., Frenkel, B., and Montecino, M. (Eds.) (1996). Mechanisms Regulating Osteoblast Proliferation and Differentiation. Academic Press, San Diego. 131. Liu, F., and Aubin, J. E. (1994). Identification and molecular characterization of preosteoblasts in the osteoblast differentiation sequence. J. Bone Miner. Res. 9, S125. 132. Liu, F., Malaval, L., and Aubin, J. E. (2003). Global amplification polymerase chain reaction reveals novel transitional stages during osteoprogenitor differentiation. J. Cell Sci. 116, 1787-1796. 133. Candeliere, G. A., Rao, Y., Floh, A., Sandier, S. D., and Aubin, J. E. (1999). cDNA fingerprinting of osteoprogenitor cells to isolate differentiation stage-specific genes. Nucleic Acids Res. 27, 1079-1083.
2. Bone Cell Biology 134. Aubin, J. E., Candeliere, G. A., and Bonnelye, E. (1999). Heterogeneity of the osteoblast phenotype. Endocrinologist 9, 25-31. 135. Liu, F., Malaval, L., Gupta, A., and Aubin, J. E. (1994). Simultaneous detection of multiple bone-related mRNAs and protein expression during osteoblast differentiation: Polymerase chain reaction and immunocytochemical studies at the single cell level. Dev. Biol. 166, 220-234. 136. Malaval, L., Modrowski, D., Gupta, A. K., Modrowski, D., Gupta, A. K., and Aubin, J. E. (1994). Cellular expression of bone-related proteins during in vitro osteogenesis in rat bone marrow stromal cell cultures. J. Cell. Physiol. 158, 555-572. 137. Pockwinse, S. M., Stein, J. L., Lian, J. B., and Stein, G. S. (1995). Developmental stage-specific cellular responses to vitamin D3 and glucocorticoids during differentiation of the osteoblast phenotype: Interrelationships of morphology and gene expression by in situ hybridization. Exp. Cell Res. 216, 244-260. 138. Liu, F., Malaval, L., and Aubin, J. E. (1997). The mature osteoblast phenotype is characterized by extensive palsticity. Exp. Cell Res. 232, 97-105. 139. Candeliere, G. A., Liu, F., and Aubin, J. E. (2001). Individual osteoblasts in the developing calvaria express different gene repertoires. Bone 28, 351-361. 140. Heersche, J. N. M., Reimers, S., Wrana, J. L., Waye, M. M. Y., and Gupta, A. K. (1992). Changes in expression of alpha 1 type 1 collagen and osteocalcin mRNA in osteoblasts and odontoblastsat different stages of maturity as shown by in situ hybridization. Proc. Finn. Dent. Soc. 88, 173-182. 141. Bianco, P., Riminucci, M., Bonucci, E., Termine, J. D., and Robey, P. G. (1993). Bone sialoprotein (BSP) secretion and osteoblast differentiation: Relationship to bromodeoxyuridine incorporation, alkaline phosphatase, and matrix deposition. J. Histochem. Cytochem. 41, 183-191. 142. Ingram, R. T., Clarke, B. L., Fisher, L. W., and Fitzpatrick, L. A. (1993). Distribution of noncollagenous proteins in the matrix of adult human bone: Evidence of anatomic and functional heterogeneity. J. Bone Miner. Res. 8, 1019-1029. 143. Ikeda, T., Nagai, Y., Yamaguchi, A., Yokose, S., and Yoshiki, S. (1995). Age-related reduction in bone matrix protein mRNA expression in rat bone tissues: Application of histomorphometry to in situ hybridization. Bone 16, 17-23. 144. Fedde, K. N., Blair, L., Silverstein, J., Coburn, S. P., Ryan, L. M., Weinstein, R. S., Waymire, K., Narisawa, S., Millan, J. L., MacGregor, G. R., and Whyte, M. P. (1999). Alkaline phosphatase knock-out mice recapitulate the metabolic and skeletal defects of infantile hypophosphatasia. J. Bone Miner. Res. 14, 2015-2026. 145. Wennberg, C., Hessle, L., Lundberg, P., Mauro, S., Narisawa, S., Lerner, U. H., and Millan, J. L. (2000). Functional characterization of osteoblasts and osteoclasts from alkaline phosphatase knockout mice. J. Bone Miner. Res. 15, 1879-1888. 146. Ducy, P., Desbois, C., Boyce, B., Pinero, G., Story, B., Dunstan, C., Smith, E., Bonadio, J., Goldstein, S., Gundberg, C., Bradley, A., and Karsenty, G. (1996). Increased bone formation in osteocalcin-deficient mice. Nature 382, 448-452. 147. Yoshitake, H., Rittling, S. R., Denhardt, D. T., and Noda, M. (1999). Osteopontin-deficient mice are resistant to ovariectomyinduced bone resorption. Proc. Natl. Acad. Sci. USA 96, 8156-8160. 148. Aubin, J. E., Gupta, A. K., Zirngbl, R., and Rossant, J. (1996). Knockout mice lacking bone sialoprotein expression have bone abnormalities. J. Bone Miner. Res. 11, S102. 149. Amling, M., Herden, S., Posl, M., Hahn, M., Ritzel, H., and Delling, G. (1996). Heterogeneity of the skeleton: Comparison of the trabecular microarchitecture of the spine, the iliac crest, the femur, and the calcaneus. J. Bone Miner. Res. 11, 36-45.
69
150. Byers, R. J., Denton, J., Hoyland, J. A., and Freemont, A. J. (1997). Differential patterns of osteoblast dysfunction in trabecular bone in patients with established osteoporosis. J. Clin. Pathol. 50, 760-764. 151. Riggs, B. L., Khosla, S., and Melton, L. J. (1998). A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J. Bone Miner. Res. 13, 763-773. 152. Calvi, L. M., Sims, N. A., Hunzelman, J. L., Knight, M. C., Giovannetti, A., Saxton, J. M., Kronenberg, H. M., Baron, R., and Schipani, E. (2001). Activated parathyroid hormone/parathyroid hormone-related protein receptor in osteoblastic cells differentially affects cortical and trabecular bone. J. Clin. Invest. 107, 277-286. 153. Parisien, M., Silverberg, S. J., Shane, E., de la Cruz, L., Lindsay, R., Bilezikian, J. P., and Dempster, D. W. (1990). The histomorphometry of bone in primary hyperparathyroidism: Preservation of cancellous bone structure. J. Clin. Endocrinol. Metab. 70, 930-938. 154. Petersen, D. N., Tkalcevic, G. T., Mansolf, A. L., RiveraGonzalez, R., and Brown, T. A. (2000). Identification of osteoblast/osteocyte factor 45 (OF45), a bone-specific cDNA encoding an RGD-containing protein that is highly expressed in osteoblasts and osteocytes. J. Biol. Chem. 275, 36172-36180. 155. Guo, R., and Quarles, L. D. (1997). Cloning and sequencing of human PEX from a bone cDNA library: Evidence for its developmental stage-specific regulation in osteoblasts. J. Bone Miner. Res. 12, 1009-1017. 156. Ruchon, A. F., Marcinkiewicz, M., Siegfried, G., Tenenhouse, H. S., DesGroseillers, L., Crine, P., and Boileau, G. (1998). Pex mRNA is localized in developing mouse osteoblasts and odontoblasts. J. Histochem. Cytochem. 46, 459-68. 157. Ecarot, B., and Desbarats, M. (1999). 1,25-(OH)2D3 downregulates expression of Phex, a marker of the mature osteoblast. Endocrinology 140, 1192-1199. 158. Ruchon, A. F., Tenenhouse, H. S., Marcinkiewicz, M., Siegfried, G., Aubin, J. E., Desgroseillers, L., Crine, P., and Boileau, G. (2000). Developmental expression and tissue distribution of phex protein: Effect of the Hyp mutation and relationship to bone markers. J. Bone Miner. Res. 15, 1440-1450. 159. Aubin, J. E., Gupta, A. K., Bhargava, U., and Turksen, K. (1996). Expression and regulation of galectin 3 in rat osteoblastic cells. J. Cell. Physiol. 169, 468-480. 160. Jamal, H. H., and Aubin, J. E. (1996). CD44 expression in fetal rat bone: In vivo and in vitro analysis. Exp. Cell Res. 223, 467-477. 161. Choi, J. Y., van Wijnen, A. J., Aslam, F., Leszyk, J. D., Stein, J. L., Stein, G. S., Lian, J. B., and Penman, S. (1998). Developmental association of the beta-galactoside-binding protein galectin-1 with the nuclear matrix of rat calvarial osteoblasts. J. Cell Sci. 111, 3035-3043. 162. Hsu, D. K., Yang, R. Y., Pan, Z., Yu, L., Salomon, D. R., FungLeung, W. P., and Liu, F. T. (2000). Targeted disruption of the galectin-3 gene results in attenuated peritoneal inflammatory responses. Am. J. Pathol. 156, 1073-1083. 163. Colnot, C., Sidhu, S. S., Balmain, N., and Poirier, F. (2001). Uncoupling of chondrocyte death and vascular invasion in mouse galectin 3 null mutant bones. Dev. Biol. 229, 203-214. 164. Carulli, J. P., Artinger, M., Swain, P. M., Root, C. D., Chee, L., Tulig, C., Guerin, J., Osborne, M., Stein, G., Lian, J., and Lomedico, P. T. (1998). High throughput analysis of differential gene expression. J. Cell. Biochem. Suppl. 30/31, 286-296. 165. Seth, A., Lee, B. K., Qi, S., and Vary, C. P. (2000). Coordinate expression of novel genes during osteoblast differentiation. J. Bone Miner. Res. 15, 1683-1696.
70
Jane E. Aubin and lohan N. M. Heersche
166. Raouf, A., and Seth, A. (2002). Discovery of osteoblast-associated genes using cDNA microarrays. Bone 30, 463-471. 167. Beck, G. R., Jr., Zerler, B., and Moran, E. (2001). Gene array analysis of osteoblast differentiation. Cell Growth Differ. 12, 61-83. 168. Yoshida, Y., Tanaka, S., Umemori, H., Minowa, O., Usui, M., Ikematsu, N., Hosoda, E., Imamura, T., Kuno, J., Yamashita, T., Miyazono, K., Noda, M., Noda, T., and Yamamoto, T. (2000). Negative regulation of BMP/Smad signaling by Tob in osteoblasts. Cell 103, 1085-1097. 169. Xiao, Z. S., Hinson, T. K., and Quarles, L. D. (1999). Cbfal isoform overexpression upregulates osteocalcin gene expression in non-osteoblastic and pre-osteoblastic cells. J. Cell. Biochem. 74, 596-605. 170. Harada, H., Tagashira, S., Fujiwara, M., Ogawa, S., Katsumata, T., Yamaguchi, A., Komori, T., and Nakatsuka, M. (1999). Cbfal isoforms exert functional differences in osteoblast differentiation. J. Biol. Chem. 274, 6972-6978. 171. Drissi, H., Luc, Q., Shakoori, R., Chuva De Sousa Lopes, S., Choi, J. Y., Terry, A., Hu, M., Jones, S., Neil, J. C., Lian, J. B., Stein, J. L., Van Wijnen, A. J., and Stein, G. S. (2000). Transcriptional autoregulation of the bone related CBFA1/RUNX2 gene. J. Cell. Physiol. 184, 341-350. 172. Satokata, I., Ma, L., Ohshima, H., Bei, M., Woo, I., Nishizawa, K., Maeda, T., Takano, Y., Uchiyama, M., Heaney, S., Peters, H., Tang, Z., Maxson, R., and Maas, R. (2000). Msx2 deficiency in mice causes pleiotropic defects in bone growth and ectodermal organ formation. Nature Genet. 24, 391-395. 173. Tribioli, C., and Lufkin, T. (1999). The murine Bapxl homeobox gene plays a critical role in embryonic development of the axial skeleton and spleen. Development 126, 5699-5711. 174. Kanzler, B., Kuschert, S. J., Liu, Y. H., and Mallo, M. (1998). Hoxa-2 restricts the chondrogenic domain and inhibits bone formation during development of the branchial area. Development 125, 2587-2597. 175. Zhou, Y. X., Xu, X., Chen, L., Li, C., Brodie, S. G., and Deng, C. X. (2000). A Pro250Arg substitution in mouse Fgfrl causes increased expression of Cbfal and premature fusion of calvarial sutures. Hum. Mol. Genet. 9, 2001-2008. 176. Hehr, U., Muenke, M., Masuda, Y., Sasaki, A., Shibuya, H., Ueno, N., Ikeda, K., and Watanabe, K. (1999). Craniosynostosis syndromes: From genes to premature fusion of skull bones. Mol. Genet. Metab. 68, 139-151. 177. Wilkie, A. O., Tang, Z., Elanko, N., Walsh, S., Twigg, S. R., Hurst, J. A., Wall, S. A., Chrzanowska, K. H., and Maxson, R. E. (2000). Functional haploinsufficiency of the human homeobox gene MSX2 causes defects in skull ossification. Nature Genet. 24, 387-390. 178. Jabs, E. W., Muller, U., Li, X., Ma, L., Luo, W., Haworth, I. S., Klisak, I., Sparkes, R., Warman, M. L., Mulliken, J. B., Snead, M. L., and Maxson, R. (1993). A mutation in the homeodomain of the human Msx-2 gene in a family affected with autosomal dominant craniosynostosis. Cell 785, 443-450. 179. Ma, L., Golden, S., Wu, L., Maxson, R., Chen, Y., Zhang, Y., Jiang, T. X., Barlow, A. J., St. Amand, T. R., Hu, Y., Heaney, S., Francis-West, P., Chuong, C. M., and Maas, R. (1996). The molecular basis of Boston-type craniosynostosis: The Pro 1484His mutation in the N-terminal arm of the MSX2 homeodomain stabilizes DNA binding without altering nucleotide sequence preferences. Hum. Mol. Genet. 5, 1915-1920. 180. Liu, Y. H., Kundu, R., Wu, L., Luo, W., Ignelzi, M. A., Snead, M. L., and Maxson, R. E. (1995). Premature suture closure and ectopic cranial bone in mice expressing Msx2 transgenes in the developing skull. Proc. Natl. Acad. Sci. USA 92, 6137-6141.
181. Liu, Y. H., Tang, Z., Kundu, R. K., Wu, L., Luo, W., Zhu, D., Sangiorgi, F., Snead, M. L., and Maxson, R. E. (1999). Msx2 gene dosage influences the number of proliferative osteogenic cells in growth centers of the developing murine skull: A possible mechanism for MSX2-mediated craniosynostosis in humans. Dev. Biol. 205, 260-274. 182. Dodig, M., Tadic, T., Kronenberg, M. S., Dacic, S., Liu, Y. H., Maxson, R., Rowe, D. W., and Lichtler, A. C. (1999). Ectopic Msx2 overexpression inhibits and Msx2 antisense stimulates calvarial osteoblast differentiation. Dev. Biol. 209, 298-307. 183. Ryoo, H. M., Hoffmann, H. M., Beumer, T., Frenkel, B., Towler, D. A., Stein, G. S., Stein, J. L., van Wijnen, A. J., and Lian, J. B. (1997). Stage-specific expression of Dlx-5 during osteoblast differentiation: Involvement in regulation of osteocalcin gene expression. Mol. Endocrinol. 11, 1681-1694. 184. Newberry, E. P., Latifi, T., and Towler, D. A. (1998). Reciprocal regulation of osteocalcin transcription by the homeodomain proteins Msx2 and Dlx5. Biochemistry 37, 16360-16368. 185. Acampora, D., Merlo, G. R., Paleari, L., Zerega, B., Postiglione, M. P., Mantero, S., Bober, E., Barbieri, O., Simeone, A., and Levi, G. (1999). Craniofacial, vestibular and bone defects in mice lacking the Distal-less-related gene Dlx5. Development 126, 3795-3809. 186. Jochum, W., David, J. P., Elliott, C., Wutz, A., Plenk, H., Jr., Matsuo, K., and Wagner, E. F. (2000). Increased bone formation and osteosclerosis in mice overexpressing the transcription factor Fra-1. Nat. Med. 6, 980-984. 187. Sabatakos, G., Sims, N. A., Chen, J., Aoki, K., Kelz, M. B., Amling, M., Bouali, Y., Mukhopadhyay, K., Ford, K., Nestler, E. J., and Baron, R. (2000). Overexpression of DeltaFosB transcription factor(s) increases bone formation and inhibits adipogenesis. Nat. Med. 6, 985-990. 188. Karsenty, G. (2000). How many factors are required to remodel bone? Nat. Med. 6, 970-971. 189. Aubin, J. E. (2001). Your partner makes all the difference. IBMSBoneKEy, January 23, 10.1138/ibmske;2001013. 190. Ducy, P., Amling, M., Takeda, S., Priemel, M., Schilling, A. F., Beil, F. T., Shen, J., Vinson, C., Rueger, J. M., and Karsenty, G. (2000). Leptin inhibits bone formation through a hypothalamic relay: A central control of bone mass. Cell 100, 197-207. 191. Li, B., Boast, S., de los Santos, K., Schieren, I., Quiroz, M., Teitelbaum, S. L., Tondravi, M. M., and Goff, S. P. (2000). Mice deficient in Abl are osteoporotic and have defects in osteoblast maturation. Nature Genet. 24, 304-308. 192. Meyer, T., Kneissel, M., Mariani, J., and Fournier, B. (2000). In vitro and in vivo evidence for orphan nuclear receptor RORalpha function in bone metabolism. Proc. Natl. Acad. Sci. USA 97, 9197-9202. 193. Bonnelye, E., Merdad, L., Kung, V., and Aubin, J. E. (2001). The orphan nuclear estrogen receptor-related receptor alpha (ERRo0 is differentially expressed during osteoblast differentiation and regulates bone formation. J. Cell. Biol. 153, 971-983. 194. Kato, M., Patel, M. S., Levasseur, R., Lobov, I., Chang, B. H., Glass, D. A., 2nd, Hartmann, C., Li, L., Hwang, T. H., Brayton, C. F., Lang, R. A., Karsenty, G., and Chan, L. (2002). Cbfal-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J. Cell. Biol. 157, 303-314. 195. Gong, Y., Slee, R. B., Fukai, N., et al.(2001). LDL receptorrelated protein 5 (LRP5) affects bone accrual and eye development. Cell 107, 513-423. 196. Little, R. D., Carulli, J. P., Del Mastro, R. G., et al.. (2002). A mutation in the LDL receptor-related protein 5 gene results in
2. Bone Cell Biology the autosomal dominant high-bone-mass trait. Am. J. Hum. Genet. 70, 11-19. 197. Boyden, L. M., Mao, J., Belsky, J., Mitzner, L., Farhi, A., Mitnick, M. A., Wu, D., Insogna, K., and Lifton, R. P. (2002). High bone density due to a mutation in LDL-receptor-related protein 5. N. Engl. J. Med. 346, 1513-1521. 198. Patel, M. S., and Karsenty, G. (2002). Regulation of bone formation and vision by LRP5. N. Engl. J. Med. 346, 1572-1574. 199. Yang, X., and Karsenty, G. (2002). Transcription factors in bone: Developmental and pathological aspects. Trends Mol. Med. 8, 340-345. 200. Rodan, G. A. (1998). Control of bone formation and resorption: Biological and clinical perspective. 25th anniversary issue: New directions and dimensions in cellular biochemistry. J. Cell. Biochem. Suppl. 30/31, 55-61. 201. Khan, S. N., Bostrom, M. P., and Lane, J. M. (2000). Bone growth factors. Orthop. Clin. North Am. 31, 375-388. 202. Gordon, E. M., Skotzko, M., Kundu, R. K., Han, B., Andrades, J., Nimni, M., Anderson, W. F., and Hall, F. L. (1997). Capture and expansion of bone marrow-derived mesenchymal progenitor cells with a transforming growth factor-betal-von Willebrand's factor fusion protein for retrovirus-mediated delivery of coagulation factor IX. Hum. Gene Ther. 8, 1385-1394. 203. Kuznetsov, S. A., Friedenstein, A. J., and Robey, P. G. (1997). Factors required for bone marrow stromal fibroblast colony formation in vitro. Br. J. Haematol. 97, 561-570. 204. Ellies, L. G., and Aubin, J. E. (1990). Temporal sequence of interleukin l oL-mediated stimulation and inhibition of bone formation by isolated fetal rat calvarial cells in vitro. Cytokine 2, 430-437. 205. Antosz, M. E., Bellows, C. G., and Aubin, J. E. (1987). Biphasic effects of epidermal growth factor on bone nodule formation by isolated rat calvaria cells in vitro. J. Bone Miner. Res. 2, 385-393. 206. Antosz, M., Bellows, C. G., and Aubin, J. E. (1989). Effects of transforming growth factor [3 and epidermal growth factor on cell proliferation and the formation of bone nodules in isolated fetal rat calvaria cells. J. Cell. Physiol. 140, 386-395. 207. Breen, E. C., Ignotz, R., McCabe, L., Lian, J. B., and Stein, G. S. (1994). TGFb alters growth and differentiation related gene expression in proliferating osteoblasts in vitro preventing development of the mature osteoblast phenotype. J. Cell. Physiol. 160, 323-335. 208. Locklin, R. M., Oreffo, R. O., and Triffitt, J. T. (1999). Effects of TGFbeta and BFGF on the differentiation of human bone marrow stromal fibroblasts. Cell. Biol. Int. 23, 185-194. 209. Hsieh, S. C., and Graves, D. T. (1998). Pulse application of platelet-derived growth factor enhances formation of a mineralizing matrix while continuous application is inhibitory. J. Cell. Biochem. 69, 169-180. 210. Aubin, J. E., and Heersche, J. N. M. (2001). Cellular actions of parathyroid hormone on osteoblast and osteoclast differentiation. In The Parathyroids (J. P. Bilezikian, R. Marcus, and M. Levine, Eds.), 2nd ed. Academic Press, San Diego. 211. Bellows, C. G., Ishida, H., Aubin, J. E., and Heersche, J. N. M. (1990). Parathyroid hormone reversibly suppresses the differentiation of osteoprogenitor cells into functional osteoblasts. Endocrinology 127, 3111-3116. 212. Ishizuya, T., Yokose, S., Hori, M., Noda, T., Suda, T., Yoshiki, S., and Yamaguchi, A. (1997). Parathyroid hormone exerts disparate effects on osteoblast differentiation depending on exposure time in rat osteoblastic cells. J. Clin. Invest. 99, 2961-2970. 213. Karaplis, A. C., and Kronenberg, H. M. (1996). Physiological roles for parathyroid hormone-related protein: Lessons from gene knockout mice. Vitamins Horm. 52, 177-193.
71
214. Lanske, B., Amling, M., Neff, L., Guiducci, J., Baron, R., and Kronenberg, H. M. (1999). Ablation of the PTHrP gene or the PTH/PTHrP receptor gene leads to distinct abnormalities in bone development. J. Clin. Invest. 104, 399-407. 215. Jilka, R. L., Weinstein, R. S., Bellido, T., Roberson, P., Parfitt, A. M., and Manolagas, S. C. (1999). Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone [see Comments]. J. Clin. Invest. 104, 439-446. 216. Schipani, E., Kruse, K., and Juppner, H. (1995). A constitutively active mutant PTH-PTHrP receptor in Jansen-type metaphyseal chondrodysplasia. Science 268, 98-100. 217. Ducy, P., and Karsenty, G. (2000). The family of bone morphogenetic proteins. Kidney Int. 57, 2207-2214. 218. Bonewald, L. F. (1996). Transforming growth factor-J3. In Principles of Bone Biology (J. P. Bilezikian, L. G. Raisz, and G. A. Rodan, Eds.), pp. 647-659. Academic Press, San Diego. 219. Erlebacher, A., and Derynck, R. (1996). Increased expression of TGF-beta 2 in osteoblasts results in an osteoporosis-like phenotype. J. Cell. Biol. 132, 195-210. 220. Erlebacher, A., Filvaroff, E. H., Ye, J. Q., and Derynck, R. (1998). Osteoblastic responses to TGF-beta during bone remodeling. Mol. Biol. Cell. 9, 1903-1918. 221. Filvaroff, E., Erlebacher, A., Ye, J., Gitelman, S. E., Lotz, J., Heillman, M., and Derynck, R. (1999). Inhibition of TGF-beta receptor signaling in osteoblasts leads to decreased bone remodeling and increased trabecular bone mass. Development 126, 4267-4279. 222. Weinstein, R. S., Jilka, R. L., Parfitt, A. M., and Manolagas, S. C. (1998). Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J. Clin. Invest. 102, 274-282. 223. Lukert, B. P., and Kream, B. E. (1996). Clinical and basic aspects of glucocorticoid action in bone. In Principles of Bone Biology (J. P. Bilezikian, L. G. Riasz, and G. A. Rodan, Eds.), pp. 533-548. Academic Press, San Diego. 224. Malaval, L., Gupta, A. K., Liu, F., Delmas, P. D., and Aubin, J. E. (1998). LIF, but not IL-6, regulates osteoprogenitor differentiation: Modulation by dexamethasone. J. Bone Miner. Res. 13, 175-184. 225. Boden, S. D., Hair, G., Titus, L., Racine, M., McCuaig, K., Wozney, J. M., and Nanes, M. S. (1997). Glucocorticoidinduced differentiation of fetal rat calvarial osteoblasts is mediated by bone morphogenetic protein-6. Endocrinology 138, 2820-2828. 226. Boden, S. D., Liu, Y., Hair, G. A., Helms, J. A., Hu, D., Racine, M., Nanes, M. S., and Titus, L. (1998). LMP-1, a LIM-domain protein, mediates BMP-6 effects on bone formation. Endocrinology 139, 5125-5134. 227. Yamada, M., Suzu, S., Tanaka-Douzono, M., Wakimoto, N., Hatake, K., Hayasawa, H., and Motoyoshi, K. (2000). Effect of cytokines on the proliferation/differentiation of stroma-initiating cells. J. Cell. Physiol. 184, 351-355. 228. van der Plas, A., Aarden, E. M., Feijen, J. H., de Boer, A. H., Wiltink, A., Alblas, M. J., de Leij, L., and Nijweide, P. J. (1994). Characteristics and properties of osteocytes in culture. J. Bone Miner. Res. 9, 1697-1704. 229. Westbroek, I., De Rooij, K. E., and Nijweide, P. J. (2002). Osteocyte-specific monoclonal antibody MAb OB7.3 is directed against Phex protein. J. Bone Miner. Res. 17, 845-853. 230. Aarden, E. M., Wassenaar, A. M., Alblas, M. J., and Nijweide, P. J. (1996). Immunocytochemical demonstration of extracellular matrix proteins in isolated osteocytes. Histochem. Cell. Biol. 106, 495-501.
72
Jane E. Aubin and lohan N. M. Heersche
231. Aarden, E. M., Nijweide, P. J., van der Plas, A., Alblas, M. J., Mackie, E. J., Horton, M. A., and Helfrich, M. H. (1996). Adhesive properties of isolated chick osteocytes in vitro. Bone 18, 305-313. 232. Klein-Nulend, J., Semeins, C. M., Ajubi, N. E., Nijweide, P. J., and Burger, E. H. (1995). Pulsating fluid flow increases nitric oxide (NO) synthesis by osteocytes but not periosteal fibroblasts--Correlation with prostaglandin upregulation. Biochem. Biophys. Res. Commun. 217, 640-648. 233. Westbroek, I., Ajubi, N. E., Alblas, M. J., Semeins, C. M., KleinNulend, J., Burger, E. H., and Nijweide, P. J. (2000). Differential stimulation of prostaglandin G/H synthase-2 in osteocytes and other osteogenic cells by pulsating fluid flow. Biochem. Biophys. Res. Commun. 268, 414-419. 234. Kato, Y., Windle, J. J., Koop, B. A., Mundy, G. R., and Bonewald, L. F. (1997). Establishment of an osteocyte-like cell line, MLO-Y4. J. Bone Miner. Res. 12, 2014-2023. 235. Bonewald, L. F. (1999). Establishment and characterization of an osteocyte-like cell line, MLO-Y4. J. Bone Miner. Metab. 17, 61-65. 236. Bord, S., Homer, A., Beavan, S., and Compston, J. (2001). Estrogen receptors alpha and beta are differentially expressed in developing human bone. J. Clin. Endocrinol. Metab. 86, 2309-2314. 237. Braidman, I. P., Hainey, L., Batra, G., Selby, P. L., Saunders, P. T., and Hoyland, J. A. (2001). Localization of estrogen receptor beta protein expression in adult human bone. J. Bone Miner. Res. 16, 214-20. 238. Hughes, D. E., Salter, D. M., and Simpson, R. (1994). CD44 expression in human bone: A novel marker of osteocytic differentiation. J. Bone Miner. Res. 9, 39-44. 239. Nakamura, H., Kenmotsu, S., Sakai, H., and Ozawa, H. (1995). Localization of CD44, the hyaluronate receptor, on the plasma membrane of osteocytes and osteoclasts in rat tibiae. Cell Tissue Res. 280, 225-233. 240. Nakamura, H., and Ozawa, H. (1996). Immunolocalization of CD44 and the ERM family in bone cells of mouse tibiae. J. Bone Miner. Res. 11, 1715-1722. 241. Noonan, K. J., Stevens, J. W., Tammi, R., Tammi, M., Hernandez, J. A., and Midura, R. J. (1996). Spatial distribution of CD44 and hyaluronan in the proximal tibia of the growing rat. J. Orthop. Res. 14, 573-581. 242. Lean, J. M., Mackay, A. G., Chow, J. W., and Chambers, T. J. (1996). Osteocytic expression of mRNA for c-fos and IGF-I: An immediate early gene response to an osteogenic stimulus. Am. J. Physiol. 270, E937-E945. 243. Mason, D. J., Hillam, R. A., and Skerry, T. M. (1996). Constitutive in vivo mRNA expression by osteocytes of beta-actin, osteocalcin, connexin-43, IGF-I, c-fos and c-jun, but not TNFalpha nor tartrate-resistant acid phosphatase. J. Bone Miner. Res. 11, 350-357. 244. Su, M., Borke, J. L., Donahue, H. J., Li, Z., Warshawsky, N. M., Russell, C. M., and Lewis, J. E. (1997). Expression of connexin 43 in rat mandibular bone and periodontal ligament (PDL) cells during experimental tooth movement. J. Dent. Res. 76, 1357-1366. 245. Divieti, P., Inomata, N., Chapin, K., Singh, R., Juppner, H., and Bringhurst, F. R. (2001). Receptors for the carboxyl-terminal region of pth(1-84) are highly expressed in osteocytic cells. Endocrinology 142, 916-925. 246. Van Loon, J. J. W. A., Veldhuijzen, J. P., and Burger, E. H. (1996). Bone and space flight: An overview. In Biological and Medical Research in Space (D. Moore, P. Bie, and H. Oser, Eds.), pp. 259-299. Springer, Berlin. 247. Lanyon, L. E. (1996). Using functional loading to influence bone mass and architecture: Objectives, mechanisms, and relationship
248.
249.
250. 251. 252.
253.
254.
255.
256. 257.
258.
259.
260.
261.
262.
263.
264.
265.
with estrogen of the mechanically adaptive process in bone. Bone 18, 37S-43S. Huiskes, R., Ruimerman, R., van Lenthe, G. H., and Janssen, J. D. (2000). Effects of mechanical forces on maintenance and adaptation of form in trabecular bone. Nature 405, 704-706. Burger, E. H., and Klein-Nulend, J. (1999). Mechanotransduction in bone--Role of the lacuno-canalicular network. FASEB J. 13, S101-S112. Basso, N., and Heersche, J. N. (2002). Characteristics of in vitro osteoblastic cell loading models. Bone 30, 347-351. Burger, E. H., and Klein-Nulend, J. (1998). Microgravity and bone cell mechanosensitivity. Bone 22, 127S-130S. Skerry, T. M., Bitensky, L., Chayen, J., and Lanyon, L. E. (1989). Early strain-related changes in enzyme activity in osteocytes following bone loading in vivo. J. Bone Miner. Res. 4, 783-788. Klein-Nulend, J., van der Plas, A., Semeins, C. M., Ajubi, N. E., Frangos, J. A., Nijweide, P. J., and Burger, E. H. (1995). Sensitivity of osteocytes to biomechanical stress in vitro. FASEB J. 9, 441-445. Ajubi, N. E., Klein-Nulend, J., Nijweide, P. J., Vrijheid-Lammers, T., Alblas, M. J., and Burger, E. H. (1996). Pulsating fluid flow increases prostaglandin production by cultured chicken osteocytes--A cytoskeleton-dependent process. Biochem. Biophys. Res. Commun. 225, 62-68. Schoenwaelder, S. M., and Burridge, K. (1999). Bidirectional signaling between the cytoskeleton and integrins. Curr. Opin. Cell. Biol. 11, 274-286. Carpenter, C. L. (2000). Actin cytoskeleton and cell signaling. Crit. Care Med. 28, N94-N99. Gerthoffer, W. T., and Gunst, S. J. (2001). Invited review: Focal adhesion and small heat shock proteins in the regulation of actin remodeling and contractility in smooth muscle. J. Appl. Physiol. 91, 963-972. Carvalho, R. S., Scott, J. E., Suga, D. M., and Yen, E. H. (1994). Stimulation of signal transduction pathways in osteoblasts by mechanical strain potentiated by parathyroid hormone. J. Bone Miner. Res. 9, 999-1011. Chow, J. W., Fox, S., Jagger, C. J., and Chambers, T. J. (1998). Role for parathyroid hormone in mechanical responsiveness of rat bone. Am. J. Physiol. 274, E 146-E 154. Jagger, C. J., Chow, J. W., and Chambers, T. J. (1996). Estrogen suppresses activation but enhances formation phase of osteogenic response to mechanical stimulation in rat bone. J. Clin. Invest. 98, 2351-2357. Skerry, T. M. (1999). Identification of novel signaling pathways during functional adaptation of the skeleton to mechanical loading: The role of glutamate as a paracrine signaling agent in the skeleton. J. Bone Miner. Metab. 17, 66-70. Gross, T. S., Srinivasan, S., Liu, C. C., Clemens, T. L., and Bain, S. D. (2002). Noninvasive loading of the murine tibia: An in vivo model for the study of mechanotransduction. J. Bone Miner. Res. 17, 493-501. Watanuki, M., Sakai, A., Sakata, T., Tsurukami, H., Miwa, M., Uchida, Y., Watanabe, K., Ikeda, K., and Nakamura, T. (2002). Role of inducible nitric oxide synthase in skeletal adaptation to acute increases in mechanical loading. J. Bone Miner. Res. 17, 1015-1025. Ishijima, M., Rittling, S. R., Yamashita, T., Tsuji, K., Kurosawa, H., Nifuji, A., Denhardt, D. T., and Noda, M. (2001). Enhancement of osteoclastic bone resorption and suppression of osteoblastic bone formation in response to reduced mechanical stress do not occur in the absence of osteopontin. J. Exp. Med. 193, 399-404. Sakai, A., Sakata, T., Tanaka, S., Okazaki, R., Kunugita, N., Norimura, T., and Nakamura, T. (2002). Disruption of the p53
2. Bone Cell Biology gene results in preserved trabecular bone mass and bone formation after mechanical unloading. J. Bone Miner. Res. 17, 119-27. 266. Chenu, C., Itzstein, C., and Espinosa, L. (2001). Absence of evidence is not evidence of absence. Redundancy blocks determination of cause and effect. J. Bone Miner. Res. 16, 1728-1729; Discussion 1731-1732. 267. Skerry, T., Genever, P., Taylor, A., Dobson, K., Mason, D., and Suva, L. (2001). Absence of evidence is not evidence of absence. The shortcomings of the GLAST knockout mouse. J. Bone Miner. Res. 16, 1729-1730; Discussion 1731-1732. 268. Gray, C., Marie, H., Arora, M., Tanaka, K., Boyde, A., Jones, S., and Attwell, D. (2001). Glutamate does not play a major role in controlling bone growth. J. Bone Miner. Res. 16, 742-749. 269. Jiang, J. X., and Cheng, B. (2001). Mechanical stimulation of gap junctions in bone osteocytes is mediated by prostaglandin E2. Cell. Adhesion Commun. 8, 283-288. 270. Cheng, B., Kato, Y., Zhao, S., Luo, J., Sprague, E., Bonewald, L. F., and Jiang, J. X. (2001). PGE(2) is essential for gap junction-mediated intercellular communication between osteocyte-like MLO-Y4 cells in response to mechanical strain. Endocrinology 142, 3464-3473. 271. Cheng, B., Zhao, S., Luo, J., Sprague, E., Bonewald, L. F., and Jiang, J. X. (2001). Expression of functional gap junctions and regulation by fluid flow in osteocyte-like MLO-Y4 cells. J. Bone Miner. Res. 16, 249-259. 272. Heino, T. J., Hentunen, T. A., and Vaananen, H. K. (2002). Osteocytes inhibit osteoclastic bone resorption through transforming growth factor-beta: Enhancement by estrogen. J. Cell. Biochem. 85, 185-197. 273. Maejima-Ikeda, A., Aoki, M., Tsuritani, K., Kamioka, K., Hiura, K., Miyoshi, T., Hara, H., Takano-Yamamoto, T., and Kumegawa, M. (1997). Chick osteocyte-derived protein inhibits osteoclastic bone resorption. Biochem. J. 322, 245-250. 274. Nesbitt, S. A., and Horton, M. A. (1997). Trafficking of matrix collagens through bone-resorbing osteoclasts. Science 276, 266-269. 275. Lakkakorpi, P. T., and Vaananen, H. K. (1991). Kinetics of the osteoclast cytoskeleton during the resorption cycle in vitro. J. Bone Miner. Res. 6, 817-826. 276. Lakkakorpi, P. T., Horton, M. A., Helfrich, M. H., Karhukorpi, E. K., and Vaananen, H. K. (1991). Vitronectin receptor has a role in bone resorption but does not mediate tight sealing zone attachment of osteoclasts to the bone surface. J. Cell. Biol. 115, 1179-1186. 277. Horton, M. A. (1997). The alpha v beta 3 integrin "vitronectin receptor." Int. J. Biochem. Cell. BioL 29, 721-725. 278. Blair, H. C., Teitelbaum, S. L., Ghiselli, R., and Gluck, S. (1989). Osteoclastic bone resorption by a polarized vacuolar proton pump. Science 245, 855-857. 279. Williams, J. P., McDonald, J. M., McKenna, M. A., Jordan, S. E., Radding, W., and Blair, H. C. (1997). Differential effects of tamoxifen-like compounds on osteoclastic bone degradation, H (+)-ATPase activity, calmodulin-dependent cyclic nucleotide phosphodiesterase activity, and calmodulin binding. J. Cell. Biochem. 66, 358-369. 280. Schlesinger, P. H., Blair, H. C., Teitelbaum, S. L., and Edwards, J. C. (1997). Characterization of the osteoclast ruffled border chloride channel and its role in bone resorption. J. Biol. Chem. 272, 18636-18643. 281. Teti, A., Blair, H. C., Schlesinger, P., Grano, M., ZamboninZallone, A., Kahn, A. J., Teitelbaum, S. L., and Hruska, K. A. (1989). Extracellular protons acidify osteoclasts, reduce cytosolic calcium, and promote expression of cell-matrix attachment structures. J. Clin. Invest. 84, 773-780.
73
282. Everts, V., Delaisse, J. M., Korper, W., Niehof, A., Vaes, G., and Beertsen, W. (1992). Degradation of collagen in the boneresorbing compartment underlying the osteoclast involves both cysteine-proteinases and matrix metalloproteinases. J. Cell. Physiol. 150, 221-231. 283. Bossard, M. J., Tomaszek, T. A., Thompson, S. K., Amegadzie, B. Y., Hanning, C. R., Jones, C., Kurdyla, J. T., McNulty, D. E., Drake, F. H., Gowen, M., and Levy, M. A. (1996). Proteolytic activity of human osteoclast cathepsin K. Expression, purification, activation, and substrate identification. J. Biol. Chem. 271, 12517-12524. 284. Gelb, B. D., Moissoglu, K., Zhang, J., Martignetti, J. A., Bromme, D., and Desnick, R. J. (1996). Cathepsin K: Isolation and characterization of the murine cDNA and genomic sequence, the homologue of the human pycnodysostosis gene. Biochem. Mol. Med. 59, 200-206. 285. Saftig, P., Hunziker, E., Wehmeyer, O., Jones, S., Boyde, A., Rommerskirch, W., Moritz, J. D., Schu, P., and von Figura, K. (1998). Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc. Natl. Acad. Sci. USA 95, 13453-13458. 286. Gowen, M., Lazner, F., Dodds, R., Kapadia, R., Feild, J., Tavaria, M., Bertoncello, I., Drake, F., Zavarselk, S., Tellis, I., Hertzog, P., Debouck, C., and Kola, I. (1999). Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization. J. Bone Miner. Res. 14, 1654-1663. 287. Atley, L. M., Mort, J. S., Lalumiere, M., and Eyre, D. R. (2000). Proteolysis of human bone collagen by cathepsin K: characterization of the cleavage sites generating by cross-linked N-telopeptide neoepitope. Bone 26, 241-247. 288. Delaisse, J. M., Eeckhout, Y., Sear, C., Galloway, A., McCullagh, K., and Vaes, G. (1985). A new synthetic inhibitor of mammalian tissue collagenase inhibits bone resorption in culture. Biochem. Biophys. Res. Commun. 133, 483-490. 289. Everts, V., Korper, W., Jansen, D. C., Steinfort, J., Lammerse, I., Heera, S., Docherty, A. J., and Beertsen, W. (1999). Functional heterogeneity of osteoclasts: Matrix metalloproteinases participate in osteoclastic resorption of calvarial bone but not in resorption of long bone. F A S E B J. 13, 1219-1230. 290. Zhao, W., Byrne, M. H., Boyce, B. F., and Krane, S. M. (1999). Bone resorption induced by parathyroid hormone is strikingly diminished in collagenase-resistant mutant mice. J. Clin. Invest. 103, 517-524. 291. Everts, V., Delaisse, J. M., Korper, W., and Beertsen, W. (1998). Cysteine proteinases and matrix metalloproteinases play distinct roles in the subosteoclastic resorption zone. J. Bone Miner. Res. 13, 1420-1430. 292. Zhao, H., Ettala, O., and Vaananen, H. K. (2002). Intracellular membrane trafficking pathways in bone-resorbing osteoclasts revealed by cloning and subcellular localization studies of small GTP-binding rab proteins. Biochem. Biophys. Res. Commun. 293, 1060-1065. 293. Salo, J., Lehenkari, P., Mulari, M., Metsikko, K., and Vaananen, H. K. (1997). Removal of osteoclast bone resorption products by transcytosis. Science 276, 270-273. 294. Gaillard, P. J., Herrmann-Erlee, M. P., Hekkelman, J. W., Burger, E. H., and Nijweide, P. J. (1979). Skeletal tissue in culture. Hormonal regulation of metabolism and development. Clin. Orthop., 196-214. 295. Gothlin, G., and Ericsson, J. L. (1973). On the histogenesis of the cells in fracture callus. Electron microscopic autoradiographic observations in parabiotic rats and studies on labeled monocytes. Virchows Arch. B Cell. Pathol. 12, 318-329.
74
Jane E. Aubin and lohan N. M. Heersche
296. Walker, D. G. (1975). Bone resorption restored in osteopetrotic mice by transplants of normal bone marrow and spleen cells. Science 190, 784-785. 297. Scheven, B. A., Visser, J. W., and Nijweide, P. J. (1986). In vitro osteoclast generation from different bone marrow fractions, including a highly enriched haematopoietic stem cell population. Nature 321, 79-81. 298. Felix, R., Hofstetter, W., and Cecchini, M. G. (1996). Recent developments in the understanding of the pathophysiology of osteopetrosis. Eur. J. Endocrinol. 134, 143-156. 299. Weir, E. C., Horowitz, M. C., Baron, R., Centrella, M., Kacinski, B. M., and Insogna, K. L. (1993). Macrophage colony-stimulating factor release and receptor expression in bone cells. J. Bone Miner. Res. 8, 1507-1518. 300. Itoh, K., Udagawa, N., Matsuzaki, K., Takami, M., Amano, H., Shinki, T., Ueno, Y., Takahashi, N., and Suda, T. (2000). Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SAOS-4/3 cells expressing recombinant PTH/PTHrP receptors. J. Bone Miner. Res. 15, 1766-1775. 301. Yasuda, H., Shima, N., Nakagawa, N., Mochizuki, S. I., Yano, K., Fujise, N., Sato, Y., Goto, M., Yamaguchi, K., Kuriyama, M., Kanno, T., Murakami, A., Tsuda, E., Morinaga, T., and Higashio, K. (1998). Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): A mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 139, 1329-1337. 302. Lacey, D. L., Timms, E., Tan, H. L., et al. (1999). OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397, 315-323. 304. Simonet, W. S., Lacey, D. L., Dunstan, C. R., et al. (1997). Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 89, 309-319. 305. Bucay, N., Sarosi, I., Dunstan, C. R., Morony, S., Tarpley, J., Capparelli, C., Scully, S., Tan, H. L., Xu, W., Lacey, D. L., Boyle, W. J., and Simonet, W. S. (1998). Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 12, 1260-1268. 306. Cappellen, D., Luong-Nguyen, N. H., Bongiovanni, S., Grenet, O., Wanke, C., and Susa, M. (2002). Transcriptional program of mouse osteoclast differentiation governed by the macrophage colony-stimulating factor and the ligand for the receptor activator ofNFkappa B. J. Biol. Chem. 277, 21971-21982. 307. Matsuo, K., Owens, J. M., Tonko, M., Elliott, C., Chambers, T. J., and Wagner, E. F. (2000). Fosll is a transcriptional target of c-Fos during osteoclast differentiation. Nature Genet. 24, 184-187. 308. Collin-Osdoby, P., Rothe, L., Anderson, F., Nelson, M., Maloney, W., and Osdoby, P. (2001). Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J. Biol. Chem. 276, 20659-20672. 309. Kasperk, C. H., Borcsok, I., Schairer, H. U., Schneider, U., Nawroth, P. P., Niethard, F. U., and Ziegler, R. (1997). Endothelin-1 is a potent regulator of human bone cell metabolism in vitro. Calcif. Tissue Int. 60, 368-374. 310. Nakagawa, M., Kaneda, T., Arakawa, T., Morita, S., Sato, T., Yomada, T., Hanada, K., Kumegawa, M., and Hakeda, Y. (2000). Vascular endothelial growth factor (VEGF) directly enhances osteoclastic bone resorption and survival of mature osteoclasts. F E B S Lett. 473, 161-164. 311. Quinn, J. M., Itoh, K., Udagawa, N., Hausler, K., Yasuda, H., Shima, N., Mizuno, A., Higashio, K., Takahashi, N., Suda, T., Martin, T. J., and Gillespie, M. T. (2001). Transforming growth
312.
313. 314.
315.
316.
317.
318.
319.
320. 321. 322.
323.
324.
325.
326.
327.
328.
factor beta affects osteoclast differentiation via direct and indirect actions. J. Bone Miner. Res. 16, 1787-1794. Itoh, K., Udagawa, N., Katagiri, T., Iemura, S., Ueno, N., Yasuda, H., Higashio, K., Quinn, J. M., Gillespie, M. T., Martin, T. J., Suda, T., and Takahashi, N. (2001). Bone morphogenetic protein 2 stimulates osteoclast differentiation and survival supported by receptor activator of nuclear factor-kappaB ligand. Endocrinology 142, 3656-3662. Eriksen, E. F., and Mosekilde, L. (1990). Estrogens and bone. Bone Miner. Res. 7, 273-312. Rassi, C. M., Lieberherr, M., Chaumaz, G., Pointillart, A., and Cournot, G. (2002). Down-regulation of osteoclast differentiation by daidzein via caspase 3. J. Bone Miner. Res. 17, 630-638. Srivastava, S., Toraldo, G., Weitzmann, M. N., Cenci, S., Ross, F. P., and Pacifici, R. (2001). Estrogen decreases osteoclast formation by down-regulating receptor activator of NF-kappa B ligand (RANKL)-induced JNK activation. J. Biol. Chem. 276, 8836-8840. Lees, R. L., Sabharwal, V. K., and Heersche, J. N. (2001). Resorptive state and cell size influence intracellular pH regulation in rabbit osteoclasts cultured on collagen-hydroxyapatite films. Bone 28, 187-194. Vignery, A., Wang, F., Qian, H. Y., Benz, E. J., Jr., and GilmoreHebert, M. (1991). Detection of the Na(+)-K(+)-ATPase alpha 3-isoform in multinucleated macrophages. Am. J. Physiol. 260, F704-F709. Enelow, R. I., Sullivan, G. W., Carper, H. T., and Mandell, G. L. (1992). Cytokine-induced human multinucleated giant cells have enhanced candidacidal activity and oxidative capacity compared with macrophages. J. Infect. Dis. 166, 664-668. Woods, C., Domenget, C., Solari, F., Gandrillon, O., Lazarides, E., and Jurdic, P. (1995). Antagonistic role of vitamin D3 and retinoic acid on the differentiation of chicken hematopoietic macrophages into osteoclast precursor cells. Endocrinology 136, 85-95. Taylor, M. V. (2002). Muscle differentiation: How two cells become one. Curr. Biol. 12, R224-R228. Lipschutz, J. H., and Mostov, K. E. (2002). Exocytosis: The many masters of the exocyst. Curr. Biol. 12, R212-R214. Yoshida, H., Hayashi, S., Kunisada, T., Ogawa, M., Nishikawa, S., Okamura, H., Sudo, T., and Shultz, L. D. (1990). The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature 345, 442-444. Wiktor-Jedrzejczak, W., Bartocci, A., Ferrante, A. W., Jr., Ahmed-Ansari, A., Sell, K. W., Pollard, J. W., and Stanley, E. R. (1990). Total absence of colony-stimulating factor 1 in the macrophage-deficient osteopetrotic (op/op) mouse. Proc. Natl. Acad. Sci. USA 87, 4828-4832. Helfrich, M. H., and Gerritsen, E. J. (2001). Formation of nonresorbing osteoclasts from peripheral blood mononuclear cells of patients with malignant juvenile osteopetrosis. Br. J. Haematol. 112, 64-68. Tsuji, T., Hughes, F. J., McCulloch, C. A., and Melcher, A. H. (1990). Effects of donor age on osteogenic cells of rat bone marrow in vitro. Mech. Ageing Dev. 51, 121-132. D'Ippolito, G., Schiller, P. C., Ricordi, C., Roos, B. A., and Howard, G. A. (1999). Age-related osteogenic potential of mesenchymal stromal stem cells from human vertebral bone marrow. J. Bone Miner. Res. 14, 1115-1122. Oreffo, R. O., Bennett, A., Carr, A. J., and Triffitt, J. T. (1998). Patients with primary osteoarthritis show no change with ageing in the number of osteogenic precursors. Scand. J. Rheumatol. 27, 415-424. Oreffo, R. O., Bord, S., and Triffitt, J. T. (1998). Skeletal progenitor cells and ageing human populations. Clin. Sci. 94, 549-555.
2. Bone Cell Biology 329. Nishida, S., Endo, N., Yamagiwa, H., Tanizawa, T., and Takahashi, H. E. (1999). Number of osteoprogenitor cells in human bone marrow markedly decreases after skeletal maturation. J. Bone Miner. Metab. 17, 171-177. 330. Bergman, R. J., Gazit, D., Kahn, A. J., Gruber, H., McDougall, S., and Hahn, T. J. (1996). Age-related changes in osteogenic stem cells in mice. J. Bone Miner. Res. 11, 568-577. 331. Egrise, D., Vienne, A., Martin, D., and Schoutens, A. (1996). Trabecular bone cell proliferation ex vivo increases with donor age in the rat: It is correlated with the extent of bone loss and not with histomorphometric indices of bone formation. Calcif. Tissue Int. 59, 45-50. 332. Gazit, D., Zilberman, Y., Ebner, R., and Kahn, A. (1998). Bone loss (osteopenia) in old male mice results from diminished activity and availability of TGF-beta. J. Cell. Biochem. 70, 478-488. 333. Pfeilschifter, J., Diel, I., Pilz, U., Brunotte, K., Naumann, A., and Ziegler, R. (1993). Mitogenic responsiveness of human bone cells in vitro to hormones and growth factors decreases with age. J. Bone Miner. Res. 8, 707-717. 334. Erdmann, J., Kogler, C., Diel, I., Ziegler, R., and Pfeilschifter, J. (1999). Age-associated changes in the stimulatory effect of transforming growth factor beta on human osteogenic colony formation. Mech. Ageing Dev. 110, 73-85. 335. Ankrom, M. A., Patterson, J. A., d'Avis, P. Y., Vetter, U. K., Blackman, M. R., Sponseller, P. D., Tayback, M., Robey, P. G., Shapiro, J. R., and Fedarko, N. S. (1998). Age-related changes in human oestrogen receptor alpha function and levels in osteoblasts. Biochem. J. 333, 787-794. 336. Fujieda, M., Kiriu, M., Mizuochi, S., Hagiya, K., Kaneki, H., and Ide, H. (1999). Formation of mineralized bone nodules by rat calvarial osteoblasts decreases with donor age due to a reduction in signaling through EP(1) subtype of prostaglandin E(2) receptor. J. Cell. Biochem. 75, 215-225. 337. Riminucci, M., Fisher, L. W., Majolagbe, A., Corsi, A., Lala, R., De Sanctis, C., Robey, P. G., and Bianco, P. (1999). A novel GNAS1 mutation, R201G, in McCune-Albright syndrome. J. Bone Miner. Res. 14, 1987-1989. 338. Bianco, P., Riminucci, M., Majolagbe, A., Kuznetsov, S. A., Collins, M. T., Mankani, M. H., Corsi, A., Bone, H. G., Wientroub, S., Spiegel, A. M., Fisher, L. W., and Robey, P. G. (2000).
339. 340.
341. 342. 343.
344. 345.
346.
347.
348.
75
Mutations of the GNAS1 gene, stromal cell dysfunction, and osteomalacic changes in non-McCune-Albright fibrous dysplasia of bone. J. Bone Miner. Res. 15, 120-128. Colman, A., and Kind, A. (2000). Therapeutic cloning: Concepts and practicalities. Trends. Biotechnol. 18, 192-196. Prockop, D. J. (1998). Marrow stromal cells as stem cells for continual renewal of nonhematopoietic tissues and as potential vectors for gene therapy. J. Cell. Biochem. Suppl. 30/31,284-285. McCarthy, M. (2000). Bioengineers bring new slant to stem-cell research. Lancet 356, 1500. Service, R. F. (2000). Tissue engineers build new bone. Science 289, 1498-1500. Weissman, I. L. (2000). Translating stem and progenitor cell biology to the clinic: Barriers and opportunities. Science 287, 1442-1446. Triffitt, J. T. (2002). Stem cells and the philosopher's stone. J. Cell. Biochem. Suppl. 38, 13-19. Horwitz, E. M., Prockop, D. J., Gordon, P. L., Koo, W. W., Fitzpatrick, L. A., Neel, M. D., McCarville, M. E., Orchard, P. J., Pyeritz, R. E., and Brenner, M. K. (2001). Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta. Blood 97, 1227-1231. Horwitz, E. M., Gordon, P. L., Koo, W. K., Marx, J. C., Neel, M. D., McNall, R. Y., Muul, L., and Hofmann, T. (2002). Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. Proc. Natl. Acad. Sci. USA 99, 8932-8937. Pereira, R. F., Halford, K. W., O'Hara, M. D., Leeper, D. B., Sokolov, B. P., Pollard, M. D., Bagasra, O., and Prockop, D. J. (1995). Cultured adherent cells from marrow can serve as longlasting precursor cells for bone, cartilage, and lung in irradiated mice. Proc. Natl. Acad. Sci. USA 92, 4857-4861. Nilsson, S. K., Dooner, M. S., Weier, H. U., Frenkel, B., Lian, J. B., Stein, G. S., and Quesenberry, P. J. (1999). Cells capable of bone production engraft from whole bone marrow transplants in nonablated mice. J. Exp. Med. 189, 729-734.
This Page Intentionally Left Blank
C
H
A
P
T
E
R
3 Prenatal Bone Development Ontogeny and Regulation BENOIT ST.-JACQUES*and JILL A. HELMS t *Department of Human Genetics, McGill University, and Genetics Unit, Shriners Hospital for Children, Montreal Quebec, Canada tDepartment of Orthopedic Surgery, University of California, San Francisco, San Francisco, California
INTRODUCTION
local level. Thus, the division of skeletal development in pre- and postnatal periods, while understandable from a clinical standpoint, is somewhat artificial from a developmental standpoint. Due to space limitation, this chapter focuses primarily on local control of the early steps of skeletogenesis. A more complete treatment of hormonal regulation of bone growth is provided in Chapter 4. Skeletogenesis in the human embryo has been well described at the anatomical and histological level. However, for obvious reasons, our current understanding of the regulation of bone formation at the molecular level derives almost completely from experimental approaches using other vertebrate embryos. In particular, advances in genetic manipulations in the mouse have allowed the identification of many genes regulating skeletogenesis [2]. Improved techniques to modulate and detect gene expression, combined with the ease of surgical manipulations, have also made the chick embryo a very powerful tool to study questions related to early patterning and organogenesis. Finally, the recent identification of the genetic basis for several hereditary skeletal disorders in human has yielded many significant insights [3,4]. This chapter emphasizes results obtained from such in vivo systems as well as from organotypic culture systems at the expense of the vast and sometimes confusing literature reporting observations on immortalized cell lines. Formation of the skeleton can best be understood as a series of steps [5] contributing to one of two processes, namely skeletal patterning or bone formation [6]. Migration of undifferentiated mesenchymal cells to their ultimate location in the embryo, their interaction with a local
"The toolbox used to pattern an organism is at hand. Add a pinch of BMP, sprinkle some Hedgehog, a touch of Wnt, and a handful of F G F and you can pattern an embryo, a limb, or an organ. The secret lies not in the ingredients themselves, but in the order and amount in which they are provided, the way they are distributed in space and time, their cellular context, and the intricate cross-regulatory interactions among different signaling pathways." [1]
The passage quoted previously is obviously an exaggeration in that it offers a very generous assessment of our current understanding of the molecular mechanisms controlling organogenesis. Nevertheless, it rightly highlights the remarkable progress made during the past 10 years in identifying many of the key molecules involved in these control mechanisms. It also illustrates the fact that in formation of the diverse skeletal elements, like any other organ, the early steps depend largely on local cell-cell and cell-matrix interactions mediated by factors acting in a paracrine or autocrine manner. Effectors of these interactions include specific receptors, molecules of the intracellular signal transduction pathways, transcription factors, and specialized extracellular matrix components. Most of these signaling pathways are also involved in formation of other organs, and most of them play multiple roles at different stages of skeletogenesis. At later developmental stages, however, many of the mechanisms and pathways that will control postnatal bone growth are also acting. These include regulatory mechanisms at the systemic (endocrine) as well as the
PediatricBone
77
Copyright 2003, ElsevierScience(USA). All rights reserved.
78
Benoit St.-Jacques and JillA. Helms
epithelium, and their condensation into cartilage and bone precursors lead to the specification of the position, number, and shape of all skeletal elements and define skeleton patterning. Mutations in genes essential for these early steps most often result in dysostoses, disorders that affect specific skeletal elements while the rest of the skeleton is normal [7]. Differentiation of the skeletal-specific cell types (chondrogenesis and osteogenesis) and the precise coordination of cellular proliferation, extracellular matrix production and remodeling, programmed cell death, and angiogenesis define bone formation. Mutations in genes controlling these processes result in dysplasias, conditions affecting cartilage and bone tissues generally [7]. Following this logical dichotomy, this chapter first presents a general overview of skeletogenesis at the cellular level and describes the embryonic origins of the skeleton as well as some of the molecular mechanisms controlling early patterning. Then, we discuss in more detail our current view of the molecular mechanisms controlling processes common to the formation of all bones, including condensation, differentiation, and growth. Reviews covering many aspects of the broad subject treated in this chapter have appeared recently and the reader is urged to refer to these for complementary information [2-15]. A recent compilation of more than 200 genes expressed in skeletal tissues also provides useful information on cellular function and associated diseases [16].
SKELETOGENESIS In this chapter, the term skeletogenesis is used when referring to the complex multistep process by which the different elements of the skeleton are formed. Thus, skeletogenesis encompasses patterning, differentiation, and growth. Bone formation is a general term used to describe the steps common to the formation of all bones and thus excludes specific patterning mechanisms. We reserve the term ossification to designate specifically the process whereby osteoblasts differentiate and the bone matrix they secrete becomes a significant component of a given skeletal element. Similarly, chondrification refers to the appearance of chondroblasts and the production of a cartilage matrix. Finally, calcification refers specifically to the process by which the original bone matrix (osteoid) or the cartilage matrix produced by hypertrophic chondrocytes become calcified~that is, enriched in calcium phosphate deposits in the form of hydroxyhapatite crystals.
M o d e s of B o n e Formation Most members of the animal kingdom have either an exoskeleton or an endoskeleton depending on whether their skeletal tissues form on the outside or inside of the body. Primitive vertebrates had both a true exoskeleton and an endoskeleton. The exoskeleton is believed to have originated early during vertebrate evolution as a series of dermal plates that covered the body and served as protective armor. Internal support for the gills, sense organs, neural tube, appendages, and organs of the trunk was provided by a cartilaginous endoskeleton, which later in evolution also came to utilize bone [17]. In modern vertebrates, most skeletal elements derive from the primitive endoskeleton. Vestiges of the exoskeleton, however, are present in the skull and pectoral girdle. Although such exoskeletal derivatives have become thoroughly integrated with elements of the endoskeleton, they still form in a manner unlike that of the endoskeleton. These bones are termed dermal based on their historical association with the skin and ectoderm. They form by direct differentiation of mesenchymal cells into osteoblasts in a process called membranous (or intramembranous) ossification in reference to their association with membranes covering the developing brain in formation of the skull vault. On the other hand, bones deriving from the primitive endoskeleton develop first as cartilage elements that are subsequently replaced by bone. Therefore, they are known as cartilage replacement bones [18], and the process by which they form is called endochondral ossification. It should be recognized, however, that in the complex process of endochondral ossification of a typical long bone, formation of the trabecular bone of the metaphysis and of the cortical bone of the diaphysis takes place by two very different mechanisms. In the first case, cartilage is replaced by bone in a true "endochondral" process. In the case of the cortical bone, perichondrial cells differentiate into osteoblasts without replacement of a cartilage intermediate. Consequently, this process is often described in the scientific literature as a type of intramembranous ossification. However, it is clear that at the molecular level, as well as from a developmental standpoint, the regulation of this type of"subperiosteal" ossification and true intramembranous ossification are significantly different. Thus, there are three different modes of bone formation: intramembranous, endochondral, and subperiosteal. Intramembranous Ossification
Intramembranous ossification begins toward the end of the second month of gestation in humans. The process has been most extensively studied in the developing
3. Prenatal Bone Development cranium, where it is often preceded by a cellular proliferation at specific sites in the mesenchyme [19]. It becomes histologically evident when a cluster of pale-staining stellate mesenchymal cells aggregate and take on a rounded basophilic appearance characteristic of osteoprogenitor cells. These gradually differentiate into mature secretory osteoblasts that actively produce the extracellular matrix rich in collagen type I that is characteristic of bone. Sites where this process occurs are called ossification centers, and most dermal bones originate from a small number of such centers. It is important to note that although the initial condensation occurs in an avascular milieu, the differentiation of osteoblasts and the onset of mineralization are intimately related to blood vessel invasion, first in the surrounding mesenchyme and ultimately in the bone rudiment [20]. The first bit of bone (spicule) is irregularly shaped and completely surrounded by the osteoblasts that secreted it. Some of the osteoblasts soon become enclosed in the matrix being formed around them and thereafter become known as osteocytes. Each osteocyte is enclosed in its own lacuna but extends projections through small channels called canaliculi to maintain contact with neighboring osteocytes and intercellular fluids outside of the ossification center. Less differentiated osteoprogenitor cells present at the periphery proliferate to supply new osteoblasts, which continue to add bone to form a well-defined longer structure called a trabecula (beam). Similar changes occur in the immediate vicinity so that new trabeculae are formed and the center of ossification expands. Some trabeculae radiate from the center. These primary ones soon become connected by secondary trabeculae to form a scaffolding characteristic of cancellous (or spongy) bone. All trabeculae increase in thickness as new bone is added on their surfaces and the primary ones increase in length by accretion on their free ends. The pattern of growth and orientation of bony trabeculae depends on the type of bone. In the case of "fiat" bones, such as the parietal or frontal, the primary trabeculae soon form a radiating network mainly parallel to the surface of the skull, although some are directed at right angles and thus add to the thickness of the center [19]. The first bone formed in the embryo is of an immature type, displaying relatively high cellularity and an almost random orientation of collagen fibers [21]. At approximately the time of birth, this woven bone is gradually replaced by the more mature lamellar bone characterized by successive layers of uniformly oriented collagen fibers. Almost all the immature bone that forms during embryonic life is eventually replaced, although some persists mixed with mature bone in the tooth sockets, near cranial sutures, in the osseous labyrinth, and near tendon and ligament attachments [22]. At an early stage, the intramembranous bone has the
79
structure of a scaffold of trabeculae with relatively little bone and with large spaces invaded by blood vessels. As remodeling occurs, the continued deposition of fresh bone lamellae on trabeculae changes the nature of the bone from cancellous (spongy) to compact (dense), with only narrow canals occupied by blood vessels [22]. Endochondral Ossification
This process also initiates with the aggregation of undifferentiated mesenchymal cells to form condensations~ Unlike in intramembranous ossification, however, cellular proliferation does not play an important part in this process. The condensation step is the result of an increase in cell packing mediated by changes in the extracellular matrix and cell-cell adhesion molecules [23]. By their positions, shapes, and sizes, these prechondrogenic condensations prefigure the different skeletal elements [24] (Fig. 1A). As in intramembranous ossification, the initial condensation forms in an avascular environment, but here it remains avascular. In the core of these condensations, cells differentiate into chondroblasts (Fig. 1B) that secrete a cartilage matrix characterized by the presence of types II, IX, and XI collagen and specific proteoglycans such as aggrecan. At the periphery of the condensation, cells surrounding the cartilage core flatten and form a thin membrane of stacked cells called the perichondrium, which insulates the cartilage from the surrounding mesenchyme [25] (Fig. 1C). Perichondrial cells retain chondrogenic potential and probably contribute to the radial expansion of the cartilage by appositional growth. As new matrix is produced, the central cells become enclosed in it and become known as chondrocytes. At this early stage, the chondrocytes and perichondrial cells proliferate rapidly, and this proliferation together with the deposition of new matrix drives the growth of the elements. At a certain stage, which is specific for each element, chondrocytes in the center undergo progressive maturation. They acquire a flattened appearance and become organized in columns along the longitudinal axis of the developing skeletal element (Fig. 1D). Columns are separated by relatively thick lateral partitions of cartilage, the longitudinal septa, whereas chondrocytes within a column are separated by thin transverse septa. Further maturation of these cells leads to the development of a hypertrophic chondrocyte phenotype characterized by cell enlargement, cessation of proliferation, and secretion of a distinct extracellular matrix rich in type X collagen that becomes progressively calcified [26] (Fig. 1D). These changes are accompanied by vascularization of the perichondrium tissue and soon after by differentiation of theinner perichondrium cells into osteoblasts, which secrete a layer of primary bone, the
80
Benoit St.-Jacques and JillA. Helms
FIGURE 1 Endochondral bone formation. Schematic representations of the different steps in the process of endochondral bone formation. (A) Mesenchymalcondensation. (B) Chondroblastdifferentiation and formation of a perichondrium (pe). (C) Maturation ofchondrocytesand appearance of enlarged (hypertrophic)cellsin the center of the element. Most chondrocytesand perichondrial cells proliferate rapidly at this stage and the element enlarges by interstitial and appositional growth. (D) Vascularization of the perichondriumand organization of an embryonic growthplate with zonesof proliferation (p), maturation (m), and hypertrophy(h). (E) Depositionof a bone collar by periosteal osteoblasts (not shown), vascular invasion of the calcified cartilage of the hypertrophic zone, and apoptosis of terminally differentiated hypertrophic chondrocytes. (F) Resorbtion of the cartilage matrix by "septoclasts" and appearance of the trabecular osteoblasts establishing the primary ossification center and the marrow space (ma).
bone collar, surrounding the hypertrophic region of the cartilage [25] (Fig. 1E). At this stage, the thin membrane covering the newly formed bone becomes known as the periosteum and continues to supply osteoblasts that produce the bone matrix of the diaphysis. Changes in the composition and properties of the cartilage matrix in the hypertrophic zone, including calcification of the longitudinal septa and the release of angiogenic factors, trigger its invasion by capillaries [27] (Fig. 1E). This results in death of the terminally differentiated hypertrophic chondrocytes and degradation of the uncalcified transverse
cartilage septa by invading septoclasts (sometimes called chondroclasts), a cell type of ill-defined origin associated with the invading capillary sprouts [28]. Remnants of the calcified longitudinal septa act as templates on which invading osteoblasts secrete the bone matrix of the first trabeculae, thus establishing the primary ossification center (Fig. 1F). Osteoclasts, which are bone-resorbing cells of hematopoietic origin, subsequently remove the newly formed bony trabeculae to generate the marrow space. The synchronous maturation and columnar organization of the chondrocytes result in a dynamic histo-
3. Prenatal Bone Development
logical structure known as the embryonic growth plate in which zones of proliferation, maturation, hypertrophy, and bone formation can be identified, proceeding from the articular ends (epiphysis) to the midshaft (diaphysis) of the element. Continued proliferation of the less mature chondrocytes at the extremities, their differentiation into hypertrophic chondrocytes, and their replacement by trabecular bone near the center result in distal displacement of the growth plate and longitudinal growth of the bone. In a typical long bone, this growth is accompanied by resorbtion of the older trabeculae to generate the marrow space of the diaphysis, thus leaving significant trabecular bone only at the extremities (metaphysis). Continued deposition of cortical bone by the periosteum (subperiosteal bone) leads to radial growth. Eventually, a secondary ossification center forms in the epiphysis distal to the growth plate, from which ossification proceeds in all directions. However, this does not modify the general organization of the growth plate, which remains active until cessation of growth after puberty. In the long bones of many species, including human, the growth plate eventually disappears and the only cartilage that remains is the articular cartilage, which forms a protective, low-friction surface at the extremities of the bones to allow smooth joint movement. As in intramembranous ossification, the first bone produced in the trabeculae and the diaphysis of the long bones is of a woven type. Removal of this immature bone by osteoclasts leads progressively to its replacement by mature lamellar bone [22]. Coordinating the different steps of the endochondral ossification process is critical in determining the size, shape, microarchitecture, and ultimately the mechanical properties of the bones. This coordination is achieved to a large extent by the action of a number of signaling pathways mediating cell-cell communication. Timing a n d S e q u e n c e of B o n e Formation in H u m a n s All skeletal elements do not start forming simultaneously in the embryo. Generally, chondrification proceeds in a rostral-caudal (head-to-tail) fashion in the axial skeleton and in a proximal-distal (shoulder-tofingertips) fashion in the limbs skeleton [19]. This is a direct consequence of the developmental origin of the different elements from the progressively forming somites and the outwardly elongating limb buds, respectively. The chondrification sequence is rapid, and early in the seventh gestational week the cartilage primordia Of all the elements of the axial and appendicular skeleton are present [29]. In the cephalic regions, cartilage formation proceeds in a caudal-to-rostral direction. It starts at the beginning of Week 7 and continues well into Week 8
81
[30]. Thus, the appearance of the cartilage primordia of the skull base occurs after that of most axial and appendicular elements, but it precedes ossification of the membranous bones of the skull vault. There is relatively little information on the timing of the formation of the mesenchymal condensations that will initiate formation of the different endochondral bones in the human embryo. On the other hand, the sequence of ossification of the different skeletal elements has been extensively studied [30-32]. The sequence of ossification in the mouse is also well-known [33] and generally resembles that in human. The following discussion highlights some general observations. Almost all primary ossification centers appear between Weeks 7 and 12 of embryonic life. In contrast, the secondary ossification centers such as in the epiphyses appear over a long period, from late fetal life until puberty. The clavicle is the first bone in the body to ossify, with the mandible and maxilla following almost immediately. The premaxilla forms in continuity with the maxilla proper, either as a mesenchymal condensation or as a center of ossification. Generally, the facial and calvarial centers appear before the basicranial centers, followed by the hyoid centers [31]. More than 100 centers of ossification appear during human skull formation [34]. Extensive fusion will take place between many of them, such that the number is reduced to 45 by the time of birth [35]. Postnatal fusion leads to further reductions. For instance, the human occipital bone ossifies from at least seven centers, two of which are intramembranous and responsible for the "interparietal" (squamous) part of the bone. Thus, in its definitive form, the occipital bone is a composite structure, and the different parts of the occipital do not completely fuse until several years after birth. In the axial skeleton, the costal centers appear first, followed by the primary vertebral centers and the sternal centers. The second to 11th rib centers appear at approximately the same time. The centers in the first and 12th ribs appear later in that order. The vertebrae ossify from three primary centers, one for the body and one for each neural arch. In the spine as in the thoracic cage, the sequence is not strictly cephalocaudal because ossification of the vertebral body starts first in the lower thoracic and upper lumbar regions and propagates in both directions from this area. Some delay is observed before the first cervical and the last two sacral centers appear [31]. Ossification centers in the neural arches appear in a cephalocaudal sequence except in the atlas and axis, in which ossification is slightly delayed [31]. The sternum arises as a pair of cartilaginous bands that fuse along the midline as the ventral body wall develops. This fused cartilage precursor subsequently subdivides into craniocaudal elements, most of which will fuse again and will ossify after the fifth month to form the body of the sternum [36].
82
Benoit St.-Jacques and Jill A. Helms
The primary ossification centers of the pectoral girdle appear before those of the pelvis in the following order: clavicle, scapula, ilium, ischium, and pubis. The centers in the humerus, femur, and then radius, ulna, and tibia appear at approximately the same time. The fibula differentiates slightly later. The bones of the hand invariably appear before their counterparts in the foot. These differ in that centers in the distal phalanges of the hand appear before those of the metacarpals, whereas the distal phalanges centers of the foot appear after the metatarsal centers [31]. The proximal and middle phalanges ossify last. Of the tarsal and carpal bones, only the talus and calcaneous generally begin to ossify before birth, with the cuboid sometimes and the lateral cuneiform rarely ossifying before birth [19].
SKELETAL ORGANIZATION AND EMBRYONIC ORIGIN OF BONES The human skeleton can be divided into three components based on the anatomical location of the elements: the craniofacial (skull), the axial (vertebrae and ribs plus sternum and sacrum), and the appendicular (limbs, including the shoulder and pelvic girdles) skeletons. These subdivisions also reflect the different embryonic origins of the bones. Whereas the axial and appendicular bones derive from somitic and lateral plate mesoderm, respectively, the craniofacial bones develop largely from the neuroectodermally derived neural crest cells with some contribution from cephalic paraxial mesoderm. This difference in germ layer of origin may be of considerable importance and recent data indicate that the molecular pathways leading to formation of these tissues are distinct. Nonetheless, it is important to note that regardless of developmental origins, all skeletal elements will eventually share similar histological structures and comprise the same few cell types: the chondrocytes in cartilage, the osteoblasts (and osteocytes) or bone-forming cells, and the osteoclasts or bone-resorbing cells, which are of a completely different origin (see Chapter 2).
Skull Anatomically, the skull is divided into the neurocranium, the part surrounding the central nervous system, and the viscerocranium, the skeleton of the face and branchial arches (also called pharyngeal arches in human). Each of these can also be subdivided into a chondrocranuim, composed of the bones that undergo endochondral ossification, and a desmocranium (or dermatocranium), composed of the bones that undergo membranous ossification.
Cartilaginous Neurocranium Formation of the skull base is one of the most complex parts of skeletogenesis and is only briefly described here. Thorough treatment of this important issue can be found in the authoritative review of Dixon [37]. The cartilage of the cranial base appears early in development as a number of condensations that follow a similar pattern in all vertebrates [38]. These centers of cartilage formation can be grouped according to their position relative to the notochord, the rod-like axial mesoderm structure that runs along the rostral-caudal axis of the early embryo. These is a parachordal region centered around the cephalic end of the notochord, a prechordal (or trabecular) region that lies anterior to the notochord, and centers associated with the sense capsules (otic, optic, and nasal) (Fig. 2A). These primordia undergo a complex pattern of growth and fusion to form an elaborate shelf-like base beneath the developing brain and ultimately form most of the bones of the cranial base as well as the deep bony support of the nasal cavity (Figs. 2B and 2C). In humans, the first chondrification centers appear on each side of the cranial end of the notochord on approximately Day 40 and soon fuse to form the rectangularshaped parachordal or basal plate destined to form the base of the occipital bone. At this early stage, the prechordal cartilages are represented by a pair of small hypophyseal cartilages and more rostrally by a pair of elongated trabecular cartilages (trabeculae cranii). The hypophyseal cartilages will fuse to form the basisphenoid cartilage that will give rise to the sella turcica and posterior part of the sphenoid bone. The trabecular cartilages also fuse to form the precursor of the presphenoid and an interorbital septum in which the perpendicular plate of the ethmoid bone will develop. Immediately caudal to the basal plate and rostral to the first cervical vertebra, four occipital somites give rise to three mesodermal condensations that will fuse with the caudal aspect of the basal plate to give rise to the part of the bassioccipital defining the foramen magnum. Chondrification centers later appear laterally to form the primordia of the condylar and supraoccipital parts of the occipital bone. Two other pairs of prechordal cartilages, the ala orbitalis (or orbitoshenoid) and the ala temporalis (or alisphenoid), also form on the ventrolateral aspects of the brain. These will grow and fuse with the main basal stem to develop into the lesser and greater wings of the sphenoid, respectively. At the same time, the cartilaginous capsules of the sense organs develop. The otic capsules are major features of the lateral part of the chondrocranium and contain the developing inner ear apparatus. They will fuse anteriorly with the parachordal region and will
3. Prenatal Bone Development
83
FIGURE 2 Development and organization of the human skull. The diagrams present lateral views of the human embryonic skull at different developmental stages: (A) 6 weeks, (B) 8 weeks, and (C) 12 weeks. The thin continuous line represents the contour of the head. The dashed line represents the contour and position of the developing brain. The different portions of the skull are represented by different shadings: gray, cartilaginous neurocranium; black, cartilaginous viscerocranium; striped, intramembranous neurocranium; white, intramembranous viscerocranium. 1, Nasal capsule; 2, trabecula crani; 3, optic capsule; 4, ala orbitalis; 5, ala temporalis; 6, hypophyseal cartilage; 7, otic capsule; 8, parachordal cartilage; 9, occipital sclerotomes; 10, first cervical sclerotome; 11, sphenoid; 12, Meckel's cartilage; 13, hyoid; 14, thyroid cartilage; 15, cricoid cartilage; 16, malleus; 17, incus; 18, Reichert's cartilage; 19, occipital; 20, petrous part of temporal; 21, lacrymal; 22, nasal; 23, premaxilla; 24, maxilla; 25, mandible; 26, tympanic ring; 27, styloid process of temporal; 28, stapes; 29, zygomatic; 30, zygomatic arch; 31, squamous part of temporal; 32, greater wing of sphenoid; 33, interparietal part of occipital; 34, parietal; 35, frontal.
ossify as the petromastoid part of the temporal bones. The nasal capsule (ectethmoid) develops as an extension of the trabecular cartilages and becomes the primary skeleton of the upper face.
spheres, these come to define the zones where bone growth slows down and the coronal, lamboid, and saggital sutures develop.
Cartilaginous Viscerocranium Dermal Neurocranium Early in human development, a delicate membrane of mesodermal origin, the meninx primitiva, encapsulates the neural tube [34,39]. This membrane later becomes divided into an inner endomeninx, which differentiates into the deeper meninges, the pia mater, and the arachnoid, and an outer ectomeninx, which gives rise to the dura mater and an outer superficial membrane with osteogenic potential. The bones of the calvaria--the frontals, parietals, and interparietal part of the occipital bone--develop by intramembranous ossification in the ectomeninx that forms the roof of the neurocranium. Ossification centers first appear in areas corresponding to the future eminences and bone formation spreads centrifugally. As development progresses, the dura mater thickens and becomes firmly attached at the dural stretches to the skull base. The dural stretches continue dorsally as frontal, parietal, and occipital dural girdles. In conjunction with a saggital reflection between the cerebral hemi-
The cranial region of an early human embryo resembles that of a fish embryo of a comparable stage. The branchial or pharyngeal arches, which appear during Weeks 4 and 5 of development, contribute to this characteristic appearance of the embryo. These represent evolutionary remnants of the gill arches of more primitive vertebrates. There are usually five identifiable pairs of arches (1-4 and 6), although only the first four are visible on the surface (Fig. 3A). They form during a period of rapid growth of the face and head, with the first arch appearing at approximately 24 days and the others in sequence at approximately 2-day intervals. Each pharyngeal arch consists of a core of mesenchymal tissue covered on the outside by the surface ectoderm and on the inside by epithelium of endodermal origin. Cartilage elements of the viscerocranium form in the mesenchyme of these pharyngeal arches. The first pharyngeal arch, or mandibular arch, develops two elevations called the mandibular and the maxillary prominences (Figs. 3A and 3B). The mandibular prominence gives rise to paired
84
Benoit St.-Jacques and JillA. Helms
FIGURE 3 Cephalicregion of a 28-day human embryo. (A) Lateral view showing the pharyngeal (branchial) arches 1-4. (B) Frontal view showing the division of the first arch into maxillary and mandibular prominences. (C) View in saggital section of the embryo depicted in A showing the contribution of neural crest cells from different axial levels to the mesenchymeof the pharyngeal arches. D, diencephalon; M, mesencephalon; RI-R8, rhombomeres 1-8 of the hindbrain; T, telencephalon; dark gray, central nervous system(CNS).
rod-like structures called Meckel's cartilages that pass ventrally from the region of the otic capsule downward and forward and meet at the midline of the future chin (Fig. 2B). They are one of the most recognizable histological features of the developing head. Meckel's cartilage is a transient structure and is not a cartilaginous precursor of the mandibular bone, which develops by intramembranous ossification. However, it may play a role in morphogenesis of the jaw by guiding the spread of the mandibular bone in anterior and transverse directions from the original center of ossification, and disruption of Meckel's cartilage does affect the shape of the mandible. It may also contribute actively to secondary palate formation by displacing the tongue from between the palatal shelves. At the very proximal or tympanic portion of the cartilage, two small condensations separate and undergo endochondral ossification to give rise to the malleus and incus of the inner ear (Fig. 2B). In human, the rostral (ventral) extremities of the left and right cartilages come in close contact but do not fuse. They remain as cartilage nodules (the chondriola symphysea) in the fibrous tissue of the symphysis of the jaw [40]. The central portion of Meckel's cartilage disappears. In the rostral half, vascular invasion occurs and resorbtion takes place by a process similar to endochondral ossification [41]. In the caudal half, cells acquire a fibroblastic phenotype and give rise to the sphenomandibular ligament [41]. Programmed cell death may also contribute to the disappear-
ance of this structure, although its importance in this process is controversial [41,42]. An elongated cartilage (Reichert's cartilage) also forms in the second pharyngeal arch (Fig. 2B). The dorsal part of this cartilage will ossify to give rise to the stapes of the middle ear and the styloid process of the temporal bone. The ventral end will form part of the hyoid bone (lesser cornu and superior part of the body), whereas the central portion regresses and forms the stylohyoid ligament. The third arch cartilage produces the remainder of the hyoid (greater cornu and inferior part of the body), whereas the fourth and sixth arches form the laryngeal cartilages, including the thyroid and cricoid cartilages. Dermal Viscerocranium
The bones of the face also derive from the mesenchyme of the pharyngeal arches but form via intramembranous ossification (Fig. 2C). The maxillary prominence of the first arch gives rise to the maxilla, which appears as an ossification center below and lateral to the cartilage of the nasal capsule. From this initial center, ossification spreads in the three dimensions to form the alveolar, frontal, and zygomatic processes. From the maxilla, bone gradually develops in the primary palate, forming the premaxillary part, which carries the incisors. Outgrowths of the maxillary prominences also form the palatine shelves, which fuse to form the secondary palate
3. Prenatal Bone Development
within which the palatine bone forms. The zygomatic and the squamous part of the temporal bone also derive from the maxillary prominence. The mandible forms by intramembranous ossification in the mesenchymal core of the ventral part of the mandibular prominence. Contrary to what occurs in other vertebrates, each half of the lower jaw develops as a single element in human. It first appears as an ossification center on the outer aspect of the ventral half of Meckel's cartilage and spreads rapidly anteriorly and posteriorly along its lateral side. Ossification later proceeds medially above and below to form a bony trough that surrounds the cartilage. Thus, Meckel's cartilage contributeslittle to the definitive mandible and is not involved in formation of the condylar cartilages.
Sutures and Synchondroses Sutures (syndesmoses) are craniofacial articulations in which contiguous margins of bones approximate each other and are united by a thin layer of fibrous tissue that permits minor movement [43]. Sutures develop initially by a wedge-shaped proliferation of cells, the osteogenic front (OF), at the periphery of the growing bones [44,45]. OFs may approximate each other in the same plane, leading to the development of end-to-end sutures (the saggital and midpalatal sutures in human), or more commonly may overlap each other, leading to the development of overlapping sutures (all other sutures in humans). Once a suture has formed, five distinct layers can be recognized histologically in most sutures: two cambial and two capsular layers of each adjoining bone, separated by a middle vascular layer [46]. With maturation, the cambial layer becomes reduced to a single layer of osteoblasts, the capsular layer thickens and its fibers become parallel to the sutural surface of the bone, and the middle layer becomes increasingly vascularized [43]. In humans, most sutures become obliterated by fusion of the bones they separate only in young adulthood or later, except for the metopic suture (between the frontal bones) that is usually closed by the third year of life. Synchondroses are remnants of the chondrocranium that persist between ossifying elements and are the principal site of cranial base growth [47]. Structurally, they have the appearance of a bipolar epiphyseal growth plate characterized by a central "germinative" area, on each side of which can be recognized zones of chondrocyte proliferation, maturation, and hypertrophy followed by a zone of primary ossification. The growth of synchondroses is controlled by the same factors regulating epiphyseal growth plate physiology and their function is severely affected in diseases of the endochondral skeleton, leading to a range of craniofacial abnormalities characteristic of many chondrodysplasias.
85
Embryonic Origin of Skull Cells Largely due to technical limitations, studies of skull development are much better established in birds than in mammals. Avian data have therefore been used for extrapolation to mammalian skull origins, including the human skull. It is clear that in both birds and mammals, head mesenchyme originates from two principal sources--the cephalic (or cranial) neural crests and the cephalic paraxial mesoderm [48] (Fig. 4A). The neural crest is a transient pluripotent cell population that originates in the folds of the developing neural tube, between the future neural and epidermal ectoderm (Figs. 4B and 4C). As the neural tube develops, neural crest cells delaminate from the prospective dorsal neural tube, undergo an epithelial-to-mesenchymal transition, and migrate in a ventral and lateral direction following a precisely determined pattern both spatially and temporally [49] (Fig. 4D). This migration is rapid and in humans probably takes place between Days 19 and 38 after fertilization, a critical period during which many teratogenic agents can induce craniofacial malformations [47]. The mesenchyme formed by neural crest cells is designated ectomesenchyme to indicate its different embryonic origin (from the ectoderm). Crest cells appear along the entire length of the neural tube and differentiate into a large number of cell types, including neurons and glial cells, melanocytes, smooth muscle, and some endocrine cells. Only cephalic neural crest cells, however, have the additional capability of forming bone, cartilage, and odontoblasts, which are the dentine-secreting cells of the teeth [49]. The contribution of crest cells from different levels of the neural tube has been precisely mapped in cell lineage studies using short-term labeling techniques. Cells originating at the forebrain and midbrain levels will contribute to the frontonasal mass to give rise to all the connective tissue of the face. Cells originating at the level of the rhombomeres (the segmented divisions of the hindbrain) migrate according to their rhombomeric origin to populate the branchial arches and will give rise to all the skeletal elements of the dermal and chondral viscerocranium (Fig. 3C). Crest cells from the posterior midbrain and rhombomeres 1 and 2 populate the first pharyngeal arch (mandibular). Cells from rhombomeres 4 6, and 7 and 8 migrate within arches 2, 3, and 4-6, respectively [49]. Although most of the cephalic mesoderm yields muscles, a detailed analysis of the contribution of cephalic mesoderm in the chick indicates that it also gives rise to the parachordal elements of the skull base. Thus, in the chick, the basipostsphenoid and orbitosphenoid, part of the otic capsule, and the supraoccipital derive from medial cephalic mesoderm [50]. Finally, as indicated previously, the bassioccipital has a different origin
86
Benoit St.-Jacques and Jill A. Helms altogether, deriving in part from the somitic m e s o d e r m of the occipital somites (paraxial mesoderm). The origin of the skull vault remains controversial. Despite discrepancies in early experimental results [49], it is likely that the entire cranial vault in the chick is neural crest derived [50,51]. However, extrapolation of the results to mouse and h u m a n skull development m u s t be regarded with caution. In rodent embryos, neural crest migration pathways at early stages were elucidated using dye injection techniques, but their contribution to m a t u r e structures could not be assessed. Recently, however, a transgenic mouse was engineered that has a p e r m a n e n t neural crest cell m a r k e r [52,53]. Analysis of neural crest contribution to different tissues in these animals generally confirmed observations in birds but also indicated that although the frontal and s q u a m o s a l bones are neural crest derived, the parietal and interparietal bones are p r o b a b l y of m e s o d e r m a l origin [54]. This interpretation is incorporated in the representation of the embryonic origin of the n e w b o r n skull elements depicted in Fig. 5. However, further studies in m a m m a l s will be required to confirm this interpretation.
Patterning of the Craniofacial Skeleton To date, a gene or c h r o m o s o m a l location have been linked to approximately 100 craniofacial m a l f o r m a t i o n s in humans, and gene targeting in mice has generated more than 90 loss-of-function m u t a n t s that show craniofacial m a l f o r m a t i o n s [55]. In m o s t of these phenotypes, skeletal elements are affected but in m a n y cases these are secondary defects resulting from axial truncation or neural tube malformation. N o t surprisingly, however, a large proportion of these m u t a t i o n s affect the specification, migration,
FIGURE 4 Origins of skull cells and neural crest cell formation. (A) Dorsal view of the cephalic region of a four-somite chick embryo showing the regions contributing cells to the skull, including the neural folds (nf), in which neural crest cells originate, and the medial head mesoderm (hm, outlined in gray), np, neural plate; nt, neural tube; s, somites. (B) Diagram of tissue interactions leading to specification of the neural ectoderm borders. The neural plate (np) is light gray and the edges of the neural plate are dark gray. Signals emanate from the nonneural ectoderm (n-ne, the prospective epidermis), the node (no), and the paraxial mesoderm (pm). The nature of the ectodermal signal is not known. Signals from the other sources probably include some FGFs and induce M s x l expression in a restricted domain. (C) Neural crest cell differentiation. M s x l expression in the prospective neural crest region (nc) induces BMP4 expression and a positive regulatory loop is established to maintain expression of both factors in the nc region and specify the neural crest cell phenotype, n, notochord; ne, neural ectoderm. (D) Neural crest cell migration. Neural crest cells (ncc) delaminate from the edges of the neural ectoderm and migrate away from the closing neural tube (nt) in a ventrolateral pattern, n, notochord; se, surface ectoderm.
FIGURE 5 Origins of the skull bones. The diagram represents the different bones of a human skull at birth. Embryonic origins of the skeletal elements are depicted by different shadings. Light gray, cephalic neural crest derived; dark gray, possibly medial head mesoderm derived; black, paraxial mesoderm derived (occipital somites).
3. Prenatal Bone Development
or differentiation of the neural crest cells that will give rise to the head skeleton. Rapid progress is being made in the identification of mechanisms controlling these processes [56-59]. Specification of the crest cell population depends on interactions between the neural plate and nonneural ectoderm (prospective epidermis) preceding neural tube closure. Creating contact between these two cell types, either in vivo or in vitro, induces neural crest cell differentiation. There is also evidence that signals from the nonaxial mesoderm are required for neural crest formation. The molecular nature of the signals involved is not completely understood but probably involves the coordinated action of members of the bone morphogenic protein (BMP) and fibroblast growth factor (FGF) families of secreted signaling molecules [56]. According to one model, lateral signals from the nonneural ectoderm (unidentified), paraxial mesoderm, and Hensen's node (possibly an FGF signal) specify the neural crestforming regions at the lateral edges of the neural plate and induce expression of the homeobox-containing transcription factor M s x l (Fig. 4B). This factor activates BMP-4 transcription to establish a positive feedback loop that restricts and maintains high expression of both genes at the border [60] (Fig. 4C). Bmp-4 signaling within the neural fold then induces or maintains the neural crest precursors as shown by the fact that inhibition of BMP signaling in the closing neural folds prevents neural crest formation [61]. Once specified, expansion of the prospective crest population depends on signals of the Wingless/Int-1 (Wnt)-related family of secreted glycoproteins expressed in the dorsal neural tube [62]. Differentiating crest cells express the gene Slug in chick and frog as well as the related gene Snail in mouse [63,64]. These encode transcription factors that are essential for the delamination process probably by regulating the expression of adhesion molecules [58]. The initiation of migration correlates with a decline in production of the adhesion molecules N-cadherin (N-CAM) and cadherin 6B. At the same time, however, cadherins 7 and 11 are upregulated, indicating that a fine regulation of cadherin expression is fundamental for this process [59,65]. The migration routes followed by crest cells are dictated by the composition of the extracellular matrix (ECM). Neural crest cells appear to be prohibited from entering particular territories in the embryo by the presence of inhibitory molecules and to be guided along specific routes by the presence of permissive, migration-promoting factors. Hyaluronic acid, fibronectin, laminins, tenascins, and various collagens and proteoglycans are found in this matrix along the routes taken by migrating crest cells. A large number of these ECM components have been tested in vitro and demonstrate permissive or nonpermissive activities [49]. Evidence of
87
a role in vivo has been obtained from gene inactivation studies and injection of blocking antibodies or antisense oligonucleotides. These studies indicate that six ECM components are pivotal determinants of crest cell migration: fibronectin, laminin isoforms 1 and 8, aggrecan, and the PG-M/versican isoforms V0 and V1 [66]. Currently, almost nothing is known about the specific signals that are responsible for target localization and cessation of neural crest migration. Early studies in the chick embryo suggested that neural crest cells were preprogrammed before their migration to give rise to different craniofacial structures and that they passively carried this positional information from the neural tube to the periphery [48,67]. However, a number of studies also contradicted this model and highlighted the plasticity of cranial neural crest populations [68]. Trainor and colleagues [69] resolved this paradox and clearly established that the migrating crest cells that will give rise to the craniofacial structures are not prespecified but respond to local influences to form different structures. For instance, the endoderm of the foregut, which lines the pharyngeal arches, appears to play a major role in instructing the neural crest cells as to the size, shape, and position of the facial skeletal elements [70]. The molecular nature of the signals produced by the endoderm is unknown. On the other hand, known signaling molecules that control patterning and growth in the central nervous system and the limb have also been implicated in patterning of the face [71]. The face forms from the outgrowth of five primordia: the frontonasal process (FNP), and the paired maxillary and mandibular processes, which surround the primitive mouth. These primordia initially consist of buds of undifferentiated mesenchyme, covered by surface ectoderm, that will undergo a complex process of growth, fusion, and differentiation to give rise to the different tissues of the face, including the different bones and cartilages. The vitamin A derivative retinoic acid (RA), the secreted signaling peptide Sonic hedgehog (Shh), BMP-2, -4, and -7, as well as members of the FGF family present in the ectoderm and the mesenchyme of the developing face influence the size, shape, and identity of these facial primordia and ultimately the facial skeleton [72-77]. Genes-encoding homeobox-containing transcription factors of the Hox family are also differentially expressed in the pharyngeal arches and determine pharyngeal arch identity [78]. The signals that control the appearance and patterning of the calvarial bones are not known. However, removal of ectoderm from the presumptive cranial aspect of the chick head or ablation of underlying neuroepithelium result in the absence of calvarial bones, implicating both tissues in an epithelial-mesenchymal inductive interaction [79,80].
88
Benoit St.-Jacques and Jill A. Helms Axial S k e l e t o n
The axial skeleton of vertebrates is the most clearly segmented structure in the body and this organization reflects its origin in the embryonic somites. Somites are transient blocks of paraxial mesoderm that form alongside the neural tube and the notochord (Fig. 6A). They bud off in a precisely timed cephalocaudal sequence from the anterior end of the unsegmented presomitic mesoderm (PSM) [81] (Fig. 6B). The segmentation process initially forms undifferentiated epithelial somites (Fig. 7A) that soon become patterned in response to signals from the surrounding tissues [82] (Fig. 7B). Cells facing the surface ectoderm differentiate into the dermomyotome, which retains an epithelial structure and is the source of trunk and limb musculature as well as the dermis of the back. The ventral half of the somite undergoes an epithelial-to-mesenchymal transition to form the sclerotome, which will give rise to the ribs and vertebrae [83,84] (Fig. 7C). Sclerotomal cells undergo extensive proliferation and migration to form condensations that prefigure the axial skeleton elements. Cells from the medial part of the sclerotome condensate around the notochord and ven-
tral neural tube to give rise to the vertebral bodies and intervertebral disks. The lateral regions of the sclerotome migrate dorsally to form the vertebral arches and in the thoracic region also ventrally to form the ribs [85] (Fig. 7D). More caudally, the sacrum derives from the upper sacral vertebrae by projections similar to those that give rise to the ribs in the thoracic region. These extend, flatten, and fuse to form the lateral mass of the sacrum [86]. In addition, in the sclerotomes, a process of resegmentation takes place whereby rostral and caudal halves of each sclerotome segregate and re-fuse with halves of neighboring somites. Thus, each vertebra and rib are derived from the caudal half of one somite fused with the rostral half of the following somite (Fig. 6A) [87]. Because the resegmentation process does not take place in the muscle compartment, the segmental muscle derived from a single somite attaches to two adjacent vertebrae [85].
Somite Formation Segmentation of the paraxial mesoderm is believed to be under the control of a "segmentation clock"
FIGURE 6 Patterningof the paraxial mesoderm and somite formation. (A) Dorsal view of a human embryo in early week 4. The neural groove is still opened at the rostral and caudal ends where the neural folds (nf) are visible, but the neural tube (nt) has closed in the center. Eight somites (s) have formed on either side of the neural tube. A ninth somite is in the process of segmenting from the presomitic mesoderm (psm). (B) Schematic representation of somite formation. Blocks of paraxial mesoderm bud off the rostral end of the presomitic mesoderm (psm) at fixed intervals as epithelial somites. Simultaneously,new mesenchymalcells are recruited into the caudal end of the psm by the process of gastrulation to maintain elongation of the psm in a caudal direction. Rostrocaudal somite polarity is established in the anterior psm before overt segmentation (SO).C, caudal half of each somite; R, rostral half of each somite; SO, newlyforming somite; S1, most recently segmented somite. Dark gray bands represent the differentiating dermomyotomes. (C) Resegmentation. Somite formation requires two types of segmentation. The initial segmentation separates the forming somite from the psm (S1). Once somites have formed, differentiation into sclerotomal and dermomyotomal compartments (DM) occurs (see also Fig. 7). In the sclerotome only, a second segmentation (resegmentation) event occurs in which rostral (R) and caudal (C) halves of each somite segregate and re-fuse with their neighboring halves to form the vertebrae and ribs.
3. Prenatal Bone Development
FIGURE 7 Sclerotome differentiation and formation of vertebrae and rib condensations. The diagrams represent transverse sections through a developing chick embryo at early stages of formation of the axial skeleton. (A) Epithelial somites. The diagram shows the position of the differentiating paraxial mesoderm [epithelial somites (es)] relative to the other tissues, im, intermediate mesoderm; lpm, lateral plate mesoderm; n, notochord; nt, neural tube; se, surface ectoderm. (B) Patterning. The ventromedial part of the somite undergoes an epithelial-to-mesenchymal transition (light gray) and initiates expression of sclerotome-specific genes such as Pax1. Shh signal from the ventral neural tube and notochord is essential to maintain this differentiating population. Noggin also acts by antagonizing BMP activity from the lateral plate mesoderm. Note that at later stages, after the cells have been exposed to Shh, a BMP signal induces chondrogenic differentiation of sclerotomal cells. In the lateral somite, Shh is required in combination with Wnt factors from the dorsal neural tube and surface ectoderm to induce myogenic differentiation. (C) Expansion. Cells of the sclerotome (s) migrate dorsally and medially to surround the notochord and neural tube. The lateral somite forms the
89
responsible for the oscillating expression of a gene encoding a basic helix-loop-helix ( b H L H ) transcription factor related to Drosophila hairy called c-hairy-1 in chick [88]. Expression of this gene appears as a wave that sweeps through the PSM once during formation of each somite. This wave does not result from cell displacement or from signal propagation but rather reflects a coordinated pulse of expression in neighboring cells [89]. In the anterior PSM, oscillations cease, resulting in the establishment of alternating bands of cells corresponding to presumptive somites. Thus, the temporal periodicity of expression (the clock) is translated into the spatial periodicity of the somites. It was recently found that the expression of a m e m b e r of the Notch l signaling pathway called lunatic fringe (Lfng, a Golgi enzyme that modifies the extracellular domain of the N o t c h l receptor) is also cyclic in the PSM, thus linking Notch signaling with the segmentation clock [90]. The importance of this signaling pathway in somitogenesis is illustrated by the perturbation of somite formation and defects in vertebrae and ribs seen in mouse embryos with null mutations in several genes encoding members of the Notch pathway. These include Notchl and Notch4, the Notch ligands delta-like 1 (Dlll) and delta-like 3 (Dll3), preselinin 1 and 2 (Psenl and Psen2), recombining binding protein suppressor of hairless (Rbpsuh; also known as Rbp-jK), Lfng, and the b H L H transcription factor mesoderm posterior 2 (Mesp2) [91-95]. In addition, deletion ofpMesogenin, encoding a b H L H transcription factor, in the mouse leads to a loss of Notch/delta pathway components as well as oscillating gene expression in the PSM and results in the complete absence of all trunk paraxial mesoderm derivatives, including vertebrae and ribs [96]. Some axial abnormalities in humans resemble the defects seen in some of these mouse mutants, suggesting that they may also be caused by mutations in genes encoding members of the N o t c h pathway [7]. At least one form of hereditary axial dysostosis has been linked to mutations in the h u m a n Dll-3 homolog, DLL3 [97]. In addition, mutations in another Notch ligand, JAGGED1, cause Alagille syndrome, a condition frequently associated with vertebral malformations [98,99]. The molecular nature of the mechanism responsible for the cyclic expression of hairy and Lnfg is unknown. It is a l s o n o t clear how segmentation is actually achieved,
dermomyotome (dm). ao, aorta. (D) Condensation. Sclerotomal cells form mesenchymal condensations surrounding the notochord and ventral neural tube. The dorsal condensation (dc) will form the neural arches of the vertebra. The ventral condensation (vc) forms the vertebral body. Lateral condensations (lc) will form the ribs (in the thoracic region). At this stage, the lateral somite has differentiated into two compartments, the dermatome (d) and the myotome (m).
90
Benoit St.-Jacques and Jill A. Helms
although it probably reflects differences in cell adhesion properties between the rostral and caudal parts of each somite and involves the Eph/ephrin signaling pathway [100-102]. Recently, the level of FGF was also shown to control the transition from immature PSM to a mature state in which cells initiate a segmentation program [103,104], and fibroblast growth factor receptor 1 (Fgfrl)-deficient mice do not form somites [105]. Segmentation of the paraxial mesoderm initially forms undifferentiated epithelial somites [81]. This epithelialization process specifically requires the activity of the bHLH) transcription factor Paraxis [106]. Sclerotome Differentiation
Differentiation of the sclerotome is controlled by the synergistic action of at least two factors, Shh and Noggin, secreted by the notochord and the floor plate of the neural tube [82]. Shh belongs to a small family of genes related to the Drosophila segment-polarity gene hedgehog (hh). Members of this family encode signaling proteins that play a fundamental role as long- and short-range signals in many aspects of embryonic development in both vertebrates and invertebrates [107]. The secreted polypeptide Noggin binds some BMP ligands with high affinity, thereby preventing interaction with their cognate receptors and signal activation [108]. Noggin is expressed in multiple sites including developing bones and is an essential modulator of BMP activity. In the most medial part of the somite, Shh antagonizes the dorsalizing activity of Wnt factors (Wnt 1, 3, and 7) secreted by cells of the dorsal neural tube and surface ectoderm to induce or maintain expression of sclerotomal markers [109-115] (Fig. 7B). Farther from the source of Shh, the combination of lower Shh concentrations and Wnt signals from dorsal tissues specifies myotome differentiation [116]. In addition to establishing the compartments of the somite, Shh signaling is also essential for cell survival in both the myotome and the sclerotome [115]. Noggin probably acts in specification of the sclerotome by antagonizing BMP-4 produced by the lateral plate mesoderm [117] (Fig. 7B). Both Shh and Noggin maintain expression of sclerotomal-specific markers, such as the paired-box transcription factors Paxl and Pax9 [110-115]. Paxl and Pax9 act in concert to maintain proliferation of sclerotomal cells [118]. Sclerotomes do not form in mice homozygous for a null allele of Shh, leading to the complete absence of vertebrae and most of the ribs [113]. Mutations in genes encoding other members of the hedgehog signaling pathway, most notably members of the Gli family of zinc finger transcription factors, also lead to severe skeletal abnormalities of the craniofacial, appendicular, and axial skeletal elements in the mouse [119]. These resemble the
spectrum of skeletal abnormalities observed in Gorlin's syndrome (nevoid basal cell carcinoma syndrome), which is caused by mutations in the human gene PATCHED1 (PTCH1) encoding the Hedgehog receptor [120,121]. Interestingly, the mouse mutant open brain (opb), which displays prominent neural tube and axial skeletal defects [122,123], was recently shown to be caused by mutation of a negative regulator of Shh signaling called Rab23 [124]. Noggin-deficient embryos also display a severe reduction of both the sclerotomal and the myotomal compartments, leading to axial defects that increase in severity in a rostral-to-caudal fashion, with the complete absence of lumbar and tail vertebrae [114,125]. Mutations in Paxl lead to severe defects in the axial skeleton [118,126-131]. Mutations in Pax9 in the mouse or PAX9 in humans result in multiple defects, reflecting expression in many tissues but without significant axial skeleton abnormalities [132,133], probably because Paxl and Pax9 serve partially redundant functions. The phenotype of compound Paxl/Pax9 mouse mutants is much more severe than that of single Paxl or Pax9 mutants, displaying a complete lack of the medial derivatives of the sclerotomes, the vertebral bodies, the intervertebral disks, and the proximal part of the ribs [118]. The Bagpipe homeobox gene 1 (Bapxl; also called Nkx3.2), which encodes a homeobox transcription factor related to Drosophila bagpipe (bap), is expressed in the sclerotome in a pattern similar to that of Paxl under the influence of SHH [134]. Inactivation of Bapxl in the mouse also leads to a specific loss of midline components of each vertebra (centra and intervertebral disks) [135-137]. On the other hand, the paired homeobox gene Uncx4.1 acts upstream of Pax9 and is specifically required for the formation of the pedicles and transverse processes of vertebrae as well as the proximal ribs [138,139]. The fact that formation of different parts of a vertebra depends on different factors probably reflects the evolutionary history of these structures whereby individual elements of the vertebra arose at different times in evolution [140]. The gene Mesenehymalforkhead-1 (Mfhl; also called Foxc2), which encodes a member of the winged-helix/ forkhead family of transcription factors, is also expressed in the sclerotome under the influence of Shh [141] and is required for normal proliferation of sclerotomal cells [142-144]. Inactivating mutations in human FOXC2 lead to hereditary lymphedema-distichiasis, a complex syndrome that shares many of the features of the Mfhl/Foxc2 null mice, including vertebral abnormalities [142,145]. As is the case for the Pax genes mentioned previously, Mfhl/Foxc2 and the related factor Mfl/ Foxcl appear to have partly overlapping functions. The absence of Mfl/Foxcl in the mouse does not lead to obvious axial defects [144] but compound Foxcl/Foxc2 mutants die early in development with more severe
3. Prenatal Bone Development defects than either single homozygote [146]. In addition to being expressed in the sclerotome, Foxcl and Foxc2 are also expressed in the PSM and the simultaneous absence of these two factors leads to downregulation of many genes related to Notch signaling and failure of somitogenesis [146]. The bHLH transcription factor Scleraxis, which is closely related to Paraxis, also appears to play an important role in the formation of the axial skeleton. Scleraxis is expressed throughout the ventral sclerotome and subsequently in the cartilage of developing vertebrae and ribs as well as in craniofacial cartilage and precursors of the long bones [147]. Scleraxis-deficient mouse embryos die before gastrulation, preventing the analysis of its potential role in cartilage formation [148]. However, using a chimeric approach, it was possible to show that Scleraxis-null cells can contribute to cartilage in the limbs and craniofacial region but not to the sclerotome [148]. This suggests a specific role for Scleraxis in specification or survival of sclerotomal cells. Differentiation of the dorsal part of vertebrae is controlled by different molecular mechanisms than those for the rest of the axial structures. Cells in the dorsomedial angle of the sclerotome migrate between the surface ectoderm and the dorsal neural tube to form the dorsal mesenchyme, from which the dorsal part of the neural arch and spinous process of each vertebra will form (Fig. 7). These cells do not maintain expression of Pax1 or Pax9 but instead, under the influence of BMP-4 (secreted by the surface ectoderm and roof plate of the neural tube), express the transcription factors Msxl and Msx2, leading to bone formation in this region [149-151]. Mutations in genes required for normal development of the myotome and that are not normally expressed in the sclerotome, including Pax3 and Myf5, also lead to abnormalities of the ribs and neural arches [152-154]. This indicates that formation of structures derived from the lateral sclerotome also depends on interactions between the sclerotome and the myotome. Platelet-derived growth factor A (PDGFA) expressed in the myotome and its receptor PDGFRA expressed in the sclerotome act downstream of Pax3 and Myf5 and appear to mediate signaling between myotome and lateral sclerotome [155,156]. The absence of Fgf-4 and Fgf-6 expression in the myotomes of Myf-5-deficient mouse embryos also suggests that members of the FGF family may be involved in this interaction [157]. Significant movement ofsclerotomal cells is involved in the formation of axial structures, but little is known about the mechanisms initiating and coordinating this migration. However, downregulation of the adhesion molecule NCAM can be seen in the mesenchymal sclerotome while high expression is maintained in the epithelial dermomyotome, suggesting a role in this process [158,159].
91
Patterning of the Axial Skeleton The bones of the axial skeleton have distinct morphological features characteristic of their position along the rostral-caudal axis. The determination of this axial identity is under the control of the homeotic genes of the HOX complex [160-164]. These genes encode a highly conserved family of homeobox-containing transcription factors. In humans, as in most vertebrates, there are 39 HOX genes organized into four clusters of 9-11 genes, named HO2fA-HOXD, that are located on different chromosomes. At the molecular level, HOX genes are believed to act by controlling the transcription of specific sets of target genes, although few such genes have been identified. In general, the order of the genes on the chromosome, within each cluster, corresponds closely to their spatial expression patterns during development [160]. Furthermore, there is extensive overlap between the expression domains of many HO2(genes at any given axial level. The specific subset of genes expressed at each level (the HOX code) determines the identity of the skeletal elements [165]. Consequently, ectopic expression and targeted deletion of Hox genes in the mouse often lead to changes in the number of vertebral elements or to homeotic transformations (changes in the shape of one element that make it resemble a different element) [161,163,166]. In the mouse, mutations in a number of genes that result in misexpression of certain Hox genes also lead to abnormal vertebral patterning. These include mutations in Fgf-rl [167], activin receptor IIB (ActRIIB) [168], the mixed-lineage leukemia (Mll) gene [169], the B lymphoma Mo-Mlv insertion 1 (bmil) protooncogene [170], the caudal-type homeobox 1 (Cdxl) gene [171], growth and differentiation factor 11 (Gdf-11) [172], and the promyelocytic leukemia zinc finger (PlzJ) gene [173]. Administration of exogenous RA during early gestation also leads to changes in the anterior limits of Hox gene expression associated with vertebral transformations [166,174,175]. Consistent with a role for RA in axial patterning, a number of retinoic acid receptor (RAR) null mutant mice exhibit vertebral homeosis, primarily in the cervical region [176-179]. However, the effect of RA on Hox genes controlling axial patterning may not be direct and was recently shown to be mediated at least in part through the activity of Cdxl, a direct RA target [180-182]. How Hox gene activity ultimately controls the shape of different axial elements is not clear, but the different phenotypes could be explained by a deficit in the formation of precartilaginous condensations and/or cellular proliferation [183]. Misexpression of some Hox genes in vivo has been shown to affect the condensation process,
92
Benoit St.-Jacques and Jill A. Helms
cellular adhesiveness, chondrocyte proliferation, and chondrocyte maturation [184-186]. Mutations in only three H O X genes have been associated with skeletal defects in humans, and in all cases it is the patterning of the limbs that is affected. Recently, however, a translocation located 60 kb from the 3' end of the HOXD complex was shown to be associated with mesomelic dysplasia (severe shortening of the forearms and lower legs) and vertebral defects [187]. This translocation does not disrupt any coding sequence but most likely exerts its deleterious effect by modifying H O X gene expression [187]. A p p e n d i c u l a r Skeleton The appendicular skeleton consists of the pectoral (shoulder) and pelvic girdles and the limb bones. The basic structure of the appendicular skeleton is remarkably conserved among amniote tetrapods and consists of four segments: a root (zonoskeleton), a proximal segment (stylopodium) consisting of a single bone (humerus or femur), a medial segment (zeugopodium) consisting of two bones (radius/ulna or tibia/fibula), and a distal and more complex part (autopodium) composed of carpus or tarsus and a variable number of digits (hand or foot). With the exception of the clavicle, which forms by a combination of intramembranous and endochondral ossification [188], all other elements of the appendicular skeleton form by endochondral ossification. In humans, limbs first appear as elevations of the ventrolateral body wall (the limb buds) toward the end of the fourth week. The upper limbs develop at the level of the caudal cervical segments and the lower limbs opposite the lumbar and rostral sacral segments [189]. The appearance of the upper limb buds precedes that of the lower limb buds by a few days. Originally, the growing limb buds consist of a central core of undifferentiated mesenchyme encased in an ectodermal jacket. As the bud elongates out of the flank, ectoderm at the distal end of the limb thickens and forms the apical ectodermal ridge (AER). The AER is one of the main regulatory centers of limb growth and patterning. Signals emanating from the AER maintain the subjacent mesenchyme as a population of undifferentiated, rapidly proliferating cells called the progress zone (PZ) (Fig. 8B). This cell population is essential for outgrowth of the limb, and ablation of the AER leads to cessation of growth and distal truncation of the limb [190]. As the limb grows, cells farther from the influence of the AER leave the PZ and begin to differentiate into cartilage and muscle. In this manner, development of the limb proceeds proximal to distal. By the sixth week of development in humans, mesenchymal condensations within the limb differentiate to form the first cartilage precursors of the long bones. The cartilages
first form as continuous rods that through a series of bifurcations and segmentations give rise to the characteristic limb skeleton [191]. At approximately Day 32, the terminal portion of the limb buds becomes flattened to form the handplates and the footplates [189]. Fingers and toes become apparent as programmed cell death separates the AER into five parts leading to continued outgrowth of the cartilaginous digital rays, accompanied by cell death of the interdigital mesenchyme. In humans, this process takes place between Days 48 and 56 of development [189]. Two sources of mesenchyme contribute to the limb. Cells from the lateral plate mesoderm (LPM) give rise to connective tissue and cartilage, whereas cells migrating from the myotomal compartment of the somites give rise to all the muscles. Of these two populations, the connective tissue/cartilage precursors determine the primary limb pattern [192]. Other components of the limb include motor axons emanating from the spinal cord and sensory axons and Schwann cells of neural crest origin. In addition, the earliest vasculature of the limb is derived from endothelial cells arising from segmental branches of the aorta and cardinal veins as well as from angioblasts (endothelial cell precursors) endogenous to the limb mesoderm [36]. Limb Bud Positioning and Induction The first step in limb development is the determination at specific levels of the flank LPM of groups of cells, the limb fields, which acquire the potential to form a limb bud. Once specified, the limb field mesenchyme can be transplanted elsewhere and form a limb bud, irrespective of the origin of the ectoderm that covers it at the transplantation site [192]. How this specification is achieved is not completely understood, but several lines of evidence support the involvement of a H o x code in positioning the vertebrate limb field. Indeed, in many vertebrates, the anterior limit of expression of specific H o x genes corresponds exactly to the level of the prospective forelimbs and differences in the position of forelimbs between chick and mouse correspond to shifts in H o x expression [162,193]. In addition, the absence of limbs in snakes also correlates well with specific changes in H o x gene expression [194]. Finally, some mutations affecting the pattern of expression of some H o x genes lead to displacement of the foreor hindlimbs [172,195]. The prepattern that sets up the limb field is then interpreted by several key tissues that together induce limb budding. In this respect, the intermediate mesoderm (IM), which lies between the somites and the LPM (Fig. 7A), appears to play an important role. In the chick embryo, extirpation of the IM leads to limb reduc-
3. Prenatal Bone Development
tion, whereas a barrier placed between IM and LPM inhibits limb induction [196,197]. These observations suggest that the IM is the source of a diffusible limb inducer that acts on the LPM. A large body of work recently led to the identification of FGF-8 as a mediator of this activity. FGF-8 protein, like many other FGFs, can induce ectopic limb formation when implanted at the interlimb level into the flank of a chick embryo. Furthermore, Fgf-8 is expressed transiently in the IM in a domain first restricted to the level of the prospective forelimb and later at the hindlimb level as well [196]. At later stages, Fgf-8 is also expressed in the limb ectoderm and contributes to the function of the AER. Interestingly, another gene of the same family, Fgf-lO, appears to mediate the limb-inducing activity of Fgf-8. Fgf-lO is initially widely expressed in the LPM, but prior to limb bud induction it becomes restricted to the LPM of the prospective limb territories. Fgf-lO-expressing cells can induce ectopic limb formation [198] and mice deficient for Fgf-lO or its receptor (an isoform of Fgf-r2) are limbless [199-201]. In these mutants, the apical ectoderm of the limb bud never expresses Fgf-8 and the AER fails to form. Moreover, F G F bead implants induce Fgf-lO expression in the LPM prior to ectopic limb initiation and the appearance of Fgf8 expression in the surface ectoderm [202]. All these observations have contributed to the current molecular model of limb induction in which FGF-8 from the IM restricts Fgf-lO expression to the LPM of the prospective limb regions, and FGF-10 subsequently induces Fgf-8 expression in the ectoderm, thereby triggering limb outgrowth [196,197,203-205]. It now appears that signaling through the Wnt pathway mediates these inductive interactions between Fgf-8 and Fgf-lO. Indeed, Wnt-2b is expressed in the LPM of the prospective forelimb area, and its ectopic expression is sufficient to induce ectopic Fgf-lO expression and ectopic limb outgrowth in the flank [204]. Expression of another Wnt gene, Wnt8c, may restrict Fgf-lO expression to the prospective hindlimb area [204]. Finally, induction of Fgf-8 expression in the ectoderm requires Wnt signaling, probably via expression of the Wnt3a gene [204,206]. Determination of Limb Identity Determination of the type of limb to be produced (forelimb vs hindlimb) appears to take place at the earliest stages of limb induction, prior to limb bud formation. For instance, prebud LPM cells taken from the forelimb field develop as a forelimb when transplanted ectopically [207]. Furthermore, the mesoderm is clearly the determinant of limb identity ([190,207,208]. Members of the T-box (Tbx) and paired-type homeobox (Pitx) gene families have been identified that are expressed exclusively in the LPM of the fore- or hindlimb
93
prior to bud formation. Tbx5 is expressed in the presumptive forelimb area and Tbx4 and Pitxl in the presumptive hindlimb area in a number of organisms [209-211]. In addition, Pitxl is an upstream regulator of Tbx4 expression because misexpression of Pitxl induces ectopic expression of Tbx4 and inactivation of Pitxl leads to reduced Tbx4 expression [212-214]. Ectopic expression of Tbx4 and Pitxl in chick forelimbs (wings) results in partial transformations to hindlimbs (legs) [212,215,216], whereas ectopic expression of Tbx5 in leg fields results in some respecification to wing identity [215,216]. Although the transformations are not complete, these data indicate that Tbx4 and Pitxl are selectors for hindlimb identity and Tbx5 is a selector of forelimb identity in chick. Furthermore, inactivation of Pitxl in the mouse leads to hindlimb skeletal elements that bear some resemblance to the corresponding bones in the forelimb [213,214]. Again, the transformation is not complete, possibly because Tbx5 is not regulated by Pitxl and its expression remains forelimb specific in mutant mice. How these selector genes interact with the FGF-8/FGF-10 regulatory loop and other possible downstream targets remains to be determined. Two mutations in human TBX genes have been linked to defects of the limb skeleton. Mutations in TBX3 cause ulnar-mammary syndrome, in which patients present with a range of alterations of the ulnar ray in the upper and lower limbs associated with apocrine, cardiac, and genital anomalies [217,218]. Holt-Oram syndrome in which patients display malformations of the radial ray of the upper limbs, associated with varied cardiac anomalies, is due to mutations in TBX5 [219,220]. Patterning of the Limb The limb is probably the part of the vertebrate body for which patterning mechanisms are best understood [197]. Indeed, a systematic study of limb patterning in chicks and mice led to the elucidation of a series of regulatory pathways that govern the establishment of the three axes of the developing limb: the proximaldistal (shoulder-to-digits) axis, the anterior-posterior (thumb-to-little finger) axis, and the dorsal-ventral (knuckles-to-palm) axis (Fig. 8A). Although the mechanisms regulating patterning along these three axes are different, they are not independent from one another and interactions between the regulatory pathways have also been identified. These interactions ensure coordination of growth and patterning along the three axes of the limb. As indicated previously, outgrowth of the limb bud and its elongation in the proximal-distal axis is dependent on the integrity of the AER (Fig. 8B). Surgical removal of the AER stops bud outgrowth and results in a
94
Benoit St.-Jacques and JillA. Helms
FIGLIRE 8 Limbbud patterning. (A) The three axes of limb growth and patterning: lateral view at the limb bud stage. A-P, anteriorposterior axis; Pr-Di, proximal-distal axis; Do-V, dorsal-ventral axis. (B) Growth and patterning centers in the elongating limb bud. A, anterior; AER, apical ectodermal ridge; P, posterior; PZ, progress zone; ZPA, zone of polarizing activity. (C) Regulatory signals in growth and patterning of the limb bud. FGFs produced by the AER induce FGF10 in the subjacent mesenchyme to maintain proliferation and prevent differentiation of cells in the PZ. FGF signals also maintain Shh expression in the ZPA. Shh induces BMP2 expression, which can inhibit AER expression of FGFs. Shh also acts through formins to induce expression of the BMP antagonist Gremlin. BMP2 maintains Gremlin expression, completing the negative feedback loop that controis BMP activity in the autopod. (D) Molecules regulating dorsalventral patterning in the limb bud. The secreted factor Wnt7a is present in the dorsal ectoderm and directs expression of Lmxl in the dorsal mesenchyme. Enl acts by inhibiting expression of Wnt7a, and therefore Lmxl, in the ventral half of the limb bud. Abutting domains of Rfngexpression in the dorsal bud and Enl expression in the ventral bud determine the position of AER formation.
truncated limb [221-223], whereas ectopic implantation of an A E R to an initiated limb bud results in the production of a second proximal-distal axis [222]. An important activity of the A E R is to keep cells of the underlying mesenchyme in a proliferative state. Members of the F G F family of growth factors appear to mediate this activity. Indeed, of all the factors expressed in the AER, only F G F s are capable of substituting for the A E R after its surgical removal [196]. However, owing to functional redundancy, it is difficult to assign a specific role to particular F G F s expressed in this tissue. Loss of function for Fgf-4 [224,225], Fgf-9 [226], or Fgf-17 [227] has no effect on limb formation. Following inactivation of Fgf-8 in the prospective limb ectoderm, patterning
and growth are abnormal but the A E R does form and a limb also develops [228,229]. Thus, it is likely that no individual Fgf expressed in the A E R is solely necessary for its function but that a combination of two or more F G F s mediate its activity. AER-produced F G F s maintain Fgf-lO expression in the limb bud mesenchyme [198], which appears essential for continued proliferation of mesenchymal cells and elongation (Fig. 8C). A E R maintenance is also controlled by BMP signaling [230,231]). In the chick, BMP-soaked beads placed under the A E R induce cell death and A E R regression resulting in truncations of the limb skeleton [232,233]. Conversely, BMP inhibition results in extension and persistence of the A E R and prolonged Fgfexpression [234]. The secreted product of the gene Gremlin was identified as the factor antagonizing BMP activity in the distal limb bud in vivo [235-237]. However, to ensure a minimum level of BMP signaling, also required as part of the distal signaling program, Gremlin expression is in turn controlled by BMP signaling in a regulatory feedback loop [235,236] (Fig. 8C). The formation and proper patterning of the different segments of the limb skeleton require the activity of Hox genes of the HoxA and HoxD clusters [238-240]. Genes of the 5~end of the HoxA cluster are sequentially induced during outgrowth of the bud and come to be expressed in domains restricted along the proximal-distal axis with borders corresponding to the major segments of the limb [241,242]. Genes of the 5~ end of the HoxD cluster are expressed in a set of overlapping domains progressively restricted along the anterior-posterior axis [242,243]. Based largely on these observations, it was first proposed that Hoxa genes determine the proximal-distal identity of the skeletal elements, whereas Hoxd genes determine anterior-posterior identity. In this model, the identity of each element is set by a combinatorial code of Hox gene expression, with each element specified by a unique code [238]. A large number of experiments involving ectopic expression and targeted disruption of Hox in the chick and the mouse have shown that this simple model is not correct. By using a variety of loss-of-function alleles in the mouse, it was possible to show that the localizations of the limb alterations reflect the temporal and structural colineraity of Hox genes of both the HoxA and -D clusters such that inactivation of 3r genes has a more proximal phenotypic boundary than that of the 5t genes. For instance, mutations in Hoxa9 and Hoxd9 affect the stylopodium, whereas mutations in groups 10 and 11 genes affect primarily the zeugopodium and mutations in groups 12 and 13 affect the autopodium [239,240]. A second observation is that, in these different domains, individual gene products quantitatively contribute to an overall protein dose and reduction in the gene dose in each set results in truncation of the corresponding
3. Prenatal Bone Development anatomical region. For instance, a progressive reduction in the dose of groups 11-13 Hox genes leads to a proportional reduction in the length and number of digits [244]. A striking example is also provided by mutations in group l I genes. Mice with individual mutations in the paralogous genes Hoxal! and Hoxdl! have relatively moderate malformations of the radius and ulna [245-247], but in the double mutant both the radius and the ulna are almost entirely eliminated [248]. Interestingly, in humans a distinct alteration of the forearm (radioulnar synostosis) was described as resulting from a heterozygous mutation in H O X A l l [249]. Recently, a balance translocation that appears to deregulate HOXD genes expression was also associated with mesomelic dysplasia (severe shortening of the zeugopods) and vertebral defects [187]. Patterning along the anterior-posterior axis is mediated by a small region of cells in the posterior mesenchyme of the limb bud known as the zone of polarizing activity (ZPA) [250] (Fig. 8B). Extirpation of the ZPA results in posterior skeletal defects [251], whereas implantation of an ectopic ZPA in the anterior mesenchyme causes mirror-image duplication of the digits [250]. This observation has long been interpreted in terms of diffusion of a morphogen from the ZPA, which sets up a gradient across the limb bud, specifying digits pattern in a concentration-dependent manner [194]. It is now known that the signaling peptide Shh mediates the polarizing activity of the ZPA. Shh expression in the limb bud colocalizes with the ZPA in many organisms [252255], and the Shh signaling peptide spreads away from its restricted source within the ZPA in a graded fashion [203,256,257] (Fig. 8C). Finally, implantation of ectopic Shh in the anterior limb bud mesenchyme leads to mirror-image duplication of digits [252,258,259]. RA can also induce digit duplication and compound mutants for different RA receptors of the RAR subfamily exhibit a range of severe limb abnormalities from reductions to duplications [177]. RA appears to act in limb patterning by inducing Shh expression, and complete inhibition of RA signaling prevents the establishment of the ZPA and the appearance of Shh expression [260-262]. It should be noted that Shh is required for growth and patterning of the intermediate and distal limb skeletal elements but not the most proximal limb structures [113,263]. In addition, even in the absence of Shh, some anterior-posterior polarity is maintained [264,265], indicating that Shh is not required for the initiation of limb outgrowth or establishment of an initial polarity within the limb field. Hedgehog signaling regulates the expression and activity of transcription factors belonging to the Ci/Gli zinc finger family [107]. In limb bud mesenchyme, Gli3 acts as a potent repressor of transcription, but this activity is antagonized by the long-range signaling of posteriorly
95
produced Shh [266]. The result is an anterior-posterior gradient of Gli3 repressor activity across the limb bud mesenchyme [266]. The importance of this patterning mechanism is illustrated by several syndromes caused by mutations affecting Shh signaling that are associated with carniofacial anomalies and malformation of the autopodium skeleton. These include Smith-LemliOpitz syndrome, attributed to a defect in sterol D7-reductase; Gorlin syndrome (basal cell nevus syndrome), caused by haploinsufficiency for the Shh receptor PATCHED1 (PTCH1); and Greig cephalopolysyndactyly, Pallister-Hall syndrome, and postaxial polydactyly type A, in which different mutations in GLI3 have been identified [267]. Mutations in the gene encoding CBP, a coactivator of the Gli transcription factor, have also been detected in Rubinstein-Taybi syndrome [268]. Mutations in SALL1, another zinc finger transcription factor gene expressed in Hedgehog signaling domains, lead to Townes-Brocks syndrome [269]. Finally, in the mouse, mutations have been identified in genes encoding factors that act to confine Shh expression to the ZPA, including Ptchl [270]; Gli3, mutated in the extra-toe (xt) [271,272] and polydactyly Nagoya (Pdn) mice [273]; the aristalless-like gene Alx4, mutated in the Strong's luxoid mouse [274,275]; and the related gene Cart 1 [276]. The bHLH transcription factor dHAND [277,278] and some HOX proteins [279-281] act as positive regulators of Shh expression. Maintenance of Shh expression in the ZPA also depends on signals from the AER and the surface ectoderm. It is not known how Shh signaling specifies the pattern of skeletal elements in the autopodium, but evidence points to BMPs as downstream signals. Indeed, Shh appears to induce dose-dependent mirror-image duplication of digits even when provided in a nondiffusible form [282]. This observation suggests the existence of secondary long-range signals, and BMPs are plausible candidates. Some Bmps are expressed in the polarizing region following Shh expression, and Bmp-2, -4, and -7 can also be ectopically induced in anterior mesenchyme by RA or Shh [282-285] (Fig. 8C). In addition, BMP signal is required for polarizing activity since in the absence of BMP signaling, ectopic Shh still induces formation of additional digits but they all have the same identity [285]. However, BMPs alone cannot reproduce all the effects of Shh on digit patterning [286]. A model accounting for these different observations was recently proposed [285] that states that Shh initially acts long range to "prime" the region of the limb competent to form digits and determines digit number. Later, Shh acts short range to induce expression of BMPs, whose morphogenetic action specifies digit identity. This model is supported by the recent demonstration that digit identity is actually specified by the interdigital mesenchyme at
96
Benoit St.-Jacques and Jill A. Helms
relatively late stages of limb bud development in a process dependent on BMP signaling [287]. BMP signaling determines the fate between digital (chondrogenic) and interdigital (apoptosis) in the distal autopod. Exogenous BMPs induce premature cell death in the interdigital mesenchyme but stimulate chondrogenesis when placed close to developing digits. Interfering with BMP signaling has the opposite effect [288]. As indicated previously, another member of the transforming growth factor-J3 (TGF-[3) superfamily, Tgf-~2, is expressed in the prechondrogenic condensations of the digits and appears to act as an inducer of chondrogenesis. TGF-[31_3 are potent inducers of chondrogenesis in limb mesenchyme micromass cultures and implantation of exogenous TGF-[3 in the interdigital mesenchyme induces formation of extra digits [288]. This is preceded by induction of Bmp-rlB in the condensations, suggesting that TGF-[32 acts by sensitizing these cells to the action of a BMP signal. However, TGF-[32 is not expressed in the more proximal elements of the stylopodium and zeugopodium, and implantation of ectopic TGF-[32 in domains destined to form these elements does not induce formation of ectopic cartilage [288]. Thus, there appears to be specific inductive signals for chondrogenesis along the proximodistal axis. Various 5' Hoxa and Hoxd genes are also involved in digit patterning. Ectopic polarizing activity (Shh or RA) induces ectopic expression of Hoxdll and -13 [282284,286]. In the chick, misexpression of Hoxdll and Hoxal3 resulted in transformations compatible with a change in identity of cartilage primordia [184,289]. In humans, mutations in only a few H O X genes have been shown to cause congenital malformations, and they affect primarily the autopodium. HoxD13 is mutated in synpolydactyly, and HoxA13 is mutated in hand-footgenital syndrome [267,290]. Classical embryology in the chick has shown that once the limb bud has formed, the surface ectoderm is responsible for specification of cell fate along the dorsal-ventral axis [291]. A number of genes are expressed specifically in either the dorsal or the ventral half of the limb bud and are candidates for determinants of dorsal-ventral patterning. Wnt7a, which encodes a secreted signaling factor, is expressed in the dorsal ectoderm and directs expression of the LIM homeodomain transcription factor Lmxl to the dorsal mesenchyme [292] (Fig. 8D). Loss-of-function mutations in either Wnt7a or Lmxl transform dorsal limb structures to a ventral fate [293,294]. Conversely, ectopic expression of either gene in the ventral limb causes dorsalization of ventral structures [292,295]. The transcription factor Engrailedl (Enl), whose expression is restricted to the ventral ectoderm, specifies ventral fates since limbs of Enl -/- mice display a double-dorsal phenotype [296]. Enl appears to
act by inhibiting expression of Wnt7a, and therefore Lmxl, in the ventral half of the limb bud [291] (Fig. 8D). Mutations in LMX1B in humans cause nail-patella syndrome, characterized by hypoplasia or aplasia of dorsally derived structures [291]. Enl also restricts expression of Radical fringe (Rfng) to the dorsal ectoderm and maintains a sharp boundary between Rfng-expressing and -nonexpressing cells. This interface determines the position of the forming AER (Fig. 8D). When Enl is ectopically expressed in the dorsal ectoderm or Rfng is ectopically produced in the ventral ectoderm, new interfaces between Rfng-expressing and -nonexpressing cells are created, giving rise to ectopic AERs and outgrowth [297-299]. Growth and patterning along the three axes of the limb are regulated by interactions between the molecular pathways defining each axis. For instance, Fgfs expression in the AER, which stimulates proximal-distal growth, is also essential to maintain Shh expression in the ZPA and therefore anterior-posterior patterning. In turn, Shh affects outgrowth by inducing BMP expression, which at high levels can induce AER regression. However, Shh also indirectly promotes expression of the BMP antagonist Gremlin in the mesenchyme. This activity of Shh requires the nuclear protein Formin, which is also essential to maintain AER expression of Fgf4 [237] and is mutated in the limb deformity (ld) mouse [300]. Thus, Shh appears to act through Formin to promote Gremlin expression and indirectly maintain Fgf4 expression in the AER (Fig. 8D). Finally, maintenance of Shh expression and development of posterior elements also require the Wnt7a signal in the dorsal ectoderm, providing a link between anterior-posterior and dorsal-ventral axes [293,301,302]. Thus, all three axes are intimately linked by the respective signals Wnt7a, FGF-4, and Shh during limb outgrowth and patterning.
MOLECULAR REGULATION OF BONE FORMATION Initiation Whether a bone forms by intramembranous or endochondral ossification, the initial steps in the process are similar [5]. After mesenchymal cell migration to the site of bone formation, an interaction between epithelial and mesenchymal tissues takes place. This molecular interaction is essential to induce the next phase, the formation of mesenchymal condensations. The final phase is the overt differentiation (osteogenesis or chondrogenesis) of cells in these condensations. The following sections review the nature of the epithelial-mesenchymal interactions and the process of condensation.
3. Prenatal Bone Development
Epithelial-Mesenchymal Interactions The requirement for an early tissue interaction to induce mesenchymal condensation is demonstrated by tissue dissociation-recombination experiments. For instance, embryonic mandibular mesenchyme can be separated from the mandibular epithelium and cultured in vitro. Mesenchyme isolated before migration or at an early stage after migration of mesenchymal cells to the final site of bone formation fails to form bone in culture. However, if early mesenchyme is combined in vitro with mandibular epithelium or if mesenchyme is isolated at a late stage, then osteogenesis takes place, indicating a requirement for epithelial-mesenchymal contact [303]. The signal from the epithelium appears to be permissive in nature. First, mandibular mesenchyme forms bone in culture when recombined with epithelia from other regions of the embryo as well, provided that they are of the correct age. Furthermore, the shape of the bone produced is independent of the source of epithelium but is dictated by the nature of the mesenchyme [303]. Finally, an epithelium such as the mandibular is incapable of inducing bone formation in a mesenchyme that is normally nonosteogenic. Such interactions have been studied in detail mostly in craniofacial structures and have been shown to be essential to induce formation of scleral ossicles and scleral cartilage, mandible and Meckel's cartilage, maxilla, palatine bone, otic vesicle, and calvarial bones, and also clavicle and limb cartilage [35,303-3061. A series of elegant studies by Hall and colleagues [303] have demonstrated that in most cases these epithelialmesenchymal interactions are short range and matrix mediated. In particular, the activity appears to reside in the ECM of the epithelial basal lamina. The molecular nature of the epithelial signal(s) is unclear but probably involves in many cases the BMPs, which form a subfamily of secreted proteins among the TGF-~ superfamily. Members of this group are characterized by a conserved C-terminal domain with several cysteine residues and undergo cellular processing by cleavage of an inactivating N-terminal domain. They act as dimers (probably heterodimers in vivo [307]) to bind a type II transmembrane receptor and induce recruitment and phosphorylation of the cytoplasmic tail of one of two type I receptors (types IA and IB). Phosphorylation of the type I receptor initiates signal transduction through various pathways, including the SMAD family of intracellular signaling molecules. At least 20 different BMPs and the related growth and differentiation factors (GDFs) have been identified in vertebrates [308]. Members of this family of growth factors were first identified as proteins present in demineralized bone matrix, which has the remarkable capacity to induce ectopic
97
bone formation in subcutaneous implants [309,310]. Purified recombinant BMPs share this capacity and are able to potentiate chondrocyte and osteoblast differentiation of cells in vitro, including that of mouse embryonic stem cells [311], bone marrow stromal stem cells, limb bud mesenchyme, periosteum, fetal calvaria, and a number of mesenchymal or preosteogenic and prechondrogenic cell lines [312]. Consequently, BMPs have long been considered in vivo "bone inducers." However, BMPs induce ectopic bone by recapitulating the events occurring during endochondral bone formation [313], and it is likely that in development they do not act by inducing ossification (production of bone matrix) per se. Indeed, the developing skeleton is neither the sole nor the main site of B M P expression, and BMPs control organogenesis in many tissues [314]. Instead, the boneforming ability of BMPs probably reflects their role in the induction of mesenchymal condensations [315]. Several BMPs known to have cartilage/bone-inducing potential accumulate in the ECM [316-319], including epithelial basal lamina [316,320], and BMP signaling has been implicated in epithelial-mesenchymal interactions in other organs [314,321]. In the case of the mandible, an epithelial-mesenchymal interaction involving BMP signaling has been documented. BMP-2, -4, and -7 are found in distal mandibular epithelium and the homeobox-containing transcription factor Msxl is present in the mandibular mesenchyme. M s x l function in the mesenchyme is essential, as demonstrated by M s x l knockout mice, which exhibit mandibular defects [322]. Expression of M s x l requires mandibular epithelium [323] and can be induced by ectopic BMPs [73], thus implicating these molecules in the early epithelial-mesenchymal interaction required for mandible formation.
Condensations Skeletal condensations have been studied most intensely in the developing limb in vivo and by means of micromass cultures of limb mesenchyme in vitro. The condensation stage is a very transient phase, rapidly followed by differentiation of the aggregated cells. At the histological level, it is characterized by a significant increase in cell-packing density in specific areas of the mesenchyme. Cells of the precartilaginous condensations can also be visualized by their affinity for the lectin peanut agglutinin (PNA) and their transient upregulation of a number of markers, including versican, tenascin, syndecan, N-CAM, N-cadherin, thrombospondin-4, type I collagen, and heparan and chondroitin sulfate proteoglycans [5]. Cell proliferation plays a role in condensation of the calvarial, scleral, and mandibular primordia but not in the precartilaginous condensations of the limb, where cell movements appear to be more
98
Benoit St.-Jacques and Jill A. Helms
important [24]. Regardless of the mechanism, the high cell density generated in the condensations leads to increased cell-cell contact as well as the formation of gap junctions facilitating intercellular communication [23,324,325]. These appear to be essential for differentiation to take place, and the extent of cellular condensation correlates with the level of subsequent chondrogenesis both in vitro and in vivo [10]. Two cell adhesion molecules implicated in the condensation process are N-cadherin and N-CAM. N-cadherin belongs to a group of calcium-dependent transmembrane glycoproteins that mediate cell-cell adhesion by homotypic interactions through their extracellular domains. The protein cytoplasmic domain interacts with the actin cytoskeleton via the catenin molecules. N-CAM is a member of the large immunoglobulin superfamily of membrane glycoproteins and also mediates cell-cell adhesion via homotypic interactions but in a calcium-independent manner. These molecules are expressed at high levels in condensing mesenchyme but disappear in differentiating cartilage and can be detected later only in the perichondrium. Much evidence shows that perturbing the functions of N-cadherin and N-CAM causes reduction or alteration of chondrogenesis both in vitro and in vivo [10]. Conversely, overexpression of N-cadherin and N-CAM in micromass cultures stimulates chondrogenesis [326,327]. Recently, cell-cell adhesion in the digit condensations was also shown to depend on Eph-ephrins interactions. The Eph receptors constitute the largest known subfamily of receptor tyrosine kinases. They are characterized by a unique cysteinerich motif in their extraceUular domain, followed by two fibronectin type III motifs. They interact with a family of at least eight ephrin ligands associated with the cell membranes via a transmembrane domain or a GPI anchor [328]. Two Eph receptors were recently implicated in the sorting and adhesion of limb mesenchymal cells in the mouse and the chick [329,330]. Furthermore, in Hoxal3 mutant mice, expression of one of these, EphA7, is reduced in mesenchymal condensations correlating with altered adhesiveness, poorly resolved condensations, and defective chondrogenesis [330]. Interestingly, misexpression of Hoxdll or Hoxal3 in the developing chick limb also affects condensation size and cell adhesiveness [184,185]. These results suggest that one of the mechanisms by which Hox transcription factors control skeletal patterning is via the regulation of cell adhesion molecules, particularly members of the Eph receptor family, at the condensation stage. Interactions between cells and the ECM also significantly affect condensation. Prior to condensation, mesenchymal cells secrete an ECM rich in hyaluronan (HA) that facilitates cell movement but prevents close cell-cell interactions. As condensation begins, a transient
increase in hyaluronidase activity leads to controlled hydrolysis of HA and reduced intercellular space, thus favoring cell-cell interactions [331,332]. Syndecan-3 is an integral membrane protein transiently expressed in large amounts during formation of the precartilage condensations and downregulated (except in the perichondrium) after chondrocyte differentiation [333]. It is a heparan sulfate proteoglycan that can interact with ECM components and heparin-binding growth factors and signaling molecules [333]. Antibodies against syndecan-3 impair the formation of precartilaginous condensations in micromass cultures of chick limb mesenchyme [334], but the mechanism of this inhibition is not clear. Condensation also coincides with upregulation of several ECM proteins, including type I collagen, fibronectin, and various proteoglycans [10]. Fibronectin is a dimeric proteoglycan present in the ECM of many tissues that plays an important role in cell migration and differentiation. Fibronectin interaction with the cellular integrin receptors can activate signaling through the focal adhesion kinase and the integrin-linked kinase pathways. Prior to condensation, it is distributed throughout the intercellular space of the mesenchyme. It accumulates in the condensations and reaches its maximal level of expression just prior to overt chondrogenesis [335]. Interaction between extracellular fibronectin and heparin-like molecules of the mesenchymal cell surface is crucial for the formation of precartilage condensations [336,337]. Antibodies specific to a certain isoform of fibronectin perturb chondrogenesis both in vitro and in vivo [338]. One mode of action of fibronectin is to stimulate N-CAM expression. Expression of the different cell-cell and cell-matrix adhesion molecules mentioned previously is modulated by signaling factors, and these are therefore also important regulators of condensation. For instance, treatment of pluripotential cells or limb bud mesenchyme with TGF-[3 stimulates expression of fibronectin, N-CAM, N-cadherin, and tenascin [339,340]. Exposure of limb bud mesenchymal cells to some BMPs also correlates with an increase in N-cadherin and N-CAM expression and stimulates chondrogenesis [5,10]. Despite these in vitro observations, it has been difficult to confirm a specific role for these signaling factors in general skeletogenesis in vivo or to assign a specific role(s) to different BMPs. Gene inactivation studies in the mouse have not been very informative in this respect. For instance, null mutations in Bmp-2 or -4, as well as in the BMP receptor type 1A gene (Bmp-rlA), lead to early embryonic lethality [341-343], whereas mice null for Bmp-3 or Bmp-3b (also known as GdflO) display no obvious embryonic phenotype in the skeleton [344,345]. Mutations in Bmp-5-7 as well as in Gdf5 [also called cartilage-derived morphogenic protein 1 (Cdmpl)] and the gene encoding the
99
3. Prenatal Bone Development
BMP receptor type 1B (Bmp-rlB) do not perturb general skeletogenesis but affect only a subset of specific skeletal elements [346,347]. The analysis of mice carrying null mutations in two of these genes found additional defects not observed in either single mutant, supporting the idea that a significant level of functional redundancy exists in this signaling pathway [347-349]. As in the mouse, mutations affecting BMP signaling in humans also lead to defects in restricted sets of skeletal elements. Mutations in only one BMP-related gene have been linked to human skeletal defects. Based on similarities with the murine braehypodism (bp) phenotype, HunterThompson acromesomelic dysplasia, in which patients present with shortened middle and distal limb segments as well as joint defects, was found to be caused by mutations in GDF5/CDMP1 [267,350]. A mutation creating a dominant negative form of CDMP1 was also found in the more severe form of acromelic dysplasia, Grebe syndrome, whereas a CDMP1 mutation creating a premature stop codon was found in a family displaying a novel type of brachydactyly [267,350]. Mutations in the gene encoding the BMP antagonist Noggin (NOG) also cause two autosomal dominant disorders--proximal symphalangism (SYM1) and multiple synostose syndrome (SYNS1), both characterized by multiple joint fusions [351]. BMP/GDF gain-of-function experiments in chick [232,286,352,353] and mouse embryos [125,354,355] lead to hyperplasia and in some cases fusion of limb cartilage elements. Conversely, broad repression of BMP signaling inhibits cartilage development [355-357]. Some of the phenotypes observed in these in vivo studies suggest that BMP/GDF signaling controls recruitment of cells into the early condensations [125,353,354]. In addition, exposure of limb bud mesenchymal cells to GDF5 increases cell-cell adhesiveness [353], supporting a role in condensation. Insightful analyses of chondrogenesis in micromass cultures of limb bud mesenchyme established that BMP signaling is indeed required for formation of prechondrogenic condensations but also for differentiation of mesenchymal cells into chondrocytes [358-360]. Interactions of the mesenchymal cells with other cell types also affect condensation. For instance, in the developing limb, there is an inverse relationship between condensations and blood vessel distribution. Vessels are initially present throughout the limb mesenchyme but undergo local regression from sites at which precartilaginous condensations will form shortly thereafter [361]. It was recently shown that this vascular regression is essential for the condensation step and subsequent chondrogenesis in the chick developing limb [361]. How vascularization interferes with the condensation process is not clear. In principle, blood vessels could represent a physical barrier to condensation, produce or transport
factors that inhibit this process, or simply create high oxygen levels incompatible with the formation of prechondrogenic condensations [361]. Interestingly, the osteogenic condensations initiating the formation of the intramembranous bones of the calvaria in the chick embryo also form in an avascular milieu [20]. I n t r a m e m b r a n o u s Bone Formation Differentiation
Osteoblasts differentiation is reviewed in Chapter 2. This section only briefly mentions the most important recent developments concerning this issue. A key regulator of osteoblast differentiation and function is Runt domain factor 2/core binding factor oL 1 (Runx2/Cbfal). Runx2/Cbfal is a transcription factor isolated by virtue of its binding to cis-regulatory elements of the gene encoding osteocalcin, the most osteoblast-specific protein known [362]. Runx2/Cbfal is absolutely necessary for osteoblast differentiation, as was unambiguously demonstrated by gene inactivation in the mouse. The skeleton of Runx2/Cbfal-deficient mice is completely devoid of osteoblasts due to a differentiation arrest as early as E 12.5--that is, almost 2 days before the normal appearance of the first mature osteoblasts in wildtype limbs [363,364]. Runx2/Cbfal acts as a positive regulator of osteoblast-specific gene expression. Forced expression of this factor is sufficient to induce osteoblastspecific gene expression in skin fibroblasts and to induce ectopic bone formation in vivo [362,365,366]. In addition, Runx2/Cbfal is required for osteoblast function beyond differentiation [367,368]. Haploinsufficiency of Cbfal causes cleidocranial dysplasia (CCD) in both mice and humans [364]. CCD is an autosomal dominant disorder characterized primarily by a delay in closure of cranial sutures, reduced or absent clavicle, and dental anomalies [364]. Runx2/Cbfal is first expressed in cells of the mesenchymal condensations believed to contain common osteochondroprogenitor cells. With development, its expression progressively increases in preosteoblasts and then in true osteoblasts but is downregulated in all nonhypertrophic chondrocytes [362]. However, Runx2/Cbfal expression is also detectable in hypertrophic chondrocytes of endochondral bones, and Runx2/Cbfal null mice display deficient chondrocyte hypertrophy, supporting a role for this factor as a regulator of chondrocyte maturation [369,370]. E n d o c h o n d r a i Bone Formation Differentiation
The overt differentiation of condensed mesenchymal cells into cartilage-producing cells is characterized by a
1O0
Benoit St.-Jacques and JillA. Helms
change in cell shape and a shift in production of ECM and adhesion molecules. Differentiating cells enlarge, become rounded, and develop extensive ER and Golgi complex for high-level synthesis and secretion of proteins. Production of N-CAM, N-cadherin, and type I collagen is downregulated, whereas that of types II, IX, and XI collagen as well as the large proteoglycan aggrecan and associated proteins is upregulated. One general observation is that differentiation seems to require a minimal condensation size. For instance, in vitro chondrogenesis depends on the initial cell density of the cultures and also correlates with the extent of condensation [10]. Furthermore, a number of null mutations in the mouse lead to ectopic cartilage formation as the result of accumulation of mesenchyme at sites where condensations normally form but are too small to chondrify [371]. A key regulator of chondroblast differentiation was identified through the discovery that mutations in the gene encoding the HMG domain DNA-binding protein SOX9 cause the rare and severe dwarfism campomelic dysplasia in humans [148,372]. During embryogenesis, Sox9 is expressed in all prechondrogenic condensations and cartilages, where it precedes the expression of the Col2al gene (type II collagen). The function of Sox9 in chondrogenesis was studied by analyzing the fate of Sox9_/_ ES cells in chimeric mouse embryos. It was shown that the mutant cells were excluded from prechondrogenic condensations and failed to express any chondrocyte-specific markers [373]. In addition, teratomas derived from these cells failed to produce any cartilage [373]. Thus, Sox9 is essential in a cell-autonomous manner at the condensation step. However, its best characterized function is in the induction of the chondrocytic phenotype. Sox9 appears to work by direct regulation of transcription of chondrocyte-specific genes. For instance, Sox9 binds to and activates an enhancer element of the Col2al gene, thus inducing production of type II collagen in a chondrocyte-specific manner [374]. Two other members of the Sox family, L-Sox5 and Sox6, interact with the same sequences and together with Sox9 activate transcription of the Col2al and aggrecan genes [375]. L-Sox5 and Sox6 have partly redundant functions and single mutants display limited but different skeletal abnormalities [376]. The Sox5;Sox6 double mutants, however, show severe generalized chondrodysplasia characterized by poor differentiation of chondroblasts that express cartilage matrix components at much lower levels than wild-type cells [376]. Thus, L-Sox5 and Sox6 are potent enhancers of chondroblast differentiation. As indicated previously, BMP signaling stimulates chondrocyte differentiation after the condensation stage [358,360]. In the sclerotome, Shh changes the compe-
tence of target cells to respond to BMP signaling. In the absence of Shh, BMP administration induces lateral plate gene expression in cultured PSM. After exposure to Shh, BMP signaling induces robust chondrogenesis instead [377]. It was recently shown that this Shh effect is mediated by the Bapxl transcription factor, which is essential for formation of the ventromedial elements of vertebrae [134]. Interestingly, Bapxl is a transcriptional repressor and probably acts by preventing expression of factors that interfere with the chondrogenic activity of BMPs [134]. Whether unrelated factors modulate a similar effect in ribs and limb cartilage elements is unknown. BMP signaling may stimulate chondrogenesis by stimulating Sox9 expression [378] or indirectly increasing Sox9 activity via regulation of the cAMP-dependent protein kinase (PKA). Indeed, cells of the prechondrogenic condensations are characterized by an increased level of intracellular cyclic AMP (cAMP) and activated PKA, and modulation of this intracellular signaling pathway has long been known to affect chondrogenesis [10]. Importantly, although this increase is seen at the condensation step, modulation of PKA activity does not affect the process of condensation but the subsequent progression from precartilage condensation to cartilage nodule [379]. Furthermore, PKA activation is induced by BMP signaling, and this activation is essential for the BMP-2-induced stimulation of chondogenesis to occur in vitro [380]. Finally, PKA phosphorylation of Sox9 increases its DNA binding and transcriptional activity [381]. Thus, one can hypothesize a molecular pathway in which BMP signaling stimulates PKA activity, which in turn increases Sox9 activity, thereby stimulating the transcription of chondrocyte-specific genes. However, Sox9 is not the only PKA target and other mechanisms are likely. For instance, PKA also phosphorylates the cAMP-response element (CRE)-binding protein, allowing it to bind the CRE and activate transcription of genes containing this regulatory sequence. During chondrogenesis, PKA also activates protein kinase Ca (PKCo0, and this activation leads to the downregulation of N-cadherin and fibronectin seen in differentiating chondrocytes [379]. PKC may also be involved in Wnt signaling and in this capacity may regulate chondrogenesis. The Writ genes encode a large family (19 members in mouse and humans) of cysteinerich secreted glycoproteins sharing homology with the Drosophila signaling factor wingless. Wnt proteins control morphogenesis and tissue patterning in a wide variety of organs [382]. Based on their biological activities in specific assays, Wnts have been divided into two functional groups, which sometimes display opposite effects. Wnt ligands interact with membrane receptors of the Frizzled (Fz) family and signal via one of two intracellular pathways. In the so-called canonical Wnt/~-catenin pathway, regulation of a number of intermediate effect-
3. Prenatal Bone Development
ors upon binding of the ligand to the receptor leads to cytoplasmic accumulation of [3-catenin. This protein eventually translocates to the nucleus to form an active transcription complex with LEF-1/TCFs factors. [3-Catenin transcriptional activity may also be regulated by adhesion molecules such as cadherins, which sequester catenins. In the Wnt/Ca 2+ pathway, signaling results in intracellular Ca 2§ release and activation of Ca2+-sensitive enzymes including PKC [383]. Ectopic expression of Wntl in developing chick limbs resulted in skeletal abnormalities consistent with a localized failure of cartilage formation [384]. Studies of Wnt activity in chick limb bud micromass cultures confirmed that Wnt l and Wnt7a inhibit chondrogenesis and that this inhibition occurs during the chondroblast differentiation stage [384,385]. However, it was also shown that BMP-induced chondrogenesis repressed WntTa expression but upregulated Wnt3a expression [386]. Thus, it is possible that different Wnt ligands will demonstrate opposite effects on chondrocyte differentiation. Two recent studies indicate that retinoid signaling via the retinoic acid receptor ot (RARo0 also acts to inhibit early chondrocyte differentiation [359,387]. These studies used a transgenic approach in the mouse to express a constitutively active RARot in the limb mesenchyme. Cells expressing the transgene did participate in mesenchymal condensations in vivo and in vitro but failed to differentiate into chondroblasts and maintained instead a prechondrogenic phenotype. In contrast, the addition of a RARoL-selective antagonist to cultures of these cells was sufficient to stimulate chondroblast differentiation and cartilage formation, even when BMP signaling was repressed. Furthermore, inhibition of RAR activity correlated with PKA activation, increased Sox9 expression, and enhanced Sox9 transcriptional activity [388]. In the developing mandibular process, Sox9 and the homeobox transcription factor Msx2 are induced by BMP-4, and the relative amount of these two factors appears to determine where chondrogenesis takes place [389]. These two factors are also expressed in a subpopulation of cranial neural crests cells that will populate the mandibular area. In this population, Msx2 represses chondrogenic differentiation until cell migration is completed within the mandibular primordium [390]. Msx factors generally act as repressors of transcription, but it is not known whether the antagonistic interaction between Sox9 and Msx2 is direct or mediated by other factors. A number of other factors inhibit chondrogenesis, including GDF11 in the limb [391], Hoxa2 in the second branchial arch [392], activin, and PDGF [9],but in most cases the stage at which inhibition takes place has not been precisely established.
101
Growth/Profiferation
The insulin-like growth factors 1 and 2 (IGF-1 and IGF-2) are part of a general growth-promoting system acting in utero and in postnatal development. These factors and their receptor (IGF-IR) are closely related in sequence and structure to insulin and the insulin receptor (IR), respectively. IR and IGF-1R are tyrosine kinase receptors, activated as heterotetrameric complexes, which act via the docking protein insulin receptor substrate 1 (IRS-1) to initiate signal transduction by the mitogen-activate protein kinase or the phosphatidyl-inositol 3 kinase pathways [393]. IGF-2 (and to a lesser degree IGF-1) also interacts with a second receptor, the mannose-6-phosphate/IGF-2 receptor (IGF-2R). This is a monomeric receptor devoid of a signaling domain. It essentially acts as a scavenger to prevent accumulation of toxic levels of IGF-2 (and possibly IGF-1) [393]. These receptors are ubiquitously expressed, indicating that insulin/IGF signaling acts on almost all cell types in the body, including the developing skeleton. IGF-1 is also produced in the liver, the main source of plasma IGF-1, and acts as an endocrine factor as well. However, recent studies showed that mouse embryos are not affected by a dramatic reduction of circulating levels of IGF-1, indicating the importance of the autocrine/paracrine role of local IGF signaling in prenatal development and growth [394,395]. In the growth plate of developing bones, IGF expression is stimulated by growth hormone. Gene inactivation studies in the mouse have confirmed the essential role of the IGF signaling pathway in development [396,397]. Igfl - / - mice are only 60% the size of their wild-type littermates at birth and most die soon after birth. The few mutants that survive remain severely growth retarded and exhibit developmental defects, supporting the involvement of IGF-1 signaling in prenatal and postnatal development. Null mutants for igf-2 display similar small size at birth but grow normally after birth, suggesting a more important role in intrauterine growth. Inactivation of the igf-lr gene leads to a more severe growth retardation (45% of normal birth weight) and perinatal lethality due to the loss of both IGF-1 and IGF-2 action. Finally, mice null for igf-2r exhibit a lethal fetal overgrowth syndrome. This lethal phenotype can be partially rescued by crossing the mutation onto a igf-2 null background, indicating that excess IGF-2 is detrimental to fetal development and that IGF-2R functions to prevents this from occurring. Although these effects are not skeletal specific, it is clear that chondrocyte proliferation in the developing endochondral bones is critically dependent on IGF signaling. FGF signaling is also recognized as an essential component of the control of chondrocyte proliferation [398]. The importance of this signaling pathway was first
102.
Benoit St.-Jacques and Jill A. Helms
revealed with the discovery that an autosomal dominant mutation in the transmembrane domain of the receptor FGF-R3 causes achondroplasia (ACH), the most common inheritable form of dwarfism in humans [399,400]. ACH is characterized by reduced growth of long bones, craniosomatic disproportions, and frontal bossing of the cranium. Interestingly, the mutation resulted in constitutive (ligand-independent) activation of FGF-R3. The related syndromes hypochondroplasia and thanatophoric dysplasia were later shown to also result from different activating mutations in FGF-R3 [398]. Furthermore, the degree of activation of the receptor was found to correlate with the severity of the chondrodysplasia. A number of mouse models harboring activating mutations in Fgf-r3 phenocopy many aspects of these diseases and confirm that reduced chondrocyte proliferation is the main cellular defect [401-407]. Conversely, Fgf-r3 inactivation in the mouse leads to increased proliferation and postnatal skeletal overgrowth [408,409]. Thus, a normal function of FGF-R3 signaling is to limit bone growth by negatively controlling chondrocyte proliferation in the growth plate. This is surprising in view of the fact that FGF signaling promotes proliferation in most cell types. This inhibitory signal could be a unique property of the FGF-R3 receptor or a peculiarity of the chondrocyte response to FGF signaling. Chondrocyte-specific expression of an activated chimeric FGF receptor containing the intracellular domain of FGF-R1 also resulted in an ACH phenotype [410]. This indicates that the response is not receptor but celltype specific. Several observations suggest that transcription factors of the signal transducer and activator of transcription (STAT) family are mediators of FGF action on chondrocytes. Activating mutations in FGF-R3 or treatment of cells with FGF induce nuclear translocation of STAT1, which in turn increases the expression of the cell cycle inhibitor p21 [411-413]. The Fgf-r3-induced ACH-like phenotypes created in mice also correlate with activation of STAT proteins and expression of cell cycle inhibitors [402,404]. Finally, in bone rudiments derived from STAT -/- animals, FGF treatment does not result in growth inhibition and crossing transgenic animals overexpressing FGF-2 into a STAT -/- background rescues the chondrodysplasia characteristic of this transgenic line [412,414]. Identification of the in vivo ligand(s) of FGF-R3 has been difficult. There are 22 known FGF ligands, many of which are expressed during endochondral ossification [398]. Furthermore, ectopic expression of Fgf-2 and Fgf-9 in the mouse led to skeletal dwarfism [415,416] but inactivation of these two genes does not affect the growth plate [226,417]. However, recent data show that growth plate histology of mice lacking Fgf-18 is similar to
that of mice lacking Fgf-r3, providing evidence for a ligand receptor relationship in the growth plate [418,419]. Part of the inhibitory effect of FGF-R3 signaling on growth plate chondrocytes is likely to be indirect and involve the regulation of expression of Indian hedgehog (Ihh). Ihh is a secreted protein closely related to Shh and signals via the same surface receptor complex composed of the multiple transmembrane proteins Patched- 1 (Ptch- 1) and Smoothened (Smo) [107]. Soon after mesenchymal condensation and the initiation of chondrocyte differentiation, Ihh becomes expressed in a broad domain in the center of each cartilage element. At that stage, Ptchl is expressed in a broader domain that encompasses almost all the chondrocytes, the future perichondrium, and some surrounding mesenchyme [420,421]. As chondrocytes in the center of each element mature and hypertrophy, Ihh expression becomes gradually restricted to the prehypertrophic chondrocytes, the more mature chondrocytes about to transition to hypertrophy and CollO expression, as well as some of the upper hypertrophic cells (Fig. 9). High levels of expression of Ptch-1 and Smo become restricted to the perichondrium but proliferating chondrocytes adjacent to the Ihh-expressing cells also continue to express the receptor complex [420-422]. Gene inactivation of Ihh leads to severe prenatal dwarfism due to a 50% decrease in chondrocyte proliferation in utero, suggesting that the prehypertrophic cells signal to maintain the high proliferation rate of Ptch-1/Smo-expressing chondrocytes [421] (Fig. 9). Recent results confirm that this interaction is direct. Chondrocyte-specific inactivation of Smo phenocopies the proliferation defect of the Ihh-deficient mice, whereas constitutive activation of Smo promotes chondrocyte proliferation [423]. Expression of the cell cycle regulator cyclin D1 is markedly downregulated when either Ihh or Smo activity is removed from chondrocytes, again supporting a direct regulation of proliferation by Ihh signaling [424]. In addition, although Ihh also controls chondrocyte maturation by regulating parathyroid hormone-related peptide (PTHrP) expression, its action on proliferation is independent of PTHrP [425]. Missense mutations in human IHH were found in three families segregating the autosomal dominant brachydactyly type A-l, characterized by shortening or the absence of the middle phalanges [426]. In addition, affected individuals in one family were significantly shorter than their nonaffected relatives, suggesting a defect in bone growth. A link between Ihh and FGF-R3 signaling is indicated by the observation that mice harboring an activating mutation in Fgf-r3 have decreased expression of Ihh, Ptch-1, and Bmp-4, whereas in Fgf-r3-deficient mice Ihh, Ptch-1, and Bmp-4 expression is upregulated [401,403,404].
3. Prenatal Bone Development
Chondrocyte Maturation PTHrP is a paracrine factor synthesized in a number of tissues that shares homology with PTH in its Nterminal domain and binds a common receptor, the PTH/PTHrP receptor 1 (PTH-R1) [196]. PTHrP was one of the first factors identified as a regulator of growth plate chondrocyte maturation. Targeting inactivation of the gene encoding either PTHrP or its receptor in the mouse resulted in a lethal phenotype characterized by skeletal dysplasia in which premature maturation of
FIGURE 9 Schematicrepresentation of the Ihh/PTHrP regulatory feedback loop controlling chondrocyte maturation in the growth plate. The diagram depicts the early growth plate of a long bone in a mouse embryo. The cartilage is surrounded by a perichondrium (pe), and zones of chondrocyte proliferation (p), maturation (m), prehypertrophy (p-hy), and hypertrophy (hy) can be seen. The cartilage matrix in the hypertrophic zone is calcified (gray shading). The primary ossification center where bone (b) is deposited by invading osteoblasts is also depicted at the bottom of the figure. Prehypertrophic chondrocytes express Ihh (dark gray shading). The Ihh signal acts directly on maturing and proliferating chondrocytes(1) expressingthe hedgehogreceptor complex Ptchl/Smo (light gray shading) and stimulates proliferation of these chondrocytes. Ihh also signals directly to perichondrial cells adjacent to the Ihh expression domain (2), and via the hedgehog signal transduction pathway it induces expression of TGF[32 in the perichondrium (3). Elevated TGF-[32upregulates Pthrp expression in cells of the articular perichondrium (4). PTHrP acts at a distance on proliferating chondrocytes expressing the Pthrl receptor (5) and slows their maturation into prehypertrophic chondrocytes (6), thus completing the negative feedback loop.
103
chondrocytes led to short-limb dwarfism and excessive bone formation at birth [427-429]. Conversely, misexpression of P T H r P in a mouse transgenic system significantly delayed chondrocyte maturation and bone formation such that mice were born with a completely cartilaginous endochondral skeleton [430]. In humans, inactivating mutations in P T H - R 1 cause Blomstrand chondrodysplasia characterized by advanced skeletal maturation with shortness of long bones and increased bone density [431-434], whereas mutations in PTH-R1 resulting in constitutive signaling cause a rare disorder, Jansen metaphyseal chondrodysplasia, characterized by widespread growth plate abnormalities including delayed mineralization [435,436]. Overexpression of a constitutively active receptor in the mouse reproduces several aspects of this disease [437]. A novel activating mutation in PTH-R1 was also identified in enchondromatosis, a condition characterized by the presence of benign cartilage tumors adjoining the growth plate [438]. Finally, PTHrP is a potent inhibitor of chondrocyte maturation in vitro [439,440]. In developing long bones in the mouse, Pthrp is expressed at highest levels by cells of the periarticular perichondrium, at the end of the bones, and at lower levels by the proliferating chondrocytes [28,428, 441443]. The Pthr-1 gene is expressed at low levels by proliferating chondrocytes and at high levels by the maturing chondrocytes adjacent to the Ihh-secreting cells [28,420,421,428,441,443--445]. Interestingly, this is where immunoreactivity for the PTHrP protein is highest [428,441], suggesting that Pthr-1 present on these maturing cells acts as a sink to prevent diffusion of the ligand and establish a sharp transition to below threshold levels of the ligand. These different observations suggested a model in which PTHrP, secreted mostly by cells of the periarticular perichondrium at the end of the developing long bones, diffuses through the zone of proliferating chondrocytes and acts on Pthr-l-expressing cells to prevent or slow their maturation into postmitotic hypertrophic chondrocytes [437,446]) (Fig. 9). A recent analysis of the fate of Pthr-1 - / - cells in chimeric mice supports this interpretation. Pthr-1 null cells undergo hypertrophy prematurely while still in the proliferative zone, surrounded by immature wild-type chondrocytes [422,447]. This confirms that Pthr-l-expressing proliferating chondrocytes are the direct target of PTHrP signaling in the developing growth plate and signaling through Pthr-1 acts in a cell autonomous manner to prevent hypertrophy. PTHrP acts, at least in part, by increasing PKA-dependent phosphorylation and transcriptional activity of Sox9 [448]. Although Sox9 is present in all nonhypertrophic chondrocytes of the growth plate, PKA-phosphorylated Sox9 is detected almost exclusively in the prehypertrophic cells expressing
104
Benoit St.-Jacques and Jill A. Helms
high levels of Pthr-1 and is not detectable in Pthr-1 null growth plates [448]. Interestingly, Pthrp expression appears to be controlled by Ihh signaling. The role of Ihh in skeletogenesis was first addressed experimentally in the chick embryo, in which it was shown that ectopic expression of Ihh prevented maturation of chondrocytes and the appearance of hypertrophic cells [445]. Moreover, the misexpression of Ihh was found to prevent the appearance of Ihh-positive chondrocytes, indicating that chondrocyte maturation was blocked early, before the transition to the prehypertrophic phenotype [445]. These phenotypic consequences of Ihh misexpression are the opposite of the phenotype resulting from inactivation of Pthrp in the mouse [28,427,429], suggesting a functional relationship between the two signaling pathways. Vortkamp and collaborators [445] showed that Ihh misexpression in the developing wing bones of the chick in fact led to upregulation of Pthrp expression by perichondrial cells adjacent to the articular surface. Using a murine limb ex vivo culture system [28], it was further shown that Hedgehog protein, like PTHrP, could prevent chondrocyte hypertrophy when added to the culture medium, but only when PTHrP signaling in the explants was intact [445]. Addition of Hedgehog protein to the culture medium of Pthrp -/- or Pthr-1 -/- explants did not prevent chondrocyte maturation. Thus, Ihh signaling appears to regulate chondrocyte maturation via its action on the PTHrP paracrine system by regulating Pthrp transcription. These observations led to a model in which Ihh and PTHrP regulate chondrocyte maturation through the establishment of a negative feedback mechanism [445] (Fig. 9). In this model, production of Ihh by prehypertrophic chondrocytes induces Pthrp expression at the periarticular surface. In turn, PTHrP signals to Pthr/-positive chondrocytes, preventing additional proliferating chondrocytes from initiating maturation and delaying the production of new cells expressing Ihh. As prehypertrophic chondrocytes progress to the hypertrophic state, they stop expressing Ihh, thereby attenuating the negative feedback mechanism. This allows new proliferating chondrocytes to initiate maturation and exit proliferation. This mechanism ensures coordination of the rates of chondrocyte proliferation and maturation throughout development. Inactivation of the Ihh gene in the mouse results in the absence of Pthrp expression leading to ectopic chondrocyte maturation, thus confirming the main features of the model [421]. There is evidence that this regulatory network is also active in the postnatal growth plate [449,450]. Because the Ihh receptor complex Ptch-1/Smo is expressed at high levels in the perichondrium, it was suggested that Ihh signals through this tissue to control Pthrp expression [445]. Recently, TGF-[32 was identified
as a perichondrial relay between these two factors [451-454].
References 1. Shilo, B.-Z. (2001). The organizer and beyond. Cell 106, 17-22. 2. Karsenty, G. (1999). The genetic transformation of bone biology. Genes Dev. 13, 3037-3051. 3. Mundlos, S., and Olsen, B. R. (1997). Heritable diseases of the skeleton. Part I: Molecular insights into skeletal developmentTranscription factors and signaling pathways. FASEB J. 11, 125-132. 4. Mundlos, S., and Olsen, B. R. (1997). Heritable diseases of the skeleton. Part II: Molecular insights into skeletal developmentMatrix components and their homeostasis. FASEB J. 11,227-233. 5. Hall, B. K., and Miyake, T. (2000). All for one and one for all: Condensations and the initiation of skeletal development. Bioessays 22, 138-147. 6. Karsenty, G. (1998). Genetics of skeletogenesis. Dev. Genet. 22, 301-313. 7. Olsen, B. R., Reginato, A. M., and Wang, W. (2000). Bone development. Annu. Rev. Cell Dev. Biol. 16, 191-220. 8. Olsen, B. R. (1999). Genetic regulation of skeletal patterning, differentiation, and growth. Bone 25, 77-79. 9. Sandell, L. J., and Adler, P. (1999). Developmental patterns of cartilage. Frontiers Biosci. 4, D731-D742. 10. DeLise, A. M., Fischer, L., and Tuan, R. S. (2000). Cellular interactions and signaling in cartilage development. Osteoarthritis Cartilage 8, 309-334. 11. Poole, A. R., Laverty, S., and Mwale, F. (2000). Endochondral bone formation and development of the axial and appendicular skeleton. In The Osteoporosis Primer (J. E. Henderson and D. Goltzman, Eds.), pp. 3-17. Cambridge Univ. Press, Cambridge, UK. 12. Karsenty, G. (2001). Genetic control of skeletal development. Novartis Foundation Symp. 232, 6-17; Discussion 17-22. 13. McLean, W., and Olsen, B. R. (2001). Mouse models of abnormal skeletal development and homeostasis. Trends Genet. 17, $38-$43. 14. Wagner, E. F., and Karsenty, G. (2001). Genetic control of skeletal development. Curr. Opin. Genet. Dev. 11, 527-532. 15. Shum, L., and Nuckolls, G. (2002). The life cycle of chondrocytes in the developing skeleton. Arthritis Res. 4, 94-106. 16. Ho, N. C., Jia, L., Driscoll, C. C., Gutter, E. M., and Francomano, C. A. (2000). A skeletal gene database. J. Bone Miner. Res. 15, 2095-2096. 17. Carroll, R. L. (1988). Vertebrate Paleontology and Evolution. Freeman, New York. 18. Patterson, C. (1977). Cartilage bones, dermal bones, and membrane bones, or the exoskeleton versus the endoskeleton. In Problems in Vertebrate Evolution (S. Andrews, R. Miles, and A. Walker, Eds.), pp. 77-121. Academic Press, London. 19. Gardner, E. (1971). Osteogenesis in the human embryo and fetus. In The Biochemistry and Physiology of Bone (G. H. Bourne, Ed.), pp. 77-118. Academic Press, New York. 20. Thompson, T. J., Owens, P. D., and Wilson, D. J. (1989). Intramembranous osteogenesis and angiogenesis in the chick embryo. J. Anat. 166, 55-65. 21. Pritchard, J. J. (1972). General histology of bone. In The Biochemistry and Physiology of Bone (G. H. Bourne, Ed.), pp. 1-20. Academic Press, New York. 22. Cormack, D. H. (1987). Ham's Histology. Lippincott, Philadelphia. 23. Thorogood, P. V., and Hinchliffe, J. R. (1975). An analysis of the condensation process during chondrogenesis in the embryonic chick hind limb. J. Embryol. Exp. Morphol. 33, 581-606.
3. Prenatal Bone Development 24. Ede, D. A. (1983). Cellular condensations and chondrogenesis. In Cartilage Development, Differentiation, and Growth (B. K. Hall, Ed.), Vol. 2, pp. 143-185. Academic Press, New York. 25. Caplan, A. I., and Pechak, D. G. (1987). The cellular and molecular embryology of bone formation. In Bone and Mieral Research (W. A. Peck, Ed.), Vol. 5, pp. 117-183. Elsevier, New York. 26. Poole, A. R. (1991). The growth plate: Cellular physiology, cartilage assembly and mineralization. In Cartilage: Molecular Aspects (S. Newman, Ed.), pp. 179-211. CRC Press, Boca Raton, FL. 27. Vu, T. H., Shipley, J. M., Bergers, G., Berger, J. E., Helms, J. A., Hanahan, D., Shapiro, S. D., Senior, R. M., and Werb, Z. (1998). MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 93, 411-422. 28. Lee, K., Deeds, J. D., and Segre, G. V. (1995). Expression of parathyroid hormone-related peptide and its receptor messenger ribonucleic acids during fetal development of rats. Endocrinology 136, 453-463. 29. Sadler, T. W. (2000). Langman's Medical Embryology. Lippincott Williams & Wilkins, Philadelphia. 30. Lemire, R. J. (2000). Embryology of the skull. In Craniosynostosis: Diagnosis, Evaluation, and Management (M. M. Cohen, Jr., and R. E. MacLean, Eds.), 2nd ed., pp. 24-34. Oxford Univ. Press, Oxford, UK. 31. Noback, C. R., and Robertson, G. G. (1951). Sequence of appearance of ossification centers in the human skeleton during the first five prenatal months. Am. J. Anat. 89, 1-28. 32. O'Rahilly, R., and Gardner, E. (1972). The initial appearance of ossification in staged human embryos. Am. J. Anat. 134, 291-307. 33. Kaufman, M. H. (1994). The Atlas of Mouse Development. Academic Press, San Diego. 34. Sperber, G. H. (1989). Craniofacial Embryology. Wright, London. 35. Dixon, A. D. (1997). Prenatal development of the facial skeleton. In Fundamentals of Craniofacial Growth (A. D. Dixon, D. A. N. Hoyte, and O. Ronning, Eds.), pp. 59-97. CRC Press, Boca Raton, FL. 36. Carlson, B. M. (1999). Human Embryology and Developmental Biology. Mosby, St. Louis. 37. Dixon, A. D. (1997). Formation of the cranial base and craniofacial joints. In Fundamentals of Craniofacial Growth (A. D. Dixon, D. A. N. Hoyte, and O. Ronning, Eds.), pp. 99-136. CRC Press, Boca Raton, FL. 38. Thorogood, P. (1988). The developmental specification of the vertebrate skull. Development 103, 141-153. 39. Hamilton, W. J., Boyd, J. D., and Mossman, H. W. (1976). Human Embryology. Macmillan, London. 40. Rodriguez-Vazquez, J. F., Merida-Velasco, J. R., MeridaVelasco, J. A., Sanchez-Montesinos, I., Espin-Ferra, J., and Jimenez-Collado, J. (1997). Development of Meckel's cartilage in the symphyseal region in man. Anat. Rec. 249, 249-254. 41. Harada, Y., and Ishizeki, K. (1998). Evidence for transformation of chondrocytes and site-specific resorption during the degradation of Meckel's cartilage. Anat. Embryol. (Berlin) 197, 439-450. 42. Trichilis, A., and Wroblewski, J. (1997). Expression of p53 and hsp70 in relation to apoptosis during Meckel's cartilage development in the mouse. Anat. Embryol. (Berlin) 196, 107-113. 43. Cohen, M. M. (2000). Sutural biology. In Craniosynostosis: Diagnosis, Evaluation, and Management (M. M. Cohen and R. E. MacLean, Eds.), 2nd ed., pp. 11-23. Oxford Univ. Press, Oxford, UK. 44. Johansen, V. A., and Hall, S. H. (1982). Morphogenesis of the mouse coronal suture. Acta Anat. (Basel) 114, 58-67. 45. Decker, J. D., and Hall, S. H. (1985). Light and electron microscopy of the newborn saggital suture. Anat. Rec. 212, 81-89. 46. Pritchard, J. J., Scott, J. H., and Girgis, F. G. (1956). The structure and development of cranial and facial sutures. J. Anat. 90, 73-86.
105
47. Dixon, A. D., Hoyte, D. A. N., and Ronning, O. (1997). Fundamentals of Craniofacial Growth. CRC Press, Boca Raton, FL. 48. Noden, D. M. (1983). The role of the neural crest in patterning of avian cranial skeletal, connective, and muscle tissues. Dev. Biol. 96, 144-165. 49. Le Douarin, N. M., and Kalcheim, C. (1999). The Neural Crest. Cambridge Univ. Press, Cambridge, UK. 50. Couly, G. F., Coltey, P. M., and Le Douarin, N. M. (1993). The triple origin of skull in higher vertebrates: A study in quail-chick chimeras. Development 117, 409-429. 51. Le Douarin, N. M., Ziller, C., and Couly, G. F. (1993). Patterning of neural crest derivatives in the avian embryo: In vivo and in vitro studies. Dev. Biol. 159, 24-49. 52. Jiang, X., Rowitch, D. H., Soriano, P., McMahon, A. P., and Sucov, H. M. (2000). Fate of the mammalian cardiac neural crest. Development 127, 1607-1616. 53. Chai, Y., Jiang, X., Ito, Y., Bringas, P., Jr., Han, J., Rowitch, D. H., Soriano, P., McMahon, A. P., and Sucov, H. M. (2000). Fate of the mammalian cranial neural crest during tooth and mandibular morphogenesis. Development 127, 1671-1679. 54. Jiang, X., Iseki, S., Maxson, R. E., Sucov, H. M., and MorrissKay, G. M. (2002). Tissue origins and interactions in the mammalian skull vault. Dev. Biol. 241, 106-116. 55. Mavrogiannis, L. A., Antonopoulou, I., Baxova, A., Kutilek, S., Kim, C. A., Sugayama, S. M., Salamanca, A., Wall, S. A., MorrissKay, G. M., and Wilkie, A. O. (2001). Haploinsufficiency of the human homeobox gene ALX4 causes skull ossification defects. Nature Genet. 27, 17-18. 56. LaBonne, C., and Bronner-Fraser, M. (1999). Molecular mechanisms of neural crest formation. Annu. Rev. CellDev. Biol. 15, 81-112. 57. Maschhoff, K. L., and Baldwin, H. S. (2000). Molecular determinants of neural crest migration. Am. J. Med. Genet. 97, 280-288. 58. Nieto, M. A. (2001). The early steps of neural crest development. Mech. Dev. 105, 27-35. 59. Krull, C. E. (2001). Segmental organization of neural crest migration. Mech. Dev. 105, 37-45. 60. Streit, A., and Stern, C. D. (1999). Establishment and maintenance of the border of the neural plate in the chick: Involvement of FGF and BMP activity. Mech. Dev. 82, 51-66. 61. Selleck, M. A., Garcia-Castro, M. I., Artinger, K. B., and BronnerFraser, M. (1998). Effects of Shh and Noggin on neural crest formation demonstrate that BMP is required in the neural tube but not ectoderm. Development 125, 4919-4930. 62. Ikeya, M., Lee, S. M., Johnson, J. E., McMahon, A. P., and Takada, S. (1997). Wnt signalling required for expansion of neural crest and CNS progenitors. Nature 389, 966-970. 63. Nieto, M. A., Sargent, M. G., Wilkinson, D. G., and Cooke, J. (1994). Control of cell behavior during vertebrate development by Slug, a zinc finger gene. Science 264, 835-839. 64. Sefton, M., Sanchez, S., and Nieto, M. A. (1998). Conserved and divergent roles for members of the Snail family of transcription factors in the chick and mouse embryo. Development 125, 3111-3121. 65. Locascio, A., and Nieto, M. A. (2001). Cell movements during vertebrate development: Integrated tissue behaviour versus individual cell migration. Curt. Opin. Genet. Dev. 11, 464-469. 66. Perris, R., and Perissinotto, D. (2000). Role of the extracellular matrix during neural crest cell migration. Mech. Dev. 95, 3-21. 67. Noden, D. M. (1986). Origins and patterning of craniofacial mesenchymal tissues. J. Craniofacial Genet. Dev. Biol. Suppl. 2, 15-31. 68. Trainor, P. A., and Krumlauf, R. (2000). Patterning the cranial neural crest: Hindbrain segmentation and Hox gene plasticity. Nat. Rev. Neurosci. 1, 116-124.
106
Benoit St.-Jacques and Jill A. Helms
69. Trainor, P. A., Ariza-McNaughton, L., and Krumlauf, R. (2002). Role of the isthmus and FGFs in resolving the paradox of neural crest plasticity and prepatterning. Science 295, 1288-1291. 70. Couly, G., Creuzet, S., Bennaceur, S., Vincent, C., and Le Douarin, N. M. (2002). Interactions between Hox-negative cephalic neural crest cells and the foregut endoderm in patterning the facial skeleton in the vertebrate head. Development 129, 1061-1073. 71. Schneider, R. A., Hu, D., and Helms, J. A. (1999). From head to toe: Conservation of molecular signals regulating limb and craniofacial morphogenesis. Cell Tissue Res. 296, 103-109. 72. Helms, J. A., Kim, C. H., Hu, D., Minkoff, R., Thaller, C., and Eichele, G. (1997). Sonic hedgehog participates in craniofacial morphogenesis and is down-regulated by teratogenic doses of retinoic acid. Dev. Biol. 187, 25-35. 73. Barlow, A. J., and Francis-West, P. H. (1997). Ectopic application of recombinant BMP-2 and BMP-4 can change patterning of developing chick facial primordia. Development 124, 391-398. 74. Hu, D., and Helms, J. A. (1999). The role of sonic hedgehog in normal and abnormal craniofacial morphogenesis. Development 126, 4873-4884. 75. Shigetani, Y., Nobusada, Y., and Kuratani, S. (2000). Ectodermally derived FGF8 defines the maxillomandibular region in the early chick embryo: Epithelial-mesenchymal interactions in the specification of the craniofacial ectomesenchyme. Dev. Biol. 228, 73-85. 76. Schneider, R. A., Hu, D., Rubenstein, J. L., Maden, M., and Helms, J. A. (2001). Local retinoid signaling coordinates forebrain and facial morphogenesis by maintaining FGF8 and SHH. Development 128, 2755-2767. 77. Lee, S. H., Fu, K. K., Hui, J. N., and Richman, J. M. (2001). Noggin and retinoic acid transform the identity of avian facial prominences. Nature 414, 909-912. 78. Trainor, P. A., and Krumlauf, R. (2001). Hox genes, neural crest cells and branchial arch patterning. Curr. Opin. Cell. Biol. 13, 698-705. 79. Hall, B. K. (1978). Developmental and Cellular Skeletal Biology. Academic Press, New York. 80. Tyler, M. S. (1983). Development of the frontal bone and cranial meninges in the embryonic chick: An experimental study of tissue interactions. Anat. Rec. 206, 61-70. 81. Brand-Saberi, B., and Christ, B. (2000). Evolution and development of distinct cell lineages derived from somites. Curr. Topics Dev. Biol. 48, 1-42. 82. Monsoro-Burq, A. H., and Le Douarin, N. (2000). Duality of molecular signaling involved in vertebral chondrogenesis. Curr. Topics Dev. Biol. 48, 43-75. 83. Christ, B., and Wilting, J. (1992). From somites to vertebral column. Anat. Anz. 174, 23-32. 84. Huang, R., Zhi, Q., Schmidt, C., Wilting, J., Brand-Saberi, B., and Christ, B. (2000). Sclerotomal origin of the ribs. Development 127, 527-532. 85. Christ, B., Huang, R., and Wilting, J. (2000). The development of the avian vertebral column. Anat. Embryol. (Berlin) 202, 179-194. 86. McLachlan, J. (1994). Medical Embryology. Addison-Wesley, Workingham, UK. 87. Huang, R., Zhi, Q., Brand-Saberi, B., and Christ, B. (2000). New experimental evidence for somite resegmentation. Anat. Embryol. (Berlin) 202, 195-200. 88. Palmeirim, I., Henrique, D., Ish-Horowicz, D., and Pourquie, O. (1997). Avian hairy gene expression identifies a molecular clock linked to vertebrate segmentation and somitogenesis. Cell 91, 639-648. 89. Pourquie, O. (1999). Notch around the clock. Curt. Opin. Genet. Dev. 9, 559-565.
90. McGrew, M. J., Dale, J. K., Fraboulet, S., and Pourquie, O. (1998). The lunatic fringe gene is a target of the molecular clock linked to somite segmentation in avian embryos. Curr. Biol. 8, 979-982. 91. Barrantes, I. B., Elia, A. J., Wunsch, K., De Angelis, M. H., Mak, T. W., Rossant, J., Conlon, R. A., Gossler, A., and de la Pompa, J. L. (1999). Interaction between Notch signalling and Lunatic fringe during somite boundary formation in the mouse. Curr. Biol. 9, 470-480. 92. Donoviel, D. B., Hadjantonakis, A. K., Ikeda, M., Zheng, H., Hyslop, P. S., and Bernstein, A. (1999). Mice lacking both presenilin genes exhibit early embryonic patterning defects. Genes Dev. 13, 2801-2810. 93. Krebs, L. T., Xue, Y., Norton, C. R., Shutter, J. R., Maguire, M., Sundberg, J. P., Gallahan, D., Closson, V., Kitajewski, J., Callahan, R., Smith, G. H., Stark, K. L., and Gridley, T. (2000). Notch signaling is essential for vascular morphogenesis in mice. Genes Dev. 14, 1343-1352. 94. Saga, Y., Hata, N., Koseki, H., and Taketo, M. M. (1997). Mesp2: A novel mouse gene expressed in the presegmented mesoderm and essential for segmentation initiation. Genes Dev. 11, 1827-1839. 95. Zhang, N., Norton, C. R., and Gridley, T. (2002). Segmentation defects of Notch pathway mutants and absence of a synergistic phenotype in lunatic fringe/radical fringe double mutant mice. Genesis 33, 21-28. 96. Yoon, J. K., and Wold, B. (2000). The bHLH regulator pMesogeninl is required for maturation and segmentation of paraxial mesoderm. Genes Dev. 14, 3204-3214. 97. Bulman, M. P., Kusumi, K., Frayling, T. M., McKeown, C., Garrett, C., Lander, E. S., Krumlauf, R., Hattersley, A. T., Ellard, S., and Turnpenny, P. D. (2000). Mutations in the human delta homologue, DLL3, cause axial skeletal defects in spondylocostal dysostosis. Nature Genet. 24, 438-441. 98. Li, L., Krantz, I. D., Deng, Y., Genin, A., Banta, A. B., Collins, C. C., Qi, M., Trask, B. J., Kuo, W. L., Cochran, J., Costa, T., Pierpont, M. E., Rand, E. B., Piccoli, D. A., Hood, L., and Spinner, N. B. (1997). Alagille syndrome is caused by mutations in human Jaggedl, which encodes a ligand for Notchl. Nature Genet. 16, 243-251. 99. Oda, T., Elkahloun, A. G., Pike, B. L., Okajima, K., Krantz, I. D., Genin, A., Piccoli, D. A., Meltzer, P. S., Spinner, N. B., Collins, F. S., and Chandrasekharappa, S. C. (1997). Mutations in the human Jaggedl gene are responsible for Alagille syndrome. Nature Genet. 16, 235-242. 100. Durbin, L., Brennan, C., Shiomi, K., Cooke, J., Barrios, A., Shanmugalingam, S., Guthrie, B., Lindberg, R., and Holder, N. (1998). Eph signaling is required for segmentation and differentiation of the somites. Genes Dev. 12, 3096-3109. 101. Holder, N., and Klein, R. (1999). Eph receptors and ephrins: Effectors of morphogenesis. Development 126, 2033-2044. 102. Durbin, L., Sordino, P., Barrios, A., Gering, M., Thisse, C., Thisse, B., Brennan, C., Green, A., Wilson, S., and Holder, N. (2000). Anteroposterior patterning is required within segments for somite boundary formation in developing zebrafish. Development 127, 1703-1713. 103. Dubrulle, J., McGrew, M. J., and Pourquie, O. (2001). FGF signaling controls somite boundary position and regulates segmentation clock control of spatiotemporal Hox gene activation. Cell 106, 219-232. 104. Sawada, A., Shinya, M., Jiang, Y. J., Kawakami, A., Kuroiwa, A., and Takeda, H. (2001). Fgf/MAPK signalling is a crucial positional cue in somite boundary formation. Development 128, 4873-4880. 105. Yamaguchi, T. P., Harpal, K., Henkemeyer, M., and Rossant, J. (1994). fgfr-1 is required for embryonic growth and mesodermal patterning during mouse gastrulation. Genes Dev. 8, 3032-3044.
3. Prenatal Bone Development 106. Burgess, R., Rawls, A., Brown, D., Bradley, A., and Olson, E. N. (1996). Requirement of the paraxis gene for somite formation and musculoskeletal patterning. Nature 384, 570-573. 107. Ingham, P. W., and McMahon, A. P. (2001). Hedgehog signaling in animal development: Paradigms and principles. Genes Dev. 15, 3059-3087. 108. Zimmerman, L. B., De Jesus-Escobar, J. M., and Harland, R. M. (1996). The Spemann organizer signal noggin binds and inactivates bone morphogenetic protein 4. Cell 86, 599-606. 109. Lee, C. S., Buttitta, L. A., May, N. R., Kispert, A., and Fan, C. M. (2000). SHH-N upregulates Sfrp2 to mediate its competitive interaction with WNT1 and WNT4 in the somitic mesoderm. Development 127, 109-118. 110. Fan, C. M., and Tessier-Lavigne, M. (1994). Patterning of mammalian somites by surface ectoderm and notochord: Evidence for sclerotome induction by a hedgehog homolog. Cell 79, 1175-1186. 111. Johnson, R. L., Laufer, E., Riddle, R. D., and Tabin, C. (1994). Ectopic expression of Sonic hedgehog alters dorsal-ventral patterning of somites. Cell 79, 1165-1173. 112. Fan, C. M., Porter, J. A., Chiang, C., Chang, D. T., Beachy, P. A., and Tessier-Lavigne, M. (1995). Long-range sclerotome induction by sonic hedgehog: Direct role of the amino-terminal cleavage product and modulation by the cyclic AMP signaling pathway. Cell 81, 457-465. 113. Chiang, C., Litingtung, Y., Lee, E., Young, K. E., Corden, J. L., Westphal, H., and Beachy, P. A. (1996). Cyclopia and defective axial patterning in mice lacking Sonic hedgehog gene function. Nature 383, 407-413. 114. McMahon, J. A., Takada, S., Zimmerman, L. B., Fan, C. M., Harland, R. M., and McMahon, A. P. (1998). Noggin-mediated antagonism of BMP signaling is required for growth and patterning of the neural tube and somite. Genes Dev. 12, 1438-1452. 115. Teillet, M., Watanabe, Y., Jeffs, P., Duprez, D., Lapointe, F., and Le Douarin, N. M. (1998). Sonic hedgehog is required for survival of both myogenic and chondrogenic somitic lineages. Development 125, 2019-2030. 116. Munsterberg, A. E., Kitajewski, J., Bumcrot, D. A., McMahon, A. P., and Lassar, A. B. (1995). Combinatorial signaling by Sonic hedgehog and Wnt family members induces myogenic bHLH gene expression in the somite. Genes Dev. 9, 2911-2922. 117. Hirsinger, E., Duprez, D., Jouve, C., Malapert, P., Cooke, J., and Pourquie, O. (1997). Noggin acts downstream of Wnt and Sonic Hedgehog to antagonize BMP4 in avian somite patterning. Development 124, 4605-4614. 118. Peters, H., Wilm, B., Sakai, N., Imai, K., Maas, R., and Bailing, R. (1999). Paxl and Pax9 synergistically regulate vertebral column development. Development 126, 5399-5408. 119. Mo, R., Freer, A. M., Zinyk, D. L., Crackower, M. A., Michaud, J., Heng, H. H., Chik, K. W., Shi, X. M., Tsui, L. C., Cheng, S. H., Joyner, A. L., and Hui, C. (1997). Specific and redundant functions of Gli2 and Gli3 zinc finger genes in skeletal patterning and development. Development 124, 113-123. 120. Johnson, R. L., Rothman, A. L., Xie, J., Goodrich, L. V., Bare, J. W., Bonifas, J. M., Quinn, A. G., Myers, R. M., Cox, D. R., Epstein, E. H., Jr., and Scott, M. P. (1996). Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science 272, 1668-1671. 121. Hahn, H., Wicking, C., Zaphiropoulous, P. G., Gailani, M. R., Shanley, S., Chidambaram, A., Vorechovsky, I., Holmberg, E., Unden, A. B., Gillies, S., Negus, K., Smyth, I., Pressman, C., Leffell, D. J., Gerrard, B., Goldstein, A. M., Dean, M., Toftgard, R., Chenevix-Trench, G., Wainwright, B., and
107
Bale, A. E. (1996). Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 85, 841-851. 122. Gunther, T., Struwe, M., Aguzzi, A., and Schughart, K. (1994). Open brain, a new mouse mutant with severe neural tube defects, shows altered gene expression patterns in the developing spinal cord. Development 120, 3119-3130. 123. Sporle, R., and Schughart, K. (1998). Paradox segmentation along inter- and intrasomitic borderlines is followed by dysmorphology of the axial skeleton in the open brain (opb) mouse mutant. Dev. Genet. 22, 359-373. 124. Eggenschwiler, J. T., Espinoza, E., and Anderson, K. V. (2001). Rab23 is an essential negative regulator of the mouse Sonic hedgehog signalling pathway. Nature 412, 194-198. 125. Brunet, L. J., McMahon, J. A., McMahon, A. P., and Harland, R. M. (1998). Noggin, cartilage morphogenesis, and joint formation in the mammalian skeleton. Science 280, 1455-1457. 126. Chalepakis, G., Fritsch, R., Fickenscher, H., Deutsch, U., Goulding, M., and Gruss, P. (1991). The molecular basis of the undulated/Pax-1 mutation. Cell 66, 873-884. 127. Koseki, H., Wallin, J., Wilting, J., Mizutani, Y., Kispert, A., Ebensperger, C., Herrmann, B. G., Christ, B., and Bailing, R. (1993). A role for Pax-1 as a mediator of notochordal signals during the dorsoventral specification of vertebrae. Development 119, 649-660. 128. Dietrich, S., Schubert, F. R., and Gruss, P. (1993). Altered Pax gene expression in murine notochord mutants: The notochord is required to initiate and maintain ventral identity in the somite. Mech. Dev. 44, 189-207. 129. Dietrich, S., and Gruss, P. (1995). Undulated phenotypes suggest a role of Pax- 1 for the development of vertebral and extravertebral structures. Dev. Biol. 167, 529-548. 130. Wallin, J., Wilting, J., Koseki, H., Fritsch, R., Christ, B., and Bailing, R. (1994). The role of Pax-1 in axial skeleton development. Development 120, 1109-1121. 131. Wilm, B., Dahl, E., Peters, H., Bailing, R., and Imai, K. (1998). Targeted disruption of Paxl defines its null phenotype and proves haploinsufficiency. Proc. Natl. Acad. Sci. USA 95, 8692-8697. 132. Peters, H., Neubuser, A., Kratochwil, K., and Bailing, R. (1998). Pax9-deficient mice lack pharyngeal pouch derivatives and teeth and exhibit craniofacial and limb abnormalities. Genes Dev. 12, 2735-2747. 133. Stockton, D. W., Das, P., Goldenberg, M., D'Souza, R. N., and Patel, P. I. (2000). Mutation of PAX9 is associated with oligodontia. Nature Genet. 24, 18-19. 134. Murtaugh, L. C., Zeng, L., Chyung, J. H., and Lassar, A. B. (2001). The chick transcriptional repressor Nkx3.2 acts downstream of Shh to promote BMP-dependent axial chondrogenesis. Dev. Cell 1, 411-422. 135. Lettice, L. A., Purdie, L. A., Carlson, G. J., Kilanowski, F., Dorin, J., and Hill, R. E. (1999). The mouse bagpipe gene controls development of axial skeleton, skull, and spleen. Proc. Natl. Acad. Sci. USA 96, 9695-9700. 136. Tribioli, C., and Lufkin, T. (1999). The murine Bapxl homeobox gene plays a critical role in embryonic development of the axial skeleton and spleen. Development 126, 5699-5711. 137. Akazawa, H., Komuro, I., Sugitani, Y., Yazaki, Y., Nagai, R., and Noda, T. (2000). Targeted disruption of the homeobox transcription factor Bapxl results in lethal skeletal dysplasia with asplenia and gastroduodenal malformation. Genes Cells 5, 499-513. 138. Leitges, M., Neidhardt, L., Haenig, B., Herrmann, B. G., and Kispert, A. (2000). The paired homeobox gene Uncx4.1 specifies
108
Benoit St.-Jacques and Jill A. Helms
pedicles, transverse processes and proximal ribs of the vertebral column. Development 127, 2259-2267. 139. Mansouri, A., Voss, A. K., Thomas, T., Yokota, Y., and Gruss, P. (2000). Uncx4.1 is required for the formation of the pedicles and proximal ribs and acts upstream of Pax9. Development 127, 2251-2258. 140. Lettice, L., Hecksher-Sorensen, J., and Hill, R. (2001). The role of Bapxl (Nkx3.2) in the development and evolution of the axial skeleton. J. Anat. 199, 181-187. 141. Furumoto, T. A., Miura, N., Akasaka, T., Mizutani-Koseki, Y., Sudo, H., Fukuda, K., Maekawa, M., Yuasa, S., Fu, Y., Moriya, H., Taniguchi, M., Imai, K., Dahl, E., Bailing, R., Pavlova, M., Gossler, A., and Koseki, H. (1999). Notochorddependent expression of MFH1 and PAX1 cooperates to maintain the proliferation of sclerotome cells during the vertebral column development. Dev. Biol. 210, 15-29. 142. Iida, K., Koseki, H., Kakinuma, H., Kato, N., MizutaniKoseki, Y., Ohuchi, H., Yoshioka, H., Noji, S., Kawamura, K., Kataoka, Y., Ueno, F., Taniguchi, M., Yoshida, N., Sugiyama, T., and Miura, N. (1997). Essential roles of the winged helix transcription factor MFH-1 in aortic arch patterning and skeletogenesis. Development 124, 4627-4638. 143. Winnier, G. E., Hargett, L., and Hogan, B. L. (1997). The winged helix transcription factor MFH1 is required for proliferation and patterning of paraxial mesoderm in the mouse embryo. Genes Dev. 11, 926-940. 144. Kume, T., Deng, K. Y., Winfrey, V., Gould, D. B., Walter, M. A., and Hogan, B. L. (1998). The forkhead/winged helix gene Mfl is disrupted in the pleiotropic mouse mutation congenital hydrocephalus. Cell 93, 985-996. 145. Fang, J., Dagenais, S. L., Erickson, R. P., Arlt, M. F., Glynn, M. W., Gorski, J. L., Seaver, L. H., and Glover, T. W. (2000). Mutations in FOXC2 (MFH-1), a forkhead family transcription factor, are responsible for the hereditary lymphedema-distichiasis syndrome. Am. J. Hum. Genet. 67, 1382-1388. 146. Kume, T., Jiang, H., Topczewska, J. M., and Hogan, B. L. (2001). The murine winged helix transcription factors, Foxcl and Foxc2, are both required for cardiovascular development and somitogenesis. Genes Dev. 15, 2470-2482. 147. Cserjesi, P., Brown, D., Ligon, K. L., Lyons, G. E., Copeland, N. G., Gilbert, D. J., Jenkins, N. A., and Olson, E. N. (1995). Scleraxis: A basic helix-loop-helix protein that prefigures skeletal formation during mouse embryogenesis. Development 121, 1099-1110. 148. Brown, D., Wagner, D., Li, X., Richardson, J. A., and Olson, E. N. (1999). Dual role of the basic helix-loop-helix transcription factor scleraxis in mesoderm formation and chondrogenesis during mouse embryogenesis. Development 126, 4317-4329. 149. Watanabe, Y., and Le Douarin, N. M. (1996). A role for BMP-4 in the development of subcutaneous cartilage. Mech. Dev. 57, 69-78. 150. Monsoro-Burq, A. H., Duprez, D., Watanabe, Y., Bontoux, M., Vincent, C., Brickell, P., and Le Douarin, N. (1996). The role of bone morphogenetic proteins in vertebral development. Development 122, 3607-3616. 151. Watanabe, Y., Duprez, D., Monsoro-Burq, A. H., Vincent, C., and Le Douarin, N. M. (1998). Two domains in vertebral development: Antagonistic regulation by SHH and BMP4 proteins. Development 125, 2631-2639. 152. Braun, T., Rudnicki, M. A., Arnold, H. H., and Jaenisch, R. (1992). Targeted inactivation of the muscle regulatory gene Myf5 results in abnormal rib development and perinatal death. Cell 71, 369-382. 153. Dickman, E. D., Rogers, R., and Conway, S. J. (1999). Abnormal skeletogenesis occurs coincident with increased apoptosis in the
Splotch (Sp2H) mutant: Putative roles for Pax3 and PDGFRalpha in rib patterning. Anat. Rec. 255, 353-361. 154. Henderson, D. J., Conway, S. J., and Copp, A. J. (1999). Rib truncations and fusions in the Sp2H mouse reveal a role for Pax3 in specification of the ventro-lateral and posterior parts of the somite. Dev. Biol. 209, 143-158. 155. Soriano, P. (1997). The PDGF alpha receptor is required for neural crest cell development and for normal patterning of the somites. Development 124, 2691-2700. 156. Tallquist, M. D., Weismann, K. E., Hellstrom, M., and Soriano, P. (2000). Early myotome specification regulates PDGFA expression and axial skeleton development. Development 127, 5059-5070. 157. Grass, S., Arnold, H. H., and Braun, T. (1996). Alterations in somite patterning of Myf-5-deficient mice: A possible role for FGF-4 and FGF-6. Development 122, 141-150. 158. Hatta, K., Takagi, S., Fujisawa, H., and Takeichi, M. (1987). Spatial and temporal expression pattern of N-cadherin cell adhesion molecules correlated with morphogenetic processes of chicken embryos. Dev. Biol. 120, 215-227. 159. Duband, J. L., Dufour, S., Hatta, K., Takeichi, M., Edelman, G. M., and Thiery, J. P. (1987). Adhesion molecules during somitogenesis in the avian embryo. J. Cell Biol. 104, 1361-1374. 160. McGinnis, W., and Krumlauf, R. (1992). Homeobox genes and axial patterning. Cell 68, 283-302. 161. Krumlauf, R. (1994). Hox genes in vertebrate development. Cell 78, 191-201. 162. Burke, A. C., Nelson, C. E., Morgan, B. A., and Tabin, C. (1995). Hox genes and the evolution of vertebrate axial morphology. Development 121, 333-346. 163. Capecchi, M. R. (1997). Hox genes and mammalian development. Cold Spring Harbor Symp. Quant. Biol. 62, 273-281. 164. Favier, B., and Dolle, P. (1997). Developmental functions of mammalian Hox genes. Mol. Hum. Reprod. 3, 115-131. 165. Kessel, M., and Gruss, P. (1990). Murine developmental control genes. Science 249, 374-379. 166. Kessel, M., and Gruss, P. (1991). Homeotic transformations of murine vertebrae and concomitant alteration of Hox codes induced by retinoic acid. Cell 67, 89-104. 167. Partanen, J., Schwartz, L., and Rossant, J. (1998). Opposite phenotypes of hypomorphic and Y766 phosphorylation site mutations reveal a function for Fgfr 1 in anteroposterior patterning of mouse embryos. Genes Dev. 12, 2332-2344. 168. Oh, S. P., and Li, E. (1997). The signaling pathway mediated by the type IIB activin receptor controls axial patterning and lateral asymmetry in the mouse. Genes Dev. 11, 1812-1826. 169. Yu, B. D., Hess, J. L., Horning, S. E., Brown, G. A., and Korsmeyer, S. J. (1995). Altered Hox expression and segmental identity in Mll-mutant mice. Nature 378, 505-508. 170. van der Lugt, N. M., Domen, J., Linders, K., van Roon, M., Robanus-Maandag, E., te Riele, H., van der Valk, M., Deschamps, J., Sofroniew, M., van Lohuizen, M., et al. (1994). Posterior transformation, neurological abnormalities, and severe hematopoietic defects in mice with a targeted deletion of the bmi1 proto-oncogene. Genes Dev. 8, 757-769. 171. Subramanian, V., Meyer, B. I., and Gruss, P. (1995). Disruption of the murine homeobox gene Cdxl affects axial skeletal identities by altering the mesodermal expression domains of Hox genes. Cell 83, 641-653. 172. McPherron, A. C., Lawler, A. M., and Lee, S. J. (1999). Regulation of anterior/posterior patterning of the axial skeleton by growth/differentiation factor 11. Nature Genet. 22, 260-264. 173. Barna, M., Hawe, N., Niswander, L., and Pandolfi, P. P. (2000). Plzf regulates limb and axial skeletal patterning. Nature Genet. 25, 166-172.
3. Prenatal Bone Development 174. Conlon, R. A., and Rossant, J. (1992). Exogenous retinoic acid rapidly induces anterior ectopic expression of murine Hox-2 genes in vivo. Development 116, 357-368. 175. Conlon, R. A. (1995). Retinoic acid and pattern formation in vertebrates. Trends Genet. 11, 314-319. 176. Lohnes, D., Kastner, P., Dierich, A., Mark, M., LeMeur, M., and Chambon, P. (1993). Function of retinoic acid receptor gamma in the mouse. Cell 73, 643-658. 177. Lohnes, D., Mark, M., Mendelsohn, C., Dolle, P., Dierich, A., Gorry, P., Gansmuller, A., and Chambon, P. (1994). Function of the retinoic acid receptors (RARs) during development (I). Craniofacial and skeletal abnormalities in RAR double mutants. Development 120, 2723-2748. 178. Chambon, P. (1996). A decade of molecular biology of retinoic acid receptors. FASEB J. 10, 940-954. 179. Mangelsdorf, D. J., Thummel, C., Beato, M., Herrlich, P., Schutz, G., Umesono, K., Blumberg, B., Kastner, P., Mark, M., Chambon, P., et al. (1995). The nuclear receptor superfamily: The second decade. Cell 83, 835-839. 180. Charite, J., de Graaff, W., Consten, D., Reijnen, M. J., Korving, J., and Deschamps, J. (1998). Transducing positional information to the Hox genes: Critical interaction of cdx gene products with position-sensitive regulatory elements. Development 125, 4349-4358. 181. Houle, M., Prinos, P., Iulianella, A., Bouchard, N., and Lohnes, D. (2000). Retinoic acid regulation of Cdxl: An indirect mechanism for retinoids and vertebral specification. Mol. Cell. Biol. 20, 6579-6586. 182. Allan, D., Houle, M., Bouchard, N., Meyer, B. I., Gruss, P., and Lohnes, D. (2001). RARgamma and Cdxl interactions in vertebral patterning. Dev. Biol. 240, 46-60. 183. Duboule, D. (1995). Vertebrate Hox genes and proliferation: An alternative pathway to homeosis? Curr. Opin. Genet. Dev. 5, 525-528. 184. Yokouchi, Y., Nakazato, S., Yamamoto, M., Goto, Y., Kameda, T., Iba, H., and Kuroiwa, A. (1995). Misexpression of Hoxa-13 induces cartilage homeotic transformation and changes cell adhesiveness in chick limb buds. Genes Dev. 9, 2509-2522. 185. Goff, D. J., and Tabin, C. J. (1997). Analysis of Hoxd-13 and Hoxd-11 misexpression in chick limb buds reveals that Hox genes affect both bone condensation and growth. Development 124, 627-636. 186. Yueh, Y. G., Gardner, D. P., and Kappen, C. (1998). Evidence for regulation of cartilage differentiation by the homeobox gene Hoxc-8. Proc. Natl. Acad. Sci. USA 95, 9956-9961. 187. Spitz, F., Montavon, T., Monso-Hinard, C., Morris, M., Ventruto, M. L., Antonarakis, S., Ventruto, V., and Duboule, D. (2002). A t(2;8) balanced translocation with breakpoints near the human HOXD complex causes mesomelic dysplasia and vertebral defects. Genomics 79, 493-498. 188. Huang, L. F., Fukai, N., Selby, P. B., Olsen, B. R., and Mundlos, S. (1997). Mouse clavicular development: Analysis of wild-type and cleidocranial dysplasia mutant mice. Dev. Dyn. 210, 33-40. 189. Moore, K. L., and Persaud, T. V. N. (1993). The Developing Human: Clinically Oriented Embryology. Saunders, Philadelphia. 190. Saunders, J. W., Cairns, J. M., and Gasseling, M. T. (1957). The role of the apical ridge of ectoderm in the differentiation of the morphological structures and inductive specificity of limb parts in the chick. J. Morphol. 101, 57-88. 191. Shubin, N. H., and Alberch, P. (1986). A morphogenetic approach to the origin and basic organization of the tetrapod limb. Evol. Biol. 20, 319-387. 192. Tabin, C. J. (1991). Retinoids, homeoboxes, and growth factors: Toward molecular models for limb development. Cell 66,199-217.
109
193. Gaunt, S. J. (2000). Evolutionary shifts of vertebrate structures and Hox expression up and down the axial series of segments: A consideration of possible mechanisms. Int. J. Dev. Biol. 44, 109-117. 194. Cohn, M. J., and Tickle, C. (1999). Developmental basis oflimblessness and axial patterning in snakes. Nature 399, 474-479. 195. Rancourt, D. E., Tsuzuki, T., and Capecchi, M. R. (1995). Genetic interaction between hoxb-5 and hoxb-6 is revealed by nonallelic noncomplementation. Genes Dev. 9, 108-122. 196. Martin, G. R. (1998). The roles of FGFs in the early development of vertebrate limbs. Genes Dev. 12, 1571-1586. 197. Capdevila, J., and Izpisua Belmonte, J. C. (2001). Patterning mechanisms controlling vertebrate limb development. Annu. Rev. Cell Dev. Biol. 17, 87-132. 198. Ohuchi, H., Nakagawa, T., Yamamoto, A., Araga, A., Ohata, T., Ishimaru, Y., Yoshioka, H., Kuwana, T., Nohno, T., Yamasaki, M., Itoh, N., and Noji, S. (1997). The mesenchymal factor, FGF10, initiates and maintains the outgrowth of the chick limb bud through interaction with FGF8, an apical ectodermal factor. Development 124, 2235-2244. 199. Min, H., Danilenko, D. M., Scully, S. A., Bolon, B., Ring, B. D., Tarpley, J. E., DeRose, M., and Simonet, W. S. (1998). Fgf-10 is required for both limb and lung development and exhibits striking functional similarity to Drosophila branchless. Genes Dev. 12, 3156-3161. 200. Sekine, K., Ohuchi, H., Fujiwara, M., Yamasaki, M., Yoshizawa, T., Sato, T., Yagishita, N., Matsui, D., Koga, Y., Itoh, N., and Kato, S. (1999). Fgfl0 is essential for limb and lung formation. Nature Genet. 21, 138-141. 201. Revest, J. M., Spencer-Dene, B., Kerr, K., De Moerlooze, L., Rosewell, I., and Dickson, C. (2001). Fibroblast growth factor receptor 2-IIIb acts upstream of Shh and Fgf4 and is required for limb bud maintenance but not for the induction of Fgf8, Fgfl0, Msxl, or Bmp4. Dev. Biol. 231, 47-62. 202. Isaac, A., Cohn, M. J., Ashby, P., Ataliotis, P., Spicer, D. B., Cooke, J., and Tickle, C. (2000). FGF and genes encoding transcription factors in early limb specification. Mech. Dev. 93, 41-48. 203. Lewis, P. M., Dunn, M. P., McMahon, J. A., Logan, M., Martin, J. F., St-Jacques, B., and McMahon, A. P. (2001). Cholesterol modification of sonic hedgehog is required for long-range signaling activity and effective modulation of signaling by Ptcl. Cell 105, 599-612. 204. Kawakami, Y., Capdevila, J., Buscher, D., Itoh, T., Rodriguez Esteban, C., and Izpisua Belmonte, J. C. (2001). WNT signals control FGF-dependent limb initiation and AER induction in the chick embryo. Cell 104, 891-900. 205. Tickle, C., and Munsterberg, A. (2001). Vertebrate limb development--The early stages in chick and mouse. Curr. Opin. Genet. Dev. 11,476-481. 206. Kengaku, M., Capdevila, J., Rodriguez-Esteban, C., De La Pena, J., Johnson, R. L., Belmonte, J. C., and Tabin, C. J. (1998). Distinct WNT pathways regulating AER formation and dorsoventral polarity in the chick limb bud. Science 280, 1274-1277. 207. Zwilling, E. (1955). Ectoderm-mesoderm relationship in the development of the chick embryo limb bud. J. Exp. Zool. 128, 423-441. 208. Saunders, J. W., and Gasseling, M. T. (1959). The differentiation of pospective thigh mesoderm grafted beneath the apical ectodermal ridge of the wing bud in the chick embryo. Dev. Biol. 1, 281-301. 209. Weatherbee, S. D., and Carroll, S. B. (1999). Selector genes and limb identity in arthropods and vertebrates. Cell 97, 283-286. 210. Ruvinsky, I., and Gibson-Brown, J. J. (2000). Genetic and developmental bases of serial homology in vertebrate limb evolution. Development 127, 5233-5244.
1 10
Benoit St.-Jacques and Jill A. Helms
211. Tamura, K., Kuraishi, R., Saito, D., Masaki, H., Ide, H., and Yonei-Tamura, S. (2001). Evolutionary aspects of positioning and identification of vertebrate limbs. J. Anat. 199, 195-204. 212. Logan, M., and Tabin, C. J. (1999). Role of Pitxl upstream of Tbx4 in specification ofhindlimb identity. Science 283,1736-1739. 213. Lanctot, C., Moreau, A., Chamberland, M., Tremblay, M. L., and Drouin, J. (1999). Hindlimb patterning and mandible development require the Ptxl gene. Development 126, 1805-1810. 214. Szeto, D. P., Rodriguez-Esteban, C., Ryan, A. K., O'Connell, S. M., Liu, F., Kioussi, C., Gleiberman, A. S., Izpisua-Belmonte, J. C., and Rosenfeld, M. G. (1999). Role of the Bicoid-related homeodomain factor Pitxl in specifying hindlimb morphogenesis and pituitary development. Genes Dev. 13, 484-494. 215. Rodriguez-Esteban, C., Tsukui, T., Yonei, S., Magallon, J., Tamura, K., and Izpisua Belmonte, J. C. (1999). The T-box genes Tbx4 and Tbx5 regulate limb outgrowth and identity. Nature 398, 814-818. 216. Takeuchi, J. K., Koshiba-Takeuchi, K., Matsumoto, K., VogelHopker, A., Naitoh-Matsuo, M., Ogura, K., Takahashi, N., Yasuda, K., and Ogura, T. (1999). Tbx5 and Tbx4 genes determine the wing/leg identity of limb buds. Nature 398, 810-814. 217. Bamshad, M., Lin, R. C., Law, D. J., Watkins, W. C., Krakowiak, P. A., Moore, M. E., Franceschini, P., Lala, R., Holmes, L. B., Gebuhr, T. C., Bruneau, B. G., Schinzel, A., Seidman, J. G., Seidman, C. E., and Jorde, L. B. (1997). Mutations in human TBX3 alter limb, apocrine and genital development in ulnar-mammary syndrome. Nature Genet. 16, 311-315. 218. Bamshad, M., Le, T., Watkins, W. S., Dixon, M. E., Kramer, B. E., Roeder, A. D., Carey, J. C., Root, S., Schinzel, A., Van Maldergem, L., Gardner, R. J., Lin, R. C., Seidman, C. E., Seidman, J. G., Wallerstein, R., Moran, E., Sutphen, R., Campbell, C. E., and Jorde, L. B. (1999). The spectrum of mutations in TBX3: Genotype/phenotype relationship in ulnarmammary syndrome. Am. J. Hum. Genet. 64, 1550-1562. 219. Li, Q. Y., Newbury-Ecob, R. A., Terrett, J. A., Wilson, D. I., Curtis, A. R., Yi, C. H., Gebuhr, T., Bullen, P. J., Robson, S. C., Strachan, T., Bonnet, D., Lyonnet, S., Young, I. D., Raeburn, J. A., Buckler, A. J., Law, D. J., and Brook, J. D. (1997). Holt-Oram syndrome is caused by mutations in TBX5, a member of the Brachyury (T) gene family. Nature Genet. 15, 21-29. 220. Basson, C. T., Bachinsky, D. R., Lin, R. C., Levi, T., Elkins, J. A., Soults, J., Grayzel, D., Kroumpouzou, E., Traill, T. A., LeblancStraceski, J., Renault, B., Kucherlapati, R., Seidman, J. G., and Seidman, C. E. (1997). Mutations in human TBX5 [corrected] cause limb and cardiac malformation in Holt-Oram syndrome. Nature Genet. 15, 30-35. 221. Saunders, J. W. (1948). The proximo-distal sequence of origin of limb parts of the chick wing and the role of the ectoderm. J. Exp. Zool. 108, 363-404. 222. Summerbell, D. (1974). A quantitative analysis of the effect of excision of the AER from the chick limb bud. J. Embryol. Exp. Morphol. 32, 651-660. 223. Rowe, D. A., and Fallon, J. F. (1982). The proximodistal determination of skeletal parts in the developing chick leg. J. Embryol. Exp. Morphol. 68, 1-7. 224. Sun, X., Lewandoski, M., Meyers, E. N., Liu, Y. H., Maxson, R. E., Jr., and Martin, G. R. (2000). Conditional inactivation of Fgf4 reveals complexity of signalling during limb bud development. Nature Genet. 25, 83-86. 225. Moon, A. M., Boulet, A. M., and Capecchi, M. R. (2000). Normal limb development in conditional mutants of Fgf4. Development 127, 989-996. 226. Colvin, J. S., White, A. C., Pratt, S. J., and Ornitz, D. M. (2001). Lung hypoplasia and neonatal death in Fgf9-null mice identify
227.
228.
229. 230.
231. 232.
233.
234.
235.
236.
237. 238. 239.
240. 241. 242.
243.
244.
245.
246.
this gene as an essential regulator of lung mesenchyme. Development 128, 2095-2106. Xu, J., Liu, Z., and Ornitz, D. M. (2000). Temporal and spatial gradients of Fgf8 and Fgfl 7 regulate proliferation and differentiation ofmidline cerebellar structures. Development 127,1833-1843. Lewandoski, M., Sun, X., and Martin, G. R. (2000). Fgf8 signalling from the AER is essential for normal limb development. Nature Genet. 26, 460-463. Moon, A. M., and Capecchi, M. R. (2000). Fgf8 is required for outgrowth and patterning of the limbs. Nature Genet. 26, 455-459. Dahn, R. D., and Fallon, J. F. (1999). Limbiting outgrowth: BMPs as negative regulators in limb development. Bioessays 21, 721-725. Dudley, A. T., and Tabin, C. J. (2000). Constructive antagonism in limb development. Curt. Opin. Genet. Dev. 10, 387-392. Macias, D., Ganan, Y., Sampath, T. K., Piedra, M. E., Ros, M. A., and Hurle, J. M. (1997). Role of BMP-2 and OP-1 (BMP-7) in programmed cell death and skeletogenesis during chick limb development. Development 124, 1109-1117. Zou, H., Choe, K. M., Lu, Y., Massague, J., and Niswander, L. (1997). BMP signaling and vertebrate limb development. Cold Spring Harbor Symp. Quant. Biol. 62, 269-272. Pizette, S., and Niswander, L. (1999). BMPs negatively regulate structure and function of the limb apical ectodermal ridge. Development 126, 883-894. Capdevila, J., Tsukui, T., Rodriquez Esteban, C., Zappavigna, V., and Izpisua Belmonte, J. C. (1999). Control of vertebrate limb outgrowth by the proximal factor Meis2 and distal antagonism of BMPs by Gremlin. Mol. Cell. 4, 839-849. Merino, R., Rodriguez-Leon, J., Macias, D., Ganan, Y., Economides, A. N., and Hurle, J. M. (1999). The BMP antagonist Gremlin regulates outgrowth, chondrogenesis and programmed cell death in the developing limb. Development 126, 5515-5522. Zuniga, A., Haramis, A. P., McMahon, A. P., and Zeller, R. (1999). Signal relay by BMP antagonism controls the SHH/FGF4 feedback loop in vertebrate limb buds. Nature 401, 598-602. Johnson, R. L., Riddle, R. D., and Tabin, C. J. (1994). Mechanisms of limb patterning. Curr. Opin. Genet. Dev. 4, 535-542. Rijli, F. M., and Chambon, P. (1997). Genetic interactions of Hox genes in limb development: Learning from compound mutants. Curr. Opin. Genet. Dev. 7, 481-487. Zakany, J., and Duboule, D. (1999). Hox genes in digit development and evolution. Cell Tissue Res. 296, 19-25. Yokouchi, Y., Sasaki, H., and Kuroiwa, A. (1991). Homeobox gene expression correlated with the bifurcation process of limb cartilage development. Nature 353, 443-445. Nelson, C. E., Morgan, B. A., Burke, A. C., Laufer, E., DiMambro, E., Murtaugh, L. C., Gonzales, E., Tessarollo, L., Parada, L. F., and Tabin, C. (1996). Analysis ofHox gene expression in the chick limb bud. Development 122, 1449-1466. Dolle, P., Izpisua-Belmonte, J. C., Falkenstein, H., Renucci, A., and Duboule, D. (1989). Coordinate expression of the murine Hox-5 complex homeobox-containing genes during limb pattern formation. Nature 342, 767-772. Zakany, J., Fromental-Ramain, C., Warot, X., and Duboule, D. (1997). Regulation of number and size of digits by posterior Hox genes: A dose-dependent mechanism with potential evolutionary implications. Proc. Natl. Acad. Sci. USA 94, 13695-13700. Small, K. M., and Potter, S. S. (1993). Homeotic transformations and limb defects in Hox All mutant mice. Genes Dev. 7, 2318-2328. Davis, A. P., and Capecchi, M. R. (1994). Axial homeosis and appendicular skeleton defects in mice with a targeted disruption of hoxd-11. Development 120, 2187-2198.
3. Prenatal Bone Development 247. Favier, B., Le Meur, M., Chambon, P., and Dolle, P. (1995). Axial skeleton homeosis and forelimb malformations in Hoxd-ll mutant mice. Proc. Natl. Acad. Sci. USA 92, 310-314. 248. Davis, A. P., Witte, D. P., Hsieh-Li, H. M., Potter, S. S., and Capecchi, M. R. (1995). Absence of radius and ulna in mice lacking hoxa- 11 and hoxd- 11. Nature 375, 791-795. 249. Thompson, A. A., and Nguyen, L. T. (2000). Amegakaryocytic thrombocytopenia and radio-ulnar synostosis are associated with HOXA11 mutation. Nature Genet. 26, 397-398. 250. Saunders, J. W., and Gasseling, M. T. (1968). Ectodermalmesenchymal interactions in the origin of limb symetry. In Epithelial-Mesenchymal Interactions (R. Fleischmajer and R. E. Billingham, Eds.), pp. 78-97. Williams & Wilkins, Baltimore. 251. Pagan, S. M., Ros, M. A., Tabin, C., and Fallon, J. F. (1996). Surgical removal of limb bud Sonic hedgehog results in posterior skeletal defects. Dev. Biol. 180, 35-40. 252. Riddle, R. D., Johnson, R. L., Laufer, E., and Tabin, C. (1993). Sonic hedgehog mediates the polarizing activity of the ZPA. Cell 75, 1401-1416. 253. Krauss, S., Concordet, J. P., and Ingham, P. W. (1993). A functionally conserved homolog of the Drosophila segment polarity gene hh is expressed in tissues with polarizing activity in zebrafish embryos. Cell 75, 1431-1444. 254. Echelard, Y., Epstein, D. J., St-Jacques, B., Shen, L., Mohler, J., McMahon, J. A., and McMahon, A. P. (1993). Sonic hedgehog, a member of a family of putative signaling molecules, is implicated in the regulation of CNS polarity. Cell 75, 1417-1430. 255. Roelink, H., Augsburger, A., Heemskerk, J., Korzh, V., Norlin, S., Ruiz i Altaba, A., Tanabe, Y., Placzek, M., Edlund, T., Jessell, T. M., et al. (1994). Floor plate and motor neuron induction by vhh-1, a vertebrate homolog of hedgehog expressed by the notochord. Cell 76, 761-775. 256. Gritli-Linde, A., Lewis, P., McMahon, A. P., and Linde, A. (2001). The whereabouts of a morphogen: Direct evidence for short- and graded long-range activity of hedgehog signaling peptides. Dev. Biol. 236, 364-386. 257. Zeng, X., Goetz, J. A., Suber, L. M., Scott, W. J., Jr., Schreiner, C. M., and Robbins, D. J. (2001). A freely diffusible form of Sonic hedgehog mediates long-range signalling. Nature 411, 716-720. 258. Chang, D. T., Lopez, A., von Kessler, D. P., Chiang, C., Simandl, B. K., Zhao, R., Seldin, M. F., Fallon, J. F., and Beachy, P. A. (1994). Products, genetic linkage and limb patterning activity of a murine hedgehog gene. Development 120, 3339-3353. 259. Lopez-Martinez, A., Chang, D. T., Chiang, C., Porter, J. A., Ros, M. A., Simandl, B. K., Beachy, P. A., and Fallon, J. F. (1995). Limb-patterning activity and restricted posterior localization of the amino-terminal product of Sonic hedgehog cleavage. Curr. Biol. 5, 791-796. 260. Helms, J. A., Kim, C. H., Eichele, G., and Thaller, C. (1996). Retinoic acid signaling is required during early chick limb development. Development 122, 1385-1394. 261. Stratford, T., Horton, C., and Maden, M. (1996). Retinoic acid is required for the initiation of outgrowth in the chick limb bud. Curr. Biol. 6, 1124-1133. 262. Lu, H. C., Revelli, J. P., Goering, L., Thaller, C., and Eichele, G. (1997). Retinoid signaling is required for the establishment of a ZPA and for the expression of Hoxb-8, a mediator of ZPA formation. Development 124, 1643-1651. 263. Kraus, P., Fraidenraich, D., and Loomis, C. A. (2001). Some distal limb structures develop in mice lacking Sonic hedgehog signaling. Mech. Dev. 100, 45-58.
111
264. Noramly, S., Pisenti, J., Abbott, U., and Morgan, B. (1996). Gene expression in the limbless mutant: Polarized gene expression in the absence of Shh and an AER. Dev. Biol. 179, 339-346. 265. Ros, M. A., Lopez-Martinez, A., Simandl, B. K., Rodriguez, C., Izpisua Belmonte, J. C., Dahn, R., and Fallon, J. F. (1996). The limb field mesoderm determines initial limb bud anteroposterior asymmetry and budding independent of sonic hedgehog or apical ectodermal gene expressions. Development 122, 2319-2330. 266. Wang, B., Fallon, J. F., and Beachy, P. A. (2000). Hedgehogregulated processing of Gli3 produces an anterior/posterior repressor gradient in the developing vertebrate limb. Cell 100, 423-434. 267. Manouvrier-Hanu, S., Holder-Espinasse, M., and Lyonnet, S. (1999). Genetics of limb anomalies in humans. Trends Genet. 15, 409-417. 268. Petrij, F., Giles, R. H., Dauwerse, H. G., Saris, J. J., Hennekam, R. C., Masuno, M., Tommerup, N., van Ommen, G. J., Goodman, R. H., Peters, D. J., et al. (1995). Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP. Nature 376, 348-351. 269. Kohlhase, J., Wischermann, A., Reichenbach, H., Froster, U., and Engel, W. (1998). Mutations in the SALL1 putative transcription factor gene cause Townes-Brocks syndrome. Nature Genet. 18, 81-83. 270. Milenkovic, L., Goodrich, L. V., Higgins, K. M., and Scott, M. P. (1999). Mouse patchedl controls body size determination and limb patterning. Development 126, 4431-4440. 271. Schimmang, T., Lemaistre, M., Vortkamp, A., and Ruther, U. (1992). Expression of the zinc finger gene Gli3 is affected in the morphogenetic mouse mutant extra-toes (Xt). Development 116, 799-804. 272. Hui, C. C., and Joyner, A. L. (1993). A mouse model of greig cephalopolysyndactyly syndrome: The extra-toesJ mutation contains an intragenic deletion of the Gli3 gene. Nature Genet. 3, 241-246. 273. Thien, H., and Ruther, U. (1999). The mouse mutation Pdn (Polydactyly Nagoya) is caused by the integration of a retrotransposon into the Gli3 gene. Mamm. Genome 10, 205-209. 274. Qu, S., Tucker, S. C., Ehrlich, J. S., Levorse, J. M., Flaherty, L. A., Wisdom, R., and Vogt, T. F. (1998). Mutations in mouse Aristaless-like4 cause Strong's luxoid polydactyly. Development 125, 2711-2721. 275. Takahashi, M., Tamura, K., Buscher, D., Masuya, H., YoneiTamura, S., Matsumoto, K., Naitoh-Matsuo, M., Takeuchi, J., Ogura, K., Shiroishi, T., Ogura, T., and Belmonte, J. C. (1998). The role of Alx-4 in the establishment of anteroposterior polarity during vertebrate limb development. Development 125, 4417-4425. 276. Qu, S., Tucker, S. C., Zhao, Q., deCrombrugghe, B., and Wisdom, R. (1999). Physical and genetic interactions between Alx4 and Cartl. Development 126, 359-369. 277. Charite, J., McFadden, D. G., and Olson, E. N. (2000). The bHLH transcription factor dHAND controls Sonic hedgehog expression and establishment of the zone of polarizing activity during limb development. Development 127, 2461-2470. 278. Fernandez-Teran, M., Piedra, M. E., Kathiriya, I. S., Srivastava, D., Rodriguez-Rey, J. C., and Ros, M. A. (2000). Role of dHAND in the anterior-posterior polarization of the limb bud: Implications for the Sonic hedgehog pathway. Development 127, 2133-2142. 279. Charite, J., de Graaff, W., Shen, S., and Deschamps, J. (1994). Ectopic expression of Hoxb-8 causes duplication of the ZPA in the forelimb and homeotic transformation of axial structures. Cell 78, 589-601.
1 12
Benoit St.-Jacques and Jill A. Helms
280. Knezevic, V., De Santo, R., Schughart, K., Huffstadt, U., Chiang, C., Mahon, K. A., and Mackem, S. (1997). Hoxd-12 differentially affects preaxial and postaxial chondrogenic branches in the limb and regulates Sonic hedgehog in a positive feedback loop. Development 124, 4523-4536. 281. Mackem, S., and Knezevic, V. (1999). Do 5'Hoxd genes play a role in initiating or maintaining A-P polarizing signals in the limb? Cell Tissue Res. 296, 27-31. 282. Yang, Y., Drossopoulou, G., Chuang, P. T., Duprez, D., Marti, E., Bumcrot, D., Vargesson, N., Clarke, J., Niswander, L., McMahon, A., and Tickle, C. (1997). Relationship between dose, distance and time in Sonic hedgehog-mediated regulation of anteroposterior polarity in the chick limb. Development 124, 4393-4404. 283. Laufer, E., Nelson, C. E., Johnson, R. L., Morgan, B. A., and Tabin, C. (1994). Sonic hedgehog and Fgf-4 act through a signaling cascade and feedback loop to integrate growth and patterning of the developing limb bud. Cell 79, 993-1003. 284. Francis, P. H., Richardson, M. K., Brickell, P. M., and Tickle, C. (1994). Bone morphogenetic proteins and a signalling pathway that controls patterning in the developing chick limb. Development 120, 209-218. 285. Drossopoulou, G., Lewis, K. E., Sanz-Ezquerro, J. J., Nikbakht, N., McMahon, A. P., Hofmann, C., and Tickle, C. (2000). A model for anteroposterior patterning of the vertebrate limb based on sequential long- and short-range Shh signalling and Bmp signalling. Development 127, 1337-1348. 286. Duprez, D., Bell, E. J., Richardson, M. K., Archer, C. W., Wolpert, L., Brickell, P. M., and Francis-West, P. H. (1996). Overexpression of BMP-2 and BMP-4 alters the size and shape of developing skeletal elements in the chick limb. Mech. Dev. 57, 145-157. 287. Dahn, R. D., and Fallon, J. F. (2000). Interdigital regulation of digit identity and homeotic transformation by modulated BMP signaling. Science 289, 438-441. 288. Macias, D., Ganan, Y., Rodriguez-Leon, J., Merino, R., and Hurle, J. M. (1999). Regulation by members of the transforming growth factor beta superfamily of the digital and interdigital fates of the autopodial limb mesoderm. Cell Tissue Res. 296, 95-102. 289. Morgan, B. A., Izpisua-Belmonte, J. C., Duboule, D., and Tabin, C. J. (1992). Targeted misexpression of Hox-4.6 in the avian limb bud causes apparent homeotic transformations. Nature 358, 236-239. 290. Goodman, F. R., and Scambler, P. J. (2001). Human HOX gene mutations. Clin. Genet. 59, 1-11. 291. Chen, H., and Johnson, R. L. (1999). Dorsoventral patterning of the vertebrate limb: A process governed by multiple events. Cell Tissue Res. 296, 67-73. 292. Riddle, R. D., Ensini, M., Nelson, C., Tsuchida, T., Jessell, T. M., and Tabin, C. (1995). Induction of the LIM homeobox gene Lmxl by WNT7a establishes dorsoventral pattern in the vertebrate limb. Cell 83, 631-640. 293. Parr, B. A., and McMahon, A. P. (1995). Dorsalizing signal Wnt7a required for normal polarity of D-V and A-P axes of mouse limb. Nature 374, 350-353. 294. Chen, H., Lun, Y., Ovchinnikov, D., Kokubo, H., Oberg, K. C., Pepicelli, C. V., Gan, L., Lee, B., and Johnson, R. L. (1998). Limb and kidney defects in Lmxlb mutant mice suggest an involvement of LMX1B in human nail patella syndrome. Nature Genet. 19, 51-55. 295. Vogel, A., Rodriguez, C., Warnken, W., and Izpisua Belmonte, J. C. (1995). Dorsal cell fate specified by chick Lmxl during vertebrate limb development. Nature 378, 71 6-720.
296. Loomis, C. A., Harris, E., Michaud, J., Wurst, W., Hanks, M., and Joyner, A. L. (1996). The mouse Engrailed-1 gene and ventral limb patterning. Nature 382, 360-363. 297. Laufer, E., Dahn, R., Orozco, O. E., Yeo, C. Y., Pisenti, J., Henrique, D., Abbott, U. K., Fallon, J. F., and Tabin, C. (1997). Expression of Radical fringe in limb-bud ectoderm regulates apical ectodermal ridge formation. Nature 386, 366-373. 298. Rodriguez-Esteban, C., Schwabe, J. W., De La Pena, J., Foys, B., Eshelman, B., and Belmonte, J. C. (1997). Radical fringe positions the apical ectodermal ridge at the dorsoventral boundary of the vertebrate limb. Nature 386, 360-366. 299. Tanaka, M., Shigetani, Y., Sugiyama, S., Tamura, K., Nakamura, H., and Ide, H. (1998). Apical ectodermal ridge induction by the transplantation of En-l-overexpressing ectoderm in chick limb bud. Dev. Growth Differ. 40, 423-429. 300. Kuhlman, J., and Niswander, L. (1997). Limb deformity proteins: Role in mesodermal induction of the apical ectodermal ridge. Development 124, 133-139. 301. Yang, Y., and Niswander, L. (1995). Interaction between the signaling molecules WNT7a and SHH during vertebrate limb development: Dorsal signals regulate anteroposterior patteming. Cell 80, 939-947. 302. Parr, B. A., Avery, E. J., Cygan, J. A., and McMahon, A. P. (1998). The classical mouse mutant postaxial hemimelia results from a mutation in the Wnt 7a gene. Dev. Biol. 202, 228-234. 303. Hall, B. K. (1994). Embryonic bone formation with special reference to epithelial-mesenchymal interactions and growth factors. In Bone: Mechanisms of Bone Development and Growth (B. K. Hall, Ed.), Vol. 8, pp. 137-192. CRC Press, Boca Raton, FL. 304. Thorogood, P. (1983). Morphogenesis of cartilage. In Cartilage: Development, Differentiation, and Growth (B. K. Hall, Ed.), Vol. 2, pp. 223-254. Academic Press, New York. 305. Hall, B. K. (1983). Tissue interactions and chondrogenesis. In Cartilage; Development, Differentiation, and Growth (B. K. Hall, Ed.), Vol. 2, pp. 187-222. Academic Press, New York. 306. Hall, B. K. (1988). The embryonic development of bone. Am. Scientist 76, 174-181. 307. Israel, D. I., Nove, J., Kerns, K. M., Kaufman, R. J., Rosen, V., Cox, K. A., and Wozney, J. M. (1996). Heterodimeric bone morphogenetic proteins show enhanced activity in vitro and in vivo. Growth Factors 13, 291-300. 308. Kawabata, M., and Miyazomo, K. (2000). Bone morphogenic proteins. In Skeletal Growth Factors (E. Canalis, Ed.), pp. 269-290. Lippincott Williams & Wilkins, Philadelphia. 309. Urist, M. R., Mikulski, A., and Lietze, A. (1979). Solubilized and insolubilized bone morphogenetic protein. Proc. Natl. Acad. Sci. USA 76, 1828-1832. 310. Sampath, T. K., and Reddi, A. H. (1981). Dissociative extraction and reconstitution of extracellular matrix components involved in local bone differentiation. Proc. Natl. Acad. Sci. USA 78, 7599-7603. 311. Kramer, J., Hegert, C., Guan, K., Wobus, A. M., Muller, P. K., and Rohwedel, J. (2000). Embryonic stem cell-derived chondrogenic differentiation in vitro: Activation by BMP-2 and BMP-4. Mech. Dev. 92, 193-205. 312. Rosen, V., Cox, K., and Hattersley, G. (1996). Bone morphogenic proteins. In Principles of Bone Biology (J. P. Bilezikian, L. G. Raisz, and G. A. Rodan, Eds.), pp. 661-671. Academic Press, New York. 313. Reddi, A. H. (1998). Role of morphogenetic proteins in skeletal tissue engineering and regeneration. Nat. Biotechnol. 16, 247-252. 314. Hogan, B. L. (1996). Bone morphogenetic proteins: Multifunctional regulators of vertebrate development. Genes Dev. 10, 1580-1594.
3. Prenatal Bone Development 315. Karsenty, G., and Wagner, E. F. (2002). Reaching a genetic and molecular understanding of skeletal development. Dev. Cell 2, 389-406. 316. Paralkar, V. M., Nandedkar, A. K., Pointer, R. H., Kleinman, H. K., and Reddi, A. H. (1990). Interaction of osteogenin, a heparin binding bone morphogenetic protein, with type IV collagen. J. Biol. Chem. 265, 17281-17284. 317. Vukicevic, S., Latin, V., Chen, P., Batorsky, R., Reddi, A. H., and Sampath, T. K. (1994). Localization of osteogenic protein- 1 (bone morphogenetic protein-7) during human embryonic development: High affinity binding to basement membranes. Biochem. Biophys. Res. Commun. 198, 693-700. 318. Suzawa, M., Takeuchi, Y., Fukumoto, S., Kato, S., Ueno, N., Miyazono, K., Matsumoto, T., and Fujita, T. (1999). Extracellular matrix-associated bone morphogenetic proteins are essential for differentiation of murine osteoblastic cells in vitro. Endocrinology 140, 2125-2133. 319. Zhu, Y., Oganesian, A., Keene, D. R., and Sandell, L. J. (1999). Type IIA procollagen containing the cysteine-rich amino propeptide is deposited in the extracellular matrix of prechondrogenic tissue and binds to TGF-betal and BMP-2. J. Cell Biol. 144, 1069-1080. 320. Paralkar, V. M., Weeks, B. S., Yu, Y. M., Kleinman, H. K., and Reddi, A. H. (1992). Recombinant human bone morphogenetic protein 2B stimulates PC12 cell differentiation: Potentiation and binding to type IV collagen. J. Cell Biol. 119, 1721-1728. 321. Jernvall, J., and Thesleff, I. (2000). Reiterative signaling and patterning during mammalian tooth morphogenesis. Mech. Dev. 92, 19-29. 322. Satokata, I., and Maas, R. (1994). Msxl deficient mice exhibit cleft palate and abnormalities of craniofacial and tooth development. Nature Genet. 6, 348-356. 323. Takahashi, Y., Bontoux, M., and Le Douarin, N. M. (1991). Epitheliomesenchymal interactions are critical for Quox 7 expression and membrane bone differentiation in the neural crest derived mandibular mesenchyme. E M B O J. 10, 2387-2393. 324. Zimmermann, B. (1984). Assembly and disassembly of gap junctions during mesenchymal cell condensation and early chondrogenesis in limb buds of mouse embryos. J. Anat. 138, 351-363. 325. Coelho, C. N., and Kosher, R. A. (1991). Gap junctional communication during limb cartilage differentiation. Dev. Biol. 144, 47-53. 326. Widelitz, R. B., Jiang, T. X., Murray, B. A., and Chuong, C. M. (1993). Adhesion molecules in skeletogenesis: II. Neural cell adhesion molecules mediate precartilaginous mesenchymal condensations and enhance chondrogenesis. J. Cell. Physiol. 156, 399-411. 327. Haas, A. R., and Tuan, R. S. (1999). Chondrogenic differentiation of murine C3H10T1/2 multipotential mesenchymal cells: II. Stimulation by bone morphogenetic protein-2 requires modulation of N-cadherin expression and function. Differentiation 64, 77-89. 328. Flanagan, J. G., and Vanderhaeghen, P. (1998). The ephrins and Eph receptors in neural development. Annu. Rev. Neurosci. 21, 309-345. 329. Wada, N., Kimura, I., Tanaka, H., Ide, H., and Nohno, T. (1998). Glycosylphosphatidylinositol-anchoredcell surface proteins regulate position-specific cell affinity in the limb bud. Dev. Biol. 202, 244-252. 330. Stadler, H. S., Higgins, K. M., and Capecchi, M. R. (2001). Loss of Eph-receptor expression correlates with loss of cell adhesion and chondrogenic capacity in Hoxal 3 mutant limbs. Development 128, 4177-4188.
1 1 ~3
331. Toole, B. P., Jackson, G., and Gross, J. (1972). Hyaluronate in morphogenesis: Inhibition of chondrogenesis in vitro. Proc. Natl. Acad. Sci. USA 69, 1384-1386. 332. Knudson, C. B., and Toole, B. P. (1987). Hyaluronate--cell interactions during differentiation of chick embryo limb mesoderm. Dev. Biol. 124, 82-90. 333. Kosher, R. A. (1998). Syndecan-3 in limb skeletal development. Microsc. Res. Tech. 43, 123-130. 334. Seghatoleslami, M. R., and Kosher, R. A. (1996). Inhibition of in vitro limb cartilage differentiation by syndecan-3 antibodies. Dev. Dyn. 207, 114-119. 335. Kulyk, W. M., Upholt, W. B., and Kosher, R. A. (1989). Fibronectin gene expression during limb cartilage differentiation. Development 106, 449-455. 336. Frenz, D. A., Akiyama, S. K., Paulsen, D. F., and Newman, S. A. (1989). Latex beads as probes of cell surface-extracellular matrix interactions during chondrogenesis: Evidence for a role for amino-terminal heparin-binding domain of fibronectin. Dev. BioL 136, 87-96. 337. Frenz, D. A., Jaikaria, N. S., and Newman, S. A. (1989). The mechanism of precartilage mesenchymal condensation: A major role for interaction of the cell surface with the amino-terminal heparin-binding domain of fibronectin. Dev. Biol. 136, 97-103. 338. Gehris, A. L., Stringa, E., Spina, J., Desmond, M. E., Tuan, R. S., and Bennett, V. D. (1997). The region encoded by the alternatively spliced exon IIIA in mesenchymal fibronectin appears essential for chondrogenesis at the level of cellular condensation. Dev. Biol. 190, 191-205. 339. Leonard, C. M., Fuld, H. M., Frenz, D. A., Downie, S. A., Massague, J., and Newman, S. A. (1991). Role of transforming growth factor-beta in chondrogenic pattern formation in the embryonic limb: Stimulation of mesenchymal condensation and fibronectin gene expression by exogenenous TGF-beta and evidence for endogenous TGF-beta-like activity. Dev. Biol. 145, 99-109. 340. Chimal-Monroy, J., and Diaz de Leon, L. (1999). Expression of N-cadherin, N-CAM, fibronectin and tenascin is stimulated by TGF-betal, beta2, beta3 and beta5 during the formation of precartilage condensations. Int. J. Dev. Biol. 43, 59-67. 341. Winnier, G., Blessing, M., Labosky, P. A., and Hogan, B. L. (1995). Bone morphogenetic protein-4 is required for mesoderm formation and patterning in the mouse. Genes Dev. 9, 2105-2116. 342. Zhang, H., and Bradley, A. (1996). Mice deficient for BMP2 are nonviable and have defects in amnion/chorion and cardiac development. Development 122, 2977-2986. 343. Mishina, Y., Suzuki, A., Ueno, N., and Behringer, R. R. (1995). Bmpr encodes a type I bone morphogenetic protein receptor that is essential for gastrulation during mouse embryogenesis. Genes Dev. 9, 3027-3037. 344. Zhao, R., Lawler, A. M., and Lee, S. J. (1999). Characterization of GDF-10 expression patterns and null mice. Dev. Biol. 212, 68-79. 345. Daluiski, A., Engstrand, T., Bahamonde, M. E., Gamer, L. W., Agius, E., Stevenson, S. L., Cox, K., Rosen, V., and Lyons, K. M. (2001). Bone morphogenetic protein-3 is a negative regulator of bone density. Nature Genet. 27, 84-88. 346. Karsenty, G. (2000). Bone morphogenic proteins and skeletal and non-skeletal development. In Skeletal Growth Factors (E. Canalis, Ed.), pp. 291-298. Lippincott Williams & Wilkins, Philadelphia. 347. Yi, S. E., Daluiski, A., Pederson, R., Rosen, V., and Lyons, K. M. (2000). The type I BMP receptor BMPRIB is required for chondrogenesis in the mouse limb. Development 127, 621-630.
1 14
Benoit St.-Jacques and Jill A. Helms
348. Storm, E. E., and Kingsley, D. M. (1996). Joint patterning defects caused by single and double mutations in members of the bone morphogenetic protein (BMP) family. Development 122, 3969-3979. 349. Solloway, M. J., Dudley, A. T., Bikoff, E. K., Lyons, K. M., Hogan, B. L., and Robertson, E. J. (1998). Mice lacking Bmp6 function. Dev. Genet. 22, 321-339. 350. Luyten, F. P., Kaplan, F. S., and Shore, E. M. (2000). Clinical disorders associated with bone morphogenic proteins. In Skeletal Growth Factors (E. Canalis, Ed.), pp. 323-334. Lippincott Williams & Wilkins, Philadelphia. 351. Gong, Y., Krakow, D., Marcelino, J., Wilkin, D., Chitayat, D., Babul-Hirji, R., Hudgins, L., Cremers, C. W., Cremers, F. P., Brunner, H. G., Reinker, K., Rimoin, D. L., Cohn, D. H., Goodman, F. R., Reardon, W., Patton, M., Francomano, C. A., and Warman, M. L. (1999). Heterozygous mutations in the gene encoding noggin affect human joint morphogenesis. Nature Genet. 21, 302-304. 352. Zou, H., Wieser, R., Massague, J., and Niswander, L. (1997). Distinct roles of type I bone morphogenetic protein receptors in the formation and differentiation of cartilage. Genes Dev. 11, 2191-2203. 353. Francis-West, P. H., Abdelfattah, A., Chen, P., Allen, C., Parish, J., Ladher, R., Allen, S., MacPherson, S., Luyten, F. P., and Archer, C. W. (1999). Mechanisms of GDF-5 action during skeletal development. Development 126, 1305-1315. 354. Tsumaki, N., Tanaka, K., Arikawa-Hirasawa, E., Nakase, T., Kimura, T., Thomas, J. T., Ochi, T., Luyten, F. P., and Yamada, Y. (1999). Role of CDMP-1 in skeletal morphogenesis: Promotion of mesenchymal cell recruitment and chondrocyte differentiation. J. Cell Biol. 144, 161-173. 355. Tsumaki, N., Nakase, T., Miyaji, T., Kakiuchi, M., Kimura, T., Ochi, T., and Yoshikawa, H. (2002). Bone morphogenetic protein signals are required for cartilage formation and differently regulate joint development during skeletogenesis. J. Bone Miner. Res. 17, 898-906. 356. Merino, R., Ganan, Y., Macias, D., Economides, A. N., Sampath, K. T., and Hurle, J. M. (1998). Morphogenesis of digits in the avian limb is controlled by FGFs, TGFbetas, and noggin through BMP signaling. Dev. Biol. 200, 35-45. 357. Capdevila, J., Tabin, C., and Johnson, R. L. (1998). Control of dorsoventral somite patterning by Wnt-1 and beta-catenin. Dev. Biol. 193, 182-194. 358. Roark, E. F., and Greer, K. (1994). Transforming growth factorbeta and bone morphogenetic protein-2 act by distinct mechanisms to promote chick limb cartilage differentiation in vitro. Dev. Dyn. 200, 103-116. 359. Weston, A. D., Rosen, V., Chandraratna, R. A., and Underhill, T. M. (2000). Regulation of skeletal progenitor differentiation by the BMP and retinoid signaling pathways. J. Cell Biol. 148, 679-690. 360. Pizette, S., and Niswander, L. (2000). BMPs are required at two steps of limb chondrogenesis: Formation of prechondrogenic condensations and their differentiation into chondrocytes. Dev. Biol. 219, 237-249. 361. Yin, M., and Pacifici, M. (2001). Vascular regression is required for mesenchymal condensation and chondrogenesis in the developing limb. Dev. Dyn. 222, 522-533. 362. Ducy, P., Zhang, R., Geoffroy, V., Ridall, A. L., and Karsenty, G. (1997). Osf2/Cbfa 1: A transcriptional activator of osteoblast differentiation. Cell 89, 747-754. 363. Komori, T., Yagi, H., Nomura, S., Yamaguchi, A., Sasaki, K., Deguchi, K., Shimizu, Y., Bronson, R. T., Gao, Y. H., Inada, M., Sato, M., Okamoto, R., Kitamura, Y., Yoshiki, S., and
364.
365.
366.
367.
368.
369.
370. 371. 372.
373. 374. 375. 376.
377. 378. 379.
Kishimoto, T. (1997). Targeted disruption of Cbfal results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 89, 755-764. Mundlos, S., Otto, F., Mundlos, C., Mulliken, J. B., Aylsworth, A. S., Albright, S., Lindhout, D., Cole, W. G., Henn, W., Knoll, J. H., Owen, M. J., Mertelsmann, R., Zabel, B. U., and Olsen, B. R. (1997). Mutations involving the transcription factor CBFA1 cause cleidocranial dysplasia. Cell 89, 773-779. Takeda, S., Bonnamy, J. P., Owen, M. J., Ducy, P., and Karsenty, G. (2001). Continuous expression of Cbfal in nonhypertrophic chondrocytes uncovers its ability to induce hypertrophic chondrocyte differentiation and partially rescues Cbfal-deficient mice. Genes Dev. 15, 467-481. Ueta, C., Iwamoto, M., Kanatani, N., Yoshida, C., Liu, Y., Enomoto-Iwamoto, M., Ohmori, T., Enomoto, H., Nakata, K., Takada, K., Kurisu, K., and Komori, T. (2001). Skeletal malformations caused by overexpression of Cbfa 1 or its dominant negative form in chondrocytes. J. Cell Biol. 153, 87-100. Ducy, P., Starbuck, M., Priemel, M., Shen, J., Pinero, G., Geoffroy, V., Amling, M., and Karsenty, G. (1999). A Cbfaldependent genetic pathway controls bone formation beyond embryonic development. Genes Dev. 13, 1025-1036. Liu, W., Toyosawa, S., Furuichi, T., Kanatani, N., Yoshida, C., Liu, Y., Himeno, M., Narai, S., Yamaguchi, A., and Komori, T. (2001). Overexpression of Cbfa 1 in osteoblasts inhibits osteoblast maturation and causes osteopenia with multiple fractures. J. Cell Biol. 155, 157-166. Inada, M., Yasui, T., Nomura, S., Miyake, S., Deguchi, K., Himeno, M., Sato, M., Yamagiwa, H., Kimura, T., Yasui, N., Ochi, T., Endo, N., Kitamura, Y., Kishimoto, T., and Komori, T. (1999). Maturational disturbance of chondrocytes in Cbfaldeficient mice. Dev. Dyn. 214, 279-290. Kim, I. S., Otto, F., Zabel, B., and Mundlos, S. (1999). Regulation of chondrocyte differentiation by Cbfal. Mech. Dev. 80, 159-170. Smith, K. K., and Schneider, R. A. (1998). Have gene knockouts caused evolutionary reversals in the mammalian first arch? Bioessays 20, 245-255. Foster, J. W., Dominguez-Steglich, M. A., Guioli, S., Kowk, G., Weller, P. A., Stevanovic, M., Weissenbach, J., Mansour, S., Young, I. D., Goodfellow, P. N., et al. (1994). Campomelic dysplasia and autosomal sex reversal caused by mutations in an SRYrelated gene. Nature 372, 525-530. Bi, W., Deng, J. M., Zhang, Z., Behringer, R. R., and de Crombrugghe, B. (1999). Sox9 is required for cartilage formation. Nature Genet. 22, 85-89. de Crombrugghe, B., Lefebvre, V., Behringer, R. R., Bi, W., Murakami, S., and Huang, W. (2000). Transcriptional mechanisms of chondrocyte differentiation. Matrix Biol. 19, 389-394. Lefebvre, V., Behringer, R. R., and de Crombrugghe, B. (2001). L-Sox5, Sox6 and Sox9 control essential steps of the chondrocyte differentiation pathway. Osteoarthritis Cartilage 9, $69-$75. Smits, P., Li, P., Mandel, J., Zhang, Z., Deng, J. M., Behringer, R. R., de Croumbrugghe, B., and Lefebvre, V. (2001). The transcription factors L-Sox5 and Sox6 are essential for cartilage formation. Dev. Cell 1, 277-290. Murtaugh, L. C., Chyung, J. H., and Lassar, A. B. (1999). Sonic hedgehog promotes somitic chondrogenesis by altering the cellular response to BMP signaling. Genes Dev. 13, 225-237. Zehentner, B. K., Dony, C., and Burtscher, H. (1999). The transcription factor Sox9 is involved in BMP-2 signaling. J. Bone Miner. Res. 14, 1734-1741. Yoon, Y. M., Oh, C. D., Kang, S. S., and Chun, J. S. (2000). Protein kinase A regulates chondrogenesis of mesenchymal cells at
3. Prenatal Bone Development
380. 381.
382. 383.
384.
385.
386.
387.
388.
389.
390.
391. 392.
393. 394.
395.
396.
the post-precartilage condensation stage via protein kinase C-alpha signaling. J. Bone Miner. Res. 15, 2197-2205. Lee, Y. S., and Chuong, C. M. (1997). Activation of protein kinase A is a pivotal step involved in both BMP-2- and cyclic AMP-induced chondrogenesis. J. Cell. Physiol. 170, 153-165. Huang, W., Zhou, X., Lefebvre, V., and de Crombrugghe, B. (2000). Phosphorylation of SOX9 by cyclic AMP-dependent protein kinase A enhances SOX9's ability to transactivate a Col2al chondrocyte-specific enhancer. Mol. Cell. Biol. 20, 4149-4158. Wodarz, A., and Nusse, R. (1998). Mechanisms of Wnt signaling in development. Annu. Rev. Cell Dev. Biol. 14, 59-88. Kuhl, M., Sheldahl, L. C., Park, M., Miller, J. R., and Moon, R. T. (2000). The Wnt/Ca 2§ pathway: A new vertebrate Wnt signaling pathway takes shape. Trends Genet. 16, 279-283. Rudnicki, J. A., and Brown, A. M. (1997). Inhibition of chondrogenesis by Wnt gene expression in vivo and in vitro. Dev. Biol. 185, 104-118. Stott, N. S., Jiang, T. X., and Chuong, C. M. (1999). Successive formative stages of precartilaginous mesenchymal condensations in vitro: Modulation of cell adhesion by Wnt-7A and BMP-2. J. Cell. Physiol. 180, 314-324. Fischer, L., Boland, G., and Tuan, R. S. (2002). Wnt signaling during BMP-2 stimulation of mesenchymal chondrogenesis. J. Cell. Biochem. 84, 816-831. Cash, D. E., Bock, C. B., Schughart, K., Linney, E., and Underhill, T. M. (1997). Retinoic acid receptor alpha function in vertebrate limb skeletogenesis: A modulator of chondrogenesis. J. Cell Biol. 136, 445-457. Weston, A. D., Chandraratna, R. A., Torchia, J., and Underhill, T. M. (2002). Requirement for RAR-mediated gene repression in skeletal progenitor differentiation. J. Cell Biol. 158, 39-51. Semba, I., Nonaka, K., Takahashi, I., Takahashi, K., Dashner, R., Shum, L., Nuckolls, G. H., and Slavkin, H. C. (2000). Positionally-dependent chondrogenesis induced by BMP4 is co-regulated by Sox9 and Msx2. Dev. Dyn. 217, 401-414. Takahashi, K., Nuckolls, G. H., Takahashi, I., Nonaka, K., Nagata, M., Ikura, T., Slavkin, H. C., and Shum, L. (2001). Msx2 is a repressor of chondrogenic differentiation in migratory cranial neural crest cells. Dev. Dyn. 222, 252-262. Garner, L. W., Cox, K. A., Small, C., and Rosen, V. (2001). Gdfl 1 is a negative regulator of chondrogenesis and myogenesis in the developing chick limb. Dev. Biol. 229, 407-420. Kanzler, B., Kuschert, S. J., Liu, Y. H., and Mallo, M. (1998). Hoxa-2 restricts the chondrogenic domain and inhibits bone formation during development of the branchial area. Development 125, 2587-2597. Clemmons, D. R. (2000). Insulin-like growth factors. In Skeletal Growth Factors (E. Canalis, Ed.), pp. 79-99. Lippincott Williams & Wilkins, Philadelphia. Yakar, S., Liu, J. L., Stannard, B., Butler, A., Accili, D., Sauer, B., and LeRoith, D. (1999). Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc. Natl. Acad. Sci. USA 96, 7324-7329. Sjogren, K., Liu, J. L., Blad, K., Skrtic, S., Vidal, O., Wallenius, V., LeRoith, D., Tornell, J., Isaksson, O. G., Jansson, J. O., and Ohlsson, C. (1999). Liver-derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice. Proc. Natl. Acad. Sci. USA 96, 7088-7092. Butler, A. A., and LeRoith, D. (2001). Minireview: Tissue-specific versus generalized gene targeting of the igfl and igflr genes and their roles in insulin-like growth factor physiology. Endocrinology 142, 1685-1688.
1 15
397. Nakae, J., Kido, Y., and Accili, D. (2001). Distinct and overlapping functions of insulin and IGF-I receptors. Endocr. Rev. 22, 818-835. 398. Ornitz, D. M., and Marie, P. J. (2002). FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease. Genes Dev. 16, 1446-1465. 399. Rousseau, F., Bonaventure, J., Legeai-Mallet, L., Pelet, A., Rozet, J. M., Maroteaux, P., Le Merrer, M., and Munnich, A. (1994). Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia. Nature 371, 252-254. 400. Shiang, R., Thompson, L. M., Zhu, Y. Z., Church, D. M., Fielder, T. J., Bocian, M., Winokur, S. T., and Wasmuth, J. J. (1994). Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia. Cell 78, 335-342. 401. Naski, M. C., Colvin, J. S., Coffin, J. D., and Ornitz, D. M. (1998). Repression of hedgehog signaling and BMP4 expression in growth plate cartilage by fibroblast growth factor receptor 3. Development 125, 4977-4988. 402. Chen, L., Adar, R., Yang, X., Monsonego, E. O., Li, C., Hauschka, P. V., Yayon, A., and Deng, C. X. (1999). Gly369Cys mutation in mouse FGFR3 causes achondroplasia by affecting both chondrogenesis and osteogenesis. J. Clin. Invest. 104, 1517-1525.
403. Chen, L., Li, C., Qiao, W., Xu, X., and Deng, C. (2001). A Ser (365)~Cys mutation of fibroblast growth factor receptor 3 in mouse downregulates Ihh/PTHrP signals and causes severe achondroplasia. Hum. Mol. Genet. 10, 457-465. 404. Li, C., Chen, L., Iwata, T., Kitagawa, M., Fu, X. Y., and Deng, C. X. (1999). A Lys644Glu substitution in fibroblast growth factor receptor 3 (FGFR3) causes dwarfism in mice by activation of STATs and ink4 cell cycle inhibitors. Hum. Mol. Genet. 8, 35-44. 405. Wang, Y., Spatz, M. K., Kannan, K., Hayk, H., Avivi, A., Gorivodsky, M., Pines, M., Yayon, A., Lonai, P., and Givol, D. (1999). A mouse model for achondroplasia produced by targeting fibroblast growth factor receptor 3. Proc. Natl. Acad. Sci. USA 96, 4455-4460. 406. Monsonego-Ornan, E., Adar, R., Feferman, T., Segev, O., and Yayon, A. (2000). The transmembrane mutation G380R in fibroblast growth factor receptor 3 uncouples ligand-mediated receptor activation from down-regulation. Mol. Cell. Biol. 20, 516-522. 407. Iwata, T., Li, C. L., Deng, C. X., and Francomano, C. A. (2001). Highly activated Fgfr3 with the K644M mutation causes prolonged survival in severe dwarf mice. Hum. Mol. Genet. 10, 1255-1264. 408. Colvin, J. S., Bohne, B. A., Harding, G. W., McEwen, D. G., and Ornitz, D. M. (1996). Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3. Nature Genet. 12, 390-397. 409. Deng, C., Wynshaw-Boris, A., Zhou, F., Kuo, A., and Leder, P. (1996). Fibroblast growth factor receptor 3 is a negative regulator of bone growth. Cell 84, 911-921. 410. Wang, Q., Green, R. P., Zhao, G., and Ornitz, D. M. (2001). Differential regulation of endochondral bone growth and joint development by FGFR1 and FGFR3 tyrosine kinase domains. Development 128, 3867-3876. 411. Su, W. C., Kitagawa, M., Xue, N., Xie, B., Garofalo, S., Cho, J., Deng, C., Horton, W. A., and Fu, X. Y. (1997). Activation of Stat 1 by mutant fibroblast growth-factor receptor in thanatophoric dysplasia type II dwarfism. Nature 386, 288-292. 412. Sahni, M., Ambrosetti, D. C., Mansukhani, A., Gertner, R., Levy, D., and Basilico, C. (1999). FGF signaling inhibits
1 16
413.
414.
415.
416.
417.
418. 419.
420.
421.
422.
423. 424.
425.
426.
427.
Benoit St.-Jacques and Jill A. Helms chondrocyte proliferation and regulates bone development through the STAT-1 pathway. Genes Dev. 13, 1361-1366. Hart, K. C., Robertson, S. C., Kanemitsu, M. Y., Meyer, A. N., Tynan, J. A., and Donoghue, D. J. (2000). Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4. Oncogene 19, 3309-3320. Sahni, M., Raz, R., Coffin, J. D., Levy, D., and Basilico, C. (2001). STAT1 mediates the increased apoptosis and reduced chondrocyte proliferation in mice overexpressing FGF2. Development 128, 2119-2129. Coffin, J. D., Florkiewicz, R. Z., Neumann, J., Mort-Hopkins, T., Dorn, G. W., 2nd, Lightfoot, P., German, R., Howles, P. N., Kier, A., O'Toole, B. A., et al. (1995). Abnormal bone growth and selective translational regulation in basic fibroblast growth factor (FGF-2) transgenic mice. Mol. Biol. Cell 6, 1861-1873. Garofalo, S., Kliger-Spatz, M., Cooke, J. L., Wolstin, O., Lunstrum, G. P., Moshkovitz, S. M., Horton, W. A., and Yayon, A. (1999). Skeletal dysplasia and defective chondrocyte differentiation by targeted overexpression of fibroblast growth factor 9 in transgenic mice. J. Bone Miner. Res. 14, 1909-1915. Montero, A., Okada, Y., Tomita, M., Ito, M., Tsurukami, H., Nakamura, T., Doetschman, T., Coffin, J. D., and Hurley, M. M. (2000). Disruption of the fibroblast growth factor-2 gene results in decreased bone mass and bone formation. J. Clin. Invest. 105, 1085-1093. Liu, Z., Xu, J., Colvin, J. S., and Ornitz, D. M. (2002). Coordination of chondrogenesis and osteogenesis by fibroblast growth factor 18. Genes Dev. 16, 859-869. Ohbayashi, N., Shibayama, M., Kurotaki, Y., Imanishi, M., Fujimori, T., Itoh, N., and Takada, S. (2002). FGF18 is required for normal cell proliferation and differentiation during osteogenesis and chondrogenesis. Genes Dev. 16, 870-879. Vortkamp, A., Pathi, S., Peretti, G. M., Caruso, E. M., Zaleske, D. J., and Tabin, C. J. (1998). Recapitulation of signals regulating embryonic bone formation during postnatal growth and in fracture repair. Mech. Dev. 71, 65-76. St.-Jacques, B., Hammerschmidt, M., and McMahon, A. P. (1999). Indian hedgehog signaling regulates proliferation and differentiation of chondrocytes and is essential for bone formation. Genes Dev. 13, 2072-2086. Chung, U. I., Lanske, B., Lee, K., Li, E., and Kronenberg, H. (1998). The parathyroid hormone/parathyroid hormone-related peptide receptor coordinates endochondral bone development by directly controlling chondrocyte differentiation. Proc. Natl. Acad. Sci. USA 95, 13030-13035. Long, F., Schipani, E., Asahara, H., Kronenberg, H., and Montminy, M. (2001). The CREB family of activators is required for endochondral bone development. Development 128, 541-550. Long, F., Zhang, X. M., Karp, S., Yang, Y., and McMahon, A. P. (2001). Genetic manipulation of hedgehog signaling in the endochondral skeleton reveals a direct role in the regulation of chondrocyte proliferation. Development 128, 5099-5108. Karp, S. J., Schipani, E., St.-Jacques, B., Hunzelman, J., Kronenberg, H., and McMahon, A. P. (2000). Indian hedgehog coordinates endochondral bone growth and morphogenesis via parathyroid hormone related-protein-dependent and -independent pathways. Development 127, 543-548. Gao, B., Guo, J., She, C., Shu, A., Yang, M., Tan, Z., Yang, X., Guo, S., Feng, G., and He, L. (2001). Mutations in IHH, encoding Indian hedgehog, cause brachydactyly type A-1. Nature Genet. 28, 386-388. Karaplis, A. C., Luz, A., Glowacki, J., Bronson, R. T., Tybulewicz, V. L., Kronenberg, H. M., and Mulligan, R. C. (1994). Lethal skeletal dysplasia from targeted disruption of
428.
429.
430.
431.
432.
433. 434.
435. 436.
437.
438.
439.
440.
the parathyroid hormone-related peptide gene. Genes Dev. 8, 277-289. Lee, K., Lanske, B., Karaplis, A. C., Deeds, J. D., Kohno, H., Nissenson, R. A., Kronenberg, H. M., and Segre, G. V. (1996). Parathyroid hormone-related peptide delays terminal differentiation of chondrocytes during endochondral bone development. Endocrinology 137, 5109-5118. Lanske, B., Karaplis, A. C., Lee, K., Luz, A., Vortkamp, A., Pirro, A., Karperien, M., Defize, L. H., Ho, C., Mulligan, R. C., Abou-Samra, A. B., Juppner, H., Segre, G. V., and Kronenberg, H. M. (1996). PTH/PTHrP receptor in early development and Indian hedgehog-regulated bone growth. Science 273, 663-666. Weir, E. C., Philbrick, W. M., Amling, M., Neff, L. A., Baron, R., and Broadus, A. E. (1996). Targeted overexpression of parathyroid hormone-related peptide in chondrocytes causes chondrodysplasia and delayed endochondral bone formation. Proc. Natl. Acad. Sci. USA 93, 10240-10245. Karperien, M., van der Harten, H. J., van Schooten, R., FarihSips, H., den Hollander, N. S., Kneppers, S. L., Nijweide, P., Papapoulos, S. E., and Lowik, C. W. (1999). A frame-shift mutation in the type I parathyroid hormone (PTH)/PTH-related peptide receptor causing Blomstrand lethal osteochondrodysplasia. J. Clin. Endocrinol. Metab. 84, 3713-3720. Karaplis, A. C., He, B., Nguyen, M. T., Young, I. D., Semeraro, D., Ozawa, H., and Amizuka, N. (1998). Inactivating mutation in the human parathyroid hormone receptor type 1 gene in Blomstrand chondrodysplasia. Endocrinology 139, 5255-5258. Zhang, N., and Gridley, T. (1998). Defects in somite formation in lunatic fringe-deficient mice. Nature 394, 374-377. Jobert, A. S., Zhang, P., Couvineau, A., Bonaventure, J., Roume, J., Le Merrer, M., and Silve, C. (1998). Absence of functional receptors for parathyroid hormone and parathyroid hormone-related peptide in Blomstrand chondrodysplasia. J. Clin. Invest. 102, 34-40. Schipani, E., Kruse, K., and Juppner, H. (1995). A constitutively active mutant PTH-PTHrP receptor in Jansen-type metaphyseal chondrodysplasia. Science 268, 98-100. Schipani, E., Langman, C. B., Parfitt, A. M., Jensen, G. S., Kikuchi, S., Kooh, S. W., Cole, W. G., and Juppner, H. (1996). Constitutively activated receptors for parathyroid hormone and parathyroid hormone-related peptide in Jansen's metaphyseal chondrodysplasia. N. Engl. J. Med. 335, 708-714. Schipani, E., Lanske, B., Hunzelman, J., Luz, A., Kovacs, C. S., Lee, K., Pirro, A., Kronenberg, H. M., and Juppner, H. (1997). Targeted expression of constitutively active receptors for parathyroid hormone and parathyroid hormone-related peptide delays endochondral bone formation and rescues mice that lack parathyroid hormone-related peptide. Proc. Natl. Acad. Sci. USA 94, 13689-13694. Hopyan, S., Gokgoz, N., Poon, R., Gensure, R. C., Yu, C., Cole, W. G., Bell, R. S., Juppner, H., Andrulis, I. L., Wunder, J. S., and Alman, B. A. (2002). A mutant PTH/PTHrP type I receptor in enchondromatosis. Nature Genet. 30, 306-310. Grimsrud, C. D., Romano, P. R., D'Souza, M., Puzas, J. E., Reynolds, P. R., Rosier, R. N., and O'Keefe, R. J. (1999). BMP-6 is an autocrine stimulator of chondrocyte differentiation. J. Bone Miner. Res. 14, 475-482. Zerega, B., Cermelli, S., Bianco, P., Cancedda, R., and Cancedda, F. D. (1999). Parathyroid hormone [PTH(1-34)] and parathyroid hormone-related protein [PTHrP(1-34)] promote reversion of hypertrophic chondrocytes to a prehypertrophic proliferating phenotype and prevent terminal differentiation of osteoblast-like cells. J. Bone Miner. Res. 14, 1281-1289.
3. Prenatal Bone Development 441. Amizuka, N., Warshawsky, H., Henderson, J. E., Goltzman, D., and Karaplis, A. C. (1994). Parathyroid hormone-related peptidedepleted mice show abnormal epiphyseal cartilage development and altered endochondral bone formation. J. Cell Biol. 126, 1611-1623. 442. Amizuka, N., Karaplis, A. C., Henderson, J. E., Warshawsky, H., Lipman, M. L., Matsuki, Y., Ejiri, S., Tanaka, M., Izumi, N., Ozawa, H., and Goltzman, D. (1996). Haploinsufficiency of parathyroid hormone-related peptide (PTHrP) results in abnormal postnatal bone development. Dev. Biol. 175, 166-176. 443. Lee, K., Deeds, J. D., Chiba, S., Un-No, M., Bond, A. T., and Segre, G. V. (1994). Parathyroid hormone induces sequential c-fos expression in bone cells in vivo: In situ localization of its receptor and c-fos messenger ribonucleic acids. Endocrinology 134, 441-450. 444. Amizuka, N., Henderson, J. E., Hoshi, K., Warshawsky, H., Ozawa, H., Goltzman, D., and Karaplis, A. C. (1996). Programmed cell death of chondrocytes and aberrant chondrogenesis in mice homozygous for parathyroid hormone-related peptide gene deletion. Endocrinology 137, 5055-5067. 445. Vortkamp, A., Lee, K., Lanske, B., Segre, G. V., Kronenberg, H. M., and Tabin, C. J. (1996). Regulation of rate of cartilage differentiation by Indian hedgehog and PTH-related protein. Science 273, 613-622. 446. Wallis, G. A. (1996). Bone growth: Coordinating chondrocyte differentiation. Curr. Biol. 6, 1577-1580. 447. Chung, U. I., Schipani, E., McMahon, A. P., and Kronenberg, H. M. (2001). Indian hedgehog couples chondrogenesis to osteogenesis in endochondral bone development. J. Clin. lnvest. 107, 295-304. 448. Huang, W., Chung, U. I., Kronenberg, H. M., and de Crombrugghe, B. (2001). The chondrogenic transcription factor Sox9
449.
450.
451.
452.
453.
454.
1 17
is a target of signaling by the parathyroid hormone-related peptide in the growth plate of endochondral bones. Proc. Natl. Acad. Sci. USA 98, 160-165. van der Eerden, B. C., Karperien, M., Gevers, E. F., Lowik, C. W., and Wit, J. M. (2000). Expression of Indian hedgehog, parathyroid hormone-related protein, and their receptors in the postnatal growth plate of the rat: Evidence for a locally acting growth restraining feedback loop after birth. J. Bone Miner. Res. 15, 1045-1055. Farquharson, C., Jefferies, D., Seawright, E., and Houston, B. (2001). Regulation of chondrocyte terminal differentiation in the postembryonic growth plate: The role of the PTHrP-Indian hedgehog axis. Endocrinology 142, 4131-4140. Alvarez, J., Sohn, P., Zeng, X., Doetschman, T., Robbins, D. J., and Serra, R. (2002). TGFbeta2 mediates the effects of hedgehog on hypertrophic differentiation and PTHrP expression. Development 129, 1913-1924. Alvarez, J., Horton, J., Sohn, P., and Serra, R. (2001). The perichondrium plays an important role in mediating the effects of TGF-betal on endochondral bone formation. Dev. Dyn. 221, 311-321. Serra, R., Karaplis, A., and Sohn, P. (1999). Parathyroid hormone-related peptide (PTHrP)-dependent and -independent effects of transforming growth factor beta (TGF-beta) on endochondral bone formation. J. Cell Biol. 145, 783-794. Serra, R., Johnson, M., Filvaroff, E. H., LaBorde, J., Sheehan, D. M., Derynck, R., and Moses, H. L. (1997). Expression of a truncated, kinase-defective TGF-beta type II receptor in mouse skeletal tissue promotes terminal chondrocyte differentiation and osteoarthritis. J. Cell Biol. 139, 541-552.
This Page Intentionally Left Blank
C
H
A
P
T
[4]
E
R
Postnatal Bone Growth Growth Plate Biology, Modeling, and Remodeling GERARD KARSENTYand HENRY M. KRONENBERG
Despite the great variety of shapes and sizes, bones grow through the use of a small number of cellular mechanisms. The most common strategy is called endochondral bone formation, which indicates that the cells and matrix of bone are organized on a matrix first synthesized by chondrocytes. The second strategy, intramembranous bone formation, involves the generation of bone more directly by differentiation of mesenchymal cells into osteoblasts without the use of a cartilage-based matrix. In Chapter 3, the mechanism used to establish the initial growth of bone was reviewed. Here, we discuss how these strategies are extended in postnatal life to ensure effective growth of bone postnatally.
ENDOCHONDRAL AND INTRAMEMBRANOUS BONE FORMATION
FIGURE 1
Although most bones use the same cellular sequence in endochondral bone formation, the dramatic, asymmetric lengthening of the appendicular long bones leads to a geometric arrangement of chondrocytes that is particularly easy to follow and analyze (Fig. 1). The initial cartilage mold forms when mesenchymal cells condense and then become recognizable chondrocytes, synthesizing collagens II, IX, and XI and aggrecan, among other matrix molecules, under the direction of transcription factors including SOX-9 [1]. The cartilage mold enlarges both through proliferation along the entire length of the mold and through secretion of a characteristic matrix. In the center of the mold, chondrocytes stop proliferating, enlarge (hypertrophy), and change the constituents of the matrix to include, for example, collagen X. The matrix is subsequently mineralized, specialized osteoclasts called
Pediatric Bone
Serial stages in e n d o c h o n d r a l b o n e f o r m a t i o n .
chondroclasts invade the region of hypertrophic chondrocytes along with blood vessels and preosteoblasts, and the hypertrophic chondrocytes undergo apoptosis [2]. The preosteoblasts become true osteoblasts and lay down a matrix dominated by collagen type I on top of the matrix left behind by the hypertrophic chondrocytes. This is the primary spongiosa, which is subsequently remodeled by further waves of osteoclasts and osteoblasts to form the secondary spongiosa, the forerunner of mature trabecular bone. The marrow space is enlarged by continual osteoclast activity, and hematopoietic precursors migrate from the fetal liver to establish marrowbased hematopoiesis. Near the ends of the bone, the same cellular sequence of chondrocyte hypertrophy, vascular invasion, and bone formation subsequently occurs at so-called secondary ossification centers. The remaining
119
Copyright 2003, Elsevier Science (USA). All rights reserved.
1 20
Gerard Karsentyand HenryM. Kronenberg
growth cartilage between the expanding bone in the primary and secondary ossification centers is then called the growth plate. Surrounding the cartilage mold, perichondrial cells carry out a distinct genetic program that both regulates the cartilage mold and, in turn, is regulated by it. These perichondrial cells, originally distinguished from chondrocytes by the absence of SOX9 expression, secrete bone morphogenic proteins (BMPs), parathyroid hormonerelated peptide (PTHrP), and other signaling molecules that regulate chondrocyte proliferation and differentiation. Perichondrial cells adjacent to prehypertrophic/ hypertrophic chondrocytes respond to Indian hedgehog and other signals from those cells to become preosteoblasts and then true osteoblasts [3,4]. These osteoblasts lay down a collagen I-containing matrix that forms intramembranous bone adjacent to the cartilage mold. After the chondrocytes disappear, the intramembranous bone remains and is remodeled by endosteal osteoclastic bone resorption and periosteal new bone formation, as preosteoblastic cells proliferate and differentiate. In humans, Haversian systems formed around invading blood vessels further enlarge the bony envelope, called cortical bone. The events just summarized indicate several sources of bone enlargement. Lengthening of the appendicular bones is primarily driven by growth plate activity. In fetal life all nonhypertrophic chondrocytes vigorously proliferate. As a formal growth plate forms, however, the chondrocytes near the top of the growth plate slow down their rate of proliferation dramatically and become "reserve" or "resting" cells that may serve as stem cells for all other chondrocytes. Under controls that are poorly understood, resting cells periodically become proliferating chondrocytes that undergo several rounds of prolifer-
ation. These proliferating cells flatten out, with their short axis parallel to the long axis of the long bone, and form columns of stacked proliferating chondrocytes, with each column representing descendants of a distinct clone of cells. The lengthening of the bone derives primarily from the substantial enlargement that each chondrocyte undergoes when it hypertrophies [5]. The large number of proliferating chondrocytes and the matrix secreted by all of the chondrocytes also contribute to bone lengthening. Because the chondrocytes and their matrix ultimately disappear, however, normal osteoblast function in the primary spongiosa is also essential to allow the expansion of the bone length generated by chondrocyte activity to be translated into permanent lengthening. The important role of the bone adjacent to the growth plate is illustrated, for example, by the short bones found in mice in which the transcription factor Cbfal (Runx2) is inactivated in osteoblasts by a dominant-negative strategy [6]. Lengthening of bone ceases when growth plate chondrocytes disappear during puberty. A small number of bones, primarily the flat bones of the skull, form by intramembranous bone formation without a cartilage mold [7]. These bones form when mesenchymal cells differentiate directly into preosteoblasts and then osteoblasts. The growth of these bones occurs by waves of proliferation and differentiation of preosteoblasts at the perimeter of the growing bones. As the perimeters of adjacent bones approach each other, a specialized structure, the suture, forms. Normal development of the cranium requires that the skull expand in close coordination with the growth of the underlying brain. At the suture, proliferating mesenchymal cells differentiate into osteoblasts; sutures normally close only when brain expansion ceases (Fig. 2) [8].
FIGURE 2 Normalrat coronal suture. Hematoxylinand eosin-stainedsectionswith periosteoal surfaceat top and dura mater at bottom. El9, EmbryonicDay 19, soon beforebirth; P1, P5, and P21, daysafter birth; b, frontal and parietal bones;s, cellularsutureblastema;ps, presumptivesuture.Arrowsindicateleadingedgesof bonefronts [reprinted with permissionfrom Opperman, L. A. (2000).Cranial sutures as intramembranousbone growthsites. Dev. Dyn.219(4), 472-485].
4. Postnatal Bone Growth
Bone growth is regulated by a large variety of paracrine and endocrine signaling systems. In this chapter, we focus on a few such systems, chosen because of their established importance in normal human physiology and disease. Regulators of bone growth are first considered, followed by a discussion of osteoblast and osteoclast biology.
GROWTH H O R M O N E AND INSULIN-LIKE GROWTH FACTOR-1 Growth hormone (GH) is a major regulator of postnatal growth of most organs and through its actions on the growth plate, GH has a dramatic effect on postnatal bone growth. GH is a protein synthesized in the anterior pituitary gland. It acts on a receptor in the cytokine receptor family found in many organs of the body. Many of the actions of GH result from its stimulation of synthesis of insulin-like growth factor-1 (IGF-1). In a classic experiment, Salmon and Daughaday found that administration of GH to hypophysectomized rats stimulated incorporation of sulfate into cartilage proteoglycans [9]. Serum from such animals could also stimulate sulfate incorporation into proteoglycans in bones cultured in vitro, but GH added to serum from hypophysectomized rats could not do so. Thus, Salmon and Daughaday concluded that GH's action on bone was indirect, through the synthesis of a factor that traveled from elsewhere to work on bone. In the strongest version of the somatomedin hypothesis [10], it was proposed that GH increased the production of what is now known as IGF-1 in the liver, and that this IGF-1 then circulated and acted on the growth plate to cause bone growth. As detailed later, this hypothesis has required substantial modification over the years. (Even the initial experiment may have missed a direct effect of GH on sulfation of proteoglycans simply because the assay was not optimal [11].) Nevertheless, the observation that GH and IGF-1 are key regulators of bone growth has stood the test of time and has led to substantial understanding of the actions of these two important factors. The crucial role of GH in controlling bone growth dates from the isolation of GH and the evidence that GH administration corrects the growth defects in patients with genetic or acquired GH deficiency. Patients and mice with mutations in the GH receptor gene (Laron dwarfism) have a similar defect in bone growth [12-18]. Studies of mice missing the GH receptor show that the mice, like people with Laron dwarfism, are of normal size at birth but have defective growth. In mice, the defect is detected Days 10-40 after birth [17]. These mice have growth plates with short proliferative columns, fewer
1 21
proliferative chondrocytes than normal, and smaller hypertrophic chondrocytes than normal. The chondrocytes in the proliferative columns proliferate more slowly than normal, as judged by incorporation of DNA precursors [17]. The formation of secondary ossification centers is delayed. Thus, these mice display defects both in proliferation of chondrocytes and in differentiation (small hypertrophic chondrocytes). IGF-1 is a member of the insulin family of growth factors and activates a distinct receptor that also mediates actions of a closely related ligand, IGF-2. Clear demonstration of the physiologic importance of IGF-1 in bone growth awaited gene ablation studies [19-21]; subsequently, one human with IGF-1 gene mutation and a phenotype analogous to that of the knockout mice was reported [22]. Unlike the fairly normal prenatal phenotype of mice missing the GH receptor, mice missing the IGF-1 gene are only 60% of normal weight at birth and have a high perinatal mortality, which varies depending on the genetic background of the particular mouse strain. These mice, like the GH receptor knockout mice, have small hypertrophic chondrocytes [17,23]. Wang et al. [23] found that proliferative columns are of normal size and that the chondrocytes proliferate at a normal rate, whereas Lupu et al. [17] found that the proliferative columns are short, with a low rate of proliferation. Although the studies differ in several respects, probably the most important difference that might explain the varying results is that the mice have distinct genetic backgrounds. As noted earlier, the observation that GH stimulates the production of IGF-1 in many cell types and the partial overlap in actions of these two factors has led to the hypothesis that many of the growth-promoting actions of GH are mediated by IGF-1. The small size of the IGF-1 knockout mice, despite their high GH levels, is consistent with this idea. Nevertheless, the finding that mice missing both the GH receptor and IGF-1 genes have a greater growth defect than either individual knockout mouse is strong genetic evidence for independent actions of GH and IGF-1 on growth. The double knockout mice have columns of proliferating chondrocytes that are substantially shorter than those of either individual knockout mouse and hypertrophic chondrocytes that are of the same small size found in both individual knockouts. The functional relationships between GH and IGF1 actions on the growth plate remain unsettled. IGF-1 can certainly increase bone growth in the absence of GH action, as best exemplified by the use of IGF-1 to treat Laron dwarfism [13,18]. Similarly, as already noted, mice with normal GH signaling and ablated IGF-1 genes have longer bones than those missing both the GH receptor and IGF-1. In fact, comparisons of the bones of GH
1 2,2
Gerard Karsentyand HenryM. Kronenberg
receptor, IGF-1, and double knockout mice suggest that the actions of GH and IGF-1 are predominantly independent and additive [17]. The presence of mRNA encoding both IGF-1 and the GH receptor in the same proliferating chondrocytes suggests that these chondrocytes are the primary target of each ligand. On the other hand, functional studies suggest that a distinct population of chondrocytes might be unique targets of GH. Although both GH and IGF-1 stimulated clonal growth of chondrocyte colonies in agar, for example, GH stimulated a distinct large population of such colonies [24]. Perhaps analogously, in vivo GH stimulated the expansion of a population of cells at the top of the growth plate that may represent prechondrocytes or chondrocyte stem cells [25]. The possibility that part of the action of GH on chondrocytes might be mediated by IGF-1 is supported by studies showing that GH stimulates production of IGF-1 mRNA in the growth plates of hypophysectomized mice given GH [26]. Furthermore, stimulation of IGF-1 mRNA in the liver after GH administration and increased circulating IGF-1 levels, as well as the decrease or virtual absence of IGF-1 in the blood of GH receptor knockout mice [14,15,17], suggest that part of the action of GH may be via IGF-1. Of course, regulation of IGF-1 by GH gives no clear indication of the functional importance of this regulation on the growth plate. Recent studies suggest that IGF-1 made by the liver may be unimportant for bone growth. Using two distinct promoters to express the Cre recombinase, the IGF-1 gene was ablated specifically from liver in vivo using the Cre-Lox approach [27,28]. In each case, circulating levels of IGF-1 decreased to approximately 20% of baseline, but the animals grew normally. Although these studies demonstrate that a large fraction of circulating IGF-1 derives from the liver, the presence of residual IGF-1 in the circulation and the possibility that liver IGF-1 gene ablation may have been incomplete during the time of greatest IGF-1-dependent growth [17] leave open the possibility that circulating IGF-1 may contribute to bone growth. IGF-2 is a close relative of IGF-1. IGF-2 in mice is synthesized only during fetal life, whereas in humans IGF-2 is synthesized by many tissues throughout life. IGF-2 acts predominantly through the IGF-1 receptor, but when this receptor is missing, IGF-2 can also act through the insulin receptor. Knockout of the IGF-2 gene leads to decreased fetal growth in analogous fashion to knockout of the IGF-1 gene [29]. Because of the action of IGF-2 on the insulin receptor, knockout of IGF-2 and the IGF-1 receptor results in a more severe growth abnormality than knockout of the IGF-1 receptor alone [30]. Since IGF-2 acts predominantly in fetal life and GH acts on growth only postnatally, there are no expected
interactions between IGF-2 and GH in mice. In humans, the possible regulation of IGF-2 by GH has not been extensively analyzed; however, GH administration lowers circulating IGF-2 levels but stimulates production of IGF-2 mRNA in human liver [31]. Mice missing both the GH receptor and IGF-1 are only 17% of normal size [17]. Presumably, if residual IGF-2 action were also blocked, size would be diminished further, were that compatible with life. These dramatic quantitative effects show that GH and IGFs importantly control bone growth in mammals. Further dissection of the important target cells within the growth plate and possible indirect effects of these endocrine/ paracrine systems, which act on multiple organs, awaits additional analysis of mice with genes knocked out of specific cell types.
FIBROBLAST GROWTH FACTORS Fibroblast growth factors (FGFs) and their receptors regulate skeletal patterning and bone growth at virtually every step from the initial outgrowth of the limb to postnatal lengthening of long bones and intramembranous bones of the skull [32]. Here, we focus on the roles of FGFs in bone growth after the initial patterning of the skeleton. Humans and mice each have 22 FGFs encoded in their genomes. A total of 23 different FGFs have been identified, although a human counterpart to mouse FGF-15 and a mouse counterpart to human FGF-19 have not been found [33]. Expression of FGF-7,-8, -17, and -18 occurs in the perichondrium surrounding the growth plate, whereas FGF-2 is expressed in the periosteum of bone. FGF-2 a n d - 9 are both expressed by chondrocytes, whereas FGF-2 is also expressed by osteoblasts. In the growing skull, FGF-2, -4, and-9 are expressed in the mesenchyme of the suture, whereas FGF-18 and -20 are expressed by differentiating osteoblasts. Four genes encode receptors for the FGF family, although the actual number of receptors is larger because of splice variants of these genes [34]. Each encodes a transmembrane protein with tyrosine kinase activity that is triggered by ligand binding at the plasma membrane. The extracellular domain contains three immunoglobulin domains that contribute to ligand-binding specificity and affinity. Splice variants of FGF-R1-3 each substitute alternative sequences in the carboxyterminal portion of the third immunoglobulin domain. Splice variants 1b-3b are expressed in epithelial cells, and splice variants lc-3c are expressed in mesenchymal cells. FGF-R3 is expressed by proliferating chondrocytes,
4. Postnatal Bone Growth
FGF-R1 is expressed by prehypertrophic and hypertrophic chondrocytes, and FGF-R2 is expressed by perichondrial cells. In the sutures of the growing, intramembranous bones of the skull, FGF-R1 is found in the mesenchyme, whereas both FGF-R1 and-2 are in the differentiating osteoblasts of sutures. FGF-R3 is expressed late at the osteoblastic front of sutures. A series of inherited human diseases and mutations in mice have demonstrated the importance of individual components of this complicated network of ligands and receptors in bone development. Genetic analysis of the role of FGF signaling in the growth plate have been complicated by the multiple roles of FGF signaling during early stages of development [34]. Nevertheless, much has been learned. Mice missing the FGF-R3 gene, normally expressed in proliferative chondrocyte columns, have elongated columns and longer bones than normal [35,36]. Humans with constitutively active FGF-R3, due to point mutations such as a glycine-toarginine mutation at residue 380 in the receptor's transmembrane domain, have a form of short-limbed dwarfism called achondroplasia. Both milder and more severe chondrodysplasias are caused by other activating mutations of FGF-R3. Corresponding transgenic animal models have helped clarify the mechanisms whereby activation of FGF-R3 leads to dwarfism. Activation of FGF-R3 in humans and mice or overexpression of FGF-2 in transgenic mice lead to a decrease in chondrocyte proliferation in the growth plate and increased apoptosis [32]. This phenotype is paradoxical since activation of FGF receptor tyrosine kinases typically leads to cellular proliferation. Substantial evidence, however, suggests that FGF-R3 can activate STAT1 in chondrocytes and thereby decrease chondrocyte proliferation. FGF-R3 activation leads to activation of STAT1, and the decrease in chondrocyte proliferation caused by FGF signaling in vivo and in vitro is blocked in chondrocytes from STAT1 -/- mice [37,38]. In addition to providing a molecular explanation for the paradoxical actions of FGF signaling in chondrocytes, these findings argue that the decrease in proliferation is a direct consequence of FGF-R3 activation in chondrocytes. In addition, in transgenic mice, activation of FGF-R3 leads to a decrease in expression of Indian hedgehog (Ihh). Since Ihh stimulates chondrocyte proliferation, this provides a further, indirect mechanism for the decrease in chondrocyte proliferation after activation of FGF-R3. Due to the plethora of FGFs expressed in bone and the many actions of FGFs early in development, it is difficult to identify the specific FGF ligands that normally activate FGF-R3 in the growth plate. In this context, the observation that mice missing FGF-18 have a growth plate phenotype that closely resembles that of the FGF-R3 knockout mouse is somewhat surprising
123
[39,40]. This observation suggests that FGF-18, synthesized in the perichondrium surrounding the growth plate, is the primary activator of FGF-R3 in chondrocytes. In the growth plate, the role of FGF-R2, expressed in the perichondrium and in osteoblasts, has been difficult to discern. The FGF-R2 knockout mouse dies in the periimplantation period [41], and chimeras in which FGF-R2 is missing from most nonplacental tissues demonstrate the essential role of FGF-R2 in initial limb outgrowth [42]. These early actions of FGF-R2 have limited analysis of the role of FGF-R2 after formation of the growth plate, however. The recent preliminary description of the conditional knockout of FGF-R2 from bone, using the Cre-Lox approach, makes such an analysis possible [43]. These mice are dwarfed, with a decrease in BrdU incorporation in proliferative chondrocytes and a smaller than normal hypertrophic zone. Presumably, the FGF-R2 in the perichondrium receives a signal that, in turn, triggers regulation of adjacent growth plate chondrocytes to increase their proliferation. The precise relevant ligands for these actions have not been identified, given the multiple FGFs expressed in chondrocytes and perichondrium. FGF-R1 is expressed in prehypertrophic and hypertrophic chondrocytes, although none of the possible functions suggested by its pattern of expression have been demonstrated. Similarly, the roles of the other FGFs expressed in the growth plate remain to be established. FGFs and their receptors have important roles in the growth of intramembranous bones and the bone adjacent to growth plates in endochondral bone formation. In the cranial vault, inappropriately rapid differentiation of osteoblasts at the sutures, when combined with normal or increased cell proliferation, can lead to craniosynostosis, the premature fusion of sutures. This is a serious condition because it does not allow the normal growth of the brain and neural structures. As noted earlier, FGFs and their receptors are expressed in sutures. Activating mutations of FGF-R1-3 in humans can cause craniosynostosis [32,44]. A mouse model of one form of craniosynostosis caused by activating mutation of FGF-R1 has been analyzed [45]. In these mice, increased incorporation of BrdU was found in osteoblasts at the suture, along with acceleration of differentiation of osteoblasts. The activated FGF-R1 caused an increase in Cbfal expression. Since Cbfal is a transcription factor essential for osteoblast differentiation and activates a large number of genes expressed in differentiated osteoblasts [46,47], the increase in cbfal expression is probably a crucial aspect of this phenotype. Humans with an activating mutation in FGF-R2 also have evidence of increased apoptosis of osteoblasts in the prematurely fusing sutures [48]. The ligands most crucial for
124
Gerard Karsenty and Henry M. Kronenberg
activating FGF receptors in sutures and osteoblasts of the limb are uncertain. However, genetic evidence in mice establishes that both FGF-2 and FGF-18 are important. Mice missing FGF-2 are osteoporotic, with a decrease in osteoblast number, decreased bone formation rate, and, in vitro, a decrease in the number of bone nodules and a decrease in the differentiation of osteoblasts in those nodules [49]. Mice missing FGF-18, in addition to the growth plate abnormalities noted earlier, also have a decrease in osteoblast number in the bones of limbs and a delay in growth of cranial bones [39,40]. Proliferation of preosteoblasts is transiently decreased in cranial sutures, and markers of differentiated osteoblasts, such as osteocalcin and osteopontin, were dramatically decreased. Thus, multiple FGFs and FGF receptors are needed for normal osteoblast production and differentiation.
THYROID HORMONE Children and rodents with hypothyroidism have decreased rates of bone lengthening. Although some of this decrease in growth plate function may be caused by associated decreases in GH levels, GH cannot fully correct abnormalities seen in rats and mice with hypothyroidism. These abnormalities include both shortened proliferative layers of chondrocytes and decreased numbers of hypertrophic chondrocytes [50]. At least some of the effects of thyroid hormone are likely to be direct effects on chondrocytes because both growth plates and isolated chondrocytes respond to T3 in vitro by increasing the conversion of proliferating to hypertrophic chondrocytes [51-53]. Genetically engineered mice missing all transcripts from both the thyroid hormone receptor 0~and b loci have a delay in development of secondary ossification centers, a decrease in the proliferative layer of chondrocytes, and a particularly dramatic decrease in hypertrophic chondrocytes [54]. This phenotype is not as severe as that in mice with congenital absence of thyroid glands, as in mice missing the pax8 gene [55]. These comparisons, as well as comparisons with mice missing selected transcripts from the complicated thyroid hormone receptor loci, suggest that nonligand-binding variants of these receptors function in the absence of thyroid hormone to generate a growth plate phenotype more severe than that in mice missing all transcripts from these loci [54]. Both receptor loci contribute to growth plate function. Some children with thyroid hormone resistance due to dominant negative mutations in the thyroid hormone receptor b gene have short stature, presumably partly through blockade of receptor action in the growth plate [56].
ESTROGEN AND ANDROGEN The effects of sex hormones on growth appear to be very species specific, so lessons from rodents cannot be easily applied to humans. In association with the increase in sex hormones in boys and girls at the time of puberty, linear bone growth accelerates, followed by the disappearance of the growth plate and permanent lack of further growth. Remarkably, several patients with defective estrogen receptor ~ [57] or defective aromatase (the enzyme that converts testosterone to estradiol) [58,59] have been identified. Studies of these patients have clarified certain aspects of the role of sex hormones in human bone growth, although little is known about the regulation of growth plate function at the molecular or even cellular level. Two girls without aromatase presented with signs of androgen excess but lack of a pubertal growth spurt until they were treated with estrogen [60]. Besides cartilage, bone cells and extracellular matrix cells are also required for skeletal growth. More specifically, the osteoblast or bone-forming cell contributes along with the chondrocyte to the longitudinal growth of the skeleton [61]. During skeletal growth, chondrocytes from the growth plate produce multiple spicules of cartilaginous extracellular matrix. These spicules enter the metaphysis, where the osteoblast adheres to them, adding a bony matrix to the cartilage to form mixed spicules. Mixed spicules located at the periphery of a given skeletal element are thought to anchor the metaphysis to the epiphysis. These more peripheral spicules grow in length, and this moves the growth plate centrifugally. This histologic observation suggests a role for the osteoblasts in the control of skeletal growth and has been confirmed by medical observations as well as by the generation and analysis of multiple mouse mutant strains.
OSTEOBLASTS AND BONE GROWTH The best human example of the critical role played by the osteoblasts in the control of longitudinal growth is provided by osteogenesis imperfecta (OI) patients. OI is a genetic disease characterized by synthesis and secretion by the osteoblasts of defective type I collagen molecules [62]. This can be viewed as a near complete arrest of osteoblast function in the most severe forms. Interestingly, all patients with severe forms of OI are shorter than expected given the existence of fractures (P. Byers, personal communication). Similar observations have been made in various mutant mouse strains that are obviously more amenable to a dissection of the cellular
4. Postnatal Bone Growth and molecular events taking place [63]. This critical role that the osteoblasts play in the control of growth illustrates the need to understand their biology during childhood and, by extension, the biology of the cells with which they interact during growth and remodeling, namely the osteoclasts. Indeed, bone, like many other organs in the body, goes through a tremendous amount of destruction and growth during childhood. Specific to bone, however, is that it is the only tissue or organ that contains a cell type (i.e., the osteoclast) whose only function is to destroy the organ hosting it. Thus, the interplay between osteoblasts and osteoclasts is particularly important. We review the current knowledge of the control of osteoblast and osteoclast differentiation and function. G e n e t i c Control of O s t e o b l a s t Differentiation a n d Function Like the chondrocyte, the osteoblast is a cell type of mesenchymal origin; however, chondrocytes may have multiple phenotypes and genotypes. Osteoblasts can be defined by several molecular criteria as those cells that express the transcription factor Cbfal, also called Runx2, and two structural proteins--~(I) collagen and osteocalcin. Transcription factors, as well as extracellular signaling molecules, have been shown to control various aspects of osteoblast biology; their numbers and variety have increased substantially in the past few years. Transcriptional Control of O s t e o b l a s t Differentiation a n d Function
Cbfal is the earliest and most specific marker of osteoblast differentiation. Functional studies have shown that it is a central regulator of osteoblast differentiation and function. The names given to this gene have changed several times since it was isolated. It was originally called PEBP2al, then AML3, Cbfal, and now Runx2 [64-66]. Cbfal is one of the mammalian homologs of the runt Drosophila transcription factor [67]. Three different lines of evidence indicate that Cbfal plays a dominant role during osteoblast differentiation, a function apparently not redundant with the function of any other gene. Following a molecular biology approach initially using the osteocalcin promoter, the only known osteoblastspecific gene, as a tool, Cbfal was identified as the factor binding to an osteoblast-specific cis-acting element present in the promoter of most genes expressed in osteoblasts [68-72]. Its expression during development and after birth is highly osteoblast specific and regulated by the bone morphogenetic proteins and other growth factors [73]. Lastly, and more important, its ectopic expression in nonosteoblastic cells leads to the expression
125
of osteoblast-specific genes in vitro and/n vivo [73]. Cbfal has been demonstrated to function as an osteoblast differentiation factor. Mouse and human genetic experiments demonstrated that this is its only function
in vivo. In a genetic approach, deletion of Cbfal in mice led to mutant animals in which the skeleton was made with chondrocytes producing cartilaginous matrix without any osteoblast, indicating that Cbfal is necessary for osteoblast differentiation [74,75]. Cbfal is also sufficient for osteoblast differentiation. This was proven by ectopic expression in primary fibroblast in vitro and in nonhypertrophic chondrocytes in vivo [76]. One study in which Cbfal deletion was performed examined Cbfa+/- mice and determined that they had hypoplastic clavicles and a delay in the structure of the fontannelles, two bone structures formed through intramembranous ossification [75]. These abnormalities are identical to those observed in a classical mouse mutation called cleidocranial dysplasia (CCD) [77]. Cbfal maps at the same location as does CCD and the two mutations are allelic [75]. The third line of evidence demonstrating the role of Cbfal in osteoblast differentiation derives from human genetic studies. Two groups, one searching for a gene causing human CCD and one searching for a disease in which Cbfal is mutated, simultaneously identified deletions, stop codon insertions, and missense mutations in CBFA1 in patients affected with CCD [78,79]. These different lines of investigation can be summarized as follows: Cbfal is expressed specifically in osteoblast progenitors, osteoblast, and, to a lesser extent, prehypertrophic chondrocytes; it is sufficient and necessary for osteoblast differentiation; and its function is dominant during osteoblast differentiation. It is not known what turns on Cbfal expression in vivo. Although BMPs can induce its expression in vitro, the time course needed for this induction is too long to be a direct effect and other signaling molecules must be involved. Moreover, there is no evidence that the BMPs control the late stage of skeletogenesis (i.e., osteoblast differentiation). Cbfal function in osteoblasts is not limited to cell differentiation during embryonic development. At least one in vivo study has shown that, in addition to development, Cbfal regulates the level of bone matrix deposited by previously differentiated osteoblasts [80]. Experiments are under way to demonstrate this second function of Cbfal, but one implication of this finding is that increasing the level of transcription of Cbfal in differentiated osteoblasts could be a treatment for osteoporosis. Several important aspects of Cbfal biology remain to be elucidated. Chief among these is whether or not Cbfal directly or indirectly controls the expression of other osteoblast-specific transcription factors. Other osteoblast-specific cis-acting elements have been described in
1 2.6
Gerard Karsentyand Henry M. Kronenberg
various genes that are expressed exclusively or mostly in osteoblasts, suggesting that other osteoblast-specific transcription factors have yet to be identified. Where these transcription factors lie in the pathway leading to osteoblast differentiation is unknown. Control of O s t e o b l a s t Differentiation by Secreted Molecules Indian hedgehog (Ihh) is one member of the hedgehog family of growth factors that is expressed in developing skeleton [81]. Misexpression experiments in chick first identified Ihh as a regulator of chondrocyte differentiation [82]. Ihh-deficient mice that survive to birth have a disorganized growth plate, as expected; however, they also have no osteoblasts in bone formed through endochondral ossification, but these appear to be present in the skull, the mandibles, and the clavicles~bones that form by intramembranous ossification [83]. It is not known whether this is a direct consequence of the absence oflhh signaling or whether it is an indirect effect. It is also unknown if this is simply a delay in osteoblast generation or an irreversible arrest of differentiation because Ihhdeficient mice die at birth. It seems clear, however, that the failure of osteoblast differentiation in bones forming through endochondral ossification may not be a consequence of the defect in chondrocyte differentiation. Transgenic mice overexpressing hedgehog-interacting protein (HIP) in choncrocytes have also been generated. HIP is a cell surface protein that binds Ihh with the same affinity as patched and antagonizes Ihh signaling [84]. Transgenic mice that overexpress HIP in chondrocytes show a chondrocyte phenotype similar to that of Ihhdeficient mice but have a large number of osteoblasts. The families of growth factors that have received a tremendous amount of attention are the BMPs. These are members of the transforming growth factor-b (TGF-b) superfamily of growth factors that can, when applied locally, induce de novo bone formation by recapitulating all the events that occur during skeleton development. The analysis of their functions in vivo has relied mostly on gene deletion experiments [85]. Although several BMPs affect skeletal patterning and joint formation, it has not been possible using this approach to show that they affect osteoblast differentiation. The best evidence that BMPs control osteoblast differentiation is indirect. Deletion of Tob, a gene encoding an antiproliferative protein, results in higher bone mass due to increased osteoblast numbers. Tob, which can associate with Smadl, -5, and-8, can repress BMP-2-induced, Smadmediated gene expression. BMP-2-induced bone formation is increased in Tob-deficient mice [86]. Interestingly, one of the BMPs, BMP-1, does not belong to the TGF-b superfamily but rather has homology to Tolloid, a gene
thought to be a protease in Drosophila based on genetic data [87]. In mouse, Bmp-1 has been demonstrated to encode a protease capable of releasing the C-terminal propeptide from the type I procollagen molecule, the most abundant protein of the bone extracellular matrix. Deletion of Bmp-1 has revealed the existence of other Bmp-l-like or Tolloid-like proteins that may also be involved in type I collagen processing [88,89]. TGF-b plays a complex role in bone remodeling. In vitro, TGF-b induces extracellular matrix synthesis by osteoblasts and affects osteoblast differentiation. In vivo, Erlebracher and Derynck [90] used a local overexpression strategy to study TGF-b function. Osteocalcin TGF-b2 transgenic mice developed a complex low bone mass phenotype characterized by an overall increase in bone resorption, a large increase of osteocyte numbers, and the presence of a hypomineralized matrix [90]. Additional mouse models overexpressing dominant negative forms of TGF-b receptors in osteoblasts or affecting the level of expression of TGF-b binding proteins will allow further determination of the role of TGF-b in osteoblast function [91]. Recently, based on genetic evidence another family of growth factors has been proposed to contribute to the control of osteoblast differentiation and proliferation the Wnt proteins [92]. Indeed, it was recently shown that the same gene is mutated in osteoporosis-pseudoglioma syndrome, an autosomal recessive form of osteoporosis [93], and in a familial form of high bone mass [94]. This gene encodes LDL receptor-related protein-5 (LRP-5). The former disease is due to the loss-of-function mutations, whereas the latter is caused by a gain-of-function mutation. Both diseases manifest after birth, indicating that the gene mutated and the pathway affected are active after birth. Lrp-5 is a vertebrate homolog of the Drosophila gene arrow, which is a coreceptor for wingless [95]. Lrp-5 acts as a corecepetor for the Wnt proteins in a cell culture assay. This finding, which is currently being investigated at the molecular level, raises the following question: Are the Wnt proteins controlling osteoblast differentiation and proliferation using as a mediator Lef/Tcf transcription factors and/or do they act in a Cbfal-dependent manner? Regardless of the answer, it seems likely, given the postnatal nature of these two phenotypes, that some Wnt proteins control osteoblast function and proliferation.
ENDOCRINE REGULATION OF BONE FORMATION The fact that bone remodeling occurs simultaneously in multiple skeletal locations is generally viewed as
4. Postnatal Bone Growth
evidence that it is controlled locally, through autocrine and/or paracrine mechanisms [96]. However, this observation is also consistent with the possibility that bone remodeling is under endocrine control. This would not be surprising since most other homeostatic functions are known to be under endocrine, if notneuroendocrine, control. Accordingly, several hormones are known to control bone remodeling. For instance, sex steroid hormones such as estradiol are clearly involved in the control of bone remodeling by affecting osteoclast differentiation and thereby bone resorption. As a result, the declining level of sex steroid hormones at menopause is a predisposing factor for osteoporosis [96,97]. Likewise, parathyroid hormone also favors bone resorption [98,99]. The hormones mentioned previously act on bone resorption in physiological conditions. This raises the following question: Is bone formation also under endocrine control? Without presaging on which aspect of bone remodeling they may act, two well-known clinical observations suggest that other hormones besides sex steroids and PTH regulate bone remodeling. The first observation is that obesity protects from bone loss [40], and the second is that menopause favors bone loss. Together, they suggest that bone mass, body weight, and reproduction are regulated by the same hormone(s). Leptin as a Regulator of Bone Formation Leptin is an attractive candidate for such a hormone. Leptin is synthesized by adipocytes and functions as a starvation and adiposity signal through its binding to the long form of its receptor located primarily in the hypothalamus [100,101]. Rodents and humans genetically deficient in leptin signaling are massively obese. The absence of leptin signaling also causes sterility (i.e., hypogonadism), a condition usually causing bone loss. Surprisingly, mice deficient in leptin (ob/ob) or its receptor (db/db) were found to have a two- or threefold higher bone mass than wild-type mice [102]. The ob/ob and db/ db mice are the only known animal models with both hypogonadism and high bone mass; therefore, they are invaluable resources for studying the molecular basis of bone remodeling. Bone histomorphometry analysis performed before and after correction of the hypogonadism of ob/ob mice showed that leptin inhibits bone formation through its action on osteoblasts, whereas it has no overt effect on osteoclast differentiation and function. Importantly, leptin action on bone formation did not involve osteoblast differentiation because ob/ob and db/db mice have a normal number of osteoblasts. This latter observation indicates that any local mode of action of leptin on bone that exists must affect previously differentiated osteoblasts and not their progenitors. The leptin receptor
127
does not appear to be expressed on differentiated osteoblasts, and in cell culture studies osteoblasts from db/db mice behave like wild-type osteoblasts. These data indicate that leptin does not directly target osteoblasts. Moreover, intracerebroventricular (ICV) infusion of leptin in ob/ob mice completely rescues their bone phenotype. The fact that this occurs without any circulating leptin in the serum of these animals demonstrates that bone formation, and therefore bone remodeling, is centrally controlled probably via the hypothalamus (Fig. 3). ICV infusion of leptin in wild-type mice causes bone loss, indicating that this regulatory loop has physiological relevance in wild-type animals [102]. By definition, if bone remodeling is a physiologic process with a hypothalamic or central component, then diseases of bone remodeling such as osteoporosis may also have a hypothalamic or central component. As is the case for the control of body weight, the role of leptin in bone formation is not merely a "mouse story." Rats deficient in leptin signaling also have a high bone mass phenotype (M. Amling and G. Karsenty, unpublished observation). Patients with generalized lipodystrophy, a condition marked by a near complete absence of adipocytes and white fat, also exhibit osteosclerosis (increased bone formation) and accelerated bone growth [103]. It is difficult to assess whether leptin-deficient patients do or do not have a high bone mass because these patients are treated with leptin early. It is known from work on ob/ob and db/db mice that the high bone mass phenotype becomes more severe as the animals age. Finally, leptin's role in bone formation may help explain why obese individuals, who are often leptin resistant [104], are protected from bone loss. These results also demonstrate the importance of leptin by showing that, like other major hormones such as thyroid hormones or cortisol, it has multiple target organs and functions (bone mass, body weight, and reproduction) without a necessary hierarchy between them. However, leptin is unlikely to be the sole central regulator of bone formation. Other undiscovered centrally acting hormones may positively or negatively regulate bone formation and possibly other aspects of bone physiology. Transcription Control of O s t e o c l a s t Differentiation a n d Function A recurrent theme in bone biology is that many of the genes identified as regulators of cell differentiation or function in the osteoclast and osteoblast lineage have been known for a long time. However, possibly because bone cells are more difficult to isolate, or possibly because skeletal development initially appeared less attractive than other organogenesis processes, they were not
128
Gerard Karsenty and Henry M. Kronenberg
originally studied in the context of the skeleton.
Pu-1 function in osteoclast differentiation is one of the best examples. Pu-1 is an ETS domain-containing transcription factor that is expressed specifically in the monocytic and B lymphoid lineages [105]. Deletion of Pu-1 results in a multilineage defect in the generation of progenitors for B and T lymphocytes, monocytes, and granulocytes. The fact that Pu-1 was thought to regulate transcription of c-fms, which plays an important role in osteoclast biology, led Tondravi et al. [106] to explore the possibility that Pu-1 might also control osteoclast development. As hypothesized by this group, Pu-l-deficient mice exhibit a classical osteopetrosis phenotype. There are no osteoclasts and no macrophages in the bone marrow of Pu-l-deficient mice. This is a cell autonomous defect that can be corrected by bone marrow transplantation [106]. Pu-1 is the earliest marker of osteoclast differentiation because it controls both macrophage and osteoclast differentiation. However, no cell type decides in an autonomous manner to differentiate along a particular lineage; thus, one of the challenges in the field is to identify the extracellular signals that induce the expression of PU-1 and of other cell-specific transcription factors involved in osteoclast differentiation. Another transcription factor that plays a critical role during osteoclast differentiation is c-fos [107], which is the cellular homolog of the v-fos oncogene and a major component of the AP-1 transcription factor. The first indication that c-fos might play a role in bone cell differentiation came from the observation that v-fos-containing constructs injected into rodents led to the appearance of osteosarcomas (malignant tumors of the osteoblast) [Ward, 1976 #352]. Likewise, transgenic mice expressing high levels of c-fos in multiple tissues and cell types eventually developed only one type of tumor---vhondroblastic osteosarcoma--and cloned cell lines derived from these transgenic mice have altered osteoblastic gene expression. Given the results of these studies, it came as a surprise that the deletion of c-fos in mice led to an early arrest of osteoclast differentiation without any overt consequences on osteoblast differentiation. As a result of this block in osteoclast differentiation, the main phenotype of c-fosdeficient mice is osteopetrosis [108,109]. The presence of a large number of macrophages in c-fos-deficient mice places c-Fos downstream of Pu-1 in the genetic pathway controlling osteoclast differentiation. The osteopetrotic phenotype of the c-fos-deficient mice was rescued by bone marrow transplantation and by expression of a c-fos transgene [110]. Although other c-fos-related proteins are expressed in osteoclasts, c-fos fulfills a unique function because no other proteins can substitute in vivo for its loss of function. However, c-fos may not be the only member of thefos gene family to contribute to osteoclast differen-
tiation because the fos-related protein Fra-1 can favor osteoclast differentiation in osteoclast macrophage precursor cell lines. A third transcription factor, NF-•B, appears to play a role early during osteoclast differentiation. NF-~:B is formed as a dimer composed of various combinations of proteins: p50, p52, p65, c-Rel, and RelB [111]. These proteins are all related by the Rel homology domain that contains the DNA-binding motif. Through genetic analysis in mice, it was shown that each of these proteins plays an essential and unique role in immune response, but no defects in bone cell differentiation were observed [112,113]. In contrast, mice deficient in both p50 and p52 harbor an osteopetrosis phenotype due to an arrest of osteoclast differentiation. These findings are also important because NF-KB seems to be one of the targets of recently identified growth factors that regulate osteoclast differentiation. The last transcription factor that plays a role in osteoclast differentiation was identified by searching the gene mutated in the mouse mutant microphtalmia (mi). mi mice have the following defects: loss of pigmentation, reduced eye size, and failure of secondary bone resorption [114]. The gene mutated in these mice encodes a bHLH transcription factor called mi [115]. In mi mice, osteoclasts differentiate normally but they fail to resorb bones, thus placing mi downstream of the transcription factors mentioned previously (Fig. 1). The wealth of transcription factors controlling osteoclast differentiation contrasting with the apparent paucity of known osteoclast-specific factors was unexpected. It suggests that many of the genes involved in bone resorption and expressed specifically in osteoclasts have not been identified. Another observation common to most of these osteopetrotic mutants is that although bone resorption was arrested, bone formation was not halted; otherwise, the osteopetrosis phenotype would not exist. In some cases, bone formation was even accelerated--a genetic indication that these two functions may be regulated by different growth factors or hormones
in vivo. Control of O s t e o c l a s t Differentiation a n d Function by S e c r e t e d M o l e c u l e s The requirement for secreted molecules to control osteoclast differentiation was first documented with the genetic elucidation of a classical mouse mutation called op/op [116]. Mice homozygous for this recessive mutation lack osteoclasts and macrophages. The osteopetrotic phenotype of op/op mice is not cured by bone marrow transplantation, indicating that it is non-cell-autonomous defect [116]. The gene mutated in op/op mice encodes the growth factor macrophage colony-stimulating factor
4. Postnatal Bone Growth
(m-CSF), a gene thought to be regulated by PU-1 [117]. Forced expression of Bcl-2, a gene that prevents apoptosis in monocytes, can partially reverse osteopetrosis of the op/op mice, suggesting that the function of m-CSF may be to favor survival of osteoclast progenitors [118]. In the past 3 years, a group of secreted molecules regulating positive or negative osteoclast differentiation have been identified. The genetic and molecular analysis of these molecules has profoundly modified our understanding of bone resorption. In a large genomic screen for novel secreted molecules, a group at Amgenidentified a novel member of the TNF receptor superfamily [119]. This novel molecule contains no hydrophobic transmembrane-spanning sequence, indicating that it is a soluble receptor. Overexpression in transgenic mice of this molecule, called osteoprotegerin (OPG), resulted in severe osteopetrosis due to an arrest of osteoclast differentiation. This molecule is identical to osteoclastogenesis inhibitory factor (OCIF), which was purified and subsequently cloned by another group at Snowbrand Pharmaceutical in Japan using a different approach [120]. The identification and the functional study of OPG/OCIF are very important for another reason. They showed that, in addition to steroid and peptide hormones, there are novel secreted molecules that can act systematically, not in a paracrine/autocrine fashion, to control osteoclast differentiation. The specificity of the function of OPG/OCIF in inhibiting osteoclast differentiation was demonstrated by the phenotype of OPG/OCIF-deficient mice. These mice develop an osteoporosis due to an increase in osteoclasts number [121,122]. The identification of a soluble receptor with such a powerful inhibitory effect on osteoclast differentiation suggested that it may be titering out an osteoclast differentiation activity. This factor was cloned by the same two groups at approximately the same time. The Amgen group used recombinant OPG/OCIF to screen for OPG/ OCIF ligand on the surface of various cell lines. They replaced the criteria of absolute novelty with the criteria of specificity of interaction with OPG. The protein they isolated had previously been cloned and called TRANCE or R A N K ligand (RANKL). RANKL is present on the membrane of the osteoblast progenitor but also as a soluble molecule in bone microenvironment. In vitro, RANKL/osteoclast differentiation factor (ODF) has all the attributes of a real osteoclast differentiation factor: It favors osteoclast differentiation in conjunction with m-CSF, it bypasses the need for stromal cells and 1,25(OH)2 vitamin D3 to induce osteoclast differentiation, and it activates mature osteoclasts to resorb mineralized bone [123]. Consistent with this cell and molecular biology data, RANKL-deficient mice lack osteoclasts and develop a severe osteopetrosis phenotype
| 29
in addition to an immunological phenotype. At the same time, Yasuda et al. [120], pursuing their systematic biochemistry and molecular biology effort, purified to homogeneity the ODF and showed that it was the R A N K ligand [120]. RANKL/ODF is also expressed and synthesized by T cells. Conceivably, the production and secretion of RANKL/ODF systematically or locally by T cells may explain some of the bone abnormalities observed in autoimmune disorders. RANKL binds to RANK because of a cellular receptor present on T cells and bone marrow stromal cells [124,125]. Transgenic mice expressing a soluble form of R A N K develop an osteopetrosis similar to the one observed in OPGL/ODF-deficient mice and polyclonal antibody against R A N K extracellular domain promotes osteoclastogenesis in bone marrow culture, suggesting that R A N K activation mediates the effect of OPGL. What signal transduction pathway is initiated following binding of RANKL to RANK? R A N K intracellular domain contains two binding sites for members of a family of proteins called TNF receptor-associated factors (TRAFs) [126]. TRAFs have been implicated in mediating signals induced by a subset of TNF receptor family members. R A N K contains a binding site for TRAF6 in the middle of its intracellular region [127]. Importantly, TRAF6-deficient mice exhibit an osteopetrotic phenotype, thus providing the beginning of a signal transduction cascade leading to osteoclast differentiation [128]. This observation is also important because TRAFs seem to control the activation of NF-•B, a transcription factor required for osteoclast differentiation. Given all the information available, it is now possible to summarize the role of each component of this signal transduction pathway (Figs. 2 and 3). Other cytokines, such as interleukin-1 (IL-1), IL-2, IL-6, and oncostatin M,, all transduce their signals through gp 130 and can induce osteoclast differentiation in vitro. Their role in vivo has been difficult to establish, possibly because of functional redundancy; nevertheless, unpublished observations from several laboratories indicate that signal transduction through the gp 130 protein plays an important role in osteoclast and osteoblast physiology [129]. Another regulatory gene whose functional skeletal identity was revealed by mouse genetics in c-src, the cellular homolog of the v-src oncogene, which belongs to a large family of tyrosine kinases, c-src is ubiquitously expressed, although its highest level of expression is in platelet and neurons [130]. However, its deletion through gene targeting led to an osteopetrotic phenotype [131]. In c-src-deficient mice, osteoclasts are present but fail to resorb mineralized bone. The mechanisms by which c-src genes control osteoclast function have been and remain the object of multiple investigations. In 1997,
130
Gerard Karsenty and Henry M. Kronenberg
Schwarzberg et al. used a transgenic approach that showed that rescue of the phenotype was not dependent of the kinase domain. In other lines of investigation, Tanaka et al. identified c-cbl as a downstream gene in a signaling pathway required for bone resorption. In 1998, Duong et al. presented evidence suggesting that phosphorylation of Pyk2, a cytoplasmic kinase activated by Src, is required for osteoclastic bone resorption. The existence of an osteopetrotic phenotype in Pyk2-deficient mice lends further credence to this finding. The list of regulatory genes controlling osteoclast differentiation and function is already surprisingly long, but it may not be complete because there are two mouse mutations causing osteopetrosis for which the mutated gene has still not been identified: oc/oc and gray lethal [132].
References 1. Bi, W., Deng, J. M., Zhang, Z., Behringer, R. R., de Crombrugghe, B. (1999). Sox9 is required for cartilage formation. Nature Genet. 22, 85-99. 2. Horton, W. E., Jr., Feng, L., and Adams, C. (1998). Chondrocyte apoptosis in development, aging and disease. Matrix Biol. 17 (2), 107-115. 3. St.-Jacques, B., Hammerschmidt, M., and McMahon, A. (1999). Indian hedgehog signaling regulates proliferation and differentiation of chondrocytes and is essential for bone formation. Genes Dev. 13 (16), 2072-2086. 4. Chung, U. I., Schipani, E., McMahon, A. P., and Kronenberg, H. M. (2001). Indian hedgehog couples chondrogenesis to osteogenesis in endochondral bone development [see Comments]. J. Clin. Invest. 107 (3), 295-304. 5. Hunziker, E. B. (1994). Mechanism of longitudinal bone growth and its regulation by growth plate chondrocytes. Microsc. Res. Technique 28 (6), 505-519. 6. Ducy, P., Starbuck, M., Priemel, M., Shen, J., Pinero, G., Geoffroy, V., et al. (1999). A Cbfal-dependent genetic pathway controls bone formation beyond embryonic development. Genes Dev. 13 (8), 1025-1036. 7. Morriss-Kay, G. M. (2001). Derivation of the mammalian skull vault. J. Anat. 199 (Pts. 1-2), 143-151. 8. Opperman, L. A. (2000). Cranial sutures as intramembranous bone growth sites. Dev. Dyn. 219 (4), 472-485. 9. Salmon, W. D. J. (1957). A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro. J. Lab. Clin. Med. 49, 825-836. 10. Daughaday, W. H., Hall, K., Raben, M. S., Salmon, W. D., Jr., van den Brande, J. L., and van Wyk, J. J. (1972). Somatomedin: Proposed designation for sulphation factor. Nature 235 (5333), 107. 11. Salmon, W. D., Jr., and Burkhalter, V. J. (1997). Stimulation of sulfate and thymidine incorporation into hypophysectomized rat cartilage by growth hormone and insulin-like growth factor-I in vitro: The somatomedin hypothesis revisited [see Comments] [erratum appears in J. Lab. Clin. Med. 1997 Jul; 130 (1):4]. J. Lab. Clin. Med. 129 (4), 430-438. 12. Zhou, Y., Xu, B. C., Maheshwari, H. G., He, L., Reed, M., Lozykowski, M., et al. (1997). A mammalian model for Laron syndrome produced by targeted disruption of the mouse growth hormone receptor/binding protein gene (the Laron mouse). Proc. Natl. Acad. Sci. USA 94 (24), 13215-13220.
13. Laron, Z. (2001). Insulin-like growth factor 1 (IGF-1): A growth hormone. Mol. Pathol. 54 (5), 311-316. 14. Coschigano, K. T., Clemmons, D., Bellush, L. L., and Kopchick, J. J. (2000). Assessment of growth parameters and life span of GHR/BP gene-disrupted mice. Endocrinology 141 (7), 2608-2613. 15. Chandrashekar, V., Bartke, A., Coschigano, K. T., and Kopchick, J. J. (1999). Pituitary and testicular function in growth hormone receptor gene knockout mice. Endocrinology 140 (3), 1082-1088. 16. Sjogren, K., Bohlooly, Y. M., Olsson, B., Coschigano, K., Tornell, J., Mohan, S., et al. (2000). Disproportional skeletal growth and markedly decreased bone mineral content in growth hormone receptor - / - mice. Biochem. Biophys. Res. Commun. 267 (2), 603-608. 17. Lupu, F., Terwilliger, J. D., Lee, K., Segre, G. V., and Efstratiadis, A. (2001). Roles of growth hormone and insulin-like growth factor 1 in mouse postnatal growth. Dev. Biol. 229, 141-162. 18. Rosenbloom, A. L., Guevara-Aguirre, J., Rosenfeld, R. G., and Francke, U. (1999). Growth hormone receptor deficiency in Ecuador. J. Clin. Endocrinol. Metab. 84 (12), 4436-4443. 19. Baker, J., Liu, J. P., Robertson, E. J., and Efstratiadis, A. (1993). Role of insulin-like growth factors in embryonic and postnatal growth. Cell 75, 73-82. 20. Liu, J. P., Baker, J., Perkins, A. S., Robertson, E. J., and Efstratiadis, A. (1993). Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igflr). Cell 75, 59-72. 21. Powell-Braxton, L., Hollingshead, P., Warburton, C., Dowd, M., Pitts-Meek, S., Dalton, D., et al. (1993). IGF-I is required for normal embryonic growth in mice. Genes Dev. 7 (12B), 2609-2617. 22. Woods, K. A., Camacho-Hubner, C., Savage, M. O., and Clark, A. J. (1996). Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor I gene [see Comments]. N. Engl. J. Med. 335 (18), 1363-1367. 23. Wang, J., Zhou, J., and Bondy, C. A. (1999). Igfl promotes longitudinal bone growth by insulin-like actions augmenting chondrocyte hypertrophy. F A S E B J. 13 (14), 1985-1990. 24. Ohlsson, C., Bengtsson, B. A., Isaksson, O. G., Andreassen, T. T., and Slootweg, M. C. (1998). Growth hormone and bone. Endocr. Rev. 19, 55-79. 25. Ohlsson, C., Nilsson, A., Isaksson, O., and Lindahl, A. (1992). Growth hormone induces multiplication of the slowly cycling germinal cells of the rat tibial growth plate. Proc. Natl. Acad. Sci. USA 89 (20), 9826-9830. 26. Reinecke, M., Schmid, A. C., Heyberger-Meyer, B., Hunziker, E. B., and Zapf, J. (2000). Effect of growth hormone and insulin-like growth factor I (IGF-I) on the expression of IGF-I messenger ribonucleic acid and peptide in rat tibial growth plate and articular chondrocytes in vivo. Endocrinology 141 (8), 2847-2853. 27. Sjogren, K., Liu, J. L., Blad, K., Skrtic, S., Vidal, O., Wallenius, V., et al. (1999). Liver-derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice. Proc. Natl. Acad. Sci. USA 96 (12), 7088-7092. 28. Yakar, S., Liu, J. L., Stannard, B., Butler, A., Accili, D., Sauer, B., et al. (1999). Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc. Natl. Acad. Sci. USA 96 (13), 7324-7329. 29. DeChiara, T. M., Efstratiadis, A., and Robertson, E. J. (1990). A growth-deficiency phenotype in heterozygous mice carrying an insulin-like growth factor II gene disrupted by targeting. Nature 345 (6270), 78-80.
4. Postnatal Bone Growth 30. Louvi, A., Accili, D., and Efstratiadis, A. (1997). Growthpromoting interaction of IGF-II with the insulin receptor during mouse embryonic development. Dev. Biol. 189, 33-48. 31. von Horn, H., Ekstrom, C., Ellis, E., Olivecrona, H., Einarsson, C., Tally, M., et al. (2002). GH is a regulator of IGF2 promoter-specific transcription in human liver. J. Endocrinol. 172 (3), 457-465. 32. Ornitz, D., and Marie, P. (2002). FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease. Genes Dev. 16 (12), 1446-1465. 33. Ornitz, D. M., and Itoh, N. (2001). Fibroblast growth factors.
49.
50.
Genome Biol. 2 (3).
34. Xu, X., Weinstein, M., Li, C., and Deng, C. (1999). Fibroblast growth factor receptors (FGFRs) and their roles in limb development. Cell Tissue Res. 296, 33-43. 35. Colvin, J. S., Bohne, B. A., Harding, G. W., McEwen, D. G., and Ornitz, D. M. (1996). Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3. Nature Genet. 12 (4), 390-397. 36. Deng, C., Wynshaw-Boris, A., Zhou, F., Kuo, A., and Leder, P. (1996). Fibroblast growth factor receptor 3 is a negative regulator of bone growth. Cell 84 (6), 911-921. 37. Sahni, M., Ambrosetti, D. C., Mansukhani, A., Gertner, R., Levy, D., and Basilico, C. (1999). FGF signaling inhibits chondrocyte proliferation and regulates bone development through the STAT-1 pathway. Genes Dev. 13 (11), 1361-1366. 38. Sahni, M., Raz, R., Coffin, J. D., Levy, D., and Basilico, C. (2001). STAT1 mediates the increased apoptosis and reduced chondrocyte proliferation in mice overexpressing FGF2. Dev. Suppl. 128 (11), 2119-2129. 39. Liu, Z., Xu, J., Colvin, J. S., and Ornitz, D. M. (2002). Coordination of chondrogenesis and osteogenesis by fibroblast growth factor 18. Genes Dev. 16 (7), 859-869. 40. Ohbayashi, N., Shibayama, M., Kurotaki, Y., Imanishi, M., Fujimori, T., Itoh, N., et al. (2002). FGF18 is required for normal cell proliferation and differentiation during osteogenesis and chondrogenesis. Genes Dev. 16 (7), 870-879. 41. Arman, E., Haffner-Krausz, R., Chen, Y., Heath, J. K., and Lonai, P. (1998). Targeted disruption of fibroblast growth factor (FGF) receptor 2 suggests a role for FGF signaling in pregastrulation mammalian development. Proc. Natl. Acad. Sci. USA 95 (9), 5082-5087. 42. Arman, E., Haffner-Krausz, R., Gorivodsky, M., and Lonai, P. (1999). Fgfr2 is required for limb outgrowth and lung-branching morphogenesis. Proc. Natl. Acad. Sci. USA 96 (21), 11895-11899. 43. Ornitz, D. M. (2002). G F G and FGF receptor signaling in skeletal development and genetic disease, Abstact #$56-1. In Program and Abstracts, Endo 2002, San Francisco, June 19-22, p. 54. 44. Baitner, A. C., Maurer, S. G., Gruen, M. B., and Di Cesare, P. E. (2000). The genetic basis of the osteochondrodysplasias. J. Pediatr. Orthop. 20 (5), 594-605. 45. Zhou, Y. X., Xu, X., Chen, L., Li, C., Brodie, S. G., and Deng, C. X. (2000). A Pro250Arg substitution in mouse Fgfr 1 causes increased expression of Cbfal and premature fusion of calvarial sutures. Hum. Mol. Genet. 9 (13), 2001-2008. 46. Ducy, P., Zhang, R., Geoffroy, V., Ridall, A. L., and Karsenty, G. (1997). Osf2/Cbfal: A transcriptional activator of osteoblast differentiation [see Comments]. Cell 89 (5), 747-754. 47. Komori, T., Yagi, H., Nomura, S., Yamaguchi, A., Sasaki, K., Deguchi, K., et al. (1997). Targeted disruption of Cbfa 1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts [see Comments]. Cell 89 (5), 755-764. 48. Lemonnier, J., Hay, E., Delannoy, P., Fromigue, O., Lomri, A., Modrowski, D., et al. (2001). Increased osteoblast apoptosis in
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.
61.
62. 63.
64.
65.
1 31
apert craniosynostosis: Role of protein kinase C and interleukin1. Am. J. Pathol. 158 (5), 1833-1842. Montero, A., Okada, Y., Tomita, M., Ito, M., Tsurukami, H., Nakamura, T., et al. (2000). Disruption of the fibroblast growth factor-2 gene results in decreased bone mass and bone formation. J. Clin. Invest. 105 (8), 1085-1093. Stevens, D. A., Hasserjian, R. P., Robson, H., Siebler, T., Shalet, S. M., and Williams, G. R. (2000). Thyroid hormones regulate hypertrophic chondrocyte differentiation and expression of parathyroid hormone-related peptide and its receptor during endochondral bone formation. J. Bone Miner. Res. 15 (12), 2431-2442. Burch, W. M., and Lebovitz, H. E. (1982). Triiodothyronine stimulation of in vitro growth and maturation of embryonic chick cartilage. Endocrinology l l l (2), 462-468. Burch, W. M., and Lebovitz, H. E. (1982). Triiodothyronine stimulates maturation of porcine growth-plate cartilage in vitro. J. Clin. Invest. 70 (3), 496-504. Robson, H., Siebler, T., Stevens, D. A., Shalet, S. M., and Williams, G. R. (2000). Thyroid hormone acts directly on growth plate chondrocytes to promote hypertrophic differentiation and inhibit clonal expansion and cell proliferation. Endocrinology 141 (10), 3887-3897. Gauthier, K., Plateroti, M., Harvey, C. B., Williams, G. R., Weiss, R. E., Refetoff, S., et al. (2001). Genetic analysis reveals different functions for the products of the thyroid hormone receptor alpha locus. Mol. Cell. Biol. 21 (14), 4748-4760. Harvey, C. B., O'Shea, P. J., Scott, A. J., Robson, H., Siebler, T., Shalet, S. M., et al. (2002). Molecular mechanisms of thyroid hormone effects on bone growth and function. Mol. Genet. Metab. 75, 17-30. Weiss, R. E., and Refetoff, S. (1996). Effect of thyroid hormone on growth. Lessons from the syndrome of resistance to thyroid hormone. Endocrinol. Metab. Clin. North Am. 25 (3), 719-730. Smith, E. P., Boyd, J., Frank, G. R., Takahashi, H., Cohen, R. M., Specker, B., et al. (1994). Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N. Engl. J. Med. 331 (16), 1056-1061. Carani, C., Qin, K., Simoni, M., Faustini-Fustini, M., Serpente, S., Boyd, J., et al. (1997). Effect of testosterone and estradiol in a man with aromatase deficiency. N. Engl. J. Med. 337 (2), 91-95. Bilezikian, J. P., Morishima, A., Bell, J., and Grumbach, M. M. (1998). Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency. N. Engl. J. Med. 339 (9), 599-603. Grumbach, M. M., and Auchus, R. J. (1999). Estrogen: Consequences and implications of human mutations in synthesis and action [see Comments]. J. Clin. Endocrinol. Metab. 84 (12), 4677-4694. Warshawsky, H. (1982). Embryology and development of the skeletal system. In The Musculoskeletal System: Embryology, Biochemistry and Physiology, pp. 33-56. Churchill Livingston, New York. Byers, P. H., and Steiner, R. D. (1992). Osteogenesis imperfecta. Annu. Rev. Med. 43, 269-282. Corral, D., Amling, M., Prienel, M., Loyer, E., Fuchs, S., Ducy, P., et al. (1998). Dissociation between bone resorption and bone formation in osteopenic transgenic mice. Proc. Natl. Acad. Sci. USA 95, 13835-13840. Ogawa, E., Maruyama, M., Kagoshima, H., Inuzuka, M., Lu, J., Satake, M., et al. (1993). PEBP2/PEA2 represents a family of transcription factors homologous to the products of the Drosohila runt gene and the human A M L 1 gene. Proc. Natl. Acad. Sci. USA 90, 6859-6863. Levanon, D., Negreanu, V., Bernstein, Y., Bar-Am, I., Avivi, L., and Groner, Y. (1994). AML1, AML2, and AML3, the human
132
66.
67.
68.
69.
70.
71.
72.
73. 74.
75.
76.
77. 78.
79.
80.
81.
82.
Gerard Karsenty and Henry M. Kronenberg
members of the runt domain gene-family: cDNA structure, expression, and chromosomal localization. Genomics 23, 425-432. Speck, N. A., and Stacy, T. (1995). A new transcription factor family associated with human leukemias. CRC Crit. Rev. Eukaryot. Gene Expression 5, 337-364. Gergen, J. P., and Wieschaus, E. (1986). Dosage requirements for runt in the segmentation of Drosophila embryos. Cell 45, 289-299. Ducy, P., and Karsenty, G. (1995). Two distinct osteoblast-specific cis-acting elements control expression of a mouse osteocalcin gene. Mol. Cell. Biol. 15, 1858-1869. Banerjee, C., McCabe, L. R., Choi, J. Y., Hiebert, S. W., Stein, J. L., Stein, G. S., et al. (1997). Runt homology domain proteins in osteoblast differentiation: AML3/CBFA1 is a major component of a bone-specific complex. J. Cell. Biochem. 66, 1-8. Li, Y. C., Amling, M., Pirro, A., Priemel, M., Meuse, J., Baron, R., et al. (1998). Normalization of mineral ion homeostasis by dietary means prevents hyperparathyroidism, rickets, and osteomalacia, but not alopecia in vitamin D receptor-ablated mice. Endocrinology 139, 4391-4396. Jimenez, M. J., Balbin, M., Lopez, J. M., Alvarez, J., Komori, T., and Lopez-Otin, C. (1999). Collagenase 3 is a target of Cbfal, a transcription factor of the runt gene family involved in bone formation. Mol. Cell. Biol. 19, 4431-4442. Porte, D., Tuckermann, J., Becker, M., Baumann, B., Teurich, S., Higgins, T., et al. 0. Both AP-1 and Cbfal-like factors are required for the induction of interstitial collagenase by parathyroid hormone. Oncogene 18, 667-678. Ducy, P., Zhang, R., Geoffroy, V., Rydall, A. L., and Karsenty, G. (1997). Osf2/Cbfa 1, a transcriptional regulator of osteoblast differentiation. Cell 89, 747-754. Komori, T., Yagi, H., Nomura, S., Yamaguchi, A., Sasaki, K., Deguchi, K., et al. (1997). Targeted disruption of Cbfa 1 results in a complete lack of bone formation owing to maturational arrest of osteoblast. Cell 89, 755-764. Otto, F., Thornell, A. P., Crompton, T., Denzel, A., Gilmour, K. C., Rosewell, I. R., et al. (1997). Cbfal, a candidate gene for cleidocranial dysplasia, is essential for osteoblast differentiation and bone development. Cell 89, 765-771. Takeda, S., Bonnamy, J. P., Owen, M. J., Ducy, P., and Karsenty, G. (2001). Continuous expression of Cbfal in non-hypertrophic chondrocytes uncovers its ability to induce hypertrophic chondrocytes differentiation and partially rescues Cbfal-deficient mice. Genes Dev. 15, 467-481. Sillence, D. O., Ritchie, H. E., and Selby, P. B. (1987). Animal model: Skeletal anomalies in mice with cleidocranial dysplasia. Am. J. Med. Genet. 27, 75-85. Lee, B., Thirunavukkararsu, K., Zhou, L., Pastore, L., Baldini, A., Hecht, J., et al. (1997). Missense mutations abolishing DNA binding of the osteoblast-specific transcription factor OSF2/Cbfal in cleidocranial dysplasia. Nature Genet. 16, 307-310. Mundlos, S., Otto, F., Mundlos, C., Mulliken, J. B., Aylsworth, A. S., Albright, S., et al. (1997). Mutations involving the transcription factor CBFA1 cause cleidocranial dysplasia. Cell 89, 773-779. Ducy, P., Starbuck, M., Priemel, M., Shen, J., Pinero, G., Geoffroy, V., et al. (1999). A'Cbfal-dependent genetic pathway controls bone formation beyond embryonic development. Genes Dev. 13, 1025-1036. Bitgood, M. J., and McMahon, A. P. (1995). Hedgehog and BMP genes are coexpressed at many diverse sites of cell-cell interaction in the mouse embryo. Dev. Biol. 172, 126-138. Vortkamp, A., Lee, K., Lanske, B., Segre, G. V., Kronenberg, H. M., and Tabin, C. J. (1996). Regulation of rate
83.
84.
85. 86.
87.
88.
89.
90. 91.
92. 93. 94.
95. 96. 97.
98.
99.
100.
of cartilage differentiation by Indian hedgehog and PTH-related protein. Science 273 (5275), 613-622. St.-Jacques, B., Hammerschmidt, M., and McMahon, A. P. (1999). Indian hedgehog signaling regulates proliferation and differentiation of chondrocytes and is essential for bone formation. Genes Dev. 13, 2072-2086. Chuang, P. T., and McMahon, A. P. (1999). Vertebrate Hedgehog signalling modulated by induction of a Hedgehog-binding protein. Nature 397, 617-621. Hogan, B. L. M. (1996). Bone morphogenetic proteins: Multifunctional regulators of vertebrate development. Genes Dev. 10, 1580-1594. Yoshida, Y., Tanaka, S., Umemori, H., Minowa, O., Usui, M., Ikematsu, N., et al. (2000). Negative regulation of BMP/Smad signaling by Tob in osteoblasts. Cell 103 (7), 1085-1097. Shimmel, M. J., Ferguson, E. L., Childs, S. R., and O'Connor, M. B. (1991). The Drosophila dorsal-ventral patterning gene tolloid is related to human bone morphogenetic protein 1. Cell 67 (469-481). Suzuki, N., Labosky, P. A., Furuta, Y., Hargett, L., Dunn, R., Fogo, A. B., et al. (1996). Failure of ventral body wall closure in mouse embryos lacking a procollagen C-proteinase encoded by Bmp 1, a mammalian gene related to Drosophila tolloid. Development 122, 3587-3595. Lee, S., Solow-Cordero, D. E., Kessler, E., Takahara, K., and Greenspan, D. S. (1997). Transforming growth factor-beta regulation of bone morphogenetic protein- 1/procollagen C-proteinase and related proteins in fibrogenic cells and keratinocytes. J. Biol. Chem. 272, 19056-19066. Erlebacher, A., and Derynck, R. (1996). Increased expression of TGF-beta 2 in osteoblasts results in an osteoporosis-like phenotype. J. Cell Biol. 132, 195-210. Erlebacher, A., Filvaroff, E. H., Ye, J. Q., and Derynck, R. (1998). Osteoblastic responses to TGF-beta during bone remodeling. Mol. Cell. Biol. 9, 1903-1918. Sharpe, C., Lawrence, N., and Arias, A. F. (2001). Wnt signalling: A theme with nuclear variations. Bioesssays 23, 311-318. Somer, H., Palotie, A., Somer, M., Hoikka, V., and Peltonen, L. (1988). Osteoporosis-pseudoglioma syndrome: Clinical, morphological, and biochemical studies. J. Med. Genet. 25, 543-549. Gong, Y., Slee, R. B., Fukai, N., Rawadi, G., Roman-Roman, S., Reginato, A. M., et al. (2001). LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107 (4), 513-523. Tamai, K., Semenov, M., Kato, Y., Spokony, R., Liu, C., Katsuyama, Y., et al. (2000). LDL-receptor-related proteins in Wnt signal transduction. Nature 407, 530-535. Mundy, G. R., Boyce, B., Yoneda, T., Bonewald, L. F., and Roodman, G. D. (1996). Cytokines and Bone Remodeling. Academic Press, San Diego. Pacifici, R. (1998). Cytokines, estrogen, and postmenopausal osteoporosis--The second decade. Endocrinology 139, 2659-2661. Chorev, M., and Rosenblat, M. (1996). Parathyroid hormone: Structure-function relations and analog design. In Principles of Bone Biology (J. P. Bilezikian, L. G. Raisz, and G. A. Rodan, Eds.), pp. 305-323. Academic Press, San Diego. Potts, J. T., and Juppner, H. (1998). Parathyroid hormone and parathyroid hormone-related peptide in calcium homeostasis, bone metabolism and bone development: the proteins, their genes and receptors. In Metabolic Bone Disease and Clinically Related Disorders (A. Press, Ed.), pp. 52-94. Academic Press, San Diego. Friedman, J. M. (2000). Obesity in the new millennium. Nature 404, 632-634.
4. Postnatal Bone Growth 101. Elmquist, J. K., Maratos-Flier, E., Saper, C. V., and Flier, J. S. (1998). Unraveling the central nervous system pathways underlying responses to leptin. Nat. Neurosci. 6, 445-450. 102. Ducy, P., Amling, M., Takeda, S., Priemel, M., Schilling, A. F., Beil, T., et al. (2000). Leptin inhibits bone formation through a hypothalamic relay: A central control of bone mass. Cell 100, 197-207. 103. Westvik, J. (1996). Radiological features in generalized lipodystrophy. Acta Paediatr. Suppl. 13, 44-51. 104. Frederick, R. C., Hamann, A., Anderson, S., Lollmann, B., Lowell, B. B., and Flier, J. S. (1995). Leptin levels reflect body lipid content in mice: Evidence for diet-induced resistance to leptin action. Nat. Med. 12. 105. Klemsz, M. J., McKercher, S. R., Celada, A., Van Beveren, C., and Maki, R. A. (1990). Themacrophage and B cell-specific transcription factor PU.1 is related to the ets oncogene. Cell 61, 113-124. 106. Tondravi, M. M., McKercher, S. R., Anderson, K., Erdmann, J. M., Quiroz, M., Maki, R., et al. (1997). Osteopetrosis in mice lacking hematopoietic transcription factor PU.1. Nature
386, 81-84. 107. Grigoriadis, A. E., Wang, Z. Q., and Wagner, E. F. (1995). Fos and bone cell development: Lessons from a nuclear oncogene. Trends Genet. 11,436-441. 108. Johnson, R. S., Spiegelman, B. M., and Papaioannou, V. (1992). Pleiotropic effects of a null mutation in the c-fos proto-oncogene. Cell 71, 577-586. 109. Wang, Z. Q., Ovitt, C., Grigoriadis, A. E., Mohle-Steinlein, U., Ruther, U., and Wagner, E. F. (1992). Bone and hematopoietic defects in mice lacking c-fos. Nature 360, 741-745. 110. Grigoriadis, A. E., Wang, Z. Q., Cecchini, M. G., Hofstetter, W., Felix, R., Fleisch, H. A., et al. (1994). c-Fos: A key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 266, 443-448. 111. Verma, I. M., Stevenson, J. K., Schwarz, E. M., Van Antwerp, D., and Miyamoto, S. (1995). Rel/NF-~cb/IKB family: Intimate tales of association and dissociation. Genes Dev. 9, 2723-2735. 112. Franzoso, G., Carlson, L., Xing, L., Poljak, L., Shores, E. W., Brown, K. D., et al. (1997). Requirement for NF-kappaB in osteoclast and B-cell development. Genes Dev. 11, 3482-3496. 113. Gerondakis, S., Grumont, R., Rourke, I., and Grossmann, M. (1998). The regulation and roles of Rel/NF-KB transcription factors during lymphocyte activation. Curr. Opin. Immunol. 10, 353-359. 114. Hertwig, P. (1942). Neue mutationen und kopplungsgruppen bei der hausmaus. Z. Indukt. Abstammungs-Verebungsl. 80, 220-246. 115. Hodgkinson, C. A., Moore, K. J., Nakayama, A., Steingrimsson, E., Copeland, N. G., Jenkins, N. A., et al. (1993). Mutations at the mouse microphthalmia locus are associated with defects in a gene encoding a novel basic helix-loop-helix zipper protein. Cell 74, 395-404. 116. Marks, S. C. J., and Lane, P. W. (1976). Osteopetrosis, a new recessive skeletal mutation on chromosome 12 of the mouse. J. Heredity 67, 11-18. 117. Zhang, Y., Proenca, R., Maffei, M., Barone, M., Leopold, L., and Friedman, J. M. (1994). Positional cloning of the mouse obese gene and its human homologue. Nature 372, 425-432.
133
118. Lagasse, E., and Weissman, I. L. (1997). Enforced expression of Bcl-2 in monocytes rescues macrophages and partially reverses osteopetrosis in op/op mice. Cell 89, 1021-1031. 119. Simonet, S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M. S., Luthy, R., et al. (1997). Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 89, 309-319. 120. Yasuda, H., Shima, N., Nakagawa, N., Mochizuki, S. I., Yano, K., Fujise, N., et al. (1998). Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): A mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 139, 442-444. 121. Bucay, N., Sarosi, I., Dunstan, C. R., Morony, S., Tarpley, J., Capparelli, C., et al. (1998). Osteoprotegrin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 12, 1260-1268. 122. Mizuno, A., Amizuka, N., Irie, K., Murakami, A., Fujise, N., Kanno, T., et al. (1998). Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem. Biophys. Res. Commun. 247, 610-615. 123. Burgess, T. L., Qian, Y., Kaufman, S., Ring, B. D., Van, G., Capparelli, C., et al. (1999). The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J. Cell Biol. 145, 527-538. 124. Dougall, W. C., Mglaccum, M., Charrier, K., Rohrbach, K., Brasel, K., De Smedt, T., et al. (1999). RANK is essential for osteoclast and lymph node development. Genes Dev. 13, 2412-2424. 125. Anderson, D. M., Maraskovsky, E., Billingsley, W. L., Dougall, W. C., Tometsko, M. E., Roux, E. R., et al. (1997). A homologue of the TNF receptor and it ligand enhance T-cell growth and dendritic-cell function. Nature 390, 175-179. 126. Wong, B. R., Josien, R., Lee, S. Y., Vologodskaia, M., Steinman, R. M., and Choi, Y. (1998). The TRAF family of signal transducers mediates NF-kB activation by the TRANCE receptor. J. Biol. Chem. 273, 28355-28359. 127. Darnay, B. J., Ni, J., Moore, P. A., and Aggarwal, B. B. (1999). Activation of NF-~:B by RANK requires tumor necrosis factor receptor-associated factor (TRAF) 6 and NF-~cB inducing kinase. Identification of a novel TRAF6 interaction motif. J. Biol. Chem. 274, 7724-7731. 128. Lomaga, M. A., Yeh, W. C., Sarosi, I., et al. (1999). TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev. 13, 1015-1024. 129. Kawasaki, K., Gao, H., Yokose, S., Kaji, Y., Nakamura, T., Suda, T., et al. (1997). Osteoclasts are present in gp 130-deficient mice. Endocrinology 138, 4959-4965. 130. Brugge, J., Cotton, P., Lustig, A., Yonemoto, W., Lipsich, L., Coussens, P., et al. (1987). Characterization of the altered form of the c-src gene product in neuronal cells. Genes Dev. 1, 287-296. 131. Boyce, B., Yoneda, T., Lowe, C., Soriano, P., and Mundy, G. R. (1992). Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice. J. Clin. Invest. 90, 1622-1627. 132. Suda, T., Udagawa, N., and Takahashi, N. (1996). Cells of bone: Osteoclast generation. In Principles o f Bone Biology (J. P. Bilezikian, L. G. Raisz, and G. A. Rodan, Eds.), pp. 87-102. Academic Press, San Diego.
This Page Intentionally Left Blank
C
H
A
P
T
E
R
5 Parathyroid Hormone and Calcium Homeostasis GORDON J. STREWLER Walter Bradford Cannon Society, Harvard Medical School, Boston, Massachusetts
CELLULAR AND EXTRACELLULAR CALCIUM HOMEOSTASIS
where the concentration of Ca 2+ is approximately 10,000fold higher than that in the cytoplasm (Table 1) [2]. One paradigm couples receptors on the cell surface to release of Ca 2+ from the endoplasmic reticulum. For example, engagement of G protein-coupled receptors by their ligands activates phospholipase C[3; engagement of tyrosine kinase receptors by their ligands similarly activates phospholipase C~/. Activated phospholipase C generates the intracellular second messenger inositol1,4,5-trisphosphate [Ins(1,4,5)P3], which diffuses to the endoplasmic reticulum, activates the Ins(1,4,5)P3 receptor (also an ion channel), and thereby releases large amounts of calcium to generate a calcium transient (Fig. 1). In a second paradigm for calcium signaling, extracellular signals direct the influx of Ca 2+ through ion channels in the plasma membrane. Signals can operate plasma membrane ion channels in three ways. First, depolarization of a cell can open voltage-operated calcium channels (e.g., on excitable muscle or nerve cells). Second, receptors such as the N-methyl-D-aspartate receptor can open calcium channels. Third, second messengers can open calcium channels. Typically, these calcium signals are transient, and mechanisms have evolved to govern the offset of calcium signals by reuptake of calcium into intracellular stores and the repletion of intracellular calcium stores from the extracellular compartment [2].
Intracellular Calcium H o m e o s t a s i s The divalent cation calcium serves an essential role in the physiology of virtually all living things. A full description of the diversity of the intracellular metabolism and functions of calcium is beyond the scope of this chapter, but calcium is a universal intracellular messenger that is utilized by virtually every cell [2]. Many enzymes and ion channels are calcium sensitive, and an impressive array of processes are regulated by changes in intracellular calcium via these proteins. These processes include muscle contraction; secretion of proteins, catecholamines, and other vesicle contents; membrane excitability; the intracellular metabolism of nutrients; cellular proliferation; and cell death (Fig. 1). Most cells maintain the baseline level of cytoplasmic ionized calcium (Ca 2+) at approximately 100 nM (Table 1) and generate calcium signals by raising the concentration of Ca 2+, or [Ca2+], in cytoplasm transiently to 500-1000nM. Cells can generate a calcium transient either by release of calcium from intracellular stores or by influx of calcium from the extracellular space,
TABLE 1
C a l c i u m c o n c e n t r a t i o n s in b o d y fluids.
Extracellular Calcium H o m e o s t a s i s
8.5-10.5 mg/dl
2.1-2.6 mmol/1
Total and Ionized Calcium
Ionized serum calcium
4.4-5.2 mg/dl
1.1-1.3 mmol/1
Protein-bound calcium
4.0-4.6 mg/dl
0.9-1.1 mmol/1
The level of extracellular calcium is significant for a variety of processes. Intracellular functions of calcium such as automaticity of nerve and muscle, contraction of muscle, release of neurotransmitters, and secretion of endocrine and exocrine factors are dependent on the
Total serum calcium
Complexed calcium Intracellular free calcium
Pediatric Bone
0.7 mg/dl 0.00018 mmol/1
0.18 mmol/1 180 nmol/1
135
Copyright2003,ElsevierScience(USA). All rights reserved.
-
Contraction
CAM-
MLCK
CAMKS Calcinounin Transcription factors
Proliferation Fert~lization Learnlng and rnernor;;
pathways s~gnaling Ins(l.4,5)P3 3-Kinase Ion channels 1 9 Membrane excitab~l~ty Synaptotagmin Phosphorylase kinase Annexin family
S100 family
---
Secretion Metabolism
Vesicle trafficking Cell proliferatton
Cell proliferation cancer and mefastas~s
ATP synthesis Stero~dsvntheeis
-
Apoptasis
FIGURE 1 Intracellular calcium signaling. Extracellular signals can activate receptor tyrosine kinases (RTK), G protein-coupled receptors, or cell depolarization (AV). These signals can operate plasma membrane calcium channels or generate Ins(1,4,5)P3 or other second messengers to release calcium from internal stores in the endoplasmic or sarcoplasmic reticulum (ERISR). Proteins that are targets for calcium signals and the calciumsensitive processes they mediate are shown on the right [redrawn with permission from Berridge, M. J., Lipp, P., and Bootman, M. D. (2000). The versatility and universality of calcium signaling. Nature Rev. Mol. Cell. Biol. 1 , 11-21].
5. Parathyroid Hormone and Calcium Homeostasis stability of the extracellular calcium concentration. In addition, cell and platelet adhesion proteins, such as integrins and cadherins, and extracellular enzymes, such as the proteases of the clotting cascade, are calcium dependent. Finally, the mineralization of bone is dependent on maintenance of normal levels of extracellular calcium and phosphate. Because the maintenance of a normal level of extracellular calcium is essential to so many processes, the calcium level is closely regulated by a set of hormones that include parathyroid hormone, vitamin D, and calcitonin. This chapter concentrates on parathyroid hormone (PTH). Although the physiology of vitamin D and calcitonin is the subject of subsequent chapters, their impact on calcium metabolism is briefly discussed. The fraction of extracellular calcium that is active in signaling is the ionized fraction, Ca 2+. In serum, the ionized calcium concentration averages 1.25 + 0.07 m M (Table 1). Only approximately 50% of the total calcium in serum is present in the ionized form. The remainder is either bound to albumin and other proteins (approximately 40%) or complexed with anions such as phosphate or citrate (approximately 10%). The proteinbound and complexed fractions of serum calcium are metabolically inert and are not regulated by hormones. For convenience, however, the total serum calcium level is routinely measured. It is thus important to appreciate that changes in the level of serum albumin, pH, or anions such as citrate or phosphate can substantially affect the total serum calcium level without affecting the biologically active fraction, [Ca2+]. If the albumin is abnormal, the ionized calcium level can be measured directly or estimated. In most clinical settings, it is adequate to correct the measured total serum calcium for changes in albumin. This is done using the following formula: Corrected serum calcium = measured serum calcium + 0.8(4 - measured serum albumin) Thus, in a patient with a serum calcium of 7.8 mg/dl and a serum albumin of 2.0 g/dl, the corrected serum calcium is 7.8 + (0.8)(4 - 2) - 9.4 mg/dl. The corrected serum calcium is in the midnormal range; it is therefore likely that the reduction in measured serum calcium is wholly attributable to hypoalbuminemia. In modern laboratories the determination of ionized calcium uses a calcium-sensitive electrode that is often incorporated in the apparatus used to measure blood gases and pH [3]. Such direct measurements are done manually. They are expensive and are more difficult to quality control than routine determinations of total serum calcium. The ionized calcium concentration will change with pH, and depending on the method, the sample either must be collected anaerobically so that
13 7
the pH of the sample does not change as CO2 escapes or the ionized calcium must be back-calculated to the physiological pH. Changes in the concentration of phosphate or citrate can affect both the total and the ionized serum calcium. For example, massive transfusion of citrated blood (in which citrate is used as an anticoagulant because of its ability to complex calcium and thus paralyze the clotting cascade) can increase the total serum calcium by complexing it while at the same time inducing tetany because of acute complexation of ionized calcium. Here, the challenge to homeostasis is too massive and acute for a successful response. In this circumstance, determination of the ionized calcium concentration is necessary to guide therapy. The product of the concentrations of Ca 2+ and phosphate in extracellular fluid (e.g., [CaZ+][Pi]) is similar to the solubility product of calcium phosphate so that a substantial acute increase in the serum concentration of either can lead to the precipitation of calcium phosphate salts in soft tissues, and this is a source of clinical problems in severe hypercalcemia or hyperphosphatemia. Tetany is most often seen in rhabdomyolysis, where large amounts of phosphate are acutely released from damaged skeletal muscle in the face of severely impaired renal function. Both total calcium and [Ca 2+] are typically low and the serum phosphorus is extremely high in patients with rhabdomyolysis who experience symptoms. Calcium Fluxes and Balance
The extracellular compartment is bounded by three interfaces that are important for systemic calcium homeostasis: the gut, the kidney, and the bone. This chapter first considers the fluxes of calcium across these boundaries in a young adult in a state of zero net calcium balance (Fig. 2), and then calcium balances during skeletal growth are discussed.
FIGURE 2 Externalcalcium balance and calcium fluxes through the extracellular fluid (ECF). Reprinted with permission from Felig, P., Baxter, J. D., Broadus, A. E., Frohman, L. A. (eds.). "Endocrinology and Metabolism, 2nd edition," McGraw-Hill, 1987.
138
Gordon i. Strewler
The average diet contains 400-1600mg of calcium (10-40 mmol). From this dietary load, the net absorption in a young healthy adult averages 100-250 mg. Calcium is absorbed throughout the small bowel, with a relative efficiency in animal studies of duodenum > jejunum > ileum. In humans, the average transport rates are similar in jejunum and ileum, but the bulk of calcium is absorbed in the ileum because of the lengthy transit through this long segment of the small intestine. Intestinal transport of calcium is saturable, with an active component that is under the control of vitamin D (see Chapter 7) and a passive component (Fig. 3). These two components can be differentiated in studies of perfused human intestinal segments [4]. The active, saturable component of calcium absorption occurs through the apical membrane of intestinal enterocytes, and calcium is then pumped out of the cell at the basolateral border (see Chapter 7). The passive component of calcium transport is a manifestation of the leakiness of the intestinal epithelium and primarily represents paracellular movement of calcium. The unidirectional flux of calcium from intestinal lumen to the blood is a linear function of the luminal calcium concentration (Fig. 3). The unidirectional backflux of calcium from blood into feces, or endogenous fecal calcium, is largely determined by the level of extracellular calcium and tends to be relatively insensitive to changes in dietary calcium intake. Its magnitude can be determined in calcium kinetic studies in which one calcium isotope is administered orally as a tracer for calcium absorption at the same time a different isotope is administered intravenously as a tracer for the backflux of calcium from blood to intestinal lumen so that unidirectional fluxes can be determined.
,,C
~ 0.6 (,)
0
Calcium kinetic studies were once done with radioactive isotopes of calcium but now are performed with stable isotopes, the concentration of which can be sensitivity to calcium intake, the obligatory loss of endogenous fecal calcium, together with the obligatory loss determined by mass spectrometry. With its relative in of calcium in the urine and sweat, represents the negative side of the external balance equation: If the absorption of dietary calcium is not sufficient to overcome these obligatory losses, net negative calcium balance will ensue. The saturability of calcium absorption (Fig. 3) is important when calcium requirements during growth and adolescence are considered because it effectively defines a threshold of calcium intake below which an increased intake will lead to increased retention in the skeleton and above which further increases in calcium intake will not (Fig. 4). Heaney [5] and others have persuasively argued that the intake corresponding to this point of inflection represents the true minimum daily requirement of calcium, and this reasoning has been used in recent reassessments of recommended calcium intake, such as that of the Food and Nutrition Board of the National Academy of Sciences in 1997 [6]. In addition to its support function, bone is a huge reservoir for calcium and phosphate. More than 99% of body calcium is stored in bone. Bone calcium is in dynamic equilibrium with the extracellular fluid (Fig. 2), with substantial bidirectional fluxes between the extracellular compartment and an exchangeable bone calcium pool that is readily demonstrable by calcium kinetic studies. The human skeleton at birth contains approximately 25 g of calcium, and the mass of calcium in bone will increase to 1000-1200g by adulthood. All of the accretion of calcium to support the growth of bones must come from the diet, so the external balance of calcium must be substantially positive during childhood and adolescence. The net bone balance of calcium will be essentially identical to the external balance since for
~176176176176176176 ..................
o
./.." ....Calculated
E =L 0.4
C o ,m
Q. i,_
o 0.2
.ID
,<
'"
/
active transport
/
E ~
_u
0
. . . . . .
Calcium intake I
I
I
|
2 4 6 8 Calcium Concentration (raM)
FIGURE 3 Intestinal calcium transport. Reprinted with permission from Felig, P., Baxter, J. D., Broadus, A. E., Frohman, L. A. (eds.). "Endocrinology and Metabolism, 3rd edition," McGraw-Hill, 1995.
FIGURE 4 Thresholdbehavior of calcium intake. Theoretical relationship of bone accumulation to intake. Below a certain value- the threshold (arrow)- bone accumulation is a linear function of intake. Above the threshold (the horizontal line), bone accumulation is limited by other factors and is no longer related to changes in calcium intake. (Copyright Robert P. Heaney, 1992. Reproduced with permission.)
139
5. Parathyroid Hormone and Calcium Homeostasis
practical purposes bone is the only storage site for calcium. These issues are discussed in detail in Chapter 9. The renal handling of calcium involves filtration at the glomerulus and reabsorption in proximal and distal nephron segments [7]. Ionized and complexed calcium is freely filterable; the filtered load of calcium approximates 8 g/day, and 98 or 99% is reabsorbed in the tubule. It was shown by micropuncture that approximately 70% of the filtered Ca 2+ is reabsorbed in the proximal tubule segments, 20% in the thick ascending limb of Henle's loop, 5-10% in the distal tubule, and less than 5% in the collecting duct system. However, it is mainly the distal handling of calcium that is under hormonal control. The renal excretion of calcium is increased markedly during natriuresis, by volume expansion, and in metabolic acidosis. Hypercalcemia generally increases the filtered load of calcium, even though G F R is reduced, reduces tubule reabsorption (by direct effects of hypercalcemia and by suppression of PTH), and usually produces a calciuresis as the net effect. Conversely, the urinary calcium excretion is low in hypocalcemia because of avid reabsorption caused by a marked reduction in the filtered load. However, at normal levels of serum calcium, substantial losses of calcium in the urine of 50-150 mg per day are obligatory, even when the intake of calcium is reduced to zero. Calcium Nutrition in Childhood and Adolescence
Calcium absorption and retention vary markedly during childhood and adolescence, with two major peaks at times of maximal skeletal growth. The first occurs in infancy. Calcium absorption averages 61 + 22% at age 6 months [1] and declines thereafter. A second peak in calcium absorption and retention occurs during puberty [8,9], beginning in the early stages [10] and peaking at 11.4 years in girls and 13.3 years in boys, approximately 1 year after attainment of peak height velocity and coincident with menarche in girls [11,12], and rapidly declining thereafter [9,11,12]. The hormonal factors that provide for absorption and retention of calcium coincident with the maximal demands of skeletal growth are incompletely understood. Calcium balance and calcium kinetic studies have been performed to determine the age dependence of the relationship between calcium intake and net calcium balance [13], as shown schematically in Fig. 4. Many such studies are summarized in Fig. 5, which shows regression lines for calcium intake versus calcium balance for infants, children, adolescents, and young adults. Note that the slopes of the regression lines are reasonably similar across the age groups: The increment in calcium balance for a given increase in calcium intake is independent of age. The minimal intake required to maintain positive
600
-
Infants j
nts
-o 400 o'} E o c
rn
/
200
/ / 0
/ j--'5 f
,
/
~-
~
~C~dren
!
~ Y o u n g adults _.,
/ / 500
1000
1500
Intake (mg/d)
FIGURE 5 Regression lines for the subthreshold regions of the intake-balance relationships in infants, children, adolescents, and young adults from the data of Matkovic and Heaney (1992). Am. J. Clin. Nutr. 55, 992-996. (Copyright Robert P. Heaney, 1992. Reproduced with permission.)
calcium balance increases markedly with age, however. Infants have the highest retention of dietary calcium and also have the lowest obligatory calcium losses. For older age groups, higher levels of calcium intake are required to sustain a positive balance, an effect that is largely accounted for by an increase in urinary calcium. Nutritional Factors That Influence Calcium Balance
Nutritional factors that influence calcium balance include sodium, protein, and vegetable nutrients. The sodium intake has a major influence on the urinary excretion of calcium: Every 100 mmol of sodium (2300 mg) excreted by the kidney increases urinary calcium by approximately 1 mmol (20-60 mg) [5]. Every gram of protein metabolized increases urinary calcium by approximately 1 mg [5]. Part of the effect of protein on calcium excretion occurs due to the use of bone buffers to neutralize acid generated from the metabolism of protein. A diet high in protein and acid ash will induce bone resorption, and the result is loss of calcium in the urine and negative calcium balance, which can be prevented by provision of dietary bicarbonate [14,15]. Overall, approximately half of the variance in calcium balance in normal women is explained by urinary losses [5], indicating that urinary excretion and the influence of sodium and protein intake are critical in determining an individual's calcium balance. The effect of vegetable nutrients on calcium absorption is less dramatic than the effects of dietary sodium and protein on urinary calcium excretion. The effect of dietary fiber is relatively small, but oxalate and phytate substantially reduce the availability of calcium; thus, as Heaney [5] summarized, the calcium in beans is approximately half as available as the calcium in milk, and the calcium in spinach and rhubarb is almost totally unavailable. The binding of calcium to phytate or oxalate in
140
Gordon J. Strewler
vegetables occurs before the food is ingested, and there is little effect of a high oxalate or phytate intake on availability of calcium from dairy sources.
PARATHYROIDS AND SECRETION AND METABOLISM OF PARATHYROID H O R M O N E A n a t o m y a n d D e v e l o p m e n t of the Parathyroid Glands The four parathyroid glands weigh an average of approximately 30mg each. The superior glands are most often found at the posterior aspect of the thyroid capsule; the inferior glands are usually near the inferior thyroid margin. The position of the inferior glands is more variable, and they are sometimes found with the thymus in the anterior mediastinum. Approximately 5% of the population has only three glands; five glands are found in 3-13% of the population, and six or more glands are occasionally present [16]. These are important features of the surgical anatomy of the parathyroids; many are the vagaries of surgery on these tiny, wandering glands. The parathyroid glands first appear during Weeks 5 or 6 of gestation, with the upper glands developing from the fourth branchial pouch. The lower glands originate together with the thymus from a more cephalad location in the third branchial pouch but migrate downward, sometimes accompanying the thymus into the mediastinum. Several transcription factors have been implicated in the development of the parathyroids and adjacent glands, including Hoxa3 [17], ablation of which causes defective development of thyroid, parathyroid, and thymus; GATA3, deficiency of which leads to hypoparathyroidism, sensorineural hearing loss, and renal anomalies [18]; and Tbxl, which is required for normal development of parathyroids, thymus, cardiac outflow tract, and the face [19]. Isolated hypoparathyroidism occurs with the loss of Glial cells missing-2 (GCMB), which is expressed exclusively in the parathyroids [20,21]. Unlike humans with loss of the GCMB gene, mice with a deletion of the Glial cells missing-2 gene have detectable PTH levels, and it has been suggested that the thymus may provide an additional source of parathyroid cells in the mouse [20]. Physiology of Parathyroid H o r m o n e Secretion The primary purpose of PTH is to regulate the serum calcium concentration within the very narrow physiological range of approximately 8.9-10.1 mg/dl; in normal humans, the individual variation of[Ca 2+] from the mean
FIGURE 6 Relationshipbetween serum calcium and simultaneous PTH. The concentration of calcium was modified by infusion of calcium (circles) or citrate (triangles). Original data from Conlin, et al. (1989). J. Clin. Endocrinol. Metab. 69, 593-599. Reprinted with permission from Strewler,G. J. and Greenspan, F. S. (eds.) "Basicand Clinical Endocrinology, 5th edition," Appleton and Large, 1997. is less than 2%. To achieve this aim, the secretion of PTH is directly controlled by the level of calcium in serum in a classical negative feedback loop. The relationship of serum calcium to PTH is steeply sigmoidal, with the steep portion of the curve corresponding to the normal range of serum calcium (Fig. 6). This relationship is required to achieve very tight control of the serum calcium: Small increments in the calcium concentration produce a major change in the level of PTH. The molecular basis of this feat lies primarily in the design of the receptor on parathyroid cells that senses the ambient level of calcium, and is described in the next section. Another feature of the system, as shown in Fig. 6, is that when maximally suppressed, the gland still "leaks" some parathyroid hormone. This leak may be important in the genesis of "tertiary" hyperparathyroidismmfor example, in persistent hypercalcemia following renal transplant in patients who developed secondary hyperparathyroidism on dialysis. Parathyroid Calcium S e n s o r
Structure and Physiologic Functions The calcium sensor on parathyroid cells is a G proteincoupled receptor (GPCR) with a large extracellular domain comprising approximately 600 amino acids, the seven membrane-spanning domains characteristic of this receptor class, and a carboxyl-terminal tail [22] (Fig. 7). It is most closely related to the metabotropic glutamate receptor and other members of family C of GPCRs, which also includes the GABAB receptors and a group of putative pheromone receptors [23]. The calciumsensing receptor is also expressed on C cells of the thyroid, where it regulates the positive feedback effects of calcium upon the secretion of calcitonin. In the distal renal
141
5. Parathyroid Hormone and Calcium Homeostasis
SP ..
o Q
*
,t NH2 *~,LL
X
X Inactivating ,
X
HS
X
Pro3
9A.la
Activating ,~Ll.all6T'hr
Ser53Pro
AsnllgT.ys
Arg62Met
Phe128I~u
Pro55Leu
Arg66Cys
Thrl 3 8 M e t
Glyl 43Glu
A~n178Asp Arg185Gln
Asp215Gly Tyr
Glu127Ala ThrI51Mst
'Glu191T-ys Oln245~xg Phe612Ser
Gln6BIBis
Phe806Se:
Pro221Sez
Arg227Leu (Gln) GIu297Lys
Cys5B2Tyr
Ser607Stop Ser657Tyz
Gly67 OArg
Arg6BOCys
Alu
Pro747F-shift PEo748Arg
O Cysteine 9Conserved
Arg?gSTrp
~C N-glycosylation
V&lSlTIle
Th=876Alu
PKC site
& Acidic
Hq
FIGURE 7 Schematic representation of the principal predicted topological features of the human Ca2+-sensing receptor: SP, signal peptide; HS, hydrophobic segment; PKC, protein kinase C. Also delineated are missense and nonsense mutations causing either familial hypocalciuric hypercalcemia or autosomal dominant hypocalcemia. These are indicated using the three-letter amino acid code, with the normal amino acid indicated before and the mutated amino acid shown after the numbers of the relevant codons [reprinted with permission from Brown, E. M., Bai, M., and Pollak, M. (1997). Familial benign hypocalciuric hypercalcemia and other syndromes of altered responsiveness to extracellular calcium. In Metabolic Bone Diseases (S. M. Krane and L. V. Avioli, Eds.), 3rd ed., pp. 479-499.Academic Press, San Diego].
nephron, the calcium-sensing receptor plays an important role in the control of renal calcium excretion within the cortical thick ascending loop of Henle, regulates the renal handling of sodium, potassium, and chloride, and probably causes the impairment of urinary concentrating ability in hypercalcemia [24]. The calcium sensor is also present in bone, cartilage, and other tissues, in which it likely has a number of additional physiological roles [22].
Calcium Binding and Receptor Activation Calcium binds to the extracellular domain of the calcium-sensing receptor [25]. Ser 147 and Ser 17~ a r e involved in calcium binding [26], and the corresponding amino acids in the metabotropic glutamate receptor and the GABAB receptor are also involved in binding of their cognate ligands. For several reasons, however, it is likely that binding of calcium is more complex. First, the steep
slope of the curve describing the relationship of extracellular [Ca 2+] strongly suggests positive cooperativity, raising the question whether multiple calcium ions are bound to a single receptor [25], such that binding of one molecule of C a 2+ increases the affinity of the receptor for binding of subsequent molecules. Second, mutations at many sites in the extracellular domain of the receptor (Fig. 7) shift its sensitivity to calcium and can produce either chronic hypercalcemia or chronic hypocalcemia, indicating that the extracellular domain is broadly involved in calcium binding. Third, the receptor dimerizes through cysteine residues in the extracellular domain [27,28] and there are functional interactions between individual members of a dimer [29]. Mutations in the calcium-sensing receptor that decrease its sensitivity to calcium produce usually lifelong mild hypercalcemia. The syndrome is called familial benign hypocalciuric hypercalcemia [30] because these mutations also reduce the sensitivity to calcium in the
142
Gordon J. Strewler
kidney, resulting in increased calcium reabsorption (see Chapter 20). Loss of both receptor copies eliminates the ability to sense calcium; the resultant syndrome of severe neonatal hypercalcemia requires total parathyroidectomy [30]. Conversely, mutations that increase sensitivity to calcium produce mild lifelong hypocalcemia and relative hypercalciuria [31]. Calcimimetic compounds have been identified that change the sensitivity of the calcium-sensing receptor and the consequent sensitivity of parathyroid hormone secretion. These drugs are used for the treatment of hyperparathyroid disorders [32,33]. The phenylalkalamine NPS R-568 and AMG073 left-shift the response of the parathyroid cell to extracellular [Ca2+], markedly decreasing the rate of PTH secretion at ambient calcium levels. NPS R-568 appears to act by modifying allosterically activation of the receptor by calcium [34]. Calcimimetic agents reduce secondary hyperparathyroidism in rat models [35-37] and preliminary results indicate that AMG073 is effective in the treatment of chronic mild primary hyperparathyroidism [38].
lntracellular Signaling by the Calcium-Sensing Receptor The calcium-sensing receptor is coupled to phospholipase C[3 by pertussis toxin-insensitive G proteins, probably Gq or Gll [25]. In response to an acute increase in extracellular [Ca2+], phospholipase C[3 is activated and the parathyroid cell cleaves the phospholipid substrate phosphoinositol-4,5-bisphosphate in the plasma membrane to produce the intracellular second messenger IP3, which diffuses to the endoplasmic reticulum and induces the transient release of calcium from its stores [25,39,40]. The function of G proteins in receptor coupling to phospholipase C is discussed later [2,41,42]. Activation of phospholipase C[3 also stimulates protein kinase C (PKC) [42a]. Exposure of cells that express the parathyroid calcium sensor to high extracellular Ca 2+ also stimulates the activity of phospholipases A2 and D, but this is probably an indirect effect of the activation of PKC [42b], involving the MAP kinase pathway [42c]. Blockade of phospholipase A2 is reported to inhibit the secretion of PTH [42d]. It is notable that the paradigm of such laboratory experiments, in which a calcium transient is induced by acutely increasing extracellular calcium, does not apply to the physiological situation, in which the secretion of parathyroid hormone is tonically maintained at a level that allows the maintenance of serum [Ca 2+] near its set point. In a manner as yet poorly understood, an intracellular signal from the calciumsensing receptor sets the tonic secretion of parathyroid hormone at a level appropriate to the set point of the gland for [Ca2+]. The signaling events for tonic PTH secretion may not be the same as for acute calcuim transients.
Mg 2+ as a PTH Secretogogue The divalent cation Mg 2+ is also a ligand for the parathyroid calcium sensor and can inhibit the secretion of PTH, although it is approximately threefold less potent than Ca 2+. The parathyroid calcium-sensing receptor probably regulates magnesium levels in vivo because individuals with familial benign hypocalciuric hypercalcemia have mild hypermagnesemia [42e] and those with activating mutations of the receptor tend to present with mild hypomagnesemia. Paradoxically, severe hypomagnesemia "paralyzes" the parathyroid glands, producing a form of reversible hypoparathyroidism. This syndrome apparently results from an effect of hypomagnesemia on the activation of G proteins [42f]. Chemistry, Biosynthesis, and Processing of Parathyroid H o r m o n e
Parathyroid Hormone Peptide Family PTH
The PTH peptide family has three members: PTH, the parathyroid hormone-related peptide (PTHrP), and the tuberoinfundibular peptide of 39 amino acids (TIP39). PTH is an 84-amino acid peptide with a molecular weight of 9300 whose sequence is highly conserved among terrestrial mammals that possess parathyroid glands (Fig. 8). As discussed in detail later, the PTH sequence encompasses an amino-terminal receptor-binding domain (amino acids 1-34) and a carboxyl-terminal domain that may have its own cognate receptor. PTHrP
PTHrP is a peptide of 139-172 amino acids in various isoforms, with limited homology to PTH overall but strong homology in the amino-terminal receptor-binding domain, where 8 of 13 residues are identical. As a consequence of conservation of their receptor-binding domains, the two peptides have essentially identical affinity for a common receptor, the PTH1 receptor (PTH1R). PTHrP is a locally active cytokine rather than a hormone [43,44]. It is present in many tissues, including mesenchymal tissues such as cartilage [45], bone [46], and skeletal, cardiac, and smooth muscle [47]; epithelia such as skin, mammary, the enamel epithelium of the teeth [48], and the intestinal mucosa; endocrine glands such as the parathyroid and pancreatic islets [48]; the placenta [48]; and regions of the central nervous system [47]. During development, PTHrP plays a critical role in endochondral bone formation [43,45]. Under the control of Indian hedgehog, it regulates entry of chondrocytes into the terminally differentiated state and thus the rate at which endochondral bone grows and is mineralized
5. Parathyroid Hormone and Calcium Homeostasis PRE $ PRO $ -31 -6 human MIPAKDNAKVMIVMLAICFLTKSDG KSVKKR bovine MMSAKDMVKVMIVMLAICFLARSDG KSVKKR porcine M M S A K D T V K V N V V N L A I C F L A R S D G K P I K K R rat MMSASTNAKVMILMLAVCLLTQADG KPVKKR canine MMSAKD~IVMFAICFLAKSDG KPVKKR chicken M T S T K N L A K A I V I L Y A I C F F T N S D G R P M N K R
PTH +i +I0 SVSEIQLMHN AVSEIQFMHN SVSEIQLMHN AVSEIQLMHN SVSEIQFMHN SVSEMQLMHN
human bovine porcine rat canine chicken
+20 +30 +40 +50 LGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQRPRK LGKHL S S N E R V E W L R K K L Q D V H N F V A L G A S I A Y R D G S S Q R P R K LGKHL S S L N N V E W L R K K L Q D V H N F V A L G A S I V H R D G G S Q R P R K LGKHLASVERMQWLRKKLQDVHNFVSLGVQMAAREG SYQNPTK LGKHL S S N E N V E W L R K K L Q D V H N F V A L G A P I A H R D G S S Q R P L K L G E H R H T V E R Q D W L Q M K L Q D V H . . S A L E ...... D A R T Q R P R N
human bovine porcine rat canine chicken
+60 +70 +80 KEDNVLVE... S H E K S L G E A .......... D K A D V N V L T K A K S Q KEDNVLVE... S H Q K S L G E A .......... D K A D V D V L I K A K P Q KEDNVLVE... S H Q K S L G E A .......... D K A A V D V L I K A K P Q KEENVLVD... G N S K S L G E G .......... D K A D V D V L V K SQ KEDNVLVE... S Y Q K S L G E A .......... D K A D V D V L T K A K S Q KEDIVLGE I R N R R L L P E H L R A A V Q K K S ID L D K A Y M N V L F K T K P .
FIGURE 8 Sequences of PTH from various species. (Reprinted with permission from "Parathyroids: Basic and Clinical Concepts" (J. P. Bilezikian, R. Marcus, and M. A. Levine, Eds.), 2nd edition, pp. 245260. Academic Press: San Diego (2001).
(see Chapters 3 and 4). It is also clear that PTHrP is necessary for normal mammary development [44,48] and tooth eruption [43], and new physiological actions continue to be identified.
TIP39 Recently identified, TIP39 is a 39-amino acid molecule with limited sequence homology with PTH: 9 of 39 residues are identical in the two peptides [49]. Its functions are not fully understood, although it may act as a releasing factor for ACTH-releasing factor, vasopression, and luteinizing hormone [50]. TIP39 was identified as an endogenous ligand for a hypothalamic receptor, PTH2R [51,52], which is closely related to PTH1R and, at least the case of the human receptor, recognizes PTH, although it has an approximately 10-fold higher affinity for TIP39, its presumed natural ligand [49].
Evolution of the P T H Peptide Family It is not clear when PTH appeared in evolution. The parathyroid glands are present only in terrestrial animals, but three receptors that recognize PTH have been identified in fish. Two are homologous to the mammalian PTH1 and PTH2 receptors, and the third is unique although closely related in sequence to PTH1R [53,54]. All three receptors respond to mammalian PTH, but only PTH1R and PTH2R respond to PTHrP and a fugu PTHrP analog. However, the zebrafish PTH2R binds tuberoinfundibular peptide preferentially. Since all three receptors efficiently recognize one or both of the other members of the family, their presence does not
143
make a strong argument for the presence of PTH in the teleost genome.
Biosynthesis and Processing of PTH The human PTH gene is on the short arm of chromosome 11 and contains three exons. The first encodes a short 5' untranslated domain, the second a prepro region of 29 amino acids, and the third the remainder of the coding sequence and the 3' untranslated domain [55,56]. As it emerges from the endoplasmic reticulum, the nascent preproPTH polypeptide is cleaved at position - 7 / - 6 to produce the 90-amino acid proPTH (Fig. 8). In contrast to the evanescence of preproPTH, proPTH has a half-life of approximately 15 min in pulse-chase studies and is converted to PTH coincidentally with arrival in the trans-Golgi. It appears that the cleavage enzyme is the ubiquitous prohormone convertase furin rather than one of the specialized convertases of neuroendocrine secretory granules such as PC2 and PC1 [57], although PC7 has recently been shown to be expressed in parathyroid cells and can cleave PTH [58]. Perhaps the use of furin is a consequence of the evolution of PTH from PTHrP, which was designed for secretion by a diversity of cells, most of which lack the specialized machinery of neuroendocrine cells [56]. The sequence of preproPTH has the general features of signal sequences that direct proteins into the lumen of the endoplasmic reticulum [59]. Deletion of 10 or more residues, including part of the hydrophobic core, prevents entry into the secretory pathway and results in rapid degradation of the nascent peptide [60]. A spontaneous mutation that disrupts the hydrophobic core and blocks translocation of the nascent peptide causes familial hypoparathyroidism [61]. The function of the pro sequence is incompletely understood. Deletion of the pro sequence results in inefficient cleavage of preproPTH, with some molecules cleaved in the pro domain [62,63]. There must be powerful evolutionary pressures to avoid infidelity of processing of the amino terminus, since an intact amino terminus is required for biological activity. It is thus possible, as Kronenberg et al. [56] have argued, that the pro domain evolved as a linker region to permit evolution of the amino terminus of PTH, the primary receptor-activating domain, to proceed at some physical distance from the end of the signal sequence, which may have had incompatible evolutionary constraints on its amino acid sequence. These evolutionary adaptations probably occurred first in PTHrP, which has similar sequence features [64]; the existence of proPTHrP has not been directly shown, however. After biogenesis in the Golgi apparatus, PTH is packaged in dense secretory granules like those of other endocrine cells and stored to await secretion. It has been estimated that glandular stores of PTH are sufficient to
144
Gordon J. Strewler
maintain maximal rates of secretion for approximately 1.5 hr. PTH is stored and secreted with the peptide chromogranin A (formerly called parathyroid secretory protein-l), a molecule that is also cosecreted with other hormones from dense neurosecretory granules. It is now becoming clear why chromogranins are obligatory fellow travelers in dense secretory granules: chromogranin A is an on/off switch that is both necessary and sufficient for biogenesis of dense secretory granules and hormone sequestration within them [65]. The Control of PTH Synthesis and Secretion by Calcium and Other Secretagogues
PTH is secreted in response to the challenge of hypocalcemia. If the challenge were acute, lasting less than 1 hr, stores of preformed PTH that reside in secretory granules would suffice. However, in response to chronic hypocalcemia, the parathyroid glands must mount a threefold response, secreting their stores of PTH; increasing transcription of the PTH gene and the biogenesis of PTH; and, over days and weeks, undergoing hyperplasia to increase the mass of parathyroid tissue available for secretion of its hormone. How are the pathways by which a decrease in the extracellular [Ca 2+] evokes an acute secretory response related to pathways by which hormone synthesis and cell growth are controlled? How is the control of cell growth in states of chronic hypocalcemic challenge (secondary hyperparathyroidism) related to the loss of full control of cell growth that characterizes primary hyperparathyroidism?
Regulation by Calcium Hypocalcemia markedly upregulates the level of PTH mRNA, but hypercalcemia reduces its level only minimally [66,67]. The parathyroid cell is thus much better equipped to respond to its primary challenge, hypocalcemia, than to adapt over hours or days to hypercalcemia, although chronic hypercalcemia will eventually reduce parathyroid gland size. Increasing medium calcium suppresses the transcription of PTH mRNA in cultured cells [68] and a putative calcium response element was identified in the upstream region of the PTH promoter [69]. However, the biological significance of these results is unclear in light of physiological studies showing minimal effects of hypercalcemia on PTH mRNA levels [66,67]. Hypocalcemia increases the level of PTH mRNA primarily by a posttranscriptional effect on the stability of PTH mRNA [70]. The cis-acting locus at which the stability of the mRNA is controlled by calcium and phosphorus is a 26-nucleotide stretch of the Y untranslated region (UTR). In hypocalcemic rats, trans-acting proteins (one of which is AUF1) [71] bind to this locus in vitro and stabilize RNA transcripts [70]. Insertion of the stability
motif from PTH mRNA into growth hormone transcripts is sufficient to confer sensitivity of the chimeric growth hormone transcripts to parathyroid cell proteins that were obtained from animals fed either a low-calcium diet or a low-phosphate diet [72], but it is not known how parathyroid proteins are modified by hypocalcemia.
Regulation by Phosphate Changes in serum phosphate levels were long thought not to regulate the secretion of PTH directly, acting instead by inducing changes in [Ca 2+] or 1,25(OH)2D. However, it is now clear that both hypophosphatemia and hyperphosphatemia influence the parathyroids directly. Hypophosphatemia decreases PTH mRNA levels by a posttranscriptional mechanism [73-75]. This is a direct effect of hypophosphatemia because it occurs under conditions in which neither the serum [Ca 2+] nor the serum 1,25(OH)2D levels are abnormal. The stability of PTH transcripts is decreased by parathyroid proteins from rats on a low-phosphate diet; thus, hypophosphatemia, like hypocalcemia, regulates PTH mRNA levels by regulating the stability of PTH mRNA. Both the cisacting locus in the PTH mRNA and the trans-acting RNA-binding proteins that the cell employs to respond to hypophosphatemia are similar to those it uses to respond to hypocalcemia [70-72]. Hyperphosphatemia increases the level of PTH mRNA from isolated parathyroid glands by a mechanism independent of calcium and 1,25(OH)2D [76,77]. The means by which the parathyroid gland senses the extracellular phosphate level is not understood, but the parathyroid possesses a sodium-coupled phosphate transporter whose levels are regulated by changes in serum phosphate and 1,25(OH)2D [78], and this transporter has been suggested to be a candidate phosphate sensor.
Regulation by 1,25(OH) 2D Parathyroid hormone and vitamin D interact in complex ways to maintain a normal serum calcium concentration. Exposure to 1,25(OH)2D downregulates PTH mRNA levels and PTH secretion in isolated parathyroid glands [79,80] and in the intact rat [81]. Transcriptional inhibition results from binding of the vitamin D receptor (VDR) to a conserved negative regulatory element in the PTH gene promoter. The sequence of this negative regulatory element resembles that of positive vitamin D response elements in other genes [82,83]; binding of the receptor must lead to differences in assembly of the transcriptional complex to induce negative rather than positive regulation of the gene. Hypocalcemia stimulates both the secretion of PTH and the production of 1,25(OH)2D, so the concentrations of the two hormones vary in tandem in most cir-
5. Parathyroid Hormone and Calcium Homeostasis
cumstances and they synergize to protect the serum calcium concentration. Hence, a negative feedback loop in which 1,25(OH)2D inhibits the secretion of PTH does not appear to be physiologically adaptive. When 1,25 (OH)2D is administered to rats made acutely hypocalcemic by the administration of phosphate, the stimulation of PTH mRNA levels is reversed. However, in animals made hypocalcemic by feeding a low-calcium diet, PTH levels increase appropriately in the face of a large increase in serum 1,25(OH)2D [84]. The relative resistance to 1,25(OH)2D during chronic hypocalcemia may be induced by nuclear accumulation of calreticulin, a calcium-binding protein that interferes with the negative regulation of transcription by the VDR [85]. This suggests that a mechanism exists to maintain a physiologically adaptive hierarchy between the contrary parathyroid effects of calcium and 1,25(OH)2D. Whatever the adaptive mechanism may be, it is efficient, since VDR knockout mice in which normocalcemia and normophosphatemia are maintained by manipulation of the diet have normal PTH levels [86]. Regulation in Uremia
The clinical implications of regulation of PTH secretion by phosphate and vitamin D are most important in uremia (see Chapter 28), in which the dual effects ofhyperphosphatemia and reduced 1,25(OH)2D levels acutely increase PTH secretion and chronically promote parathyroid gland growth, thus producing secondary hyperparathyroidism. In early renal failure hyperparathyroidism can be prevented by lowering phosphate through phosphate restriction, thus increasing the level of 1,25(OH)2D [87,88]. In chronic renal failure, dietary phosphate restriction directly ameliorates or prevents secondary hyperparathyroidism, independent of 1,25(OH)2D [76]. As important as the acute effects of dietary phosphate and vitamin D growth in the genesis of secondary hyperparathyroidism are their parallel effects on parathyroid cell. Control of Growth of the Parathyroid Glands
To maintain the appropriate number of parathyroid cells to respond to physiological stimuli, the parathyroid economy has linked the control of parathyroid gland size to the calcium sensor and also to the VDR and a phosphate sensor. These pathways allow parathyroid gland size to change in parallel with changes in synthesis and secretion of PTH so that the acute response is amplified in chronic states. In hyperparathyroid states, the normal feedback regulation of PTH secretion and the normal control of parathyroid cell growth are lost in parallel (see Chapters 20 and 28). Parfitt [89] reviewed the control of growth of the parathyroid glands in normal physiology and hyperparathyroid states.
145
The parathyroid glands have a mean weight of only 3 mg at birth but grow rapidly during the first years of life and weigh an average of 18 mg at age 2 years. They achieve their adult weight of approximately 40 mg by age 30 [89]. Thereafter, their rate of proliferation is approximately 5% per year, sufficient to compensate for cell loss and maintain a normal cell number. The glands respond to physiological demands mainly by hyperplasia, not hypertrophy, and shrink sluggishly in response to hypercalcemia. Regulation of Cell Growth by Calcium
The number of parathyroid cells is directly controlled by the calcium-sensing receptor. Loss of the receptor, as in neonatal severe hyperparathyroidism, leads to massive parathyroid hyperplasia in the face of severe hypercalcemia. A shift in the set point of the receptor, as in familial benign hypocalciuric hypercalcemia, probably increases the size of the parathyroids slightly [90]. Treatment with calcimimetic compounds that act directly at the receptor reduces parathyroid gland size and cell number in experimental models of secondary hyperparathyroidism [35-37]. Finally, as Parfitt et al. [91] noted, parathyroid adenomas, although they are clonal neoplasms caused by dysregulation of genes for parathyroid cell growth, do not grow progressively but rather enlarge very little after achieving a certain size. This behavior can be explained by a "set point" hypothesis: Parathyroid adenomas grow until the serum calcium reaches the set point for secretion of PTH and then essentially stop growing. Thus, the negative growth influence of ambient calcium concentrations above the set point dominates the control of parathyroid cell growth, even when the cells have a fundamental abnormality of growth control [89]. If correct, the set point hypothesis has an important consequence for chronic medical therapy of hyperparathyroidism, namely that drugs that reduce the serum calcium level by inhibiting bone resorption, once they lower serum calcium below the set point, will simply cause additional enlargement of the parathyroid adenoma [33]. Calcimimetic drugs potentially avoid this problem by resetting the set point. However, given that the calcium-sensing receptor is expressed in the growth plate, such drugs may affect chondrocyte growth and differentiation and may thus have adverse effects on growth in children. The relationship between parathyroid growth and the set point for hormone secretion is bidirectional: Primary abnormalities in parathyroid growth also produce a shift in the set point for PTH secretion. The set point is rightshifted in both primary and secondary hyperparathyroidism [92]. The shift in set point can be reproduced by transgenic introduction of a growth control gene, cyclin D, into parathyroid cells [93]. Thus, changes in [Ca 2+] regulate the growth of parathyroid cells, and changes in the growth of parathyroid cells reciprocally regulate the [Ca2+].
146
Gordon J. Strewler
Growth Regulation by Phosphate and Vitamin D
Hypocalcemia, hyperphosphatemia, and decreased 1,25(OH)2D levels all contribute to the genesis of parathyroid hyperplasia in uremia. 1,25(OH)zD inhibits the proliferation of parathyroid cells in vitro. Vitamin D and metabolites are used clinically to manage secondary hyperparathyroidism in patients with chronic renal failure [94] (see Chapter 28). However, the importance of 1,25(OH)zD as a regulator of parathyroid gland size in circumstances other than renal failure is less clear because the absence of the VDR does not induce the proliferation of parathyroid cells in the knockout mouse model when normal levels of serum calcium and phosphorus are maintained by dietary means [86]. Hyperphosphatemia is another stimulus to parathyroid growth, independent of changes in [Ca 2+] or 1,25(OH)zD [76]; hence, control of the serum phosphorus level by restricting dietary phosphate and administration of oral phosphate binders [calcium, aluminum-containing antacids, or sevelamer hydrochloride (Renagel)] is crucial to prevention of secondary hyperparathyroidism in patients with chronic renal failure on dialysis. Chronic oral phosphate therapy of the hereditary phosphate-wasting disorders can also lead to the development of secondary hyperparathyroidism (see Chapter 25). The means by which parathyroid cells sense changes in ambient phosphate concentrations has not been established, although the cells express a sodium-coupled phosphate transporter whose level is regulated by the extracellular phosphate concentration [78]. It has recently been suggested that an increase in the parathyroid level of the growth factor transforming growth factor-~ may mediate the growth effects of dietary phosphate and 1,25(OH)zD, which are exerted on the cell growth regulatory protein p21 wafl/cipl, a regulator of cyclin-dependent kinases [95,96]. Peripheral M e t a b o l i s m of PTH PTH is rapidly metabolized after secretion, with a disappearance half-time of approximately 2 min [56,97]. Metabolism occurs mainly in the liver (60-70%), where it is taken up and rapidly degraded by Kupffer cells [98], and in the kidney (20-30%) [56,99,100]. The removal of PTH by the kidneys is almost exclusively by glomerular filtration, after which uptake and degradation by cells of the renal tubule involve the protein megalin [101]. The rapid degradation of PTH ensures that its level in blood is set by the secretory rate. Advantage is taken of its rapid clearance when intraoperative determinations of the PTH level are used during parathyroidectomy to determine when a parathyroid adenoma has been removed [102].
Circulating PTH is a heterogeneous pool because in addition to the full-length, biological molecule, a variety of fragments are present in the circulation [56] (Fig. 9). Most of these are carboxyl-terminal fragments generated by cleavage of PTH at several sites in the region 33-43 [99,100]. They arise both by peripheral metabolism of PTH in Kupffer cells of the liver [98-100] and by direct secretion from the parathyroid gland [103,104]. Although only 10-20% of PTH is converted to carboxyl-terminal fragments, they predominate over full-length PTH in serum because they have a much longer half-life than that of PTH. Carboxyl-terminal fragments are cleared in the kidney and they therefore accumulate in renal failure [56,97]. Because they are present in such abundance, carboxyl-terminal fragments are the easiest form of PTH to measure in serum, and early PTH assays were mostly directed to determinants in the carboxyl-terminal domain. As discussed later, several lines of evidence suggest that there may be a distinct receptor for the carboxyl-terminal region of PTH, which specifies a distinct set of biological actions. Amino-terminal fragments that contain the determinants required for biological activity are presumably produced in the Kupffer cell by cleavage in the region 33-43, but they do not appear to circulate in significant amounts [100]. It has recently been found that PTH appears to be cleaved also at one of the first residues to produce a fragment that may be similar to PTH(7-84) [105-107]. Synthetic PTH(7-84) is not active at the PTH1R, although it has weak activity as a competitive antagonist of PTH(1-84)-stimulated cAMP accumulation, but it has hypocalcemic properties in vivo. These actions appear to be mediated through a putative receptor for carboxyl-terminal PTH [108-111]. Non-PTH(1-84) account for approximately one-third of the circulating species immunoreactive PTH in two-site immunoassays for the whole molecule, both in individuals with normal renal function and in renal failure [106,107,112,113]. A new generation of whole molecule PTH assays have been introduced that are specific for PTH(1-84).
i Blood
arathyroids I
1
Intact
'
t,
Carboxyl-terminal
! ',ver I I FIGURE 9 Schematic representation of the origin and clearance of PTH fragments. (Reprinted with permission from Felig, P., Baxter, J. D., Broadus, A. E., Frohman, L. A. (Eds.) "Endocrinology and Metabolism, 3rd edition," McGraw-Hill, 1995.)
5. Parathyroid Hormone and Calcium Homeostasis
147
ASSAY OF PTH For many years, the study of the physiology of the parathyroid gland and its disorders was hampered by technical difficulties in assaying the hormone [114]. PTH circulates at a low concentration (1-6 pmol/liter) compared to many other hormones. Also, PTH in blood is immunologically heterogeneous, an observation first made during pioneering efforts by Berson and Yalow to develop a radioimmunoassay of the hormone [115]. The best of the early PTH assays proved to be those that used antibodies directed at determinants in the midregion of the sequence [116]. These determinants are part of carboxyl-terminal fragments that have a long half-life compared to intact PTH and are thus present at a much higher concentration. Although they could detect PTH in the form of these fragments, midregion assays suffered problems with sensitivity and specificity. It is now recognized that PTH is appropriately suppressed in non parathyroid hypercalcemia, but early assays detected immunological activity in serum, presumably from interfering substances, and this led to considerable confusion about the role of PTH or related molecules in the pathogenesis of hypercalcemia in malignancy [117]. Intact PTH values in midregion assays were also increased in renal failure because of impaired renal clearance of the fragments. Although assays for amino-terminal, midregion, and carboxyl-terminal fragments are still in clinical use, they have no advantages over assays for the whole molecule, which are both more sensitive and more specific. The current generation of PTH assays consist of twosite assays for intact PTH [118-122]. By using two antibodies in combination (Fig. 10), it is possible to improve both the sensitivity and the specificity of the assay. In the assay serum is added to tubes containing a capture antibody that is bound to a bead or some other type of solid phase support. PTH is bound to a solid phase by the capture antibody and is then detected with a labeled second antibody. The sensitivity of two-site assays is high (<1 pmol/liter) because the individual affinities of both antibodies contribute to overall assay sensitivity. The specificity of the assays has also been improved in two ways. Nonspecific interference is reduced to negligible levels because potential interfering substances in serum are removed before the bound PTH is detected. Interference by heterogeneous PTH fragments should be eliminated by choosing the antigenic determinants for the two antibodies from opposite ends of the molecule and thus making the assay specific for the intact PTH(1-84) molecule, although the generation of intact PTH assays currently in clinical use also recognizes an almost full-length form of PTH.
FIGURE | 0 Principles of two-site assay of PTH. (Reprinted with permission from Strewler, G. J. and Greenspan, F. S. (eds.) "Basic and Clinical Endocrinology, 3rd edition," Appleton and Lange, 1997.)
A variety of two-site assay formats are available [118-122]. They differ from one another primarily in the method that is used to detect the second antibody bound to PTH: Immunoradiometric assays use radioactively labeled second antibody, thus requiring facilities that can deal with radiation hazards and the limited shelf-life of the reagent. These have largely been supplanted by enzyme-linked immunosorbent assays and immunochemiluminometric or immunofluorometric assays. Most assay formats can be automated, allowing for easy access by hospital labs, and they can be set up to allow determination of PTH in 1 hr or less so that they can be used intraoperatively to help the parathyroid surgeon determine when a parathyroid adenoma has been removed [102,123]. It was recently found that the first generation of intact PTH assays actually recognize an extended PTH fragment, hitherto unrecognized, that is truncated at the amino terminus and therefore lacks biological activity [105-107]. It is estimated that this fragment comprises approximately one-third of immunoreactive intact PTH in normal subjects (67-79%) and 33-68% in patients with uremia [106,107,112,113]. A new generation of assays have recently been introduced with antibodies that require that the entire amino terminus be present in order to recognize PTH, and they are specific for biologically active PTH(1-84); these are provisionally termed whole PTH assays to distinguish them from first-generation intact PTH assays [112]. One of them has a normal
148
Gordon J. Strewler
range of 7-36 pg/ml [112] (Fig. 11), compared to 10-65 pg/ml in intact assays. The implications of these developments for the clinical use of PTH assays remain to be determined. PTH assays are used clinically in the differential diagnosis of hypercalcemic and hypocalcemic states and in the management of patients with chronic renal failure. Intact PTH assays and whole PTH assays identify elevated PTH levels in 80-90% of patients with primary hyperparathyroidism (Fig. 11); most of the remaining patients have PTH levels in the upper normal range. A high normal PTH in ahypercalcemic patient is consistent with the diagnosis of primary hyperparathyroidism because PTH values of patients with nonparathyroid hypercalcemia are suppressed to the lower normal range or lower [124]. Conversely, a suppressed PTH in a patient with a malignant tumor and hypercalcemia essentially excludes a coincidental parathyroid tumor. Whether the whole PTH assay will improve assay performance remains to be seen. Most hypoparathyroid
FIGURE 1 1 Scatterplotof whole PTH(1-84) values in healthy controls and various patient groups. Shaded area indicates the plasma normal range (7-36pg/ml) of wholePTH(1-84). The y axis is expressed by log2 scale. The whole PTH levels of 10 patients with primary hyperparathyroidism (1~ HPT) were in the upper normal range and the overall diagnostic sensitivity was 93.9% (155/165) [from Gao et al. (2001). J. Bone Miner. Res.16, 605-614. Copyright 2001 American Society for Bone and Mineral Research).
patients have subnormal PTH values, a notable exception being those with inherited activating mutations of the parathyroid calcium-sensing receptor, who typically have mild hypocalcemia and PTH values in the lower normal range [31,125]. To diagnose and manage the two dominant forms of renal osteodystrophy, secondary hyperparathyroidism and adynamic bone disease, it is essential to monitor the PTH level [126,127]. Intact PTH assays are a considerable improvement over older radioimmunoassays for PTH fragments, but they are also interfered with by renal failure, as discussed previously [105,107,112]. Currently, research is focused on whether better clinical performance can be achieved by whole PTH assays, which appear to be minimally affected by renal insufficiency.
PARATHYROID H O R M O N E ACTION PTH a n d Mineral Ion H o m e o s t a s i s To maintain the concentration of calcium within narrow limits, PTH regulates the transfer of calcium across the three interfaces of the extracellular space--the bone, the kidney, and the intestine. The kidney and bone are direct targets of PTH, but the regulation of intestinal calcium absorption by PTH is indirect. PTH regulates the renal synthesis of 1,25(OH)2D, the active metabolite of vitamin D, which in turn controls the active entry of calcium through intestinal enterocytes. In response to hypocalcemia, PTH induces the release of calcium from skeletal stores by stimulating osteoclasts to resorb bone. The hormone thus taps the body's only substantial store of calcium to replete the extracellular compartment, for example, when the intake is low and cannot keep up with urinary losses. In bone, however, PTH targets not only the osteoclast (the bone-resorbing cell) but also the osteoblast (the bone-forming cell). Large net losses of bone mineral are averted by coupling resorption of existing bone to synthesis of new bone. The skeletal reserves of calcium are huge and repletion is efficient, so that only in rare instances (e.g., in chronic renal failure) is the integrity of the skeleton compromised by secondary hyperparathyroidism. PTH signals the kidney to conserve calcium, synthesize 1,25(OH)2D, and waste phosphate in the urine. It makes physiological sense that in order to protect the serum calcium concentration, PTH should conserve calcium by inhibiting its renal excretion. In response to hypocalcemia, PTH also activates the conversion of 25OH-vitamin D, the principal circulating form of the vitamin, to 1,25(OH)2D, its active form. As discussed in Chapter 7, the renal synthesis of 1,25(OH)2D is also regulated by the mineral ions calcium and phosphate;
5. Parathyroid Hormone and Calcium Homeostasis
the kidney thus acts to synthesize information about systemic mineral ion levels and their urinary excretion rates and set the level of 1,25(OH)zD accordingly. Through 1,25(OH)zD, the kidney dictates that the rate of calcium absorption in the intestine responds to the integrated needs of mineral ion homeostasis. PTH is also involved in the regulation of renal phosphate reabsorption. PTH increases urinary phosphate excretion at the same time as it reduces urinary calcium excretion. Why is this? The dissolution of bone mineral (hydroxyapatite) during resorption simultaneously releases calcium and phosphate into the extracellular space. Accumulation of phosphate would impair the maintenance of calcium homeostasis because of the complex interrelationships of mineral ions and the hormones that regulate their levels. Hyperphosphatemia would lower [Ca 2+] by precipitating calcium phosphate (because the normal circulating concentrations of the two ions approach their solubility product) and would inhibit the renal synthesis of 1,25(OH)zD; by these mechanisms, as well as by a direct effect, hyperphosphatemia would stimulate the additional synthesis and secretion of PTH. These entanglements are averted because PTH allows the phosphate that is liberated during bone resorption to be excreted. To understand the importance of this, consider what happens in renal failure. As phosphate accumulates because it cannot be excreted, PTH levels increase sharply. This secondary hyperparathyroidism induces further resorption of bone, creating a positive feedback loop in which bone resorption, via the serum phosphorus and PTH, begets more bone resorption. From this example, it is clear that the phosphaturic effect of PTH is an important part of integrated control of the economy of calcium and phosphate.
PTH R e c e p t o r s a n d Intracellular Signaling
PTH Receptor In its target tissues, bone and kidney, the cellular agent for the actions of PTH is a G protein-coupled receptor (GPCR) whose structure is shown schematically in Fig. 12 [128-130]. The receptor has essentially identical affinities for PTH and PTHrP and is referred to as the PTH1R or the PTH/PTHrP receptor. It has a large extracellular domain, seven membrane-spanning domains, and a cytoplasmic tail. Although the general architecture of the receptor with its seven transmembrane domains is canonical for the GPRC fainily, PTH1R is distinct in sequence from most of this huge receptor family, but it shares structural and functional motifs with a group of other GPRCs that recognize peptide ligands of 30-50 amino acids (class II GPCRs). These include receptors for calcitonin, glucagon, secre-
149
tin, vasoactive intestinal peptide, and corticotropinreleasing hormone [131]. A second GPCR, the PTH2R, is the receptor for TIP39, probably the third member of the PTH peptide family [49]; however, the human homolog of this receptor is also activated by PTH but not by PTHrP [51,52]. The PTH2R is present in the central nervous system. A third receptor has been identified in the zebrafish that, like the PTH1R, recognizes PTH and PTHrP, but not TIP39 [54]. Although distinctive structurally, class II GPCRs appear to have a similar kind of interaction with G proteins as the rest of this large family, which has thousands of members in humans. Thus, the problem of coupling PTH to an intracellular signal was solved with an ancient set of molecules whose versatility has resulted in their widespread distribution throughout evolution [132,133]. GPCRs recognize light, odors, calcium, catecholamines, and proteins, and they have existed at least since the appearance of the roundworm Caenorhabditis elegans, which remarkably devotes approximately 10% of its genome to GPRCs.
Hormone-Receptor Interaction Although PTH is an 84-amino acid peptide, all the determinants for receptor binding and activation are present in PTH(1-34). An intact amino terminus is required for activation of adenylyl cyclase, and amino-truncated peptides are weak partial agonists [e.g., PTH(3-34)] or pure antagonists [e.g., PTH(7-34)] [128,130, 134,135]. Minimization of the peptide reveals that PTH(1-11) with some substitutions to increase its activity is a reasonably potent ligand for PTH1R [136,137]; this activation domain is conserved between PTH and its more ancient relative PTHrP, which shares 8 of the first 13 amino acids of PTH. This adenylyl cyclase activation domain in PTH has an inducible s-helical conformation; it is likely that the hydrophobic environment of the membrane induces the active conformation of this domain [136]. The determinants required for activation of a second signaling pathway, phospholipase C, are less certain: Some studies suggest that the tetrapeptide PTH (29-32) is sufficient [138], whereas others suggest that an intact amino terminus is required for efficient signaling [139]. The carboxyl-terminal region of PTH(1-34) is its principal binding domain [140,141]. Several nuclear magnetic resonance structures and a crystal structure [142] indicate that PTH(1-34) and PTHrP(1-34) both possess a similar, stable ~-helical region from approximately residues 17 to 30 [143-145]. In fact, the binding domains of PTH and PTHrP are interchangeable, even though they have no primary sequence homology [140,141]. This suggests that the main structural requirement for binding is simply an amphipathic helix; indeed, insertion of a
150
Gordon J. Strewler
FIGURE 1 2 The human parathyroid hormone type 1 (PTH-1) receptor (593 amino acids), showing its predicted domain organization (the locations of the seven transmembrane s-helical domains in the sequence were predicted by the Protein-Predict computer program). The Cys disulfide linkages (connecting lines) were determined from studies on the N-terminal PTH-1 receptor fragment produced in Escherichia coli. N-linked glycosyl groups are indicated by the forked symbols. Other key residues referred to in the text are indicated by single amino acid code within open circles, some of which are labeled with sequence position number for reference. The human skeletal disease of Blomstrand's chondrodysplasia (receptor inactivity) results from a mutation at Pro132--.Leu and that of Jansen's chondrodysplasia (receptor constitutive activity) results from mutations at Arg233--.His, Thr41~ and Ile458---,Arg, all shown in dark gray. Serine (S) residues shown in dark gray in the cytoplasmic tail are phosphorylation sites. C, Cys; F, Phe; H, His; I, Ile; K, Lys; L, Leu; M, Met; N, Asn; P, Pro; Q, Gln; R, Arg; S, Ser; T, Thr; V, Val; W, Trp; Y, Tyr [reproduced with permission from Gardella, T. J., and Jfippner, H. (2001). Trends Endocrinol. Metab.12, 210. Copyright Elsevier Science, Ltd.].
"generic" helix into PTH from positions 22 to 31 will also create a potent ligand [146]. The details of PTH binding and activation of its receptor are not fully understood, but considerable insight has been gained by a combination of molecular cross-linking of PTH and the receptor [128,130,147-150], mutations in both ligand and receptor, and modeling based on the structure of PTH. The binding domain of PTH associates with the large extracellular domain of the PTH1R, allowing the amino terminus to be inserted into a shallow binding pocket formed by the transmembrane domains (Fig. 13). This model is consistent with other kinds of data [128]: The amino terminus of PTH can activate a receptor from which nearly all the large extracellular domain has been removed [151], albeit with low affinity, and the
receptor is constitutively active if the amino-terminal activation domain of PTH is tethered to it [152]. Thus, the extracellular domain is required for high-affinity binding but is dispensable for receptor activation. In order to activate the PTH receptor, binding of hormone at the outer face of the plasma membrane must transmit a signal to the cell interior, such as a conformational change in the transmembrane domains that rearranges the intracellular loops of the receptor so that they can turn the G protein switch [128,129]. Direct evidence of an agonist-induced separation of transmembrane domains 3 and 6 of the PTH1R has been reported [153]. This presumably changes the conformation of the intracellular loops that connect the transmembrane domains (Fig. 13). Several residues in
5. Parathyroid Hormone and Calcium Homeostasis
FIGURE 13 Model of hPTH(1-34) binding to the PTH/PTHrP receptor. The receptor is shown in light gray and PTH (1-34) in dark gray. The locations of contact points between the ligand and receptor that were identified by crosslinking are indicated (Serl-M425, Lys13R 186, Trp23-T33/Q 37, Lys27-L261). Reprinted with permission from "The Parathyroids: Basic and Clinical Concepts, 2nd edition," (J. P. Bilezikian, R. Marcus, and M. A. Levine,Eds.) pp. 245-260. Academic Press: San Diego (2001). intracellular loops 2 (Lys 319) and 3 (Va1384,Leu 385,Thr 387, and Lys 388) are necessary for the receptor to efficiently couple to G proteins and are thus candidates as direct sites of interaction between the receptor and Gs to activate adenylyl cyclase or between the receptor and Gq to couple the receptor to phospholipase C [154,155] (Fig. 12). Mutations in Blomstrand chondrodysplasia inactivate PTH1R [156,157], producing an embryonic lethal disorder, and mutations in the second, sixth, and seventh transmembrane domains in Jansen's chondrodysplasia (Fig. 12) render the receptor constitutively active [158], producing a chondrodysplasia and hormone-independent hypercalcemia. In both cases, the chondrodysplasia results mainly from disruption of the developmental regulation of chondrogenesis by the other ligand of the PTH 1R, PTHrP. Chondrogenesis aside, the ability of the constitutively active PTH1R to mimic primary hyperparathyroidism provides strong evidence that the PTH1R is responsible for most of the actions of PTH in bone and kidney (see Chapter 3). Regarding PTH1R, these disorders identify the regions of the receptor that are potentially important for activation, but the precise role of these residues in activation of the receptor is unknown.
1 51
[159,160]. PTH 1R mainly binds to the heterotrimeric G proteins Gs and Gq [161,162]. Each of these G proteins consists of ~, [3, and 7 subunits; in the resting state, the subunit of the G protein is bound to GDP. When PTH binds, the receptor changes the conformation of the G protein such that GDP dissociates from G~ and is replaced by GTP (Fig. 14). GTP binding switches G~ to the "on" position and dissociates it from the [37 complex so that active G~ is freed to turn on effector proteins. The effectors will generate two intracellular second messengers: Gs~ activates the catalytic subunit of adenylyl cyclase to generate cyclic AMP (cAMP) from ATP, and Gq~ activates phospholipase C[3 to cleave inositol phosphates and produce the signaling intermediate 1,4,5inositol trisphosphate (IP3). The G protein cycle is completed when GTP is hydrolyzed to GDP by the intrinsic GTPase activity of G~; this switches off the G protein, terminating its signal, and permits reassociation of G~ with [37 to reconstitute the heterotrimeric resting state (Fig. 14). cAMP generated in response to PTH diffuses through the cell and turns on a specific serine/threonine protein kinase, protein kinase A (PKA), which is localized to signaling complexes within the cell by specific anchor proteins [41,42,163]. The targets for PKA include transporters [164], cytoplasmic signal transduction molecules that produce cross talk between the cAMP signaling pathway and other pathways [165], and the phosphorylation-sensitive transcription factor CRE-binding protein (CREB), whose activity is regulated by PKA [166]. The cAMP signal is terminated by enzymes called cyclic nucleotide phosphodiesterases, which hydrolyze cAMP to AMP [167,168]. cAMP is the primary intracellular second messenger for many of the actions of PTH in kidney and bone. The best evidence for this derives from the disorder pseudohypoparathyroidism (types 1A and 1B), in which mutations that reduce the amount of Gs~ produce target
Inactive Y ~y G proteinGDP-aI
~GTPa+13y Active ~ S ~ GprOtein Activation of AC, PLC, etc.
~
GDP-(x Pi
Intracellular Signaling by the PTH Receptor G proteins are simple switches that couple the PTH receptor to two intracellular signaling pathways
FIGURE 14 The activation cycle of a G protein. Reprinted with permission from "The Parathyroids: Basic and Clinical Concepts, 2nd edition," (J. P. Bilezikian, R. Marcus, and M. A. Levine,Eds.) pp. 245260. AcademicPress: San Diego, (2001).
152
Gordon J. Strewler
organ unresponsiveness to PTH (see Chapter 20). The individual roles of PKA and PKC in the actions of PTH in its target tissues are further discussed later. Phospholipase C[3 cleaves the phospholipid substrate phosphoinositol-4,5-bisphosphate in the plasma membrane to produce the intracellular second messenger IP3, which diffuses to the endoplasmic reticulum and induces the transient release of calcium from its stores [2,41,42]. The cleavage of phosphoinositol-4,5-bisphosphate also produces a diacylglycerol that, together with calcium, activates PKC. In general, the actions of PTH are more often dependent on cAMP than Ca 2+ as an intracellular second messenger. PKC may modulate part of the effect of PTH on sodium-dependent phosphate transport [169] and stimulation of vitamin D-1 ~hydroxylase in the kidney [170], but both are markedly reduced by Gs~ mutations in pseudohypoparathyroidism (see Chapter 20), and this establishes the primacy of cAMP regulation of these actions. Treatment of bone cells with PTH translocates the PKC isozymes PKC~ and PKC[31 to the plasma membrane. Activated PKC has a role with regard to the effects of PTH on interleukin-6 (IL-6) in bone cells [171,172].
Regulation of the PTH Receptor
Regulation of Receptor Protein Exposure to the PTH ligand modifies signaling by the PTH receptor in two ways [129]. The receptor can be uncoupled from its G protein partner; in this process, called desensitization, the response to PTH is considerably dampened by a prior treatment with PTH. Occupancy of the receptor by PTH will eventually lead to the disappearance of receptors from the cell surface, a phenomenon called receptor downregulation. The two processes have independent but related mechanisms. The mechanisms for acute desensitization involve a regulatory system of G protein receptor kinases (GRKs) and arrestin proteins that is also used for desensitization of other GPRCs and is best understood in the case of the [3-adrenergic receptor [173,174]. The PTH 1R is phosphorylated on its carboxyl-terminal tail by GRK2 in response to agonist binding [175,176] and this inhibits signaling [177]. Stable expression of a dominant-negative form of GRK2 suppresses PTH-induced desensitization of PTH 1R [178]. By analogy with other GPRCs, phosphorylation of the cytoplasmic tail of the PTH1R presumably promotes the binding of arrestin proteins to the receptor, which sterically hinder the binding of its G protein partners to the receptor and thereby uncouple it from them. Receptor downregulation begins with clustering of occupied PTH receptors in clathrin-coated pits in the plasma membrane [129,179]. The pits are sites of endo-
cytosis, where bits of plasma membrane with clustered PTH receptors are pinched off and internalized as vesicles. Once in endocytic vesicles, the PTH receptor can be recycled to the cell surface or can progress down the endocytic pathway for eventual destruction in lysosomes. Endocytosis of the PTH receptor requires the sequence Tyr-Gly-Pro-Met in the cytoplasmic tail [179]; this resembles a consensus sequence for internalization of other plasma membrane proteins. The role of receptor phosphorylation and arrestin binding in the internalization process is not fully understood. In the paradigm of the [3-adrenergic receptor, phosphorylation of the receptor induced by agonist binding leads to binding of arrestin, which targets the receptor to clathrincoated pits [173,174]. A PTH1R in which all of the GRK phosphorylation sites have been mutated is internalized normally, however [180]. Expression of a dominant-negative version of GRK impairs internalization [178], and activation of the PTH receptor, whether agonist induced or constitutive, results in translocation of arrestin from cytoplasm to the cell membrane and eventual colocalization with PTH1R in intracellular vesicles [181,182]. Thus, assumption of the active conformation of the PTH1R probably induces arrestin binding and thereby targets the receptor for internalization, but it is not clear whether agonist-induced phosphorylation of the PTH receptor is required for these events. How important is receptor regulation to the biology of parathyroid hormone action? Desensitization and downregulation of renal PTH receptors occur during infusion of PTH in vivo [183] and in models of vitamin D deficiency [184,185] and uremia [186-188]. The downregulation of PTH receptors in chronic vitamin D deficiency can be prevented by parathyroidectomy [189]; however, parathyroidectomy does not prevent receptor loss in uremia, so mechanisms other than agonist-induced downregulation must be operative [190]. When given intermittently, PTH(1-34) has a powerful anabolic effect on bone [191] and will be a valuable therapeutic in osteoporosis [192], but when administered continuously it has a catabolic effect and produces osteoporosis [191]. It is intriguing that downregulation of PTH receptors may account for the profound differences between the net effects of continuous and intermittent administration of PTH, and this issue is of intense interest.
Gene Regulation The PTH1R gene is complex, with 13 introns and at least two promoters, a downstream promoter that is used in all tissues that express the gene (which mediates the effects of PTHrP in many tissues), and an upstream promoter used in the kidney [193,194]. Whether these differences simply reflect opportunities for tissue-specific gene regulation or lead to expression of structurally dif-
5. Parathyroid Hormone and Calcium Homeostasis ferent forms of the P T H 1 R remains to be established [194,195]. Exposure to PTH reduces receptor m R N A levels in osteoblasts [196,197] but not in kidneys of rats with secondary hyperparathyroidism [190,198,199]. However, hypoparathyroidism, induced by either parathyroidectomy or dietary phosphate depletion, strongly upregulates P T H 1 R m R N A levels in rat renal cortex [200]. Whether regulation of PTH receptor gene expression is truly tissue specific, and whether it is significant to systemic calcium homeostasis, awaits more studies of receptor regulation in vivo.
Another PTH Receptor The carboxyl-terminal region of PTH [PTH(35-84)] is as highly conserved during evolution as PTH(1-34), even though it is completely dispensable for activation of PTH1R. Cleavage of PTH(1-84) produces long-lived carboxyl-terminal fragments, including those that are similar to PTH(7-84) [105-107] and a family of fragments whose amino terminus is between residues 34 and 43 [99,201]. Several lines of evidence suggest that there may be a distinct receptor for the carboxyl terminus of PTH that recognizes these fragments but does not recognize the amino-terminal activation domain for the P T H 1 R [e.g., PTH(1-34)]. Saturable, specific binding sites for carboxyl-terminal fragments can be demonstrated on osteoblasts and at high concentrations on an immortalized osteocyte cell line [108-111]. Infusion of such fragments lowers the serum calcium concentration in the parathyroidectomized rat and antagonizes the calcemic effect of PTH(1-84) [110]. Exposure to PTH (7-84) in vitro inhibits calcium release from bone explants in response to either PTH or 1,25(OH)zD and also inhibits the formation of osteoclast induced by vitamin D in murine marrow cultures [111]. Previous studies have reported other effects of carboxyl-terminal PTH fragments on osteoblast function [202-204]. The putative receptor remains to be identified, and the biological significance of cleavage of PTH into carboxyl-terminal fragments that antagonize the biologic effect of its amino-terminal fragments remains to be explained.
153
therapeutic dose of hPTH(1-34) in osteoporotic women [205]. Sustained exposure to PTH also activates the process of osteoclastogenesis by which new osteoclasts appear. Chronic exposure to excess PTH produces a characteristic pattern of bone loss: osteoporosis with trabecular thinning and loss, intracortical tunneling, and subperiosteal bone resorption, the combination of which is characteristic of hyperparathyroid states (see Chapter 20). PTH induces bone resorption through activation of the R A N K L / R A N K system [46,206,207]. The receptor activator of NF-•B (RANK) is a member of the tumor necrosis factor (TNF) receptor family, and its ligand, R A N K ligand (RANKL), is a T N F family member. Evidence from genetic experiments indicates that virtually all bone resorption, whether induced by PTH, vitamin D, or a cytokine, utilizes the R A N K L / R A N K system as a final common pathway (see Chapter 2). R A N K L is expressed on the surface of stromal cells or osteoblasts, and it can be secreted as well. Activation of its receptor, R A N K , on monocyte/macrophage lineage cells is necessary, and exposure to M-CSF and R A N K L is sufficient to induce osteoclastogenesis. PTH induces osteoclastic bone resorption through an indirect effect on stromal cells and/or mature osteoblasts to increase the expression of R A N K L [208,209] and simultaneously to decrease the expression of OPG [210,211] (Fig. 15). Stimulation of osteoclastogenesis by PTH is blocked by antibodies to R A N K L [212] or by
P a r a t h y r o i d H o r m o n e Action in B o n e
Stimulation of Bone Resorption To protect the serum calcium concentration, PTH induces the resorption of bone so that calcium and phosphate are released into the blood. The acute increase in the serum calcium concentration occurs within hours and presumably involves the activation of preexisting osteoclasts. For example, serum calcium increases approximately 2 hr after administration of a
FIGURE 15 PTH induces osteoclast formation and activityby effects on RANKL and OPG. Osteoclast precursors proliferate and eventually fuse to form multinucleate osteoclasts in the presence of M-CSF and RANKL, which is presented to them on the surface of stromal cells. PTH simultaneously increases stromal cell expression of RANKL and decreases secretion of the decoy receptor OPG, which inhibits osteoclastogenesis. RANKL not only induces the formation of osteoclasts but also induces multinucleate osteoclasts on the bone surface to become active as bone-resorbing cells.
154
Gordon J. Strewler
OPG [208,213], and infusion of OPG into animals blocks the hypercalcemic response to PTH or PTHrP [214-216]. The role of stromal cells or osteoblasts as the primary recipient of the signal from PTH is consistent with the distribution of PTH receptors in bone: Marrow stromal cells and osteoblasts have receptors for PTH [217-220], but osteoclasts do not [218,221,222]. Whether immature marrow stromal cells or more mature cells of the osteoblast lineage are primarily responsible for nurturing osteoclast precursors is not clear, but RANKL levels decline and OPG levels increase during osteoblast maturation [223]. Bone resorption by mature osteoclasts in response to PTH has long been recognized as requiring coculture with osteoblasts or marrow stromal cells [224]. Highly purified cultures of isolated osteoclasts are unresponsive to PTH, but exposure to soluble RANKL is sufficient to induce bone resorption [225]. Thus, both acute effects of PTH on existing osteoclasts and chronic effects on the production of new osteoclasts are probably mediated by RANKL. It is conceivable that a parallel pathway exists in which other cytokines, such as IL-6 or IL-11, could mediate part of the effect of PTH on bone resorption [226-228]; if so, however, this is likely of secondary importance [229,230]. Stimulation of Bone Formation
Regarding calcium homeostasis, the stimulation of bone formation by PTH serves the function of linking new bone formation to bone resorption, thus restoring bone sacrificed to the demands of hypocalcemia. In the classical model of bone remodeling, bone-resorbing substances activate new teams of osteoclasts to resorb bone. After these osteoclasts have excavated a pit there is a reversal phase and then the formation of new bone in the excavated space (see Chapter 2). The signals that recruit osteoblasts to the remodeling site and control their activity have not been identified but are believed to be chemotactic signals generated by the release of factors from the resorbed bone matrix. Bone formation is coupled in space and time to prior bone resorption. The stimulation of bone formation in primary hyperparathyroidism cannot be completely explained by activation of bone remodeling units [231]. At the level of the bone remodeling unit, not only is activation frequency increased (as could be explained by a primary effect of PTH to activate bone resorption) but also the mineral apposition rate is increased, the duration of the active formation period is prolonged, and the mean wall thickness is increased [232,233]. PTH both increases the daily productivity of osteoblasts and extends their active work life by making each osteoblast more productive, by adding more osteoblasts, or both. As a result, trab-
ecular bone mass is preserved and may even be increased in primary hyperparathyroidism despite marked bone resorption [234,235]. The anabolic effect of PTH is markedly accentuated when the hormone is administered once daily--an observation [236] that has led to the introduction of PTH for osteoporosis therapy. Daily subcutaneous administration 6f PTH(1-34) causes rapid, dramatic expansion of cancellous and cortical bone mass in animals [191,237240] and humans [192,241-243], increases bone strength [244-246], and markedly reduces the incidence of new fractures in postmenopausal women [192]. It is not known why intermittent exposure to PTH has an anabolic effect whereas continuous high-dose PTH often produces net catabolism of bone [247]. It is possible that continuous exposure to PTH induces receptor downregulation and thereby diminishes the stimulation of an anabolic pathway. Intermittent treatment with PTH increases the activation frequency of bone multicellular units and greatly increases osteoblast surface [231,248-250]. The increase in osteoblast number or mineralizing surface is quantitatively greater than the increase in daily mineralization rate [248-250]; that is, there are more osteoblasts at work and/or they work longer, but they also work harder. By increasing bone formation, treatment with PTH and estrogen induces an increase in the connectivity of trabecular bone that does not occur during treatment with antiresorptive agents alone [249,251] and in high doses can virtually replace the marrow space with trabecular bone. Thus, treatment with once-daily PTH magnifies all the effects of primary hyperparathyroidism on osteoblast function. There is also preliminary evidence that PTH treatment, in addition to activating bone remodeling units, can induce bone formation on previously quiescent bone surfaces [252]. The cellular effects of PTH on osteoblasts are many [46] (Table 2), and it is not easy to synthesize a coherent view of the biochemical and cellular basis for the overall effects of PTH on osteoblast recruitment or osteoblast function. Consider osteoblast synthetic activity. PTH induces the expression of the immediate early gene families c-fos (cfos,fra-1, and fra-2) and c-jun (c-jun andjunD) [253-256]. This is mediated by phosphorylation of the transcription factor CREB by PKA [257-259] to induce binding to a CRE in the c-fos promoter [257,258]. PTH also causes cAMP-dependent phosphorylation of the transcription factor cbfal [260]. How these transcriptional effects are related to increases in osteoblast synthetic function is not clear, since the direct effect of acute PTH administration is to inhibit the transcription of the gene for type I collagen, the principal protein of bone matrix [46,261,262]. PTH also increases the number of osteoblasts on the bone surface--at least when given in anabolic regimens.
5. Parathyroid Hormone and Calcium Homeostasis TABLE 2
A.
Effects of PTH on b o n e cells.
Effects on osteoblast precursor cells. Activate immediate early genes
B.
Effects on osteoblasts.
Transcriptionfactors Induce expression of c-fos family (c-los, fra-1, fra-2) Induce expression of c-jun family (c-jun, junD)
Induce phosphorylation of cbfa-1
155
Increase secretion of TIMP Increase secretion of tissue-type plasminogen activator, urokinase Decrease secretion of PAI- 1 Effects on osteocytes Required for c-fos response to mechanical stimulation Enhances calcium influx through mechanosensitive channels.
From reference 46.
Activate destruction of cbfa-1 in proteosomes Cytokines
Insulin-like growth factors Induce secretion of IGF-1 (rat) Induce secretion of IGF-1 and IGF-2 (mouse) Induce secretion of IFGBP-4, IGFBP-5 and IGFBP-RP-1
Transforming growth factor-J3 Increase secretion of TGF-[31 and TGF-[32 Interleukin-6 cytokine family Increase secretion of interleukin-6 Increase secretion of interleukin-11 Increase secretion of LIF Other cytokines and prostaglandins Induce expression of RANKL
Inhibit secretion of osteoprotegerin Increase secretion of GM-CSF Induce synthesis of prostaglandin G/H synthase-2 Induce secretion of prostaglandin E2 Ion channels
Depolarize osteoblasts, followed by sustained hyperpolarization Inactivate quinine-sensitive potassium channels Calcium entry through L-type voltage-gated calcium channels Open calcium-sensitive potassium channels Cell shape
Induce retraction of osteoblasts
Gap junctions Increase expression of connnexin-43 Open gap junctions Bone matrix proteins and alkaline phosphatase
Decrease transcription of col(I)A1 gene, inhibit collagen synthesis Increase synthesis and secretion of osteocalcin Increase secretion of bone sialoprotein Inhibit osteopontin gene expression Stimulate or inhibit expression of alkaline phosphatase Proteases and inhibitors z
Increase secretion of stromlysin Increase secretion of gelatinase B Increase expression and secretion of collagenase-3
PTH could increase osteoblast precursors growth in bone marrow, the proliferation of osteoblast precursors, or the recruitment of osteoblast precursors to the forming surface. Intermittent PTH may increase the entry of stromal cells into the osteoblast lineage [263], although the target cell for PTH remains to be found. Transcripts for the PTH/PTHrP receptor are absent or nonabundant in STRO-l-positive, alkaline phosphatase-negative marrow stromal cells [264,265], which are thought to represent early osteoblast precursors. Intermittent PTH does not increase the proliferation of osteoblast precursors: Neither the level of m R N A for the proliferation marker histone H4 [266] nor the number of [3H]thymidine-labeled nuclei on the bone surface are increased [267]. Intermittent exposure to PTH, however, could increase homing to the bone surface of late, postmitotic osteoblast precursors in the bone marrow, which have PTH receptors [217,222]. PTH increases the life span of the active osteoblast [231]. In the mouse, intermittent treatment with a high dose of PTH reduces the rate of osteoblast apoptosis [268], although PTH treatment actually increased the number of apoptotic osteoblasts in metaphyseal bone of young rats [269]. Although inhibition of apoptosis contributes to the anabolic effect of PTH, it is not clear whether the reduction in cell death is quantitatively sufficient to account for all of it. If the life span of an active osteoblast is several months [231], then the turnover rate of osteoblasts resulting in a reduction in the rate of apoptosis would be too slow to account for the rapid expansion of the osteoblast pool, which occurs within 1 week of the onset of PTH administration in rodent models. For example, if the osteoblast life span is 100 days, the turnover rate is 1% per day, and the maximal increase in osteoblast pool size expected from complete abolition of apoptosis is also 1% per day. If a reduction in apoptosis rate were the primary effect of PTH, increases not only in mean wall thickness but also in the duration of the active formation period would be expected. It is reasonably clear that mean wall thickness is increased by anabolic PTH regimens or in primary hyperparathyroidism, but whether the duration of the active formation period is also increased has not been resolved [233,248].
156
Gordon J. Strewler
In addition to increasing the rate of osteoblast precursor formation, the exit from a preosteoblast pool onto the bone surface, orthe active life span of working osteoblasts, PTH treatment may also recruit osteoblasts from the lining cells that cover quiescent bone surfaces [267]. Recruitment from this population would induce bone formation on previously quiescent surfaces [252]. Relatively few lining cells are needed to cover large areas of quiescent surface because the cells are flat; however, it seems unlikely that there are enough cells to account for the increase in osteoblast number following PTH treatment. The fact that so many possibilities exist for the anabolic effect of PTH is symptomatic of our profound ignorance regarding the basic cellular kinetics of the osteoblast population. In order to determine more definitively the mechanisms by which PTH has its anabolic effect, we must learn much more about the origin, life span, and fate of osteoblasts. Other cytokines could mediate the effects of PTH on bone formation [46,191,231]. Continuous exposure to PTH inhibits collagen synthesis by isolated rat calvaria, but exposure to PTH for the first 24 hr of a 72-hr experiment markedly increased collagen synthesis [270]. Stimulation of collagen synthesis by PTH is blocked by antibodies to insulin-like growth factor-1 (IGF-1), but proliferation is not [271]. Treatment of intact rats with PTH increases m R N A for IGF-1 [272] and the bone matrix content of IGF-1 [272a]. PTH also regulates expression of IGF binding proteins in bone [273]. Skeletal unloading causes resistance in vitro to IGF-1 and to the anabolic effect of PTH, suggesting that resistance to IGF1 may account for resistance to PTH [274]. Conditional mutagenesis of the IGF-1 receptor gene in bone, however, produces a high turnover state with markedly increased numbers of osteoblasts--not the depression of bone turnover that might be expected with blockade of PTH action [275]. Intermittent PTH treatment of rats increases the bone matrix content of TGF-[31 [272], raising the possibility that the anabolic effects of PTH observed with intermittent administration may also be mediated, at least in part, by increased secretion of this potent osteoblast growth and differentiation factor. The effect of PTH on TGF-[3~ may be PKC mediated, whereas its effect on TGF-[32 is PKA mediated [276]. The role of PTH in bone will not be understood until the role of PTHrP is determined. PTHrP is expressed in mature osteoblasts [217,277], periosteal cells [278], lining cells [217], and preosteoblasts [279-281]. Intimate interrelationships between paracrine effects of PTHrP and endocrine effects of PTH likely occur through their shared receptor. The phenotype of hypoparathyroidism, a low turnover bone state with preservation of the trabecular bone mass, is quite different from the phenotype
of the PTH 1R knockout, which has opposite changes in both cortical and trabecular bone compartments (with the caveat that the observations were made in late-stage mouse embryos with a severe chondrodysplasia) [282]. That knockout of the ligand has an effect opposite that of knockout of the receptor raises the possibility that a different ligand, PTHrP, dominates in the physiological regulation of trabecular osteoblasts. These issues can only be clarified by tissue-specific ablation or substitution of the genes for PTHrP and the PTH1R in bone using methods such as Cre-Lox technology.
PTH Action in t h e Kidney
Reabsorption of Calcium and Magnesium To protect the serum calcium concentration and prevent urinary calcium wasting in times of scarcity, PTH increases renal calcium reabsorption [283-285]. The major effect of PTH is to increase calcium reabsorption in the distal nephron, primarily the cortical thick ascending loop of Henle (cTAL) and the connecting tubule (CNT) [85,286-289]. Approximately 60% of filtered Ca 2+, but only 20% of filtered Mg 2+, is reabsorbed by the proximal tubule. Calcium reabsorption in the proximal convoluted tubule is passive and paracellular, driven mainly by the reabsorption of sodium, and it is mildly inhibited by PTH [286,290] because PTH inhibits two of its driving forces, sodium proton exchange and sodium phosphate cotransport (Fig. 16). Both Ca 2+ and Mg 2+ are passively reabsorbed in the cTAL [283,284,291]. This is a predominant site of Mg 2+ absorption because 60% of Mg 2+ but only 20% of Ca 2+ is reabsorbed in this segment. Passive paracellular reabsorption of both cations is driven by a lumen-positive transepithelial voltage gradient. This gradient is generated by Na+-K+-Ce2 transport by the NKCC2, C1C-Kb, and R O M K transporters [291] (Fig. 16). Paracellin-1, a member of the claudin family of tight-junction proteins that is expressed only in Henle's loop and the DCT, was recently identified as the cause of an autosomal recessive renal magnesium and calcium-wasting disorder [292] and is necessary for passive paracellular conductance of Ca 2+ and Mg 2+ [293]. PTH increases the conductance of the paracellular pathway and also the driving force for transport [291,294]. It is not known whether paracellin-1 is a direct target for PTH. The calcium-sensing receptor is also expressed in Henle's loop, and activation of this receptor by luminal Ca 2+ or Mg 2+ inhibits reabsorption of these ions by reducing the transepithelial voltage gradient [25]. The major sites of PTH action are the DCT and CNT, where the final 5-10% of Ca 2+ and Mg 2+ is absorbed. Here, PTH increases Ca 2+ uptake across apical
5. Parathyroid Hormone and Calcium Homeostasis
| 57
FIGURE 16 Calcium and magnesium reabsorption in PCT and cTAL. (Left) In the PCT, Ca 2+ and Mg 2+ are passively reabsorbed via paracellular routes at rates driven by the lumen-positive transepithelial voltage and limited by the conductance of the intercellular junctions for these cations. The transpeithelial voltage is generated by paracellular diffusion of C1- ions that are progressively concentrated along the lumen by active transcellular Na + reabsorption. Major mechanisms of Na + reabsorption include Na+/H + exchange and Na+-dependent cotransport of anions (phosphate, amino acids, sulfate, etc.). (Right) In cTAL, Ca 2+ and Mg 2+ reabsorption again occurs via voltage-dependent paracellular transport. Apical NKCC2 cotransporters and ROMK K + channels maintain the lumen-positive transepithelial voltage necessary for cation transport, which is inhibited by Ca2+/MgZ+-dependent activation of the CaSR and by the loop diuretic furosemide. The channel protein paracellin-1 appears to be critical for paracellular cation transport in the cTAL and could be a target for CaSRs and PTHRs, which respectively reduce and augment cation transport in this nephron segment. Reprinted with permission from "The Parathyroids: Basic and Clinical Concepts, 2nd edition," (J. P. Bilezikian, R. Marcus, and M. A. Levine, Eds.) pp. 245-260. Academic Press: San Diego (2001).
membranes of distal tubular cells [283-285,295-297], the likely rate-limiting step in transepithelial calcium transport (Fig. 17). The molecular nature of the apical calcium channel is not entirely established: Closely related (possibly identical) channels [295], CaT2 [298] and ECaC1 [299], are candidate molecules, but neither has been shown to be regulated by PTH. Interestingly, both ECaC1 and another related transporter, CAT1, are expressed in the apical membrane of intestinal enterocytes and both are vitamin D sensitive [300,301]. Thus, in the two epithelia in which external calcium balance is determined, the intestinal enterocyte and the renal tubule epithelium, vitamin D and PTH may operate the same calcium-transporting machinery. Calcium may be ferried across the cell by a vitamin Ddependent calcium-binding protein, calbindin-D28K [302-304]. This would provide a means to move calcium while maintaining a low intracellular [Ca2+]. The import-
ance of the physiological role of calbindin is not fully resolved. A preliminary report indicates that renal calcium wasting occurs in calbindin-D28K knockout mice [304], but urinary calcium wasting does not occur in vitamin D-deficient states, suggesting that efficient calcium resorption in the distal nephron does not absolutely require a vitamin D-dependent transport step. There are two potential mechanisms for extrusion of calcium from renal epithelial cells. Increased Na+/Ca 2+ exchange has been demonstrated following PTH administration in vivo and in vitro [305-307], and PTH's effect is abolished either by elimination of the sodium gradient that drives exchange or by removing extracellular Ca 2+ [308,309]. PTH may also increase Ca 2+ extrusion by activating the basolateral CaZ+-ATPase [310], although this is not observed in all systems [311]. It is not known where or how PTH stimulates calcium transport in the distal nephron. A number of studies
158
Gordon J. Strewler
also be inserted into the apical membrane by means of vesicle trafficking [315]. Finally, PTH reportedly hyperpolarizes distal tubule cells, at least in part by increasing a basolateral chloride conductance [316], and this could secondarily affect either calcium entry or calcium efflux through the sodium-calcium exchanger.
Reabsorption of Phosphate PTH induces phosphaturia, presumably as a mechanism to dump phosphate that is absorbed along with calcium under the influence of vitamin D or that is released from bone along with calcium when bone is resorbed. The absence of the phosphaturic effect of PTH was the principal evidence used by Albright et al. [317] to conclude that target organ unresponsiveness to PTH is the basis of pseudohypoparathyroidism. PTH inhibits phosphate reabsorption by reducing the number of transporters in the apical membrane (Fig. 18)
FIGURE 1 7 PTH regulation of distal tubular calcium reabsorption. In DCT, Ca 2+ reabsorption involves apical Ca 2+ entry via voltagesensitive Ca 2§ channels and subsequent basolateral extrusion by Ca2+-ATPases and Na+/Ca 2+ exchangers driven by Na+-K+-ATPase. Multiple Ca 2+ channels are expressed here. Calbindin D28K binds and shuttles Ca 2§ from the apical membrane to the basolateral sites of active Ca 2+ extrusion, thereby buffering the cytoplasm from high concentrations of transported Ca 2+. Calbindin D28K is induced by 1,25 (OH)2D3 and may directly activate apical Ca 2+ channels, which otherwise are inhibited by intracellular Ca 2+ ions. PTHR activation leads to insertion of additional apical Ca 2+ channels, hyperpolarization of the cell (via enhancing basolateral C1- exit?) and, thus, activation of Ca 2+ channels, increased calbindin D28K expression, and stimulation of the basolateral Ca2-ATPase. The routes and mechanisms of Mg 2+ reabsorption in DCT are unknown. Reprinted with permission from "The Parathyroids: Basic and Clinical Concepts, 2nd edition," (J. P. Bilezikian, R. Marcus, and M. A. Levine, Eds.) pp. 245-260. Academic Press: San Diego (2001).
indicate that cAMP mimics the effect of PTH in isolated renal tubule segments perfused in vitro [296,308]. However, it is also reported that the effect of PTH is blocked by inhibitors of PKC but not PKA [312]. Phosphorylation of MEK by a PKC-dependent pathway has been implicated [313]. Although the rate-limiting calcium entry step is subject to regulation by PTH [285,296,297] and ECaC1 has a putative PKC phosphorylation site, it remains to be determined whether the calcium transporter is directly phosphorylated. An assembly protein such as NHERF [164,314] could be involved in assembly of a multiprotein signaling complex since the calcium channel has a PDZ interaction domain similar to that on the sodium-proton exchanger, for which regulation of a multiprotein complex is important [164]. Additional transporters could
FIGURE 18 Phosphate (Pi) reabsorption in the proximal tubule. Phosphate must be actively transported across the apical membrane of the PCT cell because of the strongly interior-negative potential and the fact that cytosolic Pi concentration (1 mM) is approximately 100fold higher than equilibrium. This transport is accomplished by an electrogenic type IIa NaPi cotransporter that is energized by the steep transmembrane Na § gradient established by the basolateral Na+-K § -ATPase. Activity of this cotransporter is reduced by PTHR activation. Mechanisms of basolateral Pi exit are not well understood, but an anion exchanger could allow Pi to leave the cell passively. Reprinted with permission from "The Parathyroids: Basic and Clinical Concepts, 2nd edition," (J. P. Bilezikian, R. Marcus, and M. A. Levine, Eds.) pp. 245L 260. Academic Press: San Diego (2001).
5. Parathyroid Hormone and Calcium Homeostasis
[169,318]. Three sodium phosphate cotransporters have been cloned. Two, the type I and type IIa NaPi cotransporters, are expressed on apical membranes of the proximal tubule, but the type IIa transporter is the main target of regulation by PTH. The level of the type IIa transporter on the apical membrane is reduced by treatment with PTH [319,320], and disruption of the type IIa cotransporter gene in the mouse largely abolishes hormone-sensitive phosphate reabsorption [321]. The type IIa cotransporter is predicted to have eight transmem brane domains and is responsible for approximately 70% of sodium-coupled phosphate reabsorption in the proximal tubule [322]. Its level on the apical membrane is also regulated by the intake of dietary phosphate, so transporter density and phosphate reclamation are maximized by a low dietary phosphate content [169,318]. The type I NaPi cotransporter is a less specific anion transport protein and the type III cotransporter is expressed in many cell types and may serve cellular housekeeping functions [169]. PTH controls the level of type IIa NaPi cotransporters on the apical membrane by regulating membrane trafficking. PTH increases the retrieval of cotransporters from the apical membrane by targeting them to clathrin-coated pits in the intermicrovillar clefts. Once there, the transporter is incorporated into vesicles together with soluble proteins from tubule fluid and internalized (Fig. 19). Vesicles containing internalized NaPi cotransporters are degraded in lysosomes, and there is no evidence that cotransporters can be recycled onto the cell surface [323,324].
159
The signaling pathway most important for inhibition of phosphate reabsorption by PTH is the cAMP pathway. There is compelling clinical evidence for this conclusion in pseudohypoparathyroidism, in which a deficiency of Gs0~ is responsible for renal unresponsiveness to the phosphaturic effect of PTH (see Chapter 20). cAMP mimics the effect of PTH [325]. In cultured renal cells, inhibition of phosphate transport is correlated with activation of PKA [326], and blockade of the cAMP pathway prevents inhibition of phosphate uptake by PTH but blockade of the PKC pathway does not [327,328]. However, it is also clear that PTH can inhibit sodium-coupled phosphate transport by using the PKC signaling pathway. Analogs of PTH with minimal adenylyl cyclase-stimulating activity are effective [329,330], and some workers report that blockade of the PKC pathway can inhibit PTH effects [331]. It thus appears that cAMP is necessary for inhibition of phosphate reabsorption but may not be sufficient, and the PKC pathway can also be used. From studies of perfused tubules it appears that an apical receptor for PTH, which faces the tubule lumen, can inhibit phosphate transport via PKC, whereas the receptor facing the bloodstream on the basolateral membrane of the tubule cell uses PKA [332]. Whether PTH filtered at the glomerulus is biologically active in the tubule remains to be determined. The molecular site targeted by PTH has not been identified. It may well not be the transporter; the type IIa cotransporter has PKC phosphorylation sites, but mutation of these residues does not abolish inhibition of transport by PTH [333,334]. A domain containing two
FIGURE 19 Regulation ofNaPi cotransport by PTH. Activation of the PTH1R on the basolateral membrane of PCT cells stimulates PKA and PKC. Activation of PKA or PKC induces a rapid decrease in activity of NaPi-2 transporters expressed on the apical surface. This may involve phosphorylation of one or more intermediary proteins (X) because consensus PKC phosphorylation sites within the NaPi-2 protein can be eliminated without affecting the regulatory effect of PKC. At least part of the PTH effect involves retrieval of surface NaPi-2 cotransporters by a microtubule-dependent process of endocytosis, lysosomal fusion, and degradation. Reprinted with permission from "The Parathyroids: Basic and Clinical Concepts, 2nd edition," (J. P. Bilezikian, R. Marcus, and M. A. Levine, Eds.) pp. 245-260. Academic Press: San Diego (2001).
160
Gordon I. Strewler
intracellular loops of the transporter is required for the effect of PTH [334]. The type IIa cotransporter interacts with a Na+/H + exchanger regulatory factor family member (NHERF-1) [314,335] and other proteins containing a PDZ domain [336], and this interaction could be important for sorting of receptors to the apical membrane, for retrieval of receptors by PTH, or both. Reabsorption of Bicarbonate
Hyperparathyroid states may be accompanied by a mild renal tubular acidosis. This acidosis is often subtle, but mild hyperchloremia is characteristic of primary hyperparathyroidism and was formerly used as a clinical sign in the differential diagnosis of hypercalcemia. The locus of this effect is the proximal renal tubule, where PTH markedly inhibits sodium bicarbonate reabsorption. Most of the rejected sodium and bicarbonate is reabsorbed in the distal nephron, so the effect on the final urine is small, but increased distal bicarbonate delivery increases distal reabsorption of calcium. PTH inhibits the activity of the sodium-proton exchanger NHE3 [283,337,338]. The receptor is phosphorylated by PKA [339,340], and this leads to an alteration in an allosteric modifier site on the cytoplasmic surface [341] and an acute reduction in sodium-proton exchange, followed 20-30 min later by a loss of receptors from the apical membrane [339]. It appears that the association of PKA with NHE3 requires the formation of a multiprotein signaling complex organized by the adapter protein NHERF-1, which brings together NHE3 and PKA bound to the scaffolding protein ezrin [314,335]. Because NHERF and related PDZ-domain scaffolding proteins are also involved in transporter and receptor trafficking [314,342], it is conceivable that a similar multiprotein complex is also an intermediate in the internalization of NHE3. Although cAMP is clearly the major second messenger for PTH with regard to bicarbonate reabsorption, dual signaling through PKC does occur [138,343]. PTH also inhibits the activity of Na+-K+-ATPase activity in the basolateral border of proximal tubule cells [344]. This inhibition, unlike many of the other transport effects of PTH, appears to be calcium and PKC mediated and to involve the generation of eicosanoids by activation of phospholipase A2 [345,346]. Vitamin D Metabolism
The effects of PTH on renal vitamin D metabolism are closely coordinated with the effects of mineral ions and vitamin D to produce exquisite regulation of the levels of 1,25(OH)2D (see Chapter 7). Two important enzymes of vitamin D metabolism are found in the kidney, both in proximal tubule. The renal 25-hydroxyvitamin D-I~-
hydroxylase (1 ~-hydroxylase) is the final step in the synthesis of the active vitamin D metabolite, and its activity is exquisitely regulated. PTH increases l~-hydroxylase activity by a direct effect on transcription of the gene [22,347] that is primarily mediated by cAMP, although some reports indicate that PKC can also be a second messenger for PTH [170]. Renal 25-hydroxyvitamin D-24-hydroxylase (24hydroxylase) is an enzyme that has the opposite effect of that of l~-hydroxylase. Both 25-hydroxyvitamin D and 1,25(OH)ED are substrates for 24-hydroxylase, and 24hydroxylation is an important degradative pathway for 1,25(OH)ED: Ablation of 24-hydroxylase leads to massive accumulation of 1,25(OH)ED with hypercalcemia and osteomalacia [348]. PTH inhibits the activity of 24-hydroxylase, thus inhibiting the metabolism of 1,25(OH)ED and its production by l~-hydroxylase, cAMP is the main second messenger for this inhibition [349,350], which results from reduced stability ofmRNA for the enzyme [351].
References 1. Abrams, S. A., Wen, J., and Stuff, J. E. (1997). Absorption of calcium, zinc, and iron from breast milk by 5- to 7-month infants. Pediatr. Res. 41, 384-390. 2. Berridge, M. J., Lipp, P., and Bootman, M. D. (2000). The versatility and universality of calcium signalling. Nat. Rev. Mol. Cell. Biol. 1, ll-21. 3. Toffaletti, J. (1995). Physiology and regulation. Ionized calcium, magnesium and lactate measurements in critical care settings. Am. J. Clin. Pathol. 104, $88-$94. 4. Sheikh, M. S., Schille, L. R., and Fordtran, J. S. (1990). In vivo intestinal absorption of calcium in humans. Miner. Electrolyte Metab. 16, 130-146. 5. Heaney, R. P. (2001). Nutrition and risk of osteoporosis. In Osteoporosis (R. Marcus, D. Feldman, and J. Kelsey, Eds.), pp. 670-700. Academic Press, San Diego. 6. Food and Nutrition Board of the National Academy of Sciences (1997). Dietary Reference Uptakes for Calcium, Magnesium, Vitamin D and Fluoride. National Academy Press, Washington, DC. 7. Friedman, P. A., and Gesek, F. A. (1993). Calcium transport in renal epithelial cells. Am. J. Physiol. 264, 181-198. 8. Weaver, C. M., Martin, B. R., Plawecki, K. L., Peacock, M., Wood, O. B., Smith, D. L., and Wastney, M. E. (1995). Differences in calcium metabolism between adolescent and adult females. Am. J. Clin. Nutr. 61, 577-581. 9. Abrams, S. A., O'Brien, K. O., and Stuff, J. E. (1996). Changes in calcium kinetics associated with menarche. J. Clin. Endocrinol. Metab. 81, 2017-2020. 10. Abrams, S. A., Copeland, K. C., Gunn, S. K., Gundberg, C. M., Klein, K. O., and Ellis, K. J. (2000). Calcium absorption, bone mass accumulation, and kinetics increase during early pubertal development in girls. J. Clin. Endocrinol. Metab. 85, 1805-1809. 11. McKay, H. A., Bailey, D. A., Mirwald, R. L., Davison, K. S., and Faulkner, R. A. (1998). Peak bone mineral accrual and age at menarche in adolescent girls: A 6-year longitudinal study. J. Pediatr. 133, 682-687. 12. Martin, A. D., Bailey, D. A., McKay, H. A., and Whiting, S. (1997). Bone mineral and calcium accretion during puberty. Am. J. Clin. Nutr. 66, 611-615.
5. Parathyroid Hormone and Calcium Homeostasis 13. Matkovic, V., and Heaney, R. P. (1992). Calcium balance during human growth: Evidence for threshold behavior. Am. J. Clin. Nutr. 55, 992-996. 14. Sebastian, A., Harris, S. T., Ottaway, J. H., Todd, K. M., and Morris, R. C., Jr. (1994). Improved mineral balance and skeletal metabolism in postmenopausal women treated with potassium bicarbonate. N. Engl. J. Med. 330, 1776-1781. 15. Frassetto, L., Morris, R. C., Jr., and Sebastian, A. (1997). Potassium bicarbonate reduces urinary nitrogen excretion in postmenopausal women. J. Clin. Endocrinol. Metab. 82, 254-259. 16. Akerstrom, G., Malmaeus, J., and Bergstrom, R. (1984). Surgical anatomy of human parathyroid glands. Surgery 95, 14-21. 17. Manley, N. R., and Capecchi, M. R. (1998). Hox group 3 paralogs regulate the development and migration of the thymus, thyroid, and parathyroid glands. Dev. Biol. 195, 1-15. 18. Van Esch, H., Groenen, P., Nesbit, M. A., Schuffenhauer, S., Lichtner, P., Vanderlinden, G., Harding, B., Beetz, R., Bilous, R. W., Holdaway, I., Shaw, N. J., Fryns, J. P., Van, de, V, Thakker, R. V., and Devriendt, K. (2000). GATA3 haplo-insufficiency causes human HDR syndrome. Nature 406, 419-422. 19. Jerome, L. A., and Papaioannou, V. E. (2001). DiGeorge syndrome phenotype in mice mutant for the T-box gene, Tbxl. Nature Genet. 27, 286-291. 20. Gunther, T., Chen, Z. F., Kim, J., Priemel, M., Rueger, J. M., Amling, M., Moseley, J. M., Martin, T. J., Anderson, D. J., and Karsenty, G. (2000). Genetic ablation of parathyroid glands reveals another source of parathyroid hormone. Nature 406, 199-203. 21. Ding, C., Buckingham, B., and Levine, M. A. (2001). Familial isolated hypoparathyroidism caused by a mutation in the gene for the transcription factor GCMB. J. Clin. Invest. 108, 1215-1220. 22. Brown, E. M., Conigrave, A., and Chattopadhyay, N. (2001). Receptors and signaling for calcium ions. In The Parathyroids: Basic and Clinical Concepts (J. P. Bilezikian, R. Marcus, and M. A. Levine, Eds.), 2nd ed., pp. 127-142. Academic Press, San Diego. 23. Kolakowski, L. F., Jr. (1994). GCRDb: A G-protein-coupled receptor database. Receptors Channels 2, 1-7. 24. Hebert, S. C., Brown, E. M., and Harris, H. W. (1997). Role of the Ca(2+)-sensing receptor in divalent mineral ion homeostasis. J. Exp. Biol. 200 (Pt. 2), 295-302. 25. Brown, E. M., and MacLeod, R. J. (2001). Extracellular calcium sensing and extracellular calcium signaling. Physiol. Rev. 81,239-297. 26. Hammerland, L. G., Krapcho, K. J., Garrett, J. E., Alasti, N., Hung, B. C., Simin, R. T., Levinthal, C., Nemeth, E. F., and Fuller, F. H. (1999). Domains determining ligand specificity for Ca 2+ receptors. Mol. Pharmacol. 55, 642-648. 27. Ward, D. T., Brown, E. M., and Harris, H. W. (1998). Disulfide bonds in the extracellular calcium-polyvalent cation-sensing receptor correlate with dimer formation and its response to divalent cations in vitro. J. Biol. Chem. 273, 14476-14483. 28. Ray, K., Hauschild, B. C., Steinbach, P. J., Goldsmith, P. K., Hauache, O., and Spiegel, A. M. (1999). Identification of the cysteine residues in the amino-terminal extracellular domain of the human Ca(2+) receptor critical for dimerization. Implications for function of monomeric Ca(2+) receptor. J. Biol. Chem. 274, 27642-27650. 29. Bai, M., Trivedi, S., Kifor, O., Quinn, S. J., and Brown, E. M. (1999). Intermolecular interactions between dimeric calciumsensing receptor monomers are important for its normal function. Proc. Natl. Acad. Sci. USA 96, 2834-2839. 30. Brown, E. M. (2000). Familial hypocalciuric hypercalcemia and other disorders with resistance to extracellular calcium. Endocrinol. Metab. Clin. North Am. 29, 503-522. 31. Pearce, S. H., Williamson, C., Kifor, O., Bai, M., Coulthard, M. G., Davies, M., Lewis-Barned, N., McCredie, D., Powell, H., Kendall-
161
Taylor, P., Brown, E. M., and Thakker, R. V. (1996). A familial syndrome of hypocalcemia with hypercalciuria due to mutations in the calcium-sensing receptor. N. Engl. J. Med. 335, 1115-1122. 32. Nemeth, E. F., and Fox, J. (1999). Calcimimetic compounds: A direct approach to controlling plasma levels of parathyroid hormone in hyperparathyroidism. Trends Endocrinol. Metab. 10, 66-71. 33. Strewler, G. J. (2000). Medical approaches to primary hyperparathyroidism. Endocrinol. Metab. Clin. North Am. 29, 523-539. 34. Nemeth, E. F., Steffey, M. E., Hammerland, L. G., Hung, B. C., Van Wagenen, B. C., DelMar, E. G., and Balandrin, M. F. (1998). Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc. Natl. Acad. Sci. USA 95, 4040-4045. 35. Olgaard, K., and Lewin, E. (2001). Prevention of uremic bone disease using calcimimetic compounds. Annu. Rev. Med. 52, 203-220. 36. Wada, M., Furuya, Y., Sakiyama, J., Kobayashi, N., Miyata, S., Ishii, H., and Nagano, N. (1997). The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor. J. Clin. Invest. 100, 2977-2983. 37. Wada, M., Nagano, N., Furuya, Y., Chin, J., Nemeth, E. F., and Fox, J. (2000). Calcimimetic NPS R-568 prevents parathyroid hyperplasia in rats with severe secondary hyperparathyroidism. Kidney Int. 57, 50-58. 38. Peacock, M., Shoback, D. M., Greth, W. E., Binder, T. A., Graves, T., Brenner, R. M., Turner, S. A., and Marcus, R. (2002). The calcimimetic AMG 073 reduces serum calcium (Ca) in patients with primary hyperparathyroidism (PHPT). J. Bone Miner. Res. 16 (Suppl 1). 39. Shoback, D. M., Thatcher, J., Leombruno, R., and Brown, E. M. (1984). The relationship between PTH secretion and cytosolic calcium concentration in dispersed bovine parathyroid cells. Proc. Natl. Acad. Sci. USA 81, 3113-3117. 40. Shoback, D. M., Membrefio, L. A., and McGhee, J. G. (1988). High calcium and other divalent cations increase inositol triphosphate in bovine parathyroid cells. Endocrinology 123, 382-389. 41. Gardner, D. G. (1997). Mechanisms of hormone action. In Basic and Clinical Endocrinology (F. S. Greenspan and G. J. Strewler, Eds.), 5th ed., pp. 58-75. Appleton & Lange, Stamford, CT. 42. Kahn, C. R., Smith, R. J., and Chin, W. W. (2002). Mechanism of action of hormones that act at the cell surface. In Williams Textbook of Endocrinology (J. D. Wilson, D. W. Foster, H. M. Kronenberg, and P. R. Larsen, Eds.), 9th ed., pp. 95-143. Saunders, Philadelphia. 42a.Membreno, L., Chen, T. H., Woodley, S., Gagucas, R., and Shoback, D. (1989). The effects of protein kinase-C agonists on parathyroid hormone release and intracellular free Ca 2+ in bovine parathyroid cells. Endocrinology 124, 789-797. 42b.Kifor, O., Diaz, R., Butters, R., and Brown, E. M. (1997). The CaZ+-sensing receptor (CAR) activates phospholipases C, A2, and D in bovine parathyroid and CaR-transfected, human embryonic kidney (HEK293) cells. J. Bone Miner. Res. 12, 715-725. 42c.Kifor, O., MacLeod, R. J., Diaz, R., Bai, M., Yamaguchi, T. Yao, T., Kifor, I., and Brown, E. M. (2001). Regulation of MAP kinase by calcium-sensing receptor in bovine parathyroid and CaR-transfected HEK193 cells. Am. J. Physiol. RenalPhysiol. 280, F291-F302. 42d.Bourdeau, A., Souberbielle, J. C., Bonnet, P., Herviaux, P., Sachs, C., and Lieberherr, M. (1992). Phospholipase-A2 action and arachidonic acid metabolism in calcium-mediated parathyroid hormone secretion. Endocrinology 130, 1339-1344. 42e.Marx, S. J., Attic, M. F., Levine, M. A., Spiegel, A. M., Downs, R. W., Jr., and Lasker, R. D. (1981). The hypocalciuric or benign variant of familial hypercalcemia: Clinical and biochemical features in fifteen kindreds. Medicine (Baltimore) 60, 397.
162
Gordon I. Strewler
42f. Quitterer, U., Hoffmann, M., Freichel, M., and Lohse, M. J. (2001). Paradoxical block of parathormone secretion is mediated by increased activity of G alpha subunits. J. Biol. Chem. 276, 6763-6769. 43. Strewler, G. J. (2000). The physiology of parathyroid hormonerelated protein. N. Engl. J. Med. 342, 177-185. 44. Wysolmerski, J. J., and Stewart, A. F. (1998). The physiology of parathyroid hormone-related protein--An emerging role as a developmental factor. Annu. Rev. Physiol. 60, 431-460. 45. Segre, G. V., and Lee, K. (2001). Endochondral bone formation: Regulation by parathyroid hormone-related peptide, indian hedgehog and parathyroid hormone. In The Parathyroids: Basic and Clinical Concepts (J. P. Bilezikian, R. Marcus, and M. A. Levine, Eds.), 2nd ed., pp. 245-260. Academic Press, San Diego. 46. Strewler, G. J. (2001). Physiologic actions of PTH and PTHrP I: Skeletal actions. In The Parathyroids: Basic and Clinical Concepts (J. P. Bilezikian, R. Marcus, and M. A. Levine, Eds.), 2nd ed., pp. 213-226. Academic Press, San Diego. 47. Clemens, T. L., and Broadus, A. E. (2001). Physiological actions of PTH and PTHrP IV: Vascular, cardiovascular and neurologic actions. In The Parathyroids: Basic and Clinical Concepts (J. P. Bilezikian, R. Marcus, and M. A. Levine, Eds.), 2nd ed., pp. 261-274. Academic Press, San Diego. 48. Wysolmerski, J. J., Stewart, A. F., and Martin, T. J. (2001). Physiological actions of PTH and PTHrP V: Epidermal, mammary, reproductive and pancreatic tissues. In The Parathyroids: Basic and Clinical Concepts (J. P. Bilezikian, R. Marcus, and M. A. Levine, Eds.), 2nd ed., pp. 275-291. Academic Press, San Diego. 49. Hoare, S. R., and Usdin, T. B. (2000). Tuberoinfundibular peptide (7-39) [TIP(7-39)], a novel, selective, high-affinity antagonist for the parathyroid hormone-1 receptor with no detectable agonist activity. J. Pharmacol. Exp. Ther. 295, 761-770. 50. Ward, H. L., Small, C. J., Murphy, K. G., Kennedy, A. R., Ghatei, M. A., and Bloom, S. R. (2001). The actions of tuberoinfundibular peptide on the hypothalamo-pituitary axes. Endocrinology 142, 3451-3456. 51. Usdin, T. B., Gruber, C., and Bonner, T. I. (1995). Identification and functional expression of a receptor selectively recognizing parathyroid hormone, the PTH2 receptor. J. Biol. Chem. 270, 15455-15458. 52. Gardella, T. J., Luck, M. D., Jensen, G. S., Usdin, T. B., and Jfippner, H. (1996). Converting parathyroid hormone-related peptide (PTHrP) into a potent PTH-2 receptor agonist. J. Biol. Chem. 271, 19888-19893. 53. Rubin, D. A., Hellman, P., Zon, L. I., Lobb, C. J., Bergwitz, C., and Jtippner, H. (1999). A G protein-coupled receptor from zebrafish is activated by human parathyroid hormone and not by human or teleost parathyroid hormone-related peptide. Implications for the evolutionary conservation of calcium-regulating peptide hormones. J. Biol. Chem. 274, 23035-23042. 54. Rubin, D. A., and Jtippner, H. (1999). Zebrafish express the common parathyroid hormone/parathyroid hormone-related peptide receptor (PTH1R) and a novel receptor (PTH3R) that is preferentially activated by mammalian and fugufish parathyroid hormone-related peptide. J. Biol. Chem. 274, 28185-28190. 55. Vasicek, T. J., McDevittt, B. E., Freeman, M. W., Fennick, B. J., Hendy, G. N., Potts, J. T., Jr., Rich, A., and Kronenberg, H. M. (1983). Nucleotide sequence of the human parathyroid hormone gene. Proc. Natl. Acad. Sci. USA 80, 2127-2131. 56. Kronenberg, H. M., Bringhurst, F. R., Segre, G. V., and Potts, T. J., Jr. (2001). Parathyroid hormone biosynthesis and metabolism. In The Parathyroids: Basic and Clinical Concepts (J. P. Bilezikian, R. Marcus, and M. A. Levine, Eds.), 2nd ed., pp. 17-30. Academic Press, San Diego.
57. Hendy, G. N., Bennett, H. P., Gibbs, B. F., Lazure, C., Day, R., and Seidah, N. G. (1995). Proparathyroid hormone is preferentially cleaved to parathyroid hormone by the prohormone convertase furin. A mass spectrometric study. J. Biol. Chem. 270, 9517-9525. 58. Canaff, L., Bennett, H. P., Hou, Y., Seidah, N. G., and Hendy, G. N. (1999). Proparathyroid hormone processing by the proprotein convertase-7: Comparison with furin and assessment of modulation of parathyroid convertase messenger ribonucleic acid levels by calcium and 1,25-dihydroxyvitamin D3. Endocrinology 140, 3633-3642. 59. Von Heijne, G. (1983). Patterns of amino acids near signalsequence cleavage sites. Eur. J. Biochem. 133, 17-21. 60. Freeman, M., Wiren, K., Rapoport, A., Lazar, M., Potts, J. T., Jr., and Kronenberg, H. M. (1987). Consequences of amino-terminal deletions of preproparathyroid hormone signal sequence. Mol. Endocrinol. 1, 628-638. 61. Arnold, A., Horst, S. A., Gardella, T. J., Baba, H., Levine, M. A., and Kronenberg, H. M. (1990). Mutation of the signal peptideencoding region of the preproparathyroid hormone gene in familial isolated hypoparathyroidism. J. Clin. Invest. 86, 1084-1087. 62. Wiren, K. M., Potts, J. T., Jr., and Kronenberg, H. M. (1988). Importance of the propeptide sequence of human preproparathyroid hormone for signal sequence function. J. BioL Chem. 263, 19771-19777. 63. Wiren, K. M., Ivashkiv, L., Ma, P., Freeman, M. W., Potts, J. T., Jr., and Kronenberg, H. M. (1989). Mutations in signal sequence cleavage domain of preproparathyroid hormone alter protein translocation, signal sequence cleavage, and membrane-binding properties. Mol. Endocrinol. 3, 240-250. 64. Lazure, C., Gauthier, D., Jean, F., Boudreault, A., Seidah, N. G., Bennett, H. P., and Hendy, G. N. (1998). In vitro cleavage of internally quenched fluorogenic human proparathyroid hormone and proparathyroid-related peptide substrates by furin. Generation of a potent inhibitor. J. Biol. Chem. 273, 8572-8580. 65. Kim, T., Tao-Cheng, J. H., Eiden, L. E., and Loh, Y. P. (2001). Chromogranin A, an "on/off" switch controlling dense-core secretory granule biogenesis. Cell 106, 499-509. 66. Naveh-Many, T., and Silver, J. (1990). Regulation of parathyroid hormone gene expression by hypocalcemia, hypercalcemia, and vitamin D in the rat. J. Clin. Invest. 86, 1313-1319. 67. Yamamoto, M., Igarashi, T., Muramatsu, M., Fukagawa, M., Motokura, T., and Ogata, E. (1989). Hypocalcemia increases and hypercalcemia decreases the steady-state level of parathyroid hormone messenger RNA in the rat. J. Clin. Invest. 83, 1053-1056. 68. Russell, J., and Sherwood, L. M. (1987). The effects of 1,25-dihydroxyvitamin D3 and high calcium on transcription of the pre-proparathyroid hormone gene are direct. Trans. Assoc. Am. Physicians 100, 256-262. 69. Okazaki, T., Ando, K., Igarashi, T., Ogata, E., and Fujita, T. (1992). Conserved mechanism of negative gene regulation by extracellular calcium. Parathyroid hormone gene versus atrial natriuretic polypeptide gene. J. Clin. Invest. 89, 1268-1273. 70. Moallem, E., Kilav, R., Silver, J., and Naveh-Many, T. (1998). RNA-protein binding and post-transcriptional regulation of parathyroid hormone gene expression by calcium and phosphate. J. Biol. Chem. 273, 5253-5259. 71. Sela-Brown, A., Silver, J., Brewer, G., and Naveh-Many, T. (2000). Identification of AUF1 as a parathyroid hormone mRNA Y-untranslated region-binding protein that determines parathyroid hormone mRNA stability. J. BioL Chem. 275, 7424-7429. 72. Kilav, R., Silver, J., and Naveh-Many, T. (2001). A conserved cisacting element in the parathyroid hormone Y-untranslated region is sufficient for regulation of RNA stability by calcium and phosphate. J. Biol. Chem. 276, 8727-8733.
5. Parathyroid Hormone and Calcium Homeostasis 73. Silver, J., Kilav, R., Sela-Brown, A., and Naveh-Many, T. (2000). Molecular mechanisms of secondary hyperparathyroidism. Pediatr. Nephrol. 14, 626-628. 74. Kilav, R., Silver, J., and Naveh-Many, T. (1995). Parathyroid hormone gene expression in hypophosphatemic rats. J. Clin. Invest. 96, 327-333. 75. Almaden, Y., Canalejo, A., Hernandez, A., Ballesteros, E., GarciaNavarro, S., Torres, A., and Rodriguez, M. (1996). Direct effect of phosphorus on PTH secretion from whole rat parathyroid glands in vitro. J. Bone Miner. Res. 11, 970-976. 76. Slatopolsky, E., Finch, J., Denda, M., Ritter, C., Zhong, M., Dusso, A., MacDonald, P. N., and Brown, A. J. (1996). Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro. J. Clin. Invest. 97, 2534-2540. 77. Almaden, Y., Canalejo, A., Ballesteros, E., Anon, G., and Rodriguez, M. (2000). Effect of high extracellular phosphate concentration on arachidonic acid production by parathyroid tissue in vitro. J. Am. Soc. Nephrol. 11, 1712-1718. 78. Miyamoto, K., Tatsumi, S., Morita, K., and Takeda, E. (1998). Does the parathyroid "see" phosphate? Nephrol. Dial. Transplant. 13, 2727-2729. 79. Silver, J., Russell, J., and Sherwood, L. M. (1985). Regulation by vitamin D metabolites of messenger ribonucleic acid for preproparathyroid hormone in isolated bovine parathyroid cells. Proc. Natl. Acad. Sci. USA 82, 4270-4273. 80. Cantley, L. K., Russell, J., Lettieri, D., and Sherwood, L. M. (1985). 1,25-Dihydroxyvitamin D3 suppresses parathyroid hormone secretion from bovine parathyroid cells in tissue culture. Endocrinology 117, 2114-2119. 81. Silver, J., Naveh-Many, T., Mayer, H., Schmeizer, H. J., and Popovtzer, M. M. (1986). Regulation by vitamin D3 metabolites of parathyroid hormone gene transcription in vivo in the rat. J. Clin. Invest. 78, 1296-1301. 82. Demay, M. B., Kiernan, M. S., DeLuca, H. F., and Kronenberg, H. M. (1992). Sequences in the human parathyroid hormone gene that bind the 1,25-dihydroxyvitamin D3 receptor and mediate transcriptional repression in response to 1,25-dihydroxyvitamin D3. Proc. Natl. Acad. Sci. USA 89, 8097-8101. 83. Okazaki, T., Igarashi, T., and Kronenberg, H. M. (1988). 5'-flanking region of the parathyroid hormone gene mediates negative regulation by 1,25-(OH)2 vitamin D3. J. BioL Chem. 263, 2203-2208. 84. Naveh-Many,T.,Friedlaender,M.M.,Mayer, H.,andSilver,J.(1989). Calcium regulates parathyroid hormone messenger ribonucleic acid (mRNA), but not calcitonin mRNA in vivo in the rat. Dominant role of 1,25-dihydroxyvitamin D. Endocrinology 125, 275-280. 85. Sela-Brown, A., Russell, J., Koszewski, N. J., Michalak, M., Naveh-Many, T., and Silver, J. (1998). Calreticulin inhibits vitamin D's action on the PTH gene in vitro and may prevent vitamin D's effect in vivo in hypocalcemic rats. Mol. Endocrinol. 12, 1193-1200. 86. Li, Y. C., Amling, M., Pirro, A. E., Priemel, M., Meuse, J., Baron, R., Delling, G., and Demay, M. B. (1998). Normalization of mineral ion homeostasis by dietary means prevents hyperparathyroidism, rickets, and osteomalacia, but not alopecia in vitamin D receptor-ablated mice. Endocrinology 139, 4391-4396. 87. Portale, A. A., Booth, B. E., Halloran, B. P., and Morris, R. C., Jr. (1984). Effect of dietary phosphorus on circulating concentrations of 1,25-dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency. J. Clin. Invest. 73, 1580-1589. 88. Portale, A. A., Halloran, B. P., and Morris, R. C., Jr. (1989). Physiologic regulation of the serum concentration of 1,25dihydroxyvitamin D by phosphorus in normal men. J. Clin. Invest. 83, 1494-1499.
163
89. Parfitt, A. M. (2001). Parathyroid growth: Normal and abnormal. In The Parathyroids: Basic and Clinical Concepts (J. P. Bilezikian, R. Marcus, and M. A. Levine, Eds.), 2nd ed., pp. 293-329. Academic Press, San Diego. 90. Thorgeirsson, U., Costa, J., and Marx, S. J. (1981). The parathyroid glands in familial hypocalciuric hypercalcemia. Hum. Pathol. 12, 229-237. 91. Parfitt, A. M., Wang, Q., and Palnitkar, S. (1998). Rates of cell proliferation in adenomatous, suppressed, and normal parathyroid tissue: Implications for pathogenesis. J. Clin. Endocrinol. Metab. 83, 863-869. 92. Brown, E. M., LeBoff, M. S., Oetting, M., Posillico, J. T., and Chen, C. (1987). Secretory control in normal and abnormal parathyroid tissue. In Recent Progress in Hormone Research (J. H. Clark, Eds.), p. 337. Harcourt Brace Javanovich, New York. 93. Imanishi, Y., Hosokawa, Y., Yoshimoto, K., Schipani, E., Mallya, S., Papanikolaou, A., Kifor, O., Tokura, T., Sablosky, M., Ledgard, F., Gronowicz, G., Wang, T. C., Schmidt, E. V., Hall, C., Brown, E. M., Bronson, R., and Arnold, A. (2001). Primary hyperparathyroidisrn caused by parathyroid-targeted overexpression of cyclin D1 in transgenic mice. J. Clin. Invest. 107, 1093-1102. 94. Martin, K. J., and Gonzalez, E. A. (2001). Vitamin D analogues for the management of secondary hyperparathyroidism. Am. J. Kidney Dis. 38, $34-$40. 95. Dusso, A. S., Pavlopoulos, T., Naumovich, L., Lu, Y., Finch, J., Brown, A. J., Morrissey, J., and Slatopolsky, E. (2001). p21 (WAF 1) and transforming growth factor-alpha mediate dietary phosphate regulation of parathyroid cell growth. Kidney Int. 59, 855-865. 96. Cozzolino, M., Lu, Y., Finch, J., Slatopolsky, E., and Dusso, A. S. (2001). p21WAF1 and TGF-alpha mediate parathyroid growth arrest by vitamin D and high calcium. Kidney Int. 60, 2109-2117. 97. Martin, K. J., Hruska, K. A., Freitag, J. J., Klahr, S., and Slatopolsky, E. (1979). The peripheral metabolism of parathyroid hormone. N. Engl. J. Med. 301, 1092-1098. 98. Bringhurst, F. R., Segre, G. V., Lampman, G. W., and Potts, J. T., Jr. (1982). Metabolism of parathyroid hormone by Kupffer cells: Analysis by reverse-phase high-performance liquid chromatography. Biochemistry 21, 4252-4258. 99. Segre, G. V., D'Amour, P., Hultman, A., and Potts, J. T., Jr. (1981). Effects of hepatectomy, nephrectomy, and nephrectomy/ uremia on the metabolism of parathyroid hormone in the rat. J. Clin. Invest. 67, 438-448. 100. Bringhurst, F. R., Stern, A. M., Yotts, M., Mizrahi, N., Segre, G. V., and Potts, J. T., Jr. (1988). Peripheral metabolism of PTH: Fate of biologically active amino terminus in vivo. Am. J. Physiol. 255, E886-E893. 101. Hilpert, J., Nykjaer, A., Jacobsen, C., Wallukat, G., Nielsen, R., Moestrup, S. K., Hailer, H., Luft, F. C., Christensen, E. I., and Willnow, T. E. (1999). Megalin antagonizes activation of the parathyroid hormone receptor. J. Biol. Chem. 274, 5620-5625. 102. Eigelberger, M. S., and Clark, O. H. (2000). Surgical approaches to primary hyperparathyroidism. Endocrinol. Metab. Clin. North Am. 29, 479-502. 103. Flueck, J. A., Dibella, F. B., Edis, A. J., Kehrwald, J. M., and Arnaud, C. D. (1977). Immunoheterogeneity of parathyroid hormone in venous effluent serum from hyperfunctioning parathyroid glands. J. Clin. Invest. 60, 1367-1375. 104. MacGregor, R. R., Jilka, R. L., and Hamilton, J. W. (1986). Formation and secretion of fragments of parathormone. Identification of cleavage sites. J. Biol. Chem. 261, 1929-1934. 105. Martin, K. J., and Gonzalez, E. A. (2001). The evolution of assays for parathyroid hormone. Curr. Opin. Nephrol. Hypertension 10, 569-574.
164
Gordon I. Strewler
106. Brossard, J. H., Cloutier, M., Roy, L., Lepage, R., GasconBarre, M., and D'Amour, P. (1996). Accumulation of a non(I-84) molecular form of parathyroid hormone (PTH) detected by intact PTH assay in renal failure: Importance in the interpretation of PTH values. J. Clin. Endocrinol. Metab. 81, 3923-3929. 107. John, M. R., Goodman, W. G., Gao, P., Cantor, T. L., Salusky, I. B., and Jiippner, H. (1999). A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: Implications for PTH measurements in renal failure. J. Clin. Endocrinol. Metab. 84, 4287-4290. 108. Inomata, N., Akiyama, M., Kubota, N., and Jiippner, H. (1995). Characterization of a novel parathyroid hormone (PTH) receptor with specificity for the carboxyl-terminal region of PTH-(1-84). Endocrinology 136, 4732-4740. 109. Divieti, P., Inomata, N., Chapin, K., Singh, R., Jiippner, H., and Bringhurst, F. R. (2001). Receptors for the carboxyl-terminal region of PTH(1-84) are highly expressed in osteocytic cells. Endocrinology 142, 916-925. 110. Nguyen-Yamamoto, L., Rousseau, L., Brossard, J. H., Lepage, R., and D'Amour, P. (2001). Synthetic carboxyl-terminal fragments of parathyroid hormone (PTH) decrease ionized calcium concentration in rats by acting on a receptor different from the PTH/PTHrelated peptide receptor. Endocrinology 142, 1386-1392. 111. Divieti, P., John, M. R., Jiippner, H., and Bringhurst, F. R. (2002). Human PTH-(7-84) inhibits bone resorption in vitro via actions independent of the type 1 PTH/PTHrP receptor. Endocrinology 143, 171-176. 112. Gao, P., Scheibel, S., D'Amour, P., John, M. R., Rao, S. D., Schmidt-Gayk, H., and Cantor, T. L. (2001). Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1-84: Implications for improvement of accurate assessment of parathyroid function. J. Bone Miner. Res. 16, 605-614. 113. Brossard, J. H., Lepage, R., Cardinal, H., Roy, L., Rousseau, L., Dorais, C., and D'Amour, P. (2000). Influence of glomerular filtration rate on non-(I-84) parathyroid hormone (PTH) detected by intact PTH assays. Clin. Chem. 46, 697-703. 114. Deftos, L. J. (2001). PTH and PTHrP immunoassays. In The Parathyroids: Basic and Clinical Concepts (J. P. Bilezikian, R. Marcus, and M. A. Levine, Eds.), 2nd ed., pp. 143-165. Academic Press, San Diego. 115. Berson, S. A., and Yalowe, R. S. (1968). Immunochemical heterogeneity of parathyroid hormone in plasma. J. Clin. Endocrinol. Metab. 28, 1037-1047. 116. Arnaud, C. D., Tsao, H. S., and Litttledike, T. (1971). Radioimmunoassay of human parathyroid hormone in serum. J. Clin. Invest. 50, 21-34. 117. Benson, R. C., Riggs, B. L., Pickard, B. M., and Arnaud, C. D. (1974). Radioimmunoassay of parathyroid hormone in hypercalcemic patients with malignant tumors. Am. J. Med. 56, 821-826. 118. Ashby, J. P., Newman, D. J., and Gow, S. M. (1997). Clinical application of intact parathyroid hormone assays. Ann. Clin. Biochem. 34 (Pt. 6), 588-598. 119. Frolich, M., Walma, S. T., Paulson, C., and Papapoulos, S. E. (1990). Immunoradiometric assay for intact human parathyroid hormone: Characteristics, clinical application and comparison with a radioimmunoassay. Ann. Clin. Biochem. 27 (Pt. 1), 69-72. 120. Frolik, C. A., Black, E. C., Chandrasekhar, S., and Adrian, M. D. (1998). Development of a scintillation proximity assay for highthroughput measurement of intact parathyroid hormone. Anal Biochem. 265, 21 6-224. 121. Michelangeli, V. P., Heyma, P., Colman, P. G., and Ebeling, P. R. (1997). Evaluation of a new, rapid and automated immunochem-
122. 123. 124.
125.
126. 127. 128. 129.
130.
131.
132. 133. 134.
135.
136.
137.
iluminometric assay for the measurement of serum intact parathyroid hormone. Ann. Clin. Biochem. 34 (Pt. 1), 97-103. Wood, P. J. (1992). The measurement of parathyroid hormone. Ann. Clin. Biochem. 29 (Pt. 1), 11-21. Howe, J. R. (2000). Minimally invasive parathyroid surgery. Surg. Clin. North Am. 80, 1399-1426. Budayr, A. A., Nissenson, R. A., Klein, R. F., Pun, K. K., Clark, O. H., Diep, D., Arnaud, C. D., and Strewler, G. J. (1989). Increased serum levels of a parathyroid hormone-like protein in malignancy-associated hypercalcemia. Ann. Intern. Med. 111, 807-812. Pollak, M. R., Brown, E. M., Estep, H. L., McLaine, P. N., Kifor, O., Park, J., Hebert, S. C., Seidman, C. E., and Seidman, J. G. (1994). Autosomal dominant hypocalcaemia caused by a Ca(2+)-sensing receptor gene mutation. Nature Genet. 8, 303-307. Martin, K. J., and Gonzalez, E. A. (2001). Strategies to minimize bone disease in renal failure. Am. J. Kidney Dis. 38, 1430-1436. Salusky, I. B., and Goodman, W. G. (2001). Adynamic renal osteodystrophy: Is there a problem? J. Am. Soc. Nephrol. 12, 1978-1985. Gardella, T. J., and Jiippner, H. (2001). Molecular properties of the PTH/PTHrP receptor. Trends Endocrinol. Metab. 12, 210-217. Nissenson, R. A. (2001). Receptors for parathyroid hormone and parathyroid hormone-related protein: Signaling and regulation. In The Parathyroids: Basic and Clinical Concepts (J. P. Bilezikian, R. Marcus, and M. A. Levine, Eds.), 2nd ed., pp. 93-103. Academic Press, San Diego. Chorev, M., Alexander, J. M., and Rosenblatt, M. (2001). Interactions of parathyroid hormone and parathyroid hormonerelated protein with their receptors. In The Parathyroids: Basic and Clinical Concepts (J. P. Bilezikian, R. Marcus, and M. A. Levine, Eds.), 2nd ed., pp. 53-91. Academic Press, San Diego. Laburthe, M., Couvineau, A., Gaudin, P., Maoret, J. J., RouyerFessard, C., and Nicole, P. (1996). Receptors for VIP, PACAP, secretin, GRF, glucagon, GLP-1, and other members of their new family of G protein-linked receptors: Structure-function relationship with special reference to the human VIP-1 receptor. Ann. N. Y. Acad. Sci. 805, 94-109. Bockaert, J., and Pin, J. P. (1999). Molecular tinkering of G protein-coupled receptors: An evolutionary success. EMBO J. 18, 1723-1729. Strader, C. D., Fong, T. M., Graziano, M. P., and Tota, M. R. (1995). The family of G-protein-coupled receptors. FASEB J. 9, 745-754. Rosenblatt, M., Segre, G. V., Tyler, G. A., Shepard, G. L., Nussbaum, S. R., and Potts, J. T., Jr. (1980). Identification of a receptor-binding region in parathyroid hormone. Endocrinology 107, 545-550. Nutt, R. F., Caulfield, M. P., Levy, J. J., Gibbons, S. W., Rosenblatt, M., and McKee, R. L. (1990). Removal of partial agonism from parathyroid hormone (PTH)-related protein-(7-34) NH2 by substitution of PTH amino acids at positions 10 and 11. Endocrinology 127, 491-493. Shimizu, N., Guo, J., and Gardella, T. J. (2001). Parathyroid hormone (PTH)-(1-14) and -(1-11) analogs conformationally constrained by alpha-aminoisobutyric acid mediate full agonist responses via the juxtamembrane region of the PTH-1 receptor. J. Biol. Chem. 276, 49003-49012. Shimizu, M., Carter, P. H., Khatri, A., Potts, J. T., Jr., and Gardella, T. J. (2001). Enhanced activity in parathyroid hormone-(1-14) and-(1-11): Novel peptides for probing ligand-receptor interactions. Endocrinology 142, 3068-3074.
5. Parathyroid Hormone and Calcium Homeostasis 138. Azarani, A., Goltzman, D., and Orlowski, J. (1996). Structurally diverse N-terminal peptides of parathyroid hormone (PTH) and PTH-related peptide (PTHRP) inhibit the Na+/H+ exchanger NHE3 isoform by binding to the PTH/PTHRP receptor type I and activating distinct signaling pathways. J. Biol. Chem. 271, 14931-14936. 139. Takasu, H., Gardella, T. J., Luck, M. D., Potts, J. T., Jr., and Bringhurst, F. R. (1999). Amino-terminal modifications of human parathyroid hormone (PTH) selectively alter phospholipase C signaling via the type 1 PTH receptor: Implications for design of signal-specific PTH ligands. Biochemistry 38, 13453-13460. 140. Caulfield, M. P., McKee, R. L., Goldman, M. E., Duong, L. T., Fisher, J. E., Gay, C. T., DeHaven, P. A., Levy, J. J., Roubini, E., Nutt, R. F., et al. (1990). The bovine renal parathyroid hormone (PTH) receptor has equal affinity for two different amino acid sequences: The receptor binding domains of PTH and PTHrelated protein are located within the 14-34 region. Endocrinology 127, 83-87. 141. Abou-Samra, A. B., Uneno, S., Jueppner, H., Keutmann, H., Potts, J. T., Jr., Segre, G. V., and Nussbaum, S. R. (1989). Nonhomologous sequences of parathyroid hormone and the parathyroid hormone related peptide bind to a common receptor on ROS 17/2.8 cells. Endocrinology 125, 2215-2217. 142. Jin, L., Briggs, S. L., Chandrasekhar, S., Chirgadze, N. Y., Clawson, D. K., Schevitz, R. W., Smiley, D. L., Tashjian, A. H., and Zhang, F. (2000). Crystal structure of human parathyroid hormone 1-34 at 0.9-A resolution. J. Biol. Chem. 275, 27238-27244. 143. Barden, J. A., and Cuthbertson, R. M. (1993). Stabilized NMR structure of human parathyroid hormone(I-34). Eur. J. Biochem. 215, 315-321. 144. Pellegrini, M., Bisello, A., Rosenblatt, M., Chorev, M., and Mierke, D. F. (1997). Conformational studies of RS-66271, an analog of parathyroid hormone-related protein with pronounced bone anabolic activity. J. Med. Chem. 40, 3025-3031. 145. Marx, U. C., Austermann, S., Bayer, P., Adermann, K., Ejchart, A., Sticht, H., et al. (1995). Structure of human parathyroid hormone 1-37 in solution. J. Biol. Chem. 270, 15194-15202. 146. Vickery, B. H., Avnur, Z., Cheng, Y., Chiou, S. S., Leafier, D., Caulfield, J. P., Kimmel, D. B., Ho, T., and Krstenansky, J. L. (1996). RS-66271, a C-terminally substituted analog of human parathyroid hormone-related protein (1-34), increases trabecular and cortical bone in ovariectomized, osteopenic rats. J. Bone Miner. Res. 11, 1943-1951. 147. Behar, V., Bisello, A., Bitan, G., Rosenblatt, M., and Chorev, M. (2000). Photoaffinity cross-linking identifies differences in the interactions of an agonist and an antagonist with the parathyroid hormone/parathyroid hormone-related protein receptor. J. Biol. Chem. 275, 9-17. 148. Adams, A. E., Bisello, A., Chorev, M., Rosenblatt, M., and Suva, L. J. (1998). Arginine 186 in the extracellular N-terminal region of the human parathyroid hormone 1 receptor is essential for contact with position 13 of the hormone. Mol. Endocrinol. 12, 1673-1683. 149. Bisello, A., Adams, A. E., Mierke, D. F., Pellegrini, M., Rosenblatt, M., Suva, L. J., and Chorev, M. (1998). Parathyroid hormone-receptor interactions identified directly by photocrosslinking and molecular modeling studies. J. Biol. Chem. 273, 22498-22505. 150. Mannstadt, M., Luck, M. D., Gardella, T. J., and Jtippner, H. (1998). Evidence for a ligand interaction site at the aminoterminus of the parathyroid hormone (PTH)/PTH-related protein receptor from cross-linking and mutational studies. J. Biol. Chem. 273, 16890-16896.
165
151. Shimizu, M., Potts, J. T., Jr., and Gardella, T. J. (2000). Minimization of parathyroid hormone. Novel amino-terminal parathyroid hormone fragments with enhanced potency in activating the type-1 parathyroid hormone receptor. J. Biol. Chem. 275, 21836-21843. 152. Shimizu, M., Carter, P. H., and Gardella, T. J. (2000). Autoactivation of type-1 parathyroid hormone receptors containing a tethered ligand. J. Biol. Chem. 275, 19456-19460. 153. Sheikh, S. P., Vilardarga, J. P., Baranski, T. J., Lichtarge, O., Iiri, T., Meng, E. C., Nissenson, R. A., and Bourne, H. R. (1999). Similar structures and shared switch mechanisms of the beta2adrenoceptor and the parathyroid hormone receptor. Zn(II) bridges between helices III and VI block activation. J. Biol. Chem. 274, 17033-17041. 154. Huang, Z., Chen, Y., Pratt, S., Chen, T. H., Bambino, T., Nissenson, R. A., and Shoback, D. M. (1996). The N-terminal region of the third intracellular loop of the parathyroid hormone (PTH)/PTH-related peptide receptor is critical for coupling to cAMP and inositol phosphate/Ca 2+ signal transduction pathways. J. Biol. Chem. 271, 33382-33389. 155. Iida-Klein, A., Guo, J., Takemura, M., Drake, M. T., Potts, J. T., Jr., Abou-Samra, A., Bringhurst, F. R., and Segre, G. V. (1997). Mutations in the second cytoplasmic loop of the rat parathyroid hormone (PTH)/PTH-related protein receptor result in selective loss of PTH-stimulated phospholipase C activity. J. Biol. Chem. 272, 6882-6889. 156. Jobert, A. S., Zhang, P., Couvineau, A., Bonaventure, J., Roume, J., Le Merrer, M., and Silve, C. (1998). Absence of functional receptors for parathyroid hormone and parathyroid hormone-related peptide in Blomstrand chondrodysplasia. J. Clin. Invest. 102, 34-40. 157. Karaplis, A. C., He, B., Nguyen, M. T., Young, I. D., Semararo, D., Ozawa, H., and Amizuka, N. (1998). Inactivating mutation in the human parathyroid hormone receptor type 1 gene in Blomstrand chondrodysplasia. Endocrinology 139, 4753-4755. 158. Schipani, E., Langman, C. B., Parfitt, A. M., Jensen, G. S., Kikuchi, S., Kooh, S. W., Cole, W. G., and Jtippner, H. (1996). Constitutively activated receptors for parathyroid hormone and parathyroid hormone-related peptide in Jansen's metaphyseal chondrodysplasia. N. Engl. J. Med. 335, 708-714. 159. Iiri, T., Farfel, Z., and Bourne, H. R. (1998). G-protein diseases furnish a model for the turn-on switch. Nature 394, 35-38. 160. Gether, U. (2000). Uncovering molecular mechanisms involved in activation of G protein-coupled receptors. Endocrinol. Rev. 21, 90-113. 161. Offermanns, S., Iida-Klein, A., Segre, G. V., and Simon, M. I. (1996). G alpha q family members couple parathyroid hormone (PTH)/PTH-related peptide and calcitonin receptors to phospholipase C in COS-7 cells. Mol. Endocrinol. 10, 566-574. 162. Schwindinger, W. F., Fredericks, J., Watkins, L., Robinson, H., Bathon, J. M., Pines, M., Suva, L. J., and Levine, M. A. (1998). Coupling of the PTH/PTHrP receptor to multiple G-proteins. Direct demonstration of receptor activation of Gs, Gq/11, and Gi(1) by [alpha-32P]GTP-gamma-azidoanilide photoaffinity labeling. Endocrine 8, 201-209. 163. Feliciello, A., Gottesman, M. E., and Avvedimento, E. V. (2001). The biological functions of A-kinase anchor proteins. J. Mol. Biol. 308, 99-114. 164. Weinman, E. J., Steplock, D., and Shenolikar, S. (2001). Acute regulation of NHE3 by protein kinase A requires a multiprotein signal complex. Kidney Int. 60, 450-454.
166
Gordon I. Strewler
165. Graves, L. M., and Lawrence, J. C., Jr. (2002). Insulin, growth factors and cAMP: Antagonism in the signal transduction pathways. Trends Endocrinol. Metab. 7, 43-50. 166. Long, F., Schipani, E., Asahara, H., Kronenberg, H., and Montminy, M. (2001). The CREB family of activators is required for endochondral bone development. Development 128, 541-550. 167. Mehats, C., Andersen, C. B., Filopanti, M., Jin, S. L., and Conti, M. (2002). Cyclic nucleotide phosphodiesterases and their role in endocrine cell signaling. Trends Endocrinol. Metab. 13, 29-35. 168. Conti, M., and Jin, S. L. (1999). The molecular biology of cyclic nucleotide phosphodiesterases. Prog. Nucleic Acid Res. Mol. Biol 63, 1-38. 169. Murer, H., Hernando, N., Forster, I., and Biber, J. (2000). Proximal tubular phosphate reabsorption: Molecular mechanisms. Physiol. Rev. 80, 1373-1409. 170. Janulis, M., Tembe, V., and Favus, M. J. (1992). Role of protein kinase C in parathyroid hormone stimulation of renal 1,25-dihydroxyvitamin D3 secretion. J. Clin. Invest. 90, 2278-2283. 171. Sanders, J. L., and Stem, P. H. (2000). Protein kinase C involvement in interleukin-6 production by parathyroid hormone and tumor necrosis factor-alpha in UMR-106 osteoblastic cells. J. Bone Miner. Res. 15, 885-893. 172. Nagy, Z., Radeff, J., and Stern, P. H. (2001). Stimulation of interleukin-6 promoter by parathyroid hormone, tumor necrosis factor alpha, and interleukin- 1beta in UMR- 106 osteoblastic cells is inhibited by protein kinase C antagonists. J. Bone Miner. Res. 16, 1220-1227. 173. Krupnick, J. G., and Benovic, J. L. (1998). The role of receptor kinases and arrestins in G protein-coupled receptor regulation. Annu. Rev. Pharmacol. Toxicol. 38, 289-319. 174. Lefkowitz, R. J. (1998). G protein-coupled receptors. III. New roles for receptor kinases and beta-arrestins in receptor signaling and desensitization. J. Biol. Chem. 273, 18677-18680. 175. Blind, E., Bambino, T., Huang, Z., Bliziotes, M., and Nissenson, R. A. (1996). Phosphorylation of the cytoplasmic tail of the PTH/PTHrP receptor. J. Bone Miner. Res. 11, 578-586. 176. Qian, F., Leung, A., and Abou-Samra, A. (1998). Agonistdependent phosphorylation of the parathyroid hormone/ parathyroid hormone-related peptide receptor. Biochemistry 37, 6240-6246. 177. Dicker, F., Quitterer, U., Winstel, R., Honold, K., and Lohse, M. J. (1999). Phosphorylation-independent inhibition of parathyroid hormone receptor signaling by G protein-coupled receptor kinases. Proc. Natl. Acad. Sci. USA 96, 5476-5481. 178. Fukayama, S., Kong, G., Benovic, J. L., Meurer, E., and Tashjian, A. H., Jr. (1997). Beta-adrenergic receptor kinase1 acutely regulates PTH/PTHrP receptor signalling in human osteoblastlike cells. Cell Signal 9, 469-474. 179. Huang, Z., Chen, Y., and Nissenson, R. A. (1995). The cytoplasmic tail of the G-protein-coupled receptor for parathyroid hormone and parathyroid hormone-related protein contains positive and negative signals for endocytosis. J. Biol. Chem. 270, 151-156. 180. Malecz, N., Bambino, T., Bencsik, M., and Nissenson, R. A. (1998). Identification of phosphorylation sites in the G proteincoupled receptor for parathyroid hormone. Receptor phosphorylation is not required for agonist-induced internalization. Mol. Endocrinol. 12, 1846-1856. 181. Ferrari, S. L., and Bisello, A. (2001). Cellular distribution of constitutively active mutant parathyroid hormone (PTH)/PTHrelated protein receptors and regulation of cyclic adenosine 3',5'monophosphate signaling by beta-arrestin2. Mol. Endocrinol. 15, 149-163.
182. Ferrari, S. L., Behar, V., Chorev, M., Rosenblatt, M., and Bisello, A. (1999). Endocytosis of ligand-human parathyroid hormone receptor 1 complexes is protein kinase C-dependent and involves beta-arrestin2. Real-time monitoring by fluorescence microscopy. J. Biol. Chem. 274, 29968-29975. 183. Mahoney, C. A., and Nissenson, R. A. (1983). Canine renal receptors for parathyroid hormone. Down-regulation in vivo by exogenous parathyroid hormone. J. Clin. Invest. 72, 411-421. 184. Forte, L. R., Nickols, G. A., and Anast, C. S. (1976). Renal adenylate cyclase and the interrelationship between parathyroid hormone and vitamin D in the regulation of urinary phosphate and adenosine cyclic 3t,Y-monophosphate excretion. J. Clin. Invest. 57, 559-568. 185. Lewin, I. G., Papapoulos, S. E., Hendy, G. N., Tomlinson, S., and O'Riordan, J. L. (1982). Reversible resistance to the renal action of parathyroid hormone in human vitamin D deficiency. Clin. Sci. (London) 62, 381-387. 186. Massry, S. G., Stein, R., Garty, J., Arieff, A. I., Coburn, J. W., Norman, A. W., and Friedler, R. M. (1976). Skeletal resistance to the calcemic action of parathyroid hormone in uremia: role of 1,25 (OH)2 D3. Kidney Int. 9, 467-474. 187. Urena, P., Kubrusly, M., Mannstadt, M., Hruby, M., Trinh, M. M., Silve, C., Lacour, B., Abou-Samra, A. B., Segre, G. V., and Drueke, T. (1994). The renal PTH/PTHrP receptor is down-regulated in rats with chronic renal failure. Kidney Int. 45, 605-611. 188. Bellorin-Font, E., Lopez, C., Diaz, K., Pernalete, N., Lopez, M., and Starosta, R. (1995). Role of protein kinase C on the acute desensitization of renal cortical adenylate cyclase to parathyroid hormone. Kidney Int. 47, 38-44. 189. Nickols, G. A., Carnes, D. L., Anast, C. S., and Forte, L. R. (1979). Parathyroid hormone-mediated refractoriness of rat kidney cyclic AMP system. Am. J. Physiol. 236, E401-E409. 190. Urena, P., Mannstadt, M., Hruby, M., Ferreira, A., Schmitt, F., Silve, C., Ardaillou, R., Lacour, B., Abou-Samra, A. B., Segre, G. V., et al. (1995). Parathyroidectomy does not prevent the renal PTH/PTHrP receptor down-regulation in uremic rats. Kidney Int. 47, 1797-1805. 191. Hock, J. M., Raisz, L. G., and Canalis, E. (2001). Parathyroid hormone: Anabolic and catabolic effects on bone and interactions with bone growth factors. In The Parathyroids: Basic and Clinical Concepts (J. P. Bilezikian, R. Marcus, and M. A. Levine, Eds.), 2nd ed., pp. 183-198. Academic Press, San Diego. 192. Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J. Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., Wang, O., and Mitlak, B. H. (2001). Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. 344, 1434-1441. 193. McCuaig, K. A., Lee, H. S., Clarke, J. C., Assar, H., Horsford, J., and White, J. H. (1995). Parathyroid hormone/parathyroid hormone related peptide receptor gene transcripts are expressed from tissue-specific and ubiquitous promoters. Nucleic Acids Res. 23, 1948-1955. 194. Joun, H., Lanske, B., Karperien, M., Qian, F., Defize, L., and Abou-Samra, A. (1997). Tissue-specific transcription start sites and alternative splicing of the parathyroid hormone (PTH)/ PTH-related peptide (PTHrP) receptor gene: A new PTH/ PTHrP receptor splice variant that lacks the signal peptide. Endocrinology 138, 1742-1749. 195. Jobert, A. S., Fernandes, I., Turner, G., Coureau, C., Prie, D., Nissenson, R. A., Friedlander, G., and Silve, C. (1996). Expression of alternatively spliced isoforms of the parathyroid hormone
5. Parathyroid Hormone and Calcium Homeostasis
196. 197.
198.
199.
200.
201.
202.
203.
204.
205.
206.
207. 208.
(PTH)/PTH-related peptide receptor messenger RNA in human kidney and bone cells. Mol. Endocrinol. 10, 1066-1076. Gonzalez, E. A., and Martin, K. J. (1996). Coordinate regulation of PTH/PTHrP receptors by PTH and calcitriol in UMR 106-01 osteoblast-like cells. Kidney Int. 50, 63-70. Jongen, J. W., Willemstein-van Hove, E. C., van der Meer, J. M., Bos, M. P., Jtippner, H., Segre, G. V., Abou-Samra, A. B., Feyen, J. H., and Herrmann-Erlee, M. P. (1996). Down-regulation of the receptor for parathyroid hormone (PTH) and PTH-related peptide by PTH in primary fetal rat osteoblasts. J. Bone Miner. Res. 11, 1218-1225. Turner, G., Coureau, C., Rabin, M. R., Escoubet, B., Hruby, M., Walrant, O., and Silve, C. (1995). Parathyroid hormone (PTH)/ PTH-related protein receptor messenger ribonucleic acid expression and PTH response in a rat model of secondary hyperparathyroidism associated with vitamin D deficiency. Endocrinology 136, 3751-3758. Largo, R., Gomez-Garre, D., Santos, S., Penaranda, C., Blanco, J., Esbrit, P., and Egido, J. (1999). Renal expression of parathyroid hormone-related protein (PTHrP) and PTH/PTHrP receptor in a rat model of tubulointerstitial damage. Kidney Int. 55, 82-90. Kilav, R., Silver, J., Biber, J., Murer, H., and Naveh-Many, T. (1995). Coordinate regulation of rat renal parathyroid hormone receptor mRNA and Na-Pi cotransporter mRNA and protein. Am. J. Physiol. 268, 1017-1022. Brain, S. D., Williams, T. J., Tippins, J. R., Morris, H. R., and Maclntyre, I. (1985). Calcitonin gene-related peptide is a potent vasodilator. Nature 313, 54-56. Sutherland, M. K., Rao, L. G., Wylie, J. N., Gupta, A., Ly, H., Sodek, J., and Murray, T. M. (1994). Carboxyl-terminal parathyroid hormone peptide (53-84) elevates alkaline phosphatase and osteocalcin mRNA levels in SaOS-2 cells. J. Bone Miner. Res. 9, 453-458. Murray, T. M., Rao, L. G., and Muzaffar, S. A. (1991). Dexamethasone-treated ROS 17/2.8 rat osteosarcoma cells are responsive to human carboxylterminal parathyroid hormone peptide hPTH (53-84): Stimulation of alkaline phosphatase. Calcif. Tissue Int. 49, 120-123. Nakamoto, C., Baba, H., Fukase, M., Nakajima, K., Kimura, T., Sakakibara, S., Fujita, T., and Chihara, K. (1993). Individual and combined effects of intact PTH, amino-terminal, and a series of truncated carboxyl-terminal PTH fragments on alkaline phosphatase activity in dexamethasone-treated rat osteoblastic osteosarcoma cells, ROS 17/2.8. Acta Endocrinol. 128, 367-372. Lindsay, R., Nieves, J., Henneman, E., Shen, V., and Cosman, F. (1993). Subcutaneous administration of the amino-terminal fragment of human parathyroid hormone-(1-34): Kinetics and biochemical response in estrogenized osteoporotic patients. J. Clin. Endocrinol. Metab. 77, 1535-1539. Hofbauer, L. C., Khosla, S., Dunstan, C. R., Lacey, D. L., Boyle, W. J., and Riggs, B. L. (2000). The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J. Bone Miner. Res. 15, 2-12. Khosla, S. (2001). Minireview: The OPG/RANKL/RANK system. Endocrinology 142, 5050-5055. Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., Tsuda, E., Morinaga, T., Higashio, K., Udagawa, N., Takahashi, N., and Suda, T. (1998). Osteoclast differentiation factor is a ligand for osteoprotegerin/ osteoclastogenesis-inhibitory factor and is identical to TRANCE/ RANKL. Proc. Natl. Acad. Sci. USA 95, 3597-3602.
167
209. Hofbauer, L. C., Lacey, D. L., Dunstan, C. R., Spelsberg, T. C., Riggs, B. L., and Khosla, S. (1999). Interleukin-lbeta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone 25, 255-259. 210. Lee, S. K., and Lorenzo, J. A. (1999). Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: Correlation with osteoclast-like cell formation. Endocrinology 140, 3552-3561. 211. Onyia, J. E., Miles, R. R., Yang, X., Halladay, D. L., Hale, J., Glasebrook, A., McClure, D., Seno, G., Churgay, L., Chandrasekhar, S., and Martin, T. J. (2000). In vivo demonstration that human parathyroid hormone 1-38 inhibits the expression of osteoprotegerin in bone with the kinetics of an immediate early gene. J. Bone Miner. Res. 15, 863-871. 212. Tsukii, K., Shima, N., Mochizuki, S., Yamaguchi, K., Kinosaki, M., Yano, K., Shibata, O., Udagawa, N., Yasuda, H., Suda, T., and Higashio, K. (1998). Osteoclast differentiation factor mediates an essential signal for bone resorption induced by 1 alpha,25-dihydroxyvitamin D3, prostaglandin E2, or parathyroid hormone in the microenvironment of bone. Biochem. Biophys. Res. Commun. 246, 337-341. 213. Lacey, D. L., Timms, E., Tan, H. L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., Hsu, H., Sullivan, J., Hawkins, N., Davy, E., Capparelli, C., Eli, A., Qian, Y. X., Kaufman, S., Sarosi, I., Shalhoub, V., Senaldi, G., Guo, J., Delaney, J., and Boyle, W. J. (1998). Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93, 165-176. 214. Yamamoto, M., Murakami, T., Nishikawa, M., Tsuda, E., Mochizuki, S., Higashio, K., Akatsu, T., Motoyoshi, K., and Nagata, N. (1998). Hypocalcemic effect of osteoclastogenesis inhibitory factor/osteoprotegerin in the thyroparathyroidectomized rat. Endocrinology 139, 4012-4015. 215. Morony, S., Capparelli, C., Lee, R., Shimamoto, G., Boone, T., Lacey, D. L., and Dunstan, C. R. (1999). A chimeric form of osteoprotegerin inhibits hypercalcemia and bone resorption induced by IL-lbeta, TNF-alpha, PTH, PTHrP, and 1,25(OH) 2D3. J. Bone Miner. Res. 14, 1478-1485. 216. Oyajobi, B. O., Anderson, D. M., Traianedes, K., Williams, P. J., Yoneda, T., and Mundy, G. R. (2001). Therapeutic efficacy of a soluble receptor activator of nuclear factor kappaB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy. Cancer Res. 61, 2572-2578. 217. Amizuka, N., Karaplis, A. C., Henderson, J. E., Warshawsky, H., Lipman, M. L., Matsuki, Y, Ejiri, S., Tanaka, M., Izumi, N., Ozawa, H., and Goltzman, D. (1996). Haploinsufficiency of parathyroid hormone-related peptide (PTHrP) results in abnormal postnatal bone development. Dev. Biol. 175, 166-176. 218. Lee, K., Deeds, J. D., Bond, A. T., Jtippner, H., Abou-Samra, A.-B., and Segre, G. V. (1993). In situ localization of PTH/PTHrP receptor mRNA in the bone of fetal and young rats. Bone 14, 341-345. 219. Fermor, B., and Skerry, T. M. (1995). PTH/PTHrP receptor expression on osteoblasts and osteocytes but not resorbing bone surfaces in growing rats. J. Bone Miner. Res. 10, 1935-1943. 220. Bos, M. P., van der Meer, J. M., Feyen, J. H., and HerrmannErlee, M. P. (1996). Expression of the parathyroid hormone receptor and correlation with other osteoblastic parameters in fetal rat osteoblasts. Calcif. Tissue Int. 58, 95-100. 221. Silve, C. M., Hradek, G. T., Jones, A. L., and Arnaud, C. D. (1982). Parathyroid hormone receptor in intact embryonic
168
Gordon I. Strewler
chicken bone: Characterization and cellular localization. J. Cell Biol. 94, 379-386. 222. Rouleau, M. F., Mitchell, J., and Goltzman, D. (1990). Characterization of the major parathyroid hormone target cell in the endosteal metaphysis of rat long bones. J. Bone Miner. Res. 5, 1043-1053. 223. Gori, F., Hofbauer, L. C., Dunstan, C. R., Spelsberg, T. C., Khosla, S., and Riggs, B. L. (2000). The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated. Endocrinology 141, 4768-4776. 224. McSheehy, P. M. J., and Chambers, T. J. (1986). Osteoblastic cells mediate osteoclastic responsiveness to parathyroid hormone. Endocrinology 118, 824-828. 225. Fuller, K., Wong, B., Fox, S., Choi, Y., and Chambers, T. J. (1998). TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J. Exp. Med. 188, 997-1001. 226. Grey, A., Mitnick, M. A., Masiukiewicz, U., Sun, B. H., Rudikoff, S., Jilka, R. L., Manolagas, S. C., and Insogna, K. (1999). A role for interleukin-6 in parathyroid hormone-induced bone resorption in vivo. Endocrinology 140, 4683-4690. 227. Greenfield, E. M., Shaw, S. M., Gornik, S. A., and Banks, M. A. (1995). Adenyl cyclase and interleukin 6 are downstream effectors of parathyroid hormone resulting in stimulation of bone resorption. J. Clin. Invest. 96, 1238-1244. 228. Girasole, G., Passeri, G., Jilka, R. L., and Manolagas, S. C. (1994). Interleukin-11: A new cytokine critical for osteoclast development. J. Clin. Invest. 93, 151 6-1524. 229. O'Brien, C. A., Gubrij, I., Lin, S. C., Saylors, R. L., and Manolagas, S. C. (1999). STAT3 activation in stromal/osteoblastic cells is required for induction of the receptor activator of NF-kappaB ligand and stimulation of osteoclastogenesis by gp 130-utilizing cytokines or interleukin- 1 but not 1,25-dihydroxyvitamin D3 or parathyroid hormone. J. Biol. Chem. 274, 19301-19308. 230. Devlin, R. D., Reddy, S. V., Savino, R., Ciliberto, G., and Roodman, G. D. (1998). IL-6 mediates the effects of IL-1 or TNF, but not PTHrP or 1,25(OH)2D3, on osteoclast-like cell formation in normal human bone marrow cultures. J. Bone Miner. Res. 13, 393-399. 231. Manolagas, S. C. (2000). Birth and death of bone cells: Basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. EndocrinoL Rev. 21, 115-137. 232. Parisien, M., Silverberg, S. J., Shane, E., de laCruz, L., Lindsay, R., Bilezikian, J. P., and Dempster, D. W. (1990). The histomorphometry of bone in primary hyperparathyroidism: Preservation of cancellous bone structure. J. Clin. Endocrinol. Metab. 70, 930-938. 233. Dempster, D. W., Parisien, M., Silverberg, S. J., Liang, X. G., Schnitzer, M., Shen, V., Shane, E., Kimmel, D. B., Recker, R., Lindsay, R., and Bilezikian, J. P. (1999). On the mechanism of cancellous bone preservation in postmenopausal women with mild primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 84, 1562-1566. 234. Parisien, M., Mellish, R. W. E., Silverberg, S. J., Shane, E., Lindsay, R., Bilezikian, J. P., and Dempster, D. W. (1992). Maintenance of cancellous bone connectivity in primary hyperparathyroidism: Trabecular strut analysis. J. Bone Miner. Res. 7, 913-919. 235. Silverberg, S. J., Shane, E., Jacobs, T. P., Siris, E., and Bilezikian, J. P. (1999). A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N. Engl. J. Med. 341, 1249-1255.
236. Bauer, W., Aub, J., and Albright, F. (1929). Studies in calcium phosphorus metabolism: Study of bone trabeculae as ready available reserve supply of calcium. J. Exp. Med. 49, 145-162. 237. Hock, J. M., Gera, I., Fonseca, J., and Raisz, L. G. (1988). Human parathyroid hormone-(1-34) increases bone mass in ovariectomized and orchidectomized rats. Endocrinology 122, 2899-2904. 238. Wronski, T. J., Pun, S., and Liang, H. (1999). Effects of age, estrogen depletion, and parathyroid hormone treatment on vertebral cancellous wall width in female rats. Bone 25, 465-468. 239. Baumann, B. D., and Wronski, T. J. (1995). Response of cortical bone to antiresorptive agents and parathyroid hormone in aged ovariectomized rats. Bone 16, 247-253. 240. Wronski, T. J., and Yen, C. F. (1994). Anabolic effects of parathyroid hormone on cortical bone in ovariectomized rats. Bone 15, 51-58. 241. Finkelstein, J. S., Klibanski, A., Schaefer, E. H., Hornstein, M. D., Schiff, I., and Neer, R. M. (1994). Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency. N. Engl. J. Med. 331, 1618-1623. 242. Lindsay, R., Nieves, J., Formica, C., Henneman, E., Woelfert, L., Shen, V., Dempster, D., and Cosman, F. (1997). Randomised controlled study of effect of parathyroid hormone on vertebralbone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 350, 550-555. 243. Lane, N. E., Sanchez, S., Modin, G. W., Genant, H. K., Ini, E., and Arnaud, C. D. (1998). Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J. Clin. Invest. 102, 1627-1633. 244. Mosekilde, L., Sogaard, C. H., McOsker, J. E., and Wronski, T. J. (1994). PTH has a more pronounced effect on vertebral bone mass and biomechanical competence than antiresorptive agents (estrogen and bisphosphonate) assessed in sexually mature, ovariectomized rats. Bone 15, 401-408. 245. Sogaard, C. H., Wronski, T. J., McOsker, J. E., and Mosekilde, L. (1994). The positive effect of parathyroid hormone on femoral neck bone strength in ovariectomized rats is more pronounced than that of estrogen or bisphosphonates. Endocrinology 134, 650-657. 246. Mosekilde, L., Sogaard, C. H., Danielsen, C. C., and Torring, O. (1991). The anabolic effects of human parathyroid hormone (hPTH) on rat vertebral body mass are also reflected in the quality of bone, assessed by biomechanical testing: A comparison study between hPTH-(1-34) and hPTH-(1-84). Endocrinology 129, 421-428. 247. Tam, C. S., Heersche, J. N. M., Murray, T. M., and Parsons, J. A. (1982). Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: Differential effects of intermittent and continuous administration. Endocrinology 110, 506-512. 248. Boyce, R. W., Paddock, C. L., Franks, A. F., Jankowsky, M. L., and Eriksen, E. F. (1996). Effects of intermittent hPTH(1-34) alone and in combination with 1,25(OH) (2)D(3) or risedronate on endosteal bone remodeling in canine cancellous and cortical bone. J. Bone Miner. Res. 11, 600-613. 249. Shen, V., Dempster, D. W., Birchman, R., Xu, R., and Lindsay, R. (1993). Loss of cancellous bone mass and connectivity in ovariectomized rats can be restored by combined treatment with parathyroid hormone and estradiol. J. Clin. Invest. 91, 2479-2487. 250. Lane, N. E., Kimmel, D. B., Nilsson, M. H., Cohen, F. E., Newton, S., Nissenson, R. A., and Strewler, G. J. (1996). Boneselective analogs of human PTH(1-34) increase bone formation in an ovariectomized rat model. J. Bone Miner. Res. 11, 614-625. 251. Dempster, D. W., Cosman, F., Kurland, E. S., Zhou, H., Nieves, J., Woelfert, L., Shane, E., Plavetic, K., Muller, R.,
5. Parathyroid Hormone and Calcium Homeostasis
252.
253.
254.
255.
256.
257.
258.
259.
260.
261.
262.
263.
264.
Bilezikian, J., and Lindsay, R. (2001). Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J. Bone Miner. Res. 16, 1846-1853. Dempster, D. W., Zhou, H., Cosman, F., Nieves, J., Adachi, J. D., Fraher, L. J., Watson, P. H., Lindsay, R., and Hodsman, A. B. (2001). PTH treatment directly stimulates bone formation in cancellous and cortical bone in humans. J. Bone Miner. Res. 16 (Suppl. 1), S179. Clohisy, J. C., Scott, D. K., Brakenhoff, K. D., Quinn, C. O., and Partridge, N. C. (1992). Parathyroid hormone induces c-fos and c-jun messenger RNA in rat osteoblastic cells. Mol. Endocrinol. 6, 1834-1842. Lee, K., Deeds, J. D., Chiba, S., Un-No, M., Bond, A. T., and Segre, G. V. (1994). Parathyroid hormone induces sequential c-fos expression in bone cells in vivo: In situ localization of its receptor and c-fos messenger ribonucleic acids. Endocrinology 134, 441-450. McCauley, L. K., Koh, A. J., Beecher, C. A., and Rosol, T. J. (1997). Proto-oncogene c-fos is transcriptionally regulated by parathyroid hormone (PTH) and PTH-related protein in a cyclic adenosine monophosphate-dependent manner in osteoblastic cells. Endocrinology 138, 5427-5433. McCauley, L. K., Koh-Paige, A. J., Chen, H., Chen, C., Ontiveros, C., Irwin, R., and McCabe, L. R. (2001). Parathyroid hormone stimulates fra-2 expression in osteoblastic cells in vitro and in vivo. Endocrinology 142, 1975-1981. Evans, D. B., Hipskind, R. A., and Bilbe, G. (1996). Analysis of signaling pathways used by parathyroid hormone to activate the c-fos gene in human SaOS2 osteoblast-like cells. J. Bone Miner. Res. 11, 1066-1074. Pearman, A. T., Chou, W. Y., Bergman, K. D., Pulumati, M. R., and Partridge, N. C. (1996). Parathyroid hormone induces c-fos promoter activity in osteoblastic cells through phosphorylated cAMP response element (CRE)-binding protein binding to the major CRE. J. Biol. Chem. 271, 25715-25721. Tyson, D. R., Swarthout, J. T., and Partridge, N. C. (1999). Increased osteoblastic c-fos expression by parathyroid hormone requires protein kinase A phosphorylation of the cyclic adenosine 3',5'-monophosphate response element-binding protein at serine 133. Endocrinology 140, 1255-1261. Selvamurugan, N., Pulumati, M. R., Tyson, D. R., and Partridge, N. C. (2000). Parathyroid hormone regulation of the rat collagenase-3 promoter by protein kinase A-dependent transactivation of core binding factor alpha 1. J. Biol. Chem. 275, 5037-5042. Kream, B. E., Lafrancis, D., Petersen, D. N., Woody, C., Clark, S., Rowe, D. W., and Lichtler, A. (1993). Parathyroid hormone represses alpha 1(I) collagen promoter activity in cultured calvariae from neonatal transgenic mice. Mol. EndocrinoL 7, 399-408. Kream, B. E., Rowe, D. W., Gworek, S. C., and Raisz, L. G. (1980). Parathyroid hormone alters collagen synthesis and procollagen mRNA levels in fetal rat calvaria. Proc. Natl. Acad. Sci. USA 77, 5654-5658. Nishida, S., Yamaguchi, A., Tanizawa, T., Endo, N., Mashiba, T., Uchiyama, Y., Suda, T., Yoshiki, S., and Takahashi, H. E. (1994). Increased bone formation by intermittent parathyroid hormone administration is due to the stimulation of proliferation and differentiation of osteoprogenitor cells in bone marrow. Bone 15, 717-723. Gronthos, S., Zannettino, A. C., Graves, S. E., Ohta, S., Hay, S. J., and Simmons, P. J. (1999). Differential cell surface expression of the STRO-1 and alkaline phosphatase antigens on discrete developmental stages in primary cultures of human bone cells. J. Bone Miner. Res. 14, 47-56.
169
265. Stewart, K., Walsh, S., Screen, J., Jefferiss, C. M., Chainey, J., Jordan, G. R., and Beresford, J. N. (1999). Further characterization of cells expressing STRO-1 in cultures of adult human bone marrow stromal cells. J. Bone Miner. Res. 14, 1345-1356. 266. Onyia, J. E., Bidwell, J., Herring, J., Hulman, J., and Hock, J. M. (1995). In vivo, human parathyroid hormone fragment (hPTH 1-34) transiently stimulates immediate early response gene expression, but not proliferation, in trabecular bone cells of young rats. Bone 17, 479-484. 267. Dobnig, H., and Turner, R. T. (1995). Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology 136, 3632-3638. 268. Jilka, R. L., Weinstein, R. S., Bellido, T., Roberson, P., Parfitt, A. M., and Manolagas, S. C. (1999). Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J. Clin. Invest. 104, 439-446. 269. Stanislaus, D., Yang, X., Liang, J. D., Wolfe, J., Cain, R. L., Onyia, J. E., Falla, N., Marder, P., Bidwell, J. P., Queener, S. W., and Hock, J. M. (2000). In vivo regulation of apoptosis in metaphyseal trabecular bone of young rats by synthetic human parathyroid hormone (1-34) fragment. Bone 27, 209-218. 270. Canalis, E., McCarthy, T. L., and CentreUa, M. (1990). Differential effects of continuous and transient treatment with parathyroid hormone related peptide (PTHrp) on bone collagen synthesis. Endocrinology 126, 1806-1812. 271. Canalis, E., Centrella, M., Burch, W., and McCarthy, T. L. (1989). Insulin-like growth factor I mediates selective anabolic effects of parathyroid hormone in bone cultures. J. Clin. Invest. 83, 60-65. 272. Watson, P., Lazowski, D., Han, V., Fraher, L., Steer, B., and Hodsman, A. (1995). Parathyroid hormone restores bone mass and enhances osteoblast insulin-like growth factor I gene expression in ovariectomized rats. Bone 16, 357-365. 272a.Pfeilschifter, J., Laukhuf, F., Muller-Beckmann, B., Blum, W. F., Pfister, T., and Ziegler, R. (1995). Parathyroid hormone increases the concentration of insulin-like growth factor-I and transforming growth factor beta 1 in rat bone. J. Clin. Invest. 96, 767-774. 273. Conover, C. A. (1996). The role of insulin-like growth factors and binding proteins in bone cell biology. In Principles of Bone Cell Biology (J. P. Bilezikian, L. G. Raisz, and G. A. Rodan, Eds.), pp. 607-618. Academic Press, San Diego. 274. Kostenuik, P. J., Harris, J., Halloran, B. P., Turner, R. T., Morey-Holton, E. R., and Bikle, D. D. (1999). Skeletal unloading causes resistance of osteoprogenitor cells to parathyroid hormone and to insulin-like growth factor-I. J. Bone Miner. Res. 14, 21-31. 275. Zhang, M., Xuan, S., Bouxsein, M. L., von Stechhow, D., Faugere, M., Malluche, H. H., Zhao, G., Rosen, C. J., Efstratiadis, A., and Clemens, T. L. (2001). Conditional mutagenesis of the IGF1 receptor gene in osteoblasts reduces cancellous bone volume and increases turnover. J. Bone Miner. Res. 16 (Suppl. 1), S 1097. 276. Wu, Y., and Kumar, R. (2000). Parathyroid hormone regulates transforming growth factor beta l and beta2 synthesis in osteoblasts via divergent signaling pathways. J. Bone Miner. Res. 15, 879-884. 277. Lee, K., Deeds, J. D., and Segre, G. V. (1995). Expression of parathyroid hormone-related peptide and its receptor messenger ribonucleic acids during fetal development of rats. Endocrinology 136, 453-463. 278. Karmali, R., Schiffmann, S. N., Vanderwinden, J. M., Hendy, G. N., Nys-DeWolf, N., Corvilain, J., Bergmann, P.,
1 70
279.
280.
281.
282.
283.
284. 285.
286.
287.
288.
289.
290.
291. 292.
293.
294.
Gordon I. Strewler and Vanderhaeghen, J. J. (1992). Expression of mRNA of parathyroid hormone-related peptide in fetal bones of the rat. Cell Tissue Res. 270, 597-600. Suda, N., Gillespie, M. T., Traianedes, K., Zhou, H., Ho, P. W., Hards, D. K., Allan, E. H., Martin, T. J., and Moseley, J. M. (1996). Expression of parathyroid hormone-related protein in cells of osteoblast lineage. J. Cell. Physiol. 166, 94-104. Oyajobi, B. O., Lomri, A., Hott, M., and Marie, P. J. (1999). Isolation and characterization of human clonogenic osteoblast progenitors immunoselected from fetal bone marrow stroma using STRO-1 monoclonal antibody. J. Bone Miner. Res. 14, 351-361. Kartsogiannis, V., Moseley, J., Mckelvie, B., Chou, S. T., Hards, D. K., Ng, K. W., Martin, T. J., and Zhou, H. (1997). Temporal expression of PTHrP during endochondral bone formation in mouse and intramembranous bone formation in an in vivo rabbit model. Bone 21, 385-392. Lanske, B., Amling, M., Neff, L., Guiducci, J., Baron, R., and Kronenberg, H. M. (1999). Ablation of the PTHrP gene or the PTH/PTHrP receptor gene leads to distinct abnormalities in bone development. J. Clin. Invest. 104, 399-407. Bringhurst, F. R., and Strewler, G. J. (2001). Renal and skeletal actions of PTH and PTHrP. In Principles of Bone Biology (J. P. Bilezikian, G. A. Rodan, and L. G. Raisz, Eds.), 2nd ed. Academic Press, San Diego. Friedman, P. A. (1999). Calcium transport in the kidney. Curr. Opin. Nephrol. Hypertension 8, 589-595. Lau, K., and Bourdeau, J. E. (1995). Parathyroid hormone action in calcium transport in the distal nephron. Curt. Opin. Nephrol. Hypertension 4, 55-63. Agus, Z. S., Gardner, L. B., Beck, L. H., and Goldberg, M. (1973). Effects of parathyroid hormone on renal tubular reabsorption of calcium, sodium, and phosphate. Am. J. Physiol. 224, 1143-1148. Imai, M. (1981). Effects of parathyroid hormone and N6,O2'dibutyryl cyclic AMP on Ca 2+ transport across the rabbit distal nephron segments perfused in vitro. Pflugers Archiv. Eur. J. Physiol. 390, 145-151. Shareghi, G. R., and Stoner, L. C. (1978). Calcium transport across segments of the rabbit distal nephron in vitro. Am. J. Physiol. 235, 367-375. Shimizu, T., Yoshitomi, K., Nakamura, M., and Imai, M. (1990). Effect of parathyroid hormone on the connecting tubule from the rabbit kidney: Biphasic response of transmural voltage. Pflugers Archiv. Eur. J. Physiol. 416, 254-261. Amiel, C., Kuntziger, H., and Richet, G. (1970). Micropuncture study of handling of phosphate by proximal and distal nephron in normal and parathyroidectomized rat. Evidence for distal reabsorption. Pflugers Arch. 317, 93-109. De Rouffignac, C., and Quamme, G. (1994). Renal magnesium handling and its hormonal control. Physiol. Rev. 74, 305-322. Simon, D. B., Lu, Y., Choate, K. A., Velaquez, H., A1Sabban, E., Praga, M., Casari, G., Bettinelli, A., Colussi, G., Rodriguez-Soriano, J., McCredie, D., Milford, D., Sanjad, S., and Lifton, R. P. (1999). Paracellin-1, a renal tight junction protein required for paracellar Mg 2+ resorption. Science 285, 103-106. Blanchard, A., Jeunemaitre, X., Coudol, P., Dechaux, M., Froissart, M., May, A., Demontis, R., Fournier, A., Paillard, M., and HouiUier, P. (2001). Paracellin-1 is critical for magnesium and calcium reabsorption in the human thick ascending limb of Henle. Kidney Int. 59, 2206-2215. Wittner, M., Mandon, B., Roinel, N., De Rouffignac, C., and Di Stefano, A. (1993). Hormonal stimulation of Ca 2+ and Mg 2+ transport in the cortical thick ascending limb of Henle's loop of
295.
296.
297.
298.
299.
300.
301.
302.
303.
304.
305.
306.
307.
308.
309.
310.
311.
the mouse: Evidence for a change in the paracellular pathway permeability. Pflugers Arch. 423, 387-396. Hoenderop, J. G., Nilius, B., and Bindels, R. J. (2002). Molecular mechanism of active Ca 2+ reabsorption in the distal nephron. Annu. Rev. Physiol. 64, 529-549. Bourdeau, J. E., and Lau, K. (1989). Effects of parathyroid hormone on cytosolic free calcium concentration in individual rabbit connecting tubules. J. Clin. Invest. 83, 373-379. Lajeunesse, D., Bouhtiauy, I., and Brunette, M. G. (1994). Parathyroid hormone and hydrochlorothiazide increase calcium transport by the luminal membrane of rabbit distal nephron segments through different pathways. Endocrinology 134, 35-41. Peng, J. B., Chen, X. Z., Berger, U. V., Vassilev, P. M., Brown, E. M., and Hediger, M. A. (2000). A rat kidney-specific calcium transporter in the distal nephron. J. Biol. Chem. 275, 28186-28194. Matsunaga, H., Stanton, B. A., Gesek, F. A., and Friedman, P. A. (1994). Epithelial Ca 2+ channels sensitive to dihydropyridines and activated by hyperpolarizing voltages. Am. J. Physiol. 267, 157-165. Wood, R. J., Tchack, L., and Taparia, S. (2001). 1,25-Dihydroxyvitamin D3 increases the expression of the CaT1 epithelial calcium channel in the Caco-2 human intestinal cell line., B M C Physiol. 1, 11. Van Cromphaut, S. J., Dewerchin, M., Hoenderop, J. G., Stockmans, I., Van Herck, E., Kato, S., Bindels, R. J., Collen, D., Carmeliet, P., Bouillon, R., and Carmeliet, G. (2001). Duodenal calcium absorption in vitamin D receptor-knockout mice: Functional and molecular aspects. Proc. Natl. Acad. Sci. USA 98, 13324-13329. Rhoten, W. B., Bruns, M. E., and Christakos, S. (1985). Presence and localization of two vitamin D-dependent calcium binding proteins in kidneys of higher vertebrates. Endocrinology 117, 674-683. Hemmingsen, C., Staun, M., Lewin, E., Nielsen, P. K., and Olgaard, K. (1996). Effect of parathyroid hormone on renal calbindin-D28k. J. Bone Miner. Res. 11, 1086-1093. Sooy, K., Kohut, J., and Christakos, S. (2000). The role of calbindin and 1,25-dihydroxyvitamin D3 in the kidney. Curr. Opin. Nephrol. Hypertension 9, 341-347. Scoble, J. E., Mills, S., and Hruska, K. A. (1985). Calcium transport in canine renal basolateral membrane vesicles. Effects of parathyroid hormone. J. Clin. Invest. 75, 1096-1105. Hanai, H., Ishida, M., Liang, C. T., and Sacktor, B. (1986). Parathyroid hormone increases sodium/calcium exchange activity in renal cells and the blunting of the response in aging. J. Biol. Chem. 261, 5419-5425. Hanai, H., Ishida, M., Liang, C. T., and Sacktor, B. (1986). Parathyroid hormone increases sodium/calcium exchange activity in renal cells and the blunting of the response in aging. J. Biol. Chem. 261, 5419-5425. Shimizu, T., Yoshitomi, K., Nakamura, N., and Imai, M. (1990). Effects of PTH, calcitonin, and cAMP on calcium transport in rabbit distal nephron segments. Am. J. Physiol. 259, F408-F414. White, K. E., Gesek, F. A., and Friedman, P. A. (1996). Structural and functional analysis of Na+/Ca ++ exchange in distal convoluted tubule cells. Am. J. Physiol. 271, F560--F570. Levy, J., Gavin, J. R. D., Morimoto, S., Hammerman, M. R., and Avioli, L. V. (1986). Hormonal regulation of (Ca 2+ + Mg 2+) ATPase activity in canine renal basolateral membrane. Endocrinology 119, 2405-2411. Bouhtiauy, D., Lajeunesse, D., and Brunette, M. G. (1991). The mechanism of parathyroid hormone action on calcium reabsorption by the distal tubule. Endocrinology 128, 251-258.
5. Parathyroid Hormone and Calcium Homeostasis 312. Hoenderop, J. G., De Pont, J. J., Bindels, R. J., and Willems, P. H. (1999). Hormone-stimulated Ca 2+ reabsorption in rabbit kidney cortical collecting system is cAMP-independent and involves a phorbol ester-insensitive PKC isotype. Kidney Int. 55, 225-233. 313. Sneddon, W. B., Liu, F., Gesek, F. A., and Friedman, P. A. (2000). Obligate mitogen-activated protein kinase activation in parathyroid hormone stimulation of calcium transport but not calcium signaling. Endocrinology 141, 4185-4193. 314. Weinman, E. J. (2001). New functions for the NHERF family of proteins. J. Clin. Invest. 108, 185-186. 315. Bacskai, B. J., and Friedman, P. A. (1990). Activation of latent Ca 2+ channels in renal epithelial cells by parathyroid hormone. Nature 347, 388-391. 316. Garcia-Ocana, A., Galbraith, S. C., Van Why, S. K., Yang, K., Golovyan, L., Dann, P., Zager, R. A., Stewart, A. F., Siegel, N. J., and Orloff, J. J. (1999). Expression and role of parathyroid hormone-related protein in human renal proximal tubule cells during recovery from ATP depletion. J. Am. Soc. Nephrol. 10, 238-244. 317. Albright, F., Burnett, C. H., Smith, P. H., and Parson, W. (1942). Pseudo-hypoparathyroidism--An example of"Seabright-Bantam syndrome." Endocrinology 30, 922-932. 318. Hernando, N., Karim-Jimenez, Z., Biber, J., and Murer, H. (2001). Molecular determinants for apical expression and regulatory membrane retrieval of the type IIa Na/Pi cotransporter. Kidney Int. 60, 431-435. 319. Kempson, S. A., Lotscher, M., Kaissling, B., Biber, J., Murer, H., and Levi, M. (1995). Parathyroid hormone action on phosphate transporter mRNA and protein in rat renal proximal tubules. Am. J. Physiol. 268, 784-791. 320. Lotscher, M., Kaissling, B., Biber, J., Murer, H., and Levi, M. (1997). Role of microtubules in the rapid regulation of renal phosphate transport in response to acute alterations in dietary phosphate content. J. Clin. Invest. 99, 1302-1312. 321. Zhao, N., and Tenenhouse, H. S. (2000). Npt2 gene disruption confers resistance to the inhibitory action of parathyroid hormone on renal sodium-phosphate cotransport. Endocrinology 141, 2159-2165. 322. Beck, L., Karaplis, A. C., Amizuka, N., Hewson, A. S., Ozawa, H., and Tenenhouse, H. S. (1998). Targeted inactivation of Npt2 in mice leads to severe renal phosphate wasting, hypercalciuria, and skeletal abnormalities. Proc. Natl. Acad. Sci. USA 95, 5372-5377. 323. Malmstrom, K., and Murer, H. (1987). Parathyroid hormone regulates phosphate transport in OK cells via an irreversible inactivation of a membrane protein. FEBS Lett. 216, 257-260. 324. Pfister, M. F., Ruf, I., Stange, G., Ziegler, U., Lederer, E., Biber, J., and Murer, H. (1998). Parathyroid hormone leads to the lysosomal degradation of the renal type II Na/Pi cotransporter. Proc. Natl. Acad. Sci. USA 95, 1909-1914. 325. Agus, Z. S., Puschett, J. B., Senesky, D., and Goldberg, M. (1971). Mode of action of parathyroid hormone and cyclic adenosine 3',5'-monophosphate on renal tubular phosphate reabsorption in the dog. J. Clin. Invest. 50, 617. 326. Martin, K. J., McConkey, C. L., Garcia, J. C., Montani, D., and Betts, C. R. (1989). Protein kinase-A and the effects of parathyroid hormone on phosphate uptake in opposum kidney cells. Endocrinology 125, 295-301. 327. Segal, J. H., and Pollock, A. S. (1990). Transfection-mediated expression of a dominant cAMP-resistant phenotype in the opossum kidney (OK) cell line prevents parathyroid hormone-induced inhibition of Na-phosphate cotransport. A protein kinase-Amediated event. J. Clin. Invest. 86, 1442-1450. 328. Martin, K. J., McConkey, C. L., Jacob, A. K., Gonzalez, E. A., Khan, M., and Baldassare, J. J. (1994). Effect of U-73,122, an
329.
330.
331.
332.
333.
334.
335.
336.
337.
338.
339.
340.
341.
342.
343.
1 71
inhibitor of phospholipase C, on actions of parathyroid hormone in opossum kidney cells. A. J. Physiol. 266, 254-258. Cole, J. A., Forte, L. R., Eber, S., Thorne, P. K., and Poelling, R. E. (1988). Regulation of sodium-dependent phosphate transport by parathyroid hormone in opossum kidney cells: Adenosine 3',5'-monophosphate-dependent and-independent mechanisms. Endocrinology 122, 2981-2989. Cole, J. A., Carnes, D. L., Forte, L. R., Eber, S., Poelling, R. E., and Thorne, P. K. (1989). Structure-activity relationships of parathyroid hormone analogs in the opossum kidney cell line. J. Bone Miner. Res. 4, 723-730. Quamme, G., Pfeilschifter, J., and Murer, H. (1989). Parathyroid hormone inhibition of Na+/phosphate cotransport in OK cells: Requirement of protein kinase C-dependent pathway. Biochim. Biophys. Acta 1013, 159-165. Traebert, M., Volkl, H., Biber, J., Murer, H., and Kaissling, B. (2000). Luminal and contraluminal action of 1-34 and 3-34 PTH peptides on renal type IIa Na-P(i) cotransporter. Am. J. Physiol. Renal Physiol. 278, F792-F798. Hayes, G., Busch, A., Lang, F., Biber, J., and Murer, H. (1995). Protein kinase C consensus sites and the regulation of renal NaPi cotransport (NaPi-2) expressed in Xenopus laevis oocytes. Pflugers Arch. 430, 819-824. Karim-Jimenez, Z., Hernando, N., Biber, J., and Murer, H. (2000). A dibasic motif involved in parathyroid hormone-induced down-regulation of the type IIa NaPi cotransporter. Proc. Natl. Acad. Sci. USA 97, 12896-12901. Zizak, M., Lamprecht, G., Steplock, D., Tariq, N., Shenolikar, S., Donowitz, M., Yun, C. H., and Weinman, E. J. (1999). cAMPinduced phosphorylation and inhibition of Na(+)/H(+) exchanger 3 (NHE3) are dependent on the presence but not the phosphorylation of NHE regulatory factor. J. Biol. Chem. 274, 24753-24758. Gisler, S. M., Stagljar, I., Traebert, M., Bacic, D., Biber, J., and Murer, H. (2001). Interaction of the type IIa Na/Pi cotransporter with PDZ proteins. J. Biol. Chem. 276, 9206-9213. Pollock, A. S., Warnock, D. G., and Strewler, G. J. (1986). Parathyroid hormone inhibition of Na+-H + antiporter activity in a cultured renal cell line. Am. J. Physiol. 250, 217-225. Helmle-Kolb, C., Montrose, M. H., and Murer, H. (1990). Parathyroid hormone regulation of Na+/H + exchange in opossum kidney cells: Polarity and mechanisms. Pflugers Archiv. Eur. J. Physiol. 416, 615-623. Zhao, H., Wiederkehr, M. R., Fan, L., Collazo, R. L., Crowder, L. A., and Moe, O. W. (1999). Acute inhibition of Na/H exchanger NHE-3 by cAMP. Role of protein kinase a and NHE-3 phosphoserines 552 and 605. J. Biol. Chem. 274, 3978-3987. Collazo, R., Fan, L., Hu, M. C., Zhao, H., Wiederkehr, M. R., and Moe, O. W. (2000). Acute regulation of Na+/H + exchanger NHE3 by parathyroid hormone via NHE3 phosphorylation and dynamin-dependent endocytosis. J. Biol. Chem. 275, 31601-31608. Miller, R. T., and Pollock, A. S. (1987). Modification of the internal pH sensitivity of the Na+/H + antiporter by parathyroid hormone in a cultured renal cell line. J. Biol. Chem. 262, 9115-9120. Weinman, E. J., Steplock, D., and Shenolikar, S. (2001). Acute regulation of NHE3 by protein kinase A requires a multiprotein signal complex. Kidney Int. 60, 450-454. Azarani, A., Goltzman, D., and Orlowski, J. (1995). Parathyroid hormone and parathyroid hormone-related peptide inhibit the apical Na+/H + exchanger NHE-3 isoform in renal cells (OK) via
1 72
344.
345.
346. 347.
Gordon l-Strewler a dual signaling cascade involving protein kinase A and C. J. Biol. Chem. 270, 20004-20010. Zhang, Y., Norian, J. M., Magyar, C. E., Holstein-Rathlou, N. H., Mircheff, A. K., and McDonough, A. A. (1999). In vivo PTH provokes apical NHE3 and NaPi2 redistribution and NaK-ATPase inhibition. Am. J. Physiol. 276, 711-719. Ominato, M., Satoh, T., and Katz, A. I. (1996). Regulation of NaK-ATPase activity in the proximal tubule: Role of the protein kinase C pathway and of eicosanoids. J. Membrane Biol. 152, 235-243. Derrickson, B. H., and Mandel, L. J. (1997). Parathyroid hormone inhibits Na(+)-K(+)-ATPase through Gq/Gll and the calciumindependent phospholipase A2. Am. J. PhysioL 272, 781-788. Murayama, A., Takeyama, K., Kitanaka, S., Kodera, Y., Kawaguchi, Y., Hosoya, T., and Kato, S. (1999). Positive and negative regulations of the renal 25-hydroxyvitamin D3 lalphahydroxylase gene by parathyroid hormone, calcitonin, and lalpha,25(OH)2D3 in intact animals. Endocrinology 140, 2224-2231.
348. St. Arnaud, R., Arabian, A., Travers, R., Barletta, F., RavalPandya, M., Chapin, K., Depovere, J., Mathieu, C., Christakos, S., Demay, M. B., and Glorieux, F. H. (2000). Deficient mineralization of intramembranous bone in vitamin D-24-hydroxylase-ablated mice is due to elevated 1,25-dihydroxyvitamin D and not to the absence of 24,25-dihydroxyvitamin D. Endocrinology 141, 2658-2666. 349. Henry, H. L. (1985). Parathyroid hormone modulation of 25hydroxyvitamin D3 metabolism by cultured chick kidney cells is mimicked and enhanced by forskolin. Endocrinology 116, 503-510. 350. Matsumoto, T., Kawanobe, Y., and Ogata, E. (1985). Regulation of 24,25-dihydroxyvitamin D-3 production by 1,25-dihydroxyvitamin D-3 and synthetic human parathyroid hormone fragment 1-34 in a cloned monkey kidney cell line (JTC-12). Biochim. Biophys. Acta 845, 358-365. 351. Zierold, C., Mings, J. A., and DeLuca, H. F. (2001). Parathyroid hormone regulates 25-hydroxyvitamin D(3)-24-hydroxylase mRNA by altering its stability. Proc. Natl. Acad. Sci. USA 98, 13572-13576.
C
H
A
P
T
61
E
R
Phosphate Homeostasis Regulatory Mechanisms JOSEPH CAVERZASIO,* HEINI MURER,t and HARRIET S. TENENHOUSE ~ *Division of Bone Diseases, University Hospital of Geneva, Geneva, Switzerland tinstitute of Physiology, University of Zurich, Zurich, Switzerland ~Departments of Pediatrics and Human Genetics, McGill University Children's Hospital Research Institute, Montreal Quebec, Canada
PHYSIOLOGICAL ASPECTS
other 10-20% is in soft tissues (primarily muscle and internal organs), extracellular fluid, and erythrocytes. In soft tissues, Pi comprises 0.1-0.3% of wet weight and is contained intracellularly as phosphorylated sugars, phospholipids, phosphoproteins, nucleic acids, and Pi. In blood, Pi is present in both erythrocytes and plasma. In plasma, phospholipids comprise the main fraction (2.2-3.1mmol/liter), followed by phosphate esters (0.9-1.5mmol/liter) and Pi (0.7-1.4mmol/liter). The concentration of Pi in plasma is not maintained at a steady-state level like that of calcium. It varies among animal species, with the highest levels in fish and the lowest in the adult human. In the fasting human, the plasma Pi concentration varies with age: 0.711.36 mmol/liter in adults, 1.28-2.0 mmol/liter in children, and 1.39-2.67 mmol/liter in newborns. The amount of Pi in plasma and extracellular fluid, approximately 15 mmol in the adult human, represents less than 0.1% of the total phosphate in the body. Plasma Pi concentrations are a reflection of the various fluxes entering and leaving the extracellular pool. Pi enters this pool from the intestine, soft tissues, and bone. It leaves the extracellular fluid through the urine, as a result of the difference between glomerular filtration and net tubular reabsorption, by back flux into the intestinal lumen, and by transfer into soft tissue and bone.
Distribution of P h o s p h a t e in the Body
Intestinal Absorption of P h o s p h a t e
The adult human body contains 15-20 tool of Pi, 8090% of which is present in bone as hydroxyapatite. The
The Pi content of foodstuffs is variable. The concentration, expressed per 100 grams, is highest in fish,
INTRODUCTION During the development and maturation of vertebrates, selective regulatory mechanisms have evolved to maintain the extracellular concentration of inorganic phosphate (Pi) at a relatively high level compared with that prevailing in the adult organism. This homeostatic process fulfills the increased need for Pi that results from increased rates of cellular growth and skeletal mineral deposition. The mechanisms responsible for the regulation of Pi homeostasis during growth are not completely understood and likely involve growth factors that also affect bone growth directly or indirectly. The importance of Pi in bone growth and mineralization is best illustrated by the occurrence of growth and skeletal abnormalities in children with Mendelian hypophosphatemic disorders. This chapter summarizes the physiological aspects of Pi homeostasis, particularly those related to growth, the molecular mechanisms involved in renal Pi transport, and the role of novel Pi regulatory factors encoded by the P H E X and FGF23 genes that are mutated in X-linked and autosomal dominant hypophosphatemic disorders, respectively.
PediatricBone
173
Copyright 2003, Elsevier Science (USA). All rights reserved.
1 74
Joseph Caverzasioet al.
liver and other organs, eggs, meat, milk, and cheese (30-200mmol). Furthermore, Pi is present in bread (30-60 mmol), vegetables (10-30 mmol), and fruit (3-10mmol). The presence of Pi in so many foodstuffs explains the rarity of Pi deficiency. Usually, a diet with enough calcium and protein is largely sufficient in Pi. The average Pi intake in humans is approximately 30-50 mmol/day. The minimum requirement is approximately 25 mmol/day for males and slightly higher for children and pregnant women. Pi is absorbed in the small intestine, where the Pi absorptive capacity is highest in the duodenum and lowest in the ileum. Pi absorption occurs by a nonsaturable, paracellular pathway as well as by a saturable energy-requiring Na-dependent process that has been localized to the mucosal surface. This explains why increasing dietary Pi intake results in a proportional increment in net Pi absorption, with no indication of saturation in intact animals. This also explains why inadequate Pi absorption results primarily from decreased Pi availability rather than from changes in the intrinsic capacity of intestinal Pi transport. A large body of evidence indicates that the active transfer of Pi across the mucosal membrane involves a vitamin D-regulated, Na-dependent high-affinity transport system [14,42,92,122]. The vitamin D sterols were shown to activate Na-dependent Pi transport by increasing the maximal velocity (Vmax) of the carrier system. The molecular identification of an intestinal Na/Pi cotransporter that is regulated by dietary Pi is described later. Extrarenal Soft Tissue Handling of P h o s p h a t e In contrast to the growing knowledge of Pi transport in intestine, bone, and particularly kidney, the molecular mechanisms mediating Pi fluxes in soft tissues remain poorly understood. Moreover, their precise role in the maintenance of serum Pi concentration and the regulatory mechanisms governing the rate of Pi transfer from the extracellular and intracellular compartments remain unclear. Evidence suggests that hormones involved in modulating carbohydrate metabolism also play a role in the regulation of soft tissue Pi flux. For example, insulin elicits a rapid increase in Pi uptake by rat hepatocytes in primary culture [25] and in skeletal muscle [123], by increasing the Vmaxof a Na-dependent Pi transport system without influencing the Km. These findings suggest that insulin mediates the insertion of preformed Pi carriers into the plasma membrane. The stimulation of Pi uptake by insulin likely occurs in response to the insulin-dependent increase in glucose metabolism, a process that utilizes ATP and increases the demand for Pi from oxidative phosphorylation.
P h o s p h a t e Transport a n d Bone A major function of bone is to act as a mechanical support. This is achieved by the mineralization of an extracellular matrix formed by osteogenic cells. Pi is essential for osteogenic function not only because it is an integral component of hydroxyapatite crystal but also because it can affect the rate of bone matrix production and bone resorption [32,65] and is essential for intracellular energy production. As mentioned previously, the plasma Pi concentration is higher in growing individuals than in adults, most likely to accommodate the increased requirement for Pi during growth and skeletal development. Although the mechanisms responsible for the regulation of Pi homeostasis during growth are not completely understood, growth factors that also affect bone growth, either directly or indirectly, likely play a role. The importance of Pi in bone development is suggested by abnormalities associated with hypophosphatemic disorders [2,9] such as X-linked hypophosphatemia, a metabolic bone disease occurring in both humans and mice (discussed later). Until recently, little was known about Pi transport in bone cells. However, recent studies demonstrate that this process is a relevant component of bone cell physiology and serves to regulate bone formation and remodeling [32,65].
Osteoclast Function and Phosphate Transport Osteoclasts are polarized cells involved in bone resorption and are exposed to high ambient Pi concentrations during the active resorptive process. Osteoclasts possess specific Pi transport systems, including a Na/Pi cotransporter whose activity is dependent on ATP production and Na+,K+-ATPase activity to maintain the inwardly directed Na gradient driving force for Pi cotransport [65]. When osteoclasts are isolated in vitro and allowed to attach to bone particles, Pi transport is stimulated, without an increment of protein synthesis [65]. The stimulatory effect of bone particles on Pi transport is prevented by peptides containing the ArgGly-Asp cell adhesion motif, implicating the involvement of integrins and cell matrix interaction in the regulation of Pi transport. The osteoclast Na/Pi cotransporter probably belongs to the type IIa family [64]. Pi transport is essential to osteoclast function and provides the substrate for ATP synthesis, which is required to support the high rates of proton transport involved in bone resorption.
Phosphate Transport and Osteogenic Cell Function Like all eukaryotic cells, osteogenic cells (i.e., osteoblasts and chondrocytes) are endowed with
6. Phosphate Homeostasis Regulatory Mechanisms
Na-dependent Pi transport systems driven by an inwardly directed Na gradient. There are several differences between Na-dependent Pi transport in osteoblasts and that in renal epithelial cells. Affinity constants for Pi are significantly higher in osteoblasts (300-500 vs 50100 txM for renal epithelial cells) and Na/Pi cotransport in osteoblasts is stimulated by an acidic extracellular pH [35], whereas renal epithelial Pi transport is stimulated by more alkaline pH. PTH, a potent osteotropic factor, stimulates Na/Pi cotransport in osteoblasts [136] but inhibits transport in renal proximal cells. Additional studies are necessary to understand the cellular and molecular mechanisms underlying these differences. Other factors that stimulate Na/Pi cotransport in osteoblasts, such as insulin-like growth factor-1 (IGF-1), platelet-derived growth factor, and fibroblast growth factor (FGF), also enhance the proliferation and/or the differentiation of bone-forming cells [103,119,143,172]. The cellular mechanisms by which these growth factors increase Pi transport in osteogenic cells are not completely understood but may involve a tyrosine phosphorylation process [32]. In addition, fluoride, another potent
IGF-1
PDGF
~
Fluoride
"~~
activator of bone formation, also stimulates Pi transport in osteoblastic cells via the activation of a tyrosine phosphorylation process [34]. Role of Pi Transport in Matrix Vesicle Function
As illustrated in Fig. 1, Pi transport in osteogenic cells not only provides sufficient Pi for metabolic processes but also serves a specialized function in matrix vesicles, which play a role in the initial events of bone matrix calcification. Primary mineralization is regulated by chondrocytes, osteoblasts, and odontoblasts and occurs in epiphyseal cartilage, embryonic bone, postnatal ossification, and the development of predentin. Two distinct but not mutually exclusive theories--collagen nucleation and matrix vesicles production--have been proposed to explain the mechanism involved in the initiation of calcification in skeletal tissues [168]. The first holds that the collagen fibril is the major site of crystal nucleation and that Ca/Pi crystals are deposited along the entire length of collagen fibrils. The alternative theory involves the participation of matrix vesicles, which are produced by
-i-
TYros
.... I
phos
^ .~'I cAMP I mRNA
PTH
Na Pi
~ Phos
Na Pi Matrix
175
Ca
vesicle ~
AIk Phos
Aci Phospholipid
FIGURE 1 Schematic representation of the regulatory factors and signal transduction mechanisms involved in the stimulation ofNa/Pi cotransport in osteoblast-like cells. Experimental evidence suggests parallel regulation of Pi transport activity in the plasma membrane of bone-forming cells and their derived matrix vesicles. With the notion that Pi transport is important for accumulation of mineral ions, it is hypothesized that Pi transport in matrix vesicles plays a significant role in the control of processes involved in the calcification of the bone matrix.
1 76
Joseph Caverzasio et al.
osteogenic cells and serve as nucleation sites for mineralization of the extracellular matrix. Matrix vesicles are small organelles (100-200nm in diameter) that have been observed in mineralizing tissues in contact with newly formed mineral crystals. Matrix vesicles arise from bone-forming cells by a process of budding from elongated tubular extensions that project from the plasma membrane of these cells [4]. The mechanism for matrix vesicle-mediated calcification is not fully understood. Several lines of evidence indicate that uptake of Ca and Pi by matrix vesicles, from the extracellular environment, is required for initiation of calcification [51]. Ca enters matrix vesicles by a protease-sensitive carrier that may be related to the annexins [55]. Matrix vesicles also express a Na-dependent Pi transport system that is similar to that in osteoblasts and chondrocytes [104], further suggesting that these structures are derived from the plasma membrane of osteogenic cells. Formation of Pi-Ca-phospholipid complexes in the vesicular space is believed to maintain a favorable Pi gradient, allowing the continuation of Pi transfer into matrix vesicles. In this system, Na only facilitates translocation of Pi across the membrane of matrix vesicles since a mechanism for maintaining the Na gradient is not present in these structures. Accumulation of Pi through this system allows calcification to occur inside matrix vesicles. The calcified vesicles then serve as nucleators of matrix calcification. Studies have shown that Pi transport activity is low in matrix vesicles released during the proliferative phase of osteoblast development but is significantly increased during osteoblast differentiation, peaking at the time of bone matrix formation [104]. The increase in Pi transport activity in matrix vesicles released during the formation of the collagenous matrix may be explained by an enrichment of Pi carriers during the differentiation process. Because Na/Pi cotransport in osteogenic cells is regulated by calciotropic hormones and growth factors, regulation of Pi transport in released matrix vesicles may represent a mechanism by which osteogenic cells modulate the calcification of extracellular matrix. The previously mentioned in vitro observations suggest that Pi transport plays an important role in osteogenic cell- and matrix vesicle-mediated calcification. To address the relevance of these in vitro findings, the molecular identity and expression of Pi transporter(s) in osteogenic cells in vivo were investigated. Data obtained indicate that the type III Na/phosphate cotransporter Pit- 1 (Glvr- 1) is expressed in osteoblastic and chondrocytic cells and is regulated by osteotropic factors [62,119,120]. In situ hybridization analyses of Pit-1 expression in developing embryonic metatarsals revealed that this Pi transporter is expressed only in a subset of hypertrophic chondrocytes during endochondral bone formation in a region in which matrix mineralization proceeds, an observation consist-
ent with a potential role for this Pi transporter in matrix calcification [121]. The recent description of the murine Pit-1 gene and its promoter region [120] will allow more detailed analyses of the functional role of this transporter in primary bone calcification. Renal Pi Transport Na/Pi cotransport across renal epithelial cells is an important determinant of plasma Pi concentration [15]. In an adult human, the plasma Pi concentration is ~l.2mmol/liter, the glomerular filtration rate ~120ml/ min, and the amount of Pi filtered daily ~210mmol. If 20% of the filtered load is excreted in the urine, the mass of Pi reabsorbed is-168 mmol/day. This net renal reabsorptive flux for Pi is ~10 times greater than the net intestinal absortive flux in adults with a dietary Pi intake of 25 mmol/day and an intestinal fractional absorption of 70%. Furthermore, the renal reabsorptive flux for Pi varies with the dietary Pi intake and the utilization of Pi by the organism [18,19]. Thus, the tubular reabsorption of Pi (TRPi) plays a central role in the regulation of plasma Pi level and Pi homeostasis. By altering the level of Pi in the extracellular fluid, the net TRPi can also influence the intracellular pool of Pi in the various tissues and the amount of Pi in bone mineral.
Overall Tubular Pi Transport In the mammalian kidney, Pi transport is a saturable process with no appreciable simple diffusion component and is characterized by a maximum rate of Pi transfer across the tubular epithelium from lumen to blood. The maximum rate is not an absolute constant but varies with the physiological or pathological condition [13,15,17,18]. The tubular maximum for Pi reabsorption per unit of glomerular filtration rate (TmPi/GFR) represents the most reliable quantitative estimate of the overall tubular Pi transport capacity. Most, if not all, significant regulatory factors or conditions that influence Pi homeostasis by altering the renal handling of Pi have been shown to exert their effect on TmPi/GFR. A very strong correlation exists between TmPi/GFR and fasting plasma Pi concentration [15,17], indicating that the capacity of the renal tubule to transport Pi is a major determinant ofextrarenal Pi homeostasis. Therefore, an understanding of the mechanisms that underlie changes in TmPi/GFR is key to our understanding of Pi homeostasis in health and disease.
Tubular Localization of Pi Reabsorption Under normal conditions, ~80-90% of the Pi filtered load is reabsorbed in the proximal tubule [13,139]. There is evidence for inter- and intranephron heterogeneity in
6. Phosphate Homeostasis Regulatory Mechanisms
proximal tubular Pi transport capacity, with higher transport rates in early ($1/$2) vs late ($3) and in deep (juxtamedullary) vs superficial (cortical) proximal tubular segments [13,139]. A small fraction of Pi reabsorption may also occur in the distal and terminal segments of the nephron [13,17]. The molecular mechanisms of proximal tubule Pi transport are described later.
Regulation of Renal Pi Transport Parathyroid Hormone
Chronic changes in parathyroid hormone (PTH) status, observed clinically or elicited experimentally, are associated with alterations in tubular Pi transport capacity. For example, in chronic hypo- or hyperparathyroid states, TmPi/GFR is increased or decreased, respectively, relative to the normal state. The mass of cAMP produced by the kidney, as estimated by the amount of cAMP excreted in the urine per milliliter of GF, is usually found to be decreased or increased in chronic hypo- and hyperparathyroidism, respectively. These findings suggest that the alterations in renal Pi handling observed in chronic states of hypo- or hyperparathyroidism are cAMP dependent. The molecular mechanism by which cAMP influences tubular Pi transport in the proximal tubule is described later. Renal Adaptation to Changes in Dietary Pi
Dietary Pi intake influences its tubular reabsorption and urinary excretion. Pi reabsorption is increased in animals fed a low Pi diet and reduced in animals on a high Pi diet. The tubular adaptation to dietary Pi is independent of PTH and calcitonin and is evident in thyroparathyroidectomized (TPTX) animals [141,164]. It is also independent of growth hormone production, as shown by studies ofhypophysectomized animals [30]. However, the response to dietary Pi restriction is influenced by growth [28]. Of interest is the finding that Pi restriction causes resistance to the phosphaturic effect of PTH [58]. In vivo micropuncture studies have shown that Pi reabsorption by proximal tubule is markedly enhanced in Pi-deprived animals. They also suggest that the adaptive response to changes in dietary Pi may involve distal nephron sites [106]. The adaptive changes in the tubular capacity to reabsorb Pi are paralleled by changes in the Na-dependent component of Pi transport across the brush-border membrane (BBM) of proximal tubular cells. The response of the BBM to changes in dietary Pi intake is specific for Pi transport. There is no change in the Na-dependent or -independent uptakes of L-proline or D-glucose measured in the same BBM vesicle preparations [110]. The effects of dietary Pi on Pi transport are
177
reflected by changes in gma x of the BBM Na/Pi cotransporter, without a change in the affinity (Km) of the transporter for Pi, indicating an increase in the number of transporters in the BBM [110]. The adaptive response to dietary Pi restriction is more pronounced and occurs more rapidly in young animals compared to adults, as demonstrated by clearance studies [28]. Two distinct responses have been observed in the renal adaptation to dietary Pi restriction. An early phase occurs rapidly and is detectable in BBM vesicles within 2-4 hr [27,95]. This is preceded by a decline in serum and urine Pi concentration. It is independent of PTH and does not require de novo protein synthesis. This early phase of adaptation likely involves changes in the rate of endocytosis and exocytosis of Na/Pi cotransporters between the BBM and endosomes. A similarly rapid but opposite adaptation in BBM Pi transport is also observed after an intravenous Pi load [37]. The chronic phase of adaptation to dietary Pi restriction takes several days to complete [164], requires de novo synthesis of new transporters [110], and participates in the long-term maintenance of Pi homeostasis. Dissociation between Na/Pi Cotransport and TmPi/GFR
Several studies have demonstrated that BBM Na/Pi cotransport is not always related to TmPi/GFR. For example, in adult rats fed control and low Pi diets, the diet-induced changes in BBM Na/Pi cotransport do not correspond to those in TmPi/GFR, determined by clearance studies in intact animals [29]. Moreover, in the Hyp mouse, an animal model for X-linked hypophosphatemia, a similar dissociation between BBM Na/Pi cotransport and TmPi/ml GFR was reported [105,151]. Taken together, these findings suggest that the BBM of the proximal tubule cell may not be the only site involved in the adaptive response and are consistent with the demonstration that the distal nephron contributes to the adaptive process [106]. Growth and Renal Pi Transport
The plasma Pi concentration is higher in infants than in children or adults [24]. Although a low GFR contributes to the retention of Pi in infancy [22], it is well documented that tubular Pi reabsorption is higher in infants and plays a major role in the maintenance of high serum Pi concentration during growth. In children, the high serum Pi levels were thought to be related to increased GH levels [60]. However, the difference in plasma GH levels between children and adults was not striking, and in pitiutary dwarfs serum Pi levels are still higher than in adult control patients [40]. Therefore, the difference in serum Pi levels between children and adults cannot be due entirely to differences in plasma GH concentrations.
1 78
Joseph Caverzasio et
Animal studies also demonstrated that both TmPi/ GFR and plasma Pi concentrations are lower in adult when compared to young growing animals [28]. The dependence of renal Pi transport on growth was also shown in thyroparathyroidectomized rats, indicating that the change in renal Pi transport with growth or age is independent of PTH [28]. In addition to the PTH/ adenylate cyclase system, neither calcitonin nor thyroxine appear to be involved in the age-dependent change in tubular Pi transport. Furthermore, the difference in renal Pi handling between young, growing and adult rats could not be attributed to changes in GFR, plasma calcium level, renal handling of Na, alterations in blood carbon dioxide tension, or the acid-base status of the animals [28]. Moreover, the lower TmPi/GFR in adult compared with young rats could not be corrected by chronic administration of GH. The age-related differences in renal Pi handling appear to correlate with the plasma concentration of 1,25-dihydroxyvitamin D3 [1,25(OH)2D], the active hormonal form of vitamin D that stimulates the intestinal absorption of Pi and Ca [28]. However, the finding that chronic administration of 1,25(OH)2D did not increase renal tubular Pi transport capacity in experimental animals [20] strongly suggests that this vitamin D metabolite is not involved in the change of renal Pi transport with growth or age. Rather, it suggests the existence of a common mechanism for the regulation of renal Pi transport and 1,25(OH)2D production with growth or age. The contribution of the growth hormone somatomedin axis to growth- and age-dependent changes in renal Pi transport and serum Pi concentration was also investigated. Chronic administration of IGF-1 increased TmPi/ ml GFR and plasma Pi in both hypophysectomized (HPX) rats and TPTX-HPX rats compared with vehicle-treated animals [31]. In HPX animals, the IGF1-dependent increase in renal Pi handling and plasma Pi was not associated with a consistent change in plasma Ca concentration or in urinary Ca excretion. The change in tubular Pi transport in response to IGF-1 was evident at the level of the BBM, consistent with proximal tubular involvement. IGF-1 also elicited a corresponding increase in plasma concentration of 1,25(OH)2D in HPX rats [31], suggesting that IGF-1 mimics the changes in tubular Pi transport with growth. In addition to its renal effects on the tubular Pi reabsorption and the production of 1,25(OH)2D, IGF-1 is also involved in the regulation of bone growth. In vivo and in vitro studies demonstrate that GH and IGF-1 have important regulatory roles in the rates of differentiation and proliferation of chondrocytes in the epiphyseal growth plate. It has been suggested that local production of IGF-1 is an important mediator of GH action in bone. IGF-1 stimulates both proliferation and differentiation
al.
of cultured osteoblasts and increases type 1 collagen synthesis, alkaline phosphatase activity, and osteocalcin production. Thus, IGF-1 appears to be an important factor in orchestrating essential events in Pi homeostasis for bone growth and development [33].
CELLULAR AND MOLECULAR ASPECTS Cellular M e c h a n i s m s
Secondary Active Transport Pi is taken up from the tubular fluid across the BBM by a Na-dependent Pi transport system(s); transcellular Pi transport is completed at the basolateral membrane by transport pathways that are not well characterized (Fig. 2) [113,114]. Both anion exchange mechanisms and Pi leak pathways have been proposed [113,114]. Na-dependent influx of Pi across the basolateral membrane has also been described and may play a role when apical Pi influx does not meet the cellular requirements.
+
basolateral
luminal
ATP
3Na+ ~ Pi
ADP+Pi
xNa+ org. anions ", I ~
v " Pi
ly
+Pi
I
2K+
I
3Na+
FIGURE 2 Secondary active Na/Pi cotransport. A type IIa Na/Pi cotransporter mediates apical Pi influx. The role of the apical type I Na/Pi cotransporter is unclear. The basolateral membrane contains the primary active Na/K pump and several Pi transport pathways that include a type III Na/Pi cotransport pathway mediating housekeeping Pi influx and poorly defined Pi efflux mechanisms. For further information see text and Refs. [113] and [114].
6. Phosphate Homeostasis RegulatoryMechanisms Studies on the physiological and pathophysiological regulation of overall renal Pi handling suggest that apical (brush-border) Na/Pi cotransport is rate limiting [113,114]. A hallmark of tubular Pi reabsorption, higher transport rates at alkaline pH values, is also a property of BBM Na/Pi cotransport [3,113,114]. Renal NA/P! Cotransporter(s)
Apical (Type I vs Type IIA) Molecular biological approaches led to the structural identification of renal BBM Na/Pi cotransporters [107,108,112-114]. Injection of mRNA, isolated from kidney cortex, led to an increase in Na-dependent Pi uptake in Xenopus laevis oocytes. This observation was the basis for the expression cloning of Na/Pi cotransporter cDNAs that stimulate high-capacity, Na-dependent Pi uptake when expressed in oocytes or in a variety of cell lines in culture [107,108,112-114].
Type I Na/Pi Cotransporter Immunohistochemical analysis of renal sections and RNA localization studies indicated that the type I "transporter" localizes to the proximal tubular BBM. However, the inter- and intranephron heterogeneity described previously was not observed for the type I Na/Pi cotransporter. Furthermore, after expression in X. laevis oocytes, type I-mediated Pi uptake did not exhibit the characteristic pH dependence of proximal tubular Pi transport [113,114]. Detailed expression studies of X. laevis oocytes indicated that the type I transporter protein shows very distinct anion channel properties and that the kinetic properties of induced Na-dependent Pi transport function was similar to that of the intrinsic oocyte Pi transport activity [23,113,114,170]. Furthermore, physiological conditions known to regulate proximal tubular Pi handling altered neither type I protein nor mRNA expression. Thus, the type I Na/Pi cotransporter seems not to be a major determinant of proximal tubular Pi handling [113,114].
Type lla Na/Pi Cotransporter The type IIa Na/Pi cotransporter is highly expressed in the proximal tubular BBM and in subapical vesicular structures. The corresponding mRNA is found only in proximal tubules. The inter- and intranephron heterogeneity of expression corresponds with that of proximal tubular reabsorptive capacities. When expressed in a variety of heterologous systems, its transport properties correspond to those observed in isolated BBM [113,114]. The type IIa Na/Pi cotransporter is a major determinant of proximal tubular Pi transport and thus a key
1 79
player in renal Pi reabsorption [93,107-109,111-114]. Interestingly, the rate of Pi transport is predominantly regulated by altering the abundance of type IIa protein in BBM (e.g., in PTH-induced phosphaturia and in dietary Pi-dependent alterations). In addition, genetically determined Pi wasting disorders are associated with altered expression levels of this transporter. Finally, gene deletion and antisense-induced suppression of corresponding type IIa Na/Pi cotransporter mRNA documented that N80% of BBM Na/Pi cotransport activity can be attributed to the type IIa Na/Pi cotransporter protein [10,118]. A related Na/Pi cotransporter (type IIb) is expressed in small intestinal BBM as well as in other epithelial tissues but not in kidney. It also plays a role in the physiological regulation of intestinal Pi reabsorption [69,71]. The gene encoding the human type IIa cotransporter (NPT2) maps to chromosome region 5q35 and the corresponding mouse gene (Npt2) to chromosome region 13B [66,87,88]. The gene structure is conserved in both species--~16 kb in length consisting of 13 exons and 12 introns [66]. The promoter structure is also conserved in the species analyzed to date (opossum, mouse, human, and rat) and contains sequences suggested to be important for transcriptional regulation by bicarbonate/carbon dioxide tension, vitamin D, and low Pi medium and for restricted expression in proximal tubular cells